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Carol Fuzeti Elias and Lucila Leico Kagohara Elias
LPS-Induced Low-Grade Inflammation Increases Hypothalamic JNK Expression and Causes
Central Insulin Resistance Irrespective of Body Weight Changes
Reprinted from: Int. J. Mol. Sci. 2017, 18, 1431, doi:10.3390/ijms18071431 . . . . . . . . . . . . . . 180
Yina Lv, Xinying Xiang, Yuhong Jiang, Leilei Tang, Yi Zhou, Huan Zhong, Jun Xiao and
Jinpeng Yan
Identification and Characterization of Lipopolysaccharide Induced TNFα Factor from Blunt
Snout Bream, Megalobrama amblycephala
Reprinted from: Int. J. Mol. Sci. 2017, 18, 233, doi:10.3390/ijms18020233 . . . . . . . . . . . . . . . 194
Tsang-Hsiung Lin, Hsing-Hao Su, Hong-Yo Kang and Tsung-Hsien Chang
The Interactive Roles of Lipopolysaccharides and dsRNA/Viruses on Respiratory Epithelial
Cells and Dendritic Cells in Allergic Respiratory Disorders: The Hygiene Hypothesis
Reprinted from: Int. J. Mol. Sci. 2017, 18, 2219, doi:10.3390/ijms18102219 . . . . . . . . . . . . . . 206
Anita Mikołajczyk and Dagmara Złotkowska
Neuroimmunological Implications of Subclinical Lipopolysaccharide from
Salmonella Enteritidis
Reprinted from: Int. J. Mol. Sci. 2018, 19, 3274, doi:10.3390/ijms19103274 . . . . . . . . . . . . . . 234
Ken Fukuda, Waka Ishida, Atsuki Fukushima and Teruo Nishida
Corneal Fibroblasts as Sentinel Cells and Local Immune Modulators in Infectious Keratitis
Reprinted from: Int. J. Mol. Sci. 2017, 18, 1831, doi:10.3390/ijms18091831 . . . . . . . . . . . . . . 254
Anita Mikołajczyk, Anna Kozłowska and Sławomir Gonkowski
Distribution and Neurochemistry of the Porcine Ileocaecal Valve Projecting Sensory Neurons in
the Dorsal Root Ganglia and the Influence of Lipopolysaccharide from Different Serotypes of
Salmonella spp. on the Chemical Coding of DRG Neurons in the Cell Cultures
Reprinted from: Int. J. Mol. Sci. 2018, 19, 2551, doi:10.3390/ijms19092551 . . . . . . . . . . . . . . 266
vi
Elisa Wirthgen, Winfried Otten, Margret Tuchscherer, Armin Tuchscherer, 
Grazyna Domanska, Julia Brenmoehl, Juliane Günther, Daniela Ohde, 
Werner Weitschies, Anne Seidlitz, Eberhard Scheuch and Ellen Kanitz
Effects of 1-Methyltryptophan on Immune Responses and the Kynurenine Pathway after 
Lipopolysaccharide Challenge in Pigs
Reprinted from: Int. J. Mol. Sci. 2018, 19, 3009, doi:10.3390/ijms19103009 . . . . . . . . . . . . . . 283
Wan-Ying Li, Fei-Mi Li, Yu-Fu Zhou, Zhong-Min Wen, Juan Ma, Ke Ya and Zhong-Ming Qian
Aspirin down Regulates Hepcidin by Inhibiting NF-κB and IL6/JAK2/STAT3 Pathways in BV-2
Microglial Cells Treated with Lipopolysaccharide
Reprinted from: Int. J. Mol. Sci. 2016, 17, 1921, doi:10.3390/ijms17121921 . . . . . . . . . . . . . . 306
Xiao Xu, Xiuying Wang, Huanting Wu, Huiling Zhu, Congcong Liu, Yongqing Hou, Bing Dai,
Xiuting Liu and Yulan Liu
Glycine Relieves Intestinal Injury by Maintaining mTOR Signaling and Suppressing AMPK,
TLR4, and NOD Signaling in Weaned Piglets after Lipopolysaccharide Challenge
Reprinted from: Int. J. Mol. Sci. 2018, 19, 1980, doi:10.3390/ijms19071980 . . . . . . . . . . . . . . 317
Carla Ribeiro Alvares Batista, Giovanni Freitas Gomes, Eduardo Candelario-Jalil, 
Bernd L. Fiebich and Antonio Carlos Pinheiro de Oliveira
Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand 
Neurodegeneration
Reprinted from: Int. J. Mol. Sci. 2019, 20, 2293, doi:10.3390/ijms20092293 . . . . . . . . . . . . . . 336
Gabriel Forn-Cunı́, Susana Merino and Juan M. Tomás
Comparative Genomics of the Aeromonadaceae Core Oligosaccharide Biosynthetic Regions
Reprinted from: Int. J. Mol. Sci. 2017, 18, 519, doi:10.3390/ijms18030519 . . . . . . . . . . . . . . . 367
vii

Preface to ”Lipopolysaccharides (LPSs)”
The outer membrane of Gram-negative bacteria reacts to changes in the environment, inhibits
the entrance of toxic compounds (such as antibiotics), plays an important role in nutrient transport,
and mediates the physiological and pathophysiological interaction of bacteria with host organisms.
Lipopolysaccharides (LPSs) play a fundamental role in the organization and integrity of the outer
membrane structure, and are critical for the maintenance of barrier function, preventing the entrance
of small hydrophobic compounds and reducing the effectiveness of antibiotics and polycationic
peptides. Because of their exposed position, LPSs also represent an ideal target for the recognition
by both antibodies and other immunological or pharmacological agents. Lipopolysaccharide (LPS)
has been considered an essential component of outer membrane biogenesis and cell viability based
on pioneering studies in the model Gram-negative organisms Escherichia coli and Salmonella.
LPSs are endotoxins, one of the most potent class of activators of the mammalian immune
system; they can be released from cell surfaces of bacteria during multiplication, lysis, and death.
Low doses of endotoxins are thought to be beneficial for the host, causing immunostimulation and
enhanced resistance to infection. On the other hand, the presence of a large amount of endotoxin in
the bloodstream, as observed during severe systemic infections, leads to strong pathophysiological
reactions such as multiorgan failure, shock, and potentially death. The medical significance of this
endotoxin and its wide range of biological properties are grounds for the ever-expanding scientific
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Abstract: A small gram-negative bacterium, Coxiella burnetii (C. burnetii), is responsible for a zoonosis
called Q fever. C. burnetii is an intracellular bacterium that can survive inside microbicidal cells like
monocytes and macrophages by hijacking several functions of the immune system. Among several
virulence factors, the lipopolysaccharide (LPS) of C. burnetii is one of the major factors involved
in this immune hijacking because of its atypical composition and structure. Thus, the aim of this
mini-review is to summarize the repressive effects of C. burnetii LPS on the antibacterial immunity
of cells.
Keywords: lipopolysaccharide; Coxiella burnetii; Q fever; phagosome; virenose
1. Introduction
Coxiella burnetii is an intracellular bacterium responsible for a worldwide zoonosis known as Q
fever [1,2]. After primary infection, approximately 60% of humans remain asymptomatic, while 40%
manifest clinical signs consisting of isolated fever, hepatitis, and pneumonia [3]. The principal clinical
manifestation of Q fever is endocarditis with a lethal prognosis without treatment. The treatment
involves a combination of doxycycline and hydroxychloroquine [1,3]. However, this long-term
treatment carries the persistent risk of relapse [4].
C. burnetii is a small bacterium measuring approximately 0.2 to 0.4 μm wide and 0.4 to 1 μm long,
and it has been classified in the Proteobacteria subdivision based on its 16S ribosomal RNA sequence.
As C. burnetii harbours lipopolysaccharide (LPS) in its membrane, it is defined as a gram-negative
bacterium. Though C. burnetii is not stained by Gram stain, it can be stained by Gimenez stain [5].
C. burnetii primarily infects domestic ruminants and pets, but arthropods have also been found to be
infected. In animals, the infection is asymptomatic but induces abortions in livestock. Both abortion
and parturition contribute to the bacteria spreading into the environment, since the placenta of infected
animals contains large amounts of C. burnetii. Contamination via aerosols also remains the major route
of infection in both animals and humans [3,6]. C. burnetii has been categorized as a biological weapon
due to its high infectivity, the possibility of producing large quantities of bacteria, its environmental
stability through a sporulation-like mechanism, and its dispersion via aerosolization [7,8]. C. burnetii
was likely used as a bio-weapon during World War II, as a Q fever outbreak was observed during this
time among army troops [9].
C. burnetii resides primarily within myeloid cells (monocytes and macrophages) [10,11] but has
also been shown to infect trophoblasts [12] and adipocytes [13]. The adaptation of C. burnetii to
its environment is probably critical for its survival. To survive within its host, C. burnetii interferes
Int. J. Mol. Sci. 2017, 18, 2509; doi:10.3390/ijms18122509 www.mdpi.com/journal/ijms1
Int. J. Mol. Sci. 2017, 18, 2509
with the host’s antimicrobial response (immunity and phagolysosome biogenesis). For this purpose,
C. burnetii has an arsenal of virulence factors [14–17], including LPS [18]. The molecular variations
observed in C. burnetii LPS, a major component of its outer membrane, contribute to its pathogenic
properties [19–21]. Moreover, the intracellular fate of virulent C. burnetii in myeloid cells is also
determined by its LPS composition [18].
2. Coxiella burnetii LPS: Structure and Composition
As observed in enterobacteria, C. burnetii displays antigenic variations, from a smooth-rough form
called Phase I to a rough form known as Phase II. The Phase I form is isolated from natural sources
and defined as a virulent form of C. burnetii. It is characterized by full-length LPS and survives inside
monocytes and macrophages [10,11]. After several passages of the virulent C. burnetii in embryonated
eggs or tissue culture, an irreversible modification is observed in the molecular weight of C. burnetii
LPS. C. burnetii harbouring a truncated LPS is defined as an avirulent microorganism and eliminated
by monocytes and macrophages [22,23]. This avirulent form does not exist in the natural environment.
It was shown that this LPS modification occurs due to a genomic deletion [3]. The difference between
the virulent and avirulent forms of C. burnetii lies in the O-antigen; specifically, LPS from virulent
C. burnetii has an O-antigen that contains unusual sugars, L-virenose, dihydrohydroxystreptose,
and galactosamine uronyl-α-(1,6)-glucosamine residues, whereas LPS from the avirulent form does
not have any O-antigen [19–21,24–32]. Virenose and dihydrohydroxystreptose have not been found in
any other enterobacterial LPSs and are thus unique biomarkers of virulent C. burnetii. Interestingly,
the lipid A molecules of both virulent and avirulent C. burnetii display the same ionic species and
fragmentation profiles in mass spectrometry, suggesting that they have very similar and likely identical
structures. The C. burnetii lipid A structure differs considerably from the published standard form
of enterobacterial lipid A. An analysis of lipid A from C. burnetii identified two major tetra-acylated
molecular species sharing the classical backbone of a dephosphorylated GlcN (acylated D-glucosamine
residues) disaccharide in which both GlcN I and GlcN II carry an amide-linked iso or normal (n)
C16:0(3-OH) [24,33]. The core polysaccharide is conserved between virulent and avirulent C. burnetii
LPSs and contains a heptasaccharide localized in the proximal region of lipid A. The heptasaccharide is
formed by two terminal D-mannoses (Man), 2- and 3,4-linked D-glycero-D-manno-heptoses, and terminal
4- and 4,5-linked 3-deoxy-D-manno-oct-2-ulosonic acid residues [20,29]. It is important to note that a
third C. burnetii LPS has been identified as an intermediate-length LPS at the surface of the Nine Mile
Crazy strain [34]. Large chromosomal deletions have been found in these avirulent C. burnetii Nine
Mile and Nine Mile Crazy strains [35]. These deletions eliminate open reading frames involved in
the biosynthesis of O-antigen sugars, including the rare sugar virenose [35]. The description of the
virenose biosynthesis pathway suggests the formation of GDP-β-D-virenose via the modification of
GDP-L-fucose by the addition of a methyl group at position C3”, and perhaps the open reading frame
CBU0691, and the inversion of the stereochemistry at position C2” [36].
3. C. burnetii LPS Interferes with Phagocytosis
It is known that phagocytosis efficiency depends on the activation of phagocytic receptor CR3
(complement receptor-3) through αvβ3 integrin and CD47 (integrin-associated protein). C. burnetii,
via its LPS, subverts receptor-mediated phagocytosis [22] by inhibiting the interplay between integrins,
including CR3, remodelling the actin cytoskeleton organization, and activating protein tyrosine kinases.
This strategy possibly determines the evolution of Q fever. C. burnetii, via its LPS, interacts with
macrophages through αvβ3 integrins, and avoids internalization by inhibiting the interaction between
αvβ3 integrins and CR3, which is essential for bacterial uptake [22,37]. Inhibition of the interplay
between αvβ3 integrins and CR3 leads to poor internalization of virulent C. burnetii compared with
its avirulent form, which harbours a truncated LPS and is largely internalized by monocytes and
macrophages. Interestingly, the inhibitory mechanism mediated by virulent C. burnetii through its LPS
does not target CD47 [22]. Note that CR3, not αvβ3 integrin, is excluded from the cytoskeleton
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protrusions formed during the cytoskeleton reorganization induced by virulent C. burnetii LPS,
thus decreasing the efficiency of phagocytosis [22,37,38]. An in-depth analysis has demonstrated that
the uptake of avirulent C. burnetii requires both CD11b/CD18 and CR3, whereas virulent organism
internalization does not involve CR3. It has been shown that the LPS from virulent C. burnetii prevents
the activation of CR3 by interfering with its lectin sites [22]. This leads to conformational changes in
the I domain and in the exposure of activation epitopes and cytoskeleton reorganization [39].
Finally, virulent C. burnetii induces early protein tyrosine kinase activation as well as the tyrosine
phosphorylation of two Src-related kinases: Hck and Lyn [40]. By contrast, the avirulent form does
not stimulate protein tyrosine kinases. Tyrosine-phosphorylated proteins co-localize with F-actin
inside protrusions. Cell membrane protrusions are induced via the activation of protein tyrosine
kinases by C. burnetii LPS, which in turn down-modulates C. burnetii uptake [40,41]. The use
of protein tyrosine kinase inhibitors rescues C. burnetii phagocytosis. It has been hypothesized
that the membrane ruffling induced by protein tyrosine kinase activation may interfere with the
co-localization of CR3 with αvβ3 integrin and C. burnetii [42,43]. It has also been shown that
C. burnetii LPS interferes with Toll Like Receptor (TLR)-2 and TLR-4 signalling through cytoskeleton
reorganization [38,41,42]. Indeed, cytoskeleton reorganization induces a redistribution of TLR-2 and
TLR-4 on the membrane of macrophages. This redistribution disrupts the colocalization between TLR-2
and TLR-4, in contrast to what is observed in macrophages challenged with LPS from the avirulent
strain of C. burnetii. Co-immunoprecipitation experiments have revealed that a possible physical link
between TLR-2 and TLR-4 is broken in cells challenged with virulent C. burnetii LPS. As a consequence,
p38α Mitogen-Activated Protein Kinase (MAPK) is not activated in macrophages challenged with
virulent C. burnetii and LPS extracted from virulent C. burnetii [18,41,44]. However, the existence of a
TLR2/TLR4/p38α MAPK axis in C. burnetii infection remains to be demonstrated.
4. C. burnetii LPS Interferes with the Antibacterial Immune Response
Macrophage immune polarization is reoriented by C. burnetii to deactivate the macrophage
microbicidal response [45,46]. Indeed, C. burnetii is responsible for atypical M2 macrophage activation,
and it has been shown to induce expression of M2 polarization-related genes (transforming growth
factor-β1, interleukin (IL)-1 receptor antagonist, Chemokine (C-C motif) ligand (CCL)18, mannose
receptor, arginase-1). By contrast, the expression of genes related to M1 polarization (tumor necrosis
factor, CD80, C-C chemokine receptor type (CCR)7) is inhibited. It is interesting to note that the
expression of arginase-1 is associated with the absence of nitric oxide production, while the expression
of the Interleukin (IL)-6 and Chemokine (C-X-C motif) ligand (CXCL)8 genes (M1-related genes) is
increased, although their proteins are weakly secreted [45]. In addition, monocytes produce high
levels of IL-10 in response to C. burnetii or its LPS. IL-10 favours the persistence of C. burnetii by
down-regulating the expression of tumor necrosis factor [47–49]. It is also responsible for the expression
of Programmed cell Death protein (PD)-1 by monocytes in vitro, and most likely, in patients with Q fever
endocarditis. The LPS of C. burnetii does not induce the expression of PD-1 by monocytes. PD-1
delivers an inhibitory signal to T cells [50,51], and its expression in Q fever contributes to the immune
suppression observed in Q fever endocarditis [52].
5. C. burnetii LPS as a Determinant Factor in Phagolysosome Biogenesis
In human macrophages, it has been observed that, in contrast to virulent C. burnetii, the avirulent
form is quickly eliminated in degradative phagolysosome-like compartments [11,47]. Their replication
is partially controlled in resident mouse peritoneal macrophages [53]. Immediately after phagocytosis,
both virulent and avirulent forms of C. burnetii are localized within an early phagosome, transiently
harbouring EEA1 (early endosome auto-antigen-1). This early phagosome undergoes a maturation
process and is transformed into a late phagosome, presenting the markers Lamp-1, CD63,
mannose-6-phosphate receptor, and V-H+ATPase and possessing an acidic pH. The major difference
between the compartments containing virulent and avirulent forms of C. burnetii is the absence of the
3
Int. J. Mol. Sci. 2017, 18, 2509
small GTPase Rab7 at the surface of the phagosome containing the virulent C. burnetii [11,17,18,23].
In contrast to the vacuole with avirulent bacteria, the phagosome containing the virulent strain
of C. burnetii does not mature in phagolysosomes [23]. Surprisingly, the intracellular trafficking
of C. burnetii LPS is similar to the trafficking of intact bacteria. Indeed, the LPSs from virulent and
avirulent C. burnetii traffic through early phagosomes characterized by the presence of the small GTPase
Rab5 and EEA1 [18,54]. Nevertheless, endosomes containing LPS purified from avirulent bacteria
develop into late endosomes (Rab7, Lamp1) and then into lysosomes containing the lysosomal enzyme
cathepsin D. The endosomes transporting LPS isolated from virulent bacteria mature from early to late
endosomes but do not become lysosomes. Interestingly, in terms of intact C. burnetii, late endosomes
containing LPS do not express the Rab7 protein on their surface [18,23,55]. This result suggests that
LPS is responsible for blocking phagolysosome maturation induced by C. burnetii. Investigations
of C. burnetii LPS have demonstrated that the LPS from pathogenic C. burnetii does not induce the
phosphorylation of p38α MAPK by Mitogen-Activated Protein Kinase Kinase (MKK)6. This defect in
the activation of p38α MAPK prevents the serine phosphorylation (S796E) of Vps41. In the absence of
phosphorylation, Vps41 does not promote the targeting of the HOPS (homotypic fusion and protein
sorting) complex to endosome–vacuole fusion sites, and thus it fails to recruit the GTP-bound Rab7
required for phagosome–lysosome fusion [56–61]. The absence of p38α MAPK activation is most
likely due to the engagement of TLR4 by two unusual sugars, virenose and dihydrohydroxystreptose,
present in the LPS of pathogenic C. burnetii. Thus, LPS from virulent C. burnetii acts as an antagonist
of TLR-4.
6. Concluding Remarks
Collectively, this evidence highlights the importance of LPS and its composition in the strategies
used by C. burnetii to infect cells and develop an efficient infection that leads to Q fever. It is interesting
to observe that the particular composition of C. burnetii LPS allows several axes of the immune
response to be modulated, ranging from phagocytosis to vesicular trafficking. Certainly, the virulence
of C. burnetii does not only depend on LPS, as other virulence factors have been identified in
C. burnetii [11,14]. The recent successful culturing of C. burnetii in axenic conditions might significantly
develop our understanding of C. burnetii infection by facilitating the identification of new virulence
factors [62,63]. Further work is required to understand the mechanisms implied in anti-microbicidal
response hijacking. It might be interesting to generate transgenic Escherichia coli expressing the LPSs
from both the virulent and avirulent C. burnetii to better understand LPS action. Similarly, as several
new C. burnetii strains that cause severe Q fever have been isolated [2], it will be interesting to analyse
their LPS composition to determine if the virulence and clinical issues observed are linked to any
particular structure or composition of LPS.
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Abstract: The high-resolution magic angle spinning nuclear magnetic resonance spectroscopy
(HR-MAS NMR) analysis of Plesiomonas shigelloides 78/89 lipopolysaccharide directly on bacteria
revealed the characteristic structural features of the O-acetylated polysaccharide in the NMR spectra.
The O-antigen profiles were unique, yet the pattern of signals in the, spectra along with their
1H,13C chemical shift values, resembled these of D-galactan I of Klebsiella pneumoniae. The isolated
O-specific polysaccharide (O-PS) of P. shigelloides strain CNCTC 78/89 was investigated by 1H and
13C NMR spectroscopy, mass spectrometry and chemical methods. The analyses demonstrated that
the P. shigelloides 78/89 O-PS is composed of →3)-α-D-Galp-(1→3)-β-D-Galf 2OAc-(1→ disaccharide
repeating units. The O-acetylation was incomplete and resulted in a microheterogeneity of the
O-antigen. This O-acetylation generates additional antigenic determinants within the O-antigen,
forms a new chemotype, and contributes to the epitopes recognized by the O-serotype specific
antibodies. The serological cross-reactivities further confirmed the inter-specific structural similarity
of these O-antigens.
Keywords: Plesiomonas shigelloides; O-antigen; lipopolysaccharide; O-acetylation; D-galactan I;
HR-MAS; NMR spectroscopy
1. Introduction
Plesiomonas shigelloides is a facultative anaerobic Gram-negative flagellated, rod-shaped bacterium
belonging to the Enterobacteriaceae family [1]. It is widely distributed in nature, but predominantly
isolated from aquatic environments and animals [2]. These bacteria are not part of the natural
human microflora. Human infections with P. shigelloides are generally related to visiting countries
with low sanitary standards [3,4], drinking unpurified water, and eating uncooked shellfish [5,6].
These bacteria are potent inducers of an invasive shigellosis-like disease [7], gastroenteritis [8],
and diarrheal disease [9]. Although the pathogenicity of P. shigelloides is not entirely understood,
lipopolysaccharide (LPS) is considered the main virulence factor. LPS is a major component of
the outer leaflet of the external membrane of Gram-negative bacteria. These are amphiphilic
molecules isolated from smooth bacterial strains (S-LPS). Structurally, they can be divided into
three distinct regions: lipid A, core oligosaccharide, and O-specific polysaccharide. These segments
are important for the biological activity [10] and take part in host–bacterium interactions [11].
The hydrophobic lipid A constitutes the most conserved part of LPS, yet lipid A structures and
the endotoxic activities that they imply vary substantially between different species of Gram-negative
bacteria [12]. The core oligosaccharides (OS) have structures that are generally conserved within
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bacterial species. The O-specific polysaccharide (O-antigen, O-specific chain) determines bacterial
O-serotype and constitutes a fingerprint of bacteria [13]. The high structural diversity of the O-specific
polysaccharides provides the serological distinction between bacterial strains. The variability of
O-antigen structures is one of the strategies used by bacteria to avoid recognition by host organisms
and to hamper the host’s defenses. Despite this variability, serological cross-reactivities between
various species occur, indicating the presence of common structural epitopes within O-antigens.
To date only several LPS structures out of 102 O-serotypes of P. shigelloides [14] have been analyzed
and reported [15–25]. All these studies exposed several characteristic features of P. shigelloides LPSs,
i.e., the lack of phosphate groups, the presence of uronic acid residues in the core oligosaccharides,
and the unusual hydrophobicity of the O-specific polysaccharides [22]. Most of the polysaccharides are
unique to the Plesiomonas species and distinguish them from other members of the Enterobacteriaceae
family. However, some O-antigens of P. shigelloides have shown cross-reactivity with antisera directed
against LPS of Shigella spp. The structure of P. shigelloides serotype O17 was found to be identical to
the Shigella sonnei phase I O-chain [19,26,27]. Two other strains of P. shigelloides share a type-specific
antigen with S. flexneri and S. dysenteriae [15,28]. The structural element α-L-Rhap(1→2)-α-L-Rhap
described in S. flexneri serotype 6 is shared with P. shigelloides and Klebsiella pneumoniae O-antigens [29].
In some aspects, this cross-reactivity of antibodies against the O-antigens is desirable as it can provide
broad protection against heterologous bacteria.
We have now identified a new O-antigen of P. shigelloides, structurally similar to this of
K. pneumoniae strain Kp20. Herein, we present the chemotyping of the O-antigen of P. shigelloides
strain CNCTC 78/89 by high-resolution magic angle spinning (HR-MAS) nuclear magnetic resonance
(NMR) spectroscopy in situ alongside the structural analysis of the isolated O-specific polysaccharide,
which supports this preliminary observations. The shared epitopes of Klebsiella and Plesiomonas
O-antigens, responsible for their serological cross-reactivities, have also been determined.
2. Results
2.1. HR-MAS NMR Analysis of P. shigelloides 78/89 Bacteria and LPS
The O-antigens of P. shigelloides 78/89 were initially investigated by HR-MAS NMR spectroscopy
as the technique allows for the direct identification of the flexible O-antigen molecules on the bacterial
cells in situ. The screening of the whole bacteria of P. shigelloides 78/89 using HR-MAS NMR technique
provided data on the O-PS spectral pattern of this strain. The HR-MAS NMR spectra of P. shigelloides
78/89 bacteria were complex and contained signals for anomeric and ring protons, as well as
resonances of other surface molecules and metabolites (Figure S1). The observed 1H resonances
and 1H,13C-correlations in the HR-MAS NMR spectra of bacteria were further complemented by the
HR-MAS NMR analysis of the isolated LPS. Both sets of data revealed distinct structural features of
the O-acetylated polysaccharide in the O-antigen of P. shigelloides 78/89. The spectra of the isolated
P. shigelloides 78/89 LPS contained main signals for three anomeric protons, resonances of the ring
protons and a distinct signal in the region of acetyl groups (δH 2.11 ppm). The observed pattern of
resonances was compared with the O-antigen structural data available in our laboratory, including
LPSs of various Klebsiella strains, and the data published previously. This O-antigen profile was unique,
however, in that a subset of signals in the 1D and HSQC-DEPT spectra as well as the 1H, 13C chemical
shift values were similar to these of K. pneumoniae strain Kp20 LPS (Figure 1). To unscramble this
similarity, the LPS of P. shigelloides 78/89 was subjected to further structural analyses.
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Figure 1. Regions of interest (ROI) extracted from the high-resolution magic angle spinning (HR-MAS)
HSQC-DEPT NMR spectra of the O-antigens of P. shigelloides strain CNCTC 78/89 (Ps78) bacteria and
LPS compared to these of K. pneumoniae strain Kp20 LPS. The regions were selected directly from the
SPARKY processed spectra using the rNMR software. The compared regions and their chemical shift
ranges include: anomeric signals (ROI.1, δH 5.45–4.96 ppm, δC 112.6–79.5 ppm), the ring resonances
(ROI.2, δH 4.57–3.51 ppm, δC 88.9–54.4 ppm) and acetyl-group resonances (ROI.3, δH 2.36–1.81 ppm,
δC 27.6–13.5 ppm). The HSQC-DEPT NMR spectra of bacteria (~4 mg dry mass) and LPS (~3 mg)
suspensions in 2H2O (total volume of ~30 μL in the Bruker Kel-F inserts) were obtained using a Bruker
4 mm HR-MAS probe on an Avance III 600 MHz spectrometer. The experiments were carried out using
a ZrO2 rotor at a spin rate of 4 kHz at 27 ◦C (the actual temperature of the bearing gas).
2.2. Isolation of LPS and O-Antigen Fractions
The LPS of P. shigelloides CNCTC 78/89 was extracted from bacterial mass by the hot phenol/water
method and purified by ultracentrifugation. The heteropolysaccharide components were released
by mild acid hydrolysis of the LPS and isolated by gel filtration on Bio-Gel P-10, yielding
four main fractions. The fractions were analyzed by matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometry and NMR spectroscopy, and identified as the O-specific
polysaccharide fraction (PSI), fraction composed of short O-specific chains substituted by core
oligosaccharide (OSII) and the core oligosaccharide (OSIII and OSIV) (Figure S2).
As the attempts to obtain the MALDI-TOF spectra of the intact PSI failed, the mass of the repeating
unit of P. shigelloides strain 78/89 has been deduced from the analysis of the partially hydrolyzed PSI
fraction. The PSI fraction was subjected to a partial acid hydrolysis with 0.5 M TFA. The MALDI-TOF
mass spectrum (Figure 2) showed the clusters of ions corresponding to oligosaccharide fragments
consisting of 3 up to 6 repeating units. The main signal at m/z 1013.63 Da corresponded to an
oligosaccharide fragment comprising three repeating units and it was accompanied by a minor signal
(m/z 1055.59) of the O-acetyled variant of the oligosaccharide. The observed mass differences indicated
the disaccharide (Δ 324 Da) and the O-acetylated disaccharide (Δ 366 Da) O-repeats.
The combined NMR and MS data of the more abundant core oligosaccharide fraction (OSIV)
indicated the presence of 11 sugar residues, together having a monoisotopic mass of 2015.65 Da.
The chemical shift values of the spin systems of the OSIV were compared with these for other core types
of P. shigelloides described to date. The acquired NMR data of the OSIV appeared very much like the
previously published core oligosaccharide structure of P. shigelloides O33:H3 (strain CNCTC 34/89) [30],
with two noticeable differences. The -4)-α-GalpNAc-(1-residue in the core of P. shigelloides 78/89 is not
O-acetylated. The disaccharide element in the outer core is built of -4)-α-GalpNAc-(1→6)-α-GlcpN-(1-,
and there is no heterogeneity related to the presence of Glcp instead of GlcpN, as was observed
previously in the core oligosaccharide of P. shigelloides O33:H3 (Table S1 and Figure S3). The OSIII
structure is also identical to the core oligosaccharide identified in the P. shigelloides O51 (strain CNCTC
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110/92) [31]. The structural identity of the core oligosaccharide was further confirmed serologically.
In the immunoblotting analysis the antiserum specific for the OS of P. shigelloides O51 reacted vividly
with the fast migrating bands of the SDS-PAGE-separated LPS fractions composed of the core
oligosaccharide linked to lipid A. Reactions were also observed for the LPS fractions composed
of the lipid A-core oligosaccharides substituted by the increasing number of the O-repeats (Figure S4).
Figure 2. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrum of
the partially hydrolyzed polysaccharide fraction of Plesiomonas shigelloides 78/89 LPS. The MALDI-TOF
mass spectrum was obtained in a positive linear mode. 2,5-Dihydroxybenzoic was used as matrix. M3,
M4, M5, and M6 represent the mass of the respective number of repeating units.
2.3. Structure Analysis of the O-Specific Polysaccharide
Initial analysis of the P. shigelloides 78/89 bacteria and LPS using HR-MAS NMR spectroscopy
provided a structural fingerprint of the O-antigen chemotype, including the 1H and 13C chemical shift
values for the O-specific polysaccharide in situ. Composition analysis of the PSI polysaccharide fraction
together with determination of the absolute configuration confirmed the presence of D-galactose
residues in galacto-furanose and galacto-pyranose ring forms. The NMR spectra of the isolated PSI
contained main signals for three anomeric protons and a distinct signal (δH 2.11 ppm) in the region
of acetyl groups. The spin systems for each residue (denoted as uppercase letters through the entire
text, tables, and figures) were assigned using COSY, TOCSY, HSQC-DEPT, HSQC-TOCSY, HMBC,
and NOESY NMR experiments (Table 1 and Figure 3).
Figure 3. Selected 1JH,C- and 3JH,C-connectivities in HSQC-DEPT and HMBC spectra of the isolated
PSI of Plesiomonas shigelloides 78/89 LPS. The inter-residue connectivities from the anomeric atoms in
HMBC spectra are marked in bold. The spectra were obtained for 2H2O solutions at 600 MHz and
30 ◦C. The uppercase letters refer to sugar residues in the O-specific polysaccharide, as described in
Table 1.
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The coupling patterns of the identified spin systems in the COSY and TOCSY spectra indicated
the galacto-configuration of all residues.




H-1 H-2 H-3 H-4 H-5 H-6, H-6′
C-1 C-2 C-3 C-4 C-5 C-6
A →3)-β-D-Galf 2OAc-(1→ 5.32 5.25
b 4.28 4.32 3.89 3.68, 3.65
107.1 81.8 82.1 82.9 70.8 62.7
B →3)-β-D-Galf -(1→ 5.20 4.40 4.06 4.24 3.86 3.66, 3.68
109.4 79.8 84.5 81.8 70.8 62.7
C →3)-α-D-Galp-(1→ 5.07 3.93 3.93 4.12 4.12 3.73, 3.68
99.5 67.2 76.9 69.2 71.3 61.1
C′ α-D-Galp-(1→ c 5.11 3.90 4.01 4.12 4.27 3.8, 3.7595.4 68.5 69.6 70.3 71.2 60.7
C* →3)-α-D-Galp-(1→ 5.08 3.94 3.95 4.11 4.11 3.69, 3.62
99.4 67.2 76.7 69.1 71.3 60.9
a Spectra were obtained for 2H2O solutions at 30 ◦C. Acetone was used as internal reference (δH/δC 2.225/31.05 ppm);
b The O-2 of this residue is O-acetylated (δCH3CO 2.11/20.5 ppm, 173.1 ppm); c The non-reducing terminal variant of
residue C.
Residue A (δH1/δC1 5.32/107.1 ppm) was identified as a 3-substituted 2-O-acetyl-β-D-
galactofuranose (β-D-Galf 2OAc) on the basis of the high chemical shift values of anomeric carbon
(δ 107.1), C-2 (δ 81.8), C-3 (δ 82.1) and C-4 (δ 82.9) as well as the similarities of the chemical shift
values of H-2, H-3, and H-4 to the published data [32]. This was further supported by the observed
correlation of H-1 with both C-3 and C-4, and a lack of correlation with C-5 in the HMBC spectrum
(Figure 3). The characteristic large downfield shift of the H-2 signal (δH 5.25) and its multiple bond
correlation with a carbonyl carbon resonance at δC 173.1 ppm in the HMBC spectrum indicated an
ester substitution at this position by an O-acetyl group (δH/δC 2.11/20.5). Similarly, residue B (δH/δC
5.2/109.4 ppm, 1JC1,H1 ~171 Hz) was recognized as the 3-substituted-β-D-galactofuranose devoid of
the O-acetyl. The chemical shift values except the H-2 were similar to these of residue A. The relatively
high chemical shift of the C-3 signal (δ 84.5) indicated a substitution by another residue. Residue
C with the H1/C1 signal at δH/δC 5.07/99.5 ppm, 1JC1,H1 ~175 Hz was assigned as a 3-substituted
α-D-galactopyranose (α-D-Galp) based on the large vicinal couplings between H-2 and H-3, the small
vicinal coupling constants between H-3, H-4 and H-5, as well as relatively high chemical shift value
of the C-3 signal (δ 76.9). The heteronuclear multiple bond correlations between H-1 and both C-3
and C-5 observed in the HMBC spectrum confirmed the pyranose ring size. The presence of the C*
variant (δH/δC 5.08/99.4 ppm) of residue C reflected the changes of chemical shifts induced by the
O-acetylation of the disaccharide repeating unit and indicated that two forms of the disaccharide
repeating units exist in the O-specific polysaccharide: the O-acetylated A-C* and non-O-acetylated B-C.
The minor anomeric signal (δH/δC 5.11/95.4 ppm, residue C’) and the corresponding spin system
observed at a lower contour level in the 2D spectra of the PSI showed chemical shift values similar to
the unsubstitited α-D-galactopyranose [33] and was attributed to a non-reducing terminal variant of
residue C, defining the biological repeating unit of the O-specific polysaccharide.
The NOESY and HMBC (Table 2, Figure 3) spectra showed inter-residue cross-peaks between the
transglycosidic protons, and between the anomeric protons and carbons at the linkage position as well
as carbons and the protons at the linkage position, respectively. The inter-residue NOEs were identified
between H-1 of residue A and H-3 of residue C* and between H-1 of residue C* and H-3 of residue A
for the O-acetylated RU as well as between H-1 of residue B and H-3 of residue C, and between H-1 of
residue C and H-3 of residue B for the non-acetylated form of the repeating unit.
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Table 2. Selected inter-residue NOE and 3JH,C-connectivities from the anomeric atoms of the O-antigen
unit of PS P. shigelloides strain CNCTC 78/89.
Residue
Atom H-1/C-1 Connectivities to Inter-Residue
(ppm) δC δH Atom/Residue
A →3)-β-D-Galf 2OAc-(1→ 5.32/107.1 76.7 3.95 C-3, H-3 of C*
B →3)-β-D-Galf -(1→ 5.20/109.4 76.9 3.93 C-3, H-3 of C
C →3)-α-D-Galp-(1→ 5.07/99.5 84.5 4.06 C-3, H-3 of B
C* →3)-α-D-Galp-(1→ 5.08/99.4 82.1 4.28 C-3, H-3 of A
The combined data indicated the disaccharide repeating unit of P. shigelloides 78/89 O-PS with the
following structure:
O-deacetylation of the O-polysaccharide rendered only signals for two anomeric protons of
residues B and C in the spectrum. Thus, the PSI NMR profile reverted to that of the D-galactan I,
and the NMR spectrum became identical to the HR-MAS NMR spectrum of K. pneumoniae Kp20 LPS
(Figure S5).
The O-acetylation of the O-specific polysaccharide in the PSI fraction was not complete. The degree
of the O-acetylation was determined by integration of the anomeric signal of the 2-O-Ac-Galf residue
(δH 5.32 ppm) in the 1H NMR spectrum of PSI relative to the resolved resonance of an anomeric
proton at 5.20 ppm (integral value of 1, corresponding to a single proton). The ratios of the integral
values have shown that ~32% of the repeating units were O-acetylated in the PSI, generating
the O-acetylation-related heterogeneity. This level of substitution was sufficient to disguise the
chemotype of pure D-galactan I. Interestingly, the NMR spectra also indicated that there was no
O-acetylation of the repeating units in the OSII fraction (Figure S2). As the isolation procedures can
cleave off or induce migration of the O-acetyl groups to neighboring positions we have also compared
volumetric integration values for the H-1/C-1 resonances in the HR-MAS HSQC-DEPT NMR spectra
in situ. The relative content of the O-acetyl groups was calculated as 29.9% in the isolated O-specific
polysaccharides, 29.4% in the isolated LPS and 25.7% in the LPS directly on bacterial cells.
2.4. Serological Analysis
Reactivities of the serotype O12-specific serum with the homologous P. shigelloides 78/89 and
K. pneumoniae Kp20 LPSs were investigated by immunoblotting, ELISA experiments and ELISA
inhibition assays. The silver stained SDS-PAGE of P. shigelloides strain 78/89 LPS showed both low and
high molecular mass LPS bands (Figure 4A). In the immunoblotting analysis (Figure 4B) the antiserum
against P. shigelloides O12 reacted vividly with the high molecular mass bands of the homologous
O-antigen of P. shigelloides 78/89.
We also observed a cross-reaction of the anti-P. shigelloides O12 serum with the high molecular
mass bands of K. pneumoniae Kp20 LPS. However, this reaction covered a broader range of the O-specific
chain length. In ELISA assay both lipopolysaccharides reacted with the serum specific for the serotype
O12, although the profiles differed (Figure 5).
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Figure 4. SDS-PAGE analysis and reactivities of P. shigelloides serotype O12-specific polyclonal
antibodies with LPSs of P. shigelloides 78/89 and K. pneumoniae Kp20 in immunoblotting. LPSs of
P. shigelloides 78/89 (Ps78) and K. pneumoniae Kp20 (Kp20) were analyzed by SDS-PAGE (1.25 μg/lane)
using 15% separating gel and visualized by silver staining method (A) or transblotted onto
nitrocellulose (B). Polyclonal antibodies specific for the O12 serotype were 200-fold diluted.
 
Figure 5. ELISA profiles of polyclonal antibodies specific for the P. shigelloides serotype O12 with LPSs
of P. shigelloides 78/89 (black line) and K. pneumoniae Kp20 (red line) as solid-phase antigens (10 μg/mL).
The depicted ELISA values are the means of four replicates.
This cross-reaction indicates the presence of antibodies that recognize the common structural
element—the non-O-acetylated disaccharide repeating unit segments in the O-antigens of P. shigelloides
78/89 and K. pneumoniae Kp20. To further assess the role of the O-acetylation in the recognition by
antibodies we used ELISA inhibition assay. The inhibitory effects of the O-deacetylated O-specific
polysaccharide of P. shigelloides strain 78/89 on the reactivity of the anti-P. shigelloides O12 serum
with LPS of P. shigelloides strain 78/89 and K. pneumoniae Kp20 were compared. The O-specific
polysaccharide devoid of the O-acetyl groups inhibited the reactions of the anti-P. shigelloides O12
antibodies with LPS of K. pneumoniae Kp20 to a maximal value of ~84% at the inhibitor concentration
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of 62.5 μg/mL, indicating the presence of antibodies specific for the epitopes different from the pure
D-galactan I. The reaction of anti-P. shigelloides O12 antibodies with LPS of P. shigelloides strain 78/89
was inhibited by the O-deacetylated O-PS to a maximal value of ~94% at the inhibitor concentration
of 250 μg/mL (Figure S6). Thus the combined data from ELISA and ELISA inhibition tests indicate
the presence of a pool of antibodies specific for the D-galactan I in the anti-P. shigelloides O12 serum,
but more importantly, the analysis suggests that the O-acetylation creates additional O-serotype-related
antigenic determinants within this O-antigen that are recognized by the O12-specific serum. However,
the exact contribution of the epitopes comprising the O-acetyl groups could not be determined as
neither the linear nor spatial distribution of the O-acetyls in the PSI was known.
3. Discussion
The O-acetylation of the O-antigens is typically investigated using the isolated O-specific
polysaccharides, obtained by mild acidic hydrolysis of the ketosidic linkage between the Kdo residue
of the heteropolysaccharide and lipid A. This isolation procedure may result in partial cleavage of
the O-acetyl groups and their migration to neighboring positions. Non-stoichiometric O-acetylation
of the O-specific polysaccharides, both native and introduced by the isolation methods, makes the
NMR spectra more complex, alters the signals of structure reporter groups for known chemotypes
and introduces new ones. Here we have presented HR-MAS NMR as a technique that allows for
a comparison of the degree of O-acetylation of the O-antigens at different stages of the isolation
procedure, as the changes in the HR-MAS NMR spectra provide immediate distinction of varying
structures [18]. This approach to the structural analysis of the O-antigens revealed that the mere
presence of the O-acetyl groups can mask the dominant chemotype. The structure of P. shigelloides
strain 78/89 LPS is unique among Plesiomonas strains. However, the pattern in the HR-MAS spectrum
of this LPS appeared similar to the HR-MAS profile of K. pneumoniae Kp20 LPS. The latter is
built of a disaccharide repeating unit →3)-β-D-Galf -(1→3)-α-D-Galp-(1→ which is identical to the
non-O-acetylated repeating unit variant of P. shigelloides strain 78/89 LPS.
The use of NMR spectroscopy, MALDI-TOF mass spectrometry, and immunochemical
analysis provided detailed structural data on the O-antigen of P. shigelloides strain 78/89 LPS.
The O-specific polysaccharide isolated from the LPS by conventional methods showed a
pattern typical for smooth-type enterobacterial lipopolysaccharide. The identified disaccharide
→3)-α-D-Galp-(1→3)-β-D-Galf 2OAc-(1→ unit exhibits O-acetylation-related heterogeneity and
constitutes a new chemotype among O-antigens of the P. shigelloides strains. As indicated by the
HR-MAS NMR analysis in situ and on the isolated LPS, the relative degree of the O-acetylation and
the position of the O-acetyl group was consistent throughout the different stages of the preparations
and analysis. The serological analysis confirmed that the strain represents serotype O12 [14]. Thus the
structure of P. shigelloides serotype O12 LPS has now been established.
We have also observed that the O-specific polysaccharide repeating units were nearly identical to
these of K. pneumoniae Kp20 LPS [34]. However, it is worth noting that their O-specific chain length
differed and that the O-antigen of P. shigelloides 78/89 showed higher-degree of polymerization, as
indicated by SDS-PAGE and immunoblotting analysis.
The shared structural element in the O-specific polysaccharide that occurs in those two strains
also explains the observed cross-reactivity with the antiserum specific for the O-antigen of P. shigelloides
O12. Since only 32% of β-D-Galf molecules in P. shigelloides 78/89 O-PS are O-acetylated, it is no
surprise that a pool of antibodies in the anti-P. shigelloides O12 serum recognizes the D-galactan I of
K.pneumoniae and the O-acetylation effects the cross-reactivity of the strains by creating an additional
epitope recognized by the O12-specific antibodies. The role of nonstoichiometric substitutions on
O antigenicity is commonly acknowledged. It is a well-known phenomenon among Salmonella and
Shigella as the introduction of acetyl or glucose can form new O-types [10].
The β-D-galactofuranosyl-(1→3)-D-galactopyranose known as D-galactan I [35] is present in the
LPS of the genus Klebsiella. This disaccharide is considered a valuable model for studies of biochemical
15
Int. J. Mol. Sci. 2017, 18, 2572
pathways for formation of the Galf -contaning glycans present in the bacterial cell wall complex
(extracellular glycocalyx) [36]. These glycans may play a critical role in the survival and pathogenicity
of microorganisms; therefore, their biosynthetic pathways could be attractive targets for drugs that
act by inhibiting cell wall biosynthesis [36]. P. shigelloides 78/89 expresses LPS with the modified
D-galactan I structure of the O-antigen.
Klebsiella and Plesiomonas are Gram-negative organisms that are frequently co-isolated from
intestinal infections. They are also isolated from different clinical specimens including respiratory tract.
Their common residence and a niche-specific selection may have contributed to the fact that the strains
share epitopes. The cross-reactivities of P. shigelloides O-antigens with antisera raised against some
strains of the genus Shigella have been previously reported [15,28]. These strains of Plesiomonas
and Shigella either had some common epitopes or structures of their O-antigens were identical.
The structural determinant →3)-α-D-Galp-(1→3)-β-D-Galf -(1→ described here for P. shigelloides 78/89
LPS is a part of the O1 antigen [35], which is the most clinically prevalent serotype of K. pneumoniae.
The type-specific cross-reactivities among non-closely related bacteria are a subject of special interest,
particularly in the case of antibiotic-resistant pathogens such as Klebsiella. Furthermore, it was reported
that K. pneumoniae strains that belong to O1 and O2 (termed D-galactan I) serogroups cause over 50%
of all Klebsiella infections worldwide [37].
Typically, O-serotypes of Klebsiella and Plesiomonas were classified using cross-absorbed sera,
indicating the differences among the epitopes recognized by polyclonal antibodies with no immediate
correlation to the chemotypes of their O-antigens.
The O-antigens are appealing targets for active and passive immunizations with a potential
for therapeutic applications. However, it is important to uncover subtle structural attributes of LPS
molecules that may have impact on the desired specificity of antibodies [38]. It is worth noting that all
such structural features could be identified using HR-MAS NMR data alone. The results of our study
demonstrate a potential application of the HR-MAS NMR technique for screening of the bacterial
O-antigen structures in situ, providing robust information on the chemotype of the O-antigens.
4. Materials and Methods
4.1. Bacteria
P. shigelloides strain CNCTC 78/89, classified as serovar O12:H12 according to Aldova’s antigenic
scheme [14], was obtained from the Institute of Hygiene and Epidemiology, Prague, Czech Republic.
The bacteria were grown on a Davies medium enriched with glucose for 24 h in 37 ◦C, killed with 0.5%
phenol, and harvested as described previously, yielding 6.48 g of freeze-dried bacteria. K. pneumoniae
strain 20 (Kp20, serogroup O2) is a bloodstream clinical isolate and was kindly provided by Szilvia
Melegh (Department of Medical Microbiology and Immunology, Medical School, University of Pecs,
Pecs, Hungary) [34]. Samples of freeze-dried bacteria and the isolated LPS used for the HR-MAS
analysis were generously supplied by Jolanta Lukasiewicz (Hirszfeld Institute of Immunology and
Experimental Therapy, Wroclaw, Poland).
4.2. Lipopolysaccharides and O-Specific Polysaccharide Fractions
LPS was isolated from bacterial cells by the hot phenol/water extraction [39] and purified by
ultracentrifugation [40]. Subsequently, O-specific polysaccharide was isolated by mild acid hydrolysis
(1.5% acetic acid containing 2% SDS at 100 ◦C for 15 min) of LPS (50 mg). SDS was removed by
extraction with 96% ethanol and the pellet was suspended in water and centrifuged. The supernatant
was fractionated by gel permeation chromatography, on Bio-Gel P-10 (1.6 × 100 cm) equilibrated with
0.05 M pyridine/acetic acid buffer, pH 5.6. The chromatography yielded a main fraction containing
O-specific polysaccharide (PSI, 7 mg), separated from shorter O-specific polysaccharide chains linked
to the core (OSII, <<1 mg) and two fractions containing unsubstituted core oligosaccharides (OSIII,
16
Int. J. Mol. Sci. 2017, 18, 2572
1.2 mg and OSIV, 5.4 mg). The eluates were monitored with a Knauer differential refractometer and all
fractions were checked by NMR spectroscopy MALDI-TOF mass spectrometry (MS).
4.3. Analytical Procedures
Monosaccharides were analyzed as their alditol acetates by GC-MS. Methylation was performed
on the isolated PS according to the method described by Hakomori [41]. Alditol acetates and partially
methylated alditol acetates were analyzed by GC-MS using an ITQ 700 (Thermo Scientific, Waltham,
MA, USA) system, equipped with a HP-1 fused-silica capillary column (0.2 mm × 12.5 m) and a
temperature gradient from 150 to 270 ◦C at 12 ◦C·min−1. The absolute configurations of the sugars
were determined as described by Gerwig et al. [42] using (−)-2-butanol for the formation of 2-butyl
glycosides. The trimethylsilylated butyl glycosides were then identified by comparison with authentic
samples on GC-MS.
4.4. O-Deacetylation of Polysaccharide
Polysaccharide (5 mg) was treated with aqueous 12.5% NH3 (1 mL) at room temperature for
16 h, after which the solution was diluted with water and freeze-dried. The product was analyzed by
NMR spectroscopy.
4.5. Partial Acid Hydrolysis
The polysaccharide (0.5 mg) was used for hydrolysis with 0.5 M trifluoroacetic acid (1 mL) at
80 ◦C. A sample (20 μL) was taken every 30 min for 2 h and the progress of hydrolysis was checked by
MALDI-TOF MS.
4.6. SDS-PAGE and Serological Analysis
The LPS was analyzed by SDS-PAGE according to the method of Laemmli with modifications [43].
The LPS bands were visualized by the silver staining method [44] and by immunoblot using
polyclonal rabbit antisera specific for the O-antigen of P. shigelloides O12 and for the OS of
P. shigelloides O33 in separate experiments. Immunoblotting was done as previously described [40].
An ELISA, using LPS as the solid-phase antigen, was performed by a modification [45] of the
method described by Voller et al. [46]. The detection systems consisted of a goat anti-rabbit
IgG conjugated with alkaline phosphatase (Bio-Rad, Richmond, CA, USA) as a second antibody
and 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium and p-nitrophenylphosphate for
immunoblotting and the ELISA test, respectively. ELISA inhibition test was performed as described
in [47]. Briefly, the serum (100 μL) at a concentration twice as high as the one giving E405nm value in
the range (0.8–2.2) was mixed with 100 μL of inhibitor solution (inhibitor concentration range from
250 μg/mL down to 0.49 μg/mL) and incubated for 1 h at 37 ◦C. The mixture (100 μL) was then
transferred to a microtiter plate with LPS, incubated for 15 min with shaking and followed by the
subsequent steps of standard ELISA protocol.
4.7. Mass Spectrometry
MALDI-TOF MS spectra of the PSI, the partially hydrolyzed PSI and the OS fractions were
acquired using Bruker Autoflex III (Bruker Daltonics, Bremen, Germany) time-of-flight instrument.
Spectra were recorded in positive and negative modes. 2,5-Dihydroxybenzoic acid was used as matrix.
4.8. NMR Spectroscopy
NMR spectra of bacteria (~4 mg dry mass) and LPS (~3 mg) suspensions in 2H2O (total volume of
~30 μL in the Bruker Kel-F inserts) were obtained using the HR-MAS technique on a Bruker Avance
III 600 MHz spectrometer (Bruker BioSpin, Rheinstetten, Germany). HR-MAS NMR experiments
were carried out at a spin rate of 4 kHz at 27 ◦C (the actual temperature of the bearing gas) using
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a Bruker 4 mm HR-MAS probe and a ZrO2 rotor, as previously described [48]. NMR spectra of the
isolated polysaccharide and oligosaccharides were recorded for 2H2O solutions at 30 ◦C on Bruker
Avance III 600 MHz spectrometer using a 5 mm inverse detection QCI cryoprobe and 1.7 mm TXI
microprobe. The polysaccharide and oligosaccharide fractions were repeatedly exchanged with 2H2O,
with intermediate lyophilization. The data were acquired and processed using Topspin 3.1 (Bruker
BioSpin, Rheinstetten, Germany). The processed spectra were assigned with the help of the SPARKY
program [49]. The signals were assigned by one- and two-dimensional experiments (COSY, TOCSY,
NOESY, HMBC, HSQC-DEPT, and HSQC-TOCSY). In the TOCSY experiments the mixing times used
were 30, 60, and 100 ms. The delay time in the HMBC experiment was 60 ms and the mixing time in
the NOESY experiment was 200 ms. Regions of interest (ROI) in the HR-MAS HSQC-DEPT spectra
were visualized using the rNMR program [50].
The relative content of the O-acetyl groups in the O-specific polysaccharides was determined
by integration of the relevant signals from their 1D 1H NMR spectra acquired with a 30◦ pulse and a
relaxation delay of 1 s. Volumetric integration of the selected resonances in the HSQC-DEPT spectra
was performed by the Gaussian fit method using built-in functions of the SPARKY program.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2572/s1.
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HR-MAS High-Resolution Magic Angle Spinning
NMR Nuclear Magnetic Resonance
COSY Correlation spectroscopy
TOCSY Total correlation spectroscopy
NOESY Nuclear Overhouser Effect spectroscopy
HSQC Heteronuclear Single Quantum Coherence
DEPT Distortionless Enhancement by polarization transfer
HMBC Heteronuclear Multiple Bond Correlation
GC Gas chromatography
MS Mass spectrometry
MALDI-TOF Matrix-assisted laser desorption ionization time-of-flight
SDS Sodium dodecyl sulfate
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1 Department of Microbiology, Institute of Genetics and Microbiology, University of Wrocław,
51-148 Wrocław, Poland; bartlomiej.dudek@uwr.edu.pl (B.D.); anna.kedziora@uwr.edu.pl (A.K.)
2 Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental
Therapy, Polish Academy of Sciences, 53-114 Wrocław, Poland; rybka@iitd.pan.wroc.pl (J.R.);
eva.krzyzewska@iitd.pan.wroc.pl (E.K.); wrybka@iitd.pan.wroc.pl (W.R.)
3 Regional Centre of Transfusion Medicine and Blood Bank, 50-345 Wrocław, Poland;
e.klausa@rckik.wroclaw.pl
* Correspondence: aleksandra.pawlak@uwr.edu.pl (A.P.); gabriela.bugla-ploskonska@uwr.edu.pl (G.B.-P.);
Tel.: +48-71-375-62-28 (A.P.); +48-71-375-63-23 (G.B.-P.)
Received: 7 August 2017; Accepted: 12 September 2017; Published: 21 September 2017
Abstract: Complement is one of the most important parts of the innate immune system. Some
bacteria can gain resistance against the bactericidal action of complement by decorating their outer
cell surface with lipopolysaccharides (LPSs) containing a very long O-antigen or with specific outer
membrane proteins. Additionally, the presence of sialic acid in the LPS molecules can provide a level
of protection for bacteria, likening them to human cells, a phenomenon known as molecular mimicry.
Salmonella O48, which contains sialic acid in the O-antigen, is the major cause of reptile-associated
salmonellosis, a worldwide public health problem. In this study, we tested the effect of prolonged
exposure to human serum on strains from Salmonella serogroup O48, specifically on the O-antigen
length. After multiple passages in serum, three out of four tested strains became resistant to serum
action. The gas-liquid chromatography/tandem mass spectrometry analysis showed that, for most
of the strains, the average length of the LPS O-antigen increased. Thus, we have discovered a link
between the resistance of bacterial cells to serum and the elongation of the LPS O-antigen.
Keywords: serum resistance; complement; Salmonella; lipopolysaccharide; sialic acid;
reptile-associated salmonellosis
1. Introduction
Complement, a component of blood serum of vertebrates, is one of the most important parts of
the immune system, playing a decisive role in the defense of the host against infections. Its activation
during infections can lead to sepsis [1,2]. Complement can be activated via the classical, alternative,
or lectin pathways. Because of the presence of complement and other parts of the immune system,
e.g., lysozymes, human serum is an extremely unfavorable environment for bacterial survival and
growth. However, several bacteria have established a number of strategies protecting them from
these conditions, one being the molecular mimicry phenomenon [3–5]. For instance, the LPSs of some
bacteria contain sialic acid (N-acetylneuraminic acid, NeuAc), which enables them to mimic human
cells and avoid the bactericidal action of serum [3–5]. Non-typhoidal Salmonella (NTS) organisms
pose a significant epidemiological problem all over the world [6–12]. Each year Salmonella rods are
the causative agents of 93.8 million cases of gastroenteritis worldwide, of which 155,000 are fatal [6].
According to the CDC (Center for Disease Control and Prevention) only 1–5% of Salmonella infections
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are laboratory confirmed and reported, so the real number of salmonellosis cases is much higher [13].
Salmonellosis is the most common illness among food-borne diseases, in some instances leading to
hospitalization and death [9–11,13,14]. NTS infections usually cause diarrhea, although they can also
lead to extra-intestinal infections, including bacteremia, sepsis, and in rare cases miscarriage [15–18].
Salmonellosis is a zoonotic infection; the animal sources of Salmonella rods are inter alia: birds, cattle,
pigs, horses, rodents, dogs, cats, reptiles, or amphibians [13,16,19], with reptiles being reported as
the most common source of Salmonella causing RAS (reptile-associated salmonellosis). Most reptiles
are asymptomatic carriers of Salmonella [17,20–22]. However, transmission of these bacteria from
reptiles to humans occurs frequently, sometimes leading to sepsis, affecting mainly children under
5 years of age, immunocompromised patients, and AIDS (acquired immune deficiency syndrome)
patients [13,16,17,20–22]. Recently, the term REPAS (reptile exotic pet-associated salmonellosis) was
proposed for these infections in the literature [20], to point out that the main source of salmonellosis in
humans are non-native reptiles, as the data show that the main carriers of Salmonella are reptiles kept
in captivity as pets, not wild ones [20,22]. RAS/REPAS cases lead more frequently to hospitalizations
than salmonellosis not connected to reptiles. There is an increasing trend in RAS/REPAS incidence,
especially among children under 3 years of age [20], which is probably connected with the current trend
for breeding reptiles in households [23–25]. A common causative agent of RAS/REPAS is Salmonella
from the O48 serogroup, containing sialic acid in the structure of lipopolysaccharides (LPSs) [26–28].
As mentioned before, the presence of NeuAc, a common constituent in outer structures of both higher
organisms and bacteria, can represent the molecular mimicry phenomenon, as it can protect bacterial
cells from the complement lytic action [3–5]. Sialic acid can also bind the complement factor H,
resulting in the inhibition of the alternative pathway activation [29]. LPS is a component of the outer
cell membrane, characteristic of most Gram-negative bacteria. LPS is built up of three main parts:
lipid A, the inner and outer core, and the O-specific polysaccharide chain. Lipid A, anchoring the
structure in the hydrophobic membrane, is linked to the non-repeating oligosaccharide core, while the
O-specific chain linked to the core oligosaccharide can contain up to 70–100 repeating oligosaccharide
units among different Salmonella strains. Each repeating unit is built up of two to eight monosaccharide
residues, e.g., mannose, rhamnose, galactose, or sialic acid [19,28,30]. The presence of terminal NeuAc
in the O-antigen units [28,31] renders the LPS structure similar to human glycosphingolipids and
enables it to take part in the molecular mimicry phenomenon. Due to its high structural variability,
the O-polysaccharide chain is used in serological classification as an O-antigenic determinant. The basic
function of the O-chain is the protection of bacteria from host immune response (especially the
alternative complement cascade and phagocytosis) [30,32]. A shortened O-specific chain of LPS is
a possible reason for its bacterial sensitivity to human serum [33–35]. In our previous study [19],
we demonstrated that various serovars of Salmonella O48 with the same structure of the O-specific
antigen differed in the number of repeating units (measured as the NeuAc/Kdo ratio). However,
the average length of the O-antigen did not correlate with bacterial cells’ susceptibility to human blood
serum action. In the present study, we concentrated on the role of sialic acid in bacterial resistance to
serum. Serum, as a challenging environment for bacterial growth, can enforce various modifications
in bacterial outer structures, which can build up the protection against complement activity. In this
study, we investigated whether prolonged contact of Salmonella O48 cells with human serum (multiple
passages) can lead to any changes in the average length of the LPS O-specific antigen, measured as the
NeuAc/Kdo ratio, and changes in bacteria susceptibility to human blood serum.
2. Results
2.1. The C3 Concentration in Serum
The level of C3 in the human serum used in this study was 1240 mg/L. This result is within the
normal range for males (970–1576 mg/L) and females (1032–1495 mg/L) (Human Complement C3 & C4:
“Nl” BindaridTM Radial Immunodiffusion Kit; The Binding site Group Ltd., Birmingham, UK).
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2.2. Passages of Bacteria in NHS (Normal Human Serum)
The strains used in the following experiments were previously tested for their initial length
of the LPS O-specific antigen [19]. All chosen strains were initially sensitive to 50% human serum
action (which was confirmed three times) and differed substantially in the O-antigen average length:
S. Hammonia with the highest NeuAc/Kdo ratio of 256%, S. Erlangen and S. Bongori with an
intermediate ratio (87% and 41%, respectively), and S. Isaszeg with the lowest NeuAc/Kdo ratio (at the
detection limit). These results were precisely described in our previous study [19]. Here, we found that
the susceptibility of the tested strains (S. Erlangen, S. Isaszeg, S. Hammonia, and S. Bongori) to normal
human serum (NHS) action changed during the passages in NHS (Figure 1, Table 1). At the start
of the experiments, all tested strains were sensitive to bactericidal action of 50% NHS. The survival
after 3 h (T3) of incubation in serum was 0.001% for S. Erlangen, 0.04% for S. Isaszeg, ≤0.00009%
for S. Bongori, and 0.06% for S. Hammonia. During the passages, three tested strains (S. Erlangen,
S. Isaszeg, and S. Hammonia) showed a tendency to a biphasic process, shown in Figure 1. They
significantly increased the survival percentage, twice during nine passages. After prolonged contact
of bacterial cells with serum (nine passages in serum), three out of four tested strains (S. Erlangen,
S. Isaszeg, S. Hammonia) became resistant to serum. After nine passages in serum, the percentage
survival of S. Erlangen, S. Isaszeg, and S. Hammonia cells was 200%, 183.78%, and 491.80%, respectively.
S. Bongori was still not considered as resistant to serum after nine passages, although its survival after
prolonged contact with NHS increased substantially up to 20,000 times (from ≤0.00009 in the first
passage to 1.80% in the ninth passage). All tested strains incubated for 3 h in NHS or heated at 56 ◦C
for 30 min (control) proliferated very intensively (Table 2), as the heating removed the bactericidal
activity of the serum. Bacterial cells of all tested strains obtained after the ninth passage in NHS were
transferred into fresh LB (lysogeny broth) medium with glycerol and frozen in −70 ◦C. After three
months, all frozen strains were re-examined and their susceptibility to bactericidal activity of 50% NHS
(survival percent) was compared to results obtained after passage 9. The results indicated that all tested
strains (S. Erlangen, S. Isaszeg, S. Hammonia, and S. Bongori) generally maintained the resistance
achieved by prolonged contact with serum. The survival of bacterial cells after 3 h of incubation with
serum was higher than 100% for S. Erlangen (643.68%), for S. Isaszeg (112.77%), and S. Hammonia
(733.33%), while for S. Bongori the resistance remained weak (0.05%). Serum heated at 56 ◦C for 30 min
was used as a control. In these conditions, all tested strains proliferated intensively (Table 2).
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Figure 1. Survival percent of Salmonella O48 strains during nine passages in 50% NHS (normal
human serum).
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2.3. SDS-PAGE (SDS-Polyacrylamide Gel Electrophoresis) of LPS
As the next step, the SDS-PAGE analysis of LPS isolated from bacterial cells before the passages
and after ninth passage in 50% NHS (normal human serum) was performed. The results showed that
LPS isolated from all tested strains produced very long O-antigen (VL-OAg: more than 100 O-specific
units in the O-chain; Figure 2). Such behavior is described in the literature as a factor influencing
bacterial resistance to human serum [35,36]. Moreover, the comparison of the LPS profile of Salmonella
O48 before passages in 50% NHS (BP) and after the ninth passage (AP) shows distinct differences in the
quantitative proportions between the short and long O-antigen regions. In the case of S. Hammonia,
there was a distinct increase in the LPS of medium length (L-OAg LPS).
Figure 2. Lipopolysaccharide (LPS) profiles of four Salmonella O48 strains before (BP) and after (AP)
nine passages in 50% normal human serum. VL-OAg: very long O-antigen; L-OAg: long O-antigen;
LMW-OAg: low molecular weight O-antigen.
2.4. GLC-MS/MS (Gas Liquid Chromatography-Mass Spectrometry) Analysis
In the lipopolysaccharide molecule of O48 serotype, the number of Kdo
(3-Deoxy-D-manno-octulosonic acid) residues is constant, while the number of repeating units in
the O-antigen changes. Since each repeating unit of the O-antigen possesses one NeuAc (sialic acid)
residue, the elongation of the O-antigen is directly linked to the increase in NeuAc content in the
molecule. Therefore, we assume that NeuAc/Kdo proportions provide important information about
the average length of the O-specific chain in the tested samples of bacteria. In our previous study,
we analyzed the NeuAc/Kdo ratio in bacterial cells in minimal Falcov’ medium using GLC-MS [19].
In the present study, we used a more sensitive GLC-MS/MS method; therefore, we could measure
the NeuAc/Kdo ratio before and after passages in NHS in single bacterial colonies on agar plates
(Figures 3 and 4). Each time, the amount of NeuAc was compared with the amount of Kdo in
bacterial cells. The results showed that for all tested strains, the average length of the LPS O-antigen
(measured as the NeuAc/Kdo ratio) increased after the passages of bacterial cells in 50% NHS,
with relatively high variability of the LPS O-antigen length among colonies from the same strain
(Figure 4). This indicates that results usually obtained for samples of bacterial cells mass are only an
average of single cells values, which differ substantially.
27
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Figure 3. S. Erlangen results of analysis of two single colonies as an example showing high and
low NeuAc (sialic acid)/Kdo (3-Deoxy-D-manno-octulosonic acid) ratio: colony 3 (black, dashed
line) and colony 4 (red, dotted line) differing in NeuAc/Kdo ratio, superimposed for better view.
MS/MS simultaneous analysis of Kdo (marker ion of m/z = 195), NeuAc (ion of m/z = 386),
and perseitol (ion of m/z = 128) as an internal standard (IS).
 
Figure 4. Results of GLC-MS/MS (Gas Liquid Chromatography-Mass Spectrometry) analysis of
NeuAc/Kdo content (%) in Salmonella O48 strains measured in single randomly selected colonies on
agar plates (averaged results; n = 5).
3. Discussion
Salmonella O48 are rare but very dangerous bacteria, especially for children under 5 years of age
and immunocompromised patients. Gastroenteritis or sepsis caused by these strains is mainly related
to contact with reptiles [13,24–27]. Complement plays a very important role in protecting the host
from sepsis caused by pathogens, especially Gram-negative bacteria [2]. Passaging bacteria in NHS is
a model of interaction between the host and pathogenic organism. Bacterial resistance to complement
proteins is not yet fully explained. As some authors described a potential role of LPS in the serum
resistance phenomenon [32,34,35], we tested whether changes in the LPS O-chain length can be a way
of adaptation and resistance generation by Salmonella O48.
In our previous study [19], we did not find a clear correlation between the LPS O-antigen
length (NeuAc/Kdo ratio) and the resistance of Salmonella O48 to bactericidal action of serum.
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Among the strains that were sensitive to serum action, we found both strains with long and short
O-antigen. From that group of sensitive strains, we selected four strains of Salmonella O48 which
varied substantially in the LPS O-antigen length for the experiments described in the present work.
Here, we show that prolonged contact of bacteria with NHS results in the extension of the average
LPS O-chain length, and that a very long O-antigen (VL-OAg) might protect bacteria from NHS action.
The research results of Murray et al. [37,38] and Bravo et al. [35] showed that VL-OAg provides serum
resistance of S. Typhimurium. Crawford et al. [39] proved the key role of VL-OAg in Salmonella
Typhimurium resistance to bile. The O-antigen length is under the control of the wzz gene. wzz is under
the control of OMPs (outer membrane proteins): OMP FepE controls VL-OAg production, and OMP
Wzz controls L-OAg production [35]. However, it is still unclear as to what extent the genes and/or
the environment are involved in this process. It is possible that both changes in the LPS length and the
OMPs arrangement in OM (outer membrane) are responsible for bacterial adaptation and survival in
the presence of serum proteins. Our experiments also include an analysis of Salmonella Enteritidis OMP
changes in the serum resistance phenomenon. The results are described in our previous works [40–42].
Considering these results as well as those of our present findings, we suggest that it is possible that both
long LPSs and certain OMPs (e.g., PgtE in S. Enteritidis) together provide resistance to the bactericidal
action of serum. Apart from the serum, there are other environmental factors influencing the length of
the LPS O-chain, e.g., growth temperature, lower amount of Mg2+ and Fe3+ in the environment, or the
growth phase of bacterial cells [35]. In our study, single colonies of the same strain from one agar plate
differed in the NeuAc/Kdo ratio. As Bravo et al. [35] showed that the longest O-chain is produced
at the late exponential and stationary phase of growth, we suppose that this difference may be due
to the growth phase or, alternatively, it can reflect the innate variability of the strains. Our results of
the NeuAc/Kdo ratio in bacterial colonies show the average length of LPS, however, the variation of
the O-antigen length between particular colonies of one strain is relatively high. One of the tested
strains (S. Bongori) did not become resistant to serum after nine passages (survival rate of bacterial
cells in T3 < 100%), although its susceptibility substantially changed. Before the passages, the strain
was much more sensitive to serum than other tested Salmonella O48 serovars. During the passages,
S. Bongori became more than four-fold more resistant to serum compared to before the passages.
Also, the average length of the O-chain of this strain increased (Figure 4), suggesting a role of LPSs in
bacterial adaptation to harsh environments.
4. Materials and Methods
4.1. Bacterial Strains and Growth Conditions
The study was carried out on four strains of Salmonella O48 serogroup: Salmonella bongori from
serovar Bongori and Salmonella enterica from serovars: Erlangen, Isaszeg, and Hammonia. The strains
were obtained from Polish Collection of Microorganisms (PCM), Hirszfeld Institute of Immunology
and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland. The list of the tested strains,
showing their origin and antigenic characteristics, is presented in Table 3.
Table 3. The origin and antigenic characteristics of the Salmonella O48 strains used in this study.
Species Subspecies Serovar Somatic (O) Antigen Source
Salmonella bongori - Bongori 48 PCM * 2547
Salmonella enterica enterica Isaszeg 48 PCM * 2550
Salmonella enterica salamae Erlangen 48 PCM * 2533
Salmonella enterica salamae Hammonia 48 PCM * 2535
* PCM—Polish Collection of Microorganisms, Hirszfeld Institute of Immunology and Experimental Therapy, Polish
Academy of Sciences, Wroclaw, Poland.
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4.2. Media
For the bactericidal assay of human serum and LPS extraction, bacterial cells were grown in
liquid medium (YP yeast extract-peptone broth: bactopeptone (Difco), yeast extract (Difco) and NaCl
(POCh, Gliwice, Poland), pH 7.0) at 37 ◦C for 18 h in a water bath with shaking. For GLC-MS/MS
analysis, the bacteria were grown in minimal Falcov’ medium (K2HPO4, KH2PO4, MgSO4, (NH4)2SO4,
glucose and NaCl, (all POCh, Gliwice, Poland)) and on nutrient agar plates (BIOCORP, Warszawa,
Poland). For bacteria storage in −70 ◦C, LB medium with 50% glycerol (POCh, Gliwice, Poland)
was used.
4.3. Sera
Normal human serum (NHS) was obtained from the Regional Center of Transfusion Medicine
and Blood Bank, Wroclaw, Poland (120 donors) and was approved by the authors’ institutional review
board (Elżbieta Klausa, DG-G/2739/11, 18.05.2011). This was conducted according to the principles
expressed in the Law on the public service of blood of 20 May 2016 and in the Directive 2002/98/EC
of the European Parliament and of the Council of 27 January 2003, establishing standards of quality
and safety for the collection, testing, processing, storage, and distribution of human blood and blood
components. Blood samples were collected into sterile tubes with clot activator and gel for serum
separation. The samples were then stored at room temperature (RT) for 30 min. After that, the samples
were centrifuged for 5 min at 3000 rpm. Only the serum samples without hemolysis and lipemia
were used for experiments. The C3 concentration in the mixed serum was quantified by radial
immunodiffusion (Human Complement C3 & C4 “Nl” BindaridTM Radial Immunodiffusion Kit;
The Binding site Group Ltd., Birmingham, UK). The collected serum was frozen in 0.5-mL aliquots at
−70 ◦C for no longer than six months. The required volume of serum was thawed immediately before
each passage and each portion was used only once.
4.4. Bactericidal Assay of NHS
The bactericidal action of NHS against the tested strains was determined as described
previously [19,29] with slight modification. Bacterial cells were grown for 18 h in 5.0 mL of YP
medium with shaking. Then 0.05 mL of the overnight bacterial culture was transferred to 3.0 mL of
fresh YP medium and incubated at 37 ◦C for 1 h in water bath with shaking. Next, bacterial cells
were centrifuged (4000 rpm for 20 min at 4 ◦C) and the pellet was suspended in physiological saline
(0.9% NaCl). Then, 1.0 mL of the suspension was transferred into 5.0 mL of physiological saline and,
after shaking, 0.5 mL of the resulting suspension was mixed with 0.5 mL of freshly thawed NHS.
The purpose of such preparation was to obtain an early log-phase culture of bacteria mixed with serum
and the initial colony forming units in 1.0 mL of medium was 106 CFU/mL (colony-forming units in
milliliter), which was verified each time. Bacterial cells mixed with serum were incubated in water
bath with shaking at 37 ◦C for 3 h. The cells were collected after 0 (T0) and 3 h (T3). The collected
samples were diluted and cultured on nutrient agar plates at 37 ◦C for 18 h. After 18 h of incubation,
the average number of colonies was estimated from agar plates, then the CFU/mL was calculated and
the value of CFU/mL at T0 was taken as 100% of bacterial cells’ survival. According to this value,
the survival percent of bacterial cells in T3 was estimated. When the survival percent of bacterial
cells in T3 was >100%, the cells were considered resistant, and those with survival rates <100% were
considered susceptible to 50% NHS bactericidal action. NHS decomplemented by heating at 56 ◦C for
30 min was used as a control (Table 2).
4.5. Passages of Bacterial Cells in NHS
Passages of bacterial cells in 50% NHS were based on the method of bactericidal action of
NHS described above. Every single passage was considered as an independent experiment on the
bactericidal action of serum. Each tested strain was passaged in serum nine times. The number of
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passages was estimated in our previous study [43] as sufficient for changing bacterial susceptibility
to NHS. The first passage was the first contact of the cells with complement. After conducting the
first passage, 10 randomly chosen bacterial colonies obtained on agar plates from T3 were used to
prepare the bacterial culture for passage 2. Those colonies were transferred into another 5 mL of fresh
YP medium, and then the experiment was carried out as described for the method of bactericidal
assay of NHS. The usage of fresh medium was necessary, as the NHS selective pressure was so high
that after 3 h of incubation of Salmonella with NHS the survival ratio of the cells was too low to
continue the experiment using NHS. That is why the cells from T3 were grown in medium without
selective pressure, and they were again prepared to obtain 106 CFU/mL and transferred back to NHS.
Serial passages of bacterial cells in 50% NHS were performed nine times, each time using colonies
obtained on agar plates from T3 in the previous passage. The control was a parallel test using medium
containing the same composition, however NHS was decomplemented by heating, as described above,
to remove the selective pressure. Bacterial cells from passage 9 were transferred into fresh LB medium
with glycerol and frozen in −70 ◦C for further analysis.
4.6. Isolation of Lipopolysaccharides and Analysis by SDS-PAGE (SDS-Polyacrylamide Gel Electrophoresis)
Lipopolysaccharides were extracted from all of the tested Salmonella O48 strains before the
passages and after ninth passage in 50% NHS. The extraction was done using a commercial RNA
isolating reagent according to Yi and Hackett [44]. Briefly, 10 mg of lyophilized bacterial cells were
suspended in 200 μL of Tri-Reagent (Sigma-Aldrich, St. Louis, MO, USA). The cell suspension was
then incubated at room temperature for 10 min for complete cell homogenization. After incubation,
200 μL of chloroform was added to create a phase separation. The mixture was than vigorously
vortexed and incubated at room temperature for an additional 10 min. The resulting mixture was
centrifuged at 14,000 rpm (Minispin Plus, Eppendorf, Hamburg, Germany) for 10 min to separate
the aqueous and organic phase. The aqueous phase was transferred to a new 1.5-mL centrifuge tube.
Distilled water (100 μL) was added to the organic phase. The mixture was vortexed, incubated at room
temperature for 10 min, and centrifuged at 14,000 rpm for 10 min. The upper aqueous phases from
both steps were combined. The water extraction steps were repeated twice. The combined aqueous
phase was lyophilized. After lyophilization, we used the cold magnesium precipitation procedure
according to Darveau and Hancock for the purification of LPS [45]. LPS was dissolved in 500 μL of
0.375 M magnesium chloride (POCh) in 95% ethanol, stored at −20 ◦C, followed by centrifugation at
14,000 rpm for 15 min. The pellet was suspended in 200 μL of distilled water and lyophilized.
LPS extracts were analyzed by discontinuous SDS-PAGE using a Laemmli buffer system [46].
Samples were applied to the slabs after mixing with Laemmli buffer (composed of 10 mM Tris-HCL,
glycerol, SDS, bromophenol blue) and heating at 98 ◦C for 7 min. Gel electrophoresis was performed
using 6% polyacrylamide stacking gel and 15% separating gel. The SDS-PAGE separation of LPS was
performed at a constant voltage (120 V), for 90 min using a Mini-Protean Tetra Cell apparatus (Bio-Rad,
Hercules, CA, USA). The separated LPS was visualized using silver staining according to Tsai and
Frasch [47] with Fomsgaard [48] and our own slight modifications [40]. The gels containing separated
LPS were photographed using a GelDoc XR imaging system (Bio-Rad, Hercules, CA, USA) under
white light.
4.7. Preparation of Samples for GLC-MS/MS Analysis
For the analysis of NeuAc content, a sample of bacteria was placed in a screw-capped tube
and an internal standard (10 μg of perseitol (Koch-Light Laboratories Ltd., Suffolk, UK)) was added.
The lyophilized sample was methanolized with 2 M HCl in CH3OH (Sigma-Aldrich, St. Louis, MO,
USA) for 1 h at 80 ◦C, evaporated with a stream of N2 at 40 ◦C, and acetylated with 100 μL of acetic
anhydride (Sigma-Aldrich) and 20 μL of pyridine (Sigma-Aldrich, St. Louis, MO, USA) at 80 ◦C for
30 min. After acetylation, the sample was dried with N2, dissolved in 100 μL of ethyl acetate (POCh,
Gliwice, Poland), and 1 μL was taken for GLC-MS/MS analysis.
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4.8. GLC-MS/MS Analysis
Samples were analyzed by the GLC-MS/MS system: Thermo FOCUS GC with ITQ 700 ion trap
detector with external ionization, equipped with Rxi-5 ms column: 30 m, 0.25 mm ID (Restek, Bellefonte,
PA, USA). In the GC method, the ion source temperature was set at 250 ◦C with automatic ionization
energy. Then, 1 μL of the sample was injected with split injection (split = 10). The MS/MS analysis
of peracetylated methyl ester of NeuAc methyl glycoside was performed with an ion of m/z 446 as
a primary ion, which was isolated and fragmented. The secondary fragment of m/z 386 was used
for the quantitation of NeuAc derivative in the sample. Kdo analysis was performed as described
previously [49]. Soon after that, a primary ion of m/z 375 was isolated from the mass spectrum of
peracetylated methyl ester ethyl glycoside of Kdo and fragmented; a secondary ion of m/z 195 was
used for the quantitation of Kdo.
4.9. Standard Curve for NeuAc Determination by GLC-MS/MS Method
NeuAc standard (1, 3, 10, 30, 100, and 300 μg/mL) with perseitol as an internal standard (1000 ng)
were methanolized (2 M HCl/CH3OH, 80 ◦C, 1 h), dried with a stream of N2, and acetylated with
200 μL acetic anhydride and 20 μL pyridine at 80 ◦C for 30 min. Samples were dissolved in 100 μL of
ethyl acetate for GLC-MSMS analysis.
In our previous study [19], we performed GLC-MS/MS analysis of the NeuAc/Kdo ratio in
bacterial Salmonella O48 cells in minimal Falcov’ medium. In this study, we decided to increase the
spectrum of research. We measured the NeuAc/Kdo ratio before and after passages in NHS in bacterial
cells grown in minimal Falcov’ medium, and single bacterial colonies taken from agar plates.
5. Conclusions
Our study shows that prolonged contact of Salmonella cells with serum results in the adaptation of
the bacteria to adverse environmental conditions. The resistance of Salmonella O48 to the bactericidal
action of the serum has a multifactorial basis. However, our results show that LPS O-chain elongation
plays a significant role in this phenomenon. Present findings constitute a significant basis for the
huge field of exploration, that will involve more detailed studies on the possible changes in the length
and structure of LPS upon challenging bacteria with complement proteins (especially the acetylation
pattern of the resulting lipopolysaccharide molecule).
In our opinion, the results clearly show that multiple passages of bacteria in human serum lead to
the resistance of the cells to the serum. There is a very significant change in the LPS O-chain length
between cells before and after multiple passages in serum. That is why we deduced that the elongation
of LPS protects bacteria from the bactericidal action of serum. We did not show the exact mechanism
of how this elongation protects bacteria from serum action; however, we can presume that either the
increased amount of sialic acid causes the molecular mimicry phenomenon or the VL-OAg creates a
barrier around the cell, so the complement proteins cannot reach the cell surface. An explanation of
this process is our team’s goal for the next investigation.
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Zmiany w ilości kwasu sjalowego w lipopolisacharydach pałeczek Salmonella O48 po pasażach w surowicy
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Abstract: Bordetella holmesii can cause invasive infections but can also be isolated from the
respiratory tract of patients with whooping-cough like symptoms. For the first time, we describe
the lipid A structure of B. holmesii reference strain ATCC 51541 (alias NCTC12912 or CIP104394)
and those of three French B. holmesii clinical isolates originating from blood (Bho1) or from
respiratory samples (FR4020 and FR4101). They were investigated using chemical analyses, gas
chromatography–mass spectrometry (GC–MS), and matrix-assisted laser desorption ionization–mass
spectrometry (MALDI–MS). The analyses revealed a common bisphosphorylated β-(1→6)-linked
D-glucosamine disaccharide with hydroxytetradecanoic acid in amide linkages. Similar to B. avium,
B. hinzii and B. trematum lipids A, the hydroxytetradecanoic acid at the C-2′ position are carrying in
secondary linkage a 2-hydroxytetradecanoic acid residue resulting of post-traductional biosynthesis
modifications. The three clinical isolates displayed characteristic structural traits compared to
the ATCC 51541 reference strain: the lipid A phosphate groups are more or less modified with
glucosamine in the isolates and reference strain, but the presence of 10:0(3-OH) is only observed
in the isolates. This trait was only described in B. pertussis and B. parapertussis strains, as well as in
B. petrii isolates by the past. The genetic bases for most of the key structural elements of lipid A were
analyzed and supported the structural data.
Keywords: Bordetellae; Bordetella holmesii; endotoxin; lipid A; structure; mass spectrometry; genomic
1. Introduction
The Bordetella genus contains at the moment a dozen species, of which at least five are responsible
for respiratory diseases in humans and/or animals. Classical Bordetellae consist of Bordetella pertussis,
a strict human pathogen responsible for whooping cough; B. parapertussis responsible for mild
whooping-cough symptoms in humans, also described as a sheep pathogen; and B. bronchiseptica,
able to infect a broad range of hosts. The Bordetellae virulence factors include toxins—such as
Int. J. Mol. Sci. 2017, 18, 1080; doi:10.3390/ijms18051080 www.mdpi.com/journal/ijms36
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pertussis toxin for B. pertussis only, adenylate cyclase-hemolysin, and lipopolysaccharide (LPS)—and
adhesins—such as filamentous hemagglutinin, fimbriae and pertactin—, all involved in the binding to
ciliated epithelial cells in the host upper respiratory tract. B. bronchiseptica and B. pertussis endotoxins
LPS have been shown to be implicated in virulence [1–4]; therefore, it is important to compare the
structures of Bordetella LPSs purified from other Bordetella pathogenic species and, particularly, from
the recent B. pertussis relative B. holmesii [5].
B. holmesii was first described in 1995 following its isolation from the blood of a patient
with septicemia [6]. At that time, this bacterium was only originating from invasive infections in
immunocompromised patients. In the past years, increasing reports of the presence of B. holmesii in
the respiratory tract of patients with pertussis-like symptoms have been published [7–13]. However,
it is not known whether this bacterium is an opportunistic or a pathogenic one, able to induce
pertussis-like symptoms in humans [14–16].
For the moment, it is not possible to differentiate B. holmesii isolates recovered from blood from
isolates recovered from respiratory samples [17–19]. About 21 genomes of B. holmesii are available
on The National Center for Biotechnology Information (NCBI) [20]. First considered as close to
B. pertussis on the basis of 16S DNA analysis, B. holmesii is now described in the same clade as
B. hinzii, B. avium and B. trematum on the basis of whole genome single nucleotide polymorphism
(SNP)-based analysis [21]. Most virulence factors usually produced by the classical Bordetella seem to
be missing in B. holmesii except a Bordetella master virulence regulatory system (bvg), a filamentous
hemagglutinin (FHA)-like protein, a bvg-intermediate phaseA protein (bipA) ortholog, and an alcaligin
operon [19,22–25]. B. holmesii LPS have only been roughly studied by Van den Akker in 1998 who
found them phenotypically and immunologically distinct from those of B. pertussis [26].
We report here the detailed lipid A structures of three B. holmesii isolates, as compared to those of
the B. holmesii reference strain ATCC 51541.
2. Results
2.1. Fatty Acids Composition
Total fatty acid analyses performed by gas chromatography—mass spectrometry (GC–MS)
revealed the presence of 3-hydroxytetradecanoic acid [14:0(3-OH)], 2-hydroxytetradecanoic acid
14:0(2-OH), 2-hydroxydodecanoic acid 12:0(2-OH), and 3-hydroxydecanoic acid 10:0(3-OH) as well as
traces of tetradecanoic acid 14:0 and dodecanoic acid 12:0 in lipids A extracted from all tested strains
and isolates. They were found to be present in the relative corresponding proportions: 2.8:1:1:0.5 for
ATCC51541, Bh01, and FR 4020 differing from the FR 4101 isolate having the following proportions of
2:1:1:1.2.
2.2. Matrix-Assisted Laser Desorption Ionization–Mass Spectrometry Structural Analyses
2.2.1. Interpretation of the Main Molecular Species in the Different Lipid a Spectra
The negative-ion spectrum of the di-phosphoryl ATCC 51541 reference strain lipid A was
heterogeneous, containing two main molecular ion signals at m/z 1376.9 and 1603.7 as illustrated
in Figure 1A. Composition of the corresponding molecular species were attributed on the basis
of the overall chemical composition: m/z 1603.7 would correspond to two glucosamine (GlcN),
two phosphates, three 14:0(3-OH), one 14:0(2-OH), and one 12:0(2-OH); and m/z 1376.9 corresponds to
m/z 1603.7 minus one 14:0(3-OH). A molecular species corresponding to m/z 1404.9 can be explained
by some microheterogeneity at the level of the 12:0(2-OH) fatty acid versus the 14:0(2-OH). The same
difference was observed between molecular species at m/z 1575.4 and 1603.7. Each of the molecular
species presented a twin species at −16, expressing the previously described heterogeneity and
peculiarity of the Bordetella genus, the reduced enzymes specificity at different positions carrying,
in some species, 2-hydroxylated fatty acids in secondary linkage [1,27–29]. The latter being known
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as a late structural modification of the structure occurring in the membrane and leading to increased
robustness of the bacterial outer membrane barrier [30].
Figure 1. Negative-ion spectrum of lipid A from Bordetella holmesii strains and isolates: (A) ATCC
51541 reference strain; (B) Bho1 isolate; (C) FR4101 isolate; and (D) FR4020 isolate. FA: Fatty acid;
GlcN: Glucosamine.
2.2.2. Distribution of the Fatty Acids on the D-Glucosamine Residues of the Clinical Isolates
The negative-ion mode matrix-assisted laser desorption ionization (MALDI) mass spectra of
lipids A isolated from the three B. holmesii isolates displayed three major peaks at m/z 1603, 1546 and
1376 (Figure 1B–D). The first and third peaks were identical to those found in ATCC 51541 lipid A
and corresponded, as explained for the reference strain, to penta- and tetra-acylated lipid A molecular
species, respectively. For isolate FR4101, the ion at m/z 1546, absent in the ATCC strain spectrum,
corresponded to the molecular species at m/z 1376 carrying an additional 10:0(3-OH) (170 units).
The peaks mentioned above were surrounded by smaller ones at −16 u, such as those at
m/z 1587, 1360 and 1531. These peaks in which the 16-u difference represented hydroxyl modifications,
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were attributed to the same structures whose secondary fatty acids linked at C-2 and C-2′, 12:0(2-OH) or
14:0(2-OH) were non-hydroxylated (14:0 or 12:0, respectively). This modification was not observed in
the FR4020 lipid A mass spectrum and might be a specific trait of this isolate, with biosynthetic
relevance. In addition, another type of micro-heterogeneity, regarding the length of fatty acids,
was observed in the first major peaks (at m/z 1603 in Figure 1A,B,D, at m/z 1376 in Figure 1A–D and
at m/z 1546 in Figure 1C) that were also doubled by minor ones at −28 u or +28 u, i.e., at m/z 1575,
1349 and 1405. The mass difference of 28 u was attributed to 2 × CH2, and related peaks were not
found systematically in the three B. holmesii lipid A mass spectra. Of note, in the Bho1 lipid A mass
spectrum, this type of heterogeneity was only observed at plus 28 u from the major peak, at m/z 1376.
In the high-mass molecular ions region, two minor peaks were observed at m/z 1773 and 1764 in Bho1
(with a really minor contribution for this isolate) and FR4020 lipid A mass spectra and, at m/z 1717 and
1708 in FR4101 mass spectrum. The peak at m/z 1773, as well as the one at m/z 1717, corresponded to
10:0 (3-OH) (170 u), resulting in a hexa-acyl lipid A molecular species in Bho1 and FR4020, and FR4101,
respectively. Interestingly, the mass difference between peaks at m/z 1764 and 1708 and penta-acyl
lipid A molecular species at m/z 1603 and 1546.9, corresponded to 161 units for GlcN. Moreover, other
two small peaks (m/z 1925 and 1869) in FR4020 and FR4101 lipid A mass spectra gave the same mass
difference with m/z 1764 and 1708, suggesting that these lipid A molecular species were carrying
2 GlcN, one at each phosphate groups. This modification is described here for the fifth time in lipid A
species of the Bordetella genus [27,31–34]. Analogous to the FR4020 mass spectrum with the exception
of peaks related to GlcN addition at m/z 1538, 1869 and 1925 (Figure 2) the mass spectrum for lipid
A from Bho1 displayed the same peaks as FR4020 mass spectrum. This indicates that both isolates
might have similar lipid A structures with the exception that Bho1 lipid A phosphate groups displayed
a lower amount of GlcN. The reference ATCC strain also showed a peak corresponding to a very
small amount of GlcN, but its presence was confirmed by statistical experiments allowing to obtain
persistent and slightly increased signals at this level.
2.2.3. Distribution of the Fatty Acids on the D-Glucosamine Residues of the Isolates and the
Reference Strain
The reference strain ATCC 51541 lipid A positive-ion MALDI mass spectrum presented in
Figure 3 gave peaks in the lower field at m/z 920.6 and 904.6. The peak at m/z 920.6 was interpreted
to correspond to an ion containing one GlcN, one phosphate, three hydroxytetradecanoic acid
residues—two 14:0(3-OH) and one 14:0(2-OH)—, the second at m/z 904.6. From this fragmentation
pattern, we concluded that these signals corresponded to the GlcN II (non-reducing) part of the lipids
A and that the 14:0(2-OH) acid was linked at C-2′ in secondary acylation. The presence of the two peaks
differing by 16 u illustrates the incomplete hydroxylation at position 2 of the 14:0 branched fatty acid.
The positive-ion MALDI mass spectra of Bho1 and FR4020 isolates also displayed a prominent
fragment peak at m/z 920.6 whereas the major peak was at m/z 864.4 in the FR4101 mass spectrum.
The first peak is attributed to a lipid A fragment that contained, according to the fragmentation
pattern [35], the distal glucosamine (GlcN II) + one phosphate + three 14:0(OH): (two 14:0(3-OH) +
one 14:0(2-OH) in secondary position). This confirms that 14:0(2-OH) was the acyloxyacyl linked at
C-2′ and consequently 12:0(2-OH) is the acyloxyacyl linked at C-2 in the three isolates. Furthermore,
it showed that 14:0(3-OH) is linked at C-3′ in Bho1 and FR4020. Concerning FR4101, the second
peak is representing a lipid A fragment composed of GlcN II + one phosphate + one 10:0(3-OH)
and two 14:0(OH) (one 14:0(3-OH) plus one 14:0(2-OH) in secondary position). This indicated that
10:0(3-OH) was ester-linked at C-3′ in GlcN II of FR4101 lipid A and confirmed that 14:0(2-OH) and
12:0(2-OH) acyl-oxy-acyls were linked at C-2′ and C-2, respectively. A small peak at m/z 694 was
observed in all isolates spectra and was attributed to the lipid A fragment at 920 minus 14:0(3-OH) in
Bho1, and FR4020, and minus 10:0(3-OH) in Bho1 (not shown).
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Figure 2. Kinetics of ester-linked fatty acids release in FR4020 in alkaline conditions and corresponding
structures. Bho1 isolate and ATCC51541 behaved similarly and independently of the presence of GlcN,
accordingly their kinetics are not presented here. Structures are displayed here without their GlcN
substitution in order to better focus on the fatty acid pattern. However, the complete structures are
presented in Figure 5.
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Figure 3. Comparison of positive-ion lipid A fragments obtained for: (A) Escherichia coli K12 taken as
a reference, (B) B. holmesii ATCC 51541, and (C) B. holmesii FR4101.
2.2.4. Linkage of Fatty Acids in B. holmesii Lipids A
It was previously shown that sequential liberation of FAs was efficient to determine their position
in the lipid A structure [32]. As shown in Table 1, the FA in ester linkages at the C-3 position are the first
ones to be liberated, followed by those at C-3′, and the acyloxy-acyl secondary ester-linked FAs come as
the last ones, this being due to steric hindrance conditions. Mass spectra at different NH4OH treatment
with length times of 15 min, 30 min, 1 h, 2 h and 5 h were recorded and compared to the initial lipid A
mass spectra at the starting point, t0 (Figures 2 and 4). The partial O-deacylation pattern, obtained by
28% NH4OH treatment, was different in B. holmesii isolates; it was related to their linkage position.
On the one hand, the time release of 10:0(3-OH) at C-3 ranged from 1 to 15 min in FR4020 and FR4101
lipids A and was illustrated by the disappearance of the hexa-acyl lipid A related peaks (at m/z 1773.8
and 1717.7 respectively) which were transformed to penta-acyl lipid A molecular species at m/z 1603.1
and 1546.9, respectively. On the other hand, the 10:0(3-OH) liberation in Bho1 took a longer time,
1–30 min (Figure 2). Then, we observed by following kinetics of sequential liberation: at the C3 position,
14:0(3-OH) was completely liberated after 1–2 h in all three clinical isolates (Figures 2 and 4). This led to
convert penta-acyl lipids A at m/z 1603.1 and 1546.9 to tetra-acyl ones at m/z 1376.6. In fact, two peaks
at m/z 1150.2 and 1177.9 appeared after 15 min in all three clinical isolates, corresponding to m/z 1376.6
−226 u and 198 u, respectively. These mass differences were attributed to 14:0(2-OH) and 12:0(2-OH)
secondary fatty acids at C-2′and C-2, respectively. Another important peak appeared at m/z 952 after
1 h in Bho1, 30 min in FR4101 and 15 min in FR4020. The structure related to this peak corresponded
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to a diacyl lipid A with two amide-linked acyl chains [14:0(3-OH)] at C-2 and C-2′on the lipid A core
made of two GlcN and two phosphate residues.
Table 1. Kinetics of ester fatty acids release from all isolates and ATCC strain. (A) Kinetics of ester
fatty acids release from lipids A from B. holmesii strains ATCC 51541, Bho1 and FR4020 isolates.
Round numbers are given for reflecting that three experiments were summarized in this table.







t0 1376 1603 1773
NH4OH, 15 min 1376 1603 1603 10:0(3-OH) C3
NH4OH, 2 h 1376 1376 1376 14:0(3-OH) C3′
NH4OH, 5 h
1178 1178 1178 12:0(2-OH) secondary C2 partial release
1150 1150 1150 14:0(2-OH) secondary C2′ partial release




t0 1376.6 1547 1717
NH4OH, 15 min 1376.6 1547 1547 10:0(3-OH) C3
NH4OH, 2 h 1376.6 1376.6 1376.6 10:0(3-OH) C3′
NH4OH, 5 h
1178 1178 1178 12:0(2-OH) secondary C2 partial release
1150 1150 1150 14:0(2-OH) secondary C2′ partial release
CH3NH2, 5 h 952 952 952
14:0(2-OH) secondary C2′
12:0(2-OH) secondary C2
t0: Starting time point.
Of particular note, the ion peak at m/z 1538 arose from addition of GlcN (161 u) to the ion
at m/z 1376.6, lasting from 15 min to 5 h in FR4020 and from 15 min to 2 h in the FR4101 lipid A
mass spectrum. The peak associated to the glucosamine modification was weak in the Bho1 mass
spectrum, but confirmed with repeated experiments. The complete O-deacylation was carried out
by releasing secondary ester-linked fatty acids with methylamine treatment (41% CH3NH2 at 37 ◦C).
The negative-ion MALDI mass spectrum from Bho1 [36] displayed two peaks, after 5 h, a major one at
m/z 952 (diacyl lipid A), accompanied by a minor one at m/z 872 (a mono-phosphorylated lipid A).
No peak at plus GlcN was observed because of the very small amount of this molecular species present
in the native molecule. In addition to these two peaks, further ones were observed in FR4101 and
FR4020 mass spectra (Figures 2 and 4), such as m/z 1113, which corresponded to 953 plus 161 units
(GlcN) in both isolates, and a very minor not indicated peak at m/z 1274 (1113 plus 161 units), thereby
demonstrating that both lipid A phosphate groups were carrying GlcN.
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Figure 4. Kinetics of ester-linked fatty acid sequential release in FR4101 lipid A.
2.3. Genomic Analyses of Genes Involved in Lipid A Biosynthesis
We analyzed the sequence of genes involved in lipid A biosynthesis, more particularly focusing on
the identification of the genomic basis for the two main differences observed in the lipid A structures
of the three B. holmesii isolates in the present study, i.e., the presence/absence of glucosamines
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and the length of the carbon chain FA at C-3′ [14:0(3-OH) or 10:0(3-OH)]. We thus explored the
Lipid A GlcN modification locus (lgm locus), the Acyl-[acyl-carrier-protein]–UDP-N-acetylglucosamine
O-acyltransferase (lpxA), the Lipid A deacylase (pagL), the LipidA palmitoyltransferase (pagP),
two oxygenases lpxO1 and lpxO2 and acyltransferase lpxL1 genes (Table 2):
(i) An orthologous sequence corresponding to the lgm locus was identified in the genome of the three
clinical isolates as in the ATCC 51541 reference strain (position 1966909..1970398). We observe no
sequence difference for this locus comprising ArnT (position 1967952..1969541) between ATCC
type strain and the three clinical isolates.
(ii) Bho1 and FR4020 lpxA sequence is identical to that of ATCC 51541 reference strain (position
3231726..3232520) but FR4101 lpxA sequence displays a non-synonymous SNP in position
508 leading to an amino acid modification (S instead of G in position 170 of LpxA protein).
We also sequenced lpxA gene from 16 additional B. holmesii isolates collected from blood or
from respiratory samples and found that this SNP was not linked to the origin of the isolates
(unpublished data).
(iii) pagL sequence is identical for the three clinical isolates and the ATCC 51541 reference strain
(position 2144078..2144623). We did not observe any sequence difference between the three tested
isolates for pagP but a difference was observed in ATCC 51541 reference strain pagL sequence
(position 630144..630686) corresponding to an additional G leading to a frameshift.
(iv) We found two homologs of lpxO in the genome of the three isolates of B. holmesii as in the
ATCC 51541 reference strain (position 2899145..2900041 for the first one and 2402394..2403293 for
the second). They respectively displayed 84% nucleotidic identity with the KF214918 lpxO1 of
B. avium ATCC 35086 and 84% nucleotidic identity with the KF214919 LpxO2 of B. avium ATCC
35086. We then identified a lpxL1 homolog in the three isolates as in ATCC 51541 reference strain
(position 1194726..1195580) with no sequence difference between them.
Table 2. Genomic basis for the structural differences observed within lipid A of Bho1, FR4020, FR4101
and the ATCC51541 reference strain. Genes of interest/position within ATCC51541 reference strain
(Accession Number: CP007494.1)/sequence differences observed between isolates.
Genes of Interest
Position within ATCC 51541 Reference
Strain (Accession Number: CP007494.1)
Sequences Differences Observed
Between Isolates
Lgm locus 1966909..1970398 None
ArnT 1967952..1969541 None
lpxA 3231726..3232520
No sequence differences between
Bho1, FR4020 and ATCC 51541
Non-synonymous SNP in position
508 for FR4101 (*)
pagL 2144078..2144623 None
pagP 630144..630686
No sequence differences between
Bho1, FR4020 and FR4101
Additional G compared to
ATCC51541 leading to a frameshift
lpxO1 (**) 2899145..2900041 None
lpxO2 (***) 2402394..2403293 None
lpxL1 1194726..1195580 None
(*) We also sequenced lpxA gene from 16 additional B. holmesii isolates collected from blood or from respiratory
samples and found that this SNP was not linked to the origin of the isolates (unpublished data); (**) 84% Nucleotidic
identity with the KF214918 lpxO1 of B. avium ATCC 35086; (***) 84% Nucleotidic identity with the KF214919 LpxO2
of B. avium ATCC 35086.
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[37] [1] [38]
Figure 5. Proposed structures of the three main molecular species of higher masses present in B. holmesii
lipid A isolates compared to those present in B. pertussis 1414, B. bronchiseptica and B. parapertussis.
3. Discussion
In the present study, we focused our analyses on the lipid A of different B. holmesii isolates
originating either from blood or respiratory samples and on the ATCC 51541 reference strain.
Mass spectrometry analyses first led to the observation of a difference in the amount of
modification with GlcN on the lipid A phosphate groups. The two clinical isolates FR4020 and FR4101
displayed a higher degree of modification compared to Bho1 and the ATCC strain. Such an hexosamine
modification has been described in other Bordetellae species such as B. pertussis, B. bronchiseptica and B.
avium and was attributed to a lgm locus encoding a glycosyl transferase ArnT [31,35,39]. An orthologous
sequence corresponding to lgm locus was identified in the genome of the three clinical isolates as in
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the ATCC 51541 reference-strain genome with no sequence difference between them. In B. pertussis
and B. bronchiseptica, the lgm locus has been reported to be bvg regulated [33]. Previous studies showed
that Bho1 isolate and ATCC 51541 reference strain both have a particular non-functional bvg system
because of a non-functional BvgA protein (due to an A insertion within bvgA sequence, leading to
a frameshift [19,22]) that could explain why less GlcN is substituting their lipid A phosphate groups
on contrary to FR4020 and FR4101. Recent sequencing and annotation of ATCC 51541 strain genome
do not report this additional A within BvgA (position 3314780..3315403) suggesting that the mutation
can occur frequently at random, according to subcultures or different ways of storage. Moreover,
this difference is not a specific trait of respiratory samples as a functional bvg system is found in
other B. holmesii isolates collected from blood [19]. All these data show that B. holmesii lipid A can be
decorated with GlcN what has already been shown to have consequences on the modulation of host
immunity via a different Toll-like receptor 4 (TLR4) activation for B. pertussis.
In addition, other specificities and differences deduced from the structural analysis seem to be
supported by the genomic analysis:
(i) The differences in length of the carbon FA at C3’, 14:0(3-OH) for Bho1, FR4020 and ATCC 51541 or
10:0(3-OH) for FR4101. LpxA is the first enzyme of the lipid A biosynthesis pathway catalyzing
the addition of an acyl chain onto the C3’ carbon [40]. We identified lpxA B. holmesii gene and
observed a non-synonymous SNP in FR4101, leading to an amino acid change, as compared to
ATCC 51541, FR4020 and Bho1 lpxA sequences. Thus, we concluded that the difference observed
in the length of the carbon FA at C3’ between FR4101 and the other isolates could be due to
this difference within lpxA gene. Analysis of additional French B. holmesii isolates also led to the
conclusion that this was not related to the blood or respiratory origin of the sample which was
also confirmed by the lpxA sequence analysis of isolates with available genomes on NCBI.
(ii) The presence of 10:0(3-OH) at C-3, like in B. pertussis [1] and B. petrii [41] is also a common trait
between the three clinical isolates. In B. pertussis, this is the consequence of the lack of activity of
the C-3 de-O-acylase PagL, which has been shown to result in a lower cytokine induction capacity
of the Bordetella human pathogens [29,42]. The presence of this fatty acid was interpreted as
resulting in the facility of such bacteria, with short-chain fatty acid structures, and low acylation
pattern, to escape the human host defense through the MD2–TLR4 complex [42,43]. We found
that the pagL gene sequence is the same for the three isolates and the ATCC 51541 strain. Both H
and S residues in the C-terminal part of PagL protein, described as essential for catalytic activity
are present in B. holmesii [44]. In B. pertussis, pagL is a pseudogene because of a frameshift
due to a deletion of “CA” bases. Such a deletion is not found in the B. holmesii sequence.
Further investigations are necessary to understand why PagL is inactive in these isolates.
(iii) The presence of a secondary palmitoyl chain at two positions of lipid A (3′ and 2). We previously
described the presence of such palmitoyl chains at C-3′ in B. avium, and in both C3′ and C2 in
B. parapertussis [27,45] as a result of PagP action. In the present study, we observed no pagP
sequence difference between the three tested isolates. They nevertheless display an additional
G insertion as compared to ATCC 51541 reference strain, leading to a frameshift that probably
explains why no palmitoyl acid is observed in these isolates.
(iv) The hydroxylation of 12:0 and 14:0 at position 2 of the two secondary acylated residues was
observed in the lipid A of the three isolates (Figure 5). In Novikov et al. [27], such hydroxylations
have been observed in B. avium, B. hinzii and B. trematum and were attributed to two homologs
of the LpxO enzyme. We found two homologs of lpxO in the genome of the three isolates of
B. holmesii as in the ATCC 51541 type strain that support the degree of hydroxylation observed.
(v) The presence of a 12:0(2-OH) residue in a secondary position at C-2 on the amide-linked
14:0(3-OH) is a common trait between all the B. holmesii structures. LpxL is a lipid A lauroyl
acyltransferase. Geurtsen et al. [46] showed that LpxL1, a homolog of the classical LpxL2 lauroyl
acytransferase, is present but usually poorly expressed in B. pertussis, compared to LpxL2 [40,46].
However, through overexpressing it in B. pertussis B213 strain, they showed that this enzyme led
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to the presence of an extra secondary 12:0(2-OH) chain at the C-2 position, like we describe here
in the B. holmesii isolates, and they reported that this type of acylation was required for efficient
infection in human macrophages and could help host infection. We found a lpxL1 homolog in the
three isolates as in ATCC 51541 type strain supporting this substitution.
All these results allowed identification of differences within lipid A structures in the different
B. holmesii strain and isolates tested supported by both structural and genomic analysis. As illustrated
in Figure 5, lipid A structures differ in their fatty acid substitution. The difference in the amount of
free amino GlcN derivatives on the phosphate groups is described herein but not shown in the figure
as only the peak intensity can be illustrating such differences.
4. Materials and Methods
4.1. Strains and Isolates
Strain ATCC 51541 was originating from the National Research Council (NRC) collection and
was grown as previously described [47]. The three human isolates were selected from the French
National Reference Center for Whooping Cough and other Bordetelloses [19]. Bho1 was isolated in
1996 from the blood of a 20 years old man with sickle-cell anemia [48]. FR4020 and FR4101 were
isolated, respectively; from nasopharyngeal swabs of an adult in 2008, and of an adolescent in
2009, both presenting Pertussis-like symptoms [19,49]. Bacteria were grown on Bordet–Gengou agar
(Difco by Becton Dickinson, NJ, USA) supplemented with 15% sheep defibrinated blood (Biomerieux,
Marcy l’Etoile, France) at 36 ◦C for 72 h, plated again for 18 h and then grown in enriched Stainer
Scholte medium [50].
4.2. LPS Preparation
LPS were extracted by the isobutyric-M ammonium hydroxide method in a 5:3 (v/v) ratio [51].
LPS preparations were further extracted with solvents CHCl3:MeOH (1:2 v/v) and CHCl3: MeOH: H2O
(3:2:0.25, v/v/v) in order to remove phospholipids and lipopeptides, then treated with enzymes to
remove DNA, RNA and protein contaminants, as described [32].
4.3. Lipid A Isolation from Whole Cells
Briefly, cells (10 mg) were washed twice with 400 μL of a fresh, single phase mixture of
CHCl3:MeOH (1:2 v/v) (Sigma, St. Louis, MO, USA) and once with 400 μL of CHCl3:MeOH: H2O
(3:2:0.25 v/v/v). The insoluble material, corresponding to washed cells, was recovered by centrifugation
in the pellet, and the supernatants were discarded. The washed cells were suspended in 400 μL of
isobutyric acid/ammonium hydroxide (M) (5:3 v/v), and kept for 1.5 h at 100 ◦C in a screw cap test
tube under magnetic stirring. The mixture was cooled in iced water, and centrifuged (2000× g for
15 min). The supernatant was diluted with water (1:3 v/v), and lyophilized. The sample was then
washed twice with 400 μL of methanol, and centrifuged (2000× g for 15 min). Finally, the insoluble
lipid A was solubilized and extracted once with 200 μL of a mixture of chloroform: methanol:water
(3:1.5:0.25 v/v/v) [52].
4.4. Lipid A Isolation from LPS as Performed by the Triethylamine Citrate (TEA) Method
A concentration of 0.01M TEA-citrate (1:1 molar ratio, pH 3.6) was used. Samples were
suspended in Eppendorf® tubes (Eppendorf AG, Hamburg, Germany) in the above-mentioned
reagents at concentrations of 5 μg/μL, or 10 μg/μL depending to their solubility. After agitation
and homogenization using an ultrasonic bath, the tubes were incubated for 1 h in a Thermomixer
system (Eppendorf AG) under stirring at 1000 rpm and 100 ◦C [53].
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4.5. Thin-Layer Chromatography
Thin-layer chromatography (TLC) was done on aluminum-backed silica-gel plates (Merck,
Darmstadt KGaA, 64271, Germany) in the solvent [54] chloroform:methanol:water:triethylamine
(12:6:1:0.04). Spots were visualized by charring after spraying with 10% sulfuric acid in ethanol for
checking samples purity.
4.6. Fatty Acid
Fatty acids were analyzed after hydrolysis of the LPS or lipids A with 4 M HCl for 2 h at
100 ◦C, and neutralization, followed by treatment with 2 M NaOH 2 h at 100 ◦C [55], extraction with
ethyl acetate, methylation of the extract with a mixture of anhydrous methanol and acetyl chloride
(10:1.5 v/v) [56]. They were identified by GC–MS for the fine characterization and confirmation of FA
composition as visualized by MALDI–MS (mass spectrometry).
4.7. O-Deacylation
Ester-linked fatty acids were likewise characterized after treating the lipids A with NH4OH
during 5 h at 50 ◦C [32] for liberation of primary ester-linked fatty acids and with methylamine for 5 h
at 50 ◦C for the secondary ester-linked fatty acids. GC–MS analysis of the methylated fatty acids was
performed as previously described. Arachidonic acid (C20, Sigma), ,was used as a standard [56].
4.8. Mass Spectrometry
MALDI negative-ion mass spectrometry analyses were performed on a PerSeptive Voyager-DE
STR model time-of-flight mass spectrometer of Applied Biosystem, (I2BC, Université de Paris Sud XI).
The apparatus is equipped with a 337 nm nitrogen laser and spectra were recorded in the linear
negative-ion mode with delayed extraction.
The ion-accelerating voltage was set at 20 kV. Dihydroxybenzoic acid (DHB) (Sigma) suspended
in 0.1 M citric acid was used as a matrix. A few microliters of lipid A were dissolved in a mixture
of chloroform:methanol:water (3:1.5:0.25 v/v/v) at 1 mg/mL and desalted with a few grains of
ion-exchange resin (Dowex 50W-X8, Sigma, St. Louis, MO, USA) (H+), in an Eppendorf tube. A 1 μL
aliquot of the solution (50 μL) was deposited on the target and covered with the same amount of the
matrix suspended at 10 mg/mL in the same mixture of solvents [39]. Different ratios between the
samples and DHB were tested when necessary. B. pertussis lipid A was used as an external standard.
4.9. Genomic Analysis
Partial genome sequences of Bho1, FR4020 and FR4101 isolates were available from Roche 454
sequencing [19]. Sequences of genes involved in lipid A biosynthesis were identified using the
NCBI nucleotide and protein blast programs (blastn and blastp) (https://blast.ncbi.nlm.nih.gov).
For lgm locus and lpxA gene, sequence differences were checked by polymerase chain reaction (PCR)
and classical Sanger sequencing using primers Lgm-bho-F: 5′-CACATGAGCGACGAGCTCTA-3′,
Lgm-bho-R: 5′-GGCTGCACTTGAACCTGTCT-3′, LpxA-bho-F: 5′-CGCACCATCTGCAAGTATCA-3′,
LpxA-bho-R: 5′-CCACCATACCAATGGACAGA-3′. PCR amplifications were done from genomic
DNA extracted with DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions.
5. Conclusions
The B. holmesii lipid A structures established in the present study differ from one to the other:
(i) Presence of free amino GlcN on the phosphate groups of lipid A structure: in Bho1 as in ATCC
51541, the failure of BvgA to function leads to a weaker substitution than in the two other isolates.
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(ii) Presence of 10:0(3-OH) at C-3, which we already observed in other Bordetella species such as
B. pertussis [31], is thought to be the consequence of the lack of activity of the 3 O-deacylase PagL,
even if genomic explanation could not be found to support this hypothesis.
(iii) The 14:0(2-OH) and 12:0(2-OH) fatty acids found in all the presented structures were previously
shown to be important structural features for the infection of human macrophages [42].
The combined structural virulent traits, characteristic of the B. holmesii lipid A structures,
demonstrate the potential strength of this bacterium in its capacity to adapt for escaping to the
host immune defenses. The efficiency of these traits, and especially the presence of the short-chain
10:0(3-OH) is already attested by the virulence of the whooping-cough pathogens B. pertussis and
B. parapertussis [31,52] and were also recently characterized in B. petrii lipid A isolates [41]. However,
no real difference of lipid A structure was observed between isolates from blood or respiratory origins
which correlates with data from other studies [18,19]. This also correlates with the fact that, in cases of
bacteremia, nasal carriage should be assessed as shown in a previous study [13].
The lipid A structures we characterized along the years on numerous strains and species always
gave important information confirmed by genomics; lipid A is a powerful taxonomic tool and this
work is another example of the kind. We demonstrated here the correlation between B. holmesii and
B. hinzii, B. avium and B. trematum also recently shown to belong to the same clade as based on whole
genome SNP-based analysis.
As already mentioned, lipid A are good bacterial markers, and their characterization in small
biological samples can now help to differentiate the human Bordetella pathogens.
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Abstract: The new type of core oligosaccharide in Proteus penneri 40A and 41 lipopolysaccharides
has been investigated by 1H and 13C NMR spectroscopy, electrospray ionization mass spectrometry
and chemical methods. Core oligosaccharides of both strains were chosen for structural analysis
based on the reactivity of LPSs with serum against P. penneri 40A core oligosaccharide–diphtheria
toxoid conjugate. Structural analyses revealed that P. penneri 40A and 41 LPSs possess an identical
core oligosaccharide.
Keywords: anti-conjugate serum; core oligosaccharide; lipopolysaccharide; NMR spectroscopy;
ESI MS; Proteus penneri
1. Introduction
P. penneri are human-opportunistic pathogens causing, in preferred conditions, several types of
infections among which urinary tract and wound infections are predominant. These Gram-negative
bacteria produce many virulence factors including LPS (endotoxin), which seems to be the most
dangerous due to its contribution to septic shock [1]. LPS of smooth bacterial strains consists
of three regions: lipid A, a core oligosaccharide (OS) and an O-polysaccharide (O-PS, O-antigen).
Only the last two have been described for the P. penneri species [2–4]. Although the P. penneri
core oligosaccharide is characterized by lower structural diversity than the O-PS part (over 26
chemotypes), it is still structurally heterogeneous (12 different structures of the outer core region
and a few variants of its inner part) [2–6]. The LPS core region may be masked by an O-polysaccharide,
but its exposition on bacterial cells is still accessible for specific immunoglobulins. This fact was
confirmed by the detection, in polyclonal rabbit antisera against Proteus strains, of anti-core-specific
antibodies recognizing low-molecular-mass LPS species not only of homologous but also heterologous
antigens [7–9]. This observation encouraged the examination of different P. penneri LPSs, in search
of antigen groups with identical or similar serological activities of their core oligosaccharides, which
would complete the Proteus classification scheme with the data on the core region serotypes. To date,
11 groups of LPS presenting one core serotype have been classified [10]. In this paper, the results of
serological studies and structural analysis are presented to show another type among P. penneri LPSs
with a common sero- and chemotype of their core oligosaccharides.
Int. J. Mol. Sci. 2018, 19, 676; doi:10.3390/ijms19030676 www.mdpi.com/journal/ijms53
Int. J. Mol. Sci. 2018, 19, 676
2. Results
2.1. Serological Studies
The rabbit polyclonal serum against the P. penneri 40A core oligosaccharide–diphtheria toxoid
conjugate (anti-conjugate serum) was obtained and tested by ELISA assay and immunoblotting
(Western blot) with the homologous and 40 other Proteus spp. LPSs. The heterologous LPSs (rough
P. penneri strains: (serotypes 4, 5, 11), R mutant of P. mirabilis (serotype 6) and smooth P. penneri strains
(O8, O17, O19a,b, O31a, O31a,b, O52, O58, O59, O61, O62, O63, O64a,b,c, O64a,c,e, O65, O67–O71,
O72a, O73a,b, O73a,c) representing different O serogroups and subgroups of the genus were selected as
described previously [7]. In ELISA, two LPSs, P. penneri 40A and 41, reacted to the titer the most strongly
with the tested serum (1:16,000); two LSPs, P. penneri 1 and 4, cross-reacted to the titer (1:8000); two other
LPSs, P. penneri 27 and 71 showed the lowest serum reactivity titers (1:2000). Residual Proteus spp.
LPSs were not cross-reacted with the tested serum. The cross-reactivity of the tested antiserum with
P. penneri 1, 4, 27, 71 LPSs indicates the presence in their core oligosaccharides of similar epitope(s)
common with core oligosaccharide of the homologous LPS. The strongly reacting LPSs, P. penneri
40A and 41, were chosen for further study. In the Western blot technique, all reactions concerned the
low-molecular-mass LPS fragments consisting of the core-lipid A moieties of tested antigens (Figure 1).
The tested antiserum was adsorbed a few times with an alkali-treated cross-reacting or homologous
antigen and checked once more in ELISA with the same LPS preparations. The adsorption of P. penneri
40A anti-conjugate serum with each of the reacting LPSs completely abolished the reactions with tested
LPSs. P. penneri 40A and 41 LPSs, which reacted strongly and similarly in all assays, have been selected
for structural studies by ESI mass spectrometry and NMR spectroscopy to check the similarity of these
core oligosaccharides.
 
Figure 1. Western blot of P. penneri LPSs with the P. penneri 40A anti-conjugate serum.
2.2. Structural Studies
The mass spectra obtained for the P. penneri 40A and 41 core oligosaccharides showed a high
degree of similarity (Figure 2A,B). To avoid unnecessary duplication, only data concerning the P. penneri
40A core oligosaccharide have been presented in the text. Table 1 presents an interpretation of all ions
in core oligosaccharide fractions which have been identified by ESI MS. The major fraction represented
by the ions at m/z 1180.42 [M+Ac+2H]2+ and m/z 1171.40 [M+Ac-H2O+2H]2+ corresponded to
the core oligosaccharide containing two hexoses (Glc and Gal); five heptoses (Hep); hexuronic
acid (GalA); hexosamine (GalN); N-acetylated hexosamine (GlcNAc); 4-amino-4-deoxyarabinose
(Ara4N); 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo); phosphoethanolamine (PEtn) and a one O-acetyl
group (OAc). Additionally, both core oligosaccharides were de-O-acetylated and checked by ESI MS.
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The differences between core oligosaccharides and their de-O-acetylated fractions were related to the
removal of the O-acetyl group from the structure. The major fraction represented by the ion at m/z
1159.30 [M+2H]2+ (Figure 2D) corresponded to the structure without an O-acetyl group in contrast with
the ion at m/z 1180.42 [M+Ac+2H]2+ (Figure 2C). These two ions were selected for further analysis by
use of positive ion mode ESI MS/MS. The main daughter ions detected in the ESI MS/MS spectra were
explained. The ion at m/z 366.43 corresponds to the GalGlcNAc fragment, while the ion at m/z 407.48
was explained by the GlcNAcGalN-OAc (Figure 2C). The daughter ion with the highest m/z 569.59
was subsequently attributed to the GalGlcNAcGalN-OAc fragment. These observations, in comparison
with NMR data, indicate that an O-acetyl group substitutes at GalpN (residue K’).
Figure 2. Positive ion mode ESI mass spectra of the core oligosaccharides from P. penneri 40A (A) and
41 (B); (C) Positive ion mode ESI MS/MS of the core oligosaccharide from P. penneri 40A represented
by ions at m/z 1180.42 and (D) at m/z 1159.30.
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Table 1. ESI MS data obtained for the core oligosaccharides of P. penneri 40A and 41.
The Observed Ion (m/z)/The Calculated Mass
The Ion Interpretation











The initial NMR investigation indicated the presence of hexosamine residue among the
constituents of the core oligosaccharide; therefore, methylation analysis was performed on N-acetylated
oligosaccharide. Methylation indicated the presence of 3,7-disubstituted Hepp, 3,4-disubstituted Hepp,
2-substituted Hepp, terminal Hepp, 4-substituted GlcpN, 4-substituted GalpN, terminal Glcp and
terminal Galp.
The 1H NMR spectrum of the P. penneri 40A core oligosaccharide (Figure 3A) contained the
main signals for eleven anomeric protons, as well as signals characteristic for the deoxy protons from
the Kdo residue. The 1H-1H COSY, TOCSY with different mixing times, 1H-13C HSQC-DEPT and
HSQC-TOCSY spectra allowed for the assignments of the H-1 to H-6 (H-7,7′, H-8,8′) signals for each
residue (marked as uppercase letters) of the core oligosaccharide (Table 2, Figure 3).
Figure 3. (A) The 1H NMR spectrum and (B,C) selected regions of the 1H-13C HSQC-DEPT spectrum
of the core oligosaccharide P. penneri 40A LPS. The cross-peaks are labeled as shown in the text.
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Residue A was recognized as a 5,8-disubstituted Kdo based on the characteristic deoxy proton
signals of H-3ax (δH 1.80 ppm), H-3eq (δH 2.19 ppm) and a high chemical shift of the C-5
(δC 75.7 ppm) signal.
Residue B at δH/δC 4.98/99.1 ppm, 1JC-1,H-1 ~170 Hz, was assigned as the terminal β-L-Ara4N
residues based on the chemical shift of the C-4 (δC 52.8 ppm) and characteristic H5, H5′/C5 (δH 3.73,
δH/δC 4.10/58.8 ppm) signals.
Residue C at δH/δC 5.07/101.6 ppm, 1JC-1,H-1 ~170 Hz, was recognized as a 3,4-disubstituted
L-glycero-α-D-manno-Hepp based on the relatively high chemical shift of the C-3 (δC 74.4 ppm) and C-4
(δC 76.5 ppm) signals.
Residue D at δH/δC 4.58/103.3 ppm, 1JC-1,H-1 ~162 Hz, was assigned as the terminal β-D-Glcp
based on the large vicinal couplings between all protons in the sugar ring.
Residue E at δH/δC 4.89/101.0 ppm, 1JC-1,H-1 ~172 Hz, was recognized as the 3,7-disubstituted
L-glycero-α-D-manno-Hepp from the relatively high chemical shifts of the C-3 (δC 79.7 ppm) and C-7
(δC 68.2 ppm) signals.
Residue F at δH/δC 4.93/100.4 ppm, 1JC-1,H-1 ~168 Hz, as well as residue I at δH/δC 5.02/103.1 ppm,
1JC-1,H-1 ~170 Hz, were assigned as terminal L-glycero-α-D-manno-Hepp.
Residue G at δH/δC 5.45/99.0 ppm, 1JC-1,H-1 ~168 Hz, was assigned as the 2,4-disubstituted
α-D-GalpA residues based on the characteristic five proton spin systems, and the high 13C chemical
shift of the C-2 (δC 72.7 ppm), C-4 (δC 80.1 ppm) and C-6 (δC 176.0 ppm) signals.
Residue H at δH/δC 5.27/95.5 ppm, 1JC-1,H-1 ~173 Hz, was recognized as a 2-substituted
D-glycero-α-D-manno-Hepp based on the relatively high chemical shift of the C-2 (δC 80.6 ppm) signal.
Additionally, the characteristic chemical shift of the C-6 (δC 72.4 ppm) signal indicates the
D-glycero-D-manno configuration [11].
Residue K’ at δH/δC 5.22/97.3 ppm, 1JC-1,H-1 ~175 Hz, was recognized as the 4-substituted
α-D-GalpN6OAc based on the chemical shift of the C-2 (δC 51.7 ppm) signal, the relatively high
chemical shift C-4 (δC 77.6 ppm) signal, and the downfield shift of the C-6 (δC 62.3 ppm) signal,
consistent with an O-acetyl group at position 6. The presence of an O-acetyl group was supported by
de-O-acetylation. The spectrum of the de-O-acetylated core oligosaccharide contained only one signal
from the N-acetyl group of residue L whereas OS also possesses an additional signal from the O-acetyl
group at GalpN (residue K’). Residue K at δH/δC 5.23/96.5 ppm, 1JC-1,H-1 ~174 Hz, represented a
variant of residue K’ caused by the lack of the O-acetyl group at O-6 of residue K’. Residue K was thus
identified as 4-substituted α-D-GalpN.
Residue L at δH/δC 4.88/99.2 ppm, 1JC-1,H-1 ~177 Hz, was recognized as the 4-substituted
α-D-GlcpNAc based on the chemical shift of the C-2 (δC 54.6 ppm) signal, the relatively high chemical
shift of the C-4 (δC 79.5 ppm) signal. Residues L’ at δH/δC 5.40/102.4 ppm, 1JC-1,H-1 ~175 Hz,
were recognized as variants of residue L (4-substituted α-D-GlcpNAc) due to the absence of the
O-acetyl group located at position 6 of residue K’.
Residue M at δH/δC 4.48/103.7 ppm, 1JC-1,H-1 ~162 Hz, was recognized as the terminal β-D-Galp
based on chemical shifts in good agreement with those of previously reported β-D-Galp [12].
Each disaccharide element of the core oligosaccharide was identified by 1H-1H NOESY (Figure 4)
and 1H-13C HMBC experiments. The NOESY spectrum showed strong inter-residue cross-peaks
between the transglycosidic protons: H-1 of B/H-8 of A, H-1 of C/H-5 of A, H-1 of D/H-4 of C, H-1
of E/H-3 of C, H-1 of G/H-3 of E, H-1 of H/H-2 of G, H-1 of I/H-2 of H, H-1 of K/H-4 of G, H-1
of L/H-4 of K’, H-1 of L’/H-4 of K and H-1 of M/H-4 of L (Figure 4). These data confirmed the
substitution positions of the monosaccharide residues and demonstrated their sequence in the core
oligosaccharide P. penneri 40A (structure inserted into Figure 2).
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Figure 4. Selected part of the NOESY spectrum of the core oligosaccharide of P. penneri 40A LPS.
The cross-peaks are labeled as shown in the text.
3. Discussion
This work provides the serological and chemical characterization of a new type of the core region
presented by P. penneri 40A and 41 LPSs. In ELISA, anti-conjugate serum P. penneri 40A reacted
differently with three groups: (I) P. penneri 40A and 41—showing the strongest serological activity;
(II) P. penneri 4 and 1—weaker reactions; and (III) P. penneri 27 and 71—the weakest serological activity.
The weakest activity of the last two LPSs was also confirmed by the results of the Western blot technique
(Figure 1). The LPS whose binding-pattern of low-molecular-mass LPS species distinguished itself
from the patterns of the tested residual LPSs was P. penneri 1. The LPS, P. penneri 4, reacted in Western
blotting similarly to P. penneri 40A and 41 but its reactivity titer in ELISA was twice as low as the titers
of P. penneri 40A and 41 LPSs. These differences in serological activity of P. penneri 1, 4, 27 and 71 LPS
core oligosaccharides compared to that observed for P. penneri 40A and 41 LPSs suggest that these two
groups of LPSs share common epitopes but do not necessarily present the same sero- and chemotype
of the core region. In many cases, LPSs, presenting one chemotype of the core region, showed similar
binding-patterns of low-molecular-mass LPS species in the Western blot technique and reacted in
ELISA up to the same value of the antiserum reactivity titers [7,8]. Due to the fact that P. penneri 40A
and 41 LPSs reacted similarly in all serological assays, they were chosen for the structural analyses.
The results of mass spectra analyses of the core oligosaccharides from P. penneri 40A and
P. penneri 41 LPS were able to reveal the structure, which had not been previously identified for
Proteus LPS core regions. The new type of structure is typical for P. penneri core regions in its
inner part containing five Hepp residues, Glcp, GalpA, Kdo and Ara4N residues and presenting
III glycoform [2,4]. Only in six P. penneri LPSs 12, 13, 14, 37, 42 and 44, can structural variations of
the inner core region be observed [2,4]. The uniqueness of P. penneri 40A and 41 core regions is found
in its outer part defined in the literature as R substituent [4]. To date, 20 different structures of R
substituent have been determined for Proteus spp. strains, among which 12 are presented by P. penneri
strains [4,13]. These structures contain from one (e.g., P. penneri 12, 13) to four sugar residues or their
N-acetylated forms (e.g., P. penneri 7, 14, 15). One structure of R substituent can be represented by
one or a few P. penneri strains [4]. The R substituent of P. penneri 40A (O64a,b,d) and the 41 (O62)
LPS core region is built of three residues (β-D-Galp-(1→4)-α-D-GlcpNAc-(1→4)-α-D-GalpN6OAc)
and it is similar to the outer core region of only one strain, P. penneri 103 (O73a,b)
(β-D-Glcp-(1→4)-α-D-GlcpNAc-(1→4)-α-D-GalpN6OAc) [4]. These two fragments differ from each
other in the terminal residue. The importance of the terminal residue in the serospecificity of the
outer core oligosaccharide region can be confirmed by the fact that P. penneri 40A anti-conjugate
serum did not react with P. penneri 103 LPS. P. penneri 103 was classified into serotype group no.
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10 together with P. penneri 75 LPS, recognized by anti-core-specific antibodies present in P. penneri
103 antiserum [10]. A similar situation also occurs in the case of two core oligosaccharide serotypes:
R1 (α-D-Glcp-(1→4)-α-D-GalpNAc-(1→2)-α-DD-Hepp-(1→6)-α-D-GlcpNGly) presented by P. penneri 7,
14 LPSs and R2 presented by P. penneri 8 LPS (α-D-GalpNAc-(1→2)-α-DD-Hepp-(1→6)-α-D-GlcpNGly)
differing in the lack of terminal residue [4,14]. The serological studies performed by use of P. penneri 7
core-specific antiserum and P. penneri 7, 8, 14 and 15 LPSs proved a crucial role of the terminal residue
from the outer core region in its serospecificity [8]. As a result, P. penneri 8 LPS and P. penneri 7, 14 and
15 LPSs were classified into two different core oligosaccharide serotypes [10]. The 6-O-acetylation of
the GalpN residue is also unique for the Proteus spp. LPS core region. In P. penneri 16 and 18, GalpN is
substituted by the phosphoethanolamine group at position 6 [4].
The results presented in this work will allow P. penneri 40A and 41 LPSs to be classified into a new
core oligosaccharide serotype group extending the core oligosaccharide serotypes scheme [10]. It is
another example of two P. penneri LPSs of one core serotype but presenting two O serotypes: P. penneri
40A (O64a,b,d) and P. penneri 41 (O62)—the first representative of this O serogroup in the core types
classification scheme.
Finding a new structure and serotype of the P. penneri LPS core region confirmed the huge
structural heterogeneity of P. penneri LPSs, a unique phenomenon among other Enterobacteriaceae.
Extension of the core serotype scheme with other representatives may be helpful in the identification of
the most common R and O serotypes needed for the selection of vaccine antigens to obtain cross-reactive
and cross-protective antibodies [10].
4. Materials and Methods
4.1. Bacterial Strains
P. penneri 40A (O64a,b,d) and 41 (O62) are clinical isolates from patients in Toronto (Canada) but
their isolation sources remain unknown. The other strains, whose LPSs were checked with the tested
serum, have been presented in another article [7]. All tested strains belong to the collection of the
Laboratory of General Microbiology, University of Lodz (Poland), where they are stored in a glycerol
mixture at −80 ◦C.
4.2. Lipopolysaccharide
The LPSs were extracted from dried bacterial cells, as previously described [7], by the
phenol–water procedure according to the method of Westphal [15] and purified with aqueous 50%
trichloroacetic acid. Alkali-treated LPSs used for the sera adsorption were prepared as described in
detail elsewhere [16].
The LPSs of P. penneri 40A and 41 were degraded by treating with 1.5% acetic acid at 100 ◦C
for 1 h and the carbohydrate portions were fractionated and monitored as described previously [7].
The fractions (O-PS, OS, and the mixture of low molecular mass) were eluted, freeze-dried and checked
by ESI mass spectrometry and NMR spectroscopy.
4.3. De-O-Acetylation of the Core Oligosaccharide
The P. penneri 40A, 41 core oligosaccharides (5 mg) were treated with aqueous 12.5% NH3 (1 mL)
at 23 ◦C for 16 h and then the solution was freeze-dried. The products were analyzed by ESI mass
spectrometry and NMR spectroscopy.
4.4. P. penneri 40A Core Oligosaccharide Conjugate
Conjugation of the P. penneri 40A core oligosaccharide with diphtheria toxoid was performed by
the method of H. J. Jennings and C. Lugowski based on the reaction of reductive amination, which
was described in detail elsewhere [17]. The P. penneri 40A anti-conjugate serum was obtained by the
immunization of New Zealand white rabbits as described previously [7].
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4.5. Serological Assays
Purified LPS samples were tested with rabbit antisera in an enzyme-linked immunosorbent assay
(ELISA), and Western blot procedure after sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) with non-adsorbed antisera and/or antisera adsorbed with selected alkali-treated LPSs.
All assays were performed as previously described [16] with some modifications [7].
4.6. Chemical Method
Methylation analysis was performed according to the method of Ciucanu and Kerek [18].
Partially methylated alditol acetates were analyzed by gas chromatography-mass spectrometry using
a Thermo Scientific ITQ system using a Zebron™ ZB-5HT (Thermo Fisher Scientific, Waltham, USA),
GC Capillary Column (30 m × 0.25 mm × 0.25 μm) and with temperature rising from 150 to 270 ◦C at
8 ◦C/min.
4.7. Instrumental Methods
ESI MS analyses were performed using a Bruker microTOF-QII mass spectrometer (Bruker Brema,
Germany) in a positive ion mode. The samples were dissolved in an acetonitrile–water–formic acid
solution (50:50:0.1, v/v/v). The spectra were scanned in the m/z 200–2200 range. The mass isolation
window for the precursor ion selection was set to 4 Da in the MS2 analyses.
All NMR spectra were recorded using a Bruker Avance III 600 Hz spectrometer equipped with a
2.5 mm microprobe, incorporating gradients along the z-axis. The measurements were performed at
298 K. The signals were assigned by one- and two-dimensional experiments: 1H-1H COSY, TOCSY
(with mixing time: 30, 60, 100 ms), NOESY and 1H-13C HSQC-DEPT, HSQC-TOCSY, and HMBC.
The data were acquired and processed using standard Bruker software. The processed spectra were
assigned with the help of the SPARKY program [19].
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Abstract: The chemical structure and genomics of the lipopolysaccharide (LPS) core oligosaccharide
of pathogenic Edwardsiella tarda strain EIB 202 were studied for the first time. The complete gene
assignment for all LPS core biosynthesis gene functions was acquired. The complete structure of core
oligosaccharide was investigated by 1H and 13C nuclear magnetic resonance (NMR) spectroscopy,
electrospray ionization mass spectrometry MSn, and matrix-assisted laser-desorption/ionization
time-of-flight mass spectrometry. The following structure of the undecasaccharide was established:
The heterogeneous appearance of the core oligosaccharide structure was due to the partial lack
of β-D-Galp and the replacement of α-D-GlcpNAcGly by α-D-GlcpNGly. The glycine location was
identified by mass spectrometry.
Keywords: Edwardsiella tarda; core oligosaccharide; MALDI-TOF MS; ESI MSn; NMR; genomic
1. Introduction
Edwardsiella tarda is a Gram-negative bacterium and a pathogen of farmed fish. It is the etiological
agent of a systematic disease called edwardsiellosis, which has been reported to affect a wide range of
freshwater and marine fish [1,2]. In addition to fish, E. tarda is also an occasional human pathogen
and known to cause both gastroenteritis and extraintestinal infections in humans [3,4]. A number
of virulence-associated systems and factors, such as the type III and type VI secretion systems, the
LuxS/AI-2 quorum sensing system, and hemolysin systems, have been identified in E. tarda [5].
Additionally, a sialidase shows a potential pathogenicity and immunogenicity [6].
In Gram-negative bacteria, the lipopolysaccharide (LPS) is one of the major structural and
immunodominant molecules of the outer membrane. It consists of three moieties: lipid A, core
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oligosaccharide, and O-specific polysaccharide (O-antigen). The O-antigen is the external component
of LPS, and its structure consists of different number of repeating units. The O-specific polysaccharide
chains are transferred to lipid A-core to form LPS, in a step involving WaaL, the putative bifunctional
enzyme named O-antigen ligase. Another interesting feature is the high chemical variability shown by
the O-antigen LPS, leading to a similar genetic variation in the genes involved in their biosynthesis,
the so-called wb cluster (for a review, see [7]). Despite the emerging importance of this pathogenic
microorganism, until now only four LPS structures of E. tarda strains were investigated [8–11].
In studies of several Enterobacteriaceae such as Escherichia coli, Salmonella enterica, and
Klebsiella pneumoniae, genes involved in LPS core biosynthesis are usually found clustered in a region
of the chromosome, the waa gene cluster [12,13]. On the other hand, a careful analysis of several full
sequenced genomes suggested that genes for the LPS core biosynthesis may not be clustered and may
be distributed between several regions, e.g., as in Yersinia pestis [14] or Proteus mirabilis [15]. In other
cases, only a single gene involved in LPS core biosynthesis is out of the waa gene cluster, for instance,
Plesiomonas shigelloides [16]. Nothing is known about the genomics or the LPS core structure from any
E. tarda strain, besides the role played by the waaL (O-antigen ligase) characterized from strain EIB
202 [17]. E. tarda strain EIB 202 was isolated from moribund fish Scophthalmus maximum in a marine
culture farm in China [18], and its full genome sequenced [19].
Here, the chemical structure of the core oligosaccharide in a pathogenic strain of E. tarda EIB 202
to proceed with the genomics of the core biosynthesis is reported for the first time.
2. Results
2.1. Isolation of the Core Oligosaccharide
LPS of E. tarda EIB 202 was isolated from bacterial mass with a yield of 0.5%. The mild acid
hydrolysis of the LPS yielded eight polysaccharide (PS) and oligosaccharide (OS) fractions: PSI-VI
consisting of a core oligosaccharide substituted by several repeating units, and OSVII and OSVIII—the
unsubstituted core oligosaccharide fractions. The high yield of PSI-VI suggested the smooth (S-LPS)
type of E. tarda EIB 202 LPS. The data presented herein concern the OSVIII fraction. The differences
between OSVII and OSVIII fractions are presented herein based on MALDI-TOF MS (matrix assisted
laser desorption/ionization-time of flight mass spectrometry) and ESI MSn (electrospray ionization
mass spectrometry) analysis.
2.2. Structure Analysis of the Core Oligosaccharide Fractions
The chemical analyses of OSVIII showed the presence of 2,3,7-trisubstituted L,D-Hepp,
3,4-disubstituted L,D-Hepp, 7-substituted L,D-Hepp, two terminal D-GlcpN, two terminal D-Glcp,
two 4-substituted D-GalpA, and 5-substituted Kdop. The analyses of OSVII showed the presence of
monosaccharides identified for OSVIII and additionally two sugar residues: the terminal D-Galp, and
3-substituted D-GlcpNAc was identified instead of the terminal D-GlcpN in OSVIII.
The 1H NMR (nuclear magnetic resonance) spectrum of the OSVIII contained main signals for
nine anomeric protons, and signals characteristic for the deoxy protons of Kdop residue belongs
to part of the core oligosaccharide (residues A–J). The HSQC-DEPT (heteronuclear single-quantum
correlation-distortionless enhancement by polarization transfer) spectra obtained for the OSVIII
fraction contained signals for nine major anomeric protons and carbons, and Kdo spin systems,
respectively (Figure 1 and Table 1).
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Figure 1. (A–D) Selected regions of the 1H–13C HSQC-DEPT (heteronuclear single-quantum
correlation–distortionless enhancement by polarization transfer) and (E) 1H–1H NOESY (nuclear
overhauser spectroscopy) spectra of the fraction OSVIII of Edwardsiella tarda EIB 202 lipopolysaccharide
(LPS); (F) anomeric region of the 1H–13C HSQC-DEPT spectrum of the fraction OSVII with marked
difference in comparison with OSVIII. The cross-peaks are labeled as shown in the text.
Residue A was identified as the 5-substituted Kdo on the basis of characteristic deoxy proton
signals at δH 1.96 ppm (H-3ax) and δH 2.29 ppm (H-3eq), as well as a high chemical shift of the C-5
signal (δC 75.7 ppm). Residue B (δH/δC 5.19/101.7 ppm, 1JC-1,H-1 ~175 Hz) was recognized as the
3,4-disubstituted L-glycero-α-D-manno-Hepp residue on the basis of the small vicinal couplings between
H-1, H-2, and H-3 and relatively high chemical shifts of the C-3 (δC 74.7 ppm) and the C-4 (δC 74.4 ppm)
signals. Residue C (δH/δC 4.51/103.3 ppm, 1JC-1,H-1 ~163 Hz) and residue H (δH/δC 4.63/103.2 ppm,
1JC-1,H-1 ~166 Hz) were recognized as the β-D-Glcp on the basis of the large vicinal couplings between
all protons in the sugar ring. Residue D (δH/δC 5.44/99.6 ppm, 1JC-1,H-1 ~175 Hz) was recognized as
the 2,3,7-trisubstituted L-glycero-α-D-manno-Hepp residue from the 1H and 13C chemical shift values,
small vicinal couplings between H-1, H-2, and H-3 and relatively high chemical shift values of the C-2
(δC 78.6 ppm), C-3 (δC 80.0 ppm), and C-7 (δC 73.3 ppm) signals. Residue E (δH/δC 4.98/103.2 ppm,
1JC-1,H-1 ~173 Hz) was recognized as the 7-substituted L-glycero-α-D-manno-Hepp from the 1H and 13C
chemical shifts, the small vicinal couplings between H-1, H-2, and H-3 and the relatively high chemical
shift value of the C-7 (δC 72.0 ppm) signal. Residues F (δH/δC 5.12/99.8 ppm, 1JC-1,H-1 ~175 Hz) was
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recognized as the 4-substituted α-D-GalpA based on the characteristic five proton spin system, the high
chemical shifts of the H-3 (δH 4.16 ppm), H-4 (δH 4.62), H-5 (δH 4.41), and C-4 (δC 77.9 ppm) signals,
the large vicinal couplings between H-2 and H-3 and small vicinal coupling between H-3, H-4, and
H-5. Residue I (δH/δC 5.47/102.5 ppm, 1JC-1,H-1 ~174 Hz) was also recognized as the 4-substituted
α-D-GalpA residue based on the similar characteristic five proton spin system. Residues G (δH/δC
5.33/95.6 ppm, 1JC-1,H-1 ~176 Hz) and J (δH/δC 5.29/97.0 ppm, 1JC-1,H-1 ~176 Hz) were recognized as
the terminal α-D-GlcpN due to the large coupling between H-1, H-2, and H-3 and the small vicinal
coupling between H-3, H-4, and H-5, as well as the chemical shift value of the C-2 (δC 55.1 and δC 55.1
for G and J, respectively). The 1D 31P NMR spectrum showed no indication of phosphate groups in
the OSVIII.
Additionally, the residue K (δH/δC 5.06/99.8 ppm, 1JC-1,H-1 ~165 Hz) was recognized as the
terminal α-D-GlcpNAc from a low 13C chemical shift of the C-2 signal (δC 54.6 ppm), and the large
vicinal couplings between all ring protons. The N-acetyl group at δH/δC 2.13/23.2 ppm (δC 175.9 ppm)
was identified. The presence of heterogeneity in OSVIII was due to partial replacement of α-D-GlcpN
(residue J) by α-D-GlcpNAc (residue K). The last sugar residue M (δH/δC 4.45/103.6 ppm, 1JC-1,H-1
~163 Hz), identified only in OSVII, was recognized as the terminal β-D-Galp due to the large vicinal
couplings between H-1, H-2, and H-3 and the small vicinal couplings between H-3, H-4, and H-5. The
terminal residue M in OSVII is linked to C-3 of → 3)-α-D-GlcpNAc (residue K) corresponding to the
terminal form of this residue in the OSVIII.
In the HSQC-DEPT spectra of OSVIII (at δH/δC 3.90/41.8 ppm), additional negative CH2 signals
were detected. These resonances showed correlation with a carbonyl carbon signals at δC 168.0 ppm
in the HMBC (heteronuclear multiple bond correlation) spectra, suggesting the presence of glycine
(residue L). This residue was also confirmed by mass spectrometry.
The monosaccharide sequence in OSVIII was established using a NOESY (nuclear overhauser
spectroscopy) and HMBC experiments. NOESY spectra showed strong inter-residue cross-peaks
between the following transglycosidic protons: H-1 of B/H-5 of A, H-1 of D/H-3 of B, H-1 of C/H-4
of B, H-1of E/H-7,7′ of D, H-1 of F/H-7,7′ of E, H-1 of G/H-4 of F, H-1 of H/H-2 of D, H-1 of I/H-3 of
D, and H-1 of J/H-4 of I. (Figure 1E). The HMBC spectrum of OSVIII confirmed substitution positions
of all of the monosaccharide residues (data not shown). Additionally, NOESY showed the cross-peak
between H-1 of K and H-4 of I*, and it also provided evidence for the heterogeneity of OSVIII with the
presence of α-D-GlcpNAc and as a substitution of 4-substituted α-D-GalpA (residue I) in OSVIII.
The OSVIII and OSVII fractions were analyzed by ES MSn and MALDI-TOF MS/MS. Ten sugar
residues: two Glc, three Hep, two GalA, two GlcN, and Kdo, give together a monoisotopic mass
of 1812.567 Da (MOSVIII). Eleven sugar residues from OSVII give together a monosotopic mass of
2016.630 Da. The negative ESI MSn (Figure 2A) mass spectrum of OSVIII showed the main ion
at m/z 905.2 [MOSVIII-2H]2− correspond to core oligosaccharide (OSVIII), and ions correspond to
core substituted with the glycine (Gly) residue at m/z 933.7 [MOSVIII+Gly-2H]2− and m/z 924.7
[MOSVIII+Gly-H2O-2H]2−. The negative ESI MSn mass spectrum of OSVII showed the main ion at
m/z 1035.8 [MOSVII+Gly-2H]2−, which represented the complete core oligosaccharide substituted by
Gly (Figure 2B).
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Figure 2. ESI (electrospray ionization) mass spectra of the core oligosaccharide fractions (A) OSVIII
and (B) OSVII of E. tarda EIB 202.
 
Figure 3. MALDI-TOF (matrix assisted laser desorption/ionization-time of flight) MS/MS
fragmentation mass spectra of the ions (A) at m/z 1870.16 [MOSVIII+Gly+H]+, (B) at m/z 1813.15
[MOSVIII+H]+, (C) at m/z 2074.19 [MOSVII+Gly+H]+, and (D) at m/z 2017.19 [MOSVII+H]+ of E. tarda
EIB 202, differing in the presence of glycine.
The location of glycine was determined by the positive ion mode MALDI-TOF MS/MS. The ions
at m/z 1813.15 [MOSVIII+H]+, at m/z 1870.16 [MOSVIII+Gly+H]+, at m/z 2017.19 [MOSVII+H]+, and at
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m/z 2074.19 [MOSVIII+Gly+H]+ were selected for further fragmentations by the use of positive ion
mode MALDI-TOF MS/MS. The main daughter ions detected in the MALDI-TOF MS/MS spectra
were explained. In Figure 3A, the ion at m/z 162.00 corresponds to GlcN, while the ion at m/z 218.98
was explained by the GlcN–Gly. The similar pair of fragment ions at m/z 1116.93 and at m/z 1059.94
with the mass difference corresponding to the glycine residue was also identified. These ions were
not identified on the spectrum of the ion m/z 1813.15 fragmentation (Figure 3B). In Figure 3C, the
daughter ion at m/z 260.94 was subsequently attributed to the GlcNAc-Gly fragment. The similar
pair of fragment ions at m/z 1911.91 and at m/z 1651.79 with the mass difference corresponding to
the glycine residue was also identified. These ions were not identified on the spectrum of the ion
at m/z 2017.19 fragmentation (Figure 3D). These observations indicate that glycine substitutes GlcN
(residue J) in OSVIII and GlcNAc (residue K) in OSVII. The positions of glycine in OSVIII and OSVII
were not determined.
2.3. Organization of the E. tarda Strain EIB 202 waa Gene Cluster
In most Enterobacteriaceae studied so far, the genes involved in core LPS biosynthesis were found
clustered (waa gene cluster). When we inspected the currently available E. tarda strain EIB 202 genome,
we found a clear region with the waa gene cluster (proteins encoded ETAE_0083 to ETAE_0072). This
waa region, like in the majority of Enterobacteriaceae, is started by the hldE (encoded protein ETAE_0083),
which codifies for the ADP-L-glycero-D-mannoheptose-6-epimerase, and the end flanked by the coaD
(encoded protein ETAE_0071) codifying for phosphopantetheine adenylyltransferase [20].
Despite the genome annotation, it seems that more of the genes are shared by different
Enterobacteriaceae mainly K. pneumoniae or P. shigelloides, which were previously characterized by
us [7,14]. Table 2 shows proteins encoded from E. tarda EIB 202 waa.
Table 2. Characteristics of the proteins encoded from E. tarda EIB 202 waa.
Protein Homologus Protein Predicted Function % Identity/Similarity
ETAE_0083 HldE Enterobacteriaceae ADP-L-glycero-D-manno Heptose-6-epimerase 85/91
ETAE_0082 WaaF Enterobacteriaceae ADP-heptose:LPS heptosyl transferase II 76/86
ETAE_0081 WaaC Enterobacteriaceae ADP-heptose:LPS heptosyl transferase I 78/84
ETAE_0080 WaaL Klebsiella pneumoniae O-antigen ligase 29/46
ETAE_0079 Similar only to WabK Klebsiella pneumoniae unknown 34/53
ETAE_0078 WapC Plesiomonas shigelloides UDP-galacturonic a transferase α(1→7) to HepIII acid 76/89
ETAE_0077 WapB Plesiomonas shigelloides UDP-N-acetyl glucosamine α(1→4) to GalAII 61/82
ETAE_0076 WabN Klebsiella pneumoniae Protein deacetilase 77/89
ETAE_0075 WaaQ Klebsiella pneumoniae ADP-heptose: LPS heptosyl 72/83
ETAE_0074 WabG Klebsiella pneumoniae UDP-galacturonic acid transferase α(1→3) to HepIII 78/87
ETAE_0073 WabH Klebsiella pneumoniae UDP-N-acetyl glucosamine transferase α(1→4) to GalAI 70/83
ETAE_0072 WaaA Enterobacteriaceae 3-deoxy-D-manno-octulosonic acid transferase 88/96
ETAE_0071 WapE Plesiomonas shigelloides UDP-galactose transferase β(1→4) to l-HepI 82/97
ETAE_0070 CoaD Enterobacteriaceae Phosphopantetehine adenylyltransferase 81/89
3. Discussion
Here, the chemical structure and genomics of the complete undecasaccharide core structure of
E. tarda EIB 202 LPS are presented for the first time. This core oligosaccharide is heterogeneous. The
heterogeneity corresponded to the partial lack of β-D-Galp and the replacement of α-D-GlcpNAcGly by
α-D-GlcpNGly. The functions of the genes found in the waa gene cluster from the E. tarda strain EIB 202
seems to be in agreement with the chemical structure of the LPS-core. The E. tarda core LPS structure is
highly similar to that of K. pneumoniae at least up to the outer-core residue GlcNI and P. shigelloides
302-73 in practically up to the last monosaccharide residue that links the O-antigen LPS [7,14]. WabH
and WapB are enzymes that transfer GlcNAc to a GalA in different acceptor substrates of LPS-core in an
α(1→4) linkage. WabG and WapC are enzymes that transfer GalA to a Hep also in different LPS-core
substrates and with different linkage, α(1→3) and α(1→7), respectively. It is important to note that
besides performing the same enzymatic functions the acceptor substrate differences determine that the
enzymes showed very little homology; furthermore, WabG and WapC are more similar among them
(26 identity and 47% similarity) than WabH and WapB are (24% identity and 46% similarity), except that
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the latter ones showed identical linkage. This point indicates the importance of the substrates in the
enzymatic reactions to build-up the LPS-core molecules. K. pneumoniae WabK is a glycosyltransferase
that incorporates a Glc residue in a β(1→4) to GlcN. E. tarda waa ORF4, according to the E. tarda
strain EIB 202 LPS-core established, as well as their low homology but unique to WabK, could be the
galatosyltransferase that incorporates a Gal residue in a β(1→4) to GlcNAc E. tarda waa Orf5 encoding
for ETAE_0079 (Table 2). All genes from the E. tarda waa cluster were found in the E. ictaluri genomes,
except for wapB and wapC, which seems to be unique for the species E. tarda. All of the other genes from
the E. tarda waa cluster (hldE, waaF, waaC, ETAE_0079, waaN, waaQ, wabG, wabH, waaA, and wapE) show
98% or more identity to the related E. ictaluri LPS-core biosynthetic genes according to their genomes.
Of course, E. ictaluri waaL, which is the O-antigen ligase, is a bifunctional enzyme recognizing the
O-antigen LPS and the LPS-core, as it usual shows a reduced identity (56%) compared to E. tarda waaL.
Nevertheless, the E. ictaluri waaL-encoded protein shows the typical transmembrane domains (data
not shown).
The E. tarda LPS motif β-Glc-(1→2)-α-L-HepII seems not to be encoded by any of the
glycosyltransferases found in the waa cluster. This LPS motif is identical to a previously studied
by us in the P. shigelloides strain 302-73 encoded by WapG. For this reason, we decided to blastx the
P. shigelloides 302-73 WapG [16] against the E. tarda strain EIB 202 genome. We found a clear unique
candidate, the gene encoding ETAE_1955, which showed 58% identity and 74% similarity to WapG.
We suggest that it could be responsible for β-Glc-residue linked to HepII-[(1→2)-α-L-HepII].
4. Materials and Methods
4.1. Growth Conditions and Isolation of the Lipopolysaccharide and the Polysaccharide
Bacteria E. tarda EIB 202 was obtained from the Y. Zhang laboratory [18]. The bacteria were grown
and harvested as described previously [21]. The LPS was extracted from bacterial cells of E. tarda EIB
202 by the hot phenol/water method [22]. LPS (200 mg) was degraded by treatment with 1.5% acetic
acid at 100 ◦C for 45 min. The supernatant was fractionated on a column (1.6 × 100 cm) of Bio-Gel P-10,
equilibrated with 0.05 M pyridine/acetic acid buffer, pH 5.4. Eluates were monitored with a Knauer
differential refractometer, and all fractions were checked by NMR spectroscopy and mass spectrometry
(MALDI-TOF and ESI MSn).
4.2. Chemical Methods
Methylation of oligosaccharide fractions was performed according to the method described by
Ciucanu and Kerek [23]. The absolute configurations of the monosaccharides were determined as
described by Gerwig et al. [24]. Alditol acetates and partially methylated alditol acetates were analyzed
by gas chromatography GC-MS with the Thermo Scientific TSQ system using an RX5 fused-silica
capillary column (0.2 mm by 30 m) and a temperature program of 150 → 270 ◦C at 12 ◦C/min.
4.3. Instrumental Methods
All NMR spectra were recorded on a Bruker Avance III 600 MHz spectrometer equipped with a
5 mm QCI cryoprobe with z-gradient. The measurements were performed at 303 K without sample
spinning and using the acetone signal (δH/δC 2.225/31.05 ppm) as an internal reference. The signals
were assigned by one- and two-dimensional experiments: 1H-1H COSY (correlation spectroscopy),
TOCSY (total correlated spectroscopy), NOESY, 1H-13C HSQC-DEPT, HSQC-TOCSY, and HMBC. In the
TOCSY experiments, the mixing times were 30, 60, and 100 ms. The NOESY experiment was performed
with the mixing time of 200 ms, and HMBC experiment with a delay of 80 ms. For observation of
phosphorus atoms, one-dimensional 31P NMR spectra were recorded. The data were acquired and
processed using standard Bruker software. The processed spectra were assigned with the help of the
SPARKY program [25].
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Core oligosaccharide (1 mg/mL in mQ) fractions were analyzed using a MALDI-TOF
Ultraflextreme (Bruker, Germany) instrument. The MALDI-TOF MS spectra were obtained in a
positive ion mode. 2,5-Dihydroxybenzoic acid (10 mg/mL in 1:1 AcN/0.2 M citric acid [v/v]) was
used as a matrix for analyses.
Negative-ion electrospray ionization mass spectra (ESI-MSn) were recorded using an Amazon SL
(Bruker Daltonics, Bremen, Germany) ion trap mass spectrometer. The samples were dissolved in a 50
μg/mL acetonitrile-water-formic acid solution (50:50:0.5 [v/v/v]).
4.4. Comparative Genomics
For each analyzed genome we gathered all coding sequence (CDS) and pseudo-CDS information
by parsing NCBI GenBank records. When we obtained the UniProt Knowledge Base records for
these loci using the cross-reference with Entrez GeneIDs and parsed them for gene names, functional
annotations, and associated COG, PFAM, and TIGRFAM protein domains were studied. To annotate
orthologs, we wrote custom scripts to analyze reference sequence alignments made to subject genomes
with blastn and tblastn via NCBI’s web application programming interface.
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Abstract: Erwinia amylovora (E. amylovora) is the first bacterial plant pathogen described and
demonstrated to cause fire blight, a devastating plant disease affecting a wide range of species
including a wide variety of Rosaceae. In this study, we reported the lipopolysaccharide (LPS) core
structure from E. amylovora strain CFBP1430, the first one for an E. amylovora highly pathogenic strain.
The chemical characterization was performed on the mutants waaL (lacking only the O-antigen LPS
with a complete LPS-core), wabH and wabG (outer-LPS core mutants). The LPSs were isolated from
dry cells and analyzed by means of chemical and spectroscopic methods. In particular, they were
subjected to a mild acid hydrolysis and/or a hydrazinolysis and investigated in detail by one and
two dimensional Nuclear Magnetic Resonance (NMR) spectroscopy and ElectroSpray Ionization
Fourier Transform-Ion Cyclotron Resonance (ESI FT-ICR) mass spectrometry.
Keywords: lipopolysaccharide; Erwinia amylovora; NMR; ESI FT-ICR; structural determination
1. Introduction
Erwinia amylovora is the causal agent of fire blight, a disease of nutritionally important members
of the family Rosaceae, such as apple and pear trees. The symptoms in apple plants are present on
rootstocks, blossoms, shoots, and fruits [1]. On fruits, the disease provokes the developent of ooze,
which is composed of bacteria, polysaccharides, and plant sap [1]. Bacteria are transported by insects,
rain, birds, wind-wipping, and hail from the ooze to flowers. From flower infection, it can also be
transferred to lateral parts of the plant through an endophytic mechanism [2].
Two major virulence determinants are known for the pathogenesis of Erwinia: (i) one involves
the hrp/dsp gene cluster, the role of which is to secrete and deliver proteins from bacteria to plant
apoplasts and cytoplasm [1]; (ii) the second is the production of two types of exopolysaccharides (EPS),
amylovoran and levan [3,4].
The outer membrane (OM) of almost all Gram-negative bacteria and of some cyanobacteria [5–8]
contains lipopolysaccharides (LPSs), where they constitute approximately 75% of the outer surface.
They are amphiphilic endotoxic molecules necessary for the viability and survival of Gram-negative
bacteria, as they seriously contribute to the structural integrity of the OM and to the protection of the
bacterial cell envelope [9].
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The colony morphology of Gram-negative bacteria can appear as smooth or rough as a
consequence of a different structure of the lipopolysaccharides, named smooth (S-LPS) or rough
(R-LPS), respectively. The structure of a S-LPS molecule can be described as three covalently linked
domains: the glycolipid portion, called lipid A; the intermediate core oligosaccharide region (core);
and the O-specific polysaccharide (O-chain) [10]. Instead, the R-LPSs (named lipooligosaccharides,
LOSs) completely lacks the O-specific polysaccharide chain, either due to genetic mutation or to the
inherent nature of bacteria [11].
Bacterial lipopolysaccharides show multiple roles in plant–microbe interactions. LPS give a
contribution to the low permeability of the outer membrane, which acts as a barrier to protect
microorganisms from plant-derived antimicrobial substances. LPS-defective mutants display
augmented in vitro sensitivity to antibiotics and antimicrobial peptides and, upon introduction into
susceptible plants, the numbers of viable bacteria often decay very quickly [12–14].
In this study we characterized the lipopolysaccharide core structure from the strain CFBP1430,
the first one completely sequenced for a highly pathogenic E. amylovora. In particular, the results
about waaL, wabH, and wabG mutants are reported. We studied wabH and wabG mutants because
we found these genes in the Erwinia amylovora strain CFBP1430 wb; they were fully characterized
in Klebsiella pneumoniae and Serratia marcescens, and both correspond to the outer-LPS core [15].
The lipooligosaccharides were degraded both by mild hydrazinolysis (O-deacylation) and hot KOH
(N-deacylation). Both products were investigated by chemical analysis, by 1H and 13C NMR
spectroscopy, and by ESI FT-ICR spectrometry.
2. Results and Discussion
2.1. Preparation and Structural Characterization of Oligosaccharides from EaΔwaaL LPS
The LPSs from the waaL, wabH, and wabG mutants (EaΔwaaL, EawabH, and EaΔwabG,
respectively) of the Erwinia amylovora strain CFBP1430 were extracted by the phenol-chloroform-light
petroleum (PCP) method. WabG is responsible for the transfer of D-GalA to the O-3 position
of L,D-Hep II, and WabH transfers a D-GlcNAc residue from UDP-GlcNAc to the D-GalA [15].
The monosaccharides composition was performed as already reported [16]. In particular, the Gas
Chromatography-Mass Spectrometry (GC-MS) analysis of methyl and octyl glycosides for EaΔwaaL
and EaΔwabH mutant LPSs revealed the following sugars; D-Glc, D-GalA, D-GlcN, L,D-Hep, D,D-Hep,
and Kdo. When this analysis was performed on EaΔwabG LPS, the lack of D-GalA and D,D-Hep
was observed.
The removal of fatty acids from EaΔwaaL LPS was performed both by strong alkaline and acetic
acid hydrolyses. The obtained products were analyzed by ESI FT-ICR mass spectrometry. In addition,
mono- and two-dimensional NMR spectroscopy (1H,1H DQF-COSY, 1H,1H TOCSY, 1H,1H ROESY,
1H,13C HSQC-DEPT, 1H,13C HSQC-TOCSY, and 1H,13C HMBC) was allowed to assign all the proton
and carbon chemical shifts of each mutant. The anomeric configurations were identified on the basis
of both 13C chemical shift values and 3JH1,H2 coupling constants. The sequence of the residues in all
the oligosaccharides was obtained both by long-range scalar couplings and by nuclear Overhauser
enhancement (NOE) data.
Starting from the totally deacylated product (L-OSKOH, Scheme 1, structures 1a–c), the negative
ion mode ESI FT-ICR mass spectrum of the sample identified eight main species (Figure 1 and Table 1).
Species M1, occurring at 2220.595 Da (calculated molecular mass 2220.586 Da), represented the higher
molecular mass oligosaccharide chain containing the phosphorylated lipid A backbone and the
core structure.
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R- -D- GalA-(1 3)- -L,D-Hep-(1 3)- -L,D-Hep-(1 5)-Kdo-(2 6)- -D-GlcN4P- -D-GlcN1P




R = -L,D-Hep-(1 2)- -D,D-Hep-(1 2), 1a
R = t- -D,D-Hep-(1 2), 1b
R = H, 1c
LM
L
Scheme 1. Structures of the totally deacylated LPS fraction (L-OSKOH) isolated from the E. amylowora
EaΔwaaL mutant.
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Figure 1. Charge deconvoluted ElectroSpray Ionization Fourier Transform-Ion Cyclotron Resonance
(ESI FT-ICR) mass spectrum of the totally deacylated lipopolysaccharide (LPS) fraction (L-OSKOH)
isolated from the E. amylowora EaΔwaaL mutant. The spectrum was acquired in negative ion mode.
The mass numbers given refer to the monoisotopic peak of the neutral molecular species.
Table 1. Composition of the main species observed in the charge deconvoluted ESI FT-ICR mass
spectrum of the totally deacylated LPS (L-OSKOH) from a E. amylowora waaL mutant (EaΔwaaL).
Species Observed Mass (Da) Calculated Mass (Da) Composition
M1 2220.595 2220.589 GlcN2P2Kdo2Hep5Glc1ΔHexA
M2 2058.390 2058.536 GlcN2P2Kdo2Hep5ΔHexA
M3 2028.528 2028.525 GlcN2P2Kdo2Hep4Glc1ΔHexA
M4 1866.475 1866.473 GlcN2P2Kdo2Hep4ΔHexA
M5 1836.464 1836.462 GlcN2P2Kdo2Hep3Glc1ΔHexA
M6 1678.444 1678.440 GlcN2P2Kdo2Hep3Glc1
M7 1674.410 1674.409 GlcN2P2Kdo2Hep3ΔHexA
M8 1644.402 1644.399 GlcN2P2Kdo2Hep2Glc1ΔHexA
In particular, the following composition was attributed to the M1 species: GlcN2P2Kdo2Hep5
Glc1ΔGalA, where ΔGalA represents an unsaturated galacturonic acid. The presence of this acid unit
in the M1 species clearly indicated that the strong alkaline conditions determined the lack of one
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or more sugars from GalA, due to a β-elimination reaction [17]. Species M3, M5, and M8 differed
from M1 in their heptoses composition, displaying four units in M3 and three and two in M5 and
M8, respectively. The remaining species, M2, M4, and M7, lacked a glucose unit respect to M1, M3,
and M5, respectively, thus confirming the terminal position for this residue, while the M6 species
lacked ΔGalA compared to M5. Further mass peaks originate from an additional phosphate group
P (Δm = +79.966 u) and/or one linked C14:0(3OH) fatty acid (Δm = +226.193 u) due to incomplete
deacylation. Finally, F1–F6 are fragments induced during the ESI process leading to the cleavage of the
lipid A backbone GlcN2P2 (Δm = −500.081 u).
Despite the complexity of the 1H-13C Heteronuclear Single Quantum Coherence-Distortionless
Enhancement by Polarization Transfer (HSQC-DEPT) experiment (Figure 2), it was possible to assign
the signals of the main species, M1, M3, and M5. All the NMR data (Table 2, structures 1a–c) strongly
suggested that the fractions L-OSKOH and the structure of the oligosaccharide OS1 obtained from the
previously published K. pneumoniae 52145 waaL mutant [17] possessed a common structural element
constituted by the residues A, B, C, D, E, F, G, H, and I (monosaccharide units are as shown in Table 2),
in agreement with the strain genomics.
 
 
Figure 2. Anomeric (a) and carbinolic (b) region of 1H-13C HSQC-DEPT of the totally deacylated LPS
(L-OSKOH) from E. amylowora waaL mutant. All the correlation cross-peaks in the anomeric region
indicate the signals of structures 1a–c. The spectrum was recorded in D2O at 298 K at 600 MHz.
Table 2. 1H and 13C chemical shifts (δ) of sugar residues of core oligosaccharides from Erwinia amylovora
LPS. Nuclear Magnetic Resonance (NMR) spectra were recorded in D2O at 600 MHz at 298 K.
Residue Nucleus
H1 H2 H3 H4 H5 H6 H7 H8
C1 C2 C3 C4 C5 C6 C7 C8
α-GlcN1P A, 1a–c
1H 5.65 3.37 3.94 3.41 4.21 3.88/4.27
13C 92.0 55.9 71.2 71.1 73.8 70.2
α-GlcN1P A, 3
1H 5.53 3.28 3.80 3.51 4.05 3.65/4.20
13C 92.0 55.9 71.0 70.9 73.4 71.0
α-GlcN1P A,4
1H 5.54 3.30 3.80 3.51 4.04 3.65/4.19
13C 92.0 57.1 71.0 71.1 73.6 71.3
β-GlcN4P B, 1a–c
1H 4.99 3.06 3.88 3.88 3.72 3.62/3.75
13C 100.9 56.9 73.1 74.6 75.6 63.5
β-GlcN4P B, 3
1H 4.72 2.93 3.73 3.72 3.60 3.35/3.57
13C 100.9 56.9 70.9 74.0 72.3 63.7
β-GlcN4P B, 4
1H 4.73 2.94 3.72 3.73 3.63 3.35/3.60




1.88/2.12 4.21 4.21 4.14 4.17 3.77/3.92




1.81/1.98 4.03 4.17 3.83 3.51 3.62-3.87
13C 36.0 71.6 70.1 74.0 73.4 64.3
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Table 2. Cont.
Residue Nucleus
H1 H2 H3 H4 H5 H6 H7 H8




1.88/2.04 3.99 4.17 3.88 3.54 3.61-3.87




1.82/2.18 4.09 4.06 3.71 4.09 3.77/3.99




1.67/2.06 3.95 3.95 3.60 3.56 3.56/3.87




1.66/2.00 3.96 3.94 3.62 3.56 3.61/3.78
13C 36.3 67.7 67.9 73.3 73.3 65.1
3,4-α-L,D-Hep E, 1a–c
1H 5.12 4.13 4.24 4.25 4.10 4.17 3.76
13C 102.2 71.5 77.1 75.1 70.1 70.2 64.5
3,4-α-L,D-Hep E, 2a,b
1H 5.12 4.07 4.23 4.23 4.10 4.15 3.75
13C 101.9 71.4 77.1 75.3 70.3 69.8 64.4
3,4-α-L,D-Hep E, 3
1H 5.19 3.95 4.06 4.19 4.18 4.00 3.69
13C 100.1 71.8 75.1 74.4 72.2 70.2 65.1
3,4-α-L,D-Hep E, 4
1H 5.16 4.00 3.99 4.15 4.12 3.98 3.68/3.89
13C 103.0 72.0 75.6 74.6 73.3 70.3 73.3
t-β-Glc F, 1a-c
1H 4.60 3.33 3.53 3.41 3.42 3.77/3.90
13C 103.8 75.3 77.0 71.7 77.7 62.5
t-β-Glc F, 2a,b
1H 4.62 3.31 3.54 3.41 3.42 3.77/3.90
13C 104.0 75.3 77.0 71.1 77.5 62.5
t-β-Glc F, 3
1H 4.46 3.18 3.41 3.26 3.30 3.63/3.78
13C 103.2 75.0 76.5 71.1 77.3 62.7
t-β-Glc F, 4
1H 4.43 3.19 3.39 3.23 3.36 3.61-3.85
13C 103.6 75.0 76.9 71.6 77.8 62.8
3,7-α-L,D-Hep G, 1a–c
1H 5.28 4.26 4.13 3.99 3.78 4.21 3.80
13C 102.1 70.8 81.1 66.9 74.0 67.1 71.2
3,7-α-L,D-Hep G, 2a,b
1H 5.26 4.12 4.03 4.01 3.90 4.17 3.77
13C 102.0 71.1 80.8 66.9 74.0 71.1 71.2
3,7-α-L,D-Hep G, 3
1H 5.27 4.08 3.89 3.83 3.92
n.d.
3.69
13C 102.2 70.7 80.6 66.9 73.3 72.7
t-α-L,D-Hep G, 4
1H 5.16 4.06 3.77 3.77 3.56 3.95 3.55
13C 100.1 71.0 72.0 67.6 73.2 70.3 64.7
t-α-L,D-Hep H, 1a–c
1H 5.02 4.04 3.90 3.89 3.67 4.06 3.72
13C 102.0 73.6 70.9 67.6 72.9 70.5 63.6
t-α-L,D-Hep H, 2a,b
1H 4.94 4.02 4.02 3.87 3.64
n.d n.d13C 101.8 73.1 71.3 67.6 72.7
t-α-L,D-Hep H, 3
1H 4.84 3.88 3.91 3.88 3.63 3.93 3.64
13C 102.9 71.3 70.3 67.0 73.4 64.6 62.9
2-Δ-GalA I, 1a,b
1H 5.58 4.02 4.53 5.82
13C 99.6 75.8 65.8 108.9
t-Δ-GalA I, 1c
1H 5.40 3.87 4.42
n.d.13C 101.6 71.9 67.3
2,4-α-GalA I, 2a,b
1H 5.48 4.07 4.22 4.23 4.47
13C 99.5 80.4 68.5 77.2 72.6 176.2
2-α-GalA I, 3
1H 5.39 3.91 3.96 4.21 4.34
13C 98.9 80.6 69.2 72.2 73.7 176.8
2-α-D,D-Hep L, 1a
1H 5.35 4.06 3.97 3.89 n.d. 4.12 3.61
13C 98.9 80.0 71.4 68.5 n.d. 72.1 63.5
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Table 2. Cont.
Residue Nucleus
H1 H2 H3 H4 H5 H6 H7 H8
C1 C2 C3 C4 C5 C6 C7 C8
t-α-D,D-Hep L, 1b
1H 5.18 4.03 3.90 3.83 3.87 4.04 3.82
13C 99.9 71.3 72.1 68.7 73.9 71.4 63.5
2-α-D,D-Hep L, 2a,b
1H 5.28 3.99 3.99 3.81 3.99 4.05 3.84
13C 96.9 80.8 71.4 68.9 75.0 71.4 63.6
2-α-D,D-Hep L, 3
1H 4.99 3.87 3.75 3.67 3.92 4.09 3.69
13C 98.3 80.6 71.7 68.7 73.3 73.1 63.1
t-α-L,D-Hep M, 1a
1H 5.09 4.07 4.07 3.88 3.70
n.d. n.d.13C 103.5 71.3 73.7 67.7 73.1
t-α-L,D-Hep M, 2a,b
1H 5.05 4.05 4.06 3.86 n.d.
n.d. n.d.13C 103.5 71.4 73.8 67.7
t-α-L,D-Hep M, 3
1H 5.21 3.89 3.75 3.83 4.18
n.d.
3.56/3.78
13C 101.9 71.5 70.1 66.8 72.1 64.8
4-α-GlcN N, 2a,b
1H 5.19 3.27 3.85 3.79 4.17 3.83
13C 97.6 55.3 72.5 77.0 72.5 61.3
6-α-Glc O, 2a,b
1H 5.49 3.62 3.74 3.90 3.54 3.88/4.20
13C 100.7 72.8 74.2 73.0 70.8 69.8
t-β-Glc P, 2a
1H 4.50 3.33 3.51 3.42 3.47 3.74/3.92
13C 103.9 74.5 77.0 71.0 77.3 62.3
2-β-Glc P, 2b
1H 4.62 4.47 3.59 3.45 3.46 3.74/3.92
13C 103.9 78.9 75.9 70.9 77.3 62.3
t-β-Glc Q, 2b
1H 4.36 3.61 3.75 3.47 4.17
n.d.13C 99.2 72.9 74.2 70.8 72.9
All the species possessed α-GlcN1P residue at the reducing end (A, H1, δ 5.65 ppm; C1, δ 92.0
ppm), originating from the lipid A backbone. The second residue of glucosamine of the lipid A (B, H1,
δ 4.99 ppm, C1, δ 100.9 ppm) was O-4 phosphorylated, as suggested by the downfield shift of both H4
and C4 chemical shifts [18]. In all the oligosaccharides corresponding to the M1–M7 species, the core
region was linked to the lipid A backbone through an α-Kdo residue C, which was substituted at O-4
position by a second residue of Kdo (D).
Residues E, G, H, L, and M were identified as five manno-configured α-heptopyranoses due
to their small coupling constants 3JH1,H2 and 3JH2,H3 values. Downfield shifted carbon signals with
respect to reference values [19] indicated substitutions at O-3 and O-4 of residue E (C3 at 77.1 and C4
at 75.1 ppm, respectively) and at O-3 and O-7 of residue G (C3 at 81.1 ppm and C7 at 71.2 ppm). Both
residues H and M were identified as terminal units as none of their carbon signals were downfield
shifted. All the heptose residues were found to be L,D-configured except for L; in fact, for this
residue, the chemical shift of its C6 at 72.1 ppm suggested a D,D-configuration [20]. In addition,
the downfield shift of its C2 resonance at 80.0 ppm clearly indicated that it was substituted at this
position. Residue I, with H1/C1 at 5.58/99.6 ppm and H4/C4 at 5.82/108.9 ppm, was identified as a
α-threo-hex-4-enuronopyranosyl unit (ΔGalA).
Finally, residue F was assigned to a β-glucose residue, on the basis of the proton multiplicities
obtained by the DQF-COSY and TOCSY experiments. No downfield carbon chemical shifts were
observed for this residue, thus indicating its terminal non reducing end position.
The sequence of the residues was deduced from the HMBC experiment, which showed
correlations between C1 of L and H2 of I, H1 of I and C3 of G, H1 of G and C3 of E, C1 of H
and H7 of G, and C1 of F and H4 of E.
In addition, residue M was found to be linked at the O-2 position of residue L, as shown by NOE
contacts among H1 of M and both H1 and H2 of L, observed in the ROESY experiment. This last
completed and confirmed the above sequence by inter-residual dipolar couplings. In the same
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spectrum, the intra-residue NOE contacts were in agreement with the assigned relative configuration
of the monosaccharides.
All these data indicated for M1 species of L-OSKOH the oligosaccharide structure 1a. Structures
1b and 1c, corresponding to the species M3 and M5, were identified on the basis of their terminal
residue D,D-heptose and ΔGalA, respectively.
The LPS of EaΔwaaL mutant was then treated with 5% acetic acid at 100 ◦C, and the
supernatant was analyzed (L-OSAcOH, Scheme 2, structures 2a,b). Gas Chromatography-Mass
Spectrometry (GC-MS) analysis of the partially methylated alditol acetates of this sample indicated the
presence of terminal L,D-heptose, terminal glucose, terminal D,D-heptose, 2-substituted D,D-heptose,
2-substituted glucose, 6-substituted glucose, 4-substituted glucosamine 3,4-substituted L,D-heptose,
and 3,7-substituted L,D-heptose. Each sugar was recognized from both its Electronic Ionization (EI)
mass spectrum and the GC column retention time, by comparison with standards. The Kdo was not
revealed in this analysis, due to the presence of its anhydro form.
The negative mode ESI FT-ICR mass spectrum of 2 (Figure 3 and Table 3) and NMR data (Table 2)
revealed a complex mixture of oligosaccharides. The main component of the mass spectrum N2 species
was revealed to possess a common part with the oligosaccharides of L-OSKOH, constituted by the
residues E, F, G, H, L, and M. In addition, the trisaccharide β-Glc-(1 → 6)-α-Glc-(1 → 4)-α-GlcN-(1 →
was present at position O-4 of α-GalA I.
NOP
-L,D-Hep-(1 2)- -D,D-Hep-(1 2)- -D-GalA-(1 3)- -L,D-Hep-(1 3)- -L,D-Hep-(1 5)-Kdo




R- -D-Glc-(1 6)- -D-Glc-(1 4)- -D-GlcN-(1
R = H, 2a
R = -D-Glc-(1 2), 2b
Q  
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Figure 3. Charge deconvoluted ESI FT-ICR mass spectrum of supernatant of the acetic acid hydrolysed
LPS fraction (L-OSAcOH) isolated from E. amylowora waaL mutant. The spectrum was acquired in
negative ion mode. The mass numbers given refer to the monoisotopic peak of the neutral molecular
species. Further mass peaks originate from a: loss of H2O (Δm = −18.010 u); b: sodium adducts
[M − H + Na] (Δm = +21,979 u); c: an additional phosphate group (P − H + Na) (Δm = +101.948 u).
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Table 3. Composition of the main species observed in the charge deconvoluted ESI FT-ICR mass
spectrum of supernatant of the acetic acid hydrolysed LPS fraction (L-OSAcOH) isolated from
E. amylowora waa L. mutant.
Species Observed Mass (Da) Calculated Mass (Da) Composition
N1 2183.699 2183.698 Kdo1Hep5Glc4GalA1GlcN1
N2 2021.646 2021.645 Kdo1Hep5Glc3GalA1GlcN1
N3 1991.632 1991.635 Kdo1Hep4Glc4GalA1GlcN1
N4 1859.597 1859.592 Kdo1Hep5Glc2GalA1GlcN1
N5 1829.590 1829.578 Kdo1Hep4Glc3GalA1GlcN1
N6 1667.541 1667.529 Kdo1Hep4Glc2GalA1GlcN1
N7 1637.527 1637.518 Kdo1Hep3Glc3GalA1GlcN1
N8 1475.476 1475.466 Kdo1Hep3Glc2GalA1GlcN1
We compared our NMR data with the data already published for deacylated oligosaccharides
from Serratia marcenscens [19], and we found very similar chemical shifts, even if we recognized in
Erwinia an additional minor component (N1 species, Table 2 and Figure 3). In fact, the molecular mass
of the N1 species indicated an additional hexose with respect to that of N2. This residue (Q, Table 2)
was identified as gluco-configurated with an α anomeric configuration, as suggested by its 3JH1,H2
anomeric coupling constant of 3.5 Hz. A long-range heteronuclear scalar coupling between H1 of
Q and C2 of P indicated that in the N1 species the oligosaccharide substituting the O-4 of GalA had
the structure: α-Glc-(1 → 2)-β-Glc-(1 → 6)-α-Glc-(1 → 4)-α-GlcN. All these data were in agreement
with the methylation analysis, except for the 2,4-disubstituted galacturonic acid residue, which was
absent in the GC-MS chromatogram. This fact could be due to the hindrance of both oligosaccharides
substituting O-2 and O-4 positions of GalA, thus preventing its methylation.
2.2. Preparation and Structural Characterization of Oligosaccharides from EaΔwabH and EaΔwabG LPSs
The LPSs from EaΔwabH and EaΔwabG mutants were completely deacylated by hydrazine
followed by the KOH reaction. After purification on a gel filtration Sephadex G10 column, the samples,
named H-OSKOH and G-OSKOH respectively, were analysed by mono- and two-dimensional NMR
experiments (Table 2). The acetic acid hydrolysis was not performed on these two mutants as no
β-degradation was observed for these samples, indicating that no information was lost.
The 1H NMR spectrum of the totally deacylated EaΔwabH LPS (H-OSKOH, Figure S1, Supporting
Information) showed nine main anomeric proton signals, assigned to residues A–M, in the range
5.6–4.4 ppm. Signals in the range 2.2–1.5 ppm, attributable to the presence of the Kdo units, were
also present.
The galacturonic acid residue (residue I, Scheme 3, structure 3) was recognized from the chemical
shift of its C6 at δ 176.8 ppm (Table 2), which correlated with its H5 proton at δ 4.34 ppm in the
Heteronuclear Multiple Bond Correlation (HMBC) experiment.
-L,D-Hep-(1 2)- -D,D-Hep-(1 2)- -D-GalA-(1 3)- -L,D-Hep-(1 3)- -L,D-Hep-(1 5)-Kdo-(2 6)- -D-GlcN4P- -D-GlcN1P




Scheme 3. Structures of the totally deacylated LPS fraction (H-OSKOH) isolated from the E. amylowora
EaΔwabH mutant.
In addition, the O-substitution at position 2 of I was inferred by the long-range between H1 of L
and C2 of I. The value of the coupling constant 3JH1,H2 of the anomeric proton was found to be 3.5 Hz,
thus indicating for residue I an α configuration. The chemical shifts of heptoses E, G, H, L, and M
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were in agreement with that already found for structure 1, as well as that of terminal β-Glc F. Finally,
both the HMBC (Figure S2) and ROESY experiments indicated the sequence shown in structure 3,
which is in agreement with strain genomics.
The 1H-NMR spectrum of the totally deacylated EaΔwabG LPS, (G-OSKOH, Figure S3, Supporting
Information) showed only five anomeric proton signals. All the 1H and 13C chemical shifts of each
residue were identified and assigned by two-dimensional NMR experiments (Table 2). NMR data,
together with glycosyl analysis, indicated the lack of the trisaccharide α-Hep-(1 → 2)-α-Hep-(1 →
2)-α-GalA. This was in agreement with the hypothesis of assignment of the wabG gene to a galacturonic
acid residue glycosyltransferase. In addition, the 1H,13C HSQC-DEPT NMR experiment (Figure S4)
revealed the absence of the inner core heptose residue H, since only two L,D-heptose anomeric signals,
E and G, were found (Scheme 4, structure 4).
This fact suggested that the lack of GalA residue may preclude the addition of heptose H to the
position O-7 of heptose G.
-L,D-Hep-(1 3)- -L,D-Hep-(1 5)-Kdo-(2 6)- -D-GlcN4P- -D-GlcN1P




Scheme 4. Structures of the totally deacylated LPS fraction (G-OSKOH) isolated from the E. amylowora
EaΔwabG mutant.
3. Experimental Section
3.1. Bacteria Growth and LPS Isolation
Dried bacteria cells from EaΔwaaL (3.3 g), EaΔwabH (2.63 g), and EaΔwabG (3.58 g) mutants
of E. amylovora strain CFBP1430 were all extracted by the PCP method [21] to give 208 mg of LPS
(LPSPCP yield 6.3% w/w of dried cells) for the waaL mutant, 124 mg of LPS for the wabH mutant
(LPSPCP yield 4.2% w/w of dried cells), and 170 mg of LPS (LPSPCP yield 4.7% w/w of dried cells) for
the wabG mutant, respectively.
3.2. Sugar Analysis
The sugar analysis was performed as reported [16]. The absolute configurations of the sugars
were determined by gas chromatography of the acetylated (S)-2-octyl glycosides [22]. The derivatized
samples were injected into an Agilent Technologies gas chromatograph 6850A equipped with a
mass selective detector 5973N and a Zebron ZB-5 capillary column (Phenomenex, Bologna, Italy,
30 m × 0.25 mm i.d., flow rate 1 mL/min, He as carrier gas). The following temperature programs
were used; 140 ◦C for 3 min, 140 ◦C → 240 ◦C at 3 ◦C/min (acetylated methyl glycosides), 150 ◦C for
5 min, 150 ◦C → 240 ◦C at 6 ◦C/min, and 240 ◦C for 5 min (acetylated octyl glycosides).
3.3. Mild Acid Hydrolysis
The LPS of the EaΔwaaL mutant (20 mg) was treated with 5% aqueous CH3COOH (2 mL, 100 ◦C
for 4 h). After centrifugation (7500 rpm, 4 ◦C, 30 min), the pellet was washed twice with water.
Then, the supernatant layers were pooled together and lyophilized. The sample was then fractionated
on a Bio-Gel P-10 column (Biorad, 1.5 × 110 cm, flow rate 15 mL/h, fraction volume 2 mL) and eluted
with water buffered with 0.05 M pyridine and 0.05 M AcOH. The fractions containing oligosaccharides
were pooled and named L-OSAcOH (10.1 mg).
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3.4. Deacylation of the LOSs
The LOS from each mutant (100 mg) was dried over phosphorus anhydride under a vacuum
and treated with hydrazine (5 mL, at 37 ◦C for 2 h) [23]. Cold acetone was added, and the pellet was
recovered after centrifugation at 4 ◦C and 7000 rpm for 30 min. After being washed three times with
acetone, it was suspended in water and lyophilized, obtaining LLOS-OH (68.6 mg), HLOS-OH (72.4 mg),
and GLOS-OH (65.9 mg).
The partially deacylated LPS (LOS-OH) from each mutant was dissolved in KOH 4 M and
incubated at 120 ◦C for 16 h. The KOH was neutralized with HCl, and the mixture was extracted
three times with CHCl3. The aqueous phases were recovered and desalted on a Sephadex G-10
column (Amersham Biosciences, Little Chalfont, UK, 2.5 × 43 cm, 31 mL·h−1, fraction volume 2.5 mL,
eluent NH4HCO3 10 mM). The eluted oligosaccharides mixture was then lyophilized (L-OSKOH 19 mg;
H-OSKOH 13 mg; G-OSKOH 20 mg).
3.5. Methylation Analysis
The linkage positions of the monosaccharides were determined by GC-MS analysis of the partially
methylated alditol acetates (PMAAs). The acetic acid oligosaccharides fraction of EaΔwaaL mutant
(1 mg) was first reduced with NaBD4 and then methylated with CH3I (100 μL) and NaOH powder in
dimethyl sulfoxide (DMSO) (300 μL) for 20 h [24].
The reduction of the carboxymethyl groups was obtained by treating the sample with sodium
boro deuteride (NaBD4). After the reaction working up, the sample was totally hydrolyzed with 2 M
trifuoroacetic acid (TFA) at 120 ◦C for 2 h, reduced again with NaBD4, and acetylated with Ac2O and
pyridine (50 μL each, 100 ◦C for 30 min) [25]. The PMAA mixture was analyzed by GC-MS with the
following temperature program: 90 ◦C for 1 min, 90 → 140 ◦C at 25 ◦C/min, 140 ◦C → 200 ◦C at
5 ◦C/min, 200 → 280 ◦C at 10 ◦C/min, and 280 ◦C for 10 min.
3.6. Mass Spectrometry Analysis
Mass spectra were (ESI FT-ICR) were performed in negative ion mode using an APEX QE
(Bruker Daltonics GmbH, Bremen, Germany) equipped with a 7 Tesla actively shielded magnet. The
sample concentration was ~10 ng/μL. The solutions were sprayed at a flow rate of 2 μL/min and
analyzed. The mass spectra obtained were charge-deconvoluted, and the mass numbers reported refer
to the monoisotopic masses of the neutral molecules.
3.7. NMR Spectroscopy
1H and 13C NMR spectra were performed using a Bruker Avance 600 MHz spectrometer
(Milano, Italy) equipped with a cryoprobe. All 2D homo- and heteronuclear experiments
(double quantum-filtered correlation spectroscopy, DQF-COSY; total correlation spectroscopy TOCSY;
rotating-frame nuclear Overhauser enhancement spectroscopy, ROESY; nuclear Overhauser effect
spectroscopy, 1H,13C HSQC-DEPT; and heteronuclear multiple bond correlation, 1H,13C HMBC) were
obtained using the standard pulse sequences available in the Bruker software (TopSpin 3.1 version).
The TOCSY and ROESY experiments were obtained with mixing times of 100 ms. Chemical shifts were
measured at 298 K in D2O.
4. Conclusions
In this work, for the first time, we have characterised the complete structure of the core
oligosaccharide from E. amylowora strain CFBP1430 LPS (Scheme 5, structure 5). To this aim, we
prepared three mutants, i.e. waaL, wabH, and wabG, the purified lipopolysaccharides of which were
characterised. The reported data showed that the core oligosaccharides here reported share structural
fragments with those of Klebsiella pneumoniae and Serratia marcescens. In particular, by comparison
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with the core of S. marcescens the present structure lacks the non-stoichiometric Ko residue, a feature
considered useful to distinguish between the genera Burkholderia and Pseudomonas.
-L,D-Hep-(1 2)- -D,D-Hep-(1 2)- -D-GalA-(1 3)- -L,D-Hep-(1 3)- -L,D-Hep-(1 5)-Kdo-(2 6)- -D-GlcN4P- -D-GlcN1P




-D-Glc-(1 2)      -D-Glc-(1 6)- -D-Glc-(1 4)- -D-GlcN-(1
Scheme 5. Core oligosaccharide structures from E. amylowora strain CFBP1430 LPS.
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Abstract: Bacterial antibiotic resistance is a rapidly expanding problem in the world today.
Functionalization of the outer membrane of Gram-negative bacteria provides protection from
extracellular antimicrobials, and serves as an innate resistance mechanism. Lipopolysaccharides (LPS)
are a major cell-surface component of Gram-negative bacteria that contribute to protecting the
bacterium from extracellular threats. LPS is biosynthesized by the sequential addition of sugar moieties
by a number of glycosyltransferases (GTs). Heptosyltransferases catalyze the addition of multiple
heptose sugars to form the core region of LPS; there are at most four heptosyltransferases found in
all Gram-negative bacteria. The most studied of the four is HepI. Cells deficient in HepI display a
truncated LPS on their cell surface, causing them to be more susceptible to hydrophobic antibiotics.
HepI–IV are all structurally similar members of the GT-B structural family, a class of enzymes that have
been found to be highly dynamic. Understanding conformational changes of heptosyltransferases are
important to efficiently inhibiting them, but also contributing to the understanding of all GT-B enzymes.
Finding new and smarter methods to inhibit bacterial growth is crucial, and the Heptosyltransferases
may provide an important model for how to inhibit many GT-B enzymes.
Keywords: LPS; lipopolysaccharide; heptosyltransferase; protein dynamics; glycosyltransferase;
GT-B; inhibitor design
1. Introduction
Well before the discovery of penicillin, bacteria have been evolving to resist natural antibiotics and
other extracellular threats [1]; however, advances in medical techniques and over use of antibiotics has lead
to an exponential increase in resistance. The resulting bacteria that are resistant to multiple antimicrobial
agents are regarded as one of the biggest threats to global health, food security and development by
both the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) [2,3].
Gram-negative bacteria are of particular concern because their peptidoglycan is protected behind the
bacterium’s outer membrane (OM). Furthermore, the physical properties of the OM enhance bacterial
survival in diverse environments and while also limiting the uptake of many drugs [4].
The overall organization of the OM is largely conserved, despite some variability between different
Gram-negative bacteria. Typically, the OM contains a phospholipid bilayer with the extracellular leaflet
being composed of a mixture of lipopolysaccharides (LPS), lipoproteins, and oligosaccharides [5–7].
LPS are the primary component of the OM in most species of Gram-negative bacteria and have been
shown to play an important role in cell motility, intestinal colonization, bacterial biofilm formation,
and antibiotic resistance [8,9]. This makes understanding the role of LPS in host-pathogen interactions
an area of great interest, especially in the development of therapeutic agents for the treatment of
gram-negative bacterial infections [10].
The LPS is composed of three main sections: a hydrophobic lipid A anchored to the membrane,
a core oligosaccharide containing octulose and heptose sugar moieties, and a repeating O-antigen
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region containing a diversity of sugars that are unique to bacterial cell surfaces (including pentoses,
deoxy-hexoses, lactyl functionalized hexoses, heptoses and nonuloses) [11–13]; these components
vary slightly between different bacteria [9,14]. The core oligosaccharide is further divided into the
inner and outer core; the inner core is highly conserved and proximal to lipid A whereas the outer
core is more variable. It is possible that the evolutionarily preserved structure of the inner core may
be crucial for establishing the barrier function of the OM [15]. As can been seen in a schematic of
E. coli OM biosynthesis, the complex synthesis and transportation of LPS involves many proteins
(Figure 1) [7,16,17]. Sequential glycosyl transfer from nucleotide sugar precursors by membrane
associated (or proximal) glycosyltransferases (GT) on the cytoplasmic face of the plasma membrane
form the inner and outer core which is then transported to the periplasm where the fully formed
O-antigen repeat is attached and the full LPS is exported to the outer leaflet [7,9,17]. Mutations in the
biosynthesis of LPS are often lethal to bacteria, with the minimalistic structure required for secretion of
LPS to the outer membrane being Kdo2-lipid A (lipid A with two 3-deoxy-D-manno-octo-2-ulosonic
acid (Kdo) sugar moieties attached) [9,18,19]. Truncation of the LPS by mutations to the inner
core display a deep-rough phenotype and exhibit hypersensitivity to hydrophobic antibiotics and
detergents [4,20,21].
Figure 1. Representative organization of Gram-negative bacterium from Escherichia coli membrane.
(A) demonstrates the sequential addition of inner core sugars to Kdo2-lipid A anchored into the inner
membrane; (B) Represents the formation of the O-antigen repeat also formed in the inner membrane;
(C) Once both are complete, they are flipped into the periplasm and the O-antigen repeats are attached
to the top of the core; (D) The whole lipopolysaccharides (LPS) is then transported across the periplasm
and peptidoglycan layer; (E) finally embedding into the outer membrane.
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2. Glycosyltransferases
Glycoslytransferases (GTs) are enzymes that catalyze the addition of various saccharides onto
other biomolecules. GTs encompass a large group of enzymes that have similar structural scaffolds,
but have evolved to utilize a vast diversity of substrates. Often, GTs act sequentially in order
to build a complex polymer—the product of one GT will then be the acceptor substrate for the
following GT. Many cellular functions such as: energy storage, cell wall structure, cell-cell interactions,
signaling, host-pathogen, and protein glycosylation are dependent upon complex carbohydrates
and polysaccharides. Due to this, biosynthesis of these chemically diverse oligosaccharides and
polysaccharides require the use of multiple GTs [22–25].
2.1. Glycosyltransferase Structural Folds
Presently, there are over 300,000 known and putative GTs according to CAZY.org
(Carbohydrate-Active enZYmes Database) and the number is ever growing [26]. Although GTs have
diverse sequences, they can be characterized into three structural classes: GT-A, GT-B, and GT-C
(Figure 2). Despite their differences, GTs catalyze the formation of a glycosidic bond, where a high-energy
sugar nucleotide donates a monosaccharide to an acceptor molecule [27]. This acceptor can be a variety
of molecules, such as oligosaccharides, monosaccharides, proteins, lipids, and others [23].
2.1.1. GT-A Structural Fold
SpsA from (Bacillus subtilis) was the first enzyme to be crystallized and characterized with a GT-A
fold [28]. This structural family is characterized by two tightly packed domains, comprised of two
βαβRossman-like folds, that are closely associated to form a continuous central β-sheet (Figure 2A).
The close proximity of the folds lead many to describe the GT-A fold as a single domain, however
there are distinct binding sites for the two substrates [25]. A short N-terminal domain binds the donor
substrate and C-terminal domain is an open groove that binds an acceptor substrate.
GT-A enzymes typically contain two Asp residues separated by a non-conserved amino acid
(DXD motif), that is located on a loop connecting the central β-sheet to an additional smaller β-sheet.
A divalent cation interacts with one or both of the Asp residues and is essential for stabilization of
the pyrophosphate group of the donor substrate. Typically absence of the cation renders the enzyme
inactive, however there are a small number of GT-A enzymes where a DXD motif and cation are
not required [29]. Additionally, in order for both substrates to bind and for catalysis to occur a
conformational change is required. Specifically, the loops adjacent to the active site, often adopt a
variety of conformations to assist in binding the substrate and performing chemistry [30].
2.1.2. GT-B Structural Fold
Similar to the GT-A structural class, the GT-B protein contains two βαβRossman-like domains.
Unlike GT-A proteins, in the GT-B structural class the two domains are connected by a linker region
with a deep cleft containing the active site separating the two domains (Figure 2B). Donor substrate
binds to the C-terminal domain, while the N-terminal domain binds the acceptor substrates. A large
domain movement is required for catalysis to occur in many GT-B enzymes [25,31–34]. There are
no divalent metal ions or DXD motif in GT-B enzymes, and it is believed that the pyrophosphate is
stabilized by charged and polar residues as well as the natural dipole of the α-helices located in the
donor substrate binding site [24].
A DNA-modifying β-glucosyltransferase was the first GT-B to be structurally characterized, and
was shown to have both an open and closed conformation. The closed conformation is at least in part
caused by binding of donor substrate uridine diphosphate glucose (UDP-glucose) [32]. Nonetheless,
donor substrate binding does not alway induce a conformational change in GT-B enzymes. For instance,
heptosyltransferase I (HepI), which has been crystallized with and without an analog to its donor
substrate, ADP-L-(glycero)-D-(manno)-heptose (ADPH), shows no donor substrate induced closure [31].
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Some GT-B enzymes are closed with acceptor bound thus, the order or ligand state required for closure
does not seem to be universal across the family.
Figure 2. Representative folds of the first glycosyltransferase (GT) enzymes crystallized in each
structural family: loops, α-helices, and β-sheets are colored salmon, cyan, and purple respectively.
(A) GT-A fold represented by SpsA from Bacillus subtilus, PDB: 1QGQ; (B) GT-B fold represented
by bacteriophage T4 β-glucosyltransferas, PDB: 1JG7; (C) GT-C fold represented by PglB from
Campylobacter lari, PDB: 3RCE.
2.1.3. GT-C Structural Fold
Until recently, the third structural fold (GT-C) was only predicted on the bases of sequence
analysis [35]. In 2011, the first GT-C structure was published for a bacterial oligosaccharyltransferase
from Campylobacter lari, comprised of 2 domains: a 13 transmembrane domain and a periplasmic
domain containing a mix of α/β folds [36]. Both GT-A and GT-C enzymes have a DXD motif,
however the location of the DXD tripeptide in GT-C family is at the carboxy-terminal end of the first
transmembrane helix. A small patch of hydrophobic amino acids following the helix is common.
Although this arrangement is similar to that of the DXD signiture in GT-A structural fold, there is no
conservation of sequence between these two regions [24,36].
2.1.4. Catalytic Mechanisms
Regardless of the structural fold, glycosyltransferases catalyze the transfer of a glycosyl group
with either inversion or retention of the stereoconfiguration at the anomeric carbon. Both GT-A and
GT-B families have been found to have inverting and retaining enzymes, however all GT-C enzymes
are predicted to utilize an inverting mechanism. While literature often states that inverting GTs
follow a SN2-like mechanism, implying an uncharged transition state, it is generally accepted that the
reaction has an oxocarbenium ion like transition state which is more correctly defined as a partially
associated SN1-like mechanism (Figure 3B) [37,38]. Unlike inverting GTs, there are multiple mechanism
for retaining enzymes. Initially, it was thought that all retaining enzymes proceed via a double
displacement mechanism with formation of a covalent glycosyl-enzyme intermediate (Figure 3C);
nevertheless, only a small percentage of GTs contain a putative nucleophilic residue that is properly
located in the active site to facilitate such a mechanism [25,39,40]. There is little direct evidence
for a double displacement mechanism in the literature, however Soya et. al. was able to observe
glycosyl-enzyme intermediates by mass spectrometry [41]. Further experimental and computational
work has shown that a front face or SNi (substitution nucleophilic internal-like) mechanism is likely
the primary pathway utilized [25,40,42,43]. While there is more support for an SNi mechanism, it is
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generally accepted that there are two classes of retaining GTs, that are classified based on the presence
or absence of a nucleophile in the active site.
Figure 3. Proposed catalytic mechanism of GT enzymes. (A) The transfer of a sugar moiety is performed
with either inversion or retention of the anomeric carbon in respect to the sugar donor substrate;
(B) Schematic of SN1-like mechanism for inverting GTs, where a single oxocarbenium ion-like transition
state is formed; (C) There are currently two mechanisms for retaining GTs enzymes either through the
formation of a short-lived oxocarbenium ion-like species or a covalent glycosyl-enzyme species.
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3. Core Heptosyltransferase Enzymes
Many GTs have been extensively studied due to their biological and medical importance.
Notable of these enzymes are the heptosyltransferases that are involved in the biosythesis of the
LPS inner core (and in some bacteria outer core). Heptosytransferases catalyze the sequential addition
of heptose moieties onto Kdo2-lipid A (Figure 4) and are characterized as GT-B enzymes inverting
reaction mechanism [44]. As mentioned earlier, in all Gram-negative bacteria, LPS is one of the major
extracellular polymeric substances protecting the cell (a schematic of which is shown in Figure 1).
For many bacteria the overall structure of LPS is highly conserved. However, as one moves away from
the membrane the structure variability between bacterial species increases. Thus, the inner core of
LPS has low variability where the outer core varies more between bacteria. Additionally, it has been
shown that the less conserved regions are not required for bacterial viability [45]. In fact, the minimal
structure required for bacterial survival is Kdo2-lipid A - the acceptor substrate for HepI [9,18,19].
Truncation of the LPS increases the bacteria sensitivity to hydrophobic antibiotics and detergents,
making the heptosyltransferases, especially HepI, novel drug targets [4,20,21].
Figure 4. The sequential addition of three heptose moieties from ADPH catalyzed by
Heptosytransferase I, II, and III (HepI, II, and III, respectively). Each moiety is color coded to match
the enzyme that catalyzed the addition (red, blue, purple for HepI, II, and III, respectively). Prior to
addition of the third heptose, WaaP phosphorylates the first heptose [46].
3.1. Multiple Sequence Alignment (MSA) of Heptosyltransferase Enzymes
Gram-negative bacteria have up to four heptosyltransferases; HepI and HepII are always present
and catalyze the addition of the first two sugars of the inner core, whereas HepIII and HepIV are found
only in some species (Figure 4). As a result HepI and HepII have been studied in many systems. To date,
there has been little work on HepIII and even less on HepIV, despite both having been identified
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or suggested in Vibrio cholerae, Escherichia coli, Yersinia pestis, and Klebsiella pneumoniae. HepIII adds
the third heptose to the inner core and HepIV adds a heptose moiety onto a glucose or galactose
located within the outer core (Figure 1) [47,48]. A multiple seuqence alignment (MSA) of HepI–IV
from Vibrio cholerae, Escherichia coli, Yersinia pestis, and Klebsiella pneumoniae shows the variability
of sequence conservation among the heptosyltransferases (Figure 5). The average similarity for all
16 heptosyltransferases is about 30%, which is consistent to the percent similarity for the HepI–IV
enzymes from the same organism. By comparing each homolog to E. coli, it can be concluded that HepI
and HepII are highly conserved with percent similarities as high as 86%. HepIII and HepIV homologues
have less then 46% similarity. It is perhaps unsurprising that each of the heptosyltransferases have
the highest sequence similarity to their homologs rather than to the paralogs within an organism.
HepIV are more divergent than HepI, most likely because the core region of LPS only varies only
slightly, thus a HepI enzyme from E. coli and V. cholerae will bind more similar acceptor substrates than
the corresponding HepIV enzymes [45].
Figure 5. Cont.
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Figure 5. Muliple sequence alignment of HepI–HepIV from Vibrio cholerae, Escherichia coli,
Yersinia pestis, and Klebsiella pneumoniae (domains for HepI E. coli HepI are annotated), using
ClustalW 2.0 (https://www.ebi.ac.uk/Tools/msa/clustalw2/) alignment program and Espript 3.0
(ESPript—http://espript.ibcp.fr) [49,50].
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Although HepI–IV are variable in their sequence, the C-terminus has the most conservation followed
by the N-terminus, while the linker is highly variable, and the overall structure of heptosyltrasferases
are homologous (Figure 6). In E. coli HepI and HepII have been crystallized, and the structure
of HepIII has been computationally predicted (Figure 6A–C) [51]. A computational model of
E. coli HepIV was created using the I-Tasser protein structure prediction program (the resulting
structure is shown in Figure 6D) and it appears similar to HepI and HepII crystal structure [52–54].
All are GT-B proteins with the the typical βαβRossman-like domains attached by a linker.
The C-terminal domain for all, binds ADPH (the donor substrate) and look nearly identical, whereas the
N-terminal domain varies slightly, likely due to their variation in acceptor substrates [31,51].
Figure 6. Structures of Heptosyltransferases (loops, α-helices, and β-sheets are colored salmon, cyan,
and purple, respectively). (A) HepI from E. coli, PDB: 2H1H; (B) HepII from E. coli, PDB: 1PSW;
(C) Computational model of HepIII from E. coli [51]; (D) Computational model of HepIV from E. coli.
To better compare the the structural variety of E. coli HepI–IV a sequence-based structural
superposition was generated using HepI (PDB:2H1H) as the reference structure, with the VMD
multiseq program. An overlay showing the conserved residues in the HepI–IV structures are displayed
in Figure 7 (the blue areas indicate highly conserved regions and the red depicts non-conserved regions).
By looking at the global conservation of heptosyltransferases, the interior is more conserved, while
the surface residues are highly variable. Additionally, it is evident that the C-terminus (binding
domain of ADPH for all heptosyltransferase enzymes) is more conserved than the N-terminal
domain. The proposed catalytic base D13 is present in all the heptosyltransferases, suggesting that the
mechanism of action for all heptosyltransferases are similiar [31]. Other specific residues, like K192 and
D261 (which were shown by mutagenesis studies in HepI to be important for chemistry), are completely
conserved for all E. coli heptosyltransferases as well as all Vibrio cholerae, Escherichia coli, Yersinia pestis,
and Klebsiella pneumoniae. It is clear that all of the heptosyltransferase enzymes are structurally similar
and many important residues are conserved not only between E. coli heptosyltransferase enzymes,
but also in multiple bacterial species. Bacterial evolution to differentiate the LPS structure enhancing
survival in different niches likely governs the sequence variability of heptosyltransferases.
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Figure 7. Overlay of Structurally aligned HepI–IV; residues are colored by sequence similarity [highly
conserved (blue) non-conserved (red)].
3.2. Heptosyltransferase I
E. coli HepI, the most characterized heptosyltransferase, can reveal insights about the function
of the other heptosyltransferase enzymes. The acceptor substrate of HepI, Kdo2-lipid A, is the
minimalistic structure required for LPS to be transported to the outer membrane. Mutations to waaC
(rfaC), the gene that codes for HepI, leads to a rough phenotype LPS and an increase in sensitivity to
hydrophobic antibiotics including: erthromycin, ampicillin, and novobiocin [10]. Early work on HepI
sought to use alternative donor substrates as ADPH was not commercially available. ADP-mannose,
GDP-manose, ADP-glucose, UDP-glucose, and UDP-galactose were tested for HepI transferase activity,
only ADP-mannose was a viable alternative substrate. ADP-mannose was characterized by Kadrmas
et al. to have an apparent Vmax of 3 μmol/min/mg and a KM of 1.47 mM. Kdo-lipid A (an analogue of
Kdo2-lipid A with only one Kdo) was a poor mannose acceptor substrate; this was unexpected since the
second Kdo moiety was not expected to influence activity since the first Kdo is the one being modified
by HepI [55]. Later work using the native substrate ADPH showed that Kdo-lipid A was in fact a
competent acceptor substrate with a KM of 46 μM [56]. Perhaps using two alternative substrates was
the reason for the poor transferase activity, and in fact Kdo-lipid A may be sufficient for the continual
formation of the inner core. Interestingly, the fatty acid chains were shown to not be important for
catalysis, as has been demonstrated to be necessary in other LPS biosynthetic enzymes. The substrate
analogue, Kdo2-lipid IVA, although missing three fatty acid chains normally present in Kdo2-lipid A,
gives a KM of 4.7 μM demonstrating that the removal of fatty acid chains does not impair chemistry.
Furthermore, HepI has activity with the fully deacylated and O-deacylated Kdo2-lipid A (ODLA and
FDLA respectively, Figure 8). Both were shown to be competent substrates; native substrate had a KM of
29 μM where the analogues displayed a KM of 1 μM (ODLA) and 0.3 μM (FDLA) [56]. Retrospectively,
it is unsurprising that the fatty acid chains would be unimportant for catalytic efficiency since they are
embedded into the inner membrane in vivo and therefore should not be accessible to influence binding.
Taken together with the slightly better catalytic efficiency for deacylated Kdo2-lipid A analogues,
these observations suggest that the tetrasaccharide portion of the substrate provides HepI with the
primary binding interactions required for acceptor substrate recognition.
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Figure 8. Strucutres of Kdo2-lipid A and analogues: (A) E. coli Kdo2-lipid A; (B) O-deacylated E. coli
Kdo2-lipid A (ODLA) and (C) fully deacylated E. coli Kdo2-lipid A (FDLA).
3.2.1. Crystal Structures of HepI
As mentioned earlier, the structure of HepI has been previously determined. Three different
structures are available in the PDB: 2GT1, 2H1H, and 2H1F corresponding to the Apo protein,
HepI·ADP-2-deoxy-2-fluoro-heptose (ADPF) complex and HepI·ADP complex, respectively [31].
By comparing the three structures it seems that HepI does not undergo a domain rotation upon
donor substrate binding like other GT-B’s. However, as there is no crystal structure in complex with
Kdo2-lipid A or any of its analogues, and it is, therefore, possible that HepI closure is induced by the
acceptor substrate or by formation of the ternary complex, as has been shown by other GT-B’s. ADPF
is a non-cleavable analogue to ADPH with a fluorine replacing a hydroxyl group in the 2′-position.
ADPF has been shown to be an inhibitor of HepI with an IC50 of 30 μM [31]. Attempts to crystallize
HepI with ADPH lead to co-crystallization with ADP, suggesting that HepI is capable of hydrolysis in
the absence of an acceptor, a phenomenon that was observed with other glycoslytransferases [34,57].
Upon crystallization of HepI, Grizot et al. performed site-directed mutagenesis to test the importance
of numerous residues on catalysis and binding of ADPH. D13A and D261A exhibit a 4688-fold and
2027-fold drop in specific activity, respectively and were suggested to be catalytic residues. K192A had
a 926-fold reduction in activity and due to its location proximal to the anomeric carbon of ADPH which
is where the deprotonated hydroxyl of Kdo2-lipid A attacks, and therefore may play an important role
in binding or catalysis and binding [31].
3.2.2. Inhibition of HepI
One goal of understanding the heptosyltransferases is to learn how to effectively inhibit them, to
date some work has been done to design inhibitors for HepI. Most inhibitors of GTs bind typically
with low μM affinities, similar to KM values of substrate. A structure-activity relationship (SAR)
study was done by Moreau et. al. on a series of 2-aryl-5-methyl-4-(5-aryl-furan-2-yl-methylene)-
2,4-dihydro-pyrazol-3-one analogues (Figure 9A) [58]. In this work, computational docking and
biochemical assays were used to assess binding. All compounds bound with low μM IC50’s and
appeared to be preferentially bound close to acceptor site of Kdo2-lipid A, specifically near where Kdo
should bind. Residues R120, H139, A140, R143, and I287 were identified as important for inhibitor
binding in this analysis, suggesting the potential importance of these residues for Kdo2-lipid A binding.
Further studies would need to be done however to test this hypothesis.
Additionally, Durka et al. published a library of synthesized multivalent glycosylated fullerene
monomers and “balls” much larger than the proposed molecules previously discussed. Like the
previous series, these compounds had inhibition constants in the low μM ranging from 7–47 μM,
again on par KM of substrates [59]. In 2016, the group published a second series of glycofullerenes
slightly varying the fullerenes in an attempt to increase inhibition. The new fullerene compounds were
competitive against Kdo2-lipid A and uncompetitive towards ADPH, which was unexpected because
the compounds were designed to mimic ADPH heptose moiety; similar to previously discussed work,
the compounds showed low μM Ki. From these findings, glycoclusters mimicking Kdo with C60 and
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other multivalent scaffolds were synthesized and IC50 were calculated. Interestingly, high nanomolar
inhibition was observed for Kdo fullerenes attached to C60 scaffolds, a degree of inhibition never
achieved for HepI and rarely for GTs [60].
Figure 9. (A) Representative core structure of 2-aryl-5-methyl-4-(5-aryl-furan-2-yl-methylene)-2,4-dihydro-
pyrazol-3-one analogues [58]; (B) Glycofullerene derivatives schematic [59].
3.2.3. Investigations of HepI Protein Dynamics
As mentioned earlier, a few GT-B glycosyltransferases have been shown to inter-convert between
an “open” and “closed” structure [32–34]. Without a crystal structure of the ternary complex of HepI,
it is unclear how/if HepI undergoes such an event. By looking at the crystal structure however, its is
clear that the catalytic base (D13) is over 8 Å away from the anomeric carbon of ADPH which is too far
away for efficient nucleophilic attack by deprotonated Kdo2-lipid A [31]. Thus, it was hypothesized
that HepI also undergoes a conformational change during the reaction. To assess protein dynamics,
HepI steady state activity was tested in a variety of viscous buffers, specifically glycerol, ethylene
glycol, and PEG 8000. Microviscogens; glycerol, and ethylene glycol, both had a strong impact on kcat
which could be explained by water reorganization being required for catalysis; this suggests that HepI
conformational dynamics are partially rate-limiting [61].
Additionally, intrinsic tryptophan (Trp) fluorescence spectroscopy was employed to see if
substrate binding induced changes in the protein fluorescence spectra [62–70]. HepI has 8 tryptophan
residues, and by examination of a computational model of the closed structure of HepI, many of the
Trp residues appear to become more buried in the protein, suggesting that upon substrate binding
there may be a change in fluorescence spectrum (Figure 10A). Fluorescence spectra were obtained with
and without substrates(Figure 10B). Consistent with crystal structures, no change was observed upon
ADPH binding alone. ODLA binding resulted in a 6 nm blue shift, suggesting that ODLA binding
induces conformational changes that lead to one or more the the Trp residues to becoming more buried
in the protein [61].
96
Int. J. Mol. Sci. 2017, 18, 2256
Figure 10. (A) HepI open structure (tan) and trypophan residues colored in green is superimposed with
a structural model of closed HepI (gray) with tryptophans colored magenta; (B) Steady state intrinsic
tryptophan emission spectra of HepI with and without substrates bound, blue shift is observed upon
ODLA binding; (C) Pre-steady state kinetics of WT HepI titrated with ODLA (fast phase, blue; slow
phase, red).
When stopped flow was used to monitor the kinetics of conformational changes in HepI,
a concentration of ODLA dependent biphasic pre-steady state kinetics was observed. Two rates
were observed, a fast rate which exhibits a hyperbolic dependence on ODLA concentration (saturates
at 80 s−1), and a concentration independent slow rate of ~5 s−1. A two step binding mechanism of
ODLA was suggested (initial collision complex between of HepI and ODLA followed one or more
conformational change(s) to form the HepI·ODLA complex). Additionally, a catalytically impaired
mutant (D13A) of HepI was tested and yielded the same pre-steady state kinetics. This suggests that
the ODLA induced change in HepI must occur prior to chemistry [61]. Subsequently, work investigated
which Trp residue(s) play(s) a role in the observed blue shift so as to better understand conformational
change(s) that occur [71]. In this work, most of the eight Trp residues were mutated to phenylalanine
(Phe). W62F and W116F both of which are located on the N-terminal ODLA binding domain, exhibited
a reduced blue shift upon ODLA binding as compared to wild-type HepI. Additionally, these residues
are located on dynamic loops (N-3 and N-7) suggesting that these loops may undergo conformational
changes when ODLA binds, leading to a change in local environment of W62 and W116. Interestingly,
the W217F mutant (Trp located on the C-terminal domain far from the ODLA binding site) resulted in
a complete loss of the blue shift upon substrate binding. Although more experiments are need to fully
understand the role of W217, upon ODLA binding, ADPH binding may be altered (ADPH is directly
moved to impact W217 conformation), suggesting communication between the two domains.
In addition to fluorescence spectroscopy, circular dichroism (CD) experiments were used to
investigate structural changes of HepI [72,73]. CD spectra for HepI demonstrate a characteristic
spectra for a protein with primarily αcontent with a double minimum with peaks at 222 nm and
211 nm. Interestingly, upon binding of ODLA there is an increase in the intensity of the second
minimum at around 211 nm consistent with a 12% increases in α-helicity (Figure 11A). The location of
these conformational changes are unknown, but most likely this is the result of structural changes of
disordered loops in HepI [71].
Protein stability was also explored by CD melts experiments (taking CD spectra at varying
temperatures) and monitoring unfolding of protein. As can be seen in Figure 11B,C, apo HepI has a
TM of 40 ◦C, however upon ODLA binding there is a large increase in stability so that even at 95 ◦C
the protein is still mostly folded [71]. It was concluded that the formation of HepI·ODLA complex
must lead to formation of hydrogen bonds and/or salt bridges (ionic interactions) between ODLA and
HepI. Without cyrstalographic evidence showing where ODLA binds, its hard to determine which
interactions induce such a stabilization. Examination of the HepI structure reveals that there are
many positively charged residues located on dynamic loops of the N-terminal domain (where ODLA
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binds) which could coordinate with negatively charged phosphate and carboxylate moieties of ODLA.
High salt reverses some of the HepI·ODLA complex stabilization, suggesting that ionic interactions are
essential for HepI·ODLA complex stabilization [71]. In sum, these data strongly support the hypothesis
of heptosyltransferases undergoing open to closed transitions.
Figure 11. (A) Far-UV circular dichroism (CD) spectra of apo HepI (red), HepI with 100 μM ADPH
(dark green), and HepI with 100 μM ODLA (blue) at 5 ◦C. Far-UV CD Melt spectra of (B) apo HepI at
5 ◦C (red), 40 ◦C (blue), 95 ◦C (green) and annealed at 5 ◦C (black) and (C) HepI with 100 μM ODLA
5 ◦C (red), 40 ◦C (blue) and 95 ◦C (green). Purple lines demonstate changes in ellipticity at 222 nm.
4. Conclusions
With the growing need for new antibiotics to treat antibiotic resistant (and multi-resistant)
bacteria, it is essential for scientists to find new and smarter ways to inhibit bacterial growth.
Heptosyltransferases are important for LPS biosynthesis and the resulting resistance. Structurally
HepI–IV are very similar and all adopt a GT-B structural fold. HepI can be used as a model for
other heptosyltransferases and GT-B enzymes to inform inhibition strategies. Perhaps disruption of
GT-B dynamics with small molecules would be an effective new strategy for inhibitor development.
Additionally, dynamics disruption could potentially allow for inhibition of multiple targets which
undergo similar dynamical changes (with a single drug targeting multiple enzymes). Promising work
has been done to understand the function of HepI and aid in designing such an inhibitor. Ultimately,
heptosyltransferases provide useful information about the GT-B structural fold and provide a model
for novel methods to inhibit many GT-B enzymes.
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Abstract: Distinguishing feature of the outer membrane (OM) of Gram-negative bacteria is its
asymmetry due to the presence of lipopolysaccharide (LPS) in the outer leaflet of the OM and
phospholipids in the inner leaflet. Recent studies have revealed the existence of regulatory controls
that ensure a balanced biosynthesis of LPS and phospholipids, both of which are essential for bacterial
viability. LPS provides the essential permeability barrier function and act as a major virulence
determinant. In Escherichia coli, more than 100 genes are required for LPS synthesis, its assembly at
inner leaflet of the inner membrane (IM), extraction from the IM, translocation to the OM, and in its
structural alterations in response to various environmental and stress signals. Although LPS are highly
heterogeneous, they share common structural elements defining their most conserved hydrophobic
lipid A part to which a core polysaccharide is attached, which is further extended in smooth bacteria
by O-antigen. Defects or any imbalance in LPS biosynthesis cause major cellular defects, which elicit
envelope responsive signal transduction controlled by RpoE sigma factor and two-component
systems (TCS). RpoE regulon members and specific TCSs, including their non-coding arm, regulate
incorporation of non-stoichiometric modifications of LPS, contributing to LPS heterogeneity and
impacting antibiotic resistance.
Keywords: LpxC; LapB; RpoE sigma factor; Rcs two-component system; lipid IVA; lipid A
modifications; Lpt transport system; noncoding small regulatory RNA
1. Introduction
The cell envelope of Gram-negative bacteria, including Escherichia coli, contains two distinct
membranes, an inner (IM) and an outer (OM) membrane separated by the periplasm, a hydrophilic
compartment that includes a layer of peptidoglycan. The OM is an asymmetric bilayer with
phospholipids forming the inner leaflet and lipopolysaccharide (LPS) forming the outer leaflet.
LPS is essential for bacterial viability. Because of the strong lateral chemical interactions, LPS provides
the essential permeability barrier function. It is a complex glycolipid, a major component of the OM
and highly heterogeneous in composition. Bacteria, like E. coli and Salmonella, contain approximately
2-3 × 106 molecules of LPS that cover more than 75% of the OM [1]. The biosynthesis, translocation
and various modifications of LPS requires the function of more than 100 genes. Several of them are
essential and unique to bacteria and hence they are excellent targets for the identification of their
inhibitors for the development of new antibiotics.
The biosynthesis of LPS begins with the acylation of UDP-GlcNAc with R-3-hydroxymyristate
derived from R-3-hydroxymyristoyl-ACP by LpxA [2]. R-3-Hydroxymyristoyl-ACP also serves as a
precursor for the synthesis of phospholipids. The second reaction of the lipid A biosynthesis is catalysed
by LpxC [UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase] a Zn2+-dependent
deacetylase, constituting the first committed step in the LPS synthesis, as the equilibrium constant
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for the first reaction catalysed by LpxA is unfavourable. Following deacetylation, a second
R-3-hydroxymyristate chain is added by LpxD leading to the synthesis of UDP-2,3-diacyl-GlcN.
This serves as a substrate for LpxH to generate 2,3-diacyl-GlcN-1-phosphate, also called lipid
X [3]. The next steps involve a condensation reaction generating the β,1′-6-linked disaccharide
by LpxB, followed by its phosphorylation at 4′ position by LpxH. This generates the lipid
IVA precursor, which serves as an acceptor for the WaaA-mediated incorporation of two
3-deoxy-α-d-manno-oct-2-ulsonic acid (Kdo) residues. Up to the synthesis of Kdo2-lipid IVA, all the
required seven enzymes are essential for the bacterial viability [4]. Kdo2-lipid IVA comprises a key
intermediate in LPS biosynthesis that acts 2-fold as a specific substrate: (i) for acyltransferases that
generate Kdo2-lipid A moiety by the transfer of two additional fatty acids to the (R)-3-hydroxyl groups
of both acyl chains, which are directly bound to position 2′ and 3′ of the non-reducing GlcN residue and
(ii) for glycosyltransferases catalyzing further steps of the core oligosaccharide biosynthesis. The E. coli
K-12 genome encodes three paralogous acyltransferases (LpxL, LpxM and LpxP), which catalyze
acylation reactions using acyl carrier protein-activated fatty acids as co-substrates [5]. At ambient
temperatures, a lauroyl residue is first transferred by LpxL to the OH group of the amide-bound
(R)-3-hydroxymyristate residue at position 2′. This catalytic step is partially replaced at low temperature
(12 ◦C) by LpxP, which transfers palmitoleate to the same position in approximately 80% of LPS
molecules [6]. The free OH group of the ester-bound (R)-3-hydroxymyristate residue at position 3′
within both pentaacylated intermediates is then myristoylated by LpxM to give a hexaacylated lipid
A moiety. However, it is noteworthy that under slow growth conditions and at low temperatures,
the lipid IVA precursor without the Kdo incorporation can be the substrate for a secondary acylation
by LpxP, LpxL, and LpxM, as observed in ΔwaaA grown at 21–23 ◦C [7].
In Enterobacteriaceae members, the core region of LPS is always attached to lipid A via a Kdo
residue. The inner core usually contains residue(s) of Kdo and l-glycero-d-manno-heptose (l,d-Hep) [4,8].
Several of lipid A biosynthesis enzymes and core biosynthetic glycosyltransferases are either inner
membrane-anchored or membrane-associated and hence the LPS synthesis occurs at the IM leaflet.
After the completion of LPS synthesis on the inner leaflet of the IM, LPS is flipped by the essential
IM-located MsbA transporter to the periplasmic side of the IM, where it is a substrate for the LptB2FG
ABC transporter for translocation, using ATP as the energy, potentially in complex with LapA/B proteins.
2. Regulatory Steps in LPS Biosynthesis
Until recent discoveries, it was presumed that LPS biosynthesis occurs in a constitutive manner.
However, recent studies have revealed regulatory controls exerted right from early steps in LPS
biosynthesis till its final delivery in the OM as highlighted below: (a) Regulation of GlmS expression for
the synthesis of UDP-GlcNAc, an essential metabolic precursor for LPS and peptidoglycan, by recruiting
GlmZ/Y noncoding small regulatory RNAs (sRNAs). (b) Balanced synthesis of phospholipids and LPS
by regulated turnover of LpxC by FtsH/LapB proteins, since they use R-3-hydroxymyristoyl-ACP as a
common precursor [9]. (c) Bacteria also ensure that only completely synthesized LPS is delivered to
the Lpt translocation system by preferential selectivity of hexaacylated LPS by the MsbA transporter
and by recruiting LapA and LapB proteins as a scaffold for various LPS biosynthetic enzymes in
the IM. (d) The transcriptional control by RfaH of the large waaQ operon encoding various LPS core
biosynthetic enzymes and the rfb operon whose products are required for O-antigen biosynthesis [10–12].
(e) Regulation of the incorporation of non-stoichiometric modifications of LPS by the induction of genes,
whose expression is controlled by BasS/R, PhoP/Q and PhoB/R two-component systems (TCSs) (Figure 1).
The expression of some of these genes is regulated either at a transcriptional or post-transcriptional
level or both [13]. (f) Some of the genes, whose products are involved in either lipid A biosynthesis,
LPS translocation or phospholipid biosynthesis, are transcriptionally regulated by the RpoE sigma
factor and the CpxA/R TCS [14]. (g) The LPS assembly in the OM requires a correctly folded outer
membrane protein LptD. Its correct folding is SurA- and DsbA-dependent, which can be further
fine-tuned by BepA for the removal of misfolded LptD.
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Figure 1. Networks of regulatory pathways that control the lipopolysaccharide (LPS) assembly
and its non-stoichiometric modifications. The RpoE sigma factor responds to severe defects in LPS
biosynthesis and is also required for transcription of genes involved in LPS biosynthesis/translocation
and modifications via sRNAs like rybB and micA. RpoE also transcribes the slrA (micL) sRNA, which
represses the Lpp synthesis and acts in a feedback manner to repress RpoE. Other regulatory controls
involve two-component systems like BasS/R, PhoP/Q, PhoB/R and Rcs system, which are required for
transcription of genes whose products are involved in lipid A and inner core modifications. The RpoH
heat shock sigma factor transcribes lapB and ftsH genes, whose products control balanced biosynthesis of
LPS and phospholipid by regulating LpxC levels. The unique transcriptional factor RfaH is required for
overcoming antitermination, enhance transcriptional elongation and couple transcription/translation of
waaQ and rfb LPS biosynthetic operons. The sRNA RirA binds to RfaH and abrogates its activity to
maintain a balanced biosynthesis of LPS.
3. Essentiality of LPS and the Minimal LPS Structure
Generally, LPS is essential for the viability of vast majority of Gram-negative bacteria with few
exceptions. Few limited exceptions include viable LPS-lacking mutants of Acinetobacter baumannii
that have mutations in either lpxA or lpxC or lpxD genes [15]. However, in such mutant strains,
the absence of LPS is compensated by increased expression of the Lol lipoprotein transport system to
increase phospholipid export, enhanced expression of poly-β-1,6-N-acetylglucosamine and elevated
expression Mla-retrograde phospholipid migration from the OM to the IM to maintain a balance in the
essential constituents of the OM [15]. Another well-studied example of dispensability of LPS include
construction of viable LPS deficient mutants of Neisseria meningitides [16].
It is well established that in bacteria, like E. coli and Salmonella, the minimal structure of LPS
that can sustain the bacterial viability up to 42 ◦C is composed of hexaacylated lipid A-Kdo2 (Re
LPS “deep-rough mutants”). Thus, ΔwaaC (lacking heptosyltransferase I) or ΔgmhD (absence of
ADP-l-glycero-d-manno-heptose-6-epimerase) mutants are viable, although they exhibit temperature
sensitive growth (unable to grow at temperatures above 43 ◦C), permeability defects, hypersensitivity
to detergents, hyperactivated RpoE-regulated stress response, inability to colonize the host, sensitivity
to antimicrobial peptides, defects in flagellar biosynthesis, compromised growth at low pH, and a
constitutive induction of Rcs-dependent exopolysaccharide [7,17–21]. Consistent with the requirement
of inner core heptose attachment to Kdo2-lipid A for cell envelope integrity, a Δ(waaC surA) mutational
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combination confers synthetic lethality [7]. SurA is a major periplasmic folding factor required for the
folding of outer membrane proteins (OMPs), including LptD [17,22]. Furthermore, the lack of other
conserved core biosynthetic genes like waaG, waaF or genes involved in the pathway of synthesis of
molecules of l-glycero-α-d-manno-heptose (heptose) such as gmhA and gmhE, also results in impairment
of growth at high temperatures [23]. A deep-rough phenotype accompanied by hypersensitivity
to detergents and antibiotics is also associated with the lack of WaaP kinase, which mediates
phosphorylation of HepI and completion of core biosynthesis [24] (Figure 1). Underacylation of
lipid A due to a lack of the LpxL lauroyl transferase is known to confer temperature sensitivity above
33 ◦C and strains lacking all three acyltransferases Δ(lpxL lpxP lpxM) cannot grow at even 30 ◦C on rich
medium [5]. Moreover, Δ(lpxL lpxP lpxM) strains exhibit gross alterations in terms of accumulation
of primarily glycoform IV/V with three Kdo residues and truncation of the terminal disaccharide [7].
Thus, complete synthesis of LPS is a requirement for bacterial fitness and survival.
During the detailed genetic construction of strains to define the minimal LPS structure in the
absence of any suppressors, it was shown that strains with LPS composed of either Kdo2-lipid IVA
Δ(waaC lpxL lpxM lpxP) or only lipid IVA (absence of WaaA Kdo transferase) can be constructed
under slow growth conditions on minimal medium at low temperatures (21–23 ◦C) [7]. Since lipid
IVA is a poor substrate for the MsbA IM LPS flippase, suppressor mutations that improved growth
characteristics of Δ(waaC lpxL lpxM lpxP) or ΔwaaA were found to map to the msbA gene [7]. It is
likely that such MsbA variants exhibit altered binding properties of lipid A and might be more relaxed
in substrate selectivity or changes in ATP binding/hydrolysis. Interestingly, ΔwaaA suppressor-free
strains synthesizing lipid IVA were found to accumulate excess of phospholipids consistent with a
balanced synthesis of LPS and phospholipids [7]. Moreover, such ΔwaaA strains under slow growth
conditions were also found to accumulate pentaacylated and hexaacylated species of lipid IVA without
any requirement for the Kdo presence. Thus, lipid IVA derivatives with myristoyl, lauroyl, palmitolyl
or palmitoleate chains could be identified from ΔwaaA strains, indicating that under such conditions
late acyltransferases can use lipid IVA as a precursor without requirement for Kdo [7]. Consistent with
these results, overexpression of the lpxL gene suppress the lethality of waaA deletions on nutrient broth
up to 37 ◦C without the need for MsbA overproduction [25].
4. Regulation of Synthesis of UDP-GlcNAc-Precursor for LPS Biosynthesis
UDP-N-acetyl-d-glucosamine (UDP-GlcNAc) is a common metabolic precursor for LPS and
peptidoglycan synthesis. Thus, regulation of biosynthesis of UDP-GlcNAc serves as an essential branch
point in controlling and coupling the synthesis of major essential constituents of the cell envelope [13].
GlmS catalyzes the synthesis of glucosamine-6-phosphate (GlcN6P) from fructose-6-phosphate and
glutamine, which constitutes the first committed step in the synthesis of UDP-GlcNAc. The amount
of glmS transcript is regulated by a feedback mechanism in response to the GlcN6P level using
homologous GlmZ and GlmY sRNAs [26,27]. These sRNAs act in a hierarchical manner to activate
the glmS expression. Under GlcN6P limiting conditions, the GlmY sRNA accumulates and sequesters
RNase adaptor protein RapZ, preventing GlmZ processing [26,27]. The GlmZ sRNA facilitates
translation of the glmS mRNA through an anti-antisense mechanism and prevents the formation of
an inhibitory structure that occludes the ribosome-binding site of glmS. Interestingly, transcription
of the glmY gene is regulated by RpoN and RpoD sigma factors using the same transcription start
site in an analogous manner to the transcriptional regulation of rpoEP2 and rpoEP3 promoters [11,28].
RpoN-regulated promoters of glmY and rpoE genes use QseF as an activator and thus this mode of
regulation may be important to sense common signals and ensure cellular homeostasis in response to
envelope stress.
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5. Coupled Regulation of LPS and Phospholipids–Regulation of Amounts of Kdo2-Lipid
A Synthesis
Regulation of LpxC occurs by regulated proteolysis mediated by FtsH [29,30]. This proteolysis
by FtsH requires the LPS assembly factor LapB [9,31]. Both FtsH and LapB are essential for bacterial
growth and their depletion causes increased synthesis of LPS at the expense of phospholipids. This is
due to stabilization of LpxC in either an ftsH or a lapB mutant, which causes diversion of a common
precursor R-3-hydroxymyristoyl-ACP towards the LPS synthesis, since LpxC and FabZ compete for
the same precursor, limiting the availability of phospholipids (Figure 1). Consistent with the notion
of coupling of phospholipid and LPS synthesis, suppressors mapping to the fabZ gene, like sfhC21
that encodes a hyperactive variant of FabZ, can bypass the essentiality of either ftsH or lapB genes [9].
Additional evidence supporting this model is based on observations that inhibition of LpxC can
be compensated by mutations that compromise the FabZ activity [32]. Similarly, overexpression of
the fabZ gene is accompanied by an upregulation of the LpxC activity and vice versa [32]. Further
supporting regulated LPS and phospholipid biosynthesis, an overexpression of noncoding sRNA
slrA can bypass the lethality of the essential lapB gene [9]. The molecular basis of this suppression
was attributed to translational repression of the gene encoding the most abundant protein Lpp, also
called Braun’s lipoprotein, with an abundance of 7 × 105 molecules per cell. Hence, SlrA is also called
MicL [33]. Each Lpp molecule has three acyl chains {phosphatidylglycerol moieties (PG)} and therefore,
when the Lpp amount is reduced due to overexpression of slrA sRNA, it causes an increase in the
amount of PG that can restore a balance between phospholipids and LPS (Figure 1). SlrA can also act
as a negative regulator of RpoE in a feedback manner, as its overproduction reduces the RpoE activity
elevated due to LPS defects in ΔlapB mutants [9]. The gene encoding SlrA sRNA is transcribed from
the RpoE-regulated promoter located within the cutC gene. This 80-nt sRNA is synthesized as a 307 nt
precursor mRNA that is processed and is located within the 3′ end of the coding region of the cutC
gene [9,33].
Although a role for LapB and FtsH for LpxC is now known, however how the proteolytic activity
of FtsH is regulated remains to be elucidated. It is likely that proteolytic activity of FtsH might be
regulated by concentration or forms of acyl-ACPs or lipid A disaccharide. Since LpxC stability is
increased in a fabI(ts) mutant suggests that membrane fatty acids might influence proteolytic activity
or add additional checkpoints in regulating lipid A and phospholipid amounts [29]. Although not
fully elaborated, regulation at the level of LpxB and LpxK may serve as additional pathways of
this co-regulation. Consistent with such a notion, LpxB has been shown earlier to co-purify with
phospholipids [34]. A regulatory checkpoint has been postulated on the basis of a reduced LpxK activity
upon reduced membrane fluidity when more saturated fatty acids are present [35]. LpxK mediates the
last essential step that completes lipid IVA biosynthesis [4]. LpxK catalyzes the phosphorylation of the
4′ hydroxyl of the distal glucosoamine of lipid A disaccharide. Under conditions like compromised
function of either LapB or FtsH, which stabilize LpxC leads to depletion of R-3-hydroxymyristoyl-ACP.
This in turn decreases the synthesis of unsaturated fatty acids, which can decrease the LpxK activity,
leading to accumulation of lipid A disaccharide [9,35]. This accumulation of lipid A disaccharide
intermediate by the feedback mechanism causes increased proteolysis of LpxC, thereby decreasing
flux of R-3-hydroxymyristoyl-ACP into a lipid A biosynthesis pathway, thus again to regain a balance
between phospholipid and lipid A biosynthesis. WaaA is also one of the substrates of FtsH protease [36].
Regulation of WaaA turnover by FtsH may be yet another step in preventing an excessive synthesis of
LPS over phospholipids. However, a direct impact of changes in WaaA concentration on either LPS
synthesis or accumulation of different glycoforms remains to be understood.
6. Assembly of LPS Requires LapB
Besides a role for turnover of LpxC in concert with FtsH, LapB has been implicated in the assembly
of LPS at the IM presumably along with LapA [9]. Genes encoding lapA and lapB are co-transcribed from
three promoters, the distal promoter located upstream of the pgsB gene, the middle promoter recognized
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by the RpoH heat shock sigma factor and the last one resembling house-keeping promoters [9]. Overall,
such a transcriptional organization suggests coupling of transcription with phospholipid metabolism
using pgpB co-transcription. PgpB encodes phosphatidylglycerophosphatase, an enzyme that is part
of the phosphatidylglycerol biosynthesis pathway, which is itself part of phospholipid metabolism.
Transcription from the heat shock promoter ensures transcription of lapA/B genes at high temperatures,
hence belonging to heat shock regulon, which comprises several chaperones and proteases.
The evidence that LapB plays a role for LPS assembly in the IM comes from experimental
evidence that include: (a) The lapB gene is essential for bacterial growth and a deletion of the lapB
gene can be constructed in the presence of suppressor that either restore phospholipid synthesis
like sfhC21, or decrease the LPS synthesis like in the presence of mutations in an early lipid A
biosynthesis pathway (lpxA, lpxC, lpxD) or when LPS is composed mostly of Kdo2-lipid A derivatives
like (waaC lapB) combination [9]. (b) The lack of LapB leads to accumulation of LPS precursor forms.
These precursor forms represent pentaacylated lipid A species, the presence of Kdo2-dilauroyl-lipid
IVA. (c) ΔlapB mutants have defects in the folding of LPS-specific enzymes like LpxM and conserved
glycosyltransferases like WaaC, WaaO. A large proportion of these enzymes is present in aggregate form
and hence LPS-specific enzymes like LpxM and core glycosyltransferase could be limiting explaining
the accumulation of LPS precursor species [9]. (d) LapB also co-purifies with heptosyltransferase I.
(e) LapA/B could function synergistically with classical chaperones like DnaK/DnaJ based on LapA/LapB
co-purification with DnaK/J, multicopy suppression of growth defects of Δ(lap lapB) mutants, even
more pronounced defects in the LPS composition when Δ(lapA lapB dnaK/J) were examined. (f) LapA/B
co-purify with LPS, Lpt proteins and FtsH. (g) A Δ(lapA-lapB) mutation is synthetically lethal with a
compromised LptD variant or when SurA is absent. (h) The absence of LapB induces a strong envelope
stress response regulated by RpoE, Cpx and Rcs systems by inducing transcription of genes, whose
products are required to maintain homeostasis in the cell envelope. LapB contains nine tetratricopeptide
repeat (TPR) motifs and a C-terminal rubredoxin domain [9,37]. Mutations in the either rubredoxin
domain or TPR/interface impair cell growth [9]. Thus, based on the essentiality of TPR repeats in LapB,
which can mediate protein-protein interactions (interaction of LapA/B with LPS-specific enzymes)
a model was presented wherein LapA/B could form a scaffold-like structure for delivery of various
acyltransferases and glycosyltransferases to the site in IM where LPS is assembled and delivered to the
Lpt complex. At such an assembly site, proteolysis of LpxC can occur given co-purification of LapA/B
with FtsH to prevent excessive LPS buildup. This may serve as an essential purpose of preventing
wasteful transfer of incompletely synthesized LPS. This model draws support from the IM association
of LpxC in Neisseria meningitidis, which requires the presence of LapB counterpart called Ght [38].
Consistent with a broad essential function of LapB, a suppressor mutation lapBV43G in the lapB gene
that confers protection against prolonged exposure to phosphate starvation and also suppresses the
mlaA-dependent hyperproduction of LPS have been reported [39,40]. Thus, LapB plays an important
role in maintaining cell envelope homeostasis and assembly of LPS.
7. Transport of LPS
7.1. MsbA-Mediated Transport of LPS Across the Inner Membrane
After the completion of core-lipid A synthesis, LPS is flipped across the IM by the essential
ATP-binding cassette MsbA transporter. Several structures have been determined, which show that
MsbA exists as a functional dimer, wherein core-lipid A binds the cytoplasmic open conformation [41,42].
Upon ATP binding, conformational change in transmembrane (TM) domains results into change from
the cytoplasmic open to the periplasmic open state causing flipping of core-lipid A into the periplasmic
leaflet of the IM. MsbA can return to the cytoplasmic open state after release of phosphate [42]. MsbA
has a higher preference for hexaacylated lipid A derivatives, thereby providing an early checkpoint to
prevent transport of early intermediates of LPS biosynthesis. Recent structural analysis of MsbA-core
lipid A revealed that MsbA recognizes a bivalent phosphoglucosamine headgroup and correct acylation
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of lipid A to achieve substrate selectivity over competing bulk membrane phospholipids [43]. The tight
packing of hexaacaylated LPS in the hydrophobic pocket suggests that MsbA packs acyl chains of
correct length and number, providing the basis of this selectivity [43].
7.2. LPS Translocation and Assembly in the Outer Membrane
After the flipping of LPS by MsbA to the periplasmic side of IM, LPS is transported for its final
localization in the OM which requires a complex of seven essential conserved proteins LptA-LptG,
whose components reside in every cell compartment and form a single transenvelope complex spanning
from the IM to the OM. Here, we briefly summarise key elements, as this topic has been aptly reviewed
recently [44–47]. The Lpt system is organized into the IM complex comprised of LptB2CFG and the
OM component of 1:1 complex of LptDE, which are bridged by a periplasmic protein component
LptA. This transenvelope complex acts as a single unit to transport LPS, since depletion of any
component leads to LPS accumulation at the IM [44–47]. Mechanistically, the ABC transporter LptB2FG
extracts LPS from the IM in an ATP-dependent manner to deliver to LptC, and LPS transfer from
LptC to LptA requires additional ATP hydrolysis [44–47], allowing LPS transit across the aqueous
periplasm for its final delivery to LptD. The evidence from co-sedimentation, pull-down experiments,
photo-cross-linking, mutational and structural analyses, assembly of liposomes from IM components
and OM components in the presence or absence of LptA, shows that, while the N-terminus of LptA
interacts with LptC at the IM, the C-terminus of LptA interacts with the periplasmic domain of the
OM LptD, creating a continuous bridge of antiparallel β-strands between the IM and the OM [44–47].
The presence of β-jellyroll domains in LptG, LptF, LptC, LptA and LptD can sequester the acyl chains
of LPS from the aqueous periplasm, using ATPase activity of LptB to transfer LPS over transenvelope
bridge [48]. In support of the single stable bridge model of LPS transport, it was shown that LptA
can promote association of liposomes containing the IM complex of LptBCFG with OM liposomes
containing the OM LptDE [49]. Furthermore, ATP-dependent transfer of LPS from LptBFG to LptC
and LptA has been demonstrated in liposomes and transfer to LptA was shown to be increased when
LptC was present [49].
Structural studies of LptD and LptE revealed that LptD folds into two domains: a β-jellyroll and
a β-barrel [50,51]. The β-jellyroll extends away from the OM and interacts with the β-jellyroll domain
of LptA suitable for binding to lipid A, while leaving the LPS oligosaccharide exposed. LPS could
be delivered directly into the cavity of the larger domain of LptD β-barrel, which is composed of
26 membrane-spanning β-strands. LptE adopts a roll-like structure located inside the barrel of LptD to
form a unique two-protein ‘barrel and plug’ architecture [50,51]. The plugging of LptE inside of the
LptD barrel causes a diminished lumen size to 45Å × 35Å on the periplasmic side. However, such a
space is sufficient to accommodate LPS. In these structures, β-strands 1 and 2 are distorted and weak
hydrogen bonding between β-strands 1 and 26 could support a lateral opening for LPS migration.
In this process, positioning of the lipid A part could be assisted by LptE, as it is known to bind LPS and
oligosaccharide could be placed in the hydrophilic cavity of LptD chamber.
Finally, LptD folding into the functional state can be a rate-limiting step. Several periplasmic
folding catalysts like DsbA, DsbC, SurA, FkpA are known to play important roles in the folding
of OMPs and periplasmic proteins [52]. Folding of LptD requires the SurA periplasmic folding
catalyst and other periplasmic folding factors, like Skp and FkpA, could further modulate efficient
folding of LptD [22]. LptD has two disulfide bridges between four non-consecutive cysteine residues,
which require the periplasmic DsbA disulfide oxidoreductase and interaction of LptD with LptE to
achieve correct folding with native disulfide bridges [53]. Additional factors like BepA may also be
required for stimulating disulfide rearrangement of LptD and degradation of misfolded LptD [54].
From the transcriptional point of view, the lptD gene is transcribed by EσE [14] and this discovery was
the beginning of series of studies that led to subsequent elucidation of the Lpt system.
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8. Regulated Structural Alterations in LPS
The LPS composition is highly heterogeneous and dynamically altered in response to various
challenges like exposure to different stress conditions or changes in growth medium. Heterogeneity
of LPS can be due to: modification of the lipid A part by the incorporation of phosphoethanolamine
(P-EtN) and 4-amino-4-deoxy-l-arabinose (l-Ara4N) that mask negative charges, the addition or
removal of acyl chains, changes in the inner core due to the incorporation of additional Kdo residue,
rhamnose (Rha), uronic acid and P-EtN and changes in number of phosphate residues, and truncation of
the outer core [55]. All these structural changes are highly regulated, important for resistance to cationic
antimicrobial peptides, for bacterial virulence in pathogenic bacteria and may have adaptive significance
in specific environmental niches. Certain modifications in the LPS structure can also contribute to
biofilm tolerance of antimicrobial compounds [56]. Lipid A of E. coli under standard growth conditions
is bisphosphorylated carbohydrate backbone disaccharide β-d-GlcpN4P-(1→6)-α-d-GlcpN1P, which is
hexaacylated without any modifications. However, exposure to low pH, excess of Fe3+, Zn2+, Al3+,
change in divalent cations concentrations, challenge by antimicrobial peptides, treatment with the
non-specific phosphatase inhibitor ammonium metavanadate (AMV), treatment with agents that disturb
the OM symmetry like exposure to chelating agents like EDTA or genetic alterations that lead to the
synthesis of tetraacylated derivatives can cause profound changes in the lipid A composition [7,55,57].
Some of these modifications are regulated at the transcriptional level, while some are subjected to a
post-transcriptional control and certain modification occur at post-translational level [13].
8.1. Regulation of Lipid A Modifications
Most prevalent non-stoichiometric modifications that occur in the lipid A part involve either
reducing the net negative charges of lipid A by modifying the 1 and/or 4′ ends of phosphate residues,
or the addition or removal of acyl chains. Most commonly observed modifications of lipid A include
the incorporation of P-EtN and l-Ara4N at 1 and/or 4′ ends, respectively [57]. Such substitutions are
known to confer resistance to cationic antimicrobial peptides like polymyxin B. This non-stoichiometric
incorporation of P-EtN and l-Ara4N residues requires IM-located EptA and ArnT transferases,
respectively with active site facing the periplasm [57]. Genes encoding these transferases are part of
operons, whose transcription is positively regulated by the BasS/R (PmrA/B) TCS with an overlap
with the PhoP/Q system. These systems specifically respond to changes in Fe3+ and divalent cationic
concentrations, respectively. The PhoP/Q system in Salmonella and in some pathogenic Gram-negative
bacteria regulates the expression of virulence genes, including those encoded in pathogenic islands.
Lipid A of strains synthesizing tetraacylated lipid A can have phosphate residues at 1 and/or 4′ ends
modified by P-EtN, since they do not incorporate l-Ara4N due to defects in translocation and such lipid
A species could be poor substrates for ArnT. Such modifications occur after the translocation at the
periplasmic side and often serve as markers for LPS translocation with l-Ara4N incorporation as a more
stringent signature [7]. In E. coli and Salmonella, the activation of PhoP/Q TCS upon depletion of Mg2+
and Ca2+ also leads to the BasS/R induction, which requires PmrD as the adaptor protein [58]. Such a
cross talk between BasS/R and PhoP/Q TCSs allows integration of signals from different environmental
cues and amplification of output response.
The majority of lipid A in E. coli K-12 contains monophosphate at positions 1 and 4′. Approximately
one-third of lipid A molecules in the E. coli K-12 outer membrane contains a diphosphate unit at
the 1 position. The enzyme LpxT is responsible for this phosphorylation at 1′ position, generating
hexaacylated lipid A with two phosphate residues under ambient growth conditions in the absence
of induction of lipid A modification systems increasing the negative charge [59]. However, upon
induction of the BasS/R system, P-EtN is incorporated at 1′ position due to inhibition of the LpxT activity.
This inhibition of LpxT activity upon BasS/R-inducing conditions is due to the expression of a short
peptide PmrR, which directly bind to LpxT [60] and hence constitutes a post-translational control [13].
In Salmonella, PhoP activation can also positively regulate lpxT transcription. The PhoP-dependent
lpxT expression induced in low Mg2+ results in 1-PP lipid A, favors further modification of lipid A
109
Int. J. Mol. Sci. 2019, 20, 356
phosphates with l-Ara4N and the exclusion of P-EtN. Thus, Salmonella favors lipid A modified with
l-Ara4N under low Mg2+ and with both l-Ara4N and P-EtN when exposed to a mildly acidic pH [61].
As RpoE and LPS structural alterations are intricately linked, an interesting regulatory control of
lipid A alteration by RpoE-regulated sRNAs has emerged. Structural analysis of LPS obtained from
several different strains under simultaneous RpoE- and BasS/R-inducing conditions shows the absence
of LpxT-dependent phosphorylation of lipid A, presumably due to the transcriptional induction of
micA [62]. The RpoE-regulated MicA sRNA can also exert an influence on lipid A composition by
connecting regulation of PhoP/Q TCS as well as LpxT to RpoE. Analysis of MicA targets revealed that
besides known OMP-encoding genes, MicA represses PhoP synthesis by base pairing in the translation
initiation region of phoP mRNA and inhibits its translation [63]. MicA sRNA could as well regulate the
LpxT synthesis at a post-transcriptional level, since a base-paring region between the seed sequence in
the micA sRNA and the lpxT mRNA has been predicted [64]. Another sRNA GcvB also represses phoP
mRNA translation by base-pairing [65].
The lipid A part can also undergo non-stoichiometric modification by PagP-dependent
palmitoylation due to the incorporation of a palmitate chain linked to the hydroxyl group of
3-hydroxymyristic acid at C-2 position of reducing-end [66]. Transcription of the pagP gene is positively
regulated by the PhoP/Q TCS and via RcsB in biofilm environment or increase in osmolarity that
requires the GadE auxiliary regulator independently of the Rcs phosphorelay cascade [56]. The PagP
enzyme is usually inactive in the OM and is post-transcriptionally activated when the OM permeability
is breached and this modification can dampen recognition by host immune responses. Another
PhoP/Q-regulated modification is PagL-dependent deacylation. The pagL gene encodes a lipid A
3-O-deacylase and this deacylation of lipid A modifies its ability to induce immune response [67].
The PagL-dependent modification also occurs post-translationally after LPS is incorporated in the
OM [13]. It is noteworthy that in Pseudomonas aeruginosa the expression of pagL is positively regulated
by sRNA (Sr006) [68]. Regulation of another deacylase LpxR with a 3′-O-deacylase activity of relevance
to pathogenicity is of interest and this modification also occurs in the OM [69,70]. The expression of
LpxR is subjected to negative regulation by MicF trans-acting base-pairing RNA. The base-pairing of
MicF within the coding sequence of the lpxR mRNA decreases its stability by promoting its degradation
by RNase E [71]. Thus, variety of mechanisms exist to modify lipid A part of LPS which involve TCSs,
the RpoE sigma factor and sRNAs and this regulation can occur at different steps of LPS biosynthesis
transcriptionally or post-transcriptionally.
8.2. Regulation of Inner Core Modifications and Switches Between Different Glycoforms
The inner core of LPS in the majority of cases generally contains an α-(2-4)-linked Kdo disaccharide,
to which l-glycero-d-manno-heptose residue (Hep) is attached at position 5 of KdoI. In E. coli, the inner
core contains three Hep residues. Although the composition of the inner core is relatively conserved,
Kdo, as well as Hep residues, can be non-stoichiometrically modified. These modifications are regulated
by the RpoE sigma factor, PhoP/Q, PhoB/R TCSs, by alarmone ppGpp and recruitment of specific sRNAs,
whose expression is regulated by these transcription factors (Figure 1). Like lipid A modifications, they
are often important for antibiotic resistance OM permeability and contribute to diversity in the LPS
composition [10,13,62]. Quite well studied modifications include the non-stoichiometric incorporation
of a P-EtN residue on the second Kdo by EptB transferase, incorporation of a third Kdo by WaaZ
transferase, the addition of Rha, which can be linked to either the second Kdo or the third Kdo,
modification of phosphorylated HepI by P-EtN using the PhoB/R-regulated EptC and incorporation of
glucuronic acid (GlcUA) by the PhoB/R-inducible WaaH glycosyltransferase with a concomitant loss of
phosphate residue on HepII [55,62].
Transcription of the eptB gene encoding P-EtN transferase specific to the second Kdo is positively
regulated by the RpoE sigma factor [7,72]. Hence, this modification of the second Kdo is quite
pronounced when the RpoE activity is induced either in the absence of RseA anti-sigma factor or
when LPS is defective as in ΔwaaC or ΔwaaF mutants [7,11,62]. Consistent with the induction of
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RpoE and regulation of the eptB transcription, the lipid A part of ΔwaaC or ΔwaaF strains were found
to lack P-EtN even under eptA-inducing conditions, but preferentially incorporating P-EtN on the
second Kdo [7,11]. However, this incorporation requires the presence of Ca2+ in the growth medium.
Furthermore, the synthesis of EptB is negatively regulated by two Hfq-dependent sRNAs MgrR and
ArcZ, although in response to different environmental signals [72,73]. Under normal growth conditions,
the PhoP-regulated MgrR sRNA via base-pairing with the eptB mRNA silences its expression due to
translational repression of the eptB mRNA. Activation of PhoP/Q induces transcription of the mgrR
sRNA. The EptB-dependent P-EtN modification of the second Kdo upon high Ca2+ concentration
can be explained by the repression of transcription of PhoP/Q-regulated mgrR and promote the
synthesis of active EptB under RpoE-inducing conditions. The Hfq-dependent ArcZ sRNA also inhibits
translation and expression of eptB by base-pairing in an ArcA/B-dependent manner in response to
oxygen concentration [72]. Quite like the P-EtN modification of lipid A, the incorporation of P-EtN
on the second Kdo confers resistance to polymyxin B. Thus, RpoE regulon members like eptB and
MicA sRNA, PhoP-regulated MgrR sRNA contribute to the incorporation of P-EtN on the second Kdo,
lipid A and regulation of glycoform switches.
8.3. Modifications in the Heptose Region of the LPS Inner Core
The inner core of LPS exhibits the limited structural diversity, since it plays a crucial role in
maintaining the OM stability. However, some non-stoichiometric substitutions have been demonstrated
in this region of LPS. These include the incorporation or loss of phosphate residues and the addition of
P-EtN, GlcN, or GlcUA. Among these, the phosphorylation of the HepI residue by WaaP is critical for
the OM permeability and also provides the attachment sites for the other substituents and ensures the
completion of core synthesis [11,24,55]. Accordingly, in E. coli K-12, phosphorylated HepI serves as
an acceptor for P-EtN, which requires the EptC phosphoethanolamine transferase [55]. Furthermore,
the HepIII residue, whose incorporation requires prior phosphorylation of HepI by WaaP, can be
modified by GlcN (in E. coli R1 and R3 isolates) or by GlcUA (in Salmonella and E. coli B, K-12, R2
and R4 core types). Importantly, the modification of the HepIII residue is always accompanied by
loss of phosphate residue at the HepII, thereby maintaining a net negative charge [55,74]. Structural
studies revealed that GlcUA is attached to O-7 of the side-chain Hep, with the phosphate residue
found at position O-4 of the HepII being absent [55] (Figure 2). WaaH shares 20% amino acid sequence
similarity with WabO of Klebsiella pneumoniae. However, WabO in K. pneumoniae is responsible for the
galacturonic acid (GalA) incorporation [75]. In E. coli K-12, waaH and eptC genes, whose products
mediate transfer of GlcUA and P-EtN modifications of the Hep I and Hep III residues respectively,
are positively regulated by the PhoB/R TCS [55]. However, the P-EtN-modification of HepI can also
occur at the basal level without a requirement for induction of either PhoB/R or BasS/R systems.
The EptC-dependent modification of HepI is important for the permeability function, as ΔeptC mutants
exhibit sensitivity to exposure to sub-lethal Zn2+ concentration or the presence of SDS [55].
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Figure 2. Schematic depiction of unmodified hexaacylated glycoform I and glycoform derivatives with
various non-stoichiometric substitutions with a third Kdo-Rha disaccharide. Various genes whose
products mediate different steps in LPS biosynthesis and incorporation of different modifications
are indicated. Glycoform I constitutes the major LPS species under non-stress conditions (A). Upon
the induction of RpoE sigma factor and conditions inducing BasS/R and PhoB/R TCSs, the lipid A
part is modified by P-EtN and l-Ara4N at 1 and 4′ position by EptA and ArnT, respectively (B). The
induction of RpoE causes increased synthesis of EptB overcoming MgrR silencing and incorporation
of P-EtN on the second Kdo (panels B1 and B2). The induction of RpoE favors pathway of the
third Kdo incorporation by increased synthesis of WaaZ and repression of WaaR by the RybB sRNA,
leading to synthesis of glycoforms with a third Kdo with attachment of Rha on the third Kdo with a
concomitant truncation of the terminal GlcIII-HepIV disaccharide shown in violet background. The
PhoB/R induction leads to the incorporation of GlcUA at the expense of HepII phosphorylation (blue
background). Lipid A can also be modified by PagP generating heptaacylated lipid A and by the
removal of acyl chains by LpxR in the OM after translocation (light brown background). Various
sRNA-mediated controls are shown in blue color.
8.4. Glycoform Switches
Up to now, at least seven structurally different glycoforms of E. coli K-12 have been characterized,
whose relative abundance varies on growth conditions such as exposure to phosphate-limiting growth
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conditions, the induction of RpoE-regulated envelope stress response and activation of specific TCSs.
These glycoforms differ due to the non-stoichiometric modifications such as P-EtN transfer to the
second Kdo, incorporation of a third Kdo, addition of sugars like Rha, GlcN, uronic acids, alterations in
the numbers of phosphate residues in the LPS core and truncation of outer core terminal disaccharide.
In initial studies using optimal growth conditions, the wild-type E. coli K-12 was found to contain
majority of LPS corresponding to glycoform I structure and only minor amounts of three additional
glycoforms II, III and IV could be observed [76]. Glycoform I contains two Kdo residues in the inner
core, and four heptoses and four hexoses attached in specific order in the inner core and the outer
core (Figure 2). However, using strains or growth conditions that exhibit the induction of RpoE
sigma factor or employing phosphate-limiting growth conditions supplemented with Fe3+ and Zn2+
(induction of PhoB/R and BasS/R TCSs) or treatment with AMV (induction of RpoE and non-specific
induction of TCSs) revealed major shifts in the LPS composition and prevalence of different glycoforms
not only in E. coli K-12 but also in E. coli strains with different core type and in Salmonella [55,62].
Using growth medium that induces BasS/R and PhoB/R TCSs, wild-type E. coli strains synthesize
more glycoform IV/V derivatives as compared to glycoform I. However, when the RpoE induction
is maximal, a near-exclusive synthesis of glycoform V and its derivatives are observed (Figure 2).
This molecular switch to the synthesis of glycoform V derivatives requires ppGpp alarmone, induction
of the RpoE-transcribed genes eptB, sRNAs micA and rybB, and the transcriptional upregulation
of waaZ with a concomitant repression of WaaR synthesis [62] (Figure 2). waaZ and waaS genes
encode the Kdo transferase required for the incorporation of the third Kdo and rhamnosyl transferase,
respectively, while as the eptB gene encodes P-EtN transferase specific to the second Kdo [62,77]
(Figure 2). Glycoforms IV and V have the same molecular masses, but are structurally different due to
the incorporation of P-EtN on the second Kdo by the RpoE-regulated EptB and attachment of Rha
to the terminal third Kdo defining glycoform V. Without RpoE induction, EptB synthesis is silenced
by the PhoP/Q-dependent MgrR sRNA (no incorporation of P-EtN on the second Kdo, instead the
attachment of Rha on the second Kdo) and hence the synthesis of glycofom IV derivatives.
One of the interesting structural features of glycoform V derivatives with a third Kdo is the
concomitant truncation of the terminal disaccharide and the incorporation of P-EtN on the second
Kdo with Rha on the third Kdo. The minimal LPS structure that can support incorporation of a third
Kdo requires WaaO-mediated addition of glucose and hence serves as a branch point in determining
switches between glycoform I and glycoform IV/V derivatives [62]. Primarily this switch is regulated
by levels of WaaR and WaaZ, whose expression are regulated by induction of RpoE and PhoB/R TCS.
Truncation of the terminal disaccharide suggested that the WaaR glycosyltransferase is limiting under
RpoE-inducing conditions. This was indeed experimentally validated by observed repression of WaaR
synthesis due to the RpoE-regulated RybB sRNA and to some extent by another RpoE-regulated
sRNA MicA (Figure 2). At the same time, transcription of the waaZ gene is induced under such
conditions. Physiologically, switch to the synthesis of glycoform derivatives with a truncation in
the outer core, hence lacking terminal heptose, might be important for escaping detection by host,
since such derivatives cannot incorporate O-antigen. Importance of the O-antigen incorporation can
be critical, as it becomes essential for survival in Salmonella in the absence of the rpoE gene [78]. Thus,
a coordinated molecular programming ensures increased synthesis of the WaaZ Kdo transferase under
RpoE-inducing conditions, and the EptB P-EtN transferase, the induction of BasS/R-dependent WaaS
synthesis with a simultaneous repression of WaaR and MgrR synthesis.
8.5. Transcriptional Regulation of Major LPS Biosynthetic Operons by RfaH
RfaH is a paralog of NusG family of universally conserved transcription factors. RfaH is unique
in its specificity for recognition of only those operons that contain a short 8-nt conserved sequence
(GGCGGTAG) in the 5′ UTR called the ops (operon polarity suppressor) pause site. Thus, RfaH
regulates the expression of genes that play important functions in virulence such as the synthesis of
LPS core, O-antigen, haemolysin, capsule and for conjugation [11,12]. Recruitment of RfaH prevents
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transcriptional termination and enhances transcriptional elongation of long waaQ and rfb operons.
Consistent with a role for regulation of expression of waaQ and rfb operons, they contain an 8-nt
conserved ops site and the JUMPstart site in their 5′ UTR and also lack a ribosome-binding site. In the
absence of RfaH, LPS is truncated, since the expression of the waaQ operon is severely compromised
and ΔrfaH mutants exhibit permeability defects, the induction of RpoE-dependent envelope stress
response and are avirulent in pathogenic bacteria [11]. RfaH without interaction with the ops site exists
in an inactive form with a closed conformation with its C-terminal domain (CTD) folded in an α helical
hairpin tightly packed against its N-terminal domain (NTD). In this conformation, the NTD of RfaH
is not accessible for DNA-RNA polymerase interaction [79]. However, upon encountering the ops
site in the presence of RNA polymerase, the CTD of RfaH folds into a β-barrel allowing recruitment
of S10 ribosomal protein to couple transcription with translation and also enhance transcriptional
elongation. Recently, a new RirA sRNA (RfaH interacting RNA) was identified while analyzing factors
that induce transcription of the rpoE gene [11]. Overexpression of the 73-nt RirA sRNA, located in the
5′ UTR of the waaQ operon, increases transcription from the rpoEP3 promoter that specifically responds
to LPS defects. RirA overexpression abrogates the synthesis of O-antigen, causes reduction of LPS
amounts and truncation in the LPS core, thus mimicking the ΔrfaH phenotype. Indeed, RirA directly
interacts with RfaH in the presence of RNA polymerase and this interaction is dependent on the
presence of the ops site within the rirA RNA [11]. This RirA-RfaH interaction could lead to loss of the
specificity for recognition of ops-containing operons, like waaQ and rfb operons, needed for LPS core
and O-antigen biosynthesis.
9. Signal Transduction in Response to LPS Defects
Integrity of the OM and homeostasis of various overall cell envelope components is critical for
growth and the viability of bacteria. This requires correct assembly of OMPs, a balance between
synthesis of peptidoglycan, phospholipids and LPS. This in bacteria requires function of various
regulon members of RpoE and Cpx TCS. Severe defects in LPS biogenesis in response to underacylation,
defects in LPS when the LPS assembly factor LapB is missing or depletion of Lpt translocation system,
truncation in the inner core or when LPS synthesis is compromised particularly when bacteria synthesize
minimal LPS derivatives like Kdo2-lipid A, Kdo2 lipid IVA or only lipid IVA derivatives, cause major
cell envelope perturbations leading to a signal response that causes activation of the RpoE sigma factor,
induction of the Rcs phosphorelay and activation of the Cpx TCS [7,9–11]. The extent of induction
of these stress responses varies depending upon the severity of defects. Early work addressing
activation of RpoE, when the OMP assembly is compromised, revealed that strains lacking GmhD
(HtrM), which synthesize Kdo2-lipid A Re LPS, overexpress exopolysaccharide and have a constitutive
elevation of RpoE response with a concomitant decrease in OMP content [17]. The exopolysaccharide
synthesis is known to be positively regulated by the Rcs TCS by increasing transcription of wca
genes [80]. Subsequently, during deciphering of the RpoE regulon, it was revealed that some of the
genes involved in either LPS biosynthesis, LPS modifications, LPS transport and factors involved
in OMP folding and insertion in the OM are part of this regulon [14]. In further studies, detailed
mutational analysis of various genes, whose products are either involved in LPS biosynthesis or LPS
modifications, coupled with mass spectrometric analysis of LPS of all such mutant derivatives and
an impact on envelope stress response was undertaken in series of studies [7,9,11]. These studies
reveal a full circuit wherein defects in LPS cause a major induction of RpoE and RpoE induction
without any mutations in LPS biosynthetic/assembly pathways lead to several alterations leading to
the accumulation of specific LPS glycoforms and various modifications (Figure 3). Some of the major
conclusions and major pathways of stress response are discussed here. These studies showed that
underacylation of LPS, when the core biosynthetic pathway is intact, does not cause any major induction
of either RpoE or Cpx systems [7]. Only when all three acyltransferases are deleted, as in a strain Δ(lpxL
lpxM lpxP), a modest induction of RpoE-dependent pathway is induced. In contrast, ΔwaaC strains
synthesizing Kdo2-lipid A LPS exhibit a nearly 3-fold induction of RpoE pathway without impacting
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the Cpx system. However, tetraacylated derivatives synthesizing Kdo2-lipid IVA like Δ(waaC lpxL)
or Δ(waaC lpxL lpxM lpxP) exhibit a 3-4-fold induction of both RpoE and Cpx pathways even under
permissive growth conditions. Consistent with these are the findings that ΔwaaA mutants synthesizing
lipid IVA precursor species exhibit maximal induction of RpoE and Cpx pathways. Given much higher
induction of RpoE in ΔwaaC mutants and lipid IVA synthesizing strains, as compared to its modest
induction in Δ(lpxL lpxM lpxP) mutants, suggests an acute requirement for the incorporation of Kdo
and initial steps in LPS core biosynthesis for cell envelope integrity. Interestingly, a Δ(lpxL lpxM lpxP)
strain was found to synthesize LPS primarily of glycoform with a third Kdo residue and a truncation of
outer core disaccharide, when grown in lipid A modifying conditions [7]. Furthermore, mutations in
some of the conserved early glycosyltransferases encoding genes, like waaF, waaG, waaO or waaP whose
product phosphorylates Heptose I, or in the absence of RfaH transcriptional factor whose product is
required to ensure transcription/translation and prevent premature termination of transcription of the
waaQ operon also induce the rpoE transcription [11].
Figure 3. Pathways of sensing defects in LPS biosynthesis/assembly: sensing via the Rcs phosphorelay
system, which leads to the induction of transcription from the sigma 70-regulated rpoEP3 promoter
requiring RcsB as activator and the activation of Qse TCS induces the rpoEP2 promoter with QseF
acting as an activator of RpoN. Severe defects in LPS induce the Rcs phosphorelay cascade leading
to phosphorylation of RcsB. Phosphorylated RcsB acts as an activator for the transcription directed
from the rpoEP3 promoter leading to the induction of RpoE-mediated stress response. The overlapping
rpoEP2 promoter also responds to LPS defects albeit to a lower extent. Severe defects in LPS also induce
the CpxR/A TCS. EσE is required to maintain envelope integrity by regulating expression of genes
whose products are involved in protein folding in the periplasm, assembly of OMPs (bam genes) and
certain genes whose products are involved in LPS biosynthesis/modifications. Release of LPS from the
Lpt system can lead to association of LPS with RseB, which relieves inhibition of RseA proteolysis and
can lead to accumulation of free RpoE without RseA.
Consistent with sensing of correct assembly of LPS by RpoE, such a phenotype was used to identify
LapA and LapB assembly factors, since the lack of LapB causes increased constitutive induction of RpoE
and Cpx regulons quite like ΔwaaA mutants [9]. As mentioned above, Δ(lapA lapB) mutants produce
more LPS due to stabilization of LpxC, accumulate precursor species of LPS with incomplete core,
defects in acylation of lipid A and reduced amounts of LptD in the OM. Thus, given the overwhelming
evidence, it is fair to conclude that severe defects in either early steps in LPS core biogenesis or when
LPS is composed of only Kdo2-lipid IVA or when LPS assembly is defective lead to the induction of
RpoE envelope stress response.
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10. Mechanism of Signal Transduction
Here, we will discuss the activation of RpoE regulon in response to LPS defects with an overlap in
the activation of the Rcs phosphorelay system, which jointly respond to LPS defects (Figure 3). We do
not know how the Cpx system senses LPS defects as it can respond to several envelope stress signals
in the IM, periplasm and OM. One of the main observations has been that only those structural LPS
changes/defects that induce the Rcs system also induce RpoE. Thus, induction of PhoB/R-dependent
GlcUA incorporation, BasS/R-dependent lipid A modifications, lack of either WaaY, or WaaZ or WaaS
or truncation of outer core neither induce the Rcs system nor the RpoE-regulated stress response [11,55].
In a comprehensive study, a systematic approach of dissection of the transcriptional regulation of
the rpoE gene and stimuli that induce or repress was taken based on previously observed RpoE
induction in ΔwaaA or strains synthesizing Kdo2-lipid IVA derivatives [7,11]. When the rpoE gene was
initially identified, two complementary studies showed that transcription of the rpoE gene is positively
autoregulated from one of its promoters since it is recognized by EσE polymerase and its activity is
induced when OMP maturation is dysfunctional or due to an imbalance in OMP expression [81,82].
However, the regulation of distal promoter or promoter region (previously called the rpoEP1 promoter)
remained elusive. Besides positive transcriptional regulation, RpoE is negatively regulated by RseA
and RseB proteins, whose encoding genes are co-transcribed with the rpoE gene [83]. The RseA inner
membrane protein associates via its cytoplasmic N-terminal domain with RpoE, thereby sequestering
RpoE in the IM under non-stress conditions [83]. This inhibitory effect of RseA is relieved upon OMP
misfolding or overexpression of some OMPs by sequential degradation of RseA initiated by DegS in
the periplasm, followed by the second site inner membrane proteolysis by RseP (EcfE) and subsequent
degradation of the N-terminal RseA in the cytoplasm [84]. The periplasmic C-terminal domain of
RseA associates with RseB and prevents RseA degradation. Since the autoregulated rpoE promoter (P6
promoter), previously called rpoEP2 promoter, responds to effective concentration of available RpoE
that complexes with core RNA polymerase, its activity reflects both transcriptional increase in the
rpoE expression and its release from RseA and hence its activity or activity of reporter promoters of its
regulon members (rpoHP3) does not directly reflect response to LPS defects.
During the studies aimed to understand the mechanism of rpoE induction in response to LPS
defects and examination of transcriptional regulation of upstream element, it turned out that the rpoE
gene is transcribed from six promoters and, among these, activity of rpoEP2 and rpoEP3 promoters is
specifically induced when LPS is defective (Figure 3). Among these, transcription from the rpoEP3
promoter is significantly induced when either the LPS core biogenesis is defective or when LPS assembly
is compromised or by challenge with LPS-binding antibiotic like polymyxin B or treatment with
agents like AMV that induce non-specifically different TCS [11]. Global mutational screen identified
insertion/deletion mutations mapping to genes involved in the early steps of LPS core biosynthesis
such as waaC, waaF, waaG, waaO and waaP. Among these, maximal 7-fold induction of the rpoEP3
promoter was observed in ΔwaaC mutants synthesizing Kdo2-lipid IVA [11]. This activation was nearly
abrogated in Δ(waaC rcsB) mutants suggesting that the signal of activation due to defective LPS requires
the RcsB response regulator [11]. Interestingly, mutations in either waaC or waaF or waaP exhibit
deep-rough phenotype accompanied by the induction of Rcs-regulated exopolysaccharide synthesis.
Analysis of various other response regulators did not show any direct participation [11]. The activity
of the same rpoEP3 promoter was found to be induced nearly 3–4 fold in ΔrfaH background and by the
overexpression of rirA sRNA [11]. The 73 nt RirA sRNA contains ops element, located in the 5′ UTR of
waaQ operon and acts by decreasing the RfaH activity, by directly binding to RfaH in the presence of
RNA polymerase. The overexpression of rirA causes a reduction in the expression of operons that
require the RfaH activity. When RirA is in excess, it causes a decrease in the expression of waaQ
operon members leading to truncation of the LPS core and abolishes the incorporation of O-antigen,
explaining the specific induction of LPS responsive rpoEP3 promoter [11]. Additional evidence that the
rpoEP3 promoter responds to LPS-specific alterations is based on an increase in transcription from
this promoter when bacteria are challenged in early growth phase by either polymyxin B or AMV.
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The induction of RpoE regulon concomitant with Rcs pathway activation is also observed when any
component of Lpt is depleted, since under such conditions LPS is modified by the Rcs-regulated colanic
acid exopolysaccharide [85].
A direct proof that the rpoEP3 promoter is positively regulated by the Rcs system comes from
in vitro DNA binding assays with purified RcsB, establishing the presence of conserved RcsB motif
in the rpoEP3 promoter region [11]. This was supported by deletion and mutational analysis of
RcsB-binding motif. Run-off assays established the authenticity of recognition by the house-keeping
sigma factor and mutational analysis reinforced that RcsB acts as a positive regulator in response to LPS
defects. Transcription from the rpoEP3 promoter is also activated in Δ(lapA-lapB) which also requires
RcsB. It should be noted that the RpoN-regulated rpoEP2 promoter also responds to LPS defects albeit
to a much-reduced extent (only a 70% to 2-fold increase as compared to the 7-fold induction by ΔwaaC)
and that too mainly upon entry into the stationary phase. Since the rpoEP2 promoter requires QseF as
an activator [11], it will be interesting to know how the Qse TCS senses LPS.
A role for sensing of LPS defects by the Rcs signalling pathway was proposed in earlier studies
by examining a mutant strain carrying rfa-1 mutation. Such a strain synthesizes LPS composed of
only two heptose residues lacking any glucose in the core region and exhibits induction of cps genes
leading to overexpression of exopolysaccharide [80]. Furthermore, it was shown that this LPS defect
requires the outer membrane lipoprotein RcsF, since induction of cps transcription in rfa-1 mutant was
abolished in ΔrcsF mutants [80]. Interestingly, overexpression of cps genes due to LPS defects did not
occur due to the increased rcsF transcription, rather could be the consequence of other mechanisms
of the RcsF activation. More recent studies on RcsF revealed that it exists in complex with many
OMPs [86] and such RcsF complex uses its positively charged, surface-exposed N-terminal domain to
detect alterations in lateral interactions between LPS molecules (changes in phosphorylation status of
the LPS core), which lead to the induction of Rcs system. This activation of Rcs pathway in turn can
activate RcsB to induce the rpoEP3 promoter when LPS defects are encountered (Figure 3).
Another model postulates that the periplasmic RseB binds to LPS that might be released in an off
pathway during translocation via the Lpt system [84]. Usually, RseB association with RseA inhibits its
proteolysis. However, LPS binding to RseB relives inhibition of proteolysis by disassociation of the
RseA-RseB complex (Figure 3). In support of this model, authors show that RseA-RseB dissociation by
LPS is inhibited in the presence of LptA, suggesting that the periplasmic accumulation of LPS, due to
release from Lpt proteins in the periplasmic bridge, can promote the dissociation of RseB from RseA
and cause RpoE induction. However, the validity of this model needs further studies as free LPS is not
known to accumulate when the LPS core is truncated and severe defects in LPS, particularly upon
accumulation in the IM when the Lpt system is depleted, also induce RpoE. Analysis of distribution of
free RpoE vs. RpoE bound to the IM in ΔwaaA has revealed that the elevated RpoE activity can be
attributed to increased release of RpoE from the IM in such mutants [87]. However, a joint signaling
when LPS is defective via the Rcs system and RseB can amplify RpoE induction and hence these models
are not mutually exclusive.
In summary, comprehensive analysis of various LPS defects has revealed that RpoE activity is
specifically induced when LPS biosynthesis or assembly is compromised by the activation of the rpoEP3
promoter with phosphorylated RcsB acting as an activator and the sensing of LPS defects occurs via
the Rcs phosphorelay system (Figure 3).
11. Conclusions
The LPS synthesis is subjected to a tight regulation at variety of steps. Regulation of LpxC
amounts by FtsH and LapB constitutes an essential step to maintain a balanced synthesis of LPS
and phospholipids. Further, MsbA by preferential selectivity of hexaacylated LPS provides an early
checkpoint, preventing transport of precursor underacylated LPS species. LapB recruits LpxC, FtsH,
glycosyltransferases, myristoyltrasferase LpxM and other proteins that are required for LPS synthesis
at the IM, presumably acting as a scaffold to deliver completely synthesized LPS to its other interacting
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partners in the Lpt transport system. LPS is heterogeneous in composition and its composition is
dynamically altered by a host of factors. These LPS alterations are regulated by the RpoE sigma factor,
TCS like BasS/R, PhoP/Q, PhoB/R and Rcs system with an overwhelming role played by noncoding
sRNAs. The Rcs system senses LPS defects resulting into phosphorylation of RcsB, which leads to
activation of transcription from rpoEP3 promoter leading to RpoE induction. Finally, the transenvelope
Lpt complex of seven essential proteins acts as a single unit and in an ATP-dependent manner ferries
LPS across the periplasmic bridge comprised of LptA for delivery to the OM component of LptD/E
in a continuous manner. Although tremendous progress has been achieved in the recent past, it is
still unknown how the LptB cytoplasmic component of Lpt system is localized to the IM and how the
proteolytic activity of FtsH is regulated by LapB protein and other factors. Further studies are also
needed to demonstrate that LapB acts as the scaffold for LPS assembly and its coordination with the
Lpt transport system, although LapA/LapB proteins have been demonstrated to co-purify with Lpt
components. As LPS is essential, its essential steps in biosynthetic pathway and Lpt transport have been
validated targets of discovery of new antibiotics. Already inhibitors of LpxC and a peptidomimetic
POL7080 based on the cationic antimicrobial peptide that inhibits the LptD activity are in advanced
clinical trails and many additional antimicrobial compounds using LPS synthesis/assembly are bound
to be discovered in future.
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Abstract: Gram-negative bacteria have a dense outer membrane (OM) coating of lipopolysaccharides,
which is essential to their survival. This coating is assembled by the LPS (lipopolysaccharide)
transport (Lpt) system, a coordinated seven-subunit protein complex that spans the cellular envelope.
LPS transport is driven by an ATPase-dependent mechanism dubbed the “PEZ” model, whereby a
continuous stream of LPS molecules is pushed from subunit to subunit. This review explores recent
structural and functional findings that have elucidated the subunit-scale mechanisms of LPS transport,
including the novel ABC-like mechanism of the LptB2FG subcomplex and the lateral insertion of
LPS into the OM by LptD/E. New questions are also raised about the functional significance of LptA
oligomerization and LptC. The tightly regulated interactions between these connected subcomplexes
suggest a pathway that can react dynamically to membrane stress and may prove to be a valuable
target for new antibiotic therapies for Gram-negative pathogens.
Keywords: lipopolysaccharides; membrane transport; Gram-negative bacteria
1. Introduction
Gram-negative bacteria protect themselves from chemical stressors by incorporating hydrophobic
lipopolysaccharide (LPS) into their outer membranes. The LPS coating acts as a physical barrier
to antibiotics and has antigenic properties that make it critical to understanding and countering
pathogenicity. Individual LPS are amphipathic, consisting of a hydrophobic lipid moiety (Lipid A) and
a hydrophilic oligosaccharide core (OS). Some bacteria add an O-antigen (Oag), a repeating saccharide
moiety that extends out from the OS core. The LPS coating is critical to the integrity of the cellular
envelope, and Gram-negative bacteria need to replenish it at an astonishing rate to survive.
LPS is synthesized at the cytoplasmic side of the inner membrane (IM) before it is transported to
the outer membrane (OM). Lipid A is synthesized in the cytoplasm via the Raetz pathway and then
ligated to the OS core [1]. It is then flipped to the outer leaflet by the ATP-binding cassette (ABC)-type
transporter MsbA [2]. The O-antigen is synthesized and transported to the periplasm by a parallel
pathway before it is ligated to the OS [3,4]. Producing LPS in the cytoplasm presents the physiologically
daunting task of getting the amphipathic LPS across two membranes, the periplasm and a substantial
concentration gradient. Gram-negative bacteria accomplish this through the specialized transportation
machinery of the LPS transport (Lpt) system, a linear protein bridge that spans the cellular envelope.
The Lpt system is an oligomeric complex consisting of Lpt proteins A through G.
The membrane-bound LptB, F, G and C subunits are connected to the LptD/E heterodimer in the OM
by periplasmic LptA (Figure 1). The LptB2FG tetramer extracts LPS from the outer leaflet of the IM
and provides the energy to drive LPS transport through an ATPase-dependent mechanism. LptC and
LptA provide a continuous LPS binding surface that conveys it to the OM. There, LptD/E inserts
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LPS laterally into the outer leaflet of the OM where it is dispersed across the extracellular surface.
With some species-dependent exceptions, all seven of the Lpt proteins are essential to LPS transport
and Gram-negative bacteria survival.
Figure 1. The Lpt (LPS transport) system forms a continuous protein bridge across the inner
membrane, periplasm and outer membrane. LptB (purple), LptG (red) and LptF (blue) extract LPS
(lipopolysaccharide) from the inner leaflet of the IM (inner membrane) through an ATPase-dependent
mechanism. LPS cross the periplasm along a continuous hydrophobic groove formed by LptC (cyan),
LptA (orange) and LptD (green). LptD and LptE (yellow) sort LPS to the outer leaflet of the outer
membrane (OM).
The LPS coating of the Gram-negative outer membrane is a literal, physical barrier to the
development of new antibiotics. Needing to cross the lipid barrier limits the physiochemical properties
of antibiotic compounds to narrow ranges of size and lipophilicity [5]. Disrupting the Lpt system
can increase cell permeability, and its OM-bound components make it more immediately accessible.
The Lpt system is therefore an excellent target for new antibiotics to directly target cell survival
or complement other compounds. Further characterization of the Lpt system’s subunit-to-subunit
interactions and LPS bindings could contribute to the rational design of new antibiotics for the
treatment of Gram-negative pathogens.
Until recently, there were major gaps in the experimentally-derived structures of the Lpt subunits.
The periplasmic LPS-binding domain of LptD was absent from the available structure, making it
difficult to visualize how the Lipid A and OS moieties crossed the membrane together. On the IM side
of the complex, the lack of LptF and LptG structures limited the structural characterization of LptB’s
extraction mechanism to predictions based on other ABC transporter systems. With the publication
of the complete LptD/E and LptB2FG structures solved by Botos et al. and Luo et al., respectively,
a complete picture of the Lpt system’s components is available [6,7]. These structures have answered
longstanding questions about the mechanisms of LPS transport and prompted intriguing new ones
about its assembly and regulation.
The recent breakthroughs in Lpt structure were accompanied by validation of the protein-bridge
“PEZ” model of LPS transport. The model wherein the Lpt subunits form a continuous complex from
the IM to the OM and LPS is propelled along it continuously by the ATPase activity of LptB has long
been favoured over the periplasmic dissolution or membrane-junction models. It is consistent with
the individual interactions between the Lpt subunits and the structural features of the Gram-negative
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cellular envelope, but direct evidence of the complete bridge and its activity was not observed until
a recent study where Sherman et al. demonstrated the Lpt-dependent transmission of LPS between
proteoliposomes [8]. Between their findings and the newly-solved Lpt structures, a more complete
structural-functional model of LPS transport is now possible.
This review was prompted by the crossing of these two major milestones in Lpt research.
The essentiality of the Lpt system and its specific role in preserving the impermeability of the
outer membrane make it a promising target for antibiotics, and these new findings could lead to
the development of new rationally-designed inhibitors. Questions remain as to how the specific
interactions within the Lpt complex facilitate LPS binding and transport. This review will summarize
the current research on the structural interactions within the Lpt system and discuss their potential
implications regarding function and regulation of OM biogenesis overall.
2. The LptB2FG Complex Drives LPS Extraction from the IM to the Periplasm
The overall mechanism of the Lpt system is often likened to a “PEZ” candy dispenser (Figure 2),
wherein a spring at the bottom of a candy-filled chamber slides the contents up as candies are
removed from the top one at a time. In vivo, this means that every LPS-binding site in the assembly
is continuously passing the molecule from the previous subunit to the next until it reaches the OM.
Obviously, this description does not account for how the individual Lpt subunits bind and release LPS,
but it is useful for emphasizing the core role of the LptB2FG complex as the “spring” that provides the
motivating force for the LPS “candy”.
Figure 2. The mechanism of LPS transport to the outer membrane is often referred to as the “PEZ”
model in reference to the spring-loaded candy dispenser. In this analogy, the LptB2FG complex is the
“spring” that pushes the LPS “candy” through the chamber (LptA and LptC) to the cap (LptD/E),
which is lifted to release them one at a time.
The subcomplex of LptF, LptG and dimeric LptB spans the IM and is responsible for extracting
LPS from the membrane and propelling it along the periplasmic bridge. The LptB dimer is located in
the cytoplasm, where it binds and hydrolyzes ATP. LptB forms a complex with the transmembrane
LptF/G dimer. This configuration resembles other ABC transporters: a cytoplasmic nucleotide-binding
domain (NBD) hydrolyzes ATP to switch the substrate cavity of the transmembrane domains (TMD)
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between inward- and outward-facing conformations [9]. In this case, the LptB dimer hydrolyzes
ATP to alter the conformation of the transmembrane LptF/G dimer. However, the mechanism of the
LptB2FG complex necessarily differs from other ABC transporters because it extracts its substrate
directly from the same leaflet of the membrane, rather than switching it from one side of the membrane
to another. LptB also differs from other ABC NBDs because it retains some ATPase activity even
when purified in vitro, whereas other ABCs are inactive without the full complex [10]. The complete
LptB2FG complex displays substantially higher ATPase activity, but curiously, activity decreases by
40% with the inclusion of LptC [7]. Until recently, these differences were difficult to explore as much of
LptB2FG’s structural mechanism had to be inferred from other ABC complexes.
LptB’s catalytic activity couples to the LptF/G heterodimer’s extraction of LPS like other ABC
transporters, wherein the coupling helices of the TMD interact with the variable Q-loop of the NBD.
Structural comparison of ATP-and ADP-bound LptB shows that ATP binding, hydrolysis and release
induce conformational changes in the Q-loop region, mediated predominantly by two conserved
residues (F90 and R91) [11]. The interaction between LptB and LptF/G evidently has some activating
effect on the catalytic domain, as ATPase activity is substantially higher with the full complex.
LptB2FG activity and subsequent LPS transport are further enhanced in the presence of the antibiotic
novobiocin, a hydrophobic DNA gyrase inhibitor [12]. Novobiocin binds to the Q-loop and directly
interacts with F90 and R91, strongly indicating that LptF/G’s effect on LptB ATPase activity is mediated
directly through their coupling interaction. The actual mechanism of this effect remains unknown,
but novobiocin is a potentially promising lead compound for the rational design of antibiotics that
target LPS export from the IM.
The crystal structures of the LptB2FG tetramer solved by Luo et al. indicate a mechanism whereby
the complex cycles through three conformational states to extract LPS from the IM to the periplasm [7]
(Figure 3):
1. Resting: The LptB nucleotide-binding sites are unoccupied, and the LptF/G cavity is
oriented inwards.
2. Open: ATP binds LptB, inducing the LptF/G cavity to open away from the IM, and receives the
Lipid A moiety of LPS, which is still embedded in the IM.
3. Close: LptB hydrolyzes ATP, inducing the LptF/G cavity to close again. LPS is forced out of the
IM into the periplasm.
 
Figure 3. The mechanism of LPS transport to the outer membrane is often referred to as the “PEZ”
model in reference to the spring-loaded candy dispenser. In this analogy, the LptB2FG complex is the
“spring” that pushes the LPS “candy” through the chamber (LptA and LptC) to the cap (LptD/E),
which is lifted to release them one at a time.
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Based on this mechanism, Luo et al. have suggested that LptB2FG represents a third distinct type
of ABC transporter, deemed type-III.
The overall mechanism of LptB2FG is consistent with structural observations, but LPS’s immediate
destination following extraction from the IM remains ambiguous. The hydrophobic grooves of the
LPS-binding domains of LptF and LptG are oriented away from and towards the IM, respectively,
suggesting they may have differing functions in the transmission of LPS. Luo et al. theorized that
the two may alternate as the binding site for LPS, although LPS binding to either component has
yet to be reported [7]. Induced crosslinking experiments have successfully characterized specific
LPS interactions with LptA and LptC, so a similar approach or other in vitro experiments could
further elucidate the proposed mechanism. Simpson et al. hypothesized that LptF/G either extracts
LPS directly through their LPS-binding domains or triggers the handoff indirectly by stimulating a
conformational change in LptC [13]. Now that a general overview of the conformational changes that
LptB2FG undergoes is available, further investigation of how LPS interacts with its various domains is
needed to understand how it facilitates transport to the other Lpt subunits.
How the LptB2FG complex interacts with the other IM-bound subunit, LptC, and how that
influences LPS extraction are still open questions. LptC reduces the ATPase of the activity of the
complex in vitro, even though its localization to the periplasmic side of the IM would imply no direct
interaction with LptB [7]. Although functional studies have confirmed that LptC is the intermediate
between the IM complex and LptA, how or why it influences LptB’s activity remains unclear.
3. LptC’s Role in IM-Periplasm Transport Is Ambiguous
LptC is essential to LPS transport and cell survival, but the function of several of its structural
elements is unclear. LptC consists of a C-terminal periplasmic domain that closely resembles the
other LPS-binding domains and a single N-terminal transmembrane helix. Its periplasmic domain
complexes with LptB2FG and LptA and has been shown to bind LPS in vivo. Although LptC is bound
to the IM, the N-terminal helix is not essential to Lpt assembly, as completely truncating it does not
affect cell survival or the formation of the LptB2FG complex [14]. LptC may localize to the IM to
improve the efficiency of Lpt assembly, but its specific interactions with the other subunits are sufficient
for LPS transport.
LptC’s essentiality is dependent on specific interactions with LptF. Benedet et al. found
that cells lacking LptC could be made viable by mutating a single LptF residue (R212) [15].
Membrane permeability increases as a result, but some LPS is still able to reach the surface. The likeliest
explanation is that the IM complex is able to recruit an additional LptA to receive LPS in the
absence of LptC. This conditional dependence also suggests that wildtype LptF forms a specific
interaction with LptC that normally excludes LptA. Benedet et al. proposed that LptC could be
a late evolutionary addition to what used to be a six-subunit complex [15]. Martorana et al. also
showed that overexpressing LptB compensates for truncation of LptC’s C-terminus (residues 139–191),
possibly by shifting the binding equilibrium in favor of the full complex [16]. If this is the case,
LptC may be important to the efficient and stable assembly of the LptB2FG complex, in addition to
directly transporting LPS.
LptC’s periplasmic domain might serve a role in stabilizing the LptB2FG complex, boosting the
efficiency of the Lpt system. Although it has been theorized that the truncated LptC may be able
to form an alternative edgewise interaction with LptA, this seems less likely than the alternative
suggested by Benedet et al. wherein LptA is able to receive LPS from the IM independent of
LptC [15]. The C-term LptC mutation could reduce the stability of the overall LptB2FGC complex,
so increased LptB expression could compensate by shifting the binding equilibrium in favor of the
LptB2FG complex.
LptC has also been shown to form a homodimer, but no functional significance has been identified.
The N-terminal edges of LptC’s periplasmic domains form a head-to-head dimer in vitro [17].
Mutations disrupting this interaction have little effect on LptC’s ability to bind LPS or LptA [18].
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LptC’s ability to dimerize may just be a side-effect of the β-jellyroll fold’s modularity, but it may be
worth accounting for in future investigations of its in vivo function.
4. LPS-Binding Domains Span the Periplasm
LptA and the periplasmic domains of LptC, LptD, LptF and LptG have divergent sequences,
but share a common OstA-like twisted β-jellyroll fold that binds the Lipid A moiety of LPS.
The 16 antiparallel β-strands form a pair of β-sheets in a “V” shape. The interior of the “V” forms a
hydrophobic groove along the interior that widens slightly near the N and C-termini [19]. This groove
likely shields Lipid A from the periplasmic environment, while the hydrophilic OS core and O-antigen
remain exposed. The β-jellyroll domains oligomerize from head-to-tail with a 90◦ twist per subunit,
forming a continuous multiprotein β-sheet and a spiraling hydrophobic groove. This rod-like oligomer
provides the path for LPS from the IM to OM. The relative arrangement of the β-jellyroll domains is
well-established, and residues essential to oligomerization have been identified; however, how these
interactions contribute to LPS transport beyond providing the shielding Lipid A in the periplasm is
still under investigation.
The Lpt β-jellyroll folds are very similar to one another, but the positioning of their N-terminal
helices varies. LptA, LptD and LptG have short N-terminal helices that loop around to the C-terminal
end of the hydrophobic groove of the jellyroll [6,7,19]. LptC and LptF lack similar helices: the
N-terminus of LptC is disordered, and the N-terminal end of the LptF periplasmic domain links
directly to helix 5 of its TM domain [7,20]. In LptD, the N-terminal helix forms one of two disulfide
bonds that are essential to functional assembly of the LptD/E complex.
The apo structures of LptA, C and D indicate that the β-jellyroll must undergo extensive
conformational changes to receive and subsequently hand off LPS. The hydrophobic cavity observed
in the crystal structures of the empty LPS-binding domains are too small to accommodate the fatty acid
chains of Lipid A [6,7,19]. A recent series of electron paramagnetic resonance (EPR) experiments by
Schultz et al. demonstrated that LPS binding induces a substantial rearrangement in the inward-facing
side of the hydrophobic groove of LptA and LptC [17,21]. The largest change is a partial unfolding of
the N-terminal edge of the pocket, while the C-terminal edge remains relatively immobile.
It was previously thought that the transfer of LPS from the periplasmic domain of LptC to LptA
is driven in part by the latter’s higher affinity for LPS. In the absence of ATP, LptA has been shown
to displace LPS from LptC in solution [20]. However, more recent assessments of the LPS affinity of
LptC and LptA suggest the difference may be small or even inverted, with Kd values ranging from
11–28 and 7–35 uM, respectively [17,21]. The transmission of LPS between Lpt β-jellyroll subunits may
therefore be a more dynamic process than the “PEZ” model implies alone, whereby the periplasmic
bridge undergoes “ripples” of ordered-disorder transitions that shuffle LPS along its length.
5. LptA Oligomerization and Membrane Stress
LptA’s function and relative placement in the Lpt system is understood, but its stoichiometry
in vivo remains uncertain. LptA is the only component of the Lpt system that lacks a transmembrane
component, as it spans the periplasmic space between the IM and OM complexes. LptA co-purifies
almost exclusively with membrane fractions when expressed at native levels, indicating that most
LptA is bound to other Lpt components rather than floating freely in the periplasm [22]. The first
crystal structure of LptA solved by Suits et al. showed it arranged in an end-to-end fibrous tetramer,
which forms a continuous hydrophobic groove between the LptA monomers (Figure 4). Mass spectral
analysis later confirmed that LptA forms 2–5-member oligomers in a concentration-dependent manner
when purified in vitro and that the resultant complexes are stabilized by LPS [23]. UV-dependent
dimers of modified LptA have been purified, although these could be experimental artifacts resulting
from the presence of tags or altered expression [24].
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Figure 4. (A) The β-jellyroll domains of LptA form a rod-like head-to-tail multimer (alternating orange
and gold) in solution with an ~90◦ rotation per subunit (blue arrow). (B) The N- and C-terminal
β-strands form a continuous β-sheet along the length of the multimer. This is likely analogous to
LptA‘s interactions with the β-jellyrolls of LptC and LptD.
The LptA-LptA binding interface probably uses the same contacts as LptA-LptC and LptA-LptD,
so it is difficult to investigate the in vivo relevance of LptA oligomerization via mutagenesis without
also disrupting LPS transport. The recent development of high-resolution in situ imaging techniques
like electron cytomography may circumvent this issue by making it possible to directly measure the
transenvelope length of the Lpt complex, although it may be necessary to first identify conditions that
favour LptA oligomerization [25].
It is tempting to speculate that LptA oligomerization allows the Lpt system to tolerate changes
in the intermembrane space resulting from osmotic stress. A single-LptA complex can bridge a
typical Escherichia coli intermembrane distance of 100 Å, but the width of the periplasm could vary
between species and in response to osmotic stress. In E. coli, the LptA appears to express at the same
level as the other monomeric components of the Lpt system under normal conditions. However,
functional analysis of the promoters associated with LptA shows additional responsiveness to changes
in LPS biogenesis [26]. It is possible that the Lpt complex varies between single and multiple-LptA
states in response to increased LptA availability, influenced either by the disruption of a single-subunit
complex or independent increases in expression.
LPS’s last stop in the periplasm is the β-jellyroll domain of LptD. The interaction between LptA
and LptD appears to be a key regulatory checkpoint in the assembly of the functional Lpt complex.
LptA binds LptD/E preferentially to LptC, so during Lpt assembly, it is likely recruited to the OM
before connecting to the IM subcomplex [22]. LptA binds the β-jellyroll of LptD in a head-to-tail
interaction like the other periplasmic domains and forms no direct interactions with LptE [27].
However, LptA does not bind LptD if its specific disulfide bonds are not formed correctly [24]. It is
intriguing that such a small difference would disrupt the otherwise robust β-jellyroll oligomerization
process, especially given that the LptD subunit shows a great deal of rotational flexibility relative to the
OM [6]. This requirement may be a specific adaptation that prevents malformed LptD from connecting
with the rest of the Lpt system.
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Recent structural advancements in our understanding of the Lpt complex suggests an ability to
dynamically respond to changes to cellular envelopes’ dimensions. The Rcs stress response system
in enterobacteria was recently shown to respond to changes in periplasmic width, suggesting that
essential transenvelope complexes are adapted to transenvelope stress [28]. Given how crucial the Lpt
system is to cell survival, it stands to reason that it would be adapted to compensate for expansions
and contractions of the periplasmic space resulting from osmotic stress. LptA could allow the system
to tolerate changes in intermembrane distance by recruiting newly-detached membrane translocons.
6. LptD/E Inserts LPS into the Outer Membrane Laterally
Until recently, the available structures of the LptD/E dimer were insufficient to fully confirm how
the OM complex conveys the Lipid A and OS moieties to the outer leaflet. The C-terminal TM portion
of LptD is a massive 26-strand β-barrel, and the LptE lipoprotein sits inside its lumen. The full-length
structure solved by Botos et al. shows that the N-terminal domain of LptD is a β-jellyroll that extends
from the periplasm and into the hydrophilic core of the OM [6]. This suggests a two-portal mechanism
whereby Lipid A is inserted directly into the membrane by the β-jellyroll, while the OS component
proceeds through the hydrophilic lumen of the β-barrel (Figure 5).
Figure 5. (A) The top-down view of the crystal structure of LptD (green) and LptE (gold) shows how
the Lipid A and OS moieties of LPS exit the IM through openings in the N-terminal β-jellyroll (grey)
and β-barrel domain (pink) respectively. This is made possible by the lateral gate that forms between
the two domains. (B) Strands β1 and β26 of the transmembrane β-barrel separate perpendicular to the
path of LPS. Proline residues on β1 and β2 (P231 and P246) limit the strands’ ability to form a sheet,
which allows β1 and β2 to separate.
A lateral gate in the β-barrel of LptD allows the Lipid A and OS moieties to proceed to the outer
leaflet of the OM. Conserved phenylalanine residues opposite one another on the β1 and β2 strands of
the barrel prevent β1 from forming a complete hydrogen bonding network with β26 [6]. This allows
β1 and β26 to slide apart, so the OS and O-antigen moieties can move out of the barrel to the cell
surface. Functional LptD/E’s very specific disulfide bond configuration restricts the size of the lateral
gate on the periplasmic side, possibly to prevent incorrect insertion of LPS into the inner leaflet of the
OM. The extracellular side of the barrel lumen is rich in negatively-charged residues, which likely help
to repel the similarly charged saccharide moieties out of the complex. LptD’s two-portal structure
gives LPS a clear path from the periplasm to its final destination on the extracellular surface.
7. LptE Is a Multifunction Facilitator of LPS Export
Unlike the other Lpt proteins, LptE’s essential functions are not obvious from the overview of the
“PEZ” model. LptE is embedded into the LptD lumen, but it is inserted into the OM independently by
the Lol pathway [29]. LptE is a lipoprotein with little structural similarity to the other Lpt components,
consisting of two α-helices closely associated with a four-strand β-sheet [30]. Rather than act as a direct
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LPS transporter, LptE appears to have three have overlapping functions in LPS transport: functional
LptD assembly, preserving membrane impermeability and distributing LPS to the cell surface.
Functional assembly of LptD requires LptE as a template. LptD assembly requires the assistance
of the BAM complex and extensive reshuffling of disulfide bonds [31,32]. Without the correct
disulfide bond configuration, LptD cannot bind LptA or export LPS. LptD is still inserted into the
OM when LptE is depleted, but the population of functionally-oxidized protein is depleted, as well.
A three-residue LptE mutant (PIS117–119R) induces a similar effect [33]. The affected region of LptE
may act as a template for LptD that ensures the cysteine residues are correctly positioned for disulfide
bond rearrangement.
LptE also preserves membrane impermeability by plugging LptD’s large cavity.
LptD’s transmembrane β-barrel is exceptionally large for a bacterial protein, consisting of
26 individual β-strands and spanning 50 Å. This large cavity structure is needed to export the diverse,
flexible OS moieties of LPS, but also produces a large gap in the membrane. The crystal structure
of LptD/E shows that LptE is positioned between the extracellular loops of the LptD β-barrel,
blocking part of the extracellular opening [30]. Grabowicz et al. identified an LptE mutant that
caused an increase in membrane permeability without affecting LptD assembly or LPS export [34].
No individual change produced the same high-permeability phenotype, but the four most N-terminal
mutations all affect residues near the extracellular end of LptE.
LptE has been shown to bind and break up surface-bound aggregates of LPS in vitro [30,35]. It is
difficult to disentangle LptE’s in vivo interactions with LPS from its other established roles in LptD
assembly and plugging, as disrupting either process also increases membrane permeability and hinders
LPS transport. However, Malojcic et al. found that mutating the positively-charged residues (R91D,
K136D) in a loop homologous to the LPS binding sites in other LPS-binding proteins disrupted binding
in vitro and increased in vivo membrane permeability without affecting LptD assembly [30]. Based on
this and the observation that LptE will break up surface-bound LPS aggregates, they proposed that
LptE facilitates the final transfer of LPS to the outer leaflet by preventing their aggregation at the
inner leaflet. Interestingly, one of Malojcic’s rationally-designed mutations, K136D, is on the same
locus as the K136W mutation in Grabowicz’s randomly-generated plugging-deficient LptE14 mutant.
This implies a degree of functional overlap between the structural components of LptE.
The LptD/E complex’s location at the extracellular surface makes it a more promising antibiotic
target than the other Lpt subunits. Antibiotic compounds do not need to permeate the LPS barrier
to reach it, and disrupting plugging of the LptD β-barrel could complement other antibiotics by
increasing the permeability of the OM. The compound murepavadin and peptide mimetics have
been shown to prevent LPS barrier biogenesis in Pseudomonas aeruginosa through direct interactions
with LptD [36,37]. Crosslinking experiments have demonstrated that the peptide mimetic interacts
with an extended region of the β-jellyroll domain found in the pseudomonads [38]. Andolina et al.
suggested that this blocks the Lipid A channel, but other mechanisms influencing LptD assembly
or LptA binding should not be discounted. Further structural characterization of the P. aeruginosa
LptD periplasmic domain, which is currently unsolved, could elucidate this mechanism and provide
clues for the rational development for more broad-spectrum antibiotics. LptE, meanwhile, may be
less promising as a target as at least one species of bacteria, Neisseria meningitidis, can survive without
LptE [39].
8. Summary
New structures and functional analyses of the Lpt system have made it possible to begin
identifying the specific subunit-to-subunit interactions that make the continuous transport of LPS
from the cytoplasm to the exterior of the outer membrane possible. The potentially novel type-III ABC
mechanism employed by the LptB2FG subcomplex raises new questions about the mechanisms of
LPS extraction and the ambiguous role of LptC. Determining how the Lpt system responds to shifts
in the periplasmic space may contribute to a broader understanding of how Gram-negative bacteria
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adapt to environmental stresses affecting the cellular envelope. The LptD/E OM complex has proven a
promising target for new antibiotics, which could be further refined through rational design informed
by the recent structural characterization of its export mechanism.
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Moehle, K.; Malojčić, G.; et al. A Peptidomimetic antibiotic interacts with the periplasmic domain of LptD
from Pseudomonas aeruginosa. ACS Chem. Biol. 2018, 13, 666–675. [CrossRef] [PubMed]
39. Bos, M.P.; Tommassen, J. The LptD chaperone LptE is not directly involved in lipopolysaccharide transport
in Neisseria meningitidis. J. Biol. Chem. 2011, 286, 28688–28696. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
135
 International Journal of 
Molecular Sciences
Review
Immune Mechanisms Underlying Susceptibility to
Endotoxin Shock in Aged Hosts: Implication in
Age-Augmented Generalized Shwartzman Reaction
Manabu Kinoshita *, Masahiro Nakashima, Hiroyuki Nakashima and Shuhji Seki *
Department of Immunology and Microbiology, National Defense Medical College, 3-2 Namiki, Tokorozawa,
Saitama 359-8513, Japan
* Correspondence: manabu@ndmc.ac.jp (M.K.); btraums@ndmc.ac.jp (S.S.); Tel.: +81-4-2995-1541 (M.K.);
Fax: +81-4-2996-5194 (M.K.)
Received: 11 June 2019; Accepted: 1 July 2019; Published: 2 July 2019
Abstract: In recent decades, the elderly population has been rapidly increasing in many countries.
Such patients are susceptible to Gram-negative septic shock, namely endotoxin shock. Mortality
due to endotoxin shock remains high despite recent advances in medical care. The generalized
Shwartzman reaction is well recognized as an experimental endotoxin shock. Aged mice are similarly
susceptible to the generalized Shwartzman reaction and show an increased mortality accompanied
by the enhanced production of tumor necrosis factor (TNF). Consistent with the findings in the
murine model, the in vitro Shwartzman reaction-like response is also age-dependently augmented in
human peripheral blood mononuclear cells, as assessed by enhanced TNF production. Interestingly,
age-dependently increased innate lymphocytes with T cell receptor-that intermediate expression,
such as that of CD8+CD122+T cells in mice and CD57+T cells in humans, may collaborate with
macrophages and induce the exacerbation of the Shwartzman reaction in elderly individuals. However,
endotoxin tolerance in mice, which resembles a mirror phenomenon of the generalized Shwartzman
reaction, drastically reduces the TNF production of macrophages while strongly activating their
bactericidal activity in infection. Importantly, this effect can be induced in aged mice. The safe
induction of endotoxin tolerance may be a potential therapeutic strategy for refractory septic shock in
elderly patients.
Keywords: LPS; septic shock; elderly; innate lymphocytes; endotoxin tolerance
1. Introduction
Severe sepsis, particularly Gram-negative sepsis, remains a grave concern for humans, being
recognized as a major leading cause of death in the United States as well as other countries [1].
Gram-negative septic shock, namely endotoxin shock, shows a particularly high mortality rate despite
recent advances in intensive care. For several decades, the elderly populations has been rapidly
increasing in many countries, and such patients are susceptible to endotoxin shock [2]. Therefore,
medical countermeasures for this population are an urgent issue to be addressed. The generalized
Shwartzman reaction is well recognized as an experimental endotoxin shock. We investigated the effect
of aging on host defenses against endotoxin shock using a mouse model and human peripheral blood
mononuclear cells (PBMCs) as an in vitro model of a Shwartzman reaction-like response, focusing
on age-related immunological changes. We found that a certain T lymphocyte population that is
age-dependently increased in mice as well as in humans collaborates with macrophages and causes
the exacerbation of endotoxin shock in elderly subjects. In this review, we demonstrate why elderly
hosts are susceptible to endotoxin shock, based on our immunological studies in murine and human
PBMCs, and we also address potential therapeutic approaches against endotoxin shock in the elderly.
Int. J. Mol. Sci. 2019, 20, 3260; doi:10.3390/ijms20133260 www.mdpi.com/journal/ijms136
Int. J. Mol. Sci. 2019, 20, 3260
2. Definition of Septic Shock
Septic shock is the most severe form of sepsis and remains a grave concern because of its high
mortality rate [3,4]. In 1991, the consensus conference of American College of Chest Physicians/Society
of Critical Care Medicine defined sepsis as a systemic inflammatory response syndrome (SIRS) to
infection [5,6]. Severe sepsis was also defined in that consensus conference as instances in which sepsis
was complicated by acute organ dysfunctions, and septic shock was defined as sepsis complicated by
either hypotension that was refractory to fluid resuscitation or by hyperlactatemia indicating tissue
hypoxia [5,6]. At the time, the criteria for SIRS were thought to be clinically useful as a screening
tool for the diagnosis of septic patients, as it can easily and simply define the severe infection and
then effective therapy can be promptly started for SIRS conditions. In addition, these definitions were
thought to be helpful for establishing patient entry criteria in clinical trials on sepsis.
One decade later, a second consensus conference was held in 2001 that endorsed most of these
concepts, but some caveats were raised: Signs of SIRS (tachycardia, increased white blood cell
count, fever elevation, tachypnea, etc.) may occur in not only infectious but also noninfectious
conditions, so these criteria of SIRS may not always be useful for distinguishing sepsis from other
critical conditions [7].
In 2016, a third consensus conference was held that defined ‘Sepsis-3′ [8]. In that conference,
‘sepsis’ was defined as life-threatening organ dysfunctions caused by a dysregulated host response to
infection, similar to the definition of ‘severe sepsis’ proposed at the first conference in 1991. Septic
shock was also defined as a subset of sepsis in which particularly profound circulatory, cellular, and
metabolic abnormalities were associated with a greater risk of multi-organ dysfunctions and mortality
than with sepsis alone [8].
3. High Mortality and Morbidity of Septic Shock in the Elderly
Aging is one of the most representative risk factors of septic shock [9]. Elderly people tend to
have various kinds of chronic comorbid illness, such as ischemic heart disease, cerebrovascular disease,
diabetes, and renal or pulmonary disease. These comorbid illnesses are presumably susceptible to
sepsis/severe sepsis, leading to shock and multi-organ dysfunctions [2]. Mortality due to septic shock
has decreased in the past decade thanks to the prompt initiation of appropriate antimicrobial therapy [10]
and sophisticated organ support therapies such as extracorporeal membrane oxygenation (ECMO),
continuous hemodiafiltration (CHDF), and direct hemoperfusion with immobilized polymyxin B
fiber (PMX-DHP) [11,12]. Nevertheless, mortality due to septic shock remains high at approximately
20% [13–15]. Gram-negative bacteremia induce a more severe inflammatory response in septic patients
than Gram-positive bacteremia [16]. Therefore, Gram-negative sepsis is prone to progress to septic
shock, and the mortality due to Gram-negative septic shock is still higher than that associated with
Gram-positive sepsis at approximately 30–40% [16–18]. Aging is also a risk factor for colonization by
Gram-negative bacteria, such as the Klebsiella, Escherichia coli, and Enterobacter species, predisposing
elderly patients to Gram-negative bacterial sepsis and septic shock [19]. Taken together, these
findings indicate that elderly patients are more susceptible to sepsis than younger ones, in particular
Gram-negative sepsis, and may suffer sepsis-induced multi-organ dysfunctions, thereby leading to
a higher mortality [2,19–21].
4. Pivotal Role of Tumor Necrosis Factor-α (TNF) in Human Endotoxin Shock
Gram-negative bacteria contain endotoxin, a main component of their bacterial envelope, that
is also known as lipopolysaccharide (LPS). Endotoxin/LPS is responsible for the pathogenesis of
septic shock induced by Gram-negative bacterial infections [22,23]. Plasma endotoxin/LPS levels are
associated with increased severity of illness, as measured by the indicator of total organ dysfunctions [24].
Endotoxin/LPS binds to toll-like receptor 4 (TLR4) expressed on the cellular membrane of macrophages
and stimulates the NF-κB-dependent inflammatory cascade to produce tumor necrosis factor (TNF),
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a strongly representative proinflammatory cytokine [23]. Though TNF is important for host antibacterial
resistance [25,26], the excessive production of TNF by the stimulation of bacterium-derived LPS may
typically cause endothelial damage, multi-organ dysfunctions, and septic shock [27]. TNF transmits
its signals into the cells through TNF-receptor (TNFR) 1 and 2, which are expressed on the surface
of various mammalian cells [28]. TNFR1 contains a cytoplasmic ‘death domain’ that induces cell
death of TNFR1-expressing cells [28]. Thus, LPS-induced increased TNF production is likely a major
contributor to endotoxin/LPS shock. Indeed, patients with septic shock show high TNF levels
in the plasma, and their TNF levels are related to the patients’ outcomes [21,29,30]. In addition,
the administration of endotoxin/LPS to healthy volunteers increased the plasma TNF levels in the
initial phase, suggesting that TNF causes the subsequent inflammatory cytokine response [31–33].
Consistently, the administration of TNF to healthy volunteers resulted in a similar inflammatory
reaction in humans to that of endotoxin/LPS administration [31,34]. TNF thus plays pivotal roles in the
inflammatory cascade in humans with endotoxemia/Gram-negative sepsis.
5. Generalized Shwartzman Reaction as an Experimental Endotoxin Shock Model
Humans are much more sensitive to LPS than other mammals, such as rodents. The administration
of 2–4 ng/kg LPS to healthy volunteers has been shown to evoke various inflammatory responses,
including the elevation of plasma TNF [31–33]. In contrast, even when mice were administered
2–4 μg/kg LPS, which was almost 1000 times the concentration administered to humans, they only
showed a slight elevation of plasma TNF without any organ damage [35]. We then considered
that induction of a hypersensitive response to LPS was important for simulating/mimicking human
endotoxin shock in mice. The generalized Shwartzman reaction is well recognized as a hypersensitive
innate immune response in experimental animals [36].
Roughly 90 years ago, Shwartzman first described the intradermal injection of the sterile culture
filtrate of the Gram-negative bacterium Bacillus Salmonella typhosus as a preparatory injection and noted
that the subsequent intravenous injection with a provocative dose of the same culture filtrate 24 h
later induced severe hemorrhagic necrosis at the first injection site in rabbits [37]. If the provocative
challenge was too short (less than 2 h) or too long (beyond 48 h), dermal necrosis did not occur.
Shwartzman also performed the experiment using a similar preparation with sterile culture filtrate
of Gram-positive streptococcal species but failed to duplicate dermal reactions, suggesting that the
heat-stable component of Gram-negative bacteria (later identified as LPS) is important for inducing this
reaction [36]. However, Shwartzman described only the localized dermal response and not the systemic
response in this phenomenon. According to the review of Chahin et al., the generalized Shwartzman
reaction was actually discovered by Sanarelli four years earlier than the report by Shwartzman [36].
The generalized Shwartzman reaction is now considered a potentially lethal endotoxin shock reaction
that can be induced by the administration of a sublethal dose of LPS into LPS-primed animals at an
interval of 24 h (Figure 1A) [38].
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Figure 1. The generalized Shwartzman reaction induced by interleukin (IL)-12 priming and subsequent
lipopolysaccharide (LPS) challenge. (A) Priming with LPS or IL-12 induces IFN-γ production in mice,
and 24 h later, subsequent LPS challenge induces substantial tumor necrosis factor (TNF) production,
resulting in the generalized Shwartzman reaction. (B) In young mice, IL-12 priming activates natural
killer (NK) and natural killer T (NKT) cells to produce IFN-γ, which primes macrophages. Subsequent
LPS challenge strongly activates the primed macrophages to produce large amounts of TNF, resulting
in the generalized Shwartzman reaction. (C) In aged mice, age-dependently increased IL-12-activating
CD8+CD122+T cells augment IFN-γproduction, resulting in the further enhancement of TNF production
by macrophages and leading to increased lethality of the generalized Shwartzman reaction. Figures are
revised from [39].
6. Generalized Shwartzman Reaction Induced by Interleukin (IL)-12 Priming and Sublethal
LPS Challenge
Though the generalized Shwartzman reaction is well recognized as an endotoxin shock model,
it cannot be induced every time in animals, as this phenomenon is likely an example of a related
phenomenon known as endotoxin tolerance [35,36,40]. Through the generalized Shwartzman reaction,
injection of interleukin (IL)-12 or IFN-γ, instead of LPS, can induce a lethal reaction in mice if they are
further challenged with a sublethal dose of LPS [41]. IL-12, which is mainly produced by macrophages,
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is a Th 1 cytokine that stimulates natural killer (NK) cells, natural killer T (NKT) cells, and T cells
to produce IFN-γ [42,43]. Neutralizing antibody against IL-12, when administered together with
the priming agent, prevents the lethal reaction in mice primed with either LPS or IL-12 but not with
IFN-γ [41]. Thus, IL-12 and its induced IFN-γ in the priming phase are crucial for the occurrence of
the generalized Shwartzman reaction (Figure 1B) [41,44]. Upon subsequent LPS challenge, the lethal
Shwartzman reaction is induced by the massive production of inflammatory cytokines, particularly
TNF, that act on the target organs already sensitized by IFN-γ and resultant multi-organ dysfunctions
in mice [41]. TNF is a key cytokine in the generalized Shwartzman reaction as well as endotoxin shock
and results in high mortality [39,41,44]. Notably, IL-12 priming rather than LPS priming can constantly
induces the lethal generalized Shwartzman reaction in mice [39,44]. We speculate that although the
doses of LPS are different from LPS tolerance, two times LPS injections (LPS priming and subsequent
challenge with LPS) may induce a LPS tolerant condition (as described later), leading to failure to
effectively induce a generalized Shwartzman reaction [35,40].
7. Crucial Role of NKT Cells and Their Produced IFN-γ for the Murine Generalized
Shwartzman Reaction
In the generalized Shwartzman reaction, which is induced by IL-12 priming and subsequent
LPS challenge in mice, depletion of both NK cells and NKT cells (by anti-NK1.1 antibody) greatly
reduced the elevation of serum IFN-γ after IL-12 priming and reduced the mortality after LPS challenge,
whereas depletion of NK cells alone (by anti-asialo GM1 antibody) only partially decreased the serum
IFN-γ and did not affect the mortality [44]. NKT cells and their produced IFN-γ may be crucial in the
priming phase for the induction of lethality in the generalized Shwartzman reaction. However, NK cells
play important roles in protecting their host against sepsis/bacterial infections [45], as they have potent
IFN-γ-producing capability in response to bacterial infection and can effectively induce bacterial killing
by macrophages, which is crucial for bacterial elimination [45]. We should not underestimate NK
cell-producing IFN-γ even in the generalized Shwartzman reaction as well as sepsis/infections.
8. Involvement of Innate Lymphocytes in the Generalized Shwartzman Reaction
The innate immune system serves as the first line of the host defense against invading bacteria. NK
cells, NKT cells, and other innate lymphocytes are crucially involved in this front-line defense [46,47].
Severe surgical stress, such as burn injury, drastically reduces the IFN-γ-producing capability of
these cells, thereby increasing susceptibility to sepsis/infection [45,48]. In turn, excessive activation of
these innate lymphocytes can induce an exaggerated inflammatory response through the substantial
production of IFN-γ [45,48]. Thus, dysregulation (including both down- and up-regulation) of
these innate lymphocyte functions can be harmful for the host defense [47,48]. In the generalized
Shwartzman reaction, these innate lymphocytes also greatly contribute to the lethality of this reaction.
The combination of both IFN-γ-producing lymphocytes (in the priming phase) and TNF-producing
macrophages (in the subsequent phase) plays a key role in the generalized Shwartzman reaction
(Figure 1B).
9. Age-Dependent Increase in Mortality Due to the Generalized Shwartzman Reaction in Mice
Interestingly, the generalized Shwartzman reaction induced by IL-12 priming and subsequent
low-dose LPS challenge drastically exacerbates the lethality with increasing age in mice (Figure 2A) [39].
We primed young C57BL/6 mice (4 weeks old) with 0.5 μg/body of IL-12, and, 24 h later, we challenged
them with 50 μg/body of LPS [39]. At such doses of IL-12 and LPS, all of the young mice survived
the generalized Shwartzman reaction (Figure 2A). However, when older mice (beyond 20 weeks old)
were primed/challenged with the same doses of IL-12 and LPS, none survived (Figure 2A), despite
showing a mean body weight that was markedly heavier than that of young mice [39]. The serum
TNF levels at 1 h after LPS challenge (following IL-12 priming) were also age-dependently increased
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in the generalized Shwartzman reaction (Figure 2B), indicating TNF-induced mortality, although no
age-dependent increase in TNF was observed in the mice challenged with LPS alone.
In contrast, the serum IFN-γ levels were not age-dependently increased in mice. However,
interestingly mononuclear cells in the liver (but not spleen) showed significantly increased IFN-γ
production by IL-12 priming in middle-aged mice (24 weeks old). NK cells and NKT cells are abundant
in the liver and have a potent IFN-γ-producing capability in response to IL-12 priming [46]; we
therefore consider that the liver plays crucial roles in the generalized Shwartzman reaction [39,44,46].
However, NK and NKT cells do not increase age-dependently [39]. Regarding age-dependent increases
in IFN-γ-producing innate lymphocytes, CD8+CD122+T cells are age-dependently increased and have
potent IFN-γ-producing capability, as described later.
Figure 2. Age-dependent increase in mortality due to the generalized Shwartzman reaction accompanied
by elevation of serum TNF. (A) Mortality due to the generalized Shwartzman reaction induced by IL-12
priming, and, subsequent LPS challenge was age-dependently increased in mice. (B) Serum TNF levels
were also age-dependently increased at 1 h after LPS challenge following IL-12 priming. Data are mean
(A) and means ± SE (B) from five mice in each age group. * p < 0.01 vs. four weeks old, using an
analysis of variance with Scheffe’s F test. Figures are revised from [39].
10. Immunosenescence and Thymus-Independent T Cells in Mice
Age-related remodeling of the immune system is termed ‘immunosenescence’ and profoundly
affects changes in the host defense [49,50]. In particular, T cell-mediated immunosenescence may be
greatly affected by thymus involution, which drastically curtails the production of thymus-dependent
T cells. However, this loss of thymic cell output with aging results in no significant changes to the
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systemic T cell counts [51]. Reductions in the peripheral T cell numbers in elderly individuals
may be compensated by the thymus-independent expansion of mature T cells [46,52]. These
thymus-independent T cells have unique characteristics of more primitive lymphocytes, such as
intermediate levels of T cell receptor (TCR) expression [46,52,53]. Their TCR intensity is lower than that
of regular αβTCR+ T cells but higher than that of immature CD4+CD8+ double-positive thymocytes
(TCR dull expression) before selection (Figure 3A) [54] (as described in detail in next paragraph).
Though aging also reportedly attenuates the macrophage function [55,56], aged mice showed no
marked reduction in cytokine productions [39,57]. It may be possible that age-dependently increased
thymus-independent T cells compensates for the reduced macrophage function in the innate immune
system in elderly hosts.
Figure 3. T cell receptor (TCR) intensity in lymphocytes of the thymus, spleen, and liver along with
subsets of liver TCR-intermediate cells. (A) Immature CD4+CD8+ double-positive cells show dull
TCR intensity in thymocytes, mature T cells show high TCR intensity in the splenocytes, and NKT
and CD8+CD122+T cells show intermediate TCR intensity in the liver mononuclear cells (indicated by
dotted circle). (B) TCR-intermediate cells in the liver include CD122+ NK1.1+ cells (NKT cells; two
thirds are CD4+), and CD122+ NK1.1− cells (two thirds are CD8+). The cells of this CD8+ subset are
called CD8+CD122+T cells and demonstrate an age-dependent increase Figures are revised from [46].
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11. Age-Dependent Increases in Murine CD8+CD122+ T Cells
Interestingly, these intermediate TCR-expressing cells are positive for CD122 [46], which is
an IL-2 receptor β-chain that contributes to the formation of IL-2 and IL-15 signaling complexes,
as both cytokines share this receptor subunit (CD122) [58,59]. CD122 is also highly expressed on
NK cells [60,61]. Among CD122+ cells with intermediate TCR (TCRint) in the murine liver, two
thirds are NK1.1 marker-positive (NKT cells), and one third are NK1.1-negative (Figure 3B) [62,63].
In these murine NKT cells, two thirds are CD4-positive, but one third are double-negative (CD4−
CD8−) [46,52]. In contrast, in the CD122+NK1.1− cells, two thirds are CD8-positive, but one
third are double-negative (Figure 3B) [46,52]. Interestingly, these CD122+ NK1.1− CD8+ cells, also
known as CD8+CD122+T cells, progressively increase with age and have a potent IFN-γ-producing
capability [39,64]. However, there are some caveats, as the antigen-specific memory CD8+T cells
with a memory phenotype (CD44int) are also CD122-positive [65], although their CD122 expression
is intermediate and distinguished from CD122high NK cells [59]. Antigen-specific memory CD8+T
cells (CD44int, CD122int) are generated/primed by various environmental antigens and long-lived [65],
while the current CD8+CD122+T cells (CD44high, CD122high) may be generated independently of
environmental antigens and are short-lived; these cells are therefore also termed ‘memory phenotype’
CD8+T cells [66–68]. They are not engaged in chronic responses to environmental antigens but are
subject to nonantigen-specific stimulation through contact with cytokines released in response to
various stressors, such as bacterial infections and/or LPS [66–68].
12. Crucial Role of CD8+CD122+T Cells in Mortality Due to the Generalized Shwartzman
Reaction in Aged Mice
By the generalized Shwartzman reaction in middle-aged mice (24 weeks old), depletion of NK
and NKT cells did not reduce the elevation of serum IFN-γ after IL-12 priming, whereas additional
depletion of CD8+CD122+T cells to NK/NKT cells (by anti-TMβ1 antibody) markedly reduced the
elevation of IFN-γ after IL-12 priming [39]. Consistently, depletion of CD8+CD122+T cells in addition
to NK/NKT cells drastically decreased the mortality due to the generalized Shwartzman reaction in
middle-aged mice, accompanied by the marked reduction in serum TNF levels after LPS challenge [39].
Adoptive transfer of CD8+CD122+T cells from aged mice markedly increased the mortality due to the
generalized Shwartzman reaction in young mice, accompanied by increases in IFN-γ after IL-12 priming
and in TNF after subsequent LPS challenge [39]. Thus, age-dependent increases in CD8+CD122+T
cells greatly contribute to the high mortality due to the generalized Shwartzman reaction in aged mice
(Figure 1C).
13. Beneficial Roles of CD8+CD122+T Cells in Host Defense
To clarify why the numbers of CD8+CD122+T cells in mice increase with age, we pretreated young
mice with IL-15, which induces CD8+CD122+T cells [57]. As expected, IL-15-induced CD8+CD122+T
cells augmented the generalized Shwartzman reaction, even in young mice, while the depletion of
these CD8+CD122+T cells eliminated this harmful effect of IL-15 [57]. Interestingly, IL-15-induced
CD8+CD122+T cells also increased the survival after lethal bacterial infection (Escherichia coli) in young
mice with enhanced IFN-γ production. In addition, IL-15-indcued CD8+CD122+T cells also increased
the anti-tumor activity against EL4 cells (murine lymphoma cells) [57]. Consistently, α-galactoceramide,
which is a synthetic ligand for NKT cells, induced the proliferation of CD8+CD122+T cells with an
anti-tumor function in mouse liver [69]. Thus, age-dependently increased CD8+CD122+T cells may
augment antibacterial and anti-tumor immune responses [57]. These beneficial effects of CD8+CD122+T
cells on the host defense appear to be rational in aged hosts, as the elderly are susceptible to bacterial
infections and tumor progression/invasion. However, there are some questions raised. Gain of
CD8+CD122+T cells may be just affected by cytokines such as IL-15, but not aging itself. While IL-15
levels are also increased in the liver of aged mice in comparison to the young mice [57]. Therefore,
aging may possibly affect the gain of CD8+CD122+T cells via an increase in IL-15 levels. However,
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phrase of ‘age-dependent immune-alteration’ that we used in this review may be termed as ‘correlation
of immunological status in the hosts at a certain age’, because strictly speaking, we just observed the
age-correlated alteration of immune system.
14. In Vitro Shwartzman Reaction-Like Response in Human Peripheral Blood Mononuclear
Cells (PBMCs)
Is such an age-dependent augmentation of the generalized Shwartzman reaction observed in
humans? Five decades ago, Starzl et al. reported three patient cases the suggesting Shwartzman
reaction after renal transplantation [70]. However, evaluating the Shwartzman reaction in healthy
volunteers is ethically unacceptable. Therefore, little information or evidence of the human Shwartzman
reaction has been gathered thus far, although humans are much more sensitive to LPS than animals.
We therefore examined the in vitro Shwartzman reaction-like response using human PBMCs
including lymphocytes and macrophages [21]. PBMCs obtained from healthy adult volunteers were
cultured with IL-12 (20 μg/mL) for 24 h, followed by culture with LPS (10 ng/mL) for 24 h to examine
their TNF production (Figure 4A). CD56+NK cells, CD56+T cells, and CD57+T cells produced IFN-γ in
response to IL-12 stimulation, and this IFN-γ primed macrophages to produce large amounts of TNF
on subsequent LPS stimulation, suggesting that an in vitro Shwartzman reaction-like response was
induced in human PBMCs (Figure 4B) [21]. Nevertheless, we should be careful of the differences in the
immune systems between the human and murine, because these immune systems are similar in some
parts but not exactly same.
Figure 4. Cont.
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Figure 4. The in vitro Shwartzman reaction-like response in human peripheral blood mononuclear
cells (PBMCs). (A) IL-12 stimulation and subsequent LPS stimulation 24 h later induced enhanced
TNF production in cultured human PBMCs, suggesting an in vitro Shwartzman reaction-like response.
(B) In PBMCs from young volunteers, IL-12 priming activates CD56+NK, CD56+T, and CD57+T cells
to produce IFN-γ, which primes macrophages. Subsequent LPS stimulation strongly activates the
primed macrophages to produce large amounts of TNF, suggesting an in vitro Shwartzman reaction-like
response. (C) In PBMCs from elderly volunteers, IL-12-priming potently activates CD57+T cells, which
show an age-dependent increase, and augments IFN-γ production, which enhances macrophage
priming. The subsequent LPS stimulation further augments the TNF production from potently primed
macrophages, suggesting an enhancement of the in vitro Shwartzman reaction-like response. Figures
are revised from [21].
15. Age-Dependent Augmentation of the In Vitro Shwartzman Reaction-Like Response in
Human PBMCs
Interestingly, PBMCs from healthy elderly volunteers (≥70 years old) markedly produced larger
amounts of TNF after LPS stimulation following IL-12 stimulation than did PBMCs from younger adult
volunteers (20–40 years old) (Figure 5A), suggesting that the in vitro Shwartzman-like reaction was
augmented in elderly PMBCs. In contrast, PBMCs from child volunteers showed no enhanced TNF
production after IL-12/LPS stimulation (Figure 5A), suggesting that the Shwartzman-like reaction did
not occur in child PBMCs [21]. IL-12-induced IFN-γ production from PBMCs was also age-dependently
increased. However, there were no marked differences in the TNF production after stimulation with
LPS alone (without IL-12 stimulation) among PBMCs from children, adults, and elderly volunteers
(Figure 5A). Thus, the age-dependent enhancement of the Shwartzman-like reaction may occur in
human PBMCs.
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Figure 5. Age-dependent increases in TNF production from human PBMCs by stimulation with IL-12
and LPS and age-dependent increases in CD56+NK, CD56+T and CD57+T cells in human PBMCs.
(A) Human PBMCs age-dependently increased TNF production by stimulation with LPS following
IL-12 stimulation but not by LPS stimulation alone. (B) The proportions of CD56+NK, CD56+T, and
CD57+T cells were age-dependently increased in human PBMCs. In particular, CD57+T cells were
markedly increased age-dependently. Data are mean ± SE (A) and mean (B) from seven, ten, and six
healthy volunteers in the child, adult, and elderly groups, respectively. ** p < 0.01, * p < 0.05, using an
analysis of variance with Scheffe’s F test. Figures are revised from [21].
The proportion of CD56+NK, CD56+T, and CD57+T cells with potent IFN-γ-producing capabilities
also increased with age in human PBMCs (Figure 5B) [21]. In particular, CD57+T cells were markedly
increased (more than five-fold) in elderly PBMCs compared with child PBMCs (Figure 5B). These
age-dependent increases in innate lymphocytes, which have potent IFN-γ-producing capability, may
play a key role in the Shwartzman reaction in humans (Figure 4C). Interestingly, both CD56+T and
CD57+T cells show intermediate TCR intensity similar to murine NKT cells and CD8+CD122+T cells,
which are involved in thymus-independent T cells [71].
16. High Mortality and Morbidity of Septic Shock in Elderly Patients Showing Similar Plasma
Endotoxin Levels as Adults (Elderly vs. Adults)
We examined the rate of septic shock and its mortality in elderly (≥70 years old) and adult
(<70 years old) patients with sepsis/severe sepsis, according to the recent definition [8]. Though both
the elderly and adult septic patients showed similar plasma endotoxin levels (7.6 vs. 7.4 pg/mL in
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average), the elderly patients showed higher serum TNF levels and were more susceptible to septic
shock than the younger adult patients, leading to an extremely high mortality due to septic shock
compared with younger patients (91% vs. 25%) (Figure 6) [21]. These findings may confirm the
characteristic clinical picture in elderly patients with sepsis/septic shock, which have been described
before, and are consistent with the experimental results of the age-dependent augmentation of the
murine generalized Shwartzman reaction [39] and the in vitro Shwartzman-like reaction using human
PBMCs [21].
Figure 6. Characteristics of septic shock in elderly patients. Plasma endotoxin levels, serum TNF levels,
proportion of septic shock rates, and mortality due to septic shock were compared between elderly and
young adult septic patients. Though both patient groups showed similar plasma endotoxin levels, the
elderly patients showed markedly higher serum TNF levels and septic shock rates, leading to a high
mortality due to septic shock. Data are means ± SE or mean from 18 elderly patients and 20 young
adult patients. ** p < 0.01, * p < 0.05, using the Mann–Whitney U-test and chi-squared test. Figure data
are revised from [21].
17. Management of Severe Sepsis/Septic Shock in Elderly Patients: Endotoxin Tolerance as a
Potential Therapeutic Strategy in the Future
Elderly patients are susceptible to Gram-negative septic shock with enhanced production of
TNF, resulting in a high mortality. When considering effective therapies for elderly patients in such
a critical condition, it may be important to reduce the inflammatory cytokine responses, particularly
the TNF production by macrophages, and augment the bactericidal activity of these macrophages.
However, this seems difficult, as both inflammatory cytokine production and bacterial killing are
closely associated with macrophage activation and appear to be synchronized phenomena at a glance.
For instance, the induction of CD8+CD122+T cells by IL-15 pretreatment rendered mice susceptible to
the generalized Shwartzman reaction (indicating an exaggerated inflammatory response) but resistant
to bacterial infection due to deriving an appropriate inflammatory response [57]. Regarding the
generalized Shwartzman reaction, aging mainly affects innate lymphocytes and does not directly affect
macrophages [21,39].
Interestingly, endotoxin tolerance mainly affects macrophages, drastically reducing the
inflammatory cytokine production—particularly TNF production—while strongly augmenting the
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bactericidal activity [35,40]. These effects can be induced in aged hosts [72,73] and do not directly affect
the innate lymphocytes because endotoxin tolerance can be induced in mice even after the elimination
of these lymphocytes (our unpublished data) (Figure 7). Though how to clinically induce endotoxin
tolerance remains unclear, the mechanisms underlying endotoxin tolerance are quite attractive for the
treatment of sepsis in elderly patients, and this therapeutic strategy may become an effective tool for
delivering critical care for refractory septic shock in elderly patients.
Figure 7. Immune mechanisms in the generalized Shwartzman reaction and endotoxin tolerance.
In the generalized Shwartzman reaction, innate lymphocytes, which are age-affected cells, are closely
involved in the priming phase to stimulate macrophages, leading to an enhanced TNF production.
In contrast, endotoxin tolerance directly affects macrophages to induce a reduction in TNF production.
18. Concluding Remarks
Elderly patients are susceptible to septic shock, particularly Gram-negative septic shock (also
known as endotoxin shock), and they have an increased associated mortality compared with younger
patients. The generalized Shwartzman reaction is well recognized as an experimental endotoxin
shock. Aged mice have similarly been shown to be susceptible to the generalized Shwartzman
reaction with an increased mortality accompanied by enhanced TNF production. Consistent with
this murine model, the in vitro Shwartzman reaction-like response was shown to be age-dependently
augmented in human PBMCs, as shown by enhanced TNF production. Interestingly, the age-dependent
increase in TCR-intermediate innate lymphocytes, such as CD8+CD122+T cells for mice and CD57+T
cells for humans, was found to be closely involved in this age-dependent augmentation of the
Shwartzman reaction.
Endotoxin tolerance mainly affects macrophages and drastically reduces their TNF production but
strongly activates their bactericidal activity in response to infection. Importantly, endotoxin tolerance
can be age-independently induced; therefore, if this tolerant condition can be safely induced in elderly
patients, it may be a useful therapeutic strategy for managing refractory septic shock in this population.
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Abstract: Lipopolysaccharides (LPS, endotoxin) are complex and indispensable components of the
outer membrane of most Gram-negative bacteria. They represent stimuli for many biological effects
with pathophysiological character. Recombinant therapeutic proteins that are manufactured using
biotechnological processes are prone to LPS contaminations due to their ubiquitous occurrence.
The maximum endotoxin load of recombinant therapeutic proteins must be below the pyrogenic
threshold. Certain matrices that are commonly used for recombinant therapeutic proteins show a
phenomenon called “Low Endotoxin Recovery (LER)”. LER is defined as the loss of detectable
endotoxin activity over time using compendial Limulus amebocyte lysate (LAL) assays when
undiluted products are spiked with known amount of endotoxin standards. Because LER poses
potential risks that endotoxin contaminations in products may be underestimated or undetected by
the LAL assay, the United States (U.S.) Food and Drug Administration’s (FDA’s) Center for Drug
Evaluation and Research (CDER) has recently started requesting that companies conduct endotoxin
spike/hold recovery studies to determine whether a given biological product causes LER. Here,
we have performed an analysis of different LPS preparations with relevant detergents studying their
acyl chain phase transition, their aggregate structures, their size distributions, and binding affinity
with a particular anti-endotoxin peptide, and correlating it with the respective data in the macrophage
activation test. In this way, we have worked out biophysical parameters that are important for an
understanding of LER.
Keywords: endotoxin; lipopolysaccharide; Low Endotoxin Recovery; phase transitions; polysorbate;
LPS aggregates; Small Angle X-ray Scattering; MAT; LAL and LER
1. Introduction
Lipopolysaccharides (LPS), the endotoxins of most Gram-negative bacteria, belong to the
strongest immune-stimulating compounds known in nature. This property may be beneficial at
low concentrations, but pathophysiological at high concentrations, leading to severe sepsis and septic
shock with high lethality [1]. Since LPS is a constituent of nearly all Gram-negative bacteria, it is a
ubiquitous contaminant. It is well-known that the lipid A part of LPS is its “endotoxic principle”,
which for most relevant bacterial species, such as Escherichia coli and Salmonella spp. consists of a
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bisphosphorylated diglucosamine backbone to which six acyl chain residues are linked [1]. There are
also lipid A with underacylated lipid A parts (tetra or pentaacyl) with low biological activity [1], which,
however, are not relevant in the context of this investigation.
LPS is able to elicit severe safety risks even at very low concentrations. Thus, in clinical studies
of Opal and co-workers, it was found that sepsis patients belonging to the survivors had a medium
LPS serum concentration of 0.3 ng/mL and the non-survivors 0.7 ng/mL [2]. The reason for this
is the fact that LPS induces a “cytokine storm” (interleukins, tumor-necrosis-factor-α (TNF-α) and
many others), leading to a septic shock. Therefore, it is of uttermost importance to control LPS-load,
in particular, in parenteral pharmaceutical formulations, such as recombinant therapeutic proteins,
which are anticipated to be injected.
Low Endotoxin Recovery (LER) poses potential risks that endotoxin contaminations in products
may be underestimated or undetected by the Limulus amebocyte lysate (LAL) assay.
There are various publications in recent years dealing with this subject, in most cases giving
no coherent explanation for the occurrence of the effect [3,4]. As one possible explanation, it was
proposed that the presence of certain buffers and detergents, in most cases citrate and polysorbate
20 and 80, leads to a drastic disaggregation of LPS down to a monomeric form, which was found
to represent an inactive form in the LAL assay, as well as the macrophage activation test (MAT) [5].
Since there are also papers that are indicative of an active monomeric form of LPS [6], and since the
assumption of a monomeric form induced by the detergents could not be verified directly to date,
we had a closer biophysical look on the phenomenon. Regarding the biological techniques to prove
the presence of LPS, usually the Limulus amebocyte lysate (LAL) assays in different modifications
(gel clot, chromogenic, turbidimetric) and the recombinant Factor C assay are used, which are all
based on the interaction of factor C of the Limulus cascade with LPS [7]. An alternative method is
the determination of the LPS-induced stimulation of human cells, such as mononuclear cells (MNCs,
monocytes, or macrophages (generally called MAT test)) [8]. It must be noted that both techniques
suffer from disadvantages: For activating the LAL test, the structural presence of only a LPS part
structure is necessary, i.e., the 4′-phosphate diglucosamine backbone of lipid A [8] in acylated form.
Therefore, a LAL signal is already seen with underacylated lipid A structures (tri-, tetra-, and pentaacyl
groups), which, in the human immune system, do not or only to a small degree elicit an inflammation
reaction [9]. Furthermore, the LAL assay can also be activated by β-D-glucans. The disadvantage of
the MAT lies in the fact that it reacts to all of the bacterial immune-stimulating toxins, i.e., also to those
from Gram-positive origin, which has been shown to result mainly from lipoproteins and/or their
shortened lipopeptide variants [10].
In the present work, we have applied a variety of biophysical techniques to gain more insight into
the LER phenomenon and to characterize a possible influence of different detergent formulations on
(i) the gel to liquid crystalline phase transition behavior of different LPS, (ii) their aggregate structure,
and (iii) aggregate sizes. Furthermore, the action of a recently well-described antimicrobial peptide
Aspidasept® [11,12] on the binding to LPS in different formulations was studied.
These data were directly correlated to their activity in the MAT. In this way, we should be able to
better understand the influences of the different parameters on LER.
2. Results and Interpretations
2.1. Gel to Liquid Crystalline Phase Transition of the Acyl Chains
All amphiphilic compounds, such as LPS, can adopt two states of order of the acyl chains,
one highly ordered (gel) with relatively rigid chains at lower temperatures, and one unordered
(liquid-like) with highly fluid chains at higher temperatures, Figure 1A. Typically, the phase
transition temperature Tc of enterobacterial LPS is around 30 to 37 ◦C, i.e., close to the physiological
temperature [13]. For the different smooth form LPS, however, due to the heterogeneous LPS
mixtures, differing in the degree of acylation and length of the saccharide chains, frequently lower
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Tc values may be observed. This parameter might be of importance for the ability of the compounds
to interact with target structures. Fourier-infrared spectroscopy (FTIR) is the method of choice,
by monitoring the symmetric stretching vibrational band at 2850–2853 cm−1 of the methylene groups,
with the former value characteristic for the gel and the latter for the liquid crystalline phase. In the
following, selected commonly used LPS from wild-type strains from E. coli O55:B5 and E. coli
O111:B4 (Sigma, Deisenhofen, Germany), LPS Rb and Rd mutants from Salmonella minnesota R345
and Salmonella minnesota R7 (own purified samples), respectively, in different buffers and detergents
were analysed. The data are shown in Figure 1B–F. As can be seen, the values of Tc are sensitively
dependent on the different formulations, with values of approximately 17 ◦C for LPS O111:B4 in buffer,
and increasing values up to 27 ◦C for the polysorbate 80 (at concentrations below the critical micellar
concentration (CMC)) preparation. Interestingly, when the polysorbate concentrations are increased to
values higher than the CMC, then the transition values considerably decrease (Figure 1B).
 
Figure 1. Effect of the formulation on the gel to liquid crystalline phase transition of lipopolysaccharides
(LPS). (A) Schematic representation of the gel to liquid-crystalline phase transition of a lipid bilayer.
Phase transitions of (B) LPS from E. coli O111:B4 in two different concentration of polysorbate 20 and
80; (C) LPS from E. coli O111:B4 in different formulations; (D) LPS from E. coli 055:B5 in different
formulations; (E) LPS from S. minnesota Rb mutant strain R345 in different formulations; and, (F) LPS
from S. minnesota Rd-mutant strain R7 in different formulations.
The measurements for LPS O55:B5 show a very broad phase transition range, which is indicative of
a very heterogeneous mixture of this smooth form LPS (Figure 1C). Again, the transition value is lowest
(appr. 25 ◦C) for the buffer system, but in this case, highest for the polysorbate 20 sample. In Figure 1B,
the phase transition behavior is measured at two polysorbate concentration (10 and 200 μg/mL),
representing values below and above their respective critical micellar concentration (CMC). It can be
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seen that there is a decrease of the Tc value at the higher polysorbate concentrations. Furthermore,
there is an increase of the Tc value in the sequence citrate, polysorbate 20, and polysorbate 80.
Since it has been found that the bioactive form within the heterogeneous wild-type strains
corresponds to R-mutants (Ra- or Rb-mutants as found in [14]), two of them were also investigated.
The data for the Rb-mutant LPS from S. minnesota (Figure 1E) clearly show a much smaller and sharp
transition range, according to the fact that this LPS is homogenous and pure. The Tc-values are lowest
for the citrate and are highest for the polysorbate formulations, and corresponds to previous findings
with values around 35 to 37 ◦C [15]. The results for a LPS Rd from S. minnesota strain R7, which has
the lowest Tc (ca. 34 ◦C) in buffer due to the short oligosaccharide chain, are presented in Figure 1F.
Surprisingly, there is a stronger increase in the phase transition temperature, as seen for the other
LPS samples.
Summarized, two tendencies are observed: for the two polysorbates, the concentration above
their CMCs (200 μg/mL) lead to a lower phase transition temperature of LPS. For the citrate and
polysorbate formulation below CMC (10 μg/mL) there is an increase in transition temperature as
compared to the HEPES control. The latter effect corresponds to an increase of the rigidity of the
hydrocarbon chains, and with that, of the whole LPS assembly.
2.2. Aggregate Structures of LPS Preparations Used in This Study
The aggregate structure of LPS was described as important parameter, which determines the
property of these amphiphilic compounds to exhibit biological activity [16,17]. For this, small-angle
X-ray scattering (SAXS) via synchrotron radiation was applied, since under near physiological
conditions (high water content) laboratory X-ray sources are not sufficient due to lack in brilliance.
In the Figure 2, the LPS samples described above were measured in the temperature range 20 (blue line)
to 80 ◦C (red line). Presented are the logarithm of the scattering intensity log I versus the scattering
vector s (s = 1d , d = spacings of the reflections). The data for LPS from E. coli O111:B4 (Figure 2A)
exhibit a complex scattering pattern, which is characteristic for a bilayered structure in the s-value
range 0.1 to 0.35/nm (reflection centered at 6.0 to 6.3 nm), and a cubic periodicity (reflections at 40 to
56 nm). Interestingly, the polysorbate formulations show changes in the aggregate structure, which is
obviously correlated with the phase transitions temperature. This can be deduced from the jump
of the reflections at 33.8 and 35.8 nm to values above 50 nm. For LPS E. coli O55:B5 (Figure 2B),
two main reflections around 5 to 6 nm and 20 to 30 nm are seen. In the case of the polysorbate 20
formulation, there is a complex reflection pattern between 20 and 50 nm. Also, in the case of LPS Rb
from S. minnesota R345, the situation is similarly complex (Figure 2C). The LPS in HEPES indicates
unresolved spectra, the LPS in citrate, and polysorbate indicate a higher degree of order, by showing
multilamellar-like reflections at 8.20 and 4.32 nm (citrate), 8.94 and 4.46 nm (polysorbate 20), and 8.92
and 4.48 nm (polysorbate 80). Moreover, the polysorbate formulations exhibit reflections at around 20
to more than 50 nm. The observation is different for LPS Rd mutant (Figure 2D). The patterns for the
sample in HEPES already exhibit some weak scattering maxima at 7.66 and 3.97 nm, which can be
assigned to a multilamellar arrangement. This is strongly expressed for the LPS in citrate, in which at
the lowest temperature peaks are clearly seen at 7.52 and 3.80 nm, 1st and 2nd order of a multilamellar
aggregate, which shift to higher values at the higher temperature due to acyl chain melting (Figure 1E).
Interestingly, no sharp reflections are seen for this LPS in the polysorbate formulations, but scattering
intensity is seen in the s-value range 0.13 to 0.35/nm.
Summarized, for the wild type LPS from E. coli O111:B4 as well as Rb-mutant from Salmonella minnesota
R345, the scattering patterns clearly indicate a complex change of the aggregate structures in the polysorbate
containing chelating buffers as compared to HEPES and citrate formulations alone, lacking the detergents.
For a forward assessment, it should be noted that the multilamellar structures that are seen here for LPS Rb
and LPS Rd correspond to the bio-inactive structures of LPS [15,17,18].
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Figure 2. Effect of the formulation on the supramolecular LPS aggregate structure. Synchrotron radiation
small-angle X-ray scattering patterns of LPSs from (A) E. coli O111:B4; (B) E. coli O55:B5; (C) S. minnesota
Rb strain R345; and, (D) S. minnesota Rd strain R7. The logarithm of the scattering intensity is plotted
versus the scattering vector s (s = 1d , with d being the spacings of the reflections).
2.3. Thermodynamics of Binding of the Synthetic Anti-LPS Peptide (SALP) Pep19-2.5 with the Different
LPS Preparations
It has been reported that particular antimicrobial peptides (AMP) from the SALP (synthetic
anti-LPS peptides) series, compound Pep19-2.5, binds and neutralizes LPS very efficiently [11,19].
This peptide is a 20’mer and consists of a N-terminal region with charged and polar amino acids and a
C-terminal region with essentially hydrophobic amino acids. It is scheduled to fight against severe
infections, such as sepsis [11]. The binding of the peptide to LPS preparations was tested here because
it is known that the lipid A backbones, in particular the lipid A phosphates, are targets for the peptides,
which is important with respect to the biological assay: Cellular activation in the MAT runs via the
binding of the bisphosphorylated lipid A backbone to the TLR4 receptor.
To test the neutralizing activity of Pep19-2.5 with the different LPS formulations, isothermal titration
calorimetry (ITC) was applied. The enthalpy change of this interaction can give information about
the kind of binding process, which may be of exothermic or endothermic nature, or a mixture of both,
with which the driving force of the interactions can be determined. In the experiments, in a first step all
of the compounds were dissolved in the respective formulations, and in a second step the peptide was
dissolved in water and was then added to the different formulations.
The data (Figure S1, Table 1) show similar binding characteristics, only for the polysorbate 20
formulation at 200 μg/mL there is an increase of the saturation curve to higher Pep19-2.5:LPS molar
ratio values. Furthermore, the data for the peptide dissolved in water and then dispersed into the LPS
formulations indicates a lower binding enthalpy of 40–50 kJ/mole at the beginning of the titration.
From the Figure S1A–C, the thermodynamic parameters can be calculated as presented in Table 1.
The ITC results show that the basic neutralization mechanisms of LPS by Pep19-2.5 remain similar for
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all of the different formulations. There are some variations of the initial enthalpy change ΔH and the
saturation values as indicated, with the values of LPS in HEPES buffer at −67 kJ/mole and saturation
value n = 0.245 exhibiting highest affinity and LPS in polysorbate 80 (10 μg/mL) at −43 kJ/mole and
n = 0.4 exhibiting lowest affinity.
Table 1. Thermodynamic parameters of the interaction of LPS from E. coli 055:B5 with the synthetic
anti-endotoxin peptide (Pep19-2.5) formulations. PS: polysorbate.
Thermodyamic
Parameters
LPS 055:B5 and Pep19-2.5 Dissolved in the Same Medium
LPS 055:B5 Dissolved in Polysorbates




















(Peptide/LPS) 0.25 0.29 0.38 0.39 0.34 0.33 0.32 0.40 0.37
Kd (nM) 862 529 225 104 78 200 218 46 261
ΔH (kJ/mol) −67.31 −59.82 −45.64 −58.35 −56.58 −48.49 −49.14 −43.00 −48.60
ΔS (kJ/mol·K) −0.10 −0.07 −0.02 −0.05 −0.05 −0.03 −0.03 0.01 −0.03
To summarize, the findings for the LPS representing different O-serotypes and formulations are
indicating similar neutralizations mechanisms, which is a matter of fact that the peptide essentially binds
to the lipid A part of LPS, its “endotoxic principle”. For all bioactive LPS, the lipid A part consists of a
hexaacylated diglucosamine moiety phosphorylated in positions 1 and 4’. Surprisingly, the neutralization
(saturation) of LPS takes place at higher peptide concentrations for the polysorbate formulations.
2.4. Stimulation of Immune Cells by the LPS in the Different Formulations (MAT)
The immune-stimulating activity of human mononuclear cells by compounds can be tested in an
ELISA (MAT), for which TNF-α as sensitive cytokine is selected, which is secreted by the cells already after
some hours. In a first step, the LPS from E. coli O55:B5 was tested in different formulations, NaCl 0.9%,
polysorbate 20 and polysorbate 80, each at two concentrations (10 and 200 μg/mL), see Figure 3. As can
be seen, the TNF-α secretion is highest for the sample in NaCl, whereas the highest concentrations of
the two polysorbate samples lead to a strong reduction of the activity, with polysorbate 20 having the
strongest influence on the reduction.
Figure 3. Secretion of tumor-necrosis-factorα (TNF-α) by human mononuclear cells induced by LPS
from E. coli O55:B5. LPS aggregates were prepared in NaCl 0.9% and polysorbate 20 and 80. Three LPS
concentrations 10, 1 and 0.1 ng/mL were tested. The error bar comes from two-fold determination of
TNF-α concentration in the ELISA.
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To examine also the dependence on the LPS chemotypes, further stimulation data were obtained
by investigating LPS O55:B5 and LPS Rb mutant R345 in different formulations (Figure 4A–C). The data
indicate differences in particular for the polysorbate formulations.
 
Figure 4. LPS-induced secretion of TNF-α by human mononuclear cells with different LPS formulations.
LPS from E. coli O55:B5 (A), LPS R345 (B), and buffers and LPS control dissolved in water (C).
Stimulation of human mononuclear cells was made at the three concentration: 1.0, 0.1 and 0.01 ng/mL,
and the activity is recalculated. The error bar results from twofold measurement of TNF-α in the ELISA.
2.5. Measurements of the Size Distribution of LPS Aggregates by Zeta Sizer
Aggregate sizes and their distributions has been discussed as a parameter, which influences
LER [3]. We therefore determined the LPS aggregate sizes and their distributions in a Zeta sizer,
by analyzing the diffusion of the aggregates via measurement of the backscatter signals. Again,
rough mutant LPS (LPS from S. minnesota Re (R595) and Ra (R60), as well as smooth form (O55:B5))
were analysed.
2.5.1. Results for Deep Rough Mutant LPS R595
In the following Figure 5 the results are presented for deep rough mutant LPS from S. minnesota
R595. On the left-hand side, the size distribution is shown, on the right-hand the side polydispersity,
i.e., the respective size distributions (see Table 2).
Table 2. Polydispersity index (PDI) for lipopolysaccharides aggregates in different formulations.
Formulation
Polydispersity Index (PDI)
LPS R595 LPS Ra LPS O55:B5
HEPES 20 mM pH 7.4 0.449 ± 0.012 0.983 ± 0.029 0.436 ± 0.004
NaCl 0.9% 0.935 ± 0.112 1.000 ± 0.000 0.524 ± 0.030
Citrate 30 mM pH 4.0 1.000 ± 0.000 1.000 ± 0.000 0.536 ± 0.018
Polysorbate 20, 10 μg/mL 1.000 ± 0.000 0.934 ± 0.073 0.514 ± 0.028
Polysorbate 20, 200 μg/mL 0.966 ± 0.058 0.966 ± 0.058 0.506 ± 0.059
Polysorbate 80, 10 μg/mL 0.911 ± 0.083 1.000 ± 0.000 0.463 ± 0.002
Polysorbate 80, 200 μg/mL 0.814 ± 0.050 1.000 ± 0.000 0.469 ± 0.056
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Figure 5. Effect of the formulation on the aggregate size of LPS. The figure shows the particle
size for seven different preparations. For each preparation, LPS aggregates are shown as LPS R595
(first bar), LPS R60 (second bar), and LPS E. coli O55:B5 (third bar). The error bar results from twofold
measurement of TNF-α in the ELISA.
It becomes clear that the LPS sample in HEPES buffer (top left) has lowest values of the peak
around 205 nm and a distribution factor of 0.45. Interestingly, the values for the aggregates in NaCl are
much higher, and are highest in the citrate formulation. In the two latter samples, also the distributions
are broadest. Both polysorbate preparations at 200 μg/mL have rather low sizes, whereas their peak
sizes at the smaller polysorbate concentrations are significantly higher.
2.5.2. Results for Rough Mutant LPS Ra with Complete Core Oligosaccharide
In the following, the results are presented for rough mutant LPS from S. minnesota R60 (Figure 5
and Table 2).
The results for the rough mutant LPS R60 with complete core oligosaccharide differs considerably
from the results for the deep rough mutant LPS. The sizes and their distributions are much more
homogenous. In general, the sizes are significantly larger than those from LPS R595. Interestingly,
the results for the preparation with polysorbate 20, 200 μg/mL, exhibits the largest sizes, whereas the
values for LPS R595 are indicative of very small sizes.
The corresponding data for the wild-type LPS O55:B5 are shown in Figure 5 and Table 2. It is
striking that the sizes of the LPS aggregates in the different formulations are considerably lower than
for the two rough mutant LPS. Furthermore, similar to LPS R595, the citrate formulation has a highest
size (285 nm), which, however, is very low as compared to the former LPS (1811 nm).
Summarized, the data give evidence for a strong dependence on the size distributions from the
LPS representing different serotypes. It should be mentioned here, that these results are of course
influenced strongly by the facts that the chemical structures of rough mutant LPS are relatively
homogenous, whereas wild type forms usually consists of a heterogenous assembly of various part
structures, containing an Ra- or Rb-type LPS as bioactive moiety [14].
2.6. Size Distribution in Relation to Cytokine Induction in Human Mononuclear Cells
The same samples, which were analysed in light scattering experiments, were added to human
mononuclear cells that were obtained after blood separation form healthy donors, and their ability to
induce tumor-necrosis-factorα (TNF-α) was measured in an ELISA (MAT). In Figure S2, the results are
shown for deep rough mutant LPS from R595 for two concentrations 10 and 1 ng/mL. At the higher
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concentration, the stimulation values are rather homogeneous, except for the citrate value, whereas at
the lower concentration, only the value for polysorbate 80 (10 μg/mL) deviates to lower values.
The results for the rough mutant LPS R60 are given in Figure S3. It can be seen that the absolute
TNF-values tend to be lower than for LPS R595. The observation of lower values for citrate at the higher
LPS concentration is also observed here, whereas the pattern of the TNF values is more homogeneous,
but significantly lower than for LPS R595.
In a similar way, data are presented for LPS S-form O55:B5 (Figure S4). Also, here, the citrate
formulation at 10 ng/mL has the lowest activity. Surprisingly, there is a great difference to the cytokine
values at 1 ng/mL. The comparison of the three LPS shows that with an increasing length of the sugar
chain, which is shortest for LPS Re, longer for LPS Ra, and longest for LPS S-form, the results become
more variable.
In another approach, the MAT was performed with two LPS (LPS R60 and O55:B5) and with
two pretreatments. Sonicated LPS should produce small, vortexed LPS large aggregate structures.
This was performed according to the findings of Komoro et al. [20], who found better reactivity in the
pyrogen test and LAL with sonicated LPS preparations. As can be deduced from Figure S5, there is no
significant difference in the response of the MAT at both sonicated and vortexed samples.
Summarized, the data presented here do not indicate a general dependence of the biological
activities in the MAT assay of different LPS preparations on the respective sizes and size distributions.
It should be noted here that the term aggregate size in a sense of a well-defined spherical form for LPS
is not well-defined, in particular, for LPS with long saccharide chains, such as S-form (wild-type) LPS.
3. Discussion
In a comprehensive analysis, we have performed biophysical analyses of different LPS formulations
(detergent, chelating buffer) being assumed to represent the major factors that are mediating the
LER-effect. In addition, we also investigated different LPS varying in size and structure, i.e.,
from wild-type (S-form) over various rough-mutants differing in the size of the LPS core-oligosaccharide
(Re-, Rd-, and Ra- mutant LPS). In a first step, we have analyzed the single constituents of the complex
compositions of the pharmaceutical, formulations, i.e., citrate, polysorbate 20 and polysorbate 80.
The data presented here can serve as the basis for further investigations, in which the complete
formulation leading to LER will be tested.
We have found in various test systems, that there are clear changes of different parameters,
with variations of the formulation. These data give hints with respect to the occurrence of the LER,
in which the LPS backbone structure shows reduced LAL reactivity.
We have analyzed the following physical-chemical parameters, which might be responsible for
the LER in LPS formulations:
• Fluidity of their hydrocarbon chains;
• Aggregate size and structure;
• Head group conformation and orientation.
Following this line, we have investigated the:
(i) (i) gel to liquid crystalline phase transition of the hydrocarbon chains of LPS, and with that,
the fluidity of the acyl chains, with Fourier-transform infrared spectroscopy (FTIR);
(ii) three-dimensional aggregate structure of LPS by using synchrotron radiation small-angle
X-ray scattering (SAXS);
(iii) LPS aggregate sizes by dynamic light scattering and have related these data to the biological
activities in the MAT;
(iv) Furthermore, the interaction of LPS with a synthetic anti-LPS peptide Pep19-2.5 was
monitored to find out whether differences in head group binding are observed.
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It has been shown that the order of the acyl chains (highly ordered = gel phase, less ordered = liquid
crystalline phase) influences the bioactivity of LPS and lipid A preparations [21]. Thus, with increasing
order (lower fluidity) interaction with target structures such as the factor C in the Limulus assay or cell
surface receptors, such as CD14 or the TLR4/MD2 complex, are impeded. Therefore, the data for the
samples with Tc increases (for example, see Figure 1E) should have lowered biological activity in the
MAT, because the acyl chains are more rigid. This relates in first line to the polysorbate formulations,
which may influence the biological responses. The SAXS data show only small, but significant,
changes of the observed aggregate structures on the different formulations. In particular, the existence
of highly ordered phases observed for the smooth, as well as rough, mutant LPS R7 and R345 for
the polysorbate formulations may give a hint for a masking process, which will be tested in further
experiments with the complete formulation system. It has been shown in previous papers [15,17] for
lipid A and rough mutant LPS as well as in a recent paper on wild-type LPS [18] that the aggregate
structure of LPS is a determinant for its biological activity in the MAT. Thus, non-lamellar, in most cases
cubic structures are the bioactive units of LPS. The observation of a shift of the broad scattering range
from 0.1 to 0.25 /nm (Figure 2A–C) to 0.13 to 0.35 (Figure 2D) indicates a new, probably highly ordered,
phase, for LPS Rd in the polysorbate formulations (interpretation from unpublished results).
Regarding the data from the size distributions presented here, the results indicate for the different
LPS mutants/smooth forms quite diverging results. The data are indicative of medium sizes for LPS
Re, high sizes for LPS Ra, and low sizes for LPS S-form. For an understanding, the results from studies
of LPS morphologies may be useful. It was found that for most rough mutant LPS spherical-like
morphologies were reported, by using cryo- and freeze-fracture electron microscopy [22]. In contrast,
in LPS with longer sugar chain, in particular S-LPS, membrane vesicles, bilayer disks, and ribbon-like
aggregates are found. These data are in accordance with the size distribution that is obtained via
ultracentrufigation, in which R-LPS showed size distribution between 100 to 600 nm, whereas for
S-LPS, the values were around 50 to 200 nm [22].
It should be noted that in the evaluation of the Zeta sizer measurements, a simple assumption
of spherical-like structures would give directly comparable results for the medium sizes. Therefore,
the size values for compounds with long saccharide chains, such as S-form LPS, are not the radius of a
sphere, but give only a medium value for its non-spherical morphology. Finally, it should be noted
that polysorbates—which are added to drug products to inhibit protein aggregation—do not lead to
LPS disaggregation at least when administered solely (see Figure S5).
Regarding the comparison of the results from the biological assay at the selected concentrations
with those of the three LPS with differences in the saccharide chain lengths in different buffers do not
show any systematic dependence of the MAT response with the aggregate sizes and their distributions.
Finally, the ITC data of LPS binding to Pep19-2.5 indicate a significantly higher peptide to LPS ratio for
binding saturation for the polysorbate formulations, which is indicative of a change in the LPS head
group conformation.
Literature data on the one hand explain the LER by increases in aggregate size and stability [23],
and, on the other hand, by a decrease down to monomers.
Reich et al. have proposed ‘the supramolecular structure of endotoxin is altered and exhibits
only a limited susceptibility in binding of the factor C of Limulus-based detection systems. Although,
in our analysis under conditions with reduced complexity (only pure citrate or polysorbates were used,
but not a combination therefrom), we observed some changes in the supramolecular assembly and the
phase transitions of the acyl chains, in particular when polysorbate is present in the LPS preparations.
Masked endotoxin may adopt a supramolecular conformation not detectable by the LAL test.
Schwarz et al. [24] have found for masked endotoxin—as evidenced by the chromogenic endpoint
LAL—the expression of pro-inflammatory cytokines and surface activation markers. This is an
observation, which we will address in future experiments, in particular by investigating the complete
system relevant in LER.
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The presented data will form the basis for detailed investigations into the dependence of
biophysical parameters of the complete detergent system, in particular on the influence of the
4′-phosphate diglucosamine backbone of the lipid A part of LPS, the recognition structure of LPS
by the Limulus assay. It is envisaged to continue the investigations by using also the factor C of the
Limulus assay in recombinant form, and possibly LPS-binding sequences of this, and comparing it with
the well-known behavior of anti-endotoxin peptides, such as Pep19-2.5.
From these observations, the following questions seem to be important with respect to the
occurrence of the LER: is the lack of endotoxin detection by LAL a problem of LPS in an undetectable,
inactive conformation or a failure of the measuring system LAL?
The headgroup conformation, in particular of the 4′-phosphate group in the lipid A part is of
central importance. We will perform in a next step an analysis via FTIR by studying the interaction of
LPS with rFC and part structures.
Could the change of the LPS conformation into in monomeric form be responsible for the LER?
Müller et al. [5] found in the MAT as well as the LAL no biological activity of LPS monomers.
There are other publications, however, which come to a completely different conclusion [25]. Therefore,
this hypothesis will be in the focus of further studies.
4. Materials and Methods
4.1. Peptides, Reagents and LPS Formulations
Lipopolysaccharides O55:B5 and O111:B4 from Escherichia coli wild-type strains (S-form LPS)
were purchased from Sigma (Deisenhofen, Germany), rough mutant LPS Ra strain R60, Rb strain
R345, Rd strain R7, and Re strain R595 from Salmonella minnesota were extracted from bacteria by
phenol/chloroform/petrol ether, according to the protocol of Galanos et al. [26]. For wild-type
strains, the chemical structure of LPS consists of the lipid A part, which represents the outer leaflet
of the bacterial outer membrane, the oligosaccharide core, and the O-antigen, a polysaccharide
moiety directing outwards. The chemical structures of the single segments of the LPS molecule
from the commonly used wild type strains are—except for the relatively homogenous lipid A moiety
(“conservative” motif [1])—not well described, and varies from strain to strain. Usually, the core
oligosaccharide, which is bound to the lipid A part, consists of 10 to 12 monosaccharide units, and the
subsequent O-antigen has a largely varying polysaccharide chain. Moreover, S-form LPS consists
of different fractions, which may have also underacylated lipid A parts [1,14]. The details of these
inhomogenities are in most cases unknown except for single analyses as for example performed by
Jiao and Galanos [14] for wild-type LPS from Salmonella abortus equi.
Rough mutant LPS lack the O-antigen, and have a varying length of the oligosaccharide, Ra with a
complete one, and the other mutants having a shorter oligosaccharide in the sequence Rb > Rc > Rd > Re.
The antimicrobial peptide Pep19-2.5 (Aspidasept®) with a sequence of GCKKYRRFRWKF KGKFWFWG
was synthesized by BACHEM (Bubendorf, Switzerland) with a purity of >95%. All of the other chemicals
were from Merck (Mannheim, Germany). Sodium citrate and polysorbate 20 and 80 was purchased from
Merck (Mannheim, Germany) and Sigma (Deisenhofen, Germany).
For all of the applied techniques listed below, the LPS samples were prepared as aqueous
dispersions in 20 mM HEPES pH 7.4, 30 mM sodium citrate pH 4.0, polysorbate 20 and 80, the latter
each at 10 and 200 μg/mL. The latter concentration corresponds to values below and above the critical
micellar concentration, respectively. LPSs were suspended directly in buffer by extensively vortexing,
sonicated in a water bath at 60 ◦C for 30 min, cooled down to 5 ◦C, and subjected to three cycles of
heating and cooling from 60 to 5 ◦C. After that, the lipid samples were stored for at least 24 h at 4 ◦C
before performing the measurements.
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4.2. Acyl Chain Melting Behavior by Fourier-Transform Infrared Spectroscopy
The infrared spectroscopic measurements were performed on a FTIR spectrometer IFS-55,
from Bruker (Karlsruhe, Germany). The lipid samples were placed in a CaF2 cuvette separated
by a 12.5 mm thick teflon spacer. Temperature-scans were performed automatically in the range
from 10 to 65–80 ◦C with a heating rate of 0.6 ◦C min−1. Every 3 ◦C, 200 interferograms were
accumulated, apodized, Fourier transformed, and converted to absorbance spectra. The phase
behaviour was monitored by using the peak position of the symmetric stretching vibration νs (CH2) in
the wavbenumber range 2850 to 2853 cm−1. The phase transition temperature Tc can be determined
by taking the midpoint of the intersection of the tangents of the curve in the gel phase with that of the
inflection point of the transition range, and the intersection of the latter with the tangent of the curve
in the liquid crystalline phase.
4.3. Aggregate Structure Determined by Small-Angle X-ray Scattering (SAXS)
The X-ray scattering measurements were performed on the X33 beamline of the European
Molecular Biology Laboratory (EMBL) outstation at HASYLAB on the storage ring PETRA of the
Deutsches Elektronen Synchrotron (DESY) at Hamburg [27].
Briefly, scattering patterns in the range of scattering vector 0.05 < s < 1 nm−1 (s = 2 sin θ/λ, 2 θ
is the scattering angle and λ the wavelength = 0.15 nm) were recorded, with exposure times of 1min
using an image plate detector with online readout (Mar345; Marresearch, Norderstedt, Germany).
Further details concerning the data acquisition and evaluation have been described previously [12].
In the diffraction patterns that are presented below, the logarithm of the diffracted intensities I(s) is
plotted versus s. The X-ray spectra were evaluated using standard procedures [11], which allow for
assigning the spacing ratios of the diffraction maxi-ma to defined three-dimensional structures of the
endotoxin: detergent samples.
Structures occuring for endotoxins comprise lamellar (L) phases with spacing ratios lying at
equidistant positions and nonlamellar phases like cubic (Q) and inverted hexagonal (HII) that are
characterized by square root spacing ratios [28].
4.4. Binding Affinity of LPS to Pep19-2.5 via Isothermal Titration Calorimetry (ITC)
The interaction of the peptide Pep19-2.5 with LPS in various formulations was analyzed by
microcalorimetric measurements in the ITC200 (GE Healthcare, Munich, Germany), as recently
described [19]. For this, 1 mM (2.71 mg/mL) Pep19-2.5 in different formulations was titrated into 430
μg LPS from E. coli O55:B5 and the measured enthalpy changes (ΔH) were recorded versus time and
the peptide: LPS concentration ratio.
4.5. Particle Size Measurements by Dynamic Light Scattering on a Zeta Sizer
Dynamic light scattering of the particle sizes of LPS aggregates was performed in different formulations,
by measuring the diffusion velocity in a Malvern Zeta sizer Nano (Malvern, Herrenberg, Germany).
The method is based on the measurement of the diffusion of small particles according to the Stokes-Einstein
equation D = μ × kB ×T (μ = mobility of the particles, kB = Boltzmann constant), measuring the
back-scattering, and calculating the autocorrelation function. Each particle scatters the light to the detector,
and the fluctuations of the scattering intensity is smaller for large than for small particles.
In detail, the LPS samples were measured for 3 min in a fixed laser position of 173◦ (backscattering),
relative to the incident laser beam. The measured intensities were correlated over time and analysed
by a multiple exponential, non-negative least square fit to obtain relative intensities for the different
particle sizes. The LPS samples at concentrations of 10 μM were dispersed in following formulations:
20 mM Hepes buffer at pH 7, 0.9% NaCl, 30 mM citrate, 10 and 200 μg/mL polysorbate 20,
respectively, and 10 and 200 μg/mL polysorbate 80. The samples were prepared by sonication
and temperature-cycled between 20–60 ◦C, and were stored at room temperature.
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4.6. Stimulation of Human Mononuclear Cells
Mononuclear cells (MNC) were isolated from heparinized blood samples that were obtained from
healthy donors, as described previously [15]. The cells were resuspended in medium (RPMI 1640),
and their number was equilibrated at 5 × 106 cells/mL. For stimulation, 200 μL MNC (1 × 106 cells)
was transferred into each well of a 96-well culture plate. The LPS formulations were preincubated
for 30 min at 37 ◦C and were added to the cultures at 20 μL per well. The cultures were incubated
for 4 h at 37 ◦C with 5% CO2. Supernatants were collected after centrifugation of the culture plates
for 10 min at 400× g and stored at 20 ◦C until immunological determination of tumor necrosis factor
alpha (TNF-α), carried out with a sandwich enzyme-linked immunosorbent assay (ELISA) using a
monoclonal antibody against TNF (clone 6b; Intex AG, Basel, Switzerland), and described previously
in detail [19].
5. Conclusions
In conclusion, the current work has laid out a number of analytical approaches to study the
LPS system and provide insight into the structural changes that the LPS might be going through,
subsequently leading to the LER effect. The next steps to be investigated will be the combination of
chelating buffers and polysorbate and study their individual impact on the LER effect, which is most
relevant for pharmaceutical preparations. Also, the study in various (chelating) buffers (e.g., histidine,
citrate, acetate, succinate, phosphate, etc.) on structural details, in the presence of polysorbate 20
and 80, respectively. In addition, the presence or absence of divalent cations, such as Mg2+ and Ca2+,
which are necessary for the formation of defined and complex negatively charged LPS aggregates,
as well as the pH-value seems to be of outmost importance for the understanding of the LER-effect on
a molecular level. Finally, the same holds true for surfactant concentrations from 0.1 to 2 mg/mL, i.e.,
in a pharmaceutical relevant range.
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Abstract: Sepsis is a severe and multifactorial disease with a high mortality rate. It represents a
strong inflammatory response to an infection and is associated with vascular inflammation and
oxidative/nitrosative stress. Here, we studied the underlying time responses in the widely used
lipopolysaccharide (LPS)-induced endotoxaemia model in mice and rats. LPS (10 mg/kg; from
Salmonella Typhosa) was intraperitoneally injected into mice and rats. Animals of every species were
divided into five groups and sacrificed at specific points in time (0, 3, 6, 9, 12 h). White blood cells
(WBC) decreased significantly in both species after 3 h and partially recovered with time, whereas
platelet decrease did not recover. Oxidative burst and iNOS-derived nitrosyl-iron hemoglobin
(HbNO) increased with time (maxima at 9 or 12 h). Immune cell infiltration (CD68 and F4/80 content)
showed an increase with time, which was supported by increased vascular mRNA expression of
VCAM-1, P-selectin, IL-6 and TNF-α. We characterized the time responses of vascular inflammation
and oxidative/nitrosative stress in LPS-induced endotoxaemic mice and rats. The results of this study
will help to interpret and compare data from different animal species in LPS-induced endotoxaemia
models for the identification of new drug targets.
Keywords: sepsis; time response; inflammation; oxidative stress; endotoxaemia; mouse; rat
1. Introduction
Sepsis is a clinical syndrome that is caused by a dysregulated and overshooting response of
the inflammatory system to an infection. Sepsis is most frequently caused by bacteria, to a lower
extend by fungi, and can rapidly become life threatening. It arises from infections of the skin, lung,
abdomen, and urinary tract. Despite aggressive treatment on intensive care unit and ambitious
effort in research, sepsis remains a leading cause of death, even in Western countries [1]. In 2008,
costs spent on hospitalizations for sepsis in the USA were estimated at $14.6 billion [2]. The early
identification of sepsis is necessary for the sufficient treatment of septic patients and scores like the
modified Sepsis-related Organ Failure Assessment score (quickSOFA) are helpful tools for initiation
of optimal therapy [3]. Nevertheless, the improvement of survival and reduction of costs can be best
achieved by better understanding of the causes and pathophysiology of sepsis.
The basic treatment regimen for sepsis did not change for decades. Early fluid supplementation
and antibiotics are known to significantly improve survival in septic shock, but clinical trials targeting
the reduction of the inflammatory response failed [4]. Although there are major limitations for the
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translation of findings of animal studies to the human setting, it cannot be denied that animal models
have significantly improved the knowledge of sepsis. In humans, sepsis is characterized by an
initial pro-inflammatory phase, which is followed by an anti-inflammatory or immunosuppressive
phase [5]. Although several animal models of sepsis were reported to mimic the inflammatory
and genomic responses of humans to septic stimuli, this is still under debate for murine sepsis
models [6,7]. An important requirement for the translation of data from animals to humans is the
detailed pathophysiologic characterization of sepsis in the animal models. However, not only different
protocols for the induction of sepsis, such as bacterial infusion model, cecal ligation and puncture
(CLP), colon ascendens stent peritonitis (CASP), and lipopolysaccharide (LPS)-induced endotoxaemia,
are used to investigate sepsis in animals. Even more problematic is the use of different species and
strains in these sepsis models. In the last years, our group used LPS-injection models in mice and rats
for three studies and we noticed some differences in inflammatory response and mortality between
the species [8–11]. Since it is already challenging to translate findings from animal models to human
sepsis, a clear characterization of the inflammatory response in each animal model of different species is
highly recommended.
With the present study, we aimed to compare the time response pattern (0, 3, 6, 9, and 12 h) of
white blood cell (WBC) derived oxidative and nitrosative stress, as well as vascular inflammation
parameters in LPS-induced endotoxaemia in mice and rats.
2. Results
2.1. Time Response of Thrombocyte Count and White Blood Cell Derived Oxidative Burst in Mice and Rats
Thrombocytes in whole blood were significantly higher at the beginning of the experiments.
After LPS injection the thrombocyte counts in mice and rats dropped similarly (Figure 1A). Already before
LPS injection, rats and mice had significantly different numbers of WBC in whole blood. In both species,
the WBC count dropped significantly at 3 h after LPS injection and increased with time showing a
partial normalization at 12 h. Of note, the WBC count showed better recovery in rats as compared to
mice (Figure 1B). Zymosan A-induced oxidative burst in whole blood was significantly higher in rats
at 0, 3, 9, and 12 h after LPS injection as compared to mice. A first significant increase of oxidative
burst was detectable at 6 h after LPS injection in mice and 9 h in rats. In both species the peak level
of oxidative burst was observed after 9 h (Figure 1C). A quite similar observation was made for the
kinetics of PDBu-induced oxidative burst. The first significant increase with time was again detected
at 6 vs. 9 h in mice as compared to rats. The maximal oxidative burst in whole blood from mice was
at 9 h for zymosan A and PDBu stimulation. In contrast to the maximal zymosan A-induced oxidative
burst in rats at 9 h, the peak level of oxidative burst was found at 12 h after LPS injection (Figure 1D).
The absolute level of oxidative burst was higher with zymosan A than with PDBu stimulation.
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Figure 1. Time response of platelets and white blood cell derived oxidative burst in mice and rats.
Thrombocyte count (green line already published in Steven et. al. BJP 2017 [10]) (A), white blood cell
(WBC) count (B) and oxidative burst (nicotinamide adenine dinucleotide phosphate-oxidase (NADPH)
oxidase and myeloperoxidase activity) in whole blood after zymosan A (C) or PDBu (D) stimulation in
mice and rats was determined by chemiluminescence (L-012) over a 12 h time response. (E,F) Oxidative
burst was normalized to the WBC count. The data are mean ± SEM from 6 different animals per group.
* p < 0.05 vs. 0 h mouse, # p < 0.05 vs. 0 h rat and § p < 0.05 vs. mouse (same point in time).
Normalization of oxidative burst to WBC count in whole blood changed not only the kinetic pattern
but also the relative level in the species significantly for both assays. Whereas, mice and rats showed a
similar level of zymosan A-induced oxidative burst at each point in time (Figure 1E), mice showed a
significantly higher PDBu-induced oxidative burst level at 6 and 9 h after LPS injection when compared
to rats (Figure 1F). Finally, after 12 h burst levels were equal in both species. Of note, although the WBC
count is higher in human subjects than in rodents, these numbers are comparable in rats and mice [12,13].
2.2. Time Response of Nitrosyl-Iron Hemoglobin and Inos Expression of Isolated WBC in Mice and Rats
Nitrosyl-iron hemoglobin (HbNO) significantly increased in mice after 9 h and in rats after 6 h
of LPS treatment. The peak levels of HbNO were detected at 12 h after LPS injection in both species.
HbNO formation was significantly (2–3-fold) higher in rats after 6, 9, and 12 h of LPS treatment as
compared to mice (Figure 2A). If corrected to WBC count, the time response of HbNO levels changed.
Rats demonstrated a strong peak after 6 h, whereas the time response of HbNO levels in mice showed
a similar pattern as compared to the data without normalization to WBC count (Figure 2B).
Vascular mRNA of iNOS increased after 3 h of LPS treatment in both species. A substantial peak
level was detected after 6 h in rats, whereas this maximum was much less pronounced in mice. mRNA
expression of iNOS decreased with time and was normalized in mice, but still significantly elevated in
rats at 12 h after LPS injection (Figure 2C). Immunohistochemical staining of aorta revealed an increase
in 3-nitrotyrosine positive proteins throughout the entire vascular wall in both species after 12 h,
although the staining was more pronounced in rats as compared to mice (Figure 2D). iNOS expression
in isolated WBC of mice and rats was elevated at 12 h after induction of endotoxaemia (Figure 2E).
However, rats showed a significantly higher iNOS protein expression as compared to mice.
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Figure 2. Time response of nitrosyl-iron hemoglobin and iNOS expression in isolated WBC of mice
and rats. Whole blood Hb-NO levels were determined by Electron Paramagnetic Resonance (EPR)
spectroscopy as a read-out of iNOS activity (A) and were normalized to the WBC count (B). qRT-PCR
was used to determine mRNA expression levels of iNOS in aortic tissue (C). iNOS protein expression
was further visualized by immunohistochemistry of paraffin embedded aortic sections after 12 h (D).
iNOS protein expression was further investigated in isolated WBC of both species after 12 h using
Western-blot technique (E). Each lane in the original blot represents a protein sample from 1–2 animals.
The data are mean ± SEM from 6 different animals per group. * p < 0.05 vs. 0 h mouse, # p < 0.05 vs.
0 h rat and § p < 0.05 vs. mouse (same point in time).
2.3. Time Response of Vascular Inflammation in Mice and Rats
VCAM-1 mRNA expression increased significantly with time in endotoxaemic mice and rats.
VCAM-1 expression in mice showed a maximum at 3 h after LPS injection (3-fold higher compared to
rats) and VCAM-1 expression declined after the 3 h maximum but was still significantly higher at all
points in time compared to 0 h. The maximum VCAM-1 expression in rats was found after 12 h of LPS
treatment with a similar amount as compared to mice and expression levels continuously increased
with time in rats (Figure 3A). Vascular mRNA expression of P-selectin showed a peak after 3 h of LPS
treatment in both species and time-dependently returned to normal levels afterwards. The absolute
expression levels and time responses were almost identical for both species (Figure 3B). IL-6 mRNA
expression showed a maximum at 3 h after LPS injection in mice and at 6 h in rats. Afterwards, the
IL-6 levels were normalized in both species with an overall almost identical time response (Figure 3C).
TNF-α mRNA expression showed a peak at 3 h after LPS injection in both species, but this maximum
was less pronounced in rats as compared to mice. Expression levels were higher at all time response
compared to 0 h values in mice and rats (Figure 3D).
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Figure 3. Time response of vascular inflammation in mice and rats. qRT-PCR was used to determine
mRNA expression levels of VCAM-1 (A), P-selectin (B), IL-6 (C) and TNF-α (D) in aortic tissue over a
12 h time response. The data are mean ± SEM from 6 different animals per group. * p < 0.05 vs. 0 h
mouse, # p < 0.05 vs. 0 h rat and § p < 0.05 vs. mouse (same point in time).
mRNA expression of CD68, as a marker for leukocyte infiltration, was increased at the 9 and 12 h
point in time (Figure 4A). Increased CD68 positive protein was also detected by immunohistochemical
staining of rat aorta at 12 h after LPS injection (Figure 4C). CD11b mRNA levels in vascular tissue showed
a time-dependent significant increase in mice at the 6, 9, and 12 h points in time (Figure 4B). F4/80
immunohistochemical staining of mouse aorta revealed more F4/80 positive protein throughout the entire
vascular wall after 12 h of LPS treatment (Figure 4D). Whereas, CD68 and F4/80 are good markers for
infiltrated macrophages, CD11b is a rather unspecific marker that is expressed on all myelomonocytic cells.
 
Figure 4. Time response of vascular inflammation in mice and rats. qRT-PCR was used to determine
mRNA expression levels of CD68 (A) in rats and CD11b in mice (B). CD68 protein levels in rats
(C) and F4/80 protein levels in mice (D) were further visualized by immunohistochemistry of paraffin
embedded aortic sections after 12 h. The data are mean ± SEM from 6 different animals per group.
* p < 0.05 vs. 0 h mouse, # p < 0.05 vs. 0 h rat (same point in time).
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3. Discussion
In this study, we provide very detailed time responses (0, 3, 6, 9, and 12 h) of oxidative/nitrosative
stress and vascular inflammation in LPS-induced endotoxaemia in mice and rats. We also provide a
detailed comparison of these time responses between mice and rats to identify species-independent
pathways that might be of relevance for human sepsis as well. LPS-induced endotoxaemia is a
frequently used model for preclinical research on sepsis. However, so far, all published studies used
different points in time and multiple species, which makes it hard to compare the disease-relevant
pathomechanisms and translate the findings to the human setting. Besides species-dependent
differences in the inflammatory response, there are even notable differences between strains of the
same species. It is known, that C57BL/6j (B6) tend to have a TH1-predominat response to pathogens,
whereas A/J, BALB/C, and DBA/2 mice have a TH2-type preference [14]. Furthermore, B6 mice when
compared to A/J mice have a significant higher mortality, which was accompanied by higher IL-10
plasma levels and myeloperoxidase activity [15]. The present study underlines the importance of
using similar time points, strains and species, and highlights some alarming differences in the time
responses and absolute changes across two animal species warranting cautious interpretation of data
from experimental studies when translating them to human sepsis.
The endotoxin LPS from gram-negative bacteria triggers inflammation by binding directly via
CD14 on monocytes and via toll-like receptors (TLR) on endothelial cells after forming a complex with
LPS binding protein (LBP) [16]. The LPS model nicely mirrors the severe inflammatory response of the
organism but does not challenge the host with living bacteria. Anti-inflammatory treatment of sepsis
should counteract the excessive inflammatory cascade and contribute to improved survival. Statins
have such anti-inflammatory properties and a recent trial tested the use of rosuvastatin in patients
suffering from acute respiratory distress syndrome (ARDS) but the results were disappointing and
statin therapy failed to improve clinical outcome [17]. Several other compounds were tested in clinical
and pre-clinical trials to find evidence for improved survival by the reduction of the inflammatory
response in sepsis, but only cortisone therapy can be found in recent clinical guidelines [4].
The importance of time responses for our understanding of the septic pathophysiology is
underlined by literature reports on different time windows or phases for human sepsis but also
LPS-induced endotoxaemia [8,18]: the first phase is between 0 and 2 h after bacterial invasion/LPS
exposure, and the second phase between 2 and 12 h. Within these two phases, pathophysiological
processes (cell activation, inflammation, and hypotension but also local endothelin-1 formation [8,18,19])
are reversible and can be pharmacologically modified [18]. The upregulation of cell activation markers
and inflammation were also observed in the present study (e.g., CD68, F4/80, VCAM-1). After these
two phases, a point of no return was postulated, and all later events contribute directly to the high
mortality (e.g., massive oxidative damage, cell death, disseminated intravasal coagulation (DIC), and
end organ failure), and cannot be easily modified by pharmacotherapy [8]. According to a clinical
study of Vargas et al. the decision on survival or death in septic shock develops between 40 and 60 h
post infection (probably the decision is already taken somewhat earlier, between 12 and 24 h) and
can be predicted from the serum pattern of the inflammation markers IL-6 and IL-8 as well as the
adhesion molecules sELAM-1 and sICAM-1 [20]. After 40 h, the level of these inflammation markers
returned to normal in the survivor group but escalated in the non-survivor group. Another clinical
study showed that the serum levels of the regulator of endothelial cell migration and endothelial
permeability VEGF-A as well as its receptor sFlt-1 were significantly upregulated (48 h after the onset
of fever) in patients with septic shock but were at normal level in patients who had developed sepsis
without shock [21]. Therefore, according to this study, the decision on development of shock or “mild”
sepsis was already taken at 48 h post infection. In an animal experimental study on septic sheep, Lange
et al. presented data on the time response of different clinical and biochemical markers and revealed
a dramatic change in the expression of NOS isoforms between 8 and 12 h post infection, which was
followed by severe worsening of the clinical parameters [22].
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In addition, a large number of studies investigated the time response of one marker in plasma or
serum such as angiopoietin-2, gelsolin, neopterin, C-reactive protein (CRP), and selenium. In summary,
despite many efforts it is not clear how the septic situation in a given animal develops to the critical
point at which the vascular biochemistry and physiology either return to normal or develop into the
lethal situation of septic shock. It is also unclear which animal model should be applied to mimick
human sepsis but some data from patients are helpful in pointing out the crucial steps involved.
In the first place this applies to the high output of prostacyclin (PGI2, measured as 6-keto-PGF1α)
before shock develops [23–26]. Of clinical importance is the fact that high levels of 6-keto-PGF1α
are associated with a bad prognosis of septic patients [23]. One may speculate that similar to the
inhibition of PGI2 synthesis in the endothelium after 1 h of LPS exposure the beneficial effects of
smooth muscle derived PGI2 after 4–12 h could be eliminated by the inhibition of its synthesis, which
could either be brought about by inhibition of inducible cyclooxygenase (COX-2) (e.g., downregulation
or nitration of COX-2 [27]) or even by nitration of PGI2 synthase after breakdown of the smooth
muscle antioxidant potential, followed by a rise of the peroxynitrite levels in this previously resistant
cell layer. Of note, despite the presence of severe hypotension, a considerable degree of vascular
dysfunction may exist, a paradox that is best explained as follows: the substantial stimulation of
the sGC/cGMP signaling cascade with high formation rates of •NO from iNOS (as shown here by
EPR-based measurement of nitrosyl-iron-Hb) may result in a desensitization of this signaling pathway,
endothelial dysfunction, and vasoconstriction [28,29]. This would provide a reasonable explanation
for the impaired vascular function despite systemic hypotension and overproduction of vasodilators.
Therefore, the time window between 12 and 24 h may have special significance for the development
of lethality.
In the third phase, NOS-2 and COX-2 expression are decreased, PGI2 synthase is nitrated/
inactivated due to huge amounts of ROS and peroxynitrite from infiltrated leukocytes and endothelial
dysfunction, at least in the larger vessels, is observed. At this time point (upon loss of vasodilators),
enhanced thrombosis is encountered [30], as also observed in our LPS treated mice [10]. The relevance
of microthrombi formation (disseminated intravascular coagulation) for the prognosis of septic
patients was also demonstrated by an increased mortality of septic patients with reduced numbers of
circulating platelets (thrombocytopenia) [31], as also observed in our LPS treated rats and mice [10,11].
This represents another hint for the loss of the potent antiaggregatory compounds PGI2 and •NO.
Therefore, the impaired vascular function observed in our previous studies, in vessels from LPS-treated
rats and mice, is in good accordance with the clinical and experimental time response of sepsis [8,10,11].
For LPS-treated rats previous studies have shown substantial hypotension at 6 h after LPS treatment
and increase in mean arterial pressure afterwards [19,32]. This would be in good accordance with the
here postulated third phase of sepsis, characterized by impaired vascular relaxation and even a mild
hypertension (at least restricted to certain vessel areas or organs) as well as the previously reported
increased endothelin-1 levels can be observed in the late phase of sepsis.
Previous studies from our group and others show that median survival of C57/Bl6j mice upon i.p.
injection of 10 mg/kg LPS is approximately 20 h after injection, whereas the median survival rate of
Wistar rats challenged with the same amount of LPS intra peritoneal was shorter (6–10 h) [8,11,33].
Interestingly, mRNA levels of inflammatory makers like VCAM-1, IL-6, and TNF-α were significantly
higher and had an earlier peak (IL-6 and VCAM-1) in mice as compared to rats, which reflects a
stronger and earlier inflammatory response in mice compared to rats. However, the time response and
absolute level of nitrosative/oxidative stress rather showed an opposite pattern. In both species WBC
count in whole blood decreased significantly after 3 h of LPS treatment, but only in rats the number of
WBC recovered significantly. Interestingly, the absolute WBC-derived oxidative burst was significantly
higher in rats when compared to mice at 0, 3, 9, and 12 h points in time.
NO mediates several beneficial effects like vasodilation, inhibition of platelet aggregation,
anti-inflammatory and anti-apoptotic effects via activating soluble guanylate cyclase (sGC) [34]. In the
setting of septic shock excessive generation of •NO by the iNOS in combination with excessive
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production of superoxide (O2•−) by NADPH oxidase of WBC leads to generation of peroxynitrite
(ONOO−). The latter is capable to affect enzyme function by oxidation or nitration, induces cell damage
by lipid peroxidation, and attacks mitochondrial enzymes leading to mitochondrial dysfunction [35].
Our data demonstrate in detail, that •NO generation in total is significantly higher in rats 6 h after
induction of sepsis, which was due to increased expression of iNOS in WBC and vascular tissue.
Together with the high burden of superoxide generation a strong peroxynitrite footprint was detectable
by immunohistochemical staining of vascular tissue. Taken together, the burden of peroxynitrite
formation in rats was higher than in mice.
4. Materials and Methods
4.1. Materials
The Bradford reagent was obtained from BioRad (Munich, Germany). The QuantiTect probe
RT-PCR Kit was purchased from Qiagen (Hilden, Germany). All TaqMan probes were purchased
from Applied Biosystems (Darmstadt, Germany). L-012 (8-amino-5-chloro-7-phenylpyrido[3,4-d]
pyridazine-1,4-(2H,3H)dione sodium salt) was purchased from Wako Pure Chemical Industries (Osaka,
Japan). For the induction of septic shock, we used LPS from Salmonella Thyphosa from Sigma-Aldrich
(St. Louis, MO, USA). All of the other chemicals were of analytical grade and were obtained from
Sigma-Aldrich, Fluka (St. Louis, MO, USA) or Merck (Darmstadt, Germany).
4.2. Animals and In Vivo Treatment
All of the animal care and experimental procedures were in accordance with the Guide for the
Care and Use of Laboratory Animals as adopted by the US National Institutes of Health, and approved
by the Ethics Committee of the University Medical Center Mainz and the Landesuntersuchungsamt
Koblenz (#23 177-07/G 14-1-039, 12 June 2014). In this study, a total number of 30 C57BL/6j mice
and 30 Wistar rats received single injection of LPS intraperitoneally at a dosage of 10 mg/kg for
both species. Animals of both species were divided into five groups, six animals each, and sacrificed
by exsanguination under isoflurane anesthesia (5% inhalant in room air) at 0, 3, 6, 9, and 12 h after
injection of LPS. All C57BL/6j mice were male, and weighed 25–30 g at the time of the experiment.
All of the Wistar rats were male, and weighed 270–330 g at the time of the experiment.
4.3. Chemiluminescence-Based Detection of Oxidative Stress in Whole Blood
Whole blood oxidative burst mainly reflects leukocyte NADPH oxidase and myeloperoxidase
activity, and was used as a global readout of the burden of oxidant formation as well as of the activation
state of inflammatory pathways. To measure whole blood leukocyte-dependent ROS formation, fresh
blood (in citrate tubes) was stimulated with phorbol ester PDBu (10 μM) or the fungal endotoxin
zymosan A (50 μg/mL) and assessed in PBS containing Ca2+/Mg2+ (1 mM) by L-012 (100 μM)
enhanced chemiluminescence (ECL) using a Centro chemiluminescence plate reader from Berthold
Technologies (Bad Wildbad, Germany) [8].
4.4. Quantification of Nitrosyl-Iron Hemoglobin in Whole Blood by Electron Paramagnetic Resonance
(EPR) Spectroscopy
NO synthesis and the burden of nitrosative stress were also assessed by the EPR-based detection
of Hb-NO. Samples of venous blood for Hb-NO/EPR studies were obtained by the puncture of
the right heart of anesthetized mice and rats; blood samples were immediately frozen and stored
in liquid nitrogen. The EPR measurements were carried out at 77 K using an X-band table-top
spectrometer MS400 from Magnettech (Berlin, Germany). The instrument settings were as follows:
10 mW microwave power, 7000 mG amplitude modulation, 100 kHz modulation frequency, 3300 G
center field, 300 G sweep width, 60 s sweep time and three scans, as described before [11].
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4.5. Isolation of White Blood Cells
The procedure was described before [36]. Briefly, erythrocytes in mice and rat blood were
separated by sedimentation in 15 mL heparin-supplemented tubes after addition of an equal volume
of dextran solution (MW 485,000, T500 9219.1 from Roth). 1.9 g dextran were dissolved in 50 mL
0.9% NaCl solution. The leukocyte-containing supernatant was centrifuged on Histopaque-1083 from
Sigma Aldrich for 30 min at 500× g at 20 ◦C, resulting in a neutrophil (PMN)-containing pellet and
the monocyte/lymphocyte-enriched (WBC) “buffy coat” between the aqueous and Ficoll phases.
The WBC fraction was collected and purified by further centrifugation for 10 min at 500× g, followed
by resuspension in PBS. The PMN pellet was freed from residual erythrocytes by hypotonic lysis in
distilled water and centrifugation at 500× g (two to three times). The total blood cell count and the
purity of the fractions were evaluated using an automated approach using a hematology analyzer
KX-21N from Sysmex Europe GmbH (Norderstedt, Germany). Typical content of WBC in each fraction
was previously published [37].
4.6. Western Blot Analysis
Isolated white blood cell proteins from mice and rats were separated by 7.5% SDS-PAGE under
reducing conditions. After blotting on a nitrocellulose membrane, immunoblotting was accomplished
using antibodies against β-actin (rabbit, monoclonal, 1:2500, Sigma-Aldrich, Seelze, Germany), and
iNOS (purified anti iNOS, mouse, monoclonal, 1:2500, BD Biosciences, Franklin Lakes, NJ). Detection
was accomplished with either Super Signal Substrate (Pierce, Rockford, IL, USA) or ECL Reagent
(Amersham, Piscataway, NJ, USA). Bands were evaluated by densitometry.
4.7. Reverse Transcription Real-Time PCR (qRT-PCR)
mRNA expression was analyzed with quantitative real-time RT-PCR, as previously described [38].
RNA from aorta and white blood cells was isolated in both species for the experiments. Briefly, total
RNA from mouse and rat aorta, and from isolated whole blood cells of mice and rats was isolated
(RNeasy Fibrous Tissue Mini Kit; Qiagen, Hilden, Germany), and 50 ng RNA was used for real-time
RT-PCR analysis with the QuantiTect Probe RT-PCR kit (Qiagen). TaqMan® gene expression assays
for vascular cell adhesion molecule 1 (VCAM-1), the cytokine interleukin 6 (IL-6), the adhesion molecule
P-selectin, the immune-signaling protein tumor necrosis factor-α (TNF-α), as well as the house keeping
gene TATA-box binding protein (TBP) were purchased as probe-and-primer sets (Applied Biosystems,
Foster City, CA) for mice and rats. TaqMan® gene expression assays for leukocyte marker CD68 in
mice and macrophage-1 antigen also known as CD11b in rats from the same provider were also tested.
The comparative Delta Ct method was used for relative mRNA quantification. Gene expression was
normalized to the endogenous control, TBP mRNA, and the amount of target gene mRNA expression
in each sample was expressed relative to that of control for every species.
4.8. Immunohistochemistry and Fluorescence Microscopy
For immunohistochemistry aorta segments from rats and mice were fixed in paraformaldehyde
(4%) and embedded in paraffin. Aortic segments from both species were stained with primary
antibodies against 3-nitrotyrosine (Millipore, Burlington MA, USA). Mouse aortic segments were
also stained with primary antibodies against F4/80 (eBioscience) and rat aortic segments were also
stained for CD68 (LS Bio, Seattle, WA, USA). Anti-rat, anti-rabbit, and LSAB (Vector; Sigma; DAKO,
Glostrup, Denmark, respectively) were used as secondary antibodies. For immunohistochemical
detection ABC reagent (Vector, Burlingame, CA, USA) and then DAB reagent (peroxidase substrate
Kit, Vector, Burlingame, CA, USA) were used.
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4.9. Statistical Analysis
Results are expressed as mean ± SEM. Two-way ANOVA (with Holm-Sidak’s correction for
comparison of multiple means) was used for comparisons of time responses of WBC, mRNA
expression (VCAM-1, P-selectin, IL-6, TNF-α), HbNO-levels and oxidative burst. One-way ANOVA
(with Bonferroni’s correction for comparison of multiple means) was used for comparisons of mRNA
expression (CD11b, CD68) and iNOS protein levels. p values < 0.05 were considered as statistically
significant. All of the statistical analyses were performed using GraphPad Prism 6.0d.
5. Conclusions
Human sepsis is poorly understood and more research is needed to understand the pathomechanisms.
Sepsis studies are often performed in different species (mice and rats) and even different strains
(C57Bl6/j, BALB/c, A/J) challenged with LPS or CLP-procedure and the results are compared to each
other. Nevertheless, the models are poorly characterized, especially with respect to time responses
for the entire set of parameters. With the present study, we present species specific, time-dependent
changes of regulators of cell activation, inflammation, and oxidative/nitrosative stress in mice and rats
after LPS-challenge. Based on our present findings, the survival of endotoxaemic animals might rather
be related to suppression of oxidative/nitrosative stress than to complete suppression of inflammatory
responses. These data can help to interpret sepsis studies performed in models of LPS-induced
endotoxaemia in mice and rats and translate these data to the human setting. Based on this study,
further time- and species-dependent characterization of sepsis relevant parameters like hemostasis,
vascular function, or immune cell differentiation and recruitment should be conducted.
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Abstract: Metabolic endotoxemia contributes to low-grade inflammation in obesity, which causes
insulin resistance due to the activation of intracellular proinflammatory pathways, such as
the c-Jun N-terminal Kinase (JNK) cascade in the hypothalamus and other tissues. However,
it remains unclear whether the proinflammatory process precedes insulin resistance or it appears
because of the development of obesity. Hypothalamic low-grade inflammation was induced by
prolonged lipopolysaccharide (LPS) exposure to investigate if central insulin resistance is induced by
an inflammatory stimulus regardless of obesity. Male Wistar rats were treated with single (1 LPS)
or repeated injections (6 LPS) of LPS (100 μg/kg, IP) to evaluate the phosphorylation of the insulin
receptor substrate-1 (IRS1), Protein kinase B (AKT), and JNK in the hypothalamus. Single LPS
increased the expression of pIRS1, pAKT, and pJNK, whereas the repeated LPS treatment failed to
recruit pIRS1 and pAKT. The 6 LPS treated rats showed increased total JNK and pJNK. The 6 LPS rats
became unresponsive to the hypophagic effect induced by central insulin administration (12 μM/5 μL,
ICV). Prolonged exposure to LPS (24 h) impaired the insulin-induced AKT phosphorylation and
the translocation of the transcription factor forkhead box protein O1 (FoxO1) from the nucleus
to the cytoplasm of the cultured hypothalamic GT1-7 cells. Central administration of the JNK
inhibitor (20 μM/5 μL, ICV) restored the ability of insulin to phosphorylate IRS1 and AKT in 6 LPS
rats. The present data suggest that an increased JNK activity in the hypothalamus underlies
the development of insulin resistance during prolonged exposure to endotoxins. Our study reveals
that weight gain is not mandatory for the development of hypothalamic insulin resistance and
the blockade of proinflammatory pathways could be useful for restoring the insulin signaling during
prolonged low-grade inflammation as seen in obesity.
Keywords: LPS tolerance; hypothalamic inflammation; insulin resistance; pJNK
1. Introduction
Chronic low-grade inflammation is associated with leptin and insulin resistance, which contributes
to the establishment of obesity and its comorbidities, such as type 2 diabetes, cancer, and cardiovascular
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diseases [1]. We have previously demonstrated that low-grade inflammation induced by repeated
injections of the Gram-negative bacterial lipopolysaccharide (6 daily doses of LPS) induces tolerance
to the hypophagic effect of the endotoxin [2,3]. The endotoxin failure to reduce food consumption
and body weight in LPS-tolerant rats is associated with unresponsiveness to leptin to phosphorylate
the signal transduction and activator of transcription 3 (pSTAT3) protein in the hypothalamic nuclei
crucial for the control of the energy homeostasis, such as the paraventricular (PVN) and arcuate
(ARC) nuclei [2]. Despite the unresponsiveness to leptin in rats treated with six daily doses of LPS,
these animals do not show body weight change as opposed to an increase of body weight and fat
mass seen in rats after seven days of a high fat diet regimen [4]. Hence, repeated exposure to LPS
might be a useful approach to dissociate the impact of the low-grade inflammation that precedes
the increased adiposity signals on the development of peripheral and hypothalamic resistance seen
in obesity.
The central infusion of insulin induces a negative energy balance comparable to the central
administration of leptin [5]. The appetite-suppressive and weight-reducing effects of insulin have been
shown in both rodents and primates [6,7]. These effects are supported by the presence of the insulin
receptor (IR) and the expression of intracellular components of the insulin signaling, the insulin
receptor substrate 1 (IRS-1), and the phosphoinositide 3-kinase (PI3K) pathway-induced proteins
in the hypothalamus [8–11]. The PI3K pathway is recruited by both insulin and leptin in the control of
energy homeostasis. Pharmacological blockade of PI3K prevents the suppression of food consumption
induced by intracerebroventricular (ICV) administration of both leptin and insulin [10,12]. The PI3K
pathway also plays a role in the hypophagia acutely induced by LPS [13]. However, the impact of
low-grade inflammation induced by prolonged LPS exposure on central insulin signaling has not
been addressed.
Hypothalamic insulin resistance may be evoked by inflammatory stimuli [14,15] via the activation
of intracellular proinflammatory pathways that increase the expression of intermediate proteins
like Jun NH2-terminal kinase (JNK), protein tyrosine phosphatase 1B (PTP1B), inhibitor of nuclear
factor kappa kinase (IKK), and endoplasmic reticulum stress [16–19]. Increased expression of these
intermediates of cytokine signaling induces insulin resistance via the alteration of IR activation and
expression, as well as by increasing the phosphorylation of the IRS-1 in serine residues, which impairs
insulin signal transduction [14,15]. The JNK is a serine kinase activated by cytokines and free fatty
acids [15,19,20] and increased JNK activity in the hypothalamus was observed in High fat diet (HFD)
fed animals [16,21]. Reinforcing the role of JNK in the development of hypothalamic insulin resistance
in HFD fed rodents, mice with JNK1 deficiency in the brain exhibit improved insulin sensitivity in both
central and peripheral tissues, preventing adipose tissue dysfunction and hepatic steatosis under HFD
feeding [21].
Despite the evident association between obesity and insulin resistance and the activation of
the JNK-mediated inflammatory pathway, it remains unclear whether the activation of this pathway
precedes the development of obesity in HFD fed animals. To circumvent this challenge, we used
prolonged LPS treatment to induce low-grade inflammation and to investigate whether the repeated
exposure to endotoxins might increase JNK phosphorylation and cause hypothalamic insulin resistance,
independently on the development of obesity. To further address the effect of endotoxins on insulin
signaling in neurons, we used cultured GT1-7 cells treated with LPS.
2. Results and Discussion
2.1. Acute, but Not Prolonged Endotoxemia, Promotes Insulin Secretion and Activates Insulin Signaling
Cascades. Short and Long-Term LPS Exposure Increases N-Terminal Kinase (JNK) Phosphorylation
in the Hypothalamus
To evaluate whether long-term endotoxemia stimulates insulin secretion and insulin signaling
in the hypothalamus, rats were treated with repeated LPS injections in comparison with single LPS
treatment. Plasma insulin levels were increased 4 h after single, but not repeated LPS treatment
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(Figure 1A). Coupled to this response, glucose levels were reduced in single LPS treated rats
(Figure 1B) at that time. Insulin secretion following acute LPS administration has been previously
described [22]. The release of insulin during the infection process is an adaptive response to the increased
production of cytokines [22–24]. Because repeated exposure to endotoxins leads to a desensitization of
the neuroendocrine and immunological systems [25], the unaltered insulin levels in the 6 LPS group,
compared with the controls, indicates a tolerance to the LPS effects.
Figure 1. Acute, but not prolonged endotoxemia, increases plasma insulin and reduces glucose levels.
Plasma insulin (A) and glucose (B) levels in saline (6 saline), single (5 saline + 1 LPS, 100 μg/kg ip),
or repeated lipopolysaccharide (6 LPS) treated-animals. The representative results of two independent
experiments (n = 6–8/group) are shown with the measurements performed with samples from the same
animal. One-way ANOVA, followed by the Fisher post hoc test were performed. Data are expressed as
means ± SE. Differences were accepted as significant at * p < 0.05.
Evaluating the activation of insulin signaling, increased phosphorylation of the IRS-1 at the tyrosine
1222 residue and Protein kinase B (AKT) at the serine 473 and T308 residues in the hypothalamus of
the single LPS group were observed, but not in repeated LPS treated rats (Figure 2A,B,E), confirming
that acute LPS activates the insulin signaling pathways in the hypothalamus. A previous study from our
group [13] reported the phosphorylation of AKT in leptin receptor-expressing neurons in the ARC of
mice after acute LPS treatment. As leptin and insulin receptors partly colocalize in the ARC neurons [26],
it is reasonable to postulate that an inflammatory stimulus is likely to increase phosphorylation
of IRS-1/AKT proteins both in response to leptin and insulin. At present, it was not possible
to determine if the single LPS treatment increases insulin signaling per se or if this is an indirect
effect mediated by the LPS-induced cytokines, as the expression of Toll-like receptor 4 in neurons
is not established [27]. The direct role of endotoxins in the activation of insulin signaling cascades
deserves further investigation. Interestingly, as opposed to the 1 LPS group, 6 LPS treated rats did not
show increased pIRS-1 and pAKT, supporting our hypothesis that prolonged endotoxemia induces
hypothalamic failure to activate insulin signaling proteins.
Insulin resistance can be induced by the increased expression of several kinases that inhibit
the eIRS-PI3K-AKT pathways, including JNK. JNK proteins are known to be recruited by LPS
as well as during HFD feeding [16,28]. JNK activation increases spontaneous action potential
firing of hypothalamic Agouti related peptide (AgRP) expressing neurons and induces both central
and peripheral leptin resistance [29]. The phosphorylation of JNK impairs the phosphorylation
of tyrosine residues of the IRS-1 and subsequently inhibits AKT activation by insulin in HFD fed
rodents [16]. In the present study, prolonged LPS exposure increased both total JNK expression and
JNK phosphorylation in the hypothalamus, whereas acute LPS treatment increased only Phospho-c-Jun
N-terminal Kinase (pJNK) expression (Figure 2C,D). It is important to highlight that the increased
pJNK expression induced by 6 LPS injection was significantly higher than that induced by the single
LPS treatment (Figure 2D). Taken together, these findings suggest that hypothalamic unresponsiveness
to insulin during a low-grade inflammation challenge could be due to a higher JNK activation.
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Figure 2. Acute endotoxemia increases phosphorylation of insulin signaling proteins whereas
prolonged endotoxemia induces higher expression of the inhibitor of insulin cascade signaling,
c-Jun N-terminal Kinase (JNK). Percentage of Phospho-Insulin receptor substrate-1 (pIRS1) (A),
Phospho-Protein kinase B (pAKT) (B), JNK (C), and Phospho-c-Jun N-terminal Kinase (pJNK) (D)
expression in the mediobasal hypothalamus of saline (6 saline), single (5 saline + 1 LPS, 100 ug/kg ip),
or repeated LPS (6 LPS) treated-animals. The representative results of two independent experiments
(n = 6–8/group) are shown with the measurements performed with samples from the same animal.
One-way ANOVA, followed by Fisher post hoc test was performed. Data are expressed as means ± SE.
Differences were accepted as significant at * p < 0.05; (E) representative photomicrographs showing
the pAKT T308 expression (green) in neurons from the arcuate (ARC) nucleus of the hypothalamus of
animals treated with 6 saline, 5 Saline + 1 LPS, and 6 LPS injections. 3V, third ventricle. Objective: 40×.
2.2. Hypophagic Effect of Central Insulin Injection Is Blunted in Acute and Prolonged
Lipopolysaccharide—Treated Rats
Hypothalamic leptin and insulin resistance are important in the pathophysiology of obesity
after high fat feeding and they have been associated with hypothalamic inflammation. In HFD fed
animals, the hypothalamic inflammation characterized by the production of cytokines and activation
of the microglia precedes the weight gain, the peripheral fat accumulation, and the development of
insulin resistance [4]. Insulin receptors are expressed in hypothalamic neurons of the melanocortin
system [30] and insulin treatment increases proopiomelanocortin (POMC) and decreases Agouti-related
peptide (AgRP)/neuropeptide Y (NPY) expression in the hypothalamus through the activation of
the IRS-PI3K-AKT pathway [30–32], inhibiting feeding responses. Neuronal IR knockout mice are obese
and sensitive to HFD [33], reinforcing the important role of central insulin action in the regulation of
energy homeostasis.
We then tested if prolonged endotoxemia could cause central insulin resistance independent of
changes in the body weight and in the peripheral sensitivity to insulin. According to previous reports,
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ICV insulin administration causes hypophagia [6,7]. As expected, we reproduced these findings
given that central insulin administration inhibited food intake in saline treated rats (Figure 3A).
The single LPS group displayed a reduced food intake and weight gain (Figure 3B), which were not
further reduced by central insulin treatment. This result indicates that acute LPS treatment recruits
the signaling cascade common to insulin signaling, as seen by the increased IRS-1 and AKT
phosphorylation after the single endotoxin injection. On the other hand, 6 LPS rats, which present
no altered food intake and weight gain, were not sensitive to the hypophagic effect of central insulin,
suggesting that LPS-tolerant rats are centrally resistant to insulin (Figure 3).
Figure 3. Prolonged endotoxemia induces resistance to the hypophagic effect of icv insulin treatment.
Effect of icv injection of vehicle (saline, 5 μL) or insulin (12 μM in 5 μL) on food intake (A) and body
weight gain (B) in saline (6 saline), single (5 saline + 1 LPS, 100 ug/kg ip), or repeated LPS (6 LPS)
treated-animals (6–8 animals per group). The representative results of two independent experiments
(n = 6–8/group) are shown. Two-way ANOVA, followed by the Fisher post hoc test were performed.
Data are expressed as means ± SE. Differences were accepted as significant at * p < 0.05.
2.3. Prolonged LPS Treatment Blocks Insulin-Induced Protein Kinase B (AKT) Phosphorylation in the Culture
of Neuronal Cells
As previously mentioned, the expression of toll-like receptors in neurons is undetermined [27].
However, it was reported that the GT1-7 cell line, derived originally from immortalized hypothalamic
neurons, expresses toll like receptors and presents increased interleukins and tumor necrosis factor
(TNF)-α mRNA expression after inflammatory stimulus with LPS [34]. To confirm whether long-term
exposure to LPS impairs insulin signaling in neurons, we performed in vitro experiments in which
we treated GT1-7 cells with LPS for short (30′) or long (24 h) periods, followed by treatment with
insulin. LPS at both 30′ and 24 h did not induce pAKT expression in GT1-7 cells. As expected, cultured
cells exhibited an increased AKT phosphorylation at both the S473 and T308 residues after insulin
treatment. Short-term exposure to LPS (30 min) did not affect insulin-induced pAKT in these cells.
Remarkably, prolonged LPS exposure (24 h) impaired the phosphorylation of AKT in both residues
after insulin treatment (Figure 4). Activation of the IRS-PI3K-AKT pathway by insulin culminates
with the sequestration of the Forkhead box protein O1 (FoxO1) into the cytoplasm, due to FoxO1
phosphorylation. FoxO1 mediates the anorectic effects of leptin and insulin in the ARC by regulating
the transcription of POMC and AgRP [35]. We performed an in vitro qualitative study to evaluate
the FoxO1 subcellular localization in GT1-7 cells under short- or long-term LPS exposure. In control
cells, FoxO1 (green) is widely expressed in the whole cell. After insulin treatment, both control
and LPS treated cells (30′) present a qualitatively higher FoxO1 expression predominantly located
in the cytoplasm, as evidenced by a clear red DAPI nuclear staining. Short-term LPS treatment did not
change FoxO1 expression/distribution in the GT1-7 cells, nor insulin-induced FoxO1 translocation
from the nucleus to the cytoplasm. Interestingly, prolonged LPS treatment impaired the ability of
insulin to induce the translocation of FoxO1 from the nucleus to the cytoplasm (Figure 5), evidencing
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the absence of insulin-induced phosphorylation and translocation of this protein to the cytoplasm.
These data strongly suggest that low-grade inflammation induced by prolonged exposure to endotoxins
impairs insulin signaling and leads to insulin resistant-like phenomena in the neurons.
 
Figure 4. Prolonged exposure to LPS impairs insulin signaling in hypothalamic neurons in vitro.
Percentage of pAKT S473 (A) and pAKT T308 (B) in the mouse GT1–7 cell line after saline (control),
short (30′) LPS (1 μg/mL), insulin (100 mM/mL), or LPS (30′) + insulin treatment. Percentage of pAKT
S473 (E) and pAKT T308 (F) in the mouse GT1–7 cell line after saline (control), prolonged (24 h) LPS
(1 μg/mL), insulin (100 mM/mL), or LPS (24 h) + insulin treatment. In Vitro experiments were performed
in 3–4 different assays. One-way ANOVA, followed by the Fisher post hoc test were performed.
Data are expressed as means ± SE. Differences were accepted as significant at * p < 0.05.
 
Figure 5. Prolonged LPS treatment impairs the ability of insulin to translocate Forkhead box protein O1
(FoxO1) from the nucleus to the cytoplasm. Representative photomicrograph of the qualitative FoxO1
immunostaning in the mouse GT1-7 cell line after short (30′) LPS (1 μg/mL), insulin (100 mM/mL),
LPS (30′) + insulin, prolonged (24 h) LPS, or LPS (24 h) + insulin treatment. FoxO1 expression is in green
and DAPI nuclear expression is in red. Scale bar: 20 μm.
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2.4. Central JNK Inhibition Restores the Hypothalamic Insulin Responsiveness in Rats Exposed to Repeated
LPS Injections
Since JNK causes insulin resistance and we have observed a higher expression of this kinase
in the hypothalamus of 6 LPS treated rats, we investigated if we could alleviate the hypothalamic
insulin resistance inhibiting the JNK activity. No effect of the selective JNK inhibitor SP600125
was observed in saline or single LPS treated animals (Figure 6A). Remarkably, JNK inhibition restored
the hypophagic effect of LPS in 6 LPS tolerant rats. Additionally, there was no further hypophagia
in 6 LPS animals treated with SP600125 after stimulation with central insulin (Figure 6A). Body weight
was not affected by JNK inhibition (Figure 6B). The data support the hypothesis that JNK plays a role
in the tolerance to the hypophagic effect of LPS during prolonged endotoxemia.
Figure 6. JNK inhibitor treatment restores the hypophagic effect of icv insulin treatment in 6 LPS-treated
animals as well as restores the ability of icv insulin to phosphorylate IRS1 and AKT in 6-LPS treated
rats. Effect of icv injection of vehicle (saline, 5 μL) or insulin (12 μM in 5 μL) on food intake (A) and
body weight gain (B) in saline (6 saline), single (5 saline + 1 LPS, 100 ug/kg ip), or repeated LPS (6 LPS)
treated-animals (6–8 animals per group) previously treated with icv injection of vehicle (saline, 5 μL) or
SP600125 (20 μM in 5 μL). The representative results of three independent experiments (n = 6–8/group)
are shown. Three-way ANOVA, followed by the Fisher post hoc test were performed. Data are expressed
as means ± SE. Differences were accepted as significant at * p < 0.05. a vs. 6 saline + vehicle + saline,
b vs. 6 saline + SP600125 + saline, c vs. 6 LPS + vehicle + Insulin, d vs. 6 LPS + vehicle + saline and
e vs. 1 LPS + vehicle + Insulin. Graphs (C,D) show the percentage of pIRS-1 and pAKT expression,
respectively, in the mediobasal hypothalamus of repeated LPS (6 LPS) treated-animals that received
an icv injection of vehicle (saline, 5 μL) or insulin (12 μM in 5 μL) and were previously treated with
an icv injection of vehicle (saline, 5 μL) or SP600125 (20 μM in 5 μL). The representative results of
two independent experiments (n = 6–8/group) are shown with the measurements performed with
samples from the same animal. One-way ANOVA, followed by the Fisher post hoc test were performed.
Data are expressed as means ± SE. Differences were accepted as significant at * p < 0.05.
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To verify if the reversion of hypophagia in LPS tolerant rats after JNK inhibition was associated
with a recovery of the hypothalamic ability to promote insulin signaling, we assessed the expression
of pIRS1 and pAKT in the 6 LPS group. Insulin-induced phosphorylation of both IRS1 and AKT
was higher in the 6 LPS rats treated with SP600125, compared with the other groups. Interestingly,
in the 6 LPS group the JNK inhibitor restored the hypophagic effect of the endotoxin, despite no
changes in the activation of insulin signaling proteins. Since it was recently demonstrated that
JNK inhibition was able to sensitize leptin’s anorectic effect by increasing leptin-induced STAT3
activation and SOCS3 downregulation in the hypothalamus of DIO animals [36], we propose that
the activation of alternative pathways not investigated in our study might account for the restoration
of the hypophagia. Interestingly, the JNK inhibitor restored the insulin signaling in 6 LPS tolerant
rats (Figure 6C,D), reinforcing the role of JNK in the development of insulin resistance during
low-grade inflammation. Supporting our results, JNK1 ablation in the CNS improves hypothalamic
and systemic insulin sensitivity in mice fed with HFD [21,37]. Administration of the JNK selective
inhibitor SP600125 restored the insulin signaling in HFD obese rats [16]. Therefore, our study
demonstrates the involvement of the intracellular pro-inflammatory JNK pathway in the development
of hypothalamic insulin resistance during prolonged endotoxemia. Our data also suggest that insulin
sensitivity can be restored through treatment with drugs that selectively inhibit this intracellular
pro-inflammatory pathway.
3. Material and Methods
3.1. Animals
Adult male Wistar rats weighing 220–250 g (Central Animal Facility of the University of
Sao Paulo-Campus Ribeirao Preto) were individually housed under controlled light (12:12 h light-dark
cycle; lights off at 06:00 p.m.) and temperature conditions (23 ± 1 ◦C), with free access to water and
food, unless otherwise stated. Food consumption and body weight were recorded daily between
03:30–04:00 p.m. Rats were acclimated to the procedures of drug administration during the experiments
by daily handling.
All procedures for the care and use of animals were approved by the Ethical Committee for
Animal Use of the Ribeirao Preto Medical School (027/2011, 28 March 2011).
3.2. Experimental Procedures
3.2.1. Effect of Single or Repeated LPS Injections on Plasma Insulin and Glucose Levels, as Well as
in the Hypothalamic Content of Insulin Signaling Proteins
Rats were assigned into three groups (n = 6–8/group): (1) saline once daily for 6 days (6 Saline),
(2) saline once daily for 5 days and an injection of LPS on the 6th day (5 Saline + 1 LPS), and (3) LPS
once daily for 6 days (6 LPS). Rats received saline (0.15 M NaCl, 1 mL/kg) or LPS (100 μg/kg, 1 mL/kg;
Serotype 026:B6; Sigma, St. Louis, MO, USA) by an intraperitoneal (IP) injection at 04:00 p.m. On the 6th
day of injection, food was withdrawn at 04:00 p.m. One set of animals was decapitated 2 h and another
one was decapitated 4 h after treatments, for trunk blood collection for plasma insulin and glucose
determination. We also collected the brains 2 h after treatments, for hypothalamic determination of
the pIRS-1, pAKT, and pJNK by Western blotting. Another set of rats were submitted to the treatment
described above and were perfused 2 h after injections for a qualitative analysis of the pAKT expression
in the ARC by immunofluorescence.
3.2.2. Effect of Central Insulin Administration (ICV) Insulin Administration in Rats Treated with
Single or Repeated LPS Injections on Food Intake and Body Weight
One week before the experiment, a cannula was placed in the lateral ventricle of the rats that
were then treated as previously described (6 Saline, 5 Saline + 1 LPS, and 6 LPS). On the day of
the experiment, at 04:00 p.m., food was withdrawn and the animals were weighed and received
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the last injection (saline or LPS). Forty-five min after the saline or LPS injection, half of each group
received an ICV injection of vehicle (saline, 5 μL) or insulin (12 μM in 5 μL; Sigma, St. Louis, MO, USA)
and after 30 min food was reoffered (n = 6–8/group). Food consumption and body weight changes
were assessed 2 and 14 h after food replacement, respectively.
3.2.3. Effect of Short and Prolonged LPS Treatment on Insulin Signaling in GT1-7 Cells
To address whether neuronal insulin signaling is affected by short (30′) or prolonged (24 h) LPS
treatment, we performed in vitro experiments using the mouse cell line GT1–7 (kindly provided by
Pamela Mellon, University of California, San Diego, CA, USA), derived originally from immortalized
GnRH hypothalamic neurons. These cells were shown to be responsive to both insulin and LPS
treatment [34]. The cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Gibco-Invitrogen,
Carlsbad, CA, USA), containing 10% fetal bovine serum and penicillin-streptomycin and maintained
at 37 ◦C in 5% CO2. In Vitro experiments were performed in 3–4 different assays. GT1-7 cells
were subjected to experimental conditions after 3 days in culture, when the cells were 90% confluent.
4 h before treatment, the cells were kept in serum free medium and then treated with vehicle (sterile
PBS), LPS (1 μg/mL) for 30 min, insulin (100 nM/mL) and LPS (1 μg/mL) for 30 min, followed by
insulin (100 nM/mL) for 30 min. Another set of GT1-7 cells culture was treated with vehicle or LPS
(1 μg/mL) for 24 h, followed by treatment with vehicle or insulin (100 nM/mL) for 30 min. At the end
of the incubations, cells were harvested and Western blottings for AKT, pAKT, and GAPDH proteins
were performed. To qualitatively evaluate the pattern of expression/distribution of the insulin-induced
expression of the transcription factor forkhead box protein O1 (FoxO1) in LPS treated cells, GT1-7 cells
were cultured overnight on glass coverslips coated with poly-L-Lysine for immunocytochemistry.
3.2.4. Effect of JNK Inhibition on Food Intake and Body Weight Measurements after ICV Insulin
Administration in Rats Treated with Single or Repeated LPS Injections.
Rats implanted with a cannula in the lateral ventricle (n = 6–8/group) were assigned into
the experimental groups (6 Saline, 1 LPS and 6 LPS) as described above. On the day of the experiment,
food was removed at 04:00 p.m. and the rats from each group were ICV pre-treated with vehicle
(saline, 5 μL) or JNK inhibitor (20 μM in 5 μL; Tocris, Ellisville, MO, USA), followed 105 min after by
vehicle (saline, 5 μL) or insulin (12 μM in 5 μL) ICV injection. Food was reoffered 30 min after vehicle
or insulin injection. Food consumption and body weight gain were assessed 2 and 14 h after food
replacement, respectively.
3.2.5. Effects of JNK Inhibition on Hypothalamic Insulin Signaling in Rats Treated with Repeated
LPS Injection
To evaluate whether JNK inhibition might restore the insulin signaling in the hypothalamus of
6 LPS treated rats, animals (n = 6–8/group) were implanted with a cannula in the lateral ventricle.
On the 6th day, at 04:00 p.m. the rats received the last IP injection of LPS and 30 min after they
received an ICV injection of vehicle (0.2% Dimethyl sulfoxide (DMSO) in 5 μL saline) or JNK inhibitor
(20 μM in 5 μL; Tocris Co.: Ellisville, MO, USA). Thereafter, the rats received an ICV injection of vehicle
or insulin 105 min after saline or LPS injection. Fifteen min after vehicle or insulin injection, the animals
were decapitated and the brains were harvested for hypothalamic pIRS-1 and pAkt measurements by
Western blotting.
3.3. Cannula Implantation in the Lateral Ventricle
Rats were anesthetized with a mixture of ketamine (60 mg/kg) and xylazine (7.5 mg/kg)
at a volume of 0.1 mL/100 g and placed in a stereotaxic instrument (model 900, David Kopf Instruments:
Tujunga, CA, USA). A stainless-steel guide cannula (10 mm) was implanted into the right lateral
ventricle of the brain. We used the following stereotaxic coordinates: AP = −0.6 mm, LL = −1.5 mm,
and depth = −3.6 mm from bregma. The cannula was held in place with two stainless-steel screws
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and dental acrylic resin on the skull. To prevent occlusion of the guide cannula, a 30-gauge metal
wire filled the cannula. After surgery, the rats received a prophylactic injection of penicillin (50,000 U,
intramuscular). The placement of the cannula was confirmed at the end of the experiment by
histological analysis.
3.4. Western Blotting Analysis of Mediobasal Hypothalamus
The mediobasal hypothalamic protein was extracted using Triton-X 100 (1%), Tris-HCl
pH 7.4 (100 mM), sodium pirofosfate (100 mM), sodium fluoride (100 mM), EDTA (10 mM),
sodium ortovanadate (10 mM), PMSF (2 mM), aprotinin (0.2 mg/mL), and leupeptin (0.2 mg/mL),
at 4 ◦C, 15,000× g for 40 min. Aliquots of the lysates containing 50 μg of protein were denatured
in Laemmli sample buffer (6% SDS, 30% glycerol, 0.02% bromophenol blue, 200 mm Tris-HCl (pH 6.8),
and 250 mm mercaptoethanol), at 95 ◦C for 5 min. Samples were blotted onto a nitrocellulose
membrane. Nonspecific binding was prevented by immersing the membranes in blocking buffer
(10% BSA in Tris-buffered saline-Tween 20, TBS-T) for 90 min at room temperature. The membranes
were then exposed overnight to the primary antibodies: rabbit anti-IRS-1 (1:4000, Cell Signaling # 2390);
rabbit anti-phospho IRS-1 tyr1222 (1:4000, Cell Signaling # 3066), rabbit anti β-actin (1:1000,
Cell Signaling # 8457), rabbit anti-AKT (1:4000, Cell Signaling # 4691), rabbit anti-phospho AKT S473
(1:4000, Cell signaling # 9271), rabbit anti-JNK (1:1000, Cell Signaling # 9252), and rabbit anti-phospho
JNK (1:10,000, Cell Signaling # 9251). The blots were rinsed in TBS-T and then incubated with
horseradish peroxidase (HRP) conjugated anti-rabbit antibody (1:5000, Cell Signaling # 7074) for
one hour at room temperature. Antibody-antigen complexes were visualized by detecting enhanced
chemiluminescence using an ECL detection system (Amersham Biosciences) on the digital images
using the Quantity One 4.5.0 software (Bio-Rad: Hercules, CA, USA). To normalize pIRS and pAKT
expression, total receptor substrate-1 (IRS1) and total AKT were used, respectively. B-actin was used to
normalize JNK and pJNK expression. Because we have used antibodies from a rabbit host, total and
phosphorylated protein expression were determined in different blots in the same running.
3.5. Western Blotting Analysis in Cell Culture
Cells were lysed in ice-cold lysis buffer (25 mM Tris pH 8.0; 1.5 mM EGTA, 0.5 mM EDTA,
protease inhibitor cocktail, and Triton X-100 1%). The total protein concentration was determined
with the Bradford reagent (Bio-Rad: Hercules, CA, USA). Equivalent amounts of proteins
(15 μg/well) were then separated by 10% SDS-PAGE and transferred to nitrocellulose membranes
(Bio-Rad). The membranes were subsequently immunoblotted with the appropriate primary antibody
at 4 ◦C overnight (rabbit anti-AKT (1:4000, Cell Signaling # 4691); rabbit anti-phospho AKT S473
(1:4000, Cell signaling # 9271); rabbit anti-phospho AKT T308 (1:4000, Cell signaling # 9275))
and then incubated with HRP conjugated secondary anti-mouse or anti-rabbit antibody
(1:4000, Jackson Immuno Research: West Grove, PA, USA). Antibody-antigen complexes were visualized
by detecting enhanced chemiluminescence using the ECL detection system (Thermo Scientific:
Waltham, MA, USA) on digital images (Bio-Rad). Equal protein loading was assessed by the expression
of GAPDH (rabbit anti-GAPDH (1:4000, Cell signaling # 5174)). Total and phosphorylated protein
expression were determined in different blots in the same running.
3.6. Immunocytochemistry for FoxO1-Dapi
Glass coverslips containing the GT1-7 cells from each experimental group were rinsed with
ice-cold PBS and fixed using 4% paraformaldehyde in PBS pH 7.4, at room temperature. After fixation,
the cells were rinsed with PBS containing 0.1% Triton-X for permeabilization. After rinsing, the cells
were incubated for 30 min in a blocking solution of 1% BSA in PBS containing 0.1% Triton-X.
Cells were incubated overnight at 4 ◦C with the primary antibody (1:5000; rabbit anti-FoxO1,
Cell signaling # 2880). After rinsing, the cells were incubated with donkey anti-rabbit IgG conjugated
with Alexa 488 secondary antibody (1:500; Jackson Immuno Research: West Grove, PA, USA).
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Slides were then mounted using a medium containing DAPI (DNA staining, red). Photomicrographs
were acquired using a Leica confocal laser scanning microscope. The immunoreactive structures
were excited using argon or helium-neon green lasers with the excitation and barrier filters set
for the fluorochrome used (green or red). Images showing the fluorescence were obtained from
sequentially acquired images of slices excited by the laser.
3.7. Plasma Insulin and Glucose Determination
Plasma insulin and glucose concentrations were measured by radioimmunoassay (Millipore:
Billerica, MA, USA) and the glucose oxidase method (Doles Regents: Goiania, GO, Brazil), respectively,
using commercial kits according to the manufacturer’s protocol.
3.8. Immunofluorescence for pAKT
Sections were rinsed with 0.1 M PBS and incubated for 48 h at room temperature with rabbit
anti-phospho AKT (1:4000, Cell signaling # 9275). After rinsing, sections were incubated with donkey
anti-rabbit IgG conjugated with Alexa 488 secondary antibody (1:400; Jackson Immuno Research:
West Grove, PA, USA). Finally, the sections were coverslipped with Fluoromont-G mounting medium
(Southern Biotechnology Associates: Birmingham, AL, USA). Photomicrographs were acquired using
a Leica confocal laser scanning microscope. The immunoreactive structures were excited using argon
or helium-neon green lasers with the excitation and barrier filters set for the fluorochrome used (green).
Images showing the fluorescence were obtained from sequentially acquired images of slices excited by
the laser.
3.9. Statistical Analysis
Results were expressed as means ± SEM and were analyzed using the Software Statistica®
(Software Statistica® 10, Tulsa, OK, USA). One-way analysis of variance (ANOVA) followed by
the Fisher post hoc test were used to analyze the experiments with single or repeated LPS treatments.
Two-way ANOVA, followed by the Fisher post hoc test, were used to analyze the experiment of
food intake and body weight gain with single or repeated LPS treatment followed by ICV insulin
administration. We used three-way ANOVA, followed by the Fisher post hoc test, to analyze
the experiments with single or repeated LPS treatments, JNK inhibitor, and insulin injection.
Differences were accepted as significant at p < 0.05.
4. Conclusions
The main finding of our study is that hypothalamic insulin resistance, induced by an inflammatory
challenge after repeated exposure to endotoxins, can be observed in the absence of increased body
weight gain. We used a model of 6 days of prolonged low-grade inflammation to cause hypothalamic
insulin resistance without body weight changes. The maintenance of this scenario could advance
to obesity and diabetes, as shown by Cani and coworkers, which used 4 weeks of endotoxemia to
induce glucose homeostasis disturbance, including peripheral insulin resistance, associated with
increased body weight [38]. The additive effects of hypothalamic and peripheral insulin resistance
during nutrient overload are the key hallmarks of obesity, which could be caused in part by
metabolic endotoxemia. The caveat of the present study is that the peripheral effects of insulin
were not investigated to assess if central resistance is coupled to systemic resistance to this hormone.
Because both peripheral and central insulin resistance are features of obesity, future studies driven to
investigate the time course of peripheral insulin effects on metabolism during prolonged endotoxemia
must be performed. Our data indicate that alleviation of low-grade inflammation, as a therapeutic
target, may help to restore insulin actions in the hypothalamus and the effects on feeding behavior.
It is also important to point out that the reduced metabolism that leads to the increased body
weight during the low-grade inflammation is not observed in the more intense inflammatory process
such as that seen in individuals or experimental animal models suffering from different cancers. In fact,
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it is known that severe inflammation induced by cancers induces an opposite metabolic profile known
as cachexia [39,40].
Other central inflammatory processes, such as Alzheimer’s disease, also leads to the development
of insensitivity to insulin actions and defects in learning and memory [41]. It is crucial to understand
the mechanisms underlying impaired insulin signaling during inflammatory processes, to advance
in the treatment of obesity and to help alleviate people suffering from degenerative disorders associated
with inflammatory markers in the brain. In this context, our study reveals that the inhibition of brain
JNK could be used as an intervention approach against obesity and its comorbidities.
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Abstract: Lipopolysaccharide induced TNFα factor (LITAF) is an important transcription factor
responsible for regulation of tumor necrosis factor α. In this study, a novel litaf gene (designated
as Malitaf ) was identified and characterized from blunt snout bream, Megalobrama amblycephala.
The full-length cDNA of Malitaf was of 956 bp, encoding a polypeptide of 161 amino acids with
high similarity to other known LITAFs. A phylogenetic tree also showed that Malitaf significantly
clustered with those of other teleost, indicating that Malitaf was a new member of fish LITAF family.
The putative maLITAF protein possessed a highly conserved LITAF domain with two CXXC motifs.
The mRNA transcripts of Malitaf were detected in all examined tissues of healthy M. amblycephala,
including kidney, head kidney, muscle, liver, spleen, gill, and heart, and with the highest expression
in immune organs: spleen and head kidney. The expression level of Malitaf in spleen was rapidly
up-regulated and peaked (1.29-fold, p < 0.05) at 2 h after lipopolysaccharide (LPS) stimulation.
Followed the stimulation of Malitaf, Matnfα transcriptional level was also transiently induced to a
high level (51.74-fold, p < 0.001) at 4 h after LPS stimulation. Taken together, we have identified a
putative fish LITAF ortholog, which was a constitutive and inducible immune response gene involved
in M. amblycephala innate immunity during the course of a pathogenic infection.
Keywords: Megalobrama amblycephala; lipopolysaccharide induced TNFα factor; lipopolysaccharide
stimulation; innate immune
1. Introduction
Blunt snout bream (Megalobrama amblycephala) is one of the major economically important species
in freshwater polyculture fish aquaculture in China [1]. It has been widely cultured because of its
herbivorous habit, faster growth rate, and delicate flesh quality, as well as increasing demand in China
during the last few decades [2,3]. In 2013, its production has reached 0.73 million tons, ranking seventh
in Chinese freshwater fish production [4]. Associated with intensive farming, however, diseases
caused by infectious bacteria, mainly Aeromonas hydrophila, frequently occur [5]. The infectious disease
outbreak with quick spreading has led to serious economic losses in M. amblycephala culture industry.
Innate immunity plays crucial roles in defense against bacterial infections in fish [6]. The innate
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immune response to a bacterial pathogen is characterized by the immediate release of pro-inflammatory
cytokines, which act as key mediators of the immune system to eliminate the pathogen [7,8]. Finding
more molecular components involved in M. amblycephala’s innate immunity, therefore, will facilitate
our understandings in the largely unveiled complex immunity in fish.
Among the pro-inflammatory cytokines, tumor necrosis factor α (TNFα) has been confirmed
to significantly trigger host immunity, increase phagocytic activity, and provoke the induction of
inflammatory cytokines [9,10]. TNFα is one of the most well-known pleiotropic cytokines and is
secreted by various cell types and can be regulated by different transcription factors, such as nuclear
factor κB (NF-κB) [11], nuclear factor of activated T-cells (NF-AT) [12], activator protein 1 (AP-1) [13],
and lipopolysaccharide induced TNFα factor (LITAF) [14]. Lipopolysaccharide induced TNFα factor
(LITAF) is an important transcription factor mediating transcription of various inflammatory cytokines,
especially TNFα [15]. It has been demonstrated that LITAF can directly interact with the signal
transducer and activator of transcription (STAT) 6B and translocates into the nucleus where it binds
to the promoter regions of TNFα and other cytokines to modulate their transcription [16]. LITAF
was initially identified and characterized in the human macrophage cell line, THP-1 [17]. Since
then, a large amount of LITAF homologues have been obtained in several aquatic animals including
mollusk [18–23], arthropod [24,25], sea cucumber (Apostichopus japonicus) [26], and amphioxus
(Branchiostoma belcheri) [27], suggesting a conserved function in innate immunity. Although the
litaf gene has been characterized in several fish species, the knowledge of the LITAF orthologs in most
teleosts is still limited [28–31].
Therefore, in the present study, we identified a novel litaf homolog cDNA (designated as Malitaf )
in M. amblycephala, analyzed its phylogenetic relationship, and characterized its expression pattern in
response to LPS stimulation. Considering that litaf is a vital regulator for tnfα expression, we therefore
subsequently investigated the expression profile of tnfα (Matnfα) in M. amblycephala. To our knowledge,
this is the first study in the LPS-induced response of Malitaf. The achieved results will provide a better
understanding of the immune defense mechanisms and further improve the healthy management
efficiency in this species.
2. Results
2.1. Isolation and Characterization of Malitaf
The complete Malitaf cDNA sequence was 956 bp, which was composed of an 88-bp length
5′-untranslated region (5′-UTR), a 486-bp open reading frame encoding a protein comprising 161 amino
acids, and a 358-bp 3′-UTR followed by a poly (A) tail (Figure 1). One putative polyadenylation signal
(AATAAA) was recognized at the nucleotide position 906, which was 21 nucleotides upstream of the
poly (A) tail. Furthermore, there were two cytokine RNA instability motifs (ATTTA) at the 3′-UTR of
Malitaf, which were also presented in the litaf gene of Paralichthys olivaceus [28]. This cDNA sequence
has been deposited in the GenBank database under accession number KX421367.
The deduced protein from Malitaf gene (MaLITAF) possessed with an estimated molecular mass
of 17.2 kDa and an isoelectric point of 6.00. The protein analysis by Basic Local Alignment Search
Tool (BLAST) showed that MaLITAF protein shared the highest identity (91.3%) with that of grass
carp (Ctenopharyngodon idellus). Multiple alignment of amino acid sequences of LITAFs from different
species revealed that the C-terminal region of the MaLITAF showed much higher homology than
that of other regions (Figure 2). Furthermore, similar to other LITAF homologues, the maLITAF
protein possessed the typical LITAF domain (91–160 aa) that contained an N-terminal CXXC “knuckle”
followed by a long hydrophobic region, and a C-terminal (H)XCXXC knuckle (Figure 2). The CXXC
and HXCXXC motifs are highly conserved among invertebrates, mammals, and fish.
A phylogenetic tree was constructed by the neighbor-joining method based on entire amino acid
sequences of LITAFs from M. amblycephala and other species. As shown in Figure 3, all LITAFs were
split into five categories, including mammalian, avian, amphibian, teleost, and invertebrate LITAFs.
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Obviously, Malitaf was located into the fish LITAF group which was distinct from the mammalian
cluster. As expected, Malitaf showed the closest relationship to C. idellus. The results indicated that
Malitaf represents a new member of fish LITAF family.
Figure 1. The nucleotide and deduced amino acid sequences of Malitaf. The predicted lipopolysaccharide
induced TNFα factor (LITAF) domain is shaded. The two CXXC motifs are in shaded boxes, and the
cysteine residues are indicated in shaded bold face. The ATTTA and AATAAA are double and wavy
underlined, respectively. “*” shows stop codon.
Figure 2. Cont.
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Figure 2. Multiple sequence alignment of LITAFs. The identical, highly conserved, and less conserved
amino acid residues are indicated by “*”, “:”, and “.”, respectively. The gaps in the alignment are
indicated by “-”. The LITAF domain was labeled above the sequences, and two motifs were indicated
with rectangles.
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Figure 3. The neighbor-joining phylogenetic tree of MaLITAF protein and other known homologues
from GenBank registered. The numbers at the nodes represent bootstrap values for 1000 replications and
the bar (0.1) indicates genetic distance. The sequences of LITAFs from other species were downloaded
from GenBank: C. idella (ACT68335), Danio rerio (NP_001002184), Ictalurus punctatus (NP_001187935),
Oncorhynchus mykiss (NP_001158593), Osmerus mordax (ACO09164), Salmo salar (ACI67257), Gallus gallus
(NP_989598), Xenopus tropicalis (NP_988970), Mus musculus (NP_064364), Homo sapiens (NP_004853), Bos
taurus (NP_001039717), Cricetulus griseus (XP_003496739), Ovis aries (XP_004020821), Rattus norvegicus
(NP_001099205), Solen grandis (AEW43450), Ruditapes philippinarum (ADX31291), Crassostrea gigas
(ABO70331), Cipangopaludina chinensis (AEX08893), Haliotis discus discus (ADI72430), Chlamys farreri
(ABI79459), Pinctada fucata (ACN70008), and A. japonicus (AIB51692).
2.2. Tissues Distribution of Malitaf
To further understand the potential function of this new gene, the presence of Malitaf mRNA
transcript in different tissues from healthy M. amblycephala was examined by quantitative real-time PCR
(qRT-PCR) analysis, which can accurately quantify transcripts at a low copy number [32]. Expression
was normalized to the tissue with the lowest observed mRNA level-kidney (set as 1). As shown
in Figure 4, the mRNA transcript of Malitaf was ubiquitously detected in a wide range of tissues
examined from healthy fish. However, the relative gene expression of Malitaf to kidney was the
highest in spleen (15.21-fold, p < 0.001), which was also observed in spleen of rock bream (Oplegnathus
fasciatus) [30], followed by head kidney (12.45-fold). The transcriptional level of Malitaf decreased
gradually in liver (11.12-fold), heart (4.9-fold), gill (2.29-fold), and muscle (1.75-fold).
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Figure 4. The expression of Malitaf mRNA in different tissues from healthy M. amblycephala. Significant
pairwise expression-level differences between tissues are indicated by different letters above the bars.
2.3. Temporal Expression of Malitaf and Matnfα after LPS Stimulation
To preliminarily unravel the potential role of Malitaf in innate immunity, we characterized the
temporal expression pattern of Malitaf in spleen in response to stimulation with LPS. As shown
in Figure 5A, the mRNA expression of Malitaf was rapidly up-regulated after LPS stimulation.
The expression reached a peak level at 2 h post-stimulation, which was about 1.29-fold higher than
control group (p < 0.05). Subsequently, it was found that its expression decreased gradually to the
control level as time elapsed. However, a significant decrease of Malitaf expression was observed at
12 h after LPS stimulation. Considering that litaf is an important regulator for tnfα expression, we
therefore tested the expression profile of Matnfα following the elevated expression of Malitaf under
LPS stimulations at different time points. As shown in Figure 5B, the transcription of Matnf maintained
the control level at 2 h post LPS stimulation. However, a sharp increase of Matnfα mRNA to peak
level was detected at 4 h post LPS stimulation (51.74-fold, p < 0.001), and then dropped to the original
level at 8 h post LPS stimulation. Interestingly, the transcription of Matnfα surged again to a higher
level at 12 and 24 h post LPS stimulation (3.66- and 1.71-fold, respectively) compared with that of the
control group.





elative expression l evel
Figure 5. Temporal expression analysis of Malitaf (A); and Matnfα (B) mRNA in spleen from
M. amblycephala after LPS stimulation. Significant pairwise expression-level differences among different
time-points are indicated by different letters above the bars.
3. Discussion
Cytokines are the key regulators of innate immunity against pathogens [33]. Until now, litaf gene
had been cloned and characterized from many organisms including both vertebrate and invertebrate
animals, which suggested a conserved function in innate immunity. In mammals, the litaf has been
199
Int. J. Mol. Sci. 2017, 18, 233
reported as an important transcript factor for the regulation of TNFα and transcription of various
inflammatory cytokines in mammals [34]. However, the information on the systemic reaction of fish
litaf s during bacterial infection was rather rare. Therefore, we cloned the novel litaf gene from blunt
snout bream and examined their expression profiles to understand its potential role in innate immunity.
The LITAF domain, which is a key feature for the LITAF family, exists in viruses, fungi, plants,
and Metazoa, [35]. In the present study, the amino acid alignment indicated a highly conserved
LITAF domain with N-terminal CXXC and C-terminal HXCXXC knuckles that formed a compact
Zn2+-binding structure. These characteristics are a key feature of intracellular Zn2+-binding domains
that the N-terminal region binds to the intracellular molecule and the hydrophobic region does not
span the membrane [36]. These observations indicated that the LITAF domain of Malitaf appears
to be capable of responding similarly to the mammalian LITAF. In a phylogenetic tree of selected
vertebrate and invertebrate LITAF amino acid sequences, the MaLITAF was obviously separated from
the mammalian cluster and formed one distinct cluster with other teleost LITAFs, suggesting that it is
a fish-specific LITAF.
We performed qRT-PCR to monitor the transcriptional level of Malitaf in various tissues from the
healthy fish. The results showed the constitutive distribution of Malitaf, indicating that its important
role in immune defense against invaders and its immune responses could be occurring in the whole
fish body. In teleost fish, spleen and head kidney could be considered as the important central immune
organs synthesizing proteins involved in fish immune defense [37]. Therefore, the higher expression
level of Malitaf in spleen and head kidney also particularly suggested its crucial role in immune
defense against potential pathogens. In other teleost fish, the constitutive expression of litaf mRNA
has been reported in a wide range of tissues, but with varying expression levels. For example, the
relative gene expression of litaf1 of rock bream was the highest in spleen. In Japanese flounder, the
litaf mRNA was detected in all examined tissues with the greatest amount in gill, followed by blood,
skin, gonad, hepatopancreas, head kidney, heart, brain, trunk kidney, and spleen in a descending
order [28]. The grouper litaf gene was also widely expressed in different tissues analyzed, including
liver, spleen, kidney, head kidney, intestine, skin, gill, brain, muscle, heart, and stomach [29]. However,
the relatively low expression levels were detected in muscle and liver. In grass carp, the litaf gene
was found to express in various tissues but with a high expression level in gill [31]. The inconsistent
constitutive expression of litaf gene among different fish species may be a reflection of physiological
differences among these species, or even environmental influences. Furthermore, the differences in litaf
gene expression are thought to be possibly due to different expressing cells and functions of litaf gene.
Certainly, further studies on functional differentiation of litaf gene between fish and other species may
yield more novel information on the immune regulatory response of fish.
The Malitaf expression was significantly induced in spleen by LPS, a compound that mimics
a Gram-negative bacteria infection, which was similar to the previous reports on human THP-1
cells [17], mouse [38], chicken macrophages [39], Pacific oyster [22], and scallop hemocytes [23].
The results strongly suggested its significantly responsive to LPS and involvement in innate immune
response against Gram-negative bacteria. After 12 h of LPS stimulation, the Malitaf mRNA has
significantly decreased, which might possibly prevent the excess production of cytokines, and then
the innate immune response to pathogens could be efficiently controlled [33]. The expression pattern
of Malitaf appeared to be similar to Japanese flounder litaf with respect to the expression profile in
response to LPS stimulation [28]. TNFα effects can be both beneficial and detrimental to the host [40].
TNFα must be tightly regulated because over-production can be lethal to the host as in septic shock
syndrome. The mouse litaf gene induces activation of tnfα gene expression by itself [38]. Inhibiting
human litaf expression in a human monocytic cell line leads to a reduction in the tnfα transcript [15].
Therefore, in the present study, we tested the expression profile of Matnfα following the elevated
expression of Malitaf under LPS stimulation. The Matnfα was also induced and rapidly peaked at
4 h, not at 2 h, post LPS administration indicating that Malitaf may significantly contribute to the
up-regulated Matnfα expression in the spleen. In addition, the associated up-regulation of Malitaf and
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Matnfα in spleen during the early phase of LPS stimulation process indicated that Malitaf may be an
essential regulator involved in M. amblycephala innate immune response, probably through regulation
of Matnfα expression.
4. Materials and Methods
4.1. Fish, LPS Stimulation, and RNA Isolation
Adult M. amblycephala (weight: 405 ± 12.4 g) were obtained from a fish farm (Changsha, China).
Fish were maintained with a flow-through water supply at room temperature. After acclimating for
one week, the normal fish were used for the stimulation experiments. LPS isolated from Escherichia
coli (L2880, Sigma, St. Louis, MO, USA) was suspended into sterilized phosphate buffered saline
(PBS), and then was intraperitoneally injected into fish at a dose of 0.1 mg/100 g fish. Afterwards,
fish were anesthetized with MS-222 (3-aminobenzoic acid ethyl ester; Sigma). Various tissues from
three healthy individuals, including kidney, head kidney, muscle, liver, spleen, gill, and heart, were
collected. Similarly, the spleen from three individuals was collected at different time points (0, 2, 4, 6,
8, 12, and 24 h) after stimulation. Total RNA from above tissues was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA), and quantified based on the absorbance at 260 nm. The integrity
of RNA was checked by agarose gel electrophoresis. The animal experiments were approved by the
Ethics Committee of School of Life Sciences of Central South University with the following reference
number (SLSEC0028) in 10 March 2015. The tissues collected at 0 h were from fish injected with the
same volume of PBS.
4.2. Cloning and Characterization of Malitaf
To obtain the partial cDNA of Malitaf, the degenerate primers were designed based on an
alignment of its counterparts from other teleost fish (Table 1). Gene-specific primers were used
to amplify each end according to the manufacturer’s instructions. All resulting PCR products
were purified and then cloned into the pMD18-T vector (TaKaRa, Dalian, China) and sequenced
bi-directionally at Sangon (Shanghai, China). The open reading frame (ORF) of Malitaf cDNA was
detected using the ORF finder (available on: http://www.ncbi.nlm.nih.gov/project/gorf). Protein
domains were predicted by the Simple Modular Architecture Research Tool (SMART) [41]. Multiple
sequence alignments were created using the Clustal W program [42]. Phylogenetic and molecular
evolutionary analyses were constructed by the Neighbor-Joining method in Molecular Evolutionary
Genetics Analysis (MEGA) software (version 7.01, Tokyo Metropolitan University, Tokyo, Japan), and
support for each node was bootstrapped with 1000 replicates [43].
4.3. Spatial and Temporal Expression Analysis of Malitaf and Matnfα
The quantitative real-time PCR (qRT-PCR) was performed to investigate Malitaf mRNA expression
levels in different tissues of healthy M. amblycephala. In addition, the mRNA expression pattern of
Malitaf and Matnfα was determined in spleen after LPS stimulation by qRT-PCR. The β-actin and
18S rRNA was selected as an internal control to verify the successful reverse transcription and to
calibrate the cDNA template in spatial and temporal expression analysis, respectively. The qRT-PCR
was implemented using an ABI 7500 Real-time PCR system (Applied Biosystems, Foster, CA, USA)
in a total volume of 20 μL, including 10 μL SYBR® Premix Ex Taq™ II (2×) (TaKaRa, Dalian, China),
0.4 μL ROX Reference Dye II (50×), 0.4 μL of each primer (10 μmol·L−1), 2 μL 1:5 diluted cDNA, and
6.8 μL of PCR-grade water. The thermal profile was 95 ◦C for 30 s followed by 40 cycles of 95 ◦C for
5 s, 60 ◦C for 34 s, and 72 ◦C for 30 s. Melting curve analysis of the amplified products was performed
at the end of each PCR to confirm that a single PCR product was generated. The 2−ΔΔCt method was
used to analyze the expression levels of Malitaf and Matnfα genes [32]. The data obtained from three
independent biological replicates were subjected to statistical analysis and the values represented the
n-fold difference relative to the references (kidney and 0 h).
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Table 1. Sequences of primers used in this study.
Primer Sequence(5′–3′) Comment























All data of qRT-PCR were presented as means ± SD and checked for homogeneity of variances
and normality. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software Inc.,
San Diego, CA, USA). Significant differences among samples were determined by one-way analysis
of variance (one-way ANOVA) followed by a Tukey’s multiple comparison test. Differences were
considered significant at p < 0.05 and extremely significant at p < 0.01.
5. Conclusions
We identified and characterized a new member of LITAF family, Malitaf, in M. amblycephala.
We confirmed that Malitaf mRNA constitutively expresses in all examined tissues and displays a
higher expression level in spleen and head kidney than in other tissues. We also demonstrated that
Malitaf expression could be induced by bacterial endotoxin LPS stimulation. Furthermore, we showed
that the expression of Matnfα, a pleiotropic cytokine regulated by Malitaf, was up-regulated associated
with the enhanced expression of Malitaf in vivo. Our results significantly suggested that Malitaf may
play a key role in blunt snout bream innate immunity. Further studies on the functions of Malitaf
will contribute to a better understanding of the fish immune system and may help elucidate fish
immunoregulatory pathways.
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Abstract: The original hygiene hypothesis declares “more infections in early childhood protect against
later atopy”. According to the hygiene hypothesis, the increased incidence of allergic disorders
in developed countries is explained by the decrease of infections. Epithelial cells and dendritic
cells play key roles in bridging the innate and adaptive immune systems. Among the various
pattern-recognition receptor systems of epithelial cells and dendritic cells, including toll-like receptors
(TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and others, TLRs
are the key systems of immune response regulation. In humans, TLRs consist of TLR1 to TLR10.
They regulate cellular responses through engagement with TLR ligands, e.g., lipopolysaccharides
(LPS) acts through TLR4 and dsRNA acts through TLR3, but there are certain common components
between these two TLR pathways. dsRNA activates epithelial cells and dendritic cells in different
directions, resulting in allergy-related Th2-skewing tendency in epithelial cells, and Th1-skewing
tendency in dendritic cells. The Th2-skewing effect by stimulation of dsRNA on epithelial cells
could be suppressed by the presence of LPS above some threshold. When LPS level decreases,
the Th2-skewing effect increases. It may be via these interrelated networks and related factors that
LPS modifies the allergic responses and provides a plausible mechanism of the hygiene hypothesis.
Several hygiene hypothesis-related phenomena, seemingly conflicting, are also discussed in this
review, along with their proposed mechanisms.
Keywords: lipopolysaccharide; double-stranded RNA; epithelial cell; dendritic cell; allergic
respiratory disorder; hygiene hypothesis; rhinovirus; respiratory syncytial virus; toll-like receptor
1. Introduction
According to the hygiene hypothesis, the increased incidence of allergic disorders in developed
countries is explained by the decrease in infections [1,2]. Several studies have shown that exposure
to more LPS (lipopolysaccharide and endotoxin), a major component of the outer membrane
of gram-negative bacteria, in early childhood protects against the later development of allergic
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disorders [3–5]. However, these studies were done in rural areas in Europe. An urban study examined
a birth cohort in the inner-city environment, and declared that exposure to specific Firmicutes and
Bacteriodetes in house dust during children’s first year of life was associated with decreased atopy
and atopic wheeze. Exposure to high levels of both allergens and this subset of bacteria in infancy was
also inversely related to the incidence of atopy or wheeze [6]. Another study focusing on the common
cold also concluded that more runny nose episodes in infancy protected against later atopy [7]. Some
questions, however, remained to be answered, especially the mechanisms of protection, the nature
of protective infections, and why, after sensitization, LPS seems to exacerbate the conditions, rather
than protect the organisms [8]. The mechanism by which LPS might downregulate allergic airway
inflammation and subsequently suppress airway hyperreactivity was not clear, but two recently
published studies proposed a plausible model that clearly elucidates the role of LPS in downregulating
allergic inflammation [9,10]. In this review, we propose a model that includes four major players:
LPS, dsRNA or viruses, epithelial cells and dendritic cells. This model is used to explore a possible
protective mechanism based on more frequent occurrences of the common cold and more LPS exposure
in early childhood (i.e., before sensitization) leading to less development of allergy.
2. Four Major Players in the Proposed Simplified Model of Hygiene Hypothesis: Epithelial Cells
(ECs), Dendritic Cells (DCs), dsRNA and LPS
2.1. Epithelial Cells Play Key Roles in Bridging the Innate and Adaptive Immune System
The airway epithelium contributes significantly to the barrier function of airway tract, which has
three active components: the mucociliary escalator, the intercellular apical junctional complexes and the
secreted antimicrobial peptides. An impaired barrier function would increase susceptibility to infection
and sensitization as well as chronic inflammation [11]. However, beyond the barrier function, which
was once thought to be the only function of epithelial cells, in recent years epithelial cells were found to
play key roles in bridging the innate and adaptive immune system [12–16]. Epithelial cells can activate
DCs, B cells, and T cells, thereby stimulating their differentiation, or modifying the above effects [12].
Epithelial-derived cytokines can also activate basophils, eosinophils, mast cells and nuocytes [17].
2.2. DCs Interact Closely with ECs to Orchestrate the Immune Responses
DCs are responsible for initiating all antigen-specific immune responses. They capture and process
antigens, express lymphocyte co-stimulatory molecules, regulate the functions of B and T lymphocytes
and secrete cytokines to initiate immune responses. In addition, they are also responsible for inducing
tolerance of T cells to innate antigens. Before recognition of the pivotal role of ECs in immune response,
most researches emphasized the DCs [18–20]. Allergens, microbial compounds and various environmental
and genetic risk factors for allergic disorders, however, often interfere with the immune functions of
airway ECs and DCs [17,21,22]. At the 2014 International DC Symposium, at least 28 different DC
subsets were described using various surface markers and nomenclature systems in distinct species [23].
However, these numerous species are generally classified into type 1 conventional DC (cCD1), type2
conventional DC (cCD2) and plasmacytoid DC (pDC) [16]. Conventional DCs, also referred to as myeloid
DCs (mDCs) [24], play important roles in the pathogenesis of allergic airway inflammation. By contrast,
pDCs are related to immune tolerance, and host defense against viral infections at the mucosal site,
thereby modulating the extent of inflammation and tissue damage [24]. Although DCs cultured in vitro
from monocytes, called moDCs, do not show the same behavior or capability as their ex vivo isolated
counterpart, they are often used for research for their easier availability [23,25].
2.3. Most Bridging Effects Start from Activation via TLRs and Other Receptors of Epithelial Cells and DCs
Among the various pattern-recognition receptor systems of ECs and DCs, including toll-like
receptors (TLRs) and NOD-like receptors (NLRs) and others, which could respond to the
pathogen-associated molecular pattern (PAMP) and the danger-associated molecular pattern (DAMP),
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TLRs are the key systems. In humans, TLRs consist of TLR1 to TLR10 and could respond to
various microbial products. However, this review discusses only the most relevant TLR3 and TLR4.
Lipopolysaccharide (LPS) acts via TLR4 and dsRNA acts via TLR3. However, there are many common
components in these two signaling pathways [26,27], which provide the mechanisms for interactive
regulation. Furthermore, TLRs may cooperate with NLRs and PARs (protease-activated receptors) in
mediating the immune response [28,29], which can be upregulated or down regulated by cytokines
and chemokines in the context [30–32].
Below, we will discuss these two TLRs of ECs and DCs in the order of TLR3/ECs, TLR4/ECs,
TLR3/DCs and TLR4/DCs.
2.4. dsRNA or Viruses Can Activate TLR3 of Respiratory Epithelial Cells and Stimulate the Production of
Various Proallergic Cytokines
dsRNA or viruses can activate the TLR3 of epithelial cells (ECs) and stimulate the production
of various proallergic cytokines [9], including thymic stromal lymphopoietin (TSLP), interleukin 33
(IL33) and IL25 [33]. Of all the TLR ligands tested, only polyI:C, representing dsRNA, the TLR3 ligand
stimulates a high level of TSLP expression in keratinocytes and human bronchial ECs. Ligands of
other TLRs induce only minimal expression of TSLP [31,32]. In the human epithelium IL33 is induced
mainly by polyI:C and flagellin, the ligands to TLR3 and TLR5, respectively [34], following parasitic or
viral infections, but also by other non-TLR factors, such as exposure to allergens. IL25 is induced by
microflora, allergens, helminth or particle (TiO2) [35]. PolyI:C induces only modest expression of IL25
in respiratory ECs [9]. Downstream Th2 cytokines, such as IL4 and IL13, of the allergic triad consisting
of TSLP, IL33 and IL25, would augment the stimulatory effect of polyI:C on ECs synergistically to
produce more Th2 cytokines, thus promoting a positive feedback cycle [31].
Although some respiratory viruses such as influenza and respiratory syncytial virus (RSV) destroy
the airway epithelial barrier, rhinovirus (RV) by itself does not cause cytopathology. The RV infection
only disrupts the epithelial barrier function, specifically disrupting tight junctions, as well as increasing
vascular leakage and mucus secretion [36]. In cultured human nasal ECs, RV infections showed
decreased zona occluden-1, claudin-1, and E-cadherin levels, consistent with the effect of polyI:C and
could expose basolateral epithelial receptors, where TLRs and other pattern recognition receptors
(PRRs) are prominently located [37]. polyI:C activates TLR3 and induces apoptosis in cells [38].
Fortunately, LPS could suppress the pathogenic effect of polyI:C on ECs, and may protect the epithelial
integrity [9].
2.5. LPS Activate TLR4 of Respiratory Epithelial Cell, Using Bidirectional Capacity to Modulate Allergic
Disorders through Multiple Pathways
LPS is composed of lipid A (a hydrophobic domain), a core oligosaccharide, and a distal
polysaccharide (or O-antigen) [39]. Core and O-antigen sugars protect bacteria from antibiotics,
the complement system, and other environmental stresses. Lipid A is the moiety that activates TLR4.
Epidemiological studies have repeatedly confirmed that exposure to environmental LPS in early
childhood would reduce the incidence of allergic disorders in later life [3,5,40]. Animal studies
confirmed LPS exposure before or shortly after sensitization protects against the development of
allergy [41], but after that critical time point LPS worsens the inflammation by attracting neutrophils
and eosinophils, possibly via dendritic cells and B cells [42] (Table 1). Neutrophilia are discussed
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2.5.1. Protective Role of LPS against Allergic Disorders
Focusing on the Role of LPS
The protective mechanism of LPS was not previously clear because LPS has little or no direct
effect of stimulating ECs to produce cytokines [31,46] (Table 2). Although LPS cause a 10-fold increase
in cytokine expression when serum is present [47], under general condition, when without other
coexisting factors, ECs are relatively resistant to LPS in producing cytokines [48]. Thus, previously via
what pathway LPS exerts its protective function was a confusing issue. However, recently, pretreatment
of LPS was found to induce the A20 protein, which is a ubiquitin-modifying enzyme, and in this
way reduce the inflammation caused by house dust mite in a mouse model [10]. Pretreated LPS
also attenuates the induction of proallergic cytokines, including TSLP and IL33 in respiratory ECs
stimulated with polyI:C and human parechovirus by attenuating TANK-binding kinase 1, IRF3,
and NF-κB activation [9]. Thus, LPS does not directly antagonize the inflammation; instead, when
pretreated before sensitization, it inhibits the effect of proallergic ligands of TLR3 and simultaneously
induces A20, which is a potent NF-κB inhibitor [49]. Pretreatment of LPS was also shown to be
protective against inflammation in other kinds of cells, including macrophages, cardiac myocytes [50],
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Focusing on the Role of LPS-Related Actions in Farming Households
The LPS levels of exposure for children from farming households are significantly higher than
those from non-farming households, and an inverse association was also noted between the LPS
exposure level and the prevalence of hay fever and atopic sensitization [3]. More than 20 studies
focusing on the issue of protection conferred by farm environment exposure against atopy development
revealed that the protective farm effect was related to microbial exposure [55]. An inverse relationship
between exposure to LPS in the mattress dust of children and the occurrence of atopic diseases was
also shown in rural environments [4]. The same pattern was noted with the diversity of microbial
exposure inversely related to the risk of asthma [56]. The unstimulated peripheral blood mononuclear
cells of farm children produced more IL10, IL12 and IFNγ than those of non-farm children, indicating
increased spontaneous production of Th1 and regulatory cytokines. Decreased TNF responses to
short-term LPS stimulation in farm-exposed children may imply tolerance [57]. The mRNA expression
of Th1/Th2/Th17-associated cell markers decreased between ages of 4.5 and 6 years, and, at the age
of six, regulatory T cells (Treg) were decreased with farm exposure and increased within asthmatics,
compared with levels at age of 4.5, implicating a critical “time window” for Treg-mediated asthma
protection via environmental exposure before age of six years [58,59]. Finally, it must be emphasized
that not all farming environments protect against the development of asthma and wheeze in children,
e.g., the keeping of hares and rabbits, using pressed hay and the presence of sheep were positively
associated [59,60].
2.5.2. The Proallergic Role of LPS
In asymptomatic one-month-old neonates colonization of the airways with one or more of the
pathogens S. pneumoniae, H. influenzae, M. catarrhalis, was associated with increased risk of a first
wheezy episode, persistent wheeze, acute exacerbation of wheeze, increased blood eosinophil counts
and total IgE and increased risk of developing asthma by the age of five years. However, the study did
not specify the mechanism of increased asthma risk, whether via ECs, DCs or their interaction [61].
Using irradiated chimeric mice, Hammad et al. demonstrated that TLR4 expression on lung ECs
is required and sufficient for house dust mite (HDM) to activate DCs and prime for Th2 responses.
Moreover, LPS binding to TLR4 of ECs in the presence of HDM led to the production of proallergic
cytokines, including TSLP, GM-CSF, IL25 and IL33. Knockout of TLR4 on ECs, but not on hematopoietic
cells, abolished HDM driven allergic airway inflammation. A TLR4 antagonist targeting exposed ECs
suppressed the airway hyperreactive features of asthma [62]. Thus, the role of LPS-TLR4 binding in
HDM-induced allergic disorders was confirmed.
2.5.3. The Pro-Inflammatory Non-Allergic Role of LPS
When the allergic state was already established, further LPS application in the airway might
induce a state of worsened inflammation with neutrophilia predominant with eosinophilia persistence
or abolished [41,54]. The airway neutrophilia could be caused by two pathways: first, direct activation
of the airway epithelial cells by LPS with production of IL8 [47], which is a strong neutrophil attractant
chemokines [63] and second, indirect pathway with Th17 cells activated first, and then the released
IL17 activates the airway epithelial cells to produce IL8 and other related cytokines [64]. Here we
have to emphasize that normal airway epithelial cells are relatively resistant to common type LPS
stimulation [47], yet they will become inflamed in the presence of blood or serum, but by contrast, not
plasma [65,66], indicating some factors in blood or serum critically influence their responses. Besides,
unusually high dose or even to the toxic level or sublethal dose as in Table 3 would activate another
non-allergic inflammatory pathway with neutrophils predominant [67–69]. LPS of strong pathogens,
such as Pseudomonas aeruginosa would cause robust airway inflammation even at a much less dose [70].
The role of LPS in pro-inflammatory or non-allergic effect is summarized in Table 3. In addition,
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2.6. dsRNA or Many Viruses Activate TLR3 of Dendritic Cells, Thus, Induce DCs with Th1-Promoting
Capacity with Some Exceptions
2.6.1. dsRNA Activates the TLR3 of DCs, and Cause Them to Become DCs with
Th1-Promoting Capacity
dsRNA can facilitate the development of Th1 cells even after the active period [73].
The Th1-promoting effect is mediated by IL12 and some unknown factor because anti-IL12 Abs
could only partially block it [73], and IL12p40/p70-deficient mice could still mount a strong Th1
response [74]. DCs pretreated with polyI:C expand T cells with high Th1 polarity (70–90%), and this
pattern is also confirmed in influenza [75].
2.6.2. Respiratory Syncytial Virus (RSV) Is Probably an Exception, Which Likely Skew DC towards DC
with Th2-Promoting Capacity
RSV infection is known to be associated with higher risk of later allergic disorders [76,77]. Clinical
studies in RSV bronchiolitis revealed low Th1 responses with reduced IFNγ production and robust
Th2 cytokines production [78]. In predisposed individuals, RSV infection cause the release of tissue
alarmins and promote a cytokine microenvironment that is Th2 prone [79]. DCs, mainly myeloid
DCs (mDCs), are likely to play pro-inflammatory roles in RSV infection and induce a Th2 response
and may increase the later risk of developing allergic asthma [80]. The Th2-biased response is quite
different from Th1 response to other respiratory viruses, such as influenza virus and adenovirus
with strong IFNγ production. Upon RSV infection, mDCs mature, strongly activate naïve T cells and
promote Th2 responses. In contrast, in healthy lungs, most of these cells are immature and unable to
activate naïve T cells [80]. However, there remain some controversies. In Stein’s series, RSV lower
respiratory infections (LRTIs) were associated with an increased infrequent and frequent wheeze by
age six. Risk decreased markedly with age and was not significant by age 13. No association between
RSV LRTIs and subsequent atopic status was noted. In addition, it was concluded that RSV LRTIs
in early childhood is an independent risk factor for the later occurrence of wheezing up to age 11
years but not at age 13. This association is not caused by an increased risk of allergic sensitization [81].
In Kotaniemi-Syrjänen’s cohort series, RSV infection was found to be associated with a relatively low
risk of later childhood asthma among young children hospitalized for wheezing. However, when
compared with non-selected school-aged children, the risk of asthma for RSV-positive children is
increased, though only less than four folds [82], not as high as reported by Sigurs et al. (12 folds) [76,77].
2.6.3. Is Rhinovirus (RV) Another Exception?
Severe rhinovirus infection in infancy is closely related to later asthma development [83]. The risk
of asthma at age six years in children who wheezed during the first three years of life with RV infection
is 9.8-fold greater in comparison with those who wheezed without RV or RSV infection [84], with
RSV-infected children displaying a 2.6-fold increase. However, in contrast to infancy, RV infection in
non-asthmatic adult generally only causes runny nose, stuffy nose and sore throat, limiting symptoms
to the upper respiratory tract only [85,86]. Whether RV infection predisposes the children to allergy or
just reveals the children who already have an allergic predisposition is an issue to be resolved [87].
Related Mechanisms of Rhinovirus Infection
dsRNA and many virus infections generally would facilitate the development of Th1 cells via
skewing DCs [73], but some strains of human rhinoviruses, e.g., HRV14, which belongs to the major
group human RV (HRV), can efficiently inhibit the T cell stimulatory capacity of DCs through binding to
its cellular receptor human intercellular adhesion molecule-1 (ICAM-1), inducing inhibitory cell surface
receptors, and induce a promiscuous and deep anergic state in co-cultured T cells, despite high levels
of MHC molecules as well as co-stimulatory molecules in in vitro study. This effect is independent
of inhibitory soluble factors such as IL10 [88]. In this way, RV induces a hypoproliferative state in
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co-cultured T cells if they can come to contact DCs, but the Th1 predominant pattern is still preserved,
only with decreased intensity. However, this study was performed by co-culturing HRV14 and DCs for
more than 24 h in the laboratory. It is not certain if the circumstances could be reproduced in infected
non-allergic individuals. Furthermore, even though the adaptive immune response was inhibited,
the net response still was Th1, with the IFNγ level much higher than the IL4 level. In addition, another
strain HRV2, belonging to a minor group, could bind to low-density lipoprotein receptor (LDLR) and
stimulate much more production of IFNγ than HRV14 stimulation without causing anergy at all. Thusm
both groups support the Th1 response, but maybe with different strengths [88].
Question: Under Normal Circumstances, Will Rhinoviruses Easily Approach DCs, as Shown in the In
Vitro Study Above?
In Arruda’s series done on nasal and nasopharyngeal biopsy tissue infected by HRV, only low
numbers of ciliated cells were infected by HRV. Infected non-ciliated epithelial cells were also detected
in the nasopharynx, indicating that only a very small proportion of cells (usually ≤10%) in the nasal
epithelium and in both ciliated and non-ciliated cells in the nasopharynx were infected [89,90]. In the
lower airway epithelium, the frequency of rhinovirus-infectable cells was noted to be similar to that
in the upper airway [90]. The infected epithelium revealed no cytopathic change, and in studies
of both natural and experimentally-induce colds, no viral RNA can be detected in the subepithelial
layer. Thus, the viral infection is confined to the epithelial layers, with the degradation product of
RV possibly via lysosome or proteasome pathways activating the epithelial cells to release various
cytokines, chemokines etc. and attracting inflammatory cells [91]. Another study concluded that RV
viremia was rare in children with respiratory infections, with 25.0% (7/28) children viremic with asthma
exacerbations, 7.7% (2/26) viremic with common cold, 4.0% (1/25) viremic with bronchiolitis, and 0%
(0/9) viremic with pneumonia [92]. Further experiments should be done to elucidate the possibilities
of direct stimulation of RV on DCs. At present, there is limited data because most HRV strains (major
groups) do not bind to murine receptor ICAM-1, so no proper murine model of HRV can be used.
In Transgenic Mouse Model
In the ICAM-1 transgenic mouse model, the minor group RV-1B caused neutrophilia and
lymphocytosis without detectable thymic stromal lymphopoietin (TSLP), IL4, IL13 and IL17. IFNγ
production was also increased in murine lung leukocytes, thus favoring Th1 response. This study
proposed that allergic airway inflammation could be exacerbated by RV-induced Th1 response [93].
However, there are approximately 150 strains of rhinovirus, and different RV strains may have different
stimulating capacities in the induction of allergic disease.
Conclusion on the Protective or Pro-Inflammatory Role of RV
For non-sensitized individuals, whether infants or adults, RV infection causes a minimal epithelial
reaction, with a minimal Th2 response, which could possibly be easily suppressed by LPS when LPS
of non-pathogenic bacteria are present. RV infections then stimulate DCs to produce a minor Th1
response (Figure 1a), because most of the infections are localized to the epithelial layers, so the viral
load on DCs is minor, and would not cause the severe neutrophilia and lymphocytosis as seen in
mouse model due to RV-1B [93]. However, in sensitized individuals, RV infections would stimulate the
ECs with junctions of epithelial layers disrupted, proallergic cytokines such as TSLP and IL33 would
be released and stimulate DCs towards Th2-promoting development. In addition, more viruses may
penetrate the epithelial layers and stimulate DCs towards Th1-promoting development. The net result
is that both Th1- and Th2-promoting activities of DCs would be increased, as noted in clinical cases of
the exacerbation of the asthmatic patients after RV infection [94]. More studies are necessary to prove
this deduction, although it is compatible with the already published data.
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Figure 1. (a) Before sensitization, when the LPS level in the environment is high, each episode of
common cold infection (dsRNA) cause no effect on epithelial cells (ECs), but stimulate dendritic
cells (DCs) to skew towards Th1 prone except RSV infection, which is Th2 prone. (b) When the LPS
level in the environment is low, each episode of common cold infection (dsRNA) then stimulate the
epithelial cells to produce proallergic cytokines, such as thymic stromal lymphopoietin (TSLP) and
IL33, which would facilitate T cells to produce more IL4, IL5 and IL13, and these Th2 cytokines would
work synergistically with dsRNA to stimulate ECs to produce more IL33 and TSLP, forming a positive
feedback cycle, and thus shaping the allergic predisposition seen clinically.
2.7. LPS Has the Potential to Activate Immature Dendritic Cells (DC) into Mature DCs with Th1- or
Th2-Promoting Capacity
LPS stimulates DCs to produce IL12 transiently and thus induces strong Th1 polarization
(the so-called “active period”), but shifts to induce Th2 polarization afterwards in the “exhausted”
period [45]. During the immune response, there is a dynamic regulation of the Th1/Th2 cells balance.
The polarity can also be influenced by the dose of superantigen toxic shock syndrome toxin-2 with a
high dosage (10 ng/mL) favoring Th1 skewing, and a low dosage (0.1 ng/mL) favoring Th2 skewing.
Exogenous IL12 or IL4 is the third factor that would move the total profile towards Th1 or Th2 polarity
respectively [45]. In this model, the predominance of IL12 or IL4 determines the central axis of Th1/Th2
polarity, with minor modifications by the high/low dose of antigens and active/exhausted factors.
Therefore, active DCs with high dose antigen in the presence of IL12 would yield the maximal Th1
response, and exhausted DCs with low dose antigen in the presence of IL4 would yield the maximal
Th2 response. In another mouse model in which ovalbumin (OVA) was used as allergen at fixed dose,
the concomitant use of 100 μg (high dose) or 0.1 μg LPS in sensitizing period led to Th1 and Th2
responses later respectively. Again the dose of LPS determines the final Th1/Th2 skewing pattern [43].
When the allergen was changed to HDM, in a mouse model, increasing doses of LPS (0.001–10 μg)
dose-dependently inhibited HDM-induced eosinophil recruitment and the production of Th2 cytokines
in the lungs, revealing a shift toward Th1 inflammation with predominant neutrophilia [95]. However,
the local switching of the airway inflammation from eosinophilia to neutrophilia did not quench the
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airway inflammation; instead, airway hyperreactivity was increased [54] in accordance with the clinical
observation [96] (Table 1).
3. The Protective Role and Mechanism of LPS: Pre-Exposure to LPS Protects the Respiratory
Epithelial Cells and Downregulates the Effect of dsRNA or Allergen in Producing Proallergic
Cytokines, Indicating a Delicate Cross-Regulation Mechanism Exists between dsRNA (TLR3
Pathway) or Allergen and LPS (TLR4 Pathway), at Least at Epithelial Level
3.1. Pretreatment with Lps Attenuates Induction of Proallergic Cytokines, TSLP and IL33 in Respiratory
Epithelial Cells Stimulated with polyI:C and Human Parechovirus.
In H292 cells, polyI:C activated the TLR3 signaling pathway with activation of the transcription
factors IRF3 and NF-κB p65/50 by I kappa B kinase (IKK) and IKK-related kinases, such as TBK-1, IKKε,
IKKα, and IKKβ. IRF3 phosphorylation was detected at 3 h after stimulation [26]. Phospho-TBK1,
-IRF3, and -NF-κB p65 (Ser456 and Ser536) was markedly increased at 12 h. The protein level of NF-κB
p65 and IκBα degradation was increased with downstream production of allergic cytokines, such as
TSLP and IL33 increased as well [9]. The polyI:C-induced IRF3 phosphorylation was inhibited by
pretreatment of high dose (30 μg/mL) LPS, but by contrast, lower dose of LPS (0.3 μg/mL) enhanced
polyI:C-mediated IRF3 phosphorylation as compared with polyI:C stimulation alone. High dose LPS
pretreatment significantly decreased IRF3 phosphorylation induced by polyI:C stimulation. The total
NF-κB p65 level was not significantly changed by LPS pretreatment, but 3 and 30 μg/mL LPS treatment
inhibited the polyI:C-induced IκBα degradation, which suggests that the polyI:C-mediated activation
of the NF-κB pathway was downregulated with high dose LPS [9].
3.2. Pretreatment with LPS Protects against Allergy through A20 Induction in Lung Epithelial Cells
After pretreatment with LPS in the mouse model, the lung levels of granulocyte macrophage
colony-stimulating factor (GM-CSF, the maturation factor of recruited lung DCs) and CCL20 protein
(the chemokine of attracting DCs [62]) induced by house dust mites were reduced through A20
induction. A20 is a negative regulator induced by allergen stimulation via NF-κB activation to avoid
deleterious effect due to overstimulation and maintains homeostasis [97]. IL33 mRNA was noted to be
decreased with Th2 cytokine levels also downregulated, including IL5 and IL13 [10].
3.3. Pretreatment with E. coli in Mice Models Protects against Allergy via Two Pathways
Pretreatment with E. coli in mice models via intranasal inoculation leads to suppression of allergic
airway inflammation by recruited γδ T cells (a subset of T cells with potent cytotoxicity and interferon-γ
production [98]), and dampening of DC function in the lung, thus decreasing the effectiveness of
presenting antigen to effector T cells [99]. These findings may be the associated events of Sections 3.1
and 3.2. Though Th1 and Treg responses do not play a role in the context, γδ T cells are noted for their
potent cytotoxicity and interferon-γ production.
3.4. Pretreatment with Salmonella enterica Serovar Typhimurium Protects against Allergic Airway
Inflammation in Mice
Intragastric pretreatment with Salmonella enterica serovar typhimurium in murine models leads to
protection from induced allergic airway inflammation via expansion of a CD11b+ Gr1+ myeloid cell
populations, which reduce airway inflammation by influencing Th2 cells. These groups of myeloid
cells consist of macrophages, immature granulocytes, early myeloid progenitors, and DCs, and exhibit
their inhibitory effect by altering GATA-3 expression and IL4 production by Th2 cells [53].
3.5. LPS Suppresses Asthma-Like Responses via Nitric Oxide Synthase (NOS2) Activity
The regulatory role of NOS2 in airway allergy was revealed. Mice were immunized with OVA on
Days 0 and 7, then on Day 14, challenged intranasally with OVA/saline to induce an allergic airway
response, and on Day 21, rechallenged with intranasal OVA concomitantly with either intranasal or
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intravenous delivery of LPS. LPS via both routes completely suppressed airway eosinophilia, but in the
intranasal group, the total cell number in the bronchoalveolar fluid was not reduced. The suppression
effect was lost in NOS2−/− mice, indicating the LPS suppressed the allergic inflammation via NOS2
activity. However, in this experiment, LPS was given after the establishment of allergic state [54]. Thus,
whether pretreatment with LPS would also work via this way must be confirmed by further study.
4. The Pro-Inflammatory Role of LPS: Why Does LPS Induce Inflammation, Instead of Protecting
against Inflammation on Many Occasions?
Although LPS acts like a protector of respiratory epithelial cells against allergic inflammation,
on many occasions, it creates difficulties by inducing a large amount of inflammatory responses,
even to the extent of shock or death of the host. There are probably several reasons for this. Table 3
summarized some concepts shaped by already published studies.
4.1. First, the Timing of Delivering LPS
In rat models, LPS protects the animal only when it is delivered before or shortly after allergen
sensitization. After that, LPS exacerbates the inflammatory responses, often with neutrophils
predominant [41]. In asthmatic children, a significant correlation was found between levels of LPS and
airway neutrophils in bronchoalveolar lavage [100].
4.2. Second, the Dose of LPS Delivered
In a mouse model, 100 ng LPS every other day for two weeks before house dust mite (HDM)
sensitization or 1 μg two weeks before HDM sensitization suppress all of the key asthma feature [10].
In contrast, when 8 mL of 100 μg/mL LPS suspension was nebulized and delivered in the mouse
model, inhalation of LPS results in acute neutrophilic inflammation of the distal air spaces of the
lungs [48]. Another mice experiment indicated that allergen sensitization with low dose LPS (0.1 μg)
and OVA induced type 2 responses with airway hyperresponsiveness, eosinophilic inflammation, and
allergen-specific IgE up-regulation, but, again, sensitization with high dose LPS (10 μg) and OVA
induced asthma phenotypes with noneosinophilic airway inflammation [43]. In an epithelial cell line
model, 30 μg/mL LPS in culture medium attenuates induction of proallergic cytokines, TSLP and IL33
in response to polyI:C or human parechovirus, but 0.3 μg/mL LPS enhanced the induction effect with
increased phosphorylation of IRF3 and decreased inhibitors of NF-κB, the IκBα on the contrary [9].
4.3. Third, the Monocytes/Macrophage or Dendritic Cells Which Are Also Activated by LPS
As little as 10 ng/mL LPS would induce the release of inflammatory and chemotactic chemokines
from these cells [101], in contrast to the 10,000 ng/mL LPS required for activation of respiratory
epithelial cells [47]. If the monocytes/ macrophage or dendritic cells were activated, they would
release several cytokines, such as tumor necrosis factor-α and IL1, and enhance epithelial barrier
dysfunction [70].
4.4. Fourth, the Synergistic Effect between LPS and Environmental Cofactors
The synergistic effect between LPS and environmental cofactors, such as concomitant ozone
exposure, causes worsened inflammation. In rat model, 100 μg LPS intranasally instilled cause
slight neutrophilia in nasal epithelia in comparison to saline (relative value 19/14), but pretreatment
with ozone before instillation of same amount of LPS cause significant neutrophilia (relative value
33/1) [102].
4.5. Fifth, the Resource of LPS Delivered
In the Copenhagen Birth Cohort Study, the presence of potentially pathogenic species, including
M. catarrhalis, H. influenzae, or S. pneumoniae, in the oropharynx of one-month-old infants significantly
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correlates with increased risk of developing asthma in later childhood, but S. aureus does not [61].
Thus, it is reasonably deduced that different LPS may have a different effect, either protective
or pro-inflammatory.
4.6. Sixth, the Presence of Serum or Whole Blood on Lung Alveolar Cells and Bronchial Epithelial Cells
The presence of serum or whole blood makes the human umbilical vein endothelial cells become
very sensitive to even 0.1 ng/mL LPS [65]. When endothelial cells were incubated with whole blood
or serum, they were fully activated with picomolar doses of LPS. In contrast, one thousand fold of
LPS were required for the same level of activation when plasma only was used. When anti-CD14
mAbs were used, the endothelial responses to LPS in the presence of blood could be almost completely
blocked. However, this enhancement effect by blood was not observed in lung epithelial cells A549 at
this minimal dose [65] as reported by Pugin. However, when the LPS level was increased to 10 ng/mL,
the serum would cause a much greater increase in cytokine expression in both alveolar epithelial cells
(A549) and bronchial epithelial cells (BEAS-2B), perhaps through different mechanisms [47], with
CD14-dependence in A549 and CD14-independence in BEAS-2B. In contrast, in the absence of serum,
LPS has to reach 10,000 ng/mL (here we use ng instead of μg to emphasize the contrast) to activate
respiratory epithelial cells. Currently, the significance of the presence of serum or blood in respiratory
epithelial cells has not yet been fully elucidated, but the contents in inflammatory exudate may play
roles in enhancing the activation of respiratory epithelial cells.
4.7. Seventh, the Type of Epithelial Cells Tested
As pointed out in Section 4.6, alveolar epithelial cells and bronchial epithelial cells react to LPS via
different mechanisms. H292 cells, which are bronchial epithelial cells, grow well even in 30,000 ng/mL
LPS up to eight days, demonstrating the relative resistance of bronchial epithelial cells [9]. Here,
we preserve the nanogram (ng) scale to emphasize the difference of LPS dosage used. By contrast,
if endothelial cells are tested, they are thousands or even millions times sensitive to LPS activation,
with pg/mL level of LPS capable of activating endothelial cells in the presence of blood, whose
concentration is only 1/1000 of the ng/mL level [66].
5. Proposed Mechanism Supporting Hygiene Hypothesis
5.1. First, Why Early Exposure to Environmental LPS, Such as Farm Dust, Would Protect against the
Development of Allergic Disorder in Later Life? Two Mechanisms May Possibly Explain the
Observed Phenomenon
5.1.1. Pre-Exposure to LPS Attenuates the Signaling Pathway Necessary for Allergic Cytokines
Production, but Spares the dsRNA/DCs Route
After a baby is exposed to more environmental LPS, which is relatively nonpathogenic, then
when it later encounters a common viral infection, the dsRNA cannot activate the epithelial cells to
produce allergic cytokines, such as TSLP, IL33 and IL25 [9]. Instead, it activates DCs to produce more
Th1-skewing cytokines [73], and thus more Th1 cells, and more IL12. In the context of more IL12, more
LPS would stimulate DCs to produce more Th1 cytokines in the presence of antigens [43,45]. Thus,
each time a baby gets a common cold, it becomes more prone to Th1. Even when an allergen is present,
a high dosage of LPS still favors the Th1 response to a later challenge [43] (Table 4) (Figure 1a).
5.1.2. Pre-Exposure to LPS Suppresses Responsiveness of Airway Epithelial Cells via Increased
Synthesis of A20
Pre-exposure of airway epithelial cells to LPS suppresses their allergic responsiveness to house
dust mite (HDM) via increasing synthesis of A20, encoded by the Tnfaip3 gene. Ex vivo cultures of
human bronchial epithelial cells revealed a similar result [10]. Other mechanisms may also be involved,
as discussed in Sections 3.3–3.5.
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Table 4. Profile of four major players of the hygiene hypothesis model in the presence of high dose LPS
before sensitization.
Cell Type High Dose LPS polyI:C or Virus
Epithelial cells Minimal or no effect [31,46].
Neutral because allergic inflammation
due to TLRs pathway activation was
blocked by pre-exposure to high dose
LPS [9].
Dendritic cells
Basically slight Th1 skewing due to high
dose LPS with no IL12/IL4 skewing in
the context [43,45] and less
Th2-promoting mDC2s [57].
Unstimulated peripheral blood
mononuclear cells produced more IL10,
IL12 and IFNγ,indicating increased
spontaneous production of Th1 and
regulatory cytokines [103].
Th1 predominant except RSV infection,
which displays Th2 pattern [73,75].
Net result: Th1 predominant #
# Here what we call high dose is relative to low dose, but not to the extent of toxic dose as in Table 3. High dose
LPS has minimal or no effect on epithelial cells, but will skew the DCs slightly toward Th1 response when no
IL12/IL4 skewing in the context, and produce less Th2-promoting mDC2s.On the other hand, the Th2-prone allergic
inflammation of polyI:C or virus was blocked by pre-exposure to high dose LPS, and polyI:C or virus will stimulate
DCs to produce Th1 predominant cytokines with the exception of RSV infection, which displays Th2 pattern. The net
result of polyI:C or virus stimulation in the presence of high dose LPS on DCs and epithelial cells would thus be
Th1 predominant.
5.2. Second, Why Is More Common Cold in Early Life Associated with Less Allergy in Later Life?
A German birth cohort multicenter allergy study (MAS) group confirmed that children with ≤1
episode of runny nose before the age of one year were more likely to be diagnosed as asthmatic at
seven years old or to have wheeze at seven years old, compared with those with ≥2 episodes, and
were more likely to be atopic before the age of five years. Similarly, having ≥1 viral infection of
the herpes type in the first three years of life was inversely associated with asthma at age seven [7].
The conclusion excludes the lower respiratory infection, which instead showed a positive association
with later wheeze in that study. No significant associations were found between bacterial, fungal, or
gastrointestinal infections and later asthma [7]. More instances of the common cold are closely related
to poorer hygiene due to more crowded living or poorer economic conditions, so on average there
would be more environmental LPS. This was described in studies by Giovannangelo et al., who found
that having more than four persons living in the home were consistently associated with up to 1.7-fold
higher endotoxin concentrations in the mattress and floor dust [104]. Similarly, in Brazil’s study, LPS
levels in day care centers and preschools were three times higher than in elementary schools [105].
Again for each episode of URI, more LPS would block the effect of dsRNA to induce allergic cytokines
at epithelial level [9], and the common cold virus would stimulate the DCs towards Th1 skewing,
because dsRNA stimulates both the maturation and resistance of DCs, and makes them capable of
trigger naïve T cells and drives polarized Th1 responses [75] (Table 4, Figure 1a). The Tucson Children’s
Respiratory Study proposed a conclusion that indirectly supports the protective effect of ‘poor hygiene’.
It states that more exposure of young children to older children at home or longer stays at day care
center confers more protection against the development of asthma and frequent wheezing in late
childhood [106]. Maier etc. confirmed that there is a significant difference of the bacterial community
structure in house dust between families with children attending day care and those without [107].
A complex question then arises: is rhinovirus beneficial or detrimental in allergic response?
According to the German MAS study above, the infection of common cold virus of course
is protective [7], and since around 50 to 83% of episodes of the common cold are caused by
rhinoviruses [85,108], so rhinovirus should be protective. However, there is a pitfall in the study:
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because in that study more lower respiratory tract infections (LRTIs) before age three is positively
associated with more wheeze at age seven [7]. Unfortunately except for the six months group,
in which RSV accounted for most of the LRTIs, rhinovirus accounts for the largest portion of pathogens
causing LRTIs alone or in combination with other viruses [82]. The other viral pathogens include RSV,
parainfluenza viruses, adenoviruses and enteroviruses etc. Thus, in those children with no wheezing
predisposition, according to Illis’s study, rhinovirus should be protective; but for those with wheezing
tendency, rhinovirus seems to play a proallergic role. Thus, again, as with the dual role of LPS [41],
rhinovirus seems to have a bidirectional capacity of enhancing or reducing the allergic tendency of
children depending on their already preexisting allergic predisposition. Another indication of the
effect of predisposition is that in children less than four years old, rates of asymptomatic infection
range from 12 to 32% [94,109–111]. Readers are encouraged to refer back to Sections 2.4 and 2.6.3 for
the protective mechanism of rhinovirus.
5.3. Summary of the Four Major Players in Hygiene Hypothesis
Usually LPS does not directly act on epithelial cells, instead, it protects the epithelial cells
against the action of dsRNA. LPS stimulates DCs to become more Th1-prone with a large dose,
and more Th2-prone with a small dose, more Th1-prone in an active period, and more Th2-prone in
an exhausted period, and the presence of IL12 or IL4 is the third factor, which would facilitate the
Th1/Th2 skewing in the presence of antigen [45]. dsRNA differentially acts on epithelial cells and
DCs, with Th2-prone on epithelial cells, and Th1-prone on DCs. Thus, before sensitization, when the
LPS level in the environment is high, each episode of common cold infection (dsRNA) has no effect
on ECs, and stimulate DCs to be more Th1-prone, except RSV infection, which is Th2-prone (Table 4
and Figure 1a). However, when the LPS level in the environment is low, each episode of common
cold infection (dsRNA) then stimulates the epithelial cells to produce proallergic cytokines, like TSLP
and IL33, which would facilitate T cells to produce more IL4, IL5 and IL13, and these Th2 cytokines
would work synergistically with dsRNA to stimulate ECs to produce more IL33 and TSLP, forming
a positive feedback cycle, and thus shaping the allergic predisposition seen clinically (Table 5 and
Figure 1b). These four players basically regulate the key networks of immune responses related to
hygiene hypothesis.
However, after sensitization has occurred, the protective effects of LPS and dsRNA may be lost,
as discussed below.
Table 5. Profile of four major players of the hygiene hypothesis model in the presence of low dose LPS
before sensitization.
Cell Type Low Dose LPS polyI:C or Virus
Epithelial cells Minimal or no effect.
Th2 predominant due to TLR3 pathway
activation with production of TSLP, IL33, IL25 etc.
[31–35], even slightly enhanced by pre-exposure
to low dose LPS [9].
Dendritic cells
Basically slight Th2 skewing due
to low dose LPS when no IL12/IL4
skewing in the context [43,45,57].
Th1 or Th2 skewing, depending on the relative
stimulatory force between Th2-prone allergic
cytokines, such as TSLP and IL33 [112,113], and
Th1-prone polyI:C or virus [73,75], except RSV,
which displays Th2 pattern.
Net result:Th2 predominant #
# Here what we call high dose is relative to low dose, but not to the extent of toxic dose as in Table 3. Low dose LPS
has minimal or no effect on epithelial cells, but will skew the DCs slightly toward Th2 response when no IL12/IL4
skewing in the context. On the other hand, the Th2-prone allergic inflammation of polyI:C or virus was not blocked,
or even slightly enhanced by pre-exposure to low dose LPS. polyI:C or virus will stimulate DCs to produce Th1
predominant cytokines with the exception of RSV infection, which displays Th2 pattern. However, Th2-prone
signals coming from epithelial cells, such as TSLP and IL33 will skew the DCs toward Th2. The net result of polyI:C
or virus stimulation in the presence of low dose LPS on DCs and epithelial cells would thus be Th2 predominant.
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6. Why Does the Hygiene Hypothesis Work Only before One Critical Time Point in Early life?
After Allergy Is Established, Why Do the dsRNA and LPS No More Play Protective Roles?
6.1. Why, in Established Atopic Patients, Does Exposure to More Environmental LPS No Longer Protect Them
against Allergy?
Tulic et al. proposed a mechanism, which stated that before or shortly after sensitization, LPS
exposure causes the production of IFNγ and/or IL12 and drives the B cells toward IgG antibody
production but inhibits class switching to IgE. Subsequently, plasma cells committed to producing
IgE are already present, and these committed IgE-producing cells are resistant to regulation by IL12
and/or IFNγ. Therefore, LPS must be present before the isotype switch to IgE has occurred in order
to exert its inhibitory effect [41]. In his study, LPS exposure on Days 6, 8 and 10 with challenging
OVA on Day 11 resulted in more cellular influx, with increases in both neutrophils and eosinophils.
Lowe performed his study on guinea pigs and concluded LPS exposure 24 h before allergen challenge
diminished airway hyperreactivity (AHR) to histamine, whereas co-administered LPS prolonged the
AHR [44]. The above rule seems to be applicable to DCs and in whole rat or mouse models, where
LPS enhances both Th1/Th2 responses after sensitization, with Th2 response seemingly resistant to
LPS treatment.
However, in Rodriguez’s study, LPS via either intranasal or intravenous route could still
completely suppress airway eosinophilia [54]. The disparity may be due to the difference of
experimental animals (rat vs. mice), the dose of LPS (50 μg/mL vs. 20 μg in one animal) and
the pathway (inhaled by aerosol in a chamber vs. intranasally or intravenously). Similarly, in Schuijs’
study, when bronchial epithelial cells were removed from asthmatic patients via endobronchial biopsy
and grown to confluence, and then cultured in air-liquid interface model, 100 ng LPS pretreatment
every other day for one week still was able to reduce the production of IL1α and GM-CSF [10]. Thus,
LPS seems protective still when considering respiratory epithelial cells only.
To reconcile these seemingly conflicting data, more studies are needed to elucidate the delicate
and complex underlying mechanisms.
6.2. Why in Established Atopic Patients, Does Exposure to Viral Infections No Longer Protect Them against
Allergies, but, Instead, Worsen the Allergic Disorders
TSLP production is increased in allergic individuals, and further synergistically enhanced by
a combination of IL4 and dsRNA [31]. This implies that in asthmatic airway, respiratory viral
infection and the recruitment of Th2 cytokine producing cells may increase the production of
TSLP and amplify Th2 inflammation. When mice challenged with the already sensitized allergen,
rhinovirus infection exacerbated neutrophilic, eosinophilic and lymphocytic airway inflammation,
airway hyperresponsiveness, mucus secretion and production of both Th1 and Th2 cytokines [93].
Thus, the mechanisms of the synergistic interaction between virus infection and allergen exposure to
increase the risk of asthma exacerbations are elucidated. Allergen exposure causes increased allergic
cytokines, which would be further increased by the concomitant activation of TLR3 of epithelial cells
by viral dsRNA. However, since most viral infections stimulate DCs to produce Th1 cytokines, so both
Th1 and Th2 cytokines would both be increased.
In addition, in healthy humans, plasmacytoid dendritic cells (pDCs) and the IFNαβ they secrete
selectively negatively regulate Th2 cytokine synthesis following RV exposure in vitro. In asthmatic
patients, this important regulatory mechanism may be lost and contribute to asthma exacerbations
during RV infections [114,115]. The pDCs may play key roles in healthy humans to negate the
Th2-prone effect of rhinovirus. For allergic patients, the environmental LPS concentration is on average
less than their normal counterpart [116], and thus confers less protection at epithelial level. Thus, when
these patients contract the common cold, dsRNA would activate the epithelial cells and induce the
production of allergic cytokines. In addition, increased Th2 cytokines in this context would augment
the dsRNA effect in stimulating epithelial cells to produce more proallergic cytokines [31].
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7. What Factors Initiate the Disruption of Immune Balance towards the Allergic Predisposition?
As mentioned above in Section 2.6.3, for some individuals allergic predisposition exists
before rhinovirus infection. In a similar manner, some risk factors are already present before
the allergy-inciting event, which make the individuals more susceptible to the development of
allergic disorders. The proposed mechanisms leading to allergic predisposition include mostly
genetic deficiency [10], airway and gut microbial dysbiosis (i.e., deviations from healthy microbial
compositions) [79], and possibly environmental hazard factors.
7.1. Genetic Deficiency
Defects in TLR7/interferon regulatory factor 7 (IRF7) signaling predisposes to severe viral
bronchiolitis and subsequent asthma [117,118]. Levels of plasmacytoid DCs (pDCs) during infancy
were inversely correlated with childhood respiratory tract infections and wheezing up to age five
years [24]. Reduced circulating pDCs during early life predisposes young children to more frequent
and more severe respiratory tract viral infections and more wheezing. Recently several SNPs in the
TNFAIP3 interacting protein (TNIP-1) were identified as associated with asthma, further supporting
the importance of the A20 protective pathway [10]. Furthermore, common mutations in TLR4 are
associated with differences in LPS responsiveness in humans, and these people are hyporesponsive to
inhaled LPS [119]. Children sensitized to any allergen early in life and sensitized to inhalant allergens
by the age of seven years were found to be at a significantly increased risk of being asthmatic at this
age if a positive parental history of asthma or atopy was present, with the effect being strongest for
maternal asthma, indicating the existence of an underlying determining genetic factor [120].
7.2. Microbial Dysbiosis
7.2.1. Airway Microbial Dysbiosis
The microbes inhabiting the lower airways show substantial differences between asthmatics and
healthy subjects. Though there are some variations, generally speaking, in asthmatics, more Hemophilus,
Moraxella, Neisseria and Streptococcus spp. were found, but less Bacteroides [79,121]. However, once
again, whether the difference of microbiome precedes and leads to the development of allergic
disorders or just develops after sensitization begins needs more study to reach a firm conclusion.
However, just as we have discussed above, the amount of protective LPS in the environment (which
represent the amount of LPS inhaled) or the type of LPS (pathogenic or non-pathogenic) in the airways
are closely related with later atopy development [61,122]. Here, we have to point out the importance
of organ specificity of LPS in determining its role of protection or pro-inflammation. For example,
S. typhimurium is an intestinal pathogen of mice, but it could protect against airway inflammation
when applied before or shortly after sensitization [41].
7.2.2. Gut Microbial Dysbiosis
Human guts are colonized with many trillions of bacteria, viruses and eukaryotes. Their
colonization in early life plays an important role in the development of our immune system [123].
During a critical period in early life, disruption of the optimal host-commensal interactions, i.e.,
dysbiosis of these microbes might cause allergic disorders [124]. For example, babies born by cesarean
section harbor more Staphylococcus, Corynebacterium and Propionibacterium than those born vaginally, but
less Lactobacillus, Prevotella and Sneathia species [125]. The resulting change of microbiota in the intestine
may lead to aberrant long-term colonization and subsequent altering of immune development [126].
Cesarean delivery is associated with a significantly increased rate of allergic disorders [127], supporting
this conclusion.
A modified hygiene hypothesis suggests that an altered normal intestinal colonization pattern
in infancy, which fails to induce immunological tolerance, could be responsible for the increase in
allergies [128]. Two other studies concluded that bacterial diversity in the intestinal flora of infancy
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was inversely associated with the risk of later allergic sensitization [129,130]. Therapeutic trials
with various strains of oral probiotics achieved success to varying degrees by restoring intestinal
homeostasis and preventing or alleviating allergy, at least in part by interacting with the intestinal
immune cells [131–133], although this conclusion is not agreed with by all [134,135].
Microbial products and metabolites can also affect allergic inflammation. Dietary fermentable
fiber content changes the gut and lung microbiota, and the metabolized fibers consequently increase
the concentration of circulating short-chain fatty acids (SCFAs), which protect against allergic lung
inflammation [136], possibly via promoting peripheral regulatory T-cell generation [137].
7.3. Environmental Hazard Factors
Exposure to air pollutants, including higher levels of O3 and others, can cause acute exacerbations
in those who already have allergic respiratory disorders, but its role in the initiation of new cases of
asthma is not yet confirmed [138]. A cohort study of 3863 children confirmed the association between
traffic-related air pollution and the development of asthma and allergies during the first eight years
of life. According to the study, PM2.5 levels and NO2 were associated with a significant increase in
incidence and prevalence of asthma [139]. In another study, infants at high familial risk for asthma were
recruited and the birth year home exposures to NO, NO2 and PM2.5 were found to be associated with a
markedly increased risk of asthma at age of seven with an odds ratio around 3 [140]. Indoor dampness
and mold are also determinants for developing asthma. Chemical emissions from damp structures
and surface materials may be other causal agents related to the development of asthma [141,142].
8. Conclusions
8.1. LPS Has a High Potential for Prevention Modality; However, Application of LPS as Treatment Modality
Should Be Considered Cautiously
LPS, or maybe farm dust, attenuates the induction of proallergic cytokines, including TSLP, IL33,
and others in respiratory epithelial cells in response to viral infection, and it does not disturb the
Th1-prone effect of viruses on DCs. Thus, it should be a high potential candidate for applications of
prevention modality against allergic development. However, although LPS is promising as a prevention
modality against allergic disorders, the application of LPS is questionable after the establishment of
allergic disorders, and may exacerbate preexisting disorders. The original Th1/Th2 balance model is
not applicable since many studies have confirmed the presence of both increased Th1 and Th2 cells in
asthmatic airways [143], and specifically, both Th1 and Th17 cells are crucial for the development of
neutrophilic inflammation in the airways [144–146].
8.2. Limitations of the Proposed Model
In our simplified model, the role of regulatory T cells (Treg), Th17, innate lymphoid cells group
2 (ILC2) and signaling via other pathways, such as NOD-like receptors were not presented due to
insufficient studies to propose an incorporating mechanism. Allergens also were not mentioned,
both because allergens act via different pathways and because their relationship with the hygiene
hypothesis is not yet clear.
8.3. The Content of “Hygiene Hypothesis” Could Be Modified
The original statement pointing out “more infections in early childhood protect against later
atopy” could be modified into “more non-epithelium-damaging viral infections in the presence of
organ-specific non-pathogenic bacteria (or certain bacterial products) in early childhood protect against
later atopy” to accommodate most of the exceptions.
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Abstract: Mounting evidence has indicated that lipopolysaccharide (LPS) is implicated in
neuroimmunological responses, but the body’s response to subclinical doses of bacterial endotoxin
remains poorly understood. The influence of a low single dose of LPS from Salmonella Enteritidis,
which does not result in any clinical symptoms of intoxication (subclinical lipopolysaccharide),
on selected cells and signal molecules of the neuroimmune system was tested. Five juvenile
crossbred female pigs were intravenously injected with LPS from S. Enteritidis (5 μg/kg body
weight (b.w.)), while five pigs from the control group received sodium chloride in the same way.
Our data demonstrated that subclinical LPS from S. Enteritidis increased levels of dopamine in
the brain and neuropeptides such as substance P (SP), galanin (GAL), neuropeptide Y (NPY), and
active intestinal peptide (VIP) in the cervical lymph nodes with serum hyperhaptoglobinaemia and
reduction of plasma CD4 and CD8 T-lymphocytes seven days after lipopolysaccharide administration.
CD4 and CD8 T-lymphocytes from the cervical lymph node and serum interleukin-6 and tumour
necrosis factor α showed no significant differences between the control and lipopolysaccharide
groups. Subclinical lipopolysaccharide from S. Enteritidis can affect cells and signal molecules of the
neuroimmune system. The presence of subclinical lipopolysaccharide from S. Enteritidis is associated
with unknown prolonged consequences and may require eradication and a deeper search into the
asymptomatic carrier state of Salmonella spp.
Keywords: LPS from S. Enteritidis; neuropeptides; dopamine; CD4 T-lymphocytes; CD8 T-lymphocytes;
haptoglobin; cytokines; cervical lymph nodes; prefrontal cortex; substantia nigra
1. Introduction
Our growing knowledge of the role of viruses and bacteria as a cause of mental disorders, cancer,
and neurodegenerative and metabolic diseases may help in preventing certain human chronic diseases
that pose serious public health problems [1–5]. Endotoxin LPS (lipopolysaccharide) is one of the most
important bacterial components contributing to many chronic diseases and sepsis [6]. Lipopolysaccharide
animal models for induction of Parkinson’s disease have been used by many researchers [7–10].
The mechanisms underlying Parkinson’s disease (PD) models indicate that LPS induces microglial
activation. LPS inflammation by the activation of glial cells and a series of inflammatory mediators,
including proinflammatory cytokines, chemokines, reactive oxygen species, and nitric oxide, plays an
important role in neurodegenerative diseases, including PD, Alzheimer’s disease (AD), amyotrophic
lateral sclerosis, psychiatric disorders, cognitive impairment, and depression [11–14]. Recent evidence
suggests that LPS may play an important role in some neurodegeneration and metabolic diseases, not
only in rodents but also in humans [15,16]. Pretorius et al. [17] point to the potentially important role
of even very low LPS concentrations (0.2 ng/L) in healthy individuals in the etiology of PD, and they
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hypothesized that lipopolysaccharide-binding protein may have a protective role in the context of PD.
LPS is probably associated with AD neuropathology in humans because it is able to transit physiological
barriers to access the brain [18].
How LPS given peripherally induces its effects on the brain is still not clear. Banks et al. [19]
suggested that high doses of LPS, in contrast to low doses, can disrupt the blood brain barrier (BBB).
They suggested that at low peripheral doses of LPS, the amount entering the brain is below that needed
to directly affect the brain. Only about 0.025% of an intravenously administered dose of LPS from
Salmonella enterica reaches the brain parenchyma [20]. Despite the low passage of LPS across the
BBB, LPS could potentially affect brain function by a release of substances from the periphery that
can either cross the BBB; interact with immune cells; or alter BBB permeability and functions of the
BBB, for example, through dysfunction of vascular endothelial cells or induction of the synthesis of
mediators by the cells of the blood–cerebrospinal fluid barrier (BCSFB) and the BBB. Both the BCSFB
and the BBB seem equipped to convey signals to the brain parenchyma in response to a low dose
of LPS [21,22]. On the other hand, it is known that LPS or its constituents can persist in various
tissues and organs for years [23,24]. A large part of LPS is rapidly cleared from the circulation, but
the remaining ~20% of LPS could be bound to immune cells such as monocytes, tissue macrophages,
neutrophils, or platelets, and thus could potentially be involved in signalling [25].
Knowledge of asymptomatic Salmonella infection and latent carriers is limited, but it is well known
that LPS causing symptoms of disease can induce an acute phase reaction in humans and animals
and release pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumour necrosis factor α
(TNF-α) [26–28]. Additionally, haptoglobin (Hp), a positive acute-phase protein in response to IL-6,
can modulate the inflammatory response induced by LPS. Hp interacts with both resting and activated
CD4 and CD8 T-lymphocytes and can play a modulating role in type 1 and 2 T-helper cells, balancing
immune responses. [29,30].
LPS can also influence neuropeptides, which are neuroimmune modulators in the communication
between the nervous system and the immune system. A single low dose of LPS of S. Enteritidis can
modulate main enteric neuropeptides [31]. Neuropeptides are widely distributed and involved in many
physiological and pathological processes. Neuropeptides of neural and non-neural origin are released
in the lymphoid organs such as lymph nodes (LN) and contribute to the modulation of the function
of many immunological cells, including lymphocytes and monocytes. Galanin (GAL), neuropeptide
Y (NPY), substance P (SP), and vasoactive intestinal peptide (VIP) represent the neuropeptides most
involved in neuroimmune modulation. [32–34]. Recent studies have illustrated the importance of
immune regulation by neuropeptides through direct effects on and CD4 and CD8 lymphocytes [35].
One of the more important catecholamines in health and disease is dopamine (DA). A growing
body of research now suggests that not only neuropeptides, but also catecholamines, serve as a link
between the nervous and immune systems during physiological and pathological processes [36].
Among its many roles, DA also plays an important role in the immune system. In the immune system,
DA acts upon receptors present in immune cells, especially lymphocytes and can be synthesized and
released by immune cells themselves [37]. The presence of DA receptors in immune cells suggests
that DA plays a physiological role in the regulation of the immune response, and that its deregulation
could be involved in many pathological processes such as autoimmune disorders, schizophrenia, and
Parkinson’s disease [38,39]. In addition, a decrease of DA in substantia nigra (SN) can lead to PD,
and dysregulation of DA in the prefrontal cortex (PFC) is associated with schizophrenia and other
psychiatric disorders [40,41].
DA interactions between the nervous and immune systems may be very important in connection
with the discovery of meningeal lymphatic vessels [42,43]. Louveau et al. [43] demonstrated that
meningeal lymphatic vessels were capable of carrying leukocytes to the deep cervical lymph nodes
(dcLN) and, at later time points, to the superficial cervical lymph nodes (scLN). Additionally,
cerebrospinal fluid (CSF) drained from the subarachnoid space along the olfactory nerves to nasal
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lymphatic vessels and subsequently migrated to the scLN [44,45]. Recent studies have also indicated
the critical role of the cervical lymph nodes (cLN) on influencing neuroimmunological reactions [46].
In summary, mounting evidence has highlighted that LPS is implicated in neuroimmunological
response, but the knowledge of the body’s responses to subclinical doses of bacterial endotoxin
remains poorly understood. Taking into consideration all of the facts mentioned above, we are the
first to test the influence of a low single dose of LPS from S. Enteritidis, which does not result in any
clinical symptoms of intoxication (subclinical LPS), and which can hypothetically take place during,
for example, the asymptomatic carrier state of Salmonella spp. on selected cells and signal molecules of
the neuroimmune system:
(1) Peripheral blood levels of CD4 T-lymphocytes, CD8 T-lymphocytes, IL-6, TNF-α, and Hp
(2) cLN levels of CD4 T-lymphocytes, CD8 T-lymphocytes and neuropeptides such as GAL, NPY, SP
and VIP
(3) SN and PFC levels of DA
In our study, animal experiments remain essential, and appropriate animal models are irreplaceable
because to expose humans to even such low doses of LPS with unknown prolonged consequences is
not ethical in scientific studies. In addition, the study of human active substance is hampered by tissue
inaccessibility for biopsy. It should be noted that using the pig as a biomedical model plays a critical role
in understanding the physiological and pathophysiological processes in the human body. Experiments
that use the pig as a biomedical model have very good repeatability of results and recapitulation of
human conditions, because pigs are phylogenetically closer to humans than rodents [47,48].
2. Results
On each day during the experiment, all animals were assessed by a veterinary surgeon as being
clinically healthy. All animals in the LPS and control groups were without any symptoms of disease
during this investigation. The low dose of LPS S. Enteritidis used in this experiment did not evoke
any differences in health status, appearance, temperature, or body weight in animals of the LPS group
compared with the control group during the entire period of the experiment. Similar body weights
with no significant statistically changes were observed between LPS and control group (Figure 1A).
Both in the LPS and in the control group, each measurement of the rectal temperature in the morning
(Figure 1B) and in the afternoon (Figure 1C) fluctuated in the normal temperature range of pigs.
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Figure 1. The daily body weights and rectal temperatures in the control group (Con), which received
saline, and in the treatment group (LPS), which received lipopolysaccharide (LPS) from S. Enteritidis
at a dose of 5 μg/kg body weight (b.w.); n = 5 pigs/group. (A) The body weights were determined
once a day in the morning (between 07:00 and 07:30). The first measurement was before premedication
and LPS or NaCl administration (day 0), and the final measurement was on the last day of the
experiment before antecedent sample collection (day 7). (B) The rectal temperatures were measured
in the morning (between 07:00 and 07:30). The first measurement was before premedication and LPS
or NaCl administration (day 0), and the final measurement was on the last day of the experiment
before antecedent sample collection (day 7). (C) The rectal temperatures in the afternoon (between
17:00 and 17:30). The first measurement was day 0 (in the day of LPS or NaCl administration), the final
measurement was on day 6 of the experiment. The body weight per day and rectal temperatures in
the morning and in the afternoon were presented as the mean from group ± SD. The results of rectal
temperature and body weight were compared between the control and the LPS group using Student’s
t-test. The result of rectal temperature and body weight was not statistically significant.
The effects of LPS on studied levels of parameters and active substances from the blood, scLN,
and brain seven days after administration of LPS S. Enteritidis are shown in Figures 2–5. Figure 2
depicts the levels of Hp, IL-6, and TNF-α in the peripheral blood of animals from the control and LPS
group. After the administration of LPS S. Enteritidis, pigs had significantly enhanced serum levels
of Hp. The level of Hp was almost three-fold higher compared with the control group and amounted to
3599.71 ± 135.69 μg/mL (an increase from 1330.97 ± 344.67 to 3599.71 ± 135.69) (Figure 2A). Although
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Figure 2. Concentrations of acute phase protein and cytokines in the peripheral blood in the control
group (Con), which received saline, and in the treatment group (LPS), which received LPS from
S. Enteritidis at a dose of 5 μg/kg b.w.; n = 5 pigs/group. Bars represent mean ± SD (standard
deviation). The statistical analysis was performed by one-way analysis of variance (ANOVA) and
Tukey’s tests. (A) Serum concentrations of haptoglobin (Hp). The result was statistically different
at p < 0.001 as compared with the control group (B) Serum concentrations of interleukin-6 (IL-6).
The result was not statistically significant. (C) Serum concentrations of tumour necrosis factor α
(TNF-α). The result was not statistically significant.
Figure 3 depicts the percentage of CD4 and CD8 T-lymphocytes in peripheral blood of animals
from the control and LPS group. A decrease in the mean percentage of both plasma CD4 T-lymphocytes
from 26.13 ± 1.49 (in control group) to 18.54 ± 1.16 (in LPS group) and plasma CD8 T-lymphocytes
from 42.01 ± 5.46 (in control group) to 33.63 ± 5.64 (in LPS group) was noted (Figure 3).
DA levels were determined in the brain tissue. Figure 4 depicts the DA levels in SN and PFC
in the control group and the LPS group. Compared with the control, the values of DA increased
significantly following the injection of LPS from 91.86 ± 3.05 to 138.58 ± 10.07 ng/g in SN and from
15.41 ± 2.46 to 53.59 ± 3.90 ng/g in PFC (Figure 4).
Figure 3. Cont.
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Figure 3. Percentages of CD4 and CD8 T-lymphocytes in the peripheral blood in the control group (Con),
which received saline, and in the treatment group (LPS), which received LPS from S. Enteritidis at a
dose of 5 μg/kg b.w.; n = 5 pigs/group. Bars represent mean ± SD (standard deviation). The statistical
analysis was performed by one-way ANOVA and Tukey’s tests. Statistically different at p = 0.044
(for the percentage of plasma CD8 T-lymphocytes) and p < 0.001(for the percentage of plasma CD4
T-lymphocytes) as compared with the control group. Panels A and B present exemplary dot plots with
distribution of CD4 and CD8 T-lymphocytes of the control and treatment group. Samples were stained
with FITC Anti-Pig CD4a (BD) and PE Anti-Pig CD8a (BD) and analysed on flow cytometer (Beckman
Coulter).
Figure 4. Concentrations of dopamine (DA) in substantia nigra (SN) and in the prefrontal cortex (PFC)
in control groups (Con), which received saline, and treatment group (LPS) following the administration
of subclinical LPS from S. Enteritidis. Bars represent mean ± SD (standard deviation); n = 5 pigs/group.
The statistical analysis was performed by one-way ANOVA and Tukey’s tests. In both SN and PFC,
statistically significant differences of DA concentration for p < 0.001 as compared with the control
group were observed.
The results of the concentration of neuropeptides and the measurements of the percentage of CD4
and CD8 T-lymphocytes in scLN after LPS administration are depicted in Figures 5 and 6. The levels
of all studied neuropeptides reached with LPS were significantly greater than in the control group.
LPS induced an increased level of GAL (from 1.76 ± 0.21 to 3.17 ± 0.43), NPY (from 2.09 ± 0.14 to
3.04 ± 0.46), SP (from 2.36 ± 0.26 to 2.97 ± 0.33), and VIP (from 0.58 ± 0.08 to 1.03 ± 0.14) (Figure 5).
An analysis of the percentages of CD4 T-lymphocytes and CD8 T-lymphocytes in scSN showed no
significant differences between the control and the LPS group (Figure 6).
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Figure 5. Concentrations of neuropeptides: galanin (GAL), neuropeptide Y (NPY), substance P (SP),
and vasoactive intestinal peptide (VIP) in the superficial cervical lymph nodes (scLN). Bars represent
mean ± SD (standard deviation); n = 5 pigs/group; Con—the control group, which received saline;
LPS—the treatment group, which received LPS from S. Enteritidis at a dose of 5 μg/kg b.w. (in saline
solution). The statistical analysis was performed by one-way ANOVA and Tukey’s tests. The results
were statistically different at p < 0.001 as compared with the control group.
Figure 6. Percentages of CD4 and CD8 T-lymphocytes in the superficial cervical lymph nodes (scLN) in
the control group (Con), which received saline, and in the treatment group (LPS), which received LPS
from S. Enteritidis at a dose of 5 μg/kg b.w.; n = 5 pigs/group. Bars represent mean ± SD (standard
deviation). The statistical analysis was performed by one-way ANOVA and Tukey’s tests. The result
was not statistically significant. Panels A and B present exemplary dot plots with distribution of CD4
and CD8 T-lymphocytes of the control and treatment group. Samples were stained with FITC Anti-Pig
CD4a (BD) and PE Anti-Pig CD8a (BD) and analysed on flow cytometer (Beckman Coulter).
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3. Discussion
Although the role of LPS as a major pro-inflammatory component released by gram-negative
bacteria has been widely established, knowledge of asymptomatic LPS infections remains limited.
It may be the case that some of the pathogens or their components, which are able to persist
in organisms without causing any symptoms of the disease, can interfere with neural or/and
immunological cell functions. To understand the mechanisms of the ability of Salmonella spp. to
survive in various host cells, the activity of their lipopolysaccharides may be very important for both
eradication strategies and the prevention of various disease processes, including neurodegenerative
diseases. Additionally, the intra-species and inter-species LPS influence on the immune response
control of bacterial infections and LPS biological activity varies [49–51]. Even LPS derived from two
related species of G-bacteria impacted the regulation of Th-cell responses and T-cell cytokine balances in
different ways [52]. Our previous in vitro observations confirmed that LPS shows differences in activity
to SP and GAL even within particular serotypes of Salmonella spp. [53]. Therefore, considerations of
different LPS biological activity depending on various bacterial sources and long-term consequences
of LPS different doses must be considered in a research strategy. The ability of LPS to impact cell
responses may be attributed to the different bacterial source of LPS, the dosage of LPS, and the time
of LPS or the presence of its metabolites in the body. Niehaus [24] reported that 14 years after a
laboratory worker developed polyneuropathy, encephalopathy, and parkinsonism after accidental
exposure to Salmonella Minnesota LPS—the lipopolysaccharides had not been detoxified by the body.
Thus, considering the probable neuroimmunological effects of subclinical S. Enteritidis LPS with
unknown prolonged consequences—it can be seen that asymptomatic Salmonella infection and latent
carriers are more serious problems than had been assumed [54]. In this study, we investigated the
effects of subclinical S. Enteritidis LPS in vivo, focusing on the neuroimmune response of Hp, IL-6,
TNF-α, and CD4 and CD8 T-lymphocytes in peripheral blood, selected neuropeptides and CD4 and
CD8 T-lymphocytes in cLN, and DA in PFC and SN.
Our data demonstrated that seven days after the administration of LPS S. Enteritidis, pigs had
significantly increased serum levels of Hp, but did not have increased serum levels of TNF-α or
IL-6 compared with the control group (Figure 1A–C). Previous studies have used the administration
of single or repeated doses of LPS, leading to clinical symptoms of intoxication, which induced
short-term increases in serum IL-6 and TNF-α. Qin et al. [55] indicated that a single high dose
of systemic LPS in mice led to a decline in the short-term increase of TNF-α to return to the base
level by 9 h post treatment, and induced a significant chronic loss of DA neurons beginning at
seven months post-treatment. Calvano and Coyle [56] suggested (using the human endotoxin model
generated using LPS from E. coli O:113 in normal human volunteers) that serum TNF-α and IL-6
peaked at 1.5–2 h after endotoxin administration and again became undetectable after 4 and 6 h,
respectively. Similarly, previous studies [57,58] have shown that 12 h after the injection of LPS from
E. coli, pro-inflammatory cytokines such as IL-6 and TNF-α maintained the same levels as in the
control pigs. Despite the lack of differences in the proinflammatory cytokines’ levels in our study,
the Hp level was significantly increased. It may be the case that serum levels of Hp were altered
in response to subclinical LPS challenges because asymptomatic LPS results in an inflammatory
process. It seems likely that subclinical inflammatory activity takes place in the case of such a low
dose of LPS with an absence of clinical symptoms of a disease. It is worth noting that, because of
the relationship of inflammatory processes with psychiatric and neurodegenerative diseases, Hp is
the most frequently studied acute phase protein in major depression and has provided the most
consistent results. Hyperhaptoglobinaemia in major depression is significantly related to the activation
of cell-mediated immunity from activated T-lymphocytes to monocytes [59]. Major depression patients
have abnormal levels of IL-6 and TNF-α, and increased Hp [60]. Robertson et al. [61] found alterations
in lymphocyte T subsets without differences in the total numbers of T-cells in patients with multiple
sclerosis and with major depression. We have observed a decrease in both plasma CD4 and CD8
T-lymphocytes after subclinical S. Enteritidis LPS administration (Figure 3). Juffermans et al. [62]
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observed a decrease in the number of the fraction of CD4 T-lymphocytes in peripheral blood in
healthy volunteers four hours after intravenous administration of LPS from E. coli. This is in line
with our observations of decreased CD4 T-lymphocytes (Figure 3). However, Juffermans et al. [62]
assessed the effects of a single high dose of LPS that caused clinical symptoms of intoxication, rather
than the subclinical dose of LPS as was observed in our study. Palmer et al. [63] reported decreased
CD4/CD8 T-cell ratios in human subjects without any symptoms of intoxication, but with the presence
of subclinical LPS in serum; unfortunately, they did not investigate the source of LPS from the specific
bacterial groups that were present in the body.
To our knowledge, there are no prior studies that describe the effect of a single subclinical dose
of LPS S. Enteritidis on the changes of DA in pig SN and PCF. Our studies have shown that levels
of DA in the SN and PFC were significantly greater in the group that received asymptomatic LPS
from S. Enteritidis than in the control group (Figure 4). Previous studies have described DA levels
as a consequence of the inflammation response after S. Typhimurium [64] or LPS from E. coli [64,65]
administration, and that is probably the main reason why they are not in accordance with our results.
We used a dose that does not result in any clinical symptoms, as well as LPS from different gram-negative
bacteria than that used by the above-mentioned researchers. Guzmán et al. [64] demonstrated that DA
levels decreased in hemisphere regions and did not change in cortex regions, the cerebellum, or the
medulla oblongata five days after oral administration of S. Typhimurium in rats. Another study [65]
showed that intrastriatal injection of LPS from E. coli in a high dose decreased the content of DA in the
rat SN 72 h after an injection. Noworyta-Sokołowska et al. [66] suggested that a high single i.p. LPS from
E. coli administration does not affect the striatal DA level 180 min after LPS administration, but LPS given
repeatedly for five days decreased the DA level. The data indicate that repeated doses and a long period
of time are necessary for the progression of inflammation symptoms induced by LPS. Considering the
differences between the previous studies and our study, we conclude that subclinical LPS affect DA in
a different way than LPS in inducing symptoms of intoxication. It is known that higher levels of DA
released in the ventromedial prefrontal cortex play an important role in reward and motivation, and
drugs like cocaine, amphetamines, and heroin are highly addictive because they increase the release
of DA and then act as DA re-uptake inhibitors. Repeated stressors may also influence the onset of, or
relapse to, a number of DA-related disorders [67]. The latest findings [68] show DA dysregulation in
different regions of the brain in schizophrenia. Enhancing DA levels in SN during DA treatment for
Parkinson’s disease can cause psychotic side effects mimicking the symptoms of schizophrenia. On the
other hand, reducing dopaminergic transmission in the treatment of schizophrenia and psychosis can
cause Parkinson-like symptoms. Furthermore, data from previous studies [40] have provided evidence
for brain DA dysregulation in the schizophrenic brain and confirmed a deficit in DA release in PFC in
schizophrenia. Moreover, pathophysiology of the DA synthesis and/or release in mania and in bipolar
depression is still inconsistent. Both DA agonists and anti-dopaminergics can improve bipolar depressive
symptoms [41]. Hence, finding the hypothetical relationships that may increase DA levels in SN and PFC
seven days after subclinical LPS administration with psychiatric or/and neurodegenerative disorders is
difficult and requires further research.
Neuropeptides (like DA), which can be called neuroimmune transmitters, also play
neuroimmunological roles as modulatory molecules between immune and nervous cells [69]. Both
neuropeptides and DA can be released by neuronal and immunological cells. Under specific stimuli,
these cells may release modulatory molecules into the extracellular compartment, thus enabling
communications between other cells. As an example, T lymphocytes express neuropeptide receptors
for SP and VIP. SP and VIP are released from the lymphoid organs from neuronal and immune cells.
At the same time, neural cells express receptors for cytokines, which are released from the immune
system and affect neural differentiation. The nervous and immune systems may produce and respond
to mediators of immune–neuronal interaction, such as neurotransmitters and cytokines [69]. As we
can see, the nervous system is necessary for full immune function and vice-versa, but the abnormal
activity of immune or nervous cells may result in disease. In the present study, subclinical LPS increase
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all examined neuropeptide concentrations in cLN. SP and VIP are the best-studied immunomodulatory
neuropeptides. Specific high-affinity receptors for both have been identified on lymphocytes and
monocytes, which suggests that they are involved in the direct interaction between immune cells. SP is
an immunostimulatory neuropeptide and modulates a number of important immunological functions,
including direct effects on T-cell activation [22]. VIP is a well-known anti-inflammatory mediator and
may have a dual role in the neuromodulatory system. VIP is generally a suppressive neuropeptide
for T-cell proliferation, but can also enhance certain lymphocyte functions by interacting with different
VIP receptors and can inhibit activation-induced apoptosis in T lymphocytes [70]. NPY modulates
differentiation of T-helper cells and plays an important homeostatic role in balancing disturbances
of neuroimmune systems. In addition, NPY is also able to modulate the immunomodulatory effects
of other neuropeptides and acts as a neuroimmune transmitter and co-transmitter in neuroimmune
crosstalk [33,71]. NPY infusion improves survival during septic shock induced by LPS in mice [72].
The beneficial effects of NPY result from its vasoconstrictor abilities and potentiation of catecholaminergic
vasopressor effects, as well as improved critical immune functions [73]. Although the influence of GAL
on lymphocytes has not been thoroughly studied, it was found that this neuropeptide has a potent
anti-proliferative influence on (at least) certain lymphocyte subpopulations [74]. Considering the above
information and our findings of the high level of GAL, NPY, SP, and VIP in cLN seven days after
subclinical LPS administration, we hypothesize that dysregulation of neuropeptides is connected with
their influence on immune cells. This hypothesis may particularly be confirmed by the fact that in the
present study, despite increasing the selected neuropeptides, LPS did not increase either CD4 or CD8
T-lymphocyte levels in cLN. It should be noted that changes in immune cell functions can also influence
the expression of neuropeptides in lymphoid organs [75]. Therefore, it is possible that neuropeptides
act as a negative feedback inhibitor to decrease CD4 and CD8 T-lymphocyte levels, which have been
upregulated in response to LPS.
The observable occurrence of functional interconnections between the nervous and immune
systems is inextricably interlinked by recent studies revealing the meningeal lymphatic vessels.
The cLN appear to be critical for this neuroimmunological connection [41–43,76]. Ligation of the
collecting vessels draining to the dcLN resulted in the distension of the dural lymphatic vessels
and the accumulation of T-lymphocytes, which suggests that the meningeal lymphatic vessels’
pathway may play a role in antigen presentation and in the movement of peripheral immune cells
out of the brain to cLN [42]. Surprisingly, CD4 T-lymphocytes are required for normal learning
and memory in the brain, because removal of the dcLN disrupted T-cells circulation and induced
learning and memory impairments in mice [77]. Additional experiments have shown that whereas
CD8 T-lymphocytes deficiency is negligible, the participation of CD4 T-lymphocytes is important
for promoting neurodegeneration of DAergic neurons in the SN of mice undergoing PD [78,79].
The presence of infiltrating immune cells in the central nervous system parenchyma has been detected
in most studied neurodegenerative diseases [38,80,81]. Recent evidence suggests that exposure to a
high dose of LPS in vitro leads to suppression of CD8 T-lymphocyte proliferation in the mice spleen but
not in cLN [82]. The suppression of T-cells in the spleen, but not in the cLN, makes it possible for the
continuation of T-cell activation in cLN. Similarly, in the current study, subclinical LPS did not make any
direct (or indirect, probably thanks to neuropeptides) changes in the CD4 and CD8 T-lymphocyte levels
in comparison with the control group (Figure 6). The presence of receptors for DA, neuropeptides,
cytokines, and LPS on T cells in the LN [83] and the possibility of interaction in cLN between CD4 and
CD8 lymphocytes and neuropeptides, together with the discovery of meningeal lymphatic vessels,
may indicate the existence of relationships that until now have not been considered. A biological
factor such as LPS and a pathological process from Alzheimer’s to Parkinson’s disease, schizophrenia,
and depression may be linked to a dysfunctional neuroimmune system. Moreover, our study is very
interesting in reference to a recent study by Kozina et al. [84], which suggested that peripheral immune
signalling plays an unexpected and very important role in the neurodegeneration process.
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In our in vivo studies, in comparison with in vitro systems, an account was taken of the normal
anatomical distribution of CD 4 and CD8 T-lymphocytes and neuropeptides in LN and DA in the brain
and of the integration of the effects of those cells and active substances with cytokines and Hp in blood.
Numerous studies investigating the neuroimmunological system have focused on in vitro systems
in which concentrations of neuroimmune-active substances could be outside the physiological range
and in which no account was taken of the normal anatomical distribution of lymphocytes and neural
innervation of lymphoid organs and peripheral and central tissues. Our in vivo study integrated the
effect of LPS on the levels of neuropeptides, DA, CD4 T-lymphocytes, CD8 T-lymphocytes, acute phase
cytokines, and Hp derived from different tissue and cells following asymptomatic LPS stimulation.
4. Materials and Methods
4.1. Animal Housing, Health Status, and LPS Administration
All experimental procedures were approved by the Local Ethical Committee for Animal
Experimentation in Olsztyn, Poland (decision no.: 73/2015, from 29 September 2015). Animals
were kept and treated in accordance with all institutional and national guidelines applicable within
the Republic of Poland, as per the Federal Law of 15 January 2015 on Animal Welfare for Science and
Education (Dz.U.2015.0.266).
The study was performed on ten juvenile crossbred female pigs (Pietrain × Duroc) and was
conducted when the pigs were between eight and nine weeks of age with body weights of 16–18 kg.
The animals were maintained for two weeks prior to the experiment in order to allow adaptation to the
new environment. The pigs were kept under standard laboratory conditions and fed commercial feed
for pigs of this age group. Following assessment by a veterinary surgeon (DVM, Ph.D.), only clinically
healthy animals with negative results of analyses of Salmonella spp. in faecal samples qualified for
the experiment.
After a two-week adaptive period, pigs included in the experiment were randomly divided into
two groups (five pigs each): a control and a treatment group (LPS group). In the morning, animals
of both groups were subjected to premedication, according to the method previously described [85],
with an intramuscular injection of atropine (Atropinum Sulfuricum Polfa Warszawa S.A., Poland,
0.035 mg/kg b.w.), ketamine (Bioketan, Vetoquinol Biowet Sp. z o.o., Poland and Vetoquinol S.A.,
France, 7.0 mg/kg b.w.), and medetomidine (Cepetor, CP-Pharma Handelsges mbH, Germany,
0.063 mg/kg b.w.). The premedication of animals allowed accurate and safe (for investigators)
injections of LPS. Under premedication, the control animals were injected with 10 mL of 0.9%
NaCl (sodium chloride 0.9% WET Baxter, 9 g/1000 mL, Baxter Sp. z o.o. Poland) saline solution
into the marginal ear vein, while pigs of the treatment group received lipopolysaccharides from
Salmonella enterica serotype Enteritidis in the same way (i.e., intravenously) (L7770 Sigma, Aldrich,
Germany) at a dose of 5 μg/kg b.w. (in 10 mL saline solution). Such a dose has been previously
described as a “low single dose”, which does not result in any clinical symptoms of disease [31,56]. All
procedures and drugs were managed and administered by a veterinary surgeon (DVM, Ph.D.).
During the clinical assessment of the pigs’ health status, conducted by a veterinary surgeon,
the observations of the animal care staff were always considered. In addition, during the physical
examination, the measurements of temperature and body weight, both in the control and LPS group,
were taken into accounts. Pigs were individually weighed once a day in the morning (between 07:00
and 07:30). The body weight data were presented as the mean from group ± SD (standard deviation).
Rectal temperature was determined using an animal digital thermometer (model SC 12, SCALA
Electronic GmbH, Stahnsdorf, Germany). Temperatures were determined twice daily: in the morning
(between 07:00 and 07:30) and in the afternoon (between 17:00 and 17:30) during the seven days
after LPS administration. The first measurement was taken before premedication and LPS or NaCl
administration, and the final measurement was taken on the last day of the experiment before the
antecedent sample collection. The temperature data were presented as the mean from group ± SD.
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4.2. Sample Collection
After a seven-day period, which has been described as sufficient for the emergence of changes
in the nervous system in previous studies [31,86,87], all animals were pre-medicated (in the above-
described manner) and subjected to general anaesthesia using propofol (Scanofol, NORBROOK,
Northern Ireland, IRL.PN, 4.5 mg/kg b.w. given intravenously into the marginal ear vein). Blood
from the LPS-treated animals and the control group was taken from the vena orbital sinus. Serum
was harvested after centrifugation and stored at −80 ◦C for further analyses of IL-6, TNF-α, and Hp.
Heparinised blood samples were collected to isolate peripheral blood mononuclear cells (PBMCs).
After euthanasia, with pentobarbital (Morbital, Biowet Puławy Sp. z o.o, Poland, 60–70 mg/kg b.w.,
given intravenously), the scLN were then isolated [88]. Next, the brains were rapidly removed from the
skulls. The SN and PFC were isolated as described by Jelsing et al. [89]. The right dorsal scLN, the SN,
and the fragment of PFC were frozen immediately after collection in liquid nitrogen and were stored at
−80 ◦C until processing for further analysis. The left dorsal scLN was used for lymphocyte isolation.
4.3. Lymphocytes Isolation Phenotyping
4.3.1. Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from Blood
PBMCs were isolated by gradient centrifugation [90]. An equal volume of phosphate buffered
saline (PBS) was mixed with blood. The mixture was layered on Histopaque-1077 (10771, Sigma)
at a 3:1 ratio (v/v) and centrifuged at 512× g/18 ◦C for 35 min (Eppendorf 5804R, Hamburg,
Germany). Mononuclear cells were aspired and washed in incomplete medium (RPMI 1640 cat.
no. 11875093; Thermo Fisher Scientific supplemented with 10 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) and 10 units/mL penicillin–streptomycin solution, Waltham, MA,
USA), centrifuged at 413× g/10 ◦C for 10 min, and suspended in 1 mL of incomplete medium.
The number of lymphocytes was calculated using a Burker Cell Counter after Trypan Blue staining.
4.3.2. Lymphocytes Isolation from the scLN
The scLN were dounced in incomplete medium and filtered through an 80 μm nylon filter to
remove cell debris. The cells were then washed and centrifuged at 413× g (Eppendorf 5418R, Hamburg,
Germany) at 10 ◦C for 10 min and suspended in 1 mL of incomplete medium [91]. The number of
lymphocytes was calculated using a Burker Cell Counter after Trypan Blue staining.
4.3.3. Lymphocyte Phenotyping
Lymphocytes were stained with fluorescein isothiocyanate (FITC) Mouse Anti-Pig CD4a
(cat. no. 559585; BD Biosecinesces, Clone 74-12-4) and phycoerythrin (PE )Mouse Anti-Pig CD8a
(cat. no. 559584; BD Biosciences, Clone 76-2-11). Cells were incubated at 4 ◦C for 15 min, washed with
FACS buffer (PBS: 0.1 M phosphate buffered saline, pH = 7.2 supplemented with 5% foetal bovine
serum), and centrifuged at 10 ◦C for 10 min and 413× g (Eppendorf 5418R). The supernatant was
removed and the cells were fixed in 2% paraformaldehyde and analysed using a MoFloTM XDP flow
cytometer (Beckman Coulter Inc., Miami, Fullerton, CA, USA) equipped with a 488 nm air-cooled
argon laser. Forward scatter, side scatter, and green and red fluorescence channels were used to
collect specific multi-parameter data from the cells. A total of 50,000 events were collected from each
sample. The data were analysed with the Summit 5.2 (Beckman-Coulter Inc., Miami, FL, USA) software
package. The gating tree was set as follows: forward-scattered light (FSC)/side-scattered light (SSC)
(represent distribution cells on size and intracellular composition) lymphocytes were gated in the
range 100–150 kDa, followed by CD4+ and CD8+ [92].
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4.4. Measurement of Serum Concentration of Hp, IL-6, and TNF-α
The serum concentrations of Hp, IL-6, and TNF-α were quantified by commercial the enzyme-
linked immunosorbent assay (ELISA) kits:
- Pig Haptoglobin ELISA (HAPT-9, Life Diagnostic Inc., West Chester, PA, USA); sensitivity range
from 18.75 to 300 ng/mL
- Quantizing® ELISA Porcine IL-6 (P6000B, R&D Systems, Minneapolis, MN, USA); sensitivity
range from 0.68 to 4.30 pg/mL
- Quantizing® ELISA Porcine TNF-α (PTA00, R&D Systems, Minneapolis, MN, USA); sensitivity
range from 2.8 to 5.0 pg/mL
For all analyses, serum samples were tested in duplicate, according to the manufacturer’s
recommendations. These assays employed the quantitative sandwich enzyme immunoassay technique.
A monoclonal antibody specific for a particular protein was pre-coated onto a microplate.
The standards, control, and samples were pipetted into the wells and, if it was present, it was bound
by the immobilized antibody. After washing away any unbound substances, an enzyme-linked
monoclonal antibody specific for peptides was added to the wells. Following a wash step, a substrate
solution was added to the wells. After stopping the enzyme reaction, the intensity of the colour was
measured. The sample values were then read off the standard curve.
4.5. Brain Sample Preparation and Determination of DA Concentrations
Quantitative determination of DA in SN and in PFC was carried out using a commercially
available Dopamine ELISA kit (RE59161 IBL International; Hamburg, Germany) according to
previously described protocols [93,94]. Briefly, brain samples were weighed and homogenized with an
extract solution containing acetonitrile (0.5 mL/100 mg brain tissue), 0.1 M HCl (0.4 mL/100 mg brain
tissue), 27 mM ethylenedinitrilotetraacetic acid (EDTA) water solution (0.1 mL/100 mg tissue), and
SIGMAFAST Protease Inhibitor Cocktail Tablet EDTA free (cat. no. S8830; Sigma-Aldrich, St. Louis,
MO, USA). The sample was then centrifuged at 4500× g (Eppendorf 5804) and the supernatant
was filtered on syringe filters without pre-filtering (Millex-HV Filter, 0.45 μm, PVDF, Millipore,
Burlington, MA, USA). Samples were concentrated on a miVac centrifugal vacuum concentrator,
model DNA-23050-800, with SpeedTrap (Genevac Limited, Ipswich, UK) for 2 h, and then lyophilized
using an ALPHA 1-4 LSC freeze dryer (MARTIN CHRIST Gefriertrocknungsanlagen GmbH Germany,
Osterode am Harz, Germany). Lyophilized samples were stored at −80 ◦C until analysis. A dopamine
ELISA kit was then used according to the manufacturer’s recommendations. First, DA extraction from
all samples (unknown, standards, and controls) was done on 24 wells plates with extraction, shaking,
and releasing steps (all reagents provided in the kit) followed by ELISA (protocol provided in manual).
An Infinite 200 spectrophotometer (Tecan Group, Männedorf, Switzerland) with Magellan software
was used to read samples absorbance at a wavelength of 450 nm and calculate dopamine concentration
in unknown samples. The results were presented as the average per group ± SD.
4.6. Purification and Determination of Neuropeptide Levels from scLN
The levels of GAL, NPY, SP, and VIP were determined in the scLN in the three-step procedure
described below.
4.6.1. Sample Preparation and High-Temperature Extraction
Brain peptide extracts from tissues were prepared according to the Conlon procedure [95]. Briefly,
frozen tissue was cut into small pieces and 10 mL of hot 1 M acetic acid was added per gram tissue
and boiled for 5 min. The samples were then homogenized using Ultra Turax IKA T-25 (Jankel &
Kunkel IKA, Germany) at RT for 5 min and centrifuged at 4 ◦C for 40 min at 4500× g (Eppendorf 5804).
The supernatant was subject to solid-phase extraction (SPE) step.
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4.6.2. Solid-Phase Extraction (SPE) and Concentration
The supernatants were filtered through syringe filters with a graduated glass fibre pre-filter
(Millex-HPF HV Filter, 0.45 μm, PVDF, Millipore). Trifluoroacetic acid (TFA) was added to filtrates
to obtain a final concentration of 0.1% (v/v). A Sep-Pak Plus Light Cartridge (130 mg of C18
sorbent per cartridge, Waters, Milford, MA, USA) was used according to the producer’s protocol
using a Baker Vacuum Manifold SPE-12G unit (J.T.Baker, Germany). Samples were concentrated
on a miVac centrifugal vacuum concentrator, model DNA-23050-800, with SpeedTrap (Genevac
Limited, UK) for 2h, and then lyophilized using an ALPHA 1-4 LSC freeze dryer (MARTIN CHRIST
Gefriertrocknungsanlagen GmbH Germany). Lyophilized samples were stored at −80 ◦C until analysis.
All chemicals used were of commercial origin with high performance liquid chromatography
(HPLC) grade purity: glacial acetic acid (cat. no. 951503, J.T. Baker), trifluoroacetic acid–TFA
(cat. no. 9470, J.T. Baker) and acetonitrile–LC-MS reagent (cat. no. 9821.1000, J.T. Baker, Germany).
4.6.3. Enzyme-Linked Immunosorbent Assay for Quantitative Determination of GAL, NPY, SP, and
VIP in scLN
For quantitative determination of GAL, NPY, SP, and VIP in scLN, the following commercial
ELISA tests were used: Galanin (GAL) EIA kit, 0–10 ng/mL (S-1210; Peninsula Laboratories
International, Inc., San Carlos, CA, USA); Neuropeptide Y (NPY) EIA kit, 0–100 ng/mL (EK-049-03CE;
Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA); Substance P EIA kit, 0–5 ng/mL (S-1180;
Peninsula Laboratories International, Inc., San Carlos, CA, USA); and Vasoactive Intestinal Peptide
(VIP) EIA kit, 0–25 ng/mL (EK-064-16CE; Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA).
The manufacturers provided reagents for each assay and protocols (temperatures of incubation, sample
volume, reagent volumes) and we followed them. All tests were based on the standard sandwich
ELISA method. Briefly, samples together with primary antibodies were put on plates and incubated
at room temperature. The plate was then washed and conjugated antibodies were added, and the
plates were incubated. After washing, a one-step substrate reagent was added to each well and the
plates were incubated again at room temperature. The reaction was terminated with a stop reagent.
The absorbance was read at λ = 450 nm on a microplate spectrophotometer Infinite 200 (Tecan) for
each sample.
A four-parameter ELISA curve was prepared for each determined neuropeptide (an Excel sheet
was provided by Peninsula Laboratories service). Each sample was assayed in duplicate and the
peptide concentration was read from the curve. Each peptide concentration was presented as the mean
from group ± SD per g of tissue.
4.7. Statistical Analysis
The results of body weight and rectal temperature were compared between the control and
LPS group using Student’s t-test at a significance level of p < 0.05. The other results were analysed
statistically using a one-way analysis of variance (ANOVA) and the significance of differences between
groups was determined using Tukey’s test at a significance level of p < 0.05. The data were expressed
as mean values ± SD and the calculations were performed with SigmaPlot 12 (Systat Software Inc.,
Cracow, Poland)
5. Conclusions
In conclusion, the results of this study indicate that subclinical LPS from S. Enteritidis can affect
cells and signal molecules involved in the neuroimmune interaction. We demonstrated increasing levels
of DA in the brain and neuropeptides in cLN with a decrease in plasma CD4 and CD8 T-lymphocyte
levels after subclinical S. Enteritidis LPS administration. Moreover, our data indicate that LPS
increases serum Hp levels seven days after S. Enteritidis LPS administration. It is possible that
even such low doses of LPS from S. Enteritidis that do not result in any clinical symptoms of the
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disease may require eradication, which may be very important, especially in connection with the
asymptomatic carrier state of Salmonella spp. Understanding how asymptomatic LPS from S. Enteritidis
impact neuroimmune transmitters and neuroimmune T-lymphocytes responses may be useful for the
prevention of pathological processes. Additionally, the results of our study and our considerations
in this paper may be helpful in assessing the long-term consequences of low doses of LPS from
S. Enteritidis. This is especially important in the era of using LPS in developing drugs ranging from
vaccines and cancer therapy to immunostimulants, which are becoming increasingly common in use.
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Abstract: The cornea serves as a barrier to protect the eye against external insults including microbial
pathogens and antigens. Bacterial infection of the cornea often results in corneal melting and scarring
that can lead to severe visual impairment. Not only live bacteria but also their components such as
lipopolysaccharide (LPS) of Gram-negative bacteria contribute to the development of inflammation
and subsequent corneal damage in infectious keratitis. We describe the important role played by
corneal stromal fibroblasts (activated keratocytes) as sentinel cells, immune modulators, and effector
cells in infectious keratitis. Corneal fibroblasts sense bacterial infection through Toll-like receptor
(TLR)–mediated detection of a complex of LPS with soluble cluster of differentiation 14 (CD14) and
LPS binding protein present in tear fluid. The cells then initiate innate immune responses including
the expression of chemokines and adhesion molecules that promote the recruitment of inflammatory
cells necessary for elimination of the infecting bacteria. Infiltrated neutrophils are activated by corneal
stromal collagen and release mediators that stimulate the production of pro–matrix metalloproteinases
by corneal fibroblasts. Elastase produced by Pseudomonas aeruginosa (P. aeruginosa) activates these
released metalloproteinases, resulting in the degradation of stromal collagen. The modulation of
corneal fibroblast activation and of the interaction of these cells with inflammatory cells and bacteria is
thus important to minimize corneal scarring during treatment of infectious keratitis. Pharmacological
agents that are able to restrain such activities of corneal fibroblasts without allowing bacterial growth
represent a potential novel treatment option for prevention of excessive scarring and tissue destruction
in the cornea.
Keywords: fibroblast; keratocyte; cornea; lipopolysaccharide; bacteria; chemokine; adhesion
molecule; collagen; tear fluid
1. Introduction
The cornea is located on the external surface at the front of the eyeball and differs from most
other tissues in that it is transparent and avascular, properties that allow it to contribute to ocular
refraction. The cornea has a relatively simple structure consisting of three layers: the epithelium,
stroma, and endothelium with each layer consisting of a different type of structural cell—epithelial
cells, keratocytes, and endothelial cells, respectively. Given its location, the cornea is frequently
exposed to external insults including microbes, antigens, and inflammatory mediators.
Worldwide, bacterial keratitis is a major cause of visual disturbance and blindness as a result of
the corneal melting and scarring that occur if the infection is not treated promptly and appropriately.
The Gram-negative bacterium, Pseudomonas aeruginosa is one of the most common isolates from
individuals with microbial keratitis, especially those who use extended-wear contact lenses [1–3].
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Not only live bacteria but also their components or products, including the lipopolysaccharide
(LPS, also known as lipoglycan or endotoxin) of Gram-negative bacteria, are able to initiate keratitis
and subsequent corneal damage [4]. Given that the cornea is an avascular tissue and contains few
immune cells, corneal resident cells function as sentinel cells as well as immune modulators during
corneal inflammation [5–7]. Whereas the corneal epithelium serves as an effective barrier to protect
the eye from external agents, corneal stromal fibroblasts (activated keratocytes) play a key role in
the recruitment of inflammatory cells into the cornea during acquired or innate immune responses.
We previously showed that corneal fibroblasts, but not corneal epithelial cells, recognize the T helper 2
(Th2) cytokines interleukin (IL)-4 and IL-13 in tear fluid [8] and express the chemokines eotaxin
(CCL11) [9,10] and thymus- and activation-regulated chemokine (CCL17) [11] as well as vascular cell
adhesion molecule-1 in response to such recognition [9,12]. Corneal fibroblasts may thus play an
important role in the corneal inflammation associated with severe ocular allergic diseases by promoting
the recruitment of eosinophils (via CCL11) and Th2 cells (via CCL17) to the cornea [5,6].
Corneal fibroblasts also recognize bacterial components such as LPS through Toll-like receptors
(TLRs) expressed on their surface and thereby activate appropriate innate immune responses in
bacterial keratitis. In this review, we will address the role of corneal fibroblasts in LPS-related ocular
surface inflammation.
2. Innate Immune Responses to LPS in Corneal Cells
LPS is a component of the cell membrane in Gram-negative bacteria and is a potent secretagogue
for various cytokines produced by inflammatory cells. Among various TLRs, TLR4 recognizes LPS
of Gram-negative bacteria [13]. Although human corneal epithelial cells have been shown to express
TLR4, its role in such cells has been unclear. Whereas some studies found this receptor to be functional
in corneal epithelial cells [14], others reported that it is expressed intracellularly and therefore does not
confer sensitivity to LPS, with the consequent “immunosilent environment” preventing unnecessary
responses to commensal bacteria [15]. Although LPS is anchored in the outer membrane of bacteria,
it is released spontaneously during bacterial growth. LPS released into tear fluid is not able to stimulate
stromal fibroblasts unless the barrier function of the corneal epithelium is compromised. Thus, it is
thought to enter the corneal stroma by diffusion only at sites of epithelial abrasion [16].
Injection of LPS into the corneal stroma induced rapid infiltration of inflammatory cells including
neutrophils and monocytic cells into the stroma and led to the development of corneal ulceration in
rabbits [17,18]. On the basis of these observations, we hypothesized that stromal resident fibroblasts
recognize the presence of LPS and trigger inflammatory cell infiltration through expression of
chemokines and adhesion molecules. We found that human corneal fibroblasts express TLR4, cluster
of differentiation (CD)14, and MD-2, that these proteins form functional LPS receptors [19], and that
the cells initiate innate immune responses to LPS through activation of this receptor complex. Corneal
fibroblasts produce cytokines and chemokines including IL-6, monocyte chemotactic protein (MCP) 1
(CCL2), and IL-8 (CXCL8), but not IL-1β or tumor necrosis factor-α (TNF-α), in response to LPS
(Figure 1). LPS-stimulated corneal fibroblasts also express intercellular adhesion molecule (ICAM) 1
(also known as CD54) [19,20]. Given that the chemotactic activities of MCP-1 and IL-8 as well as
adhesion to ICAM-1 expressed on the surface of structural cells mediate the local infiltration and
activation of monocytes and neutrophils, the activation of corneal fibroblasts by direct stimulation with
LPS may be an important step in the pathogenesis of bacterial infection in the cornea. The cytokine
IL-1β plays an essential role in bacterial clearance as well as in the recruitment of neutrophils
into the cornea during infectious keratitis [21,22]. However, IL-1β is secreted predominantly by
infiltrated inflammatory cells—in particular, by neutrophils themselves—rather than by resident cells.
The mechanisms of cleavage and activation of pro–IL-1β are thought to differ between murine models
of P. aeruginosa keratitis and Streptococcus pneumoniae keratitis [21,22]. Infection with P. aeruginosa
stimulates the production of IL-1β by cultured corneal fibroblasts in a manner that is largely dependent
on the sensing of extracellular flagellin of the bacteria by TLR5 [23].
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Figure 1. Effects of lipopolysaccharide (LPS) on chemokine release and the abundance of ICAM-1
mRNA in human corneal fibroblasts. Cells were incubated for 24 h (A,B) or 6 h (C) with or without LPS
(10 ng/mL) from Escherichia coli (E. coli), Salmonella minnesota (S. minnesota), or Pseudomonas aeruginosa
(P. aeruginosa) as well as in the absence (open bars) or presence (closed bars) of 0.5% human
serum. The amounts of IL-8 (A) and MCP-1 (B) released into the culture medium were then
determined by enzyme-linked immunosorbent assays, and the amount of ICAM-1 mRNA in the
cells (C) was determined by reverse transcription and real-time polymerase chain reaction analysis.
Data are means ± standard error of the mean (SEM) of quadruplicates from representative experiments.
* p < 0.05 versus the corresponding value for cells incubated in the absence of LPS. Reprinted with
permission from [19].
The various effects of LPS on corneal fibroblasts were found to be potentiated by the presence of a
low concentration of human serum (Figure 1) [19], suggesting that factors in serum may contribute to
the activation of these cells by LPS. Several serum proteins and lipids bind to LPS, and we found that
two serum-derived soluble factors—LPS binding protein (LBP) and soluble CD14 (sCD14)—potentiate
LPS-induced innate immune responses in corneal fibroblasts [24]. LPS is an amphipathic molecule
with a small hydrophilic domain and a large hydrophobic component [25]. Lipid A, the lipophilic
portion of LPS, is necessary for endotoxic activity and is highly conserved structurally [26]. In an
aqueous environment such as tear fluid, LPS forms polymeric aggregates with the lipid A region
facing inward and the hydrophilic polysaccharide component facing outward [25]. Polymeric forms of
LPS bind poorly to cells and fail to provoke responses at low concentrations [27]. LBP is produced
mostly by the liver and was initially identified as an acute-phase reactant in serum. LBP binds
LPS and renders it monomeric, thereby exposing the active lipid A moiety. LBP thus facilitates
detection of LPS by its receptors expressed on corneal fibroblasts [18,28,29]. CD14 exists in two forms:
a glycophosphatidylinositol-anchored membrane-bound form (mCD14), and a soluble form. Various
cell types including inflammatory cells as well as human corneal fibroblasts constitutively express
mCD14 at the cell surface, whereas sCD14 forms a complex with LPS that is thought to bind to
mCD14-negative cells and thereby to confer sensitivity to LPS. LPS-induced innate immune responses
including the expression of chemokines and adhesion molecules in corneal fibroblasts are enhanced by
the addition of either LBP or sCD14 (Figure 2) [24]. Although the cornea lacks blood vessels, soluble
serum factors are present in the tear fluid that covers the ocular surface. We and others have shown
that the tear fluid of healthy adults contains both sCD14 and LBP (Figure 3) [30,31] and our in vitro
experiments suggest that they are present at concentrations sufficient to support maximal effects of
LPS on innate immune responses in corneal fibroblasts.
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Figure 2. Concentration-dependent effects of soluble cluster of differentiation 14 (sCD14) and LPS
binding protein (LBP) on IL-8 release by human corneal fibroblasts. Cells deprived of serum for 24 h
were incubated for 24 h in the absence (open circles) or presence (closed circles) of LPS (10 ng/mL) and
with the indicated concentrations of sCD14 (A) or LBP (B), after which the amount of IL-8 released
into the culture medium was determined. Data are means ± SEM of triplicates from representative
experiments. * p < 0.01 versus the corresponding value for cells incubated with LPS in the absence of
sCD14 or LBP. Reprinted with permission from [24].
Figure 3. Concentrations of sCD14 and LBP in human tear fluid and serum from the same individuals.
Circles, individual values; bars, mean values. Reprinted with permission from [31].
Taken together, these various observations suggest that sCD14 and LBP in tear fluid bind LPS and
enhance the perception of LPS by corneal fibroblasts, thereby contributing to the first line of immune
defense of the cornea against microorganisms.
The innate immune recognition of intracellular LPS by a TLR4-independent mechanism was
recently uncovered [32,33]. The lipid A moiety of LPS, when present in the cytoplasm, was thus
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found to trigger noncanonical inflammasome activation that results in the activation of caspase-11,
pyroptosis, and the proteolytic processing of pro-IL-1β and pro-IL-18. However, the presence of this
intracellular LPS-sensing pathway and its potential role in corneal fibroblasts remains to be elucidated.
3. Therapeutic Intervention Targeting the Role of Corneal Fibroblasts in Infectious Keratitis
The treatment for individuals with bacterial keratitis is administration of appropriate antibiotics.
However, LPS is rapidly released from bacteria as a consequence of antibiotic therapy [34], and once
corneal fibroblasts have been activated by such released LPS, antibiotics are not able to influence the
inflammatory responses of these cells. Although such responses by corneal fibroblasts are the first
line of immune defense in the avascular cornea and are important for protection of the host from
pathogens at the early stage of infection, persistent and excessive inflammatory responses result in the
destruction of corneal tissue.
Keratocytes contribute to maintenance of corneal stromal structure by synthesizing and
degrading stromal extracellular matrix proteins including collagen under physiological conditions.
Such degradation of the stromal matrix is mediated by matrix metalloproteinases (MMPs) derived
from the cells [35,36]. Under pathological conditions such as bacterial infection, the interaction of
corneal fibroblasts with invading bacteria and infiltrated neutrophils leads to excessive degradation
of stromal collagen. The results of in vitro experiments in which corneal fibroblasts are cultured in
a three-dimensional collagen gel suggest that factors including IL-1 secreted by collagen-stimulated
neutrophils augment collagen degradation by corneal fibroblasts through a stimulatory effect on
pro-MMP synthesis [37]. During infection with P. aeruginosa, pseudomonal elastase both degrades type
I collagen directly and promotes collagen degradation by corneal fibroblasts through the activation of
pro-MMPs released from the fibroblasts [38]. The uncontrolled and prolonged activation of corneal
fibroblasts by inflammatory cells or infectious pathogens may therefore lead to destruction of the
corneal stroma and corneal scarring. Given the important role of the cornea in ocular refraction, such
scarring of the cornea directly results in a loss of vision. It is therefore important that, regardless of
the causative factors, corneal inflammation be treated in such a manner as to ensure minimal scarring.
Given that infiltration of inflammatory cells into the avascular cornea is regulated by chemokines
released by corneal fibroblasts and that stromal collagen degradation is mediated by MMPs produced
by these cells, the targeting of stromal fibroblast function is a potential approach to the treatment of
corneal inflammation [7]. Although corticosteroids are potent immunosuppressants and attenuate
both collagen degradation by corneal fibroblasts as well as the infiltration of mononuclear cells into
the cornea in a rabbit model of LPS-induced keratitis [17,39], steroids also promote the proliferation of
infecting pathogens. There are currently no eyedrops clinically available for the treatment of infectious
keratitis that are able to suppress an excessive inflammatory response without adverse effects.
Given that activation of nuclear factor–κB (NF-κB) is a key step in the LPS-induced expression
of chemokines and adhesion molecules in corneal fibroblasts [19], drugs that are able to inhibit the
NF-κB signaling pathway in these cells might be expected to limit the infiltration of immune cells
into the cornea. Triptolide, which is present in extracts of the Chinese herb Tripterygium wilfordii
hook f, possesses anti-inflammatory activity for various cell types including immune cells and tissue
resident cells. Triptolide inhibits the activation of NF-κB and thereby attenuates both LPS-induced
chemokine and adhesion molecule expression in as well as collagen degradation by human corneal
fibroblasts [20,40].
Rebamipide eyedrops were recently introduced to the Japanese market for the treatment of dry
eye on the basis of the mucin secretagogue activity of this drug. Rebamipide also manifests various
anti-inflammatory effects on corneal epithelial cells and gastric epithelial cells. We recently showed that
rebamipide increases the barrier function of human corneal epithelial cells, attenuates the loss of such
barrier function induced by the proinflammatory cytokine TNF-α, and inhibits the TNF-α–induced
expression of IL-6 and IL-8 in these cells [41]. Rebamipide also suppresses the LPS-induced
synthesis of IL-8 through inhibition of NF-κB signaling in human corneal fibroblasts (Figure 4) [42].
258
Int. J. Mol. Sci. 2017, 18, 1831
Rebamipide may therefore prove effective for the treatment of not only dry eye–related epitheliopathy,
but also corneal stromal inflammation associated with bacterial infection or allergy.
Figure 4. Effect of rebamipide on IL-8 release induced by LPS in human corneal fibroblasts. Cells were
incubated first for 1 h with the indicated concentrations of rebamipide and then for 48 h in the
additional absence (open circles) or presence either of LPS (100 ng/mL, triangles) plus 0.5% human
serum or of tumor necrosis factor-α (TNF-α) (10 ng/mL, closed circles), after which the concentration
of IL-8 in culture supernatants was determined. Data are means ± SEM of quadruplicates from a
representative experiment. ** p < 0.01 versus the corresponding value for cells incubated without
rebamipide. Reprinted with permission from [42].
A small peptide derived from human pancreatitis-associated protein [43] and an 11-amino
acid peptide (RNPRGEEGGPW) derived from hepatocyte growth factor [44] were both found
to inhibit the LPS-induced expression of chemokines such as IL-8 and MCP-1 as well as the
adhesion molecule ICAM-1 in corneal fibroblasts by preventing NF-κB activation. These peptides
also attenuated the corneal inflammation associated with LPS-induced keratitis in mice. In addition,
an inhibitor of hyaluronic acid synthesis, 4-methylumbelliferone, as well as hyaluronic acid of high
molecular weight were each shown to attenuate the LPS-induced up-regulation of the expression
of inflammatory cytokines including IL-6 and IL-8 in rabbit corneal fibroblasts [45]. Furthermore,
leukocyte infiltration into the cornea associated with LPS-induced keratitis was found to be restrained
in mice deficient in urokinase-type plasminogen activator (uPA) compared with wild-type mice, and
the LPS-induced production of both chemokines and MMP-9 was attenuated in corneal fibroblasts from
the u-PA-deficient mice compared with those from wild-type mice. These results suggest that targeting
of uPA in corneal fibroblasts may inhibit LPS-induced corneal inflammation through down-regulation
of chemokine production [46].
Endogenous antimicrobial peptides play a key role in defense against infection at the ocular
surface. These molecules are essentially small cationic peptides with broad-spectrum antimicrobial
activity against bacteria, fungi, and viruses. Defensins and cathelicidins are two major categories
of mammalian antimicrobial peptides and are present at the ocular surface [47,48]. At the ocular
surface, α-defensins including human neutrophil peptides 1 to 3 are derived mostly from infiltrating
neutrophils, whereas β-defensins such as human β-defensins 1 to 3 are synthesized and secreted by
corneal or conjunctival epithelial cells. LL37 is the only member of the cathelicidin family in humans
and is secreted by corneal epithelial cells and fibroblasts [49]. The expression of antimicrobial peptides
in epithelial cells at the ocular surface is up-regulated in response to bacterial infection through TLRs.
TLR2 activation by peptidoglycan or lipopeptide from Staphylococcus aureus enhanced the production
of LL37 and human β-defensin-2 in corneal epithelial cells [50,51]. LPS from P. aeruginosa was also
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found to stimulate the expression of human β-defensin–2 in corneal and conjunctival epithelial cells
via activation of TLR4 [52]. In addition, P. aeruginosa flagellin induced the production of human
β-defensin–2 and LL37 by corneal epithelial cells through the activation of TLR5 [53]. Several peptides
with antimicrobial properties have been tested in vitro as well as in in vivo models for their potential
either alone or in combination with antibiotics to treat infectious keratitis [54].
Drugs that are able to suppress immune responses as well as kill bacteria are also good candidates
for the treatment of infectious keratitis. In addition to their direct antimicrobial action, recent studies
have revealed that some antimicrobial peptides have pleiotropic effects on various cell types [55].
Among such antimicrobial peptides present at the ocular surface in humans, LL37 and angiogenin
have been found to have anti-inflammatory effects on corneal fibroblasts. LL37 reportedly stimulates
corneal epithelial wound healing as well as cytokine synthesis by corneal epithelial cells [55]. We have
shown that LL37 directly suppresses LPS-induced innate immune responses in corneal fibroblasts
(Figure 5), in contrast to its action in corneal epithelial cells. LL37 thus inhibited the expression of IL-6,
IL-8, and ICAM-1, as well as the activation of NF-κB, induced by LPS in corneal fibroblasts, whereas
it did not attenuate such effects elicited by TNF-α. These inhibitory effects of LL37 on cytokine and
adhesion molecule expression thus appeared not to be attributable to nonspecific suppression of NF-κB
signaling but rather to be mediated by the binding of LL37 to LPS or to CD14 at the cell surface [56].
We have also shown that exogenous LL37 did not induce corneal inflammation but instead significantly
suppressed LPS-induced keratitis in mice (Figure 6). Taken together, these observations suggest that
administration of LL37 may be beneficial for the treatment of infectious keratitis on the basis of both
its inhibitory effects on corneal fibroblasts and its antimicrobial and pro-wound healing activities.
Angiogenin is a pro-angiogenic molecule but also acts as an antimicrobial peptide in tear
fluid [57,58]. In addition, angiogenin was shown to inhibit the LPS-induced production of IL-6,
IL-8, MCP-1, MCP-2, and TNF-α by corneal fibroblasts [59]. Angiogenin may therefore also have a
beneficial action in infectious keratitis as a result of its antimicrobial activity and its attenuation of
innate immune responses of corneal fibroblasts.
Figure 5. Effects of LL37 on LPS- or TNF-α–induced IL-8 and ICAM-1 expression in human corneal
fibroblasts. Cells were incubated first for 2 h with the indicated concentrations of (A) or 1 μM (B) LL37
and then for 48 h (A) or 24 h (B) in the additional presence of LPS (100 ng/mL) plus 0.5% human
serum (closed circles), of 0.5% human serum alone (open circles), or of TNF-α (10 ng/mL, triangles).
The concentration of IL-8 in culture supernatants (A) and the cell surface expression of ICAM-1 (B)
were then determined. ** p < 0.01 versus the corresponding value for cells incubated without LL37 (A).
** p < 0.01 versus the corresponding value for cells incubated with 0.5% serum alone; †† p < 0.01 versus
the corresponding value for cells incubated without LL37 (B). Reprinted with permission from [56].
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Figure 6. Effects of LL37 in a mouse model of LPS-induced keratitis. (A) The cornea was scratched
and either LL37, LPS, both LPS and LL37, or phosphate-buffered saline (PBS) vehicle was applied.
After 24 h, the eye was enucleated for immunohistofluorescence staining of neutrophils in the cornea.
The corneal epithelium (ep) and stroma (st) are indicated. Scale bar, 200 μm; (B) the number of
infiltrating neutrophils in the corneal stroma in images similar to those in (A) was counted. Data are
means ± SEM for one section examined for each of four eyes. ** p < 0.01 versus the value for PBS alone;
†† p < 0.01 versus the value for LPS alone. Reprinted with permission from [56].
4. Conclusions
The studies described in this review highlight the central role of corneal fibroblasts in the
development of corneal inflammation during infectious keratitis (Figure 7). Corneal fibroblasts sense
bacterial infection through the detection of LPS by TLR with the assistance of sCD14 and LBP in tear
fluid. Such detection of LPS by corneal fibroblasts triggers innate immune responses including the
expression of chemokines and adhesion molecules that promote the recruitment of inflammatory
cells, mostly neutrophils, and the consequent elimination of infecting bacteria. Appropriate resolution
of infectious inflammation may be prevented, however, by the prolonged overproduction of such
inflammatory mediators by corneal fibroblasts, leading to tissue remodeling or destruction and,
eventually, to corneal stromal scarring. Infiltrated neutrophils are activated by corneal stromal collagen
and release factors including IL-1 that stimulate the production of pro-MMPs by corneal fibroblasts.
Certain proteases such as elastase produced by P. aeruginosa activate these released pro-MMPs and
thereby promote stromal collagen degradation. Corneal fibroblasts thus act as sentinel cells, immune
modulators, and effector cells in infectious keratitis. Modulation of corneal fibroblast activation and
of the interaction of these cells with inflammatory cells or infecting bacteria is therefore critical to
minimize corneal scarring during treatment of infectious keratitis. Drugs that are able to restrain these
activities of corneal fibroblasts are needed to expand and improve the treatment options available
for infectious keratitis. Pharmacological agents described in this review may provide such novel
treatment options to prevent excessive scarring and tissue destruction in the cornea by regulating
corneal fibroblast function.
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Figure 7. Role of corneal fibroblasts in bacterial keratitis. LPS released from bacteria binds to LBP and
sCD14 in tear fluid, and the LPS-LBP-sCD14 complex then activates corneal fibroblasts. The activated
fibroblasts promote inflammatory cell recruitment through expression of chemokines and adhesion
molecules. Infiltrated neutrophils are activated by corneal stromal collagen and secrete inflammatory
mediators including IL-1 that stimulate pro-MMP secretion by fibroblasts. The released pro-MMPs are
activated by bacterial proteases such as Pseudomonas aeruginosa elastase, and the active MMPs then
degrade stromal collagen, leading to corneal melting.
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Abstract: The ileocecal valve (ICV)—a sphincter muscle between small and large intestine—plays
important roles in the physiology of the gastrointestinal (GI) tract, but many aspects connected with
the innervation of the ICV remain unknown. Thus, the aim of this study was to investigate the
localization and neurochemical characterization of neurons located in the dorsal root ganglia and
supplying the ICV of the domestic pig. The results have shown that such neurons mainly located in
the dorsal root ganglia (DRG) of thoracic and lumbar neuromers show the presence of substance P
(SP), calcitonin gene-related peptide (CGRP), and galanin (GAL). The second part of the experiment
consisted of a study on the influence of a low dose of lipopolysaccharide (LPS) from Salmonella
serotypes Enteritidis Minnesota and Typhimurium on DRG neurons. It has been shown that the
LPS of these serotypes in studied doses does not change the number of DRG neurons in the cell
cultures, but influences the immunoreactivity to SP and GAL. The observed changes in neurochemical
characterization depend on the bacterial serotype. The results show that DRG neurons take part in
the innervation of the ICV and may change their neurochemical characterization under the impact of
LPS, which is probably connected with direct actions of this substance on the nervous tissue and/or
its pro-inflammatory activity.
Keywords: ileocecal valve (ICV); LPS from S. Enteritidis; LPS from S. Minnesota; LPS from
S. Typhimurium; neuropeptides of DRG
1. Introduction
The innervation of the gastrointestinal (GI) tract consists of two parts: the intestinal nervous
system (ENS) and extrinsic innervation [1–4]. The ENS, located in the wall of the oesophagus, stomach,
and intestine, is built of millions of neuronal cells divided into ganglionated plexuses, whose quantity
depends on animal species [5]. Enteric neurons are very diverse in their morphology, physiology,
and neurochemical characteristics and regulate the majority of the functions of the GI tract [1,5].
Due to the significant degree of the independence from the brain, the ENS is called the “second”
or “intestinal” brain [6]. However, despite a high degree of autonomy, the ENS is, to some extent,
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controlled by the central nervous system by the extrinsic innervation of the GI tract. This innervation
consists of three fundamental parts, including parasympathetic efferent innervation, sympathetic
efferent innervation and afferent innervation [7,8]. The precise localization of neurons participating
in the extrinsic innervation of the stomach and intestine clearly depends on innervated segment of
the GI tract. In the case of the parasympathetic nervous system, the major part of the GI tract (from
oesophagus to transverse colon) is innervated by fibres which are branches of the vagal nerve [7].
Only caudal fragments of the GI tract (descending colon, rectum and anus) are supplied by nerves
originating from the parasympathetic nuclei within the intermediolateral column of the sacral spinal
cord [9]. In turn, sympathetic neurons innervating the GI tract may be located in the sympathetic
chain ganglia and prevertebral ganglia, including the celiac, superior and inferior mesenteric, or pelvic
ganglia [2,3,7]. Apart from sympathetic and parasympathetic extrinsic innervation, the GI tract is also
supplied by afferent nerves which conduct sensory and pain stimuli from the stomach and intestine to
the central nervous system. These nerves are the processes of neuronal cells situated in the nodose
ganglia of the vagal nerve or dorsal root ganglia [8]. Previous studies have shown that sensory neurons
supplying the gut may contain a wide range of neuronal active substances [8,10]. Among them,
the most important factors in sensory and pain stimuli conduction seem to be substance P (SP) and
calcitonin gene-related peptide (CGRP). Moreover, it is known that sensory neuronal cells innervating
the GI tract may undergo neurochemical changes during pathological processes taking part in the
stomach and intestine [8–10], but knowledge concerning these aspects is extremely limited.
The ileocecal valve (ICV), a sphincter muscle between small and large intestine, prevents the
reflux of colonic content to the ileum and serves as a barrier to the entering of colonic microbial flora
to the small intestine [11–13]. It should be underlined that previous studies on the innervation of the
ICV are few [12] and the sensory neurons innervating this part of the GI tract have not been studied
at all. On the other hand, it is known that the organization of the ICV innervation is specific [12,14]
and disturbances within it may play important roles in disorders of this part of the GI tract, including
constipation, feeling bloated, and/or diarrhoea [12,15]. The knowledge of why the ICV can become
impaired, which can lead to many pathological processes such as small intestine bacterial overgrowth
(SIBO), is still unclear. This assumes that it is rather the composition of the bacterial species that is
more crucial than the number of bacteria. Maybe interaction of some bacteria or some bacterial toxins
with the nervous system can also play a role in ICV dysfunction. Due to the above, the study of the
interaction between sensory neurons supplying ICV and lipopolysaccharide (LPS) from Salmonella spp.
seems very interesting.
It should be pointed out that the ileum and cecum were the main sites of Salmonella growth in a
latent carrier mouse. Thus, parts of the intestine can be strategic places for Salmonella proliferation in
animals without showing any clinical symptoms of disease during latent infection [16]. Additionally,
LPS can be derived from the dead Salmonella existing in this part of the intestine. It is known that LPS is
present within the cellular membrane of all Gram-negative bacteria and demonstrates negative activity
on living organisms [17]. Namely, this substance damages various internal organs, which is connected
with the release of free radicals. Moreover, LPS acts on the immunological system, causing fever and
septic shock [18]. Previous studies have also shown that LPS may affect the nervous system and is
involved in, or connected with, neurodegenerative diseases. However, apart from the fact that LPS
may change the expression of the neuronal factor in the internal organs [19–21], knowledge concerning
changes in neurochemical characterization of neuronal cells under the influence of this substance
is lacking. Moreover, it is known that LPS is not a homogeneous substance [22–26]. Additionally,
LPS from different species are characterized by various activities [23,27,28] but, until now, the studies
on differences in LPS activity derived from various serotypes connected with the influence of this
substance on neuronal neurochemical characterization have not yet been studied.
It should be also underlined that the selection of the domestic pig as an experimental animal
during this investigation was not accidental. It is relatively well known that the domestic pig is very
good animal model of processes occurring in the human organism, due to well confirmed biochemical,
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neurochemical, and physiological similarities between these species [29]. Thus, the results obtained
during this study may reflect the mechanisms connected with the influence of LPS on the human
nervous system. The aim of these studies was to investigate the distribution and neurochemistry of
the DRG sensory neurons supplying the ICV under physiological conditions Moreover, the influence
of a low dose of LPS from various serotypes of Salmonella on the neurochemical characterization of
neurons located in DRG during the cell cultures has been also studied.
2. Results
During the present study, neuronal cells supplying the ICV were observed in bilateral DRG from
neuromers Th7 to L4, and the differences between right and left DRG were not very clear (Figure 1).
Figure 1. The distribution of fast blue (FB)-labelled neurons supplying the porcine ileocecal valve
located in dorsal root ganglia (DRG). The total number of FB-positive neurons located in left and right
DRG was considered as 100% (separately for left and right DRG).
The largest number of FB-positive cells was located in neuromers Th13 (16.88 ± 2.81% of all
FB+ neurons) in the right DRG and 14.54 ± 3.07% in the left DRG). A slightly lower number of neuronal
cells supplying the ICV was noted in neuromers Th9–Th12 (from 11.82 ± 2.90% to 12.41 ± 2.36% in
right DRG and from 10.95 ± 2.26% to 13.16 ± 2.32% in left DRG) and L1–L2, respectively, 13.81 ± 2.58%
and 9.70 ± 2.41% in right DRG, and 12.42 ± 3.85% and 10.37 ± 1.87% in left DRG). Significantly fewer
neurons were present in neuromers Th7–Th8 (2.29 ± 2.10% and 5.18 ± 3.10% in right DRG and
2.34 ± 1.51% and 7.76 ± 1.81% in left DRG) and L3 (3.62 ± 1.71% in right DRG and 4.45 ± 2.51% in left
DRG), and within the neuromer L4, FB+ neuronal cells were observed only sporadically (FB+ neurons
were observed only in left DRG in quantities of 0.51 ± 1.15%). The total average number of FB+
neurons investigated in one animal amounted to 219.00 ± 67.30 (108.40 ± 35.98 in right DRG and
110.60 ± 32.24 in left DRG)
The highest number of sensory neurons supplying the ICV showed immunoreactivity to CGRP.
The percentage of CGRP-positive cells amounted to 57.33 ± 6.89% of all FB+ cells (Figure 2A).
The presence of SP was observed in a slightly lower percentage of the ICV projecting neurons
(Figure 2B). This value reached 50.10 ± 8.71%. In turn, neurons immunoreactive to GAL were the least
numerous. GAL was noted in 39.52 ± 5.33% of all FB-positive cells (Figure 3C).
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Figure 2. Fast blue-positive neurons in the dorsal root ganglia (DRG) supplying the ileocecal valve
(ICV) (indicated with arrows) immunoreactive to calcitonin gene related peptide (CGRP) (A), substance
P (SP) (B) and galanin (GAL) (C).
Regarding in vitro culture, it should be underlined that we tried to count both all FB-labelled
neurons projecting to the ICV and unlabelled neurons projecting to other parts of the intestine and
other organs. Unfortunately, the number of FB-labelled neurons was too low to get reliable statistically
results and, therefore, the results obtained from all the population of labelled and un-labelled neurons
are presented in the present study.
Studies conducted on cell cultures have shown that LPS derived from all bacterial serotypes
studied did not change the average number of neurons on a glass coverslip. The number of neurons
in the control group amounted to 48.07 ± 7.62, whereas under the influence of LPS, they achieved
48.69 ± 7.85, 48.66 ± 8.92, and 48.10 ± 8.73 under the impact of LPS S. Enteritidis, LPS S. Minnesota
and LPS S. Typhimurium, respectively.
Moreover, during the present study, the influence of LPS on neurons immunoreactive to SP
and/or GAL was observed and changes clearly depended on bacterial serotype. In control animals,
SP-positive cells amounted to 60.90 ± 3.34% of all neurons. LPS S. Enteritidis caused the increase of
the number of SP + neurons to 82.09 ± 4.43%, whereas LPS S. Minnesota and LPS S. Typhimurium
resulted in a decrease in the percentage of such cells (to 41.48 ± 3.67% and 30.83 ± 3.71%, respectively)
(Figure 3).
Figure 3. The percentage of neurons in dorsal root ganglia (DRG) immunoreactive to substance P (SP)
in the control group and under the impact of LPS from S. Enteritidis (LPS-E), S. Minnesota (LPS-M),
and S. Typhimurium (LPS-T). Statistically different at p < 0.001 as compared to the control group.
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A different situation was observed in the case of GAL-positive neurons. In control animals,
the percentage of such cells amounted to 55.44 ± 4.16%. LPS S. Enteritidis and LPS S. Minnesota
caused the decrease in the number of GAL + neurons (to 27.51 ± 1.40% and 26.82 ± 7.08%, respectively),
whereas under the impact of LPS S. Typhimurium, this value achieved 52.81 ± 6.80% and was not
significantly statistically different from the percentage observed in the control group (Figure 4).
Figure 4. The percentage of neurons in dorsal root ganglia (DRG) immunoreactive to galanin (GAL)
in control group and under the impact of LPS from S. Enteritidis (LPS-E), S. Minnesota (LPS-M),
and S. Typhimurium (LPS-T). Statistically different at p < 0.001 as compared to the control group.
During the present investigation, the influence of LPS derived from all bacterial serotypes studied
on the percentage of CGRP-positive neurons was not observed. The percentage of such neurons
amounted to 67.19 ± 3.49% in control group, 67.52 ± 3.96% in LPS S. Enteritidis group, 69.08 ± 4.51%
in LPS S. Minnesota group and 67.53 ± 5.35% in the LPS S. Typhimurium group. Differences between
the mentioned above values were not statistically significant (Figure 5).
Figure 5. The percentage of neurons in dorsal root ganglia immunoreactive to calcitonin gene-related
peptide (CGRP) in control group and under the impact of LPS from S. Enteritidis (LPS-E), S. Minnesota
(LPS-M), and S. Typhimurium (LPS-T). Statistically significant differences for p < 0.001 as compared to
the control group.
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The analysis of the cell viability (MTT assay) demonstrated that a 24 h exposure to the low dose of
LPS from studied serotypes of Salmonella spp. did not exert any toxic or proliferative effect on neuronal
and non-neuronal DRG cells viability of DRG (Figure 6).
Figure 6. The effect of a low dose (0.5 ng/mL) of LPS from different serotypes of Salmonella spp: LPS
from Salmonella Enteritidis (LPS-E), LPS from Salmonella Minnesota (LPS-M), LPS from Salmonella
Typhimurium (LPS-T) on DRG cell viability. Cell viability was assessed using the MTT method.
Data are presented as means of the percentage of the untreated control cells ± SE (n = 4).
Representative examples of dorsal root ganglia (DRG) neurons supplying the ileocecal valve
observed during the present study in the cell culture are visualised in Figures 7 and 8.
Figure 7. Examples of dorsal root ganglia (DRG) neurons supplying the ileocecal valve (FB-positive,
blue) (C,F,I), immunoreactive to tubulin (TUBB3 used here as a neuronal marker, green) (A,D,G) and
substance P (SP) (B), galanin (GAL) (E) or calcitonin gene-related peptide (CGRP) (H) in cell cultures
of the control group.
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Figure 8. Examples of dorsal root ganglia (DRG) neurons supplying the ileocecal valve (FB-positive
blue) (C,F,I) immunoreactive to tubulin (TUBB3 used here as a neuronal marker, green) (A,D,G) and
substance P (SP) (B), galanin (GAL) (E), and calcitonin gene-related peptide (CGRP) (H) (all these
substances in red) in cell cultures treated with lipopolysaccharides from Salmonella Enteritidis (A–C),
Salmonella Typhimurium (D–F) and Salmonella Minnesota (G–I).
3. Discussion
The results obtained in this study indicate that the ICV, similar to other parts of the gastrointestinal
tract, is supplied by neurons located in DRG [30]. Similar to previous studies, where DRG neuronal
cells supplying the stomach, duodenum, ileum, and colon were described in various mammal
species [30–33], observations made during the present investigations show that DRG plays a role in
ICV sensory innervation in the domestic pig. On the other hand, the relatively low number of FB+
neurons observed in this study suggest that sensory components of the vagal nerve may play more
important functions in the innervation of the ICV. This is according to the previous studies, where it
was found that the network of processes derived from DRG neurons in the colon is more extensive than
in the stomach and jejunum [30,32]. This is connected with the fact that branches of the vagal nerve
supply the GI tract from the oesophagus to the proximal colon [34]. The majority of FB+ neuronal cells
innervating the ICV investigated in this study were located in the thoracic and lumbar DRG, which is
generally consistent with the distribution of previously described DRG neuronal cells supplying the
small intestine.
Previous studies have shown that neuronal cells located in the DRG may contain (apart from
typical substances involved in the sensory and pain stimuli conductions, such as SP and CGRP) a wide
range of active neuronal factors, including GAL, CART peptide, vasoactive intestinal polypeptide,
nitric oxide, somatostatin, and many others [35,36]. During the present study, the majority of DRG
neurons supplying the ICV also contain SP and/or CGRP. SP is a member of the tachykinin family.
It is a substance participating in sensory and pain stimuli conduction and has been observed in sensory
neuronal cells and fibres in the central and peripheral nervous system of numerous species, including
human [37–41]. It should be underlined that SP, besides sensory functions, may also participate in
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other various regulatory processes within the GI tract. In particular, it is known that SP regulates
the intestinal motility and secretory activity [37], blood flow within the intestine and mesentery [42],
as well immunological processes [43].
The second important substance participating in sensory and pain conduction, which has been
observed in sensory neurons supplying the ICV, is CGRP. This peptide, similarly to SP, has been described
in various central and peripheral sensory nervous structures of a wide range of mammals [44,45].
Within the digestive tract of some species, CGRP is considered to be a marker of intrinsic primary
afferent neurons, which belong to the enteric nervous system and are a component of short intramural
reflexes taking place without the central nervous system [46]. CGRP within the GI tract is also involved in
regulatory processes connected with blood flow, secretory activity, and the absorption of nutrients [47,48].
Moreover, this peptide takes part in the protection of the intestinal mucosal layer against injuries and
regulates intestinal motility [49].
The third substance studied in this investigation—GAL—is a not classical factor taking part in
sensory or pain stimuli conduction. Nevertheless, the presence of GAL has been described in sensory
neuronal structures supplying various internal organs [50,51]. It is known that GAL takes part in the
regulation of other neurotransmitters by acting on the ion channels within the membrane of neuronal
cells [52,53]. Besides sensory conduction, GAL in the GI system regulates the intestinal motility and
secretory activity and the character of processes regulated by GAL clearly depends on the animal
species and the fragment of the intestine [54,55].
In the light of the previous investigations, it is known that all neuronal factors studied during
this experiment participate in regulatory processes not only under physiological conditions, but are
also involved in pathological mechanisms of various diseases and intoxications with a wide range
substances. Evidence of this includes changes in the expression of SP, CGRP, and GAL both in the
enteric nervous system and extrinsic neuronal cells supplying the intestine under the influence of
inflammatory processes, neuronal damage, intoxication with mycotoxins, and other toxicological
substances and many other pathological stimuli [38,56]. For SP, these changes may be connected
with neuroprotective properties and the participation of this peptide in inflammatory processes [38].
Namely, it is known that SP acting on lymphocytes and macrophages stimulates the secretion
of pro-inflammatory cytokines, including IL-1 and TNF-α—the most important inflammatory
mediator [37,43]. In turn, GAL is known from neuroprotective functions in the central and peripheral
nervous system, which have primarily been described during brain injuries and neurodegenerative
diseases [57]. Moreover, GAL (contrary to SP) plays an anti-inflammatory role by enhancing synthesis
and secretion of IFN-γ and IL-12/23 while simultaneously decreasing the levels of TNF-α and
IL-1β [58]. However, CGRP, whose role in intestinal diseases has not been fully elucidated, may inhibit
the expression of TNF-α and IL-1β and take part in mechanisms connected with the development
of diarrhoea [59]. On the other hand, the participation of CGRP in neuroprotective processes within
the innervation of the intestine, despite changes in CGRP expression under various pathological
stimuli [60], has not yet been confirmed.
Changes in the immunoreactivity of DRG neurons observed during the present study probably
result from the above-mentioned functions of neuronal factors under the impact of LPS. These changes
may be connected with neuroprotective and/or adaptive processes used to maintain homeostasis
within the nervous tissues These may result from the pro-inflammatory activity of LPS, described
in the previous investigations. In particular, it is known that one of the components of LPS —lipid
A—strongly induces synthesis and the secretion of pro-inflammatory substances [61]. However, a more
likely cause of the observed changes is the direct impact of LPS on neuronal cells. It should be
underlined that this impact in the light of the previous studies is not clear and depends on LPS dose.
On the one hand, the neurotoxic activity of LPS is relatively well-known. Previous investigations
have described the involvement of this substance in neurodegenerative processes in various parts
of the nervous system [62–64]. Moreover, LPS is used as a factor inducing experimental Parkinson’s
disease in rodents [65–68]. On the other hand, it has been shown that low doses of LPS are essential to
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promote the survival of enteric and hippocampal neurons. Anitaha et al. [69] found that for enteric
neuronal survival, microbial-neuronal interaction is essential and a low dose of LPS is essential to
maintain neuronal survival, although at higher doses LPS results in neuronal toxicity. Low dose LPS
treatment (10 ng/mL) promoted enteric neuronal survival through the activation of NF-κB and TLR4.
None of our studied serotypes of Salmonella spp. influenced the neuron counts and furthermore,
we saw that neurons treated with 0.5 μg/mL LPS have longer and denser neurites compared to the
control group. This is only a subjective observation which has not been supported by any analysis
of neuron morphology. Perhaps, hypothetically, it was in connection with the role of glial cells,
but we did not study it because it was not the intended goal of our study. Additionally, LPS in
a low dose has been shown to promote the survival of hippocampal neurons through increased
expression of a granulocyte colony-stimulating factor [70]. But, in the central nervous system (CNS),
hippocampal neurogenesis and neurological functions were attenuated by lipopolysaccharide-induced
TLR4 activation [71]. Moreover, some studies have shown the protective effect of LPS pre-treatment [72]
and endotoxin tolerance provides (enhances) the ischemic resistance of neuronal cells [73]. In contrast,
Chen et al. [74] reported that pre-conditioning with a super-low or low dose of LPS exacerbates sepsis
mortality. Further studies may be required to find consistent issues to combine the different results of
various studies.
4. Materials and Methods
The present study consisted of two experiments conducted on nine immature sows of the
Pietrain × Duroc breed. All animals were kept in standard laboratory conditions and fed with
complete feeding stuff appropriate to the age and species of animals for two weeks prior to the
experiment in order to allow adaptation to the new environment. The experiments took place when
the pigs were 8–9 weeks of age with body weights of 16–18 kg. Both administration of the drugs
and the performance of surgical procedures were performed by a veterinary doctor (DVM, Ph.D.).
All procedures in the experiment were approved by the Local Ethical Commission of Experiments on
Animals in Olsztyn (decision number 73/2015 from 29 September 2015).
4.1. Experiment No. 1: Localization and Neurochemical Characterization of Neurons Located in the Dorsal Root
Ganglia and Supplying the ICV
The first experiment was conducted to study the sensory neurons located in dorsal root ganglia
and supplying the ileocecal valve (ICV). For this part of the experiment, five pigs were used.
4.1.1. Surgical Procedures Surgery
Before surgical procedures, five animals were pre-medicated using the method previously
described by Mikolajczyk [75] with intramuscular injection of atropine (Atropinum Sulfuricum Polfa
Warszawa S.A., Warszawa, Poland, 0.035 mg/kg b.w.), ketamine (Bioketan, Vetoquinol Biowet Sp.
z o.o., Poland and Vetoquinol S.A., Lure, France, 7.0 mg/kg b.w.), and medetomidine (Cepetor,
CP-Pharma Handelsges mbH, Burgdorf, Germany, 0.063 mg/kg b.w.). After 15 min. the animals were
subjected to the general anaesthesia with propofol (Scanofol, NORBROOK, Newry, Northern Ireland,
IRL.PN, 4.5 mg/kg b.w. given intravenously) and median laparotomy. During the transaction surgery
procedure, a conventional midline incision of the abdominal wall was made. The cecum and ileum
were identified and the ICV was isolated from the abdominal cavity. The ICV was injected with 50 μL
of a 5% aqueous solution of the fluorescence retrograde neuronal tracer fast blue (FB; EMSChemie
GmbH, Groß-Umstadt, Germany, ten injections, 5 μL each) using a Hamilton syringe equipped with a
26-gauge needle. Close attention was paid to avoiding any contamination of the surrounding tissues
with FB due to the hydrostatic leakage from the injection canal. To avoid leakage, the needle was left
in each site of FB injection for up to a minute. The peritoneum with the transverse abdominal muscles,
the internal and external abdominal oblique muscles, and the cutaneous muscle with subcutaneous
fascia were closed in a simple continuous pattern. The skin was closed in a subcuticular pattern.
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4.1.2. Sample Collection and Processing
After three weeks, the animals were again pre-medicated (as described above) and euthanized
with pentobarbital (Morbital, Biowet Puławy Sp. z o.o, Poland, 60–70 mg/kg b.w., given intravenously).
After death, the thoracic, lumbar, and sacral dorsal root ganglia were collected. Ganglia were fixed
in 4% buffered paraformaldehyde (pH 7.4) for 30 min. and rinsed in phosphate buffer for three days
(at 40 ◦C). They then added a 18% sucrose solution and stored it for least three weeks at 40 ◦C. After this
period, the ganglia were frozen at −20 ◦C and cut into 10 μm-thick sections using a cryostat (HM 525,
Microm International, Germany).
4.1.3. Immunofluorescence Procedures with Counting Neurons
The sections were subjected to examination for the presence of neurons containing FB using
a fluorescence Olympus BX51 microscope equipped with an appropriate filter set. Sections with
FB-positive cells were subjected to typical single immunofluorescence technique by the method
described previously by Gonkowski et al. [76]. Basically, during this method, fragments of DRG were
subjected to (1) drying at room temperature (rt) for 1 h; (2) “blocking” in the solution containing 10%
normal goat serum, 0.1% bovine serum albumin, 0.01% NaN3, Triton X-100 and thimerozal in PBS
for 1 h (rt); (3) incubation with antibodies directed towards SP, CGRP or galanin (GAL) (overnight;
rt, in a humid chamber); (4) incubation with secondary antibodies conjugated with appropriate
fluorochromes (alexa fluor 594 or 488) to visualise the complexes “antigen—primary antibody”.
The specifications and working dilution of primary and secondary antisera are presented in Table 1.
Table 1. List of antisera and reagents used in immunohistochemical investigations.
Primary antibodies
Antigen Code Species Working dilution Supplier
CGRP AB5920 Rabbit 1:1600 Chemicon Int Temecula, OH, USA
GAL T-5036 Guinea Pig 1:2000 Peninsula San Carlos, CA, USA
SP 8450-0505 Rat 1:1000 Bio-Rad (AbD Serotec),Kidlington, UK
Secondary antibodies
Reagents Working dilution Supplier
Alexa fluor 546 donkey anti-rabbit IgG 1:1000 Invitrogen Carlsbad, CA, USA
Alexa fluor 546 donkey anti-guinea pig IgG 1:1000 Invitrogen
Alexa fluor 488 goat anti-rat IgG 1:1000 Invitrogen
To confirm the specificity of the method routine standard controls, such as pre-absorption of
the neuropeptide antisera with appropriate antigen, omission and replacement of primary antisera
by non-immune sera were performed. To determine the percentage of neurons supplying the ICV
immunoreactive to SP, CGRP, or GAL, at least 50 FB+ neuronal cells from each animal were evaluated
for the presence of the particular neuronal factors. This relatively low number of neurons included
in the experiment was caused by the relatively small number of all neuronal cells supplying the ICV.
The obtained data was pooled, expressed as means ± SD.
4.2. Experiment No. 2: Culturing of Primary Sensory Neurons and Various Serotypes of Salmonella spp.
The second experiment conducted during this investigation consisted of a study of the influence
of a low dose (0.5 ng/mL [77,78] of LPS from various types of Salmonella spp. serotypes: LPS from
Salmonella enterica subsp. enterica serotype Enteritidis (L7770 Sigma), LPS from Salmonella enterica
subsp. enterica serotype Minnesota (L4641 Sigma), LPS from Salmonella enterica subsp. enterica
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serotype Typhimurium (L6143 Sigma) on the neurochemical characterization of neurons located
in DRG. Thus, during the in vitro experiment, four groups of cultures were used: control, Enteritidis
(LPS-E), Minnesota (LPS-M), and Typhimurium (LPS-T). For this part of the experiment, four pigs
were used.
4.2.1. Sample Collection and Processing
After three weeks, all animals were again pre-medicated and subjected to general anaesthesia
conducted as described above. During anaesthesia, the left and right thoracic (Th7–Th13) ganglia and
lumbar (L1–L4) ganglia were exposed. For DRG exposure, an incision was made in the skin of the
dorsal midline. The superficial muscular fascia was incised and the paraspinal muscles separated by a
combination of sharp and blunt dissection, exposing the lumbar and thoracic vertebrae. A rongeur
was used to remove bone fragments of spinal nerves as well as the intervertebral foramina from which
they emerge, which were exposed along with particular ganglia. The animals were then euthanized
with pentobarbital (in the above-described manner).
DRG were removed and transferred into cold RPMI 1640 W/HEPES W/GLUTAMAX-I medium
(cat. no. 72400021, Life Technologies Polska Sp. z.o.o.; Warszawa, Poland) and antibiotic and
antimycotic (cat. no. 15240062, Life Technologies Polska Sp. z.o.o.; Poland).
4.2.2. Cell Culture and Treatments
Cell cultures were prepared as described previously [79,80]. Briefly, following removal of
connective tissue, DRG were incubated in collagenase (cat. no. 17100017, Life Technologies Polska
Sp. z.o.o.; Poland) for 60 min followed by 0.5% trypsin/EDTA (15400054, Life Technologies Polska
Sp. z.o.o.; Poland). Neurons were dissociated by passages through a fire-polished Pasteur pipette and
centrifuged at a low speed (10 min, 700 rpm). After final centrifugation, the pellet was suspended
with TNB 100TM medium (cat. no. F8023; Biochrom AG, Berlin, Germany) containing: antibiotic and
antimycotic and protein-lipid complex TM (cat. no. F8820; Biochrom AG, Germany). Equal volumes
(50 μL) containing DRG neurons were seeded on glass coverslip (12 mm in diameter) coated with
poly-D-lysine (0.01% solution; cat. no. P7280; Aldrich)/laminin (1 mg/mL L-2020, Sigma) placed
in six-well multi-dishes (cat. no. 353046; BD Biosciences; Franklin Lakes, NJ, USA) at a density of
50–70 per glass. Cultures were cultivated in TNB medium 1 mL per well with 5 ng/mL nerve growth
factor beta (NGF; N1408; Sigma Aldrich; Berlin, Germany) to maintain the survival of neurons [81].
After 36 h incubation at 37 ◦C in 5% CO2, the medium was replaced with fresh medium in the control
and with fresh medium with the addition of 0.5 ng/mL LPS from S. Enteritidis, LPS from S. Minnesota
(L4641 Sigma), LPS from S. Typhimurium (L6143 Sigma) in the LPS-treated group. We decided to use
a 36 h cell primary neuron culture because extensive neurite outgrowth was observed after 24 h of
culture [82].
4.2.3. Immunocytochemical Labelling
After 60 h (including 24 h of culture with the addition of LPS to the media) in culture, neurons
were fixed with 4% paraformaldehyde for 20 min, permeabilised with 0.01% Triton X-100 (X100-100ML;
Sigma Aldrich; Germany) in PBS (P5493; Sigma Aldrich; Germany) for 5 min and blocked with blocking
buffer (10% goat serum in PBS) for 30 min. DRG neurons were incubated with primary antibodies
against substance P (8450-0004; AbD Serotec; Regensburg, Germany; 1:3000), calcitonin gene-related
peptide (AB43873; Abcam; Cambridge, UK; 1:18,000), galanin (AB5909; Merck Millipore; Burlington,
MA, USA; 1:16,400) and neuron-specific β-III tubulin (MAB1195; R&D Systems; Minneapolis, MN,
USA; 1:1000) diluted in blocking buffer for 1 h at room temperature and then incubated with
secondary Alexa-555- and Alexa-488-conjugated antibody (A31572; A-11001, Invitrogen, Carlsbad,
CA, USA; 1:1000) for 60 min at RT. We stained all DRG neurons (FB-labelled and FB-unlabelled) using
neuron-specific β-III tubulin [83] in co-localization with CGRP, SP, and GAL [84].
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4.2.4. Counting Cultured Neurons
Both FB-labelled neurons projecting to the ICV and unlabelled neurons projecting to other organs
(also large extent, the colon) [85] were counted.
The experiment in vitro was performed in duplicate with two replicate wells (four coverslips in
one well, i.e., eight coverslips per one animal) for each group of cultures (control, Enteritidis, Minnesota
and Typhimurium). The number of neurons in the control and after LPS treatment group were counted
and then expressed in percentage. FB-traced neurons were identified in the cell cultures by their blue
fluorescence under the UV illumination using fluorescence Olympus BX51 microscope (V1 module,
excitation range 330–385 nm and barrier filter at 420 nm). The number of β-III tubulin neurons in all
studied groups (control and with the addition of LPS to the medium) was considered as the number of
total neurons (100%). The number of neurons containing studied substances (β-III tubulin, CGRP, GAL,
and SP) in intact and LPS-treated group was quantified using a fluorescent Olympus BX51 microscope
(Shinjuku, Tokyo, Japan) equipped with an appropriate filter sets for Alexa 488 (B1 module, excitation
filter 450–480 nm) and Alexa 555 (G1, excitation filter 510–550 nm). Microphotographs were acquired
using 20× objectives and a PC equipped with a CCD camera operated by Cell Sens Dimension image
analysis software (Olympus, Warsaw, Poland).
4.2.5. MTT Assay
To determine the cell viability by MTT assay, DRG cells were prepared as described before using
six well multi-dishes with glass coverslips and seeded in a 96-well plate (CytoOne cat no: CC7682-7596).
After 36 h incubation at 37 ◦C in 5% CO2 the cells were treated with 0.5 ng/mL LPS from S. Enteritidis,
LPS from S. Minnesota, and LPS from S. Typhimurium or tested without LPS (control group) and
incubated at 37 ◦C in 5% CO2 for 24 h. After incubation, 50 μL MTT (Thiazolyl Blue Tetrazolium
Bromide 5 mg/mL, M5655 Sigma) was added and the plates were incubated at 37 ◦C in 5% CO2 for
4 h. At the end of the incubation period, the supernatants were removed, and 100 μL of dimethyl
sulfoxide (DMSO 34943, Sigma) was added to each well to enable the release of the blue reaction
product-formazan. The absorbance at 570 nm was read on a microplate reader Infinite 200 (Tecan)
and the results were expressed as a percentage of the absorbance measured in control cells and in the
LPS-treated culture.
4.3. Statistical Analysis
All data were expressed as the mean ± standard deviation (SD) from independent experiments
performed using five animals in the experiment 1 (n = 5) and four animals in experiment 2 (n = 4).
Statistical analysis was determined using one-way analysis of variance (ANOVA) followed by Tukey’s
test for multiple comparisons (Statistica software /version 13.1 /StatSoft, Cracow, Poland). P values
less than 0.05 were considered significant.
5. Conclusions
To sum up, the results obtained during the present study have shown that sensory processes
supplying the ICV may derive from neurons located in DRG from neuromers Th7 to L4. The ICV
sensory neurons contained SP, CGRP, and GAL. Moreover, it has been shown that the dose of LPS
used in the in vitro study did not change the number of DRG neurons from neuromers Th7 to L4
supplying the ICV and other organs and tissues, but influenced their neurochemical characterization.
The observed changes clearly depended on the bacterial serotype of LPS. This is proof that structural
differences of LPS—not only between bacterial species, but also within particular serotypes of one
species—result in varied impact on the nervous system. Moreover, the obtained results have shown
that SP and GAL, contrary to CGRP, are involved in the processes connected with the impact of LPS.
Changes in the expression of these substances may result from the direct influence of LPS on the
nervous structures and/or pro-inflammatory activity of LPS. However, the explanation of the exact
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mechanisms connected with LPS-induced fluctuations in neurochemical characterization of DRG
neurons requires further study.
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projecting to different chambers of the rat heart. Neurosci. Lett. 2010, 469, 314–318. [CrossRef] [PubMed]
37. Shimizu, Y.; Matsuyama, H.; Shiina, T.; Takewaki, T.; Furness, J.B. Tachykinins and their functions in the
gastrointestinal tract. Cell. Mol. Life Sci. 2008, 65, 295–311. [CrossRef] [PubMed]
279
Int. J. Mol. Sci. 2018, 19, 2551
38. Gonkowski, S. Substance P as a neuronal factor in the enteric nervous system of the porcine descending
colon in physiological conditions and during selected pathogenic processes. Biofactors 2013, 39, 542–551.
[CrossRef] [PubMed]
39. Mistrova, E.; Kruzliak, P.; Chottova Dvorakova, M. Role of substance P in the cardiovascular system.
Neuropeptides 2016, 58, 41–51. [CrossRef] [PubMed]
40. Chi, G.; Huang, Z.; Li, X.; Zhang, K.; Li, G. Substance P Regulation in Epilepsy. Curr. Neuropharmacol. 2018,
16, 43–50. [CrossRef] [PubMed]
41. Lénárd, L.; László, K.; Kertes, E.; Ollmann, T.; Péczely, L.; Kovács, A.; Kállai, V.; Zagorácz, O.; Gálosi, R.;
Karádi, Z. Substance P and neurotensin in the limbic system: Their roles in reinforcement and memory
consolidation. Neurosci. Biobehav. Rev. 2018, 85, 1–20. [CrossRef] [PubMed]
42. De Fontgalland, D.; Wattchow, D.A.; Costa, M.; Brookes, S.J. Immunohistochemical characterization of the
innervation of human colonic mesenteric and submucosal blood vessels. Neurogastroenterol. Motil. 2008, 20,
1212–1226. [CrossRef] [PubMed]
43. Zhao, D.; Kuhnt-Moore, S.; Zeng, H.; Pan, A.; Wu, J.S.; Simeonidis, S.; Moyer, M.P.; Pothoulakis, C. Substance
P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases.
Biochem. J. 2002, 368, 665–672. [CrossRef] [PubMed]
44. Eftekhari, S.; Salvatore, C.A.; Johansson, S.; Chen, T.B.; Zeng, Z.; Edvinsson, L. Localization of CGRP, CGRP
receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res. 2015,
1600, 93–109. [CrossRef] [PubMed]
45. Kestell, G.R.; Anderson, R.L.; Clarke, J.N.; Haberberger, R.V.; Gibbins, I.L. Primary afferent neurons
containing calcitonin gene-related peptide but not substance P in forepaw skin, dorsal root ganglia, and spinal
cord of mice. J. Comp. Neurol. 2015, 523, 2555–2569. [CrossRef] [PubMed]
46. Brehmer, A.; Croner, R.; Dimmler, A.; Papadopoulos, T.; Schrödl, F.; Neuhuber, W. Immunohistochemical
characterization of putative primary afferent (sensory) myenteric neurons in human small intestine.
Auton. Neurosci. 2004, 112, 49–59. [CrossRef] [PubMed]
47. Nuki, C.; Kawasaki, H.; Kitamura, K.; Takenaga, M.; Kangawa, K.; Eto, T.; Wada, A. Vasodilator effect of an
adrenomeullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. Biochem. Biophys.
Res. Commun. 1993, 196, 245–251. [CrossRef] [PubMed]
48. Barada, K.A.; Saade, N.E.; Atweh, S.F.; Khoury, C.I.; Nassar, C.F. Calcitonin gene-related peptide regulates
amino acid absorption across rat jejunum. Regul. Pept. 2000, 90, 39–45. [CrossRef]
49. Lambrecht, N.; Burchert, M.; Respondek, M.; Muller, K.M.; Peskar, B.M. Role of calcitonin gene-related
peptide and nitric oxide in thegastroprotective effect of capsaicin in the rat. Gastroenterology 1993, 104,
1371–1380. [CrossRef]
50. Wynick, D.; Thompson, S.W.; McMahon, S.B. The role of galanin as a multi-functional neuropeptide in the
nervous system. Curr. Opin. Pharmacol. 2001, 1, 73–77. [CrossRef]
51. Pidsudko, Z. Immunohistochemical characteristics and distribution of sensory dorsal root Ganglia neurons
supplying the urinary bladder in the male pig. J. Mol. Neurosci. 2014, 52, 71–81. [CrossRef] [PubMed]
52. Sarnelli, G.; Vanden Berghe, P.; Raeymaekers, P.; Janssens, J.; Tack, J. Inhibitory effects of galanin on evoked
[Ca2+]I responses in cultured myenteric neurons. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286,
1009–1014. [CrossRef] [PubMed]
53. Piqueras, L.; Tache, Y.; Martinez, V. Galanin inhibits gastric acid secretion through a somatostatin-
independent mechanism in mice. Peptides 2005, 25, 1287–1295. [CrossRef] [PubMed]
54. Fox-Threlkeld, J.E.T.; McDonald, T.J.; Cipris, S.; Woskowska, Z.; Daniel, E.E. Galanin inhibition of
vasoactive intestinal polypeptide release and circular muscle motility in the isolated perfused canine ileum.
Gastroenterology 1991, 101, 1471–1476. [CrossRef]
55. Botella, A.; Delvaux, M.; Frexinos, J.; Bueno, L. Comparative effects of galanin on isolated smooth muscle
cells from ileum in five mammalian species. Life Sci. 1992, 50, 1253–1261. [CrossRef]
56. Vasina, V.; Barbara, G.; Talamonti, L.; Stanghellini, V.; Corinaldesi, R.; Tonini, M.; De Ponti, F.; De Georgio, R.
Enteric neuroplasticy evoked by inflammation. Auton. Neurosci. 2006, 126, 264–272. [CrossRef] [PubMed]
57. Kawa, L.; Barde, S.; Arborelius, U.P.; Theodorsson, E.; Agoston, D.; Risling, M.; Hökfelt, T. Expression of
galanin and its receptors are perturbed in a rodent model of mild, blast-induced traumatic brain injury.
Exp. Neurol. 2016, 279, 159–167. [CrossRef] [PubMed]
280
Int. J. Mol. Sci. 2018, 19, 2551
58. Lang, R.; Kofler, B. The galanin peptide family in inflammation. Neuropeptides 2011, 45, 1–8. [CrossRef]
[PubMed]
59. Holzmann, B. Modulation of immune responses by the neuropeptide CGRP. Amino Acids 2013, 45, 1–7.
[CrossRef] [PubMed]
60. Makowska, K.; Obremski, K.; Gonkowski, S. The Impact of T-2 Toxin on Vasoactive Intestinal
Polypeptide-Like Immunoreactive (VIP-LI) Nerve Structures in the Wall of the Porcine Stomach and
Duodenum. Toxins 2018, 10, 138. [CrossRef] [PubMed]
61. Korneev, K.V.; Arbatsky, N.P.; Molinaro, A.; Palmigiano, A.; Shaikhutdinova, R.Z.; Shneider, M.M.; Pier, G.B.;
Kondakova, A.N.; Sviriaeva, E.N.; Sturiale, L.; et al. Structural Relationship of the Lipid A Acyl Groups to
Activation of Murine Toll-Like Receptor 4 by Lipopolysaccharides from Pathogenic Strains of Burkholderia
mallei, Acinetobacter baumannii, and Pseudomonas aeruginosa. Front. Immunol. 2015, 6, 595. [CrossRef]
[PubMed]
62. Nguyen, M.D.; D’Aigle, T.; Gowing, G.; Julien, J.P.; Rivest, S. Exacerbation of motor neuron disease by
chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2004,
24, 1340–1349. [CrossRef] [PubMed]
63. Choi, D.Y.; Liu, M.; Hunter, R.; Cass, W.A.; Pandya, J.D.; Sullivan, P.G.; Shin, E.J.; Kim, H.C.; Gash, D.M.;
Bing, G. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE 2009, 4, e5482. [CrossRef]
[PubMed]
64. Zhan, X.; Stamova, B.; Jin, L.W.; DeCarli, C.; Phinney, B.; Sharp, F.R. Gram-negative bacterial molecules
associate with Alzheimer disease pathology. Neurology 2016, 87, 2324–2332. [CrossRef] [PubMed]
65. Liu, M.; Bing, G. Lipopolysaccharide Animal Models for Parkinson’s Disease. Parkinson’s Dis. 2011,
2001, 327089. [CrossRef] [PubMed]
66. Hoban, D.B.; Connaughton, E.; Connaughton, C.; Hogan, G.; Thornton, C.; Mulcahy, P.; Moloney, T.C.;
Dowd, E. Further characterisation of the LPS model of Parkinson’s disease: A comparison of intra-nigral
and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal
neurodegeneration in the rat. Brain. Behav. Immun. 2013, 27, 91–100. [CrossRef] [PubMed]
67. Sharma, N.; Nehru, B. Characterization of the lipopolysaccharide induced model of Parkinson’s disease:
Role of oxidative stress and neuroinflammation. Neurochem. Int. 2015, 87, 92–105. [CrossRef] [PubMed]
68. Huang, B.; Liu, J.; Ju, C.; Yang, D.; Chen, G.; Xu, S.; Zeng, Y.; Yan, X.; Wang, W.; Liu, D.; et al. Licochalcone
A Prevents the Loss of Dopaminergic Neurons by Inhibiting Microglial Activation in Lipopolysaccharide
(LPS)-Induced Parkinson’s Disease Models. Int. J. Mol. Sci. 2017, 18, 2043. [CrossRef] [PubMed]
69. Anitha, M.; Vijay-Kumar, M.; Sitaraman, S.V.; Gewirtz, A.T.; Srinivasan, S. Gut Microbial Products Regulate
Murine Gastrointestinal Motility via Toll-like Receptor 4 Signaling. Gastroenterology 2012, 143, 1006–1016.
[CrossRef] [PubMed]
70. Li, Z.X.; Li, Q.Y.; Qiao, J.; Lu, C.Z.; Xiao, B.G. Granulocyte-colony stimulating factor is involved in low-dose
LPS-induced neuroprotection. Neurosci. Lett. 2009, 465, 128–132. [CrossRef] [PubMed]
71. Ye, Y.; Yang, Y.; Chen, C.; Li, Z.; Jia, Y.; Su, X.; Wang, C.; He, X. Electroacupuncture Improved Hippocampal
Neurogenesis Following Traumatic Brain Injury in Mice through Inhibition of TLR4 Signaling Pathway.
Stem Cells Int. 2017, 2017, 5841814. [CrossRef] [PubMed]
72. Nakasone, M.; Nakaso, K.; Horikoshi, Y.; Hanaki, T.; Kitagawa, Y.; Takahashi, T.; Inagaki, Y.; Matsura, T.
Preconditioning by low dose LPS prevents subsequent LPS-induced severe liver injury via Nrf2 activation in
mice. Yonago Acta Medica 2016, 59, 223–231. [PubMed]
73. Orio, M.; Kunz, A.; Kawano, T.; Anrather, J.; Zhou, P.; Iadecola, C. Lipopolysaccharide Induces Early
Tolerance to Excitotoxicity via Nitric Oxide and CGMP. Stroke 2007, 38, 2812–2817. [CrossRef] [PubMed]
74. Chen, K.; Geng, S.; Yuan, R.; Diao, N.; Upchurch, Z.; Li, L. Super-Low Dose Endotoxin Pre-Conditioning
Exacerbates Sepsis Mortality. EBioMedicine 2015, 2, 324–333. [CrossRef] [PubMed]
75. Mikołajczyk, A. Safe and Effective Anaesthesiological Protocols in Domestic Pig. Ann. Warsaw. Univ. Life Sci
SGGW Anim. Sci. 2016, 55, 219–227.
76. Gonkowski, S.; Rychlik, A.; Nowicki, M.; Nieradka, R.; Bulc, M.; Całka, J. A population of nesfatin 1-like
immunoreactive (LI) cells in the mucosal layer of the canine digestive tract. Res. Vet. Sci. 2012, 93, 1119–1121.
[CrossRef] [PubMed]
281
Int. J. Mol. Sci. 2018, 19, 2551
77. Gao, H.M.; Jiang, J.; Wilson, B.; Zhang, W.; Hong, J.S.; Liu, B. Microglial Activation-Mediated Delayed
and Progressive Degeneration of Rat Nigral Dopaminergic Neurons: Relevance to Parkinson’s Disease.
J. Neurochem. 2002, 81, 1285–1297. [CrossRef] [PubMed]
78. Gao, H.M.; Liu, B.; Zhang, W.; Hong, J.S. Synergistic Dopaminergic Neurotoxicity of MPTP and Inflammogen
Lipopolysaccharide: Relevance to the Etiology of Parkinson’s Disease. J. Neurosci. 2003, 23, 1228–1236.
[CrossRef] [PubMed]
79. Marvaldi, L.; Thongrong, S.; Kozłowska, A.; Irschick, R.; Pritz, C.O.; Bäumer, B.; Ronchi, G.; Geuna, S.;
Hausott, B.; Klimaschewski, L. Enhanced axon outgrowth and improved long-distance axon regeneration in
sprouty2 deficient mice. Dev. Neurobiol. 2015, 75, 217–231. [CrossRef] [PubMed]
80. Kozłowska, A.; Mikołajczyk, A.; Klimaschewski, L.; Majewski, M. Fibroblast Growth Factor (FGF) Promotes
Axon Elongation in Galanin Expressing Dorsal Root Ganglia (DRG) Neurons Supplying Urinary Bladder of
the Pig-an in Vitro Study. Eur. Urol. Suppl. 2016, 15, e1233. [CrossRef]
81. Loy, B.; Apostolova, G.; Dorn, R.; McGuire, V.A.; Arthur, J.S.; Dechant, G. P38α and P38β Mitogen-Activated
Protein Kinases Determine Cholinergic Transdifferentiation of Sympathetic Neurons. J. Neurosci. 2011, 31,
12059–12067. [CrossRef] [PubMed]
82. Lee, S.; Levine, J. Isolation and Growth of Adult Mouse Dorsal Root Ganglia Neurons. Bio-Protocol 2015, 5,
e1601. [CrossRef]
83. Heinrich, T.; Hübner, C.A.; Kurth, I. Isolation and Primary Cell Culture of Mouse Dorsal Root Ganglion
Neurons. Bio-Protocol 2016, 6, e1785. [CrossRef]
84. Ohtori, S.; Takahashi, K.; Moriya, H. Existence of brain-derived neurotrophic factor and vanilloid receptor
subtype 1 immunoreactive sensory DRG neurons innervating L5/6 intervertebral discs in rats. J. Orthop. Sci.
2003, 8, 84–87. [CrossRef] [PubMed]
85. Christianson, J.A.; Liang, R.; Ustinova, E.E.; Davis, B.M.; Fraser, M.O.; Pezzonea, M.A. Convergence of
Bladder and Colon Sensory Innervation Occurs at the Primary Afferent Level. Pain 2007, 128, 235–243.
[CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
282
 International Journal of 
Molecular Sciences
Article
Effects of 1-Methyltryptophan on Immune Responses
and the Kynurenine Pathway after
Lipopolysaccharide Challenge in Pigs
Elisa Wirthgen 1,2, Winfried Otten 1,*, Margret Tuchscherer 1, Armin Tuchscherer 3,
Grazyna Domanska 4, Julia Brenmoehl 5, Juliane Günther 5, Daniela Ohde 5, Werner Weitschies 6,
Anne Seidlitz 6, Eberhard Scheuch 7 and Ellen Kanitz 1,*
1 Institute of Behavioural Physiology, Leibniz Institute for Farm Animal Biology (FBN),
D-18196 Dummerstorf, Germany; elisa.wirthgen@googlemail.com (E.W.);
mtuchsch@fbn-dummerstorf.de (M.T.)
2 Department of Paediatrics, Institute University Children’s Hospital Rostock, D-18057 Rostock, Germany
3 Institute of Genetics and Biometry, Leibniz Institute for Farm Animal Biology (FBN),
D-18196 Dummerstorf, Germany; atuchsch@fbn-dummerstorf.de
4 Institute of Immunology and Transfusion Medicine, University of Greifswald,
D-17475 Greifswald, Germany; grazyna.domanska@uni-greifswald.de
5 Institute of Genome Biology, Leibniz Institute for Farm Animal Biology (FBN),
D-18196 Dummerstorf, Germany; brenmoehl@fbn-dummerstorf.de (J.B.);
j.guenther@fbn-dummerstorf.de (J.G.); ohde@fbn-dummerstorf.de (D.O.)
6 Institute of Pharmacy, University of Greifswald, D-17489 Greifswald, Germany;
werner.weitschies@uni-greifswald.de (W.W.); anne.seidlitz@uni-greifswald.de (A.S.)
7 Institute of Pharmacology, University of Greifswald, D-17489 Greifswald, Germany;
scheuch@uni-greifswald.de
* Correspondence: otten@fbn-dummerstorf.de (W.O.); ellen.kanitz@fbn-dummerstorf.de
(E.K.);Tel.: +49-38208-68809(W.O.); +49-38208-68807(E.K.)
Received: 9 August 2018; Accepted: 26 September 2018; Published: 2 October 2018
Abstract: An enhanced indoleamine 2,3-dioxygenase 1 (IDO1) activity is associated with an increased
mortality risk in sepsis patients. Thus, the preventive inhibition of IDO1 activity may be
a promising strategy to attenuate the severity of septic shock. 1-methyltryptophan (1-MT)
is currently in the interest of research due to its potential inhibitory effects on IDO1 and
immunomodulatory properties. The present study aims to investigate the protective and
immunomodulatory effects of 1-methyltryptophan against endotoxin-induced shock in a porcine
in vivo model. Effects of 1-MT were determined on lipopolysaccharide (LPS)-induced tryptophan
(TRP) degradation, immune response and sickness behaviour. 1-MT increased TRP and its metabolite
kynurenic acid (KYNA) in plasma and tissues, suppressed the LPS-induced maturation of neutrophils
and increased inactivity of the animals. 1-MT did not inhibit the LPS-induced degradation of TRP
to kynurenine (KYN)—a marker for IDO1 activity—although the increase in KYNA indicates that
degradation to one branch of the KYN pathway is facilitated. In conclusion, our findings provide
no evidence for IDO1 inhibition but reveal the side effects of 1-MT that may result from the proven
interference of KYNA and 1-MT with aryl hydrocarbon receptor signalling. These effects should be
considered for therapeutic applications of 1-MT.
Keywords: indoleamine 2,3-dioxygenase; kynurenine pathway; methyltryptophan; LPS; pig
1. Introduction
Indoleamine 2,3-dioxygenase 1 (IDO1)-mediated degradation of tryptophan (TRP) along
the kynurenine pathway plays a significant role as a counter-regulatory mechanism within the
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inflammatory immune response [1]. Endotoxin-induced IDO1 activation results in the depletion
of TRP and the generation of biologically active TRP metabolites such as kynurenine (KYN), kynurenic
acid (KYNA) and quinolinic acid (QUIN), which have important immuno- and neuromodulatory
properties [2–5]. In sepsis, it is proposed that an early hyper-inflammatory phase is followed or
overlapped by a prolonged state of immunosuppression, which are potentially life-threatening by the
development of septic shock or sepsis-induced immunoparalysis, respectively [6]. Clinical studies have
shown an association of enhanced IDO1 activity in the early pro-inflammatory stage of sepsis with
an increased disease severity [7] and increased hypotension, which contributes to septic shock due to
acute circulatory failure [8]. However, it remains unclear whether the increased IDO1 activity reflects
a compensatory response or contributes to overshooting inflammation. During ongoing sepsis, there
are indices that a prolonged elevated IDO1 activity increases the risk for poor outcome by provoking
the maintenance of a protracted immunosuppressive phase, diminishing immune responsiveness
and host defence [7,9,10]. In these clinical studies, the enhanced IDO1 activity was characterized by
an accelerated TRP degradation, resulting in an increased KYN/TRP ratio or increased levels of KYN
or KYNA. The finding that IDO1 knockout mice are protected against lipopolysaccharide (LPS)-induced
septic shock [11] also supports the assumption that an enhanced endotoxin-induced activation of
IDO1 provokes detrimental effects within conditions of sepsis. Compared with wild-type mice, IDO1
knockout mice had a higher survival rate within 48 h after an endotoxin shock accompanied by lower
levels of the pro-inflammatory cytokines TNF-α and IL-12 and simultaneously higher levels of the
anti-inflammatory cytokine IL-10, 4 h after LPS. These results indicate that IDO1 may elicit detrimental
pro-inflammatory effects in the early stage of sepsis in contrast to the mainly immunosuppressive
effects assumed during ongoing sepsis. In view of these findings, the inhibition of IDO1 activity
may be a promising strategy for the prevention of endotoxin-induced shock e.g., after surgery.
In patients, who expected a surgery, psychological stress enhanced IDO1 activity already in the pre-
and also in the postoperative period, which may contribute to postoperative modulation of immune
response [3]. Therefore, the inhibition of IDO1 before a scheduled surgery may reduce the risk for poor
outcome associated with an enhanced IDO1 activity during sepsis. Further studies, e.g., on cancer in
humans, are investigating the inhibition of IDO1 activity using applications of 1-methyltryptophan
(1-MT) as a possible therapeutic approach [12]. 1-MT has been shown to inhibit IDO1 activation in
mice, concomitant with a restoration of T-cell proliferation in vitro [13] and of antibacterial defence
concurrent with a reduction of depression-like behaviour [3]. Furthermore, the application of 1-MT
reduced TNF-α and increased IL-10 in response to endotoxin shock, supporting the findings in IDO1
knockout mice [11].
In a previous study of our group, a pig model for systemic IDO1 activation by intraperitoneal (i.p.)
LPS stimulation was established. It resulted in the LPS-induced increase of inflammatory cytokines
such as TNF-α and IL-10 followed by the depletion of TRP and an increased generation of TRP
metabolites such as KYN and KYNA in plasma, and IDO1 protein expression in blood and various
organs [14]. In a subsequent study, the pharmacokinetic properties of 1-MT after subcutaneous (s.c.)
application were evaluated and a model for systemic accumulation of 1-MT in plasma and tissues was
developed [15]. It is the aim of the present study to examine the protective and immunomodulatory
effects of 1-MT against LPS-induced shock in a porcine model, because pigs (Sus scrofa domestica)
provide obvious advantages with respect to their relevance to human pathophysiology compared
with rodents. This species closely resembles humans in anatomy, genetics and physiology and is
increasingly used as a model for humans in biomedical research [16–18]. We hypothesize that 1-MT
may inhibit IDO1 activity, resulting in reduced catalytic degradation of TRP and altered metabolite
profile along the KYN pathway after LPS challenge. We suppose that this could result in an attenuation
of the LPS-induced innate immune response due to the complex immunomodulatory properties of
KYN pathway. Hence, the immune response was characterized by cytokines, haematopoiesis and
sickness behaviour. An altered activity of IDO1 by 1-MT and its effects on KYN pathway were
validated by the measurement of TRP and the downstream metabolites KYN, KYNA and QUIN.
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2. Results
2.1. 1-MT Modifies TRP and Its Metabolites in Plasma
According to the experimental design shown in Figure 6, 1-MT was applied 84, 60, 36 and 12 h
before the LPS injection (0 h) and 12 h after LPS. Pairwise comparisons revealed no differences in the
basal concentrations of TRP, KYN, KYNA, QUIN and the KYN/TRP ratio immediately before the first
1-MT application at the time point −84 h (Figure 1A–E). The repeated s.c. administrations of 1-MT
significantly increased plasma concentrations of TRP and KYNA at 60, 36 and 12 h before LPS, whereas
KYN, the KYN/TRP ratio and QUIN were not affected by 1-MT.
Figure 1. Effects of repeated s.c. 1-MT applications on plasma TRP (A), KYN (B), KYN/TRP ratio (C),
KYNA (D) and QUIN (E) before LPS application. Pre-treatment with MYR was used as a control.
TRP and its metabolites were measured using MS/MS and the KYN/TRP ratio was used as a marker
for IDO1 activity. The s.c. 1-MT or MYR applications (indicated by black arrows) were injected directly
after each blood sampling. The results are presented as LS-means ± SE. Significant differences between
the 1-MT- and MYR-pre-treated groups were calculated using the Tukey–Kramer test and are indicated
for each time point. 1-MT: n = 24; MYR: n = 23; *** p < 0.001.
Immediately before the LPS application (0 h), KYNA concentrations were significantly increased
by 1-MT (Figure 2D, Figure A2D). Likewise, 1-MT generally increased plasma TRP and KYNA after
application of LPS or NaCl and reduced plasma concentrations of QUIN (Table 1). Administration of
LPS induced a reduction of TRP and an increase of KYN, KYN/TRP ratio, KYNA and QUIN compared
to NaCl (Table 1). Significant interactions between 1-MT and LPS effects were found for TRP and KYNA.
LPS significantly decreased TRP in Myritol (MYR)-treated controls but not in 1-MT animals and
significantly increased KYNA in 1-MT but not in MYR animals (Table 1).
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Table 1. Pairwise comparisons of the pre-treatment 1-MT vs. MYR and the treatment LPS vs. NaCl in












1-MT vs. MYR LPS vs. NaCl Interaction
TRP (μM) 127.38 A 129.67 A 115.63 B 122.29 C 1.10 <0.001 <0.001 <0.05
KYN (μM) 1.64 A 0.99 B 1.54 A,B 1.17 A,B 0.16 0.78 <0.01 0.40
KYN/TRP ratio 1.22 A 0.83 B 1.30 A 0.98 A,B 0.11 0.22 <0.001 0.69
KYNA (μM) 11.9 A 11.5 B 2.1 C 2.1 C 0.07 <0.001 <0.001 <0.01
QUIN (μM) 1.98 A 1.83 A 2.18 B 1.98 A 0.05 <0.01 <0.001 0.36
Concentrations of TRP, KYN, KYNA, Ratio (KYN × 100/TRP) are presented as LS-means (LSM) and SE. Within a row,
values with different superscript letters differ with p < 0.05. 1-MT: n = 24, MYR: n = 23; LPS: n = 23; NaCl: n = 24.
Detailed pairwise comparisons between the different sampling times show that LPS induced
a significant decrease of plasma TRP in both 1-MT and MYR pre-treated animals between 3 and
12 h after i.p. application (Figure 2A). However, only in MYR treated animals, TRP was also
reduced 12 and 24 h after LPS compared to 0 h. LPS caused a significant increase of KYN and the
KYN/TRP ratio at 6 h after administration, which was not affected by 1-MT, respectively (Figure 2B,C).
KYNA concentrations were significantly elevated in 1-MT animals at all sampling times (Figure 2D).
Further, KYNA concentrations increased in 1-MT animals between 0 to 3 h after LPS, whereas no
changes were found in the MYR group. Plasma levels of QUIN increased from 1 to 12 h after LPS
in the MYR-treated but not in 1-MT-treated animals (Figure 2E). There was a significant decrease of
QUIN from 12 to 24 h after LPS, which was not affected by 1-MT.
For a better evaluation of the LPS effect on KYNA in 1-MT animals, differences compared with
basal levels were calculated and shown as Figure A1. In 1-MT animals, LPS application induced
an additional increase in KYNA compared with NaCl-treated 1-MT animals. With the exception
of KYNA, the application of NaCl in control animals induced no time-dependent changes of TRP
metabolites (Figure A2).
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Figure 2. Effects of 1-MT on LPS-induced changes of TRP (A), KYN (B), KYN/TRP ratio (C), KYNA (D)
and QUIN (E) in plasma. As a control for 1-MT-induced effects the excipient MYR was used. TRP and
its metabolites were measured using MS/MS and the KYN/TRP ratio was used as a marker for
IDO1 activity. LPS was injected i.p. directly after blood sampling at 0 h. The animals received
the fifth s.c. 1-MT or MYR injection at 12 h after LPS. The results are presented as LS-means ± SE.
Tukey–Kramer procedure was used for all pairwise comparisons. Significant differences are indicated
between 1-MT and MYR groups for each time point by asterisks, and between the sampling times
by hashes. For the sampling times 0, 1, 3, 6 h: n = 11-12/group (total n = 47); for time point 24 h:
n = 5-6/group (total n = 23); *** p < 0.001, ** p < 0.01, * p < 0.05, # p < 0.01.
2.2. 1-MT Modifies TRP Metabolites in Tissues
TRP, KYN and KYNA were detectable in several tissues and pairwise comparisons of
1-MT vs. MYR and LPS vs. NaCl groups are shown in Table 2. 1-MT significantly increased TRP
concentrations in the prefrontal cortex, adrenal gland, muscle, lung, liver, heart, hippocampus,
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hypothalamus and spleen. KYN was detectable in liver, lung, spleen and hippocampus, but was not
affected by 1-MT pre-treatment (Table 2). KYNA was detectable in lung, kidney and liver, and was
increased in lung and kidney by 1-MT pre-treatment (Table 2).












Amygdala 1094 1067 88 0.83 892 1269 88 <0.01
Prefrontal cortex 563 416 29 <0.001 477 502 29 0.47
Adrenal gland 1062 855 46 <0.001 926 992 46 0.22
Muscle 484 385 19 <0.001 397 472 18 <0.01
Lung 489 393 32 <0.05 396 486 31 <0.05
Liver 715 619 33 <0.05 597 737 32 <0.01
Heart 685 569 41 <0.05 569 685 39 <0.05
Hippocampus 224 178 11 <0.01 189 213 11 0.12
Hypothalamus 79 67 4 <0.05 70 76 4 0.19
Spleen 746 636 31 <0.05 687 696 32 0.84
Kidney 1337 1249 42 0.10 1211 1375 42 <0.01
Thyroid gland 459 495 30 0.31 469 485 29 0.67
KYN (nmol/g protein)
Liver 604.86 590.86 35.62 0.64 586.74 608.98 34.99 0.48
Lung 123.16 156.84 21.97 0.29 180.15 99.85 22.08 <0.05
Spleen 12.83 11.45 1.79 0.58 18.28 6.00 1.80 <0.001
Hippocampus 19.69 19.74 1.78 0.98 19.50 19.93 1.78 0.87
KYNA (nmol/g protein)
Lung 3.83 2.4 0.34 <0.01 3.34 2.90 0.005 0.30
Kidney 0.71 0.57 0.05 <0.05 0.65 0.63 0.05 0.80
Liver 5.84 4.75 0.46 0.06 5.64 4.95 0.47 0.23
Results of TRP, KYN and KYNA concentrations are presented as LS-means (LSM) and SE. 1-MT: n = 24; MYR: n = 23;
LPS: n = 23; NaCl: n = 24.
Application of LPS induced a significant decrease of TRP concentrations in the amygdala,
muscle, lung, liver, heart and kidney and an increase of KYN in lung and spleen (Table 2).
A significant interaction between 1-MT and LPS effects was only found for TRP in the adrenal gland.
LPS significantly decreased TRP in the adrenal gland of MYR but not of 1-MT animals (p < 0.001).
2.3. Application of LPS Induces A Reduction of 1-MT in Plasma and Tissue
1-MT was not detectable either in plasma or in tissues of MYR animals. In 1-MT animals, plasma
1-MT concentrations decreased 6, 12 and 24 h after LPS compared to concentrations at 0 h (Figure 3A).
In the NaCl group, 1-MT was decreased after 12 h, the time of the next 1-MT application, and increased
until 24 h. Comparison of both treatments revealed that after 24 h plasma 1-MT was significantly lower
in LPS than in NaCl animals. In tissues, the application of LPS also induced a reduction of 1-MT in
liver, lung, kidney, spleen and heart (Figure 3B).
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Figure 3. Effects of LPS on 1-MT concentrations in plasma (A) and tissues (B). Treatment with NaCl
was used as a control. MYR-pre-treated animals are not shown due to the absence of 1-MT. 1-MT
was quantified using MS/MS. LPS or NaCl (indicated by black arrows) were injected i.p. directly
after blood sampling at 0 h. The animals received the fifth s.c. 1-MT injection at 12 h after LPS/NaCl
treatment as indicated. The data are presented as LS-means ± SE. In plasma (A), significant differences
between the time points were calculated using the Tukey–Kramer test and indicated by hashes
within each treatment group. Significant differences between LPS and NaCl groups (p < 0.05) are
indicated using differing letters (A, B). For time points 0, 1, 3, 6 h: n = 12/group. For time point 24 h:
n = 6/group. The data for 1-MT in tissues (B) include both sampling times (6 and 24 h, n = 12/group)
after i.p. application. Significant differences between LPS and NaCl treatment were calculated using
the Tukey–Kramer test and are indicated for each tissue, respectively. # p < 0.01.
2.4. 1-MT Modulates Inflammatory Response after LPS Application
White blood cells, including lymphocytes and neutrophils were measured before (0 h) and 6
and 24 h after LPS. Summarized over all sampling times, number of lymphocytes was significantly
increased in 1-MT animals, irrespective of LPS or NaCl administration (1-MT: 8.3 ± 0.6, MYR:
7.1 ± 0.6 cells × 106/mL, p < 0.05). In contrast, the number of neutrophils was generally reduced in
1-MT animals (1-MT: 7.7 ± 0.4, MYR 9.1 ± 0.4 cells × 106/mL, p < 0.05). LPS affected the cell number of
lymphocytes, neutrophils, myelocytes and band neutrophils and the N/L ratio 6 h after i.p. application.
In contrast, NaCl induced no significant changes 6 and 24 h after application. Pairwise comparisons
showed no significant differences between 1-MT and MYR pre-treated groups immediately before
LPS at time 0 h. LPS induced a decrease of lymphocytes 6 h after i.p. application in both 1-MT and
MYR pre-treated animals followed by an increase at 24 h (Figure 4A). An increase of neutrophils was
observed in MYR, but not in 1-MT treated animals 6 h after LPS (Figure 4B). The LPS-induced reduction
of lymphocytes and increase of neutrophils resulted in an increased neutrophil to lymphocyte (N/L)
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ratio at 6 h after LPS (Figure 4C) in both 1-MT and MYR pre-treated groups. However, this increase was
significantly reduced in 1-MT animals. This was mainly caused by a reduced increase of myelocytes
(Figure 4D) and band neutrophils (Figure 4E) in 1-MT animals 6 h after LPS application. Cell number
of segmented neutrophils was not affected by 1-MT or LPS (Figure 4F).
Figure 4. Effects of LPS on the number of lymphocytes (A), neutrophils (B), N/L ratio (C),
myelocytes (D), band neutrophils (E) and segmented neutrophils (F) and its interference by 1-MT.
Treatment with NaCl and pre-treatment with MYR were used as control groups. LPS or NaCl were
injected i.p. directly after blood sampling at 0 h. The animals received the fifth s.c. 1-MT injection at 12 h
after LPS/NaCl treatment to prevent a decline in 1-MT levels during the period of the LPS response.
The cell number was measured by differential leukocyte counts using a total of 200 leukocytes per
animal and time point. All data are presented as LS-means ± SE. Significant differences between 1-MT-
and MYR-pre-treated groups were calculated using the Tukey–Kramer test and are indicated for each
time point/period by asterisks. Significant differences between the time points are indicated by hashes
within each treatment group. For time points 0 and 6 h: n = 11-12/group (total n = 47); for time point
24 h: n = 5-6/group (total n = 23); *** p < 0.001, # p < 0.01.
The concentrations of TNF-α and IL-10, measured immediately before the LPS application (0 h),
were not affected by 1-MT. Treatment with LPS induced a significant increase of plasma TNF-α and
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IL-10 with the highest concentrations 1 h after LPS and an increase of skin temperature (Figure 5A–C).
Pairwise comparisons show that these increases were not affected by 1-MT. Administration of LPS induced
sickness behaviour within the 5-h period after administration as shown by inactivity (relative frequency:
LPS: 99.97 ± 0.008%, NaCl: 83.36 ± 1.07%, p < 0.01) and the occurrence of sickness symptoms
(mean number: LPS: 0.69 ± 0.03, NaCl: 0.006 ± 0.01, p < 0.001). The severity of sickness after LPS
was not affected by 1-MT. However, the pre-treatment with 1-MT increased the inactivity of NaCl-treated
control pigs (relative frequency: 1-MT + NaCl: 87.34 ± 1.29%, MYR + NaCl: 78.43 ± 1.67%, p < 0.01).
Figure 5. Effects of LPS on plasma TNF-α (A), plasma IL-10 (B) and skin temperature (C) and its
interference by 1-MT. Treatment with NaCl and pre-treatment with MYR were used as control groups.
LPS or NaCl were injected i.p. directly after blood sampling at 0 h, respectively. The animals received
the fifth s.c. 1-MT injection at 12 h after LPS/NaCl treatment to prevent a decline in 1-MT levels
during the period of the LPS response. The cytokines TNF-α and IL-10 were quantified by ELISA.
Skin temperature was measured using an infrared thermometer directly before blood sampling. All data
are presented as LS-means ± SE. For multiple pair-wise comparisons Tukey–Kramer procedure
was used. Significant differences between time points are indicated by hashes. For time points 0,
1, 3, 6 h: n = 11-12/group (total n = 47); for time points 12 and 24 h: n = 5-6/group (total n = 23);
# p < 0.01.
2.5. 1-MT Modifies mRNA Expression of Porcine Lung Fibroblasts
A supplementary experiment was conducted to evaluate potential interactions of 1-MT or
TRP with aryl hydrocarbon receptor (AhR) or inflammatory signalling pathways in a primary cell
culture of porcine lung fibroblasts (See Appendix ??). The results show that 1-MT significantly
increased the mRNA expression of cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1),
a marker for AhR activation, compared to the TRP and medium control. The expression of IL-8,
granulocyte-macrophage colony-stimulating factor (GM-CSF) and inducible nitric oxide synthase
(iNOS) was not affected neither by the 1-MT nor the TRP treatment (Figure A3). TNF-α was expressed
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on very low levels near or below the detection limit and was not increased, neither by stimulation with
1-MT nor with TRP (data not shown).
3. Discussion
In this study, immunomodulatory effects of 1-MT on LPS-induced IDO1 activation were
investigated in a porcine model to reveal new insights into the IDO1-mediated effects during the
early stage of inflammatory immune response. Our results show that administrations of 1-MT did
not diminish the LPS-induced conversion of TRP to KYN, indicating no inhibition of IDO1 activity
in vivo. However, 1-MT increased TRP and enhanced the formation of KYNA, a metabolite in the
KYN pathway with various immuno- and neuromodulatory functions. In addition, 1-MT caused
a modulation of the LPS-induced increase of N/L ratio.
3.1. 1-MT-Induced Increases in TRP and KYNA
The results of this study show that 1-MT increased the concentrations of TRP in plasma and
several tissues, independently of LPS treatment. This may be the result of reduced TRP degradation or
increased availability associated with the administration of 1-MT. In vivo, plasma TRP concentrations
are affected by both IDO1 and tryptophan 2,3-dioxygenase 2 (TDO2). Homeostasis of TRP is
mainly regulated by TDO2 [19], which is not inhibited by 1-MT [20,21], whereas IDO1 expression
is predominantly induced by inflammatory stimuli, such as the cytokines TNF-α or IFN-γ [19].
The increased levels of TRP in our study may reflect a reduced degradation as a result of IDO inhibition
due to 1-MT. However, the finding that the LPS-induced increase of KYN was not diminished by 1-MT
does not support the assumption of IDO inhibition. According to the manufacturer’s information,
1-MT has a purity of at least 95%. As confirmed by our own HPLC analyses, the L-1-MT contains
approximately 5% TRP (data not shown), which corresponds to an s.c. TRP uptake of 0.05 g TRP per
day, in addition to a daily dietary uptake of approximately 1.2 to 1.6 g TRP from the digestive tract.
Studies in human glioblastoma cells indicate that TRP contamination of commercially available 1-MT
(L-isomer) is converted to KYN in vitro [22]. In addition to TRP contamination of 1-MT, a removal
of the methyl group of 1-MT by enzymes or chemical processes would result in an increase in TRP
concentrations that could not be distinguished from endogenous TRP. Whether TRP contamination of
1-MT and/or demethylation caused the increase in TRP could not be clarified in this study.
Our results show that the production of KYNA, but not KYN, was increased in plasma and
tissues in response to 1-MT, independently of LPS. This indicates an enhanced degradation of TRP to
one branch of the KYN pathway, which may be a result of increased levels of available TRP. This finding
is supported by studies in rats, in which dietary supplementation of TRP induced an increase in
urinary excretion of TRP metabolites including KYNA [23]. Furthermore, studies in mice have shown
that a repeated application of 1-MT, which also contains low amounts of TRP, results in increased
plasma concentrations of KYNA [3]. In recent years, numerous in vivo and in vitro studies have been
directed toward the immunomodulatory functions of KYNA. It has been shown that KYNA mediates
immunosuppressive effects such as a reduced cytokine response during inflammation in mice [3,5]
or acts as a mediator of early recruitment of human monocytes [2]. Moreover, KYNA has been
described as a potent natural AhR ligand [24]. AhR signalling is involved in counter-regulatory effects
such as reprogramming of the LPS-induced cytokine response and suppression of adaptive immune
response [25,26]. Furthermore, AhR is an important regulator of cell physiology and contributes to the
proper function of the hepatic, haematopoietic, cardiovascular and immune system [27].
3.2. 1-MT Does Not Inhibit the Production of KYN But Is Diminished after LPS Treatment
Previous studies in rodents and in cell cultures showed that 1-MT (L-isomer) reduced the
production of metabolites in the KYN pathway and prevented the depletion of TRP [3,13,28,29].
In studies using a recombinant IDO1 enzyme in cell-free assay systems, the L-isomer of
1-MT (Ki = 19 μM/L) was found to be a more potent inhibitor of IDO1 than the D-isomer
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(Ki > 100 μM/L) [13]. However, the results of this study provide no evidence of an inhibitory
effect of the L-isomer of 1-MT on the LPS-induced KYN production in plasma, lung and spleen.
Nevertheless, the LPS-induced depletion of TRP was attenuated by the 1-MT-induced general
increase in TRP. In vitro studies have shown that the 1-MT-induced increase in TRP may impede
the antimicrobial and immunoregulatory functions of LPS-induced TRP depletion [22], facilitating
chronic infections due to impaired pathogen growth arrest [12].
One reason for the lack of IDO1 inhibition could be that the concentration of 1-MT was too
low to inhibit IDO1 activity in vivo. A phase I trial of tumour patients using 1-MT (D-isomer) as
an IDO1 inhibitor has shown that doses higher than 1200 mg 1-MT/patient do not increase peak
serum levels [30], indicating a limited accumulation of the applied 1-MT. This finding is in accordance
with our previous findings showing that a steady-state 1-MT concentration is already reached after
the second 1-MT injection of 1000 mg/animal/day [15], increasing 1-MT to plasma levels similar to
those of TRP. Even in lung and spleen, in which 1-MT was approximately 2- to 3-fold higher than the
corresponding TRP levels [15], no inhibition of LPS-induced KYN production was detected, assuming
that 1-MT did not inhibit IDO1 activity.
It has been shown that 1-MT binds to the ferrous IDO1 enzyme, but the additional methyl group
prevents degradation along the KYN pathway due to steric effects [20]. The results of the present study
reveal that LPS induces a reduction of 1-MT in plasma and several tissues, which might be a result of
an increased urinary clearance and/or of catalytic degradation. There are few indices showing that both
IDO1 and TDO2 are able to catalyse 1-MT (L-isomer) with low affinity (Km = 150 μM) in comparison to
TRP (Km = 7 μM), resulting in the generation of KYN or methyl-KYN [31,32]. However, the results of
our study show no evidence of additional production of KYN after LPS treatment. Furthermore, in the
subsequent HPLC analysis, using α-methyl-KYN as a reference standard, no methyl-KYN was
detectable in samples after LPS treatment (data not shown).
3.3. 1-MT Mediates Immunomodulatory Effects
In the experimental design of this study, IDO1 activation was induced by LPS resulting in
an inflammatory response that provoked an increase in pro- and anti-inflammatory cytokines such as
TNF-α or IL-10. Contrary to findings in mice [11], no significant effect of 1-MT on the plasma cytokine
response or sickness severity was found. However, the results show that 1-MT induced a modulation
of LPS-induced immune response. 1-MT reduced the increase in the immature myelocytes and
band neutrophils in response to LPS, indicating a suppression of adequate neutrophil maturation.
This may also explain the generally reduced number of neutrophils by 1-MT. Furthermore, 1-MT
reduced the LPS-induced increase of the N/L ratio, which is used as an early marker of acute
inflammation [33,34]. These results support findings in human cancer and dendritic cells, revealing
that 1-MT has transcriptional effects that may promote immunosuppressive effects [35,36].
1-MT enhanced the inactivity of the NaCl-treated animals and elevated number of lymphocytes,
which might reflect a response to a repeated inflammatory stimulation [37,38]. In vitro, there are
indications that 1-MT interferes with TLR signalling in dendritic cells, independently of IDO1
activity [35]. Furthermore, there are indications in human and mouse cells that 1-MT itself acts
as an agonist for AhR, enabling the transcriptional expression of AhR-specific target genes [39],
which may affect inflammatory pathways. Results of the supplementary experiment show that 1-MT
significantly increased the mRNA expression of CYP1A1, which is described as a sensitive marker for
AhR activation [40], thus confirming the findings in mouse and human cell lines [39]. In addition, no
increased expression of inflammatory mediators such as IL-8, GM-CSF, TNF-α and iNOS was detected
on transcription levels after 1-MT incubation. Further, elevated TRP levels, simulating the 5% of TRP
contained in 1-MT, had no significant effects on gene expression. Our findings that 1-MT itself acts
as an AhR ligand and increases plasma and tissue concentrations of the endogenous AhR ligand
KYNA in vivo should be taken into account when using 1-MT for therapeutic applications and require
further investigation.
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4. Materials and Methods
4.1. Animals
Male German Landrace pigs (n = 96), bred and raised in the experimental pig unit of the Leibniz
Institute for Farm Animal Biology, were used in two experiments. All pigs received standard processing
(oral iron supplementation and castration) within the first three days of life. At the beginning of the
experiments, the pigs were seven weeks old and weighed between 12 and 18 kg. The pigs were
fed a commercial diet and had free access to water. All procedures involving animal handling
and treatment were in accordance with the German animal protection law and were approved
by the responsible authority (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei,
Mecklenburg-Vorpommern; Rostock; Germany; LALLF M-V/TSD/7221.3-1.1-027/10; 02 Juni 2010).
4.2. Experimental Design
The effects of 1-MT application on TRP metabolism and endotoxin-induced immune response
were investigated in two experiments (Figure 6). The first experiment focused on 1-MT-induced effects
on blood and tissue parameters before and during the 24 h period after a single endotoxin application
(n = 48). In the second experiment, the influence of 1-MT on LPS-induced sickness behaviour and
haematopoiesis was investigated (n = 48). Both experiments were conducted in three replicates with
16 animals each. One week prior to the commencement of the experiments, animals were housed
in single pens. In each experiment, half of the animals received daily administrations of 1 g 1-MT
(L-isomer, purity 95%; Sigma-Aldrich, Deisenhofen, Germany) over a period of five days. The dose
was selected according to a preceding experiment. At the time of LPS injection (0 h) steady state
plasma levels of 1-MT were achieved and 1-MT was accumulated in tissues at a level equal to or
higher than TRP (for details and pharmacokinetics see Wirthgen et al., 2016 [15]). Injections were
given s.c. in the popliteal fossa of the hind legs and split in two doses of 0.5 g of 1-MT in 4.0 mL of
triglyceride solution Myritol®318 (MYR) (Caesar und Loretz GmbH, Hilden, Germany), which was
used as an excipient. Control animals received an equivalent volume of the MYR solution. Injections of
MYR or 1-MT were given at 08:00 p.m. on five consecutive days (84, 60, 36 and 12 h before, and 12 h
after the i.p. LPS/NaCl application). Health status was continuously checked by visual inspection
twice daily, and the daily feed uptake was measured. Repetitive s.c. administration of MYR or 1-MT
(suspended in MYR) caused local swelling around the puncture sites. However, no fever response or
significant changes in feed uptake or body weight were observed.
At 8:00 a.m. on the fifth day, half of the pre-treated and control animals received a single i.p.
administration of LPS with a dose of 50 μg/kg live weight (Escherichia coli O111:B4; Sigma-Aldrich,
Deisenhofen, Germany) dissolved in 3 mL sterile endotoxin-free 0.9% NaCl according to a previous
description [41]. The other animals were treated with an equivalent volume of NaCl. Twelve hours
before LPS/NaCl application, the feed was removed to avoid an interference of feed uptake with TRP
metabolism during the sampling period immediately after endotoxin challenge.
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Figure 6. The effects of 1-MT application on TRP metabolism and LPS-induced immune response were
investigated in two experiments. In both experiments, 1-MT and its control MYR were repeatedly
injected subcutaneously (s.c.) as indicated, aiming at maximum levels of 1-MT at the time of LPS or
NaCl injections at 0 h according to the 1-MT kinetics. In experiment 1 (n = 47), blood samples were
taken before and at 0, 1, 3, 6, 12 and 24 h after LPS/NaCl application and tissue was sampled after 6 h
(n = 24) and after 24 h (n = 23). In experiment 2 (n = 48), blood samples were taken before and at 0, 6, 12
and 24 h after LPS/NaCl application and behaviour was observed in the period from 0 to 5 h. Both
experiments were conducted in three replicates with 15 or 16 animals each.
4.2.1. Experiment 1: Effects of 1-MT on Inflammatory Response and KYN Pathway
Because one animal had to be excluded due to health problems, 47 animals were used in total in
this experiment, distributed in the following treatment groups as described above: 1-MT + LPS (n = 12),
1-MT + NaCl (n = 12), MYR + LPS (n = 11) and MYR + NaCl (n = 12). Before every s.c. 1-MT/MYR
application, blood was collected to analyse plasma concentrations of 1-MT and TRP metabolites.
In addition, blood samples were collected immediately before i.p. LPS/NaCl administration (0 h)
and at 1, 3, 6, 12 and 24 h after administration for analyses of 1-MT, TRP metabolites and cytokines
(TNF-α, IL-10) in plasma. Blood sampling was carried out while pigs were in a supine position by
anterior vena cava puncture with the whole procedure lasting less than one minute. Blood samples
were collected in ice-cooled tubes containing EDTA or heparin and centrifuged at 2000× g for 10 min
at 4 ◦C. The blood plasma was then stored at −80 ◦C until analysis. Before s.c. 1-MT injections and
before blood samplings during LPS challenge, skin temperature was measured in the inguinal region
using an infrared thermometer (ThermoScan IRT 4020, Braun, Kronberg, Germany).
For collecting tissues, six animals each from every treatment group were euthanized by an injection
of T61 (Intervet, Unterschleißheim, Germany) at 6 and 24 h after LPS/NaCl. These times of tissue
collection were chosen because they represent the temporal dynamics of IDO1 activity based on
alterations of TRP metabolite concentrations as shown previously [14]. After euthanasia, liver, lung,
muscle (Musculus deltoideus), adrenal gland, spleen, thyroid gland, heart, kidney and brain tissues
were quickly removed. The hypothalamus, hippocampus, amygdala and prefrontal cortex were
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dissected from the brain, frozen in liquid nitrogen and stored at −80 ◦C. The stereotaxic atlas of the pig
brain served as a reference [42]. Tissues were analysed for 1-MT and TRP metabolite concentrations.
4.2.2. Experiment 2: Effects of 1-MT on Behaviour and Haematopoiesis
In experiment 2, a total of 48 animals were used. Animals were pre-treated with 1-MT or MYR
and received either an LPS or NaCl administration in accordance with experiment 1. Blood samples
were collected before every s.c. application of 1-MT/MYR, immediately before (0 h), and 6, 12 and
24 h after LPS/NaCl administration. Evaluation of sickness behaviour was conducted from 0 to 5 h
after LPS/NaCl treatment. Differential leukocyte counts were evaluated at 0, 6 and 24 h after i.p.
LPS/NaCl application.
4.3. Analyses
4.3.1. Quantification of 1-MT and TRP Metabolites
The determination of 1-MT, TRP, KYN, KYNA and QUIN in EDTA plasma and tissues was
performed using methods that have been previously described in detail [14,15] using an HPLC-system
(Perkin Elmer, series 200, Darmstadt, Germany) and an API2000 tandem mass spectrometer
equipped with an electrospray ion source (ABSciex, Darmstadt, Germany). The main quality
parameters of between-day and within-day accuracy and precision as well as the analytical ranges
and linearity (correlation coefficient, R) are provided in Table 3. The obtained results adhere to
international recommendations [43,44]. As an indicator for IDO1 activation, the ratio of KYN and TRP
(KYN × 100/TRP) was calculated [45].
Table 3. Analytic quality parameters for 1-MT, TRP and its metabolites.
Analyte Accuracy (%) Precision (%) Range (μM) Linearity (R)
1-MT −7.8–4.0 2.3–7.0 2.3-69 0.9966–0.9992
TRP −5.9–3.3 1.7–9.9 1.2–49 0.9986–0.9995
KYN −9.5–13.5 3.9–14.5 0.24–24 0.9969–0.9990
KYNA −9.9–15.7 6.8–14.9 0.01–0.32 0.9931–0.9946
QUIN −19.8–18.4 7.6–19.8 18–359 0.9590–0.9957
4.3.2. TNF-α and IL-10 Assays
The concentrations of TNF-α and IL-10 were analysed in duplicate in blood plasma using
a commercially available pig ELISA kit (Invitrogen, Frederick, MD, USA) according to the
manufacturer’s instructions. The sensitivities of the TNF-α and IL-10 assays were 3 pg/mL. The intra-
and inter-assay coefficients of variation (CV) of TNF-α were 6.2% and 8.2%, respectively. The intra-
and inter-assay CVs of IL-10 were 6.3% and 9.4%, respectively [46].
4.3.3. Differential Leukocyte Counts
A blood smear was prepared followed by air drying. The object slide was then incubated for
2 min in May–Grünwald solution and washed with aqua dest, followed by an incubation in Giemsa
solution (1:20) for 30 min. After washing with aqua dest, the slide was dried. To calculate the
leukocyte distribution, a total of 200 leukocytes was counted using microscopy. The cell types were
differentiated as lymphocytes, monocytes, basophiles, eosinophils and neutrophils with subdivision
into neutrophilic myelocytes, band neutrophils and segmented neutrophils [47]. As a marker
for early acute inflammation and physiological stress, the neutrophil to lymphocyte count ratio
(N/L ratio) was calculated [33]. The N/L ratio is a biomarker reacting very early in the course of acute
inflammation [34].
296
Int. J. Mol. Sci. 2018, 19, 3009
4.3.4. Behavioural Observations
The behaviour of each animal was observed using scan sampling [48] every 5 min over a period
of 5 h after i.p. LPS/NaCl application, resulting in 60 observations per animal. Thus, at the time
of observation, individual behaviour categorized as symptoms of sickness, activity or inactivity
was assessed for each animal (Table 4). A value of 1 was assigned to indicate the occurrence
of a specific behaviour, whereas a value 0 was assigned to denote its absence. To evaluate the
severity of sickness, the values of all sickness symptoms were summed for each observation point
for each animal (minimum number = 0, maximum number = 5) and calculated as the mean number.
Furthermore, an animal was characterized as active or inactive if the behaviour of the category was
recorded at the time of observation. Then, the activity level was calculated as the percentage of the
whole observation period of 5 h for each animal.
Table 4. Categories and their related behaviours used for the assessment of sickness severity
and activity.
Category Behaviour
Symptoms of Sickness Shivering; impeded respiration; vomiting; diarrhoea; circulatory insufficiency
Activity Walking; drinking; employment with feed, bedding, trough, toy or piglet fromneighbouring pen
Inactivity Lying; sitting; standing without movement
4.4. Statistics
Statistical analyses were performed using SAS software, version 9.4 for Windows
(SAS Institute Inc., Cary, NC, USA). Descriptive statistics and tests for normality were calculated
with the UNIVARIATE procedure provided with the Base SAS software.
Blood and tissue parameters and skin temperature were evaluated by ANOVA using the MIXED
procedure with SAS/STAT software. In experiment 1, plasma TRP metabolites were evaluated before
LPS/NaCl application. This model comprised the fixed effects pre-treatment (1-MT, MYR), sampling
time (−84, −60, −36, −12 h), replicate (1, 2, 3) and their multiple interactions. The repeated statement in
the MIXED procedure and a compound symmetry block diagonal structure of the residual covariance
matrix were used with respect to repeated measurements on the same animal. For the plasma
parameters and skin temperature from experiment 1 after LPS/NaCl application, ANOVA comprised
the fixed effects pre-treatment (1-MT, MYR), treatment (LPS, NaCl), sampling time (0, 1, 3, 6, 24 h)
and replicate (1, 2, 3), their multiple interactions, and the random effect sow and repeated statement
(as described above). For evaluation of tissue parameters, data of both sampling times (6 and 24 h)
were combined and ANOVA consisted of the fixed effects pre-treatment (1-MT, MYR), treatment
(LPS, NaCl) and replicate (1, 2, 3), their multiple interactions and the random sow effect. For blood
parameters in experiment 2, ANOVA comprised the fixed effects pre-treatment (1-MT, MYR), treatment
(LPS, NaCl), sampling time (0, 6, 12, 24 h) and replicate (4, 5, 6), their multiple interactions and the
random effect sow. The repeated statement in the MIXED procedure was used as described above.
To evaluate sickness severity during the 5 h observation period after LPS, the GLIMMIX procedure
was applied using a Poisson model (model statement: distribution = Poisson, link = log) comprising the
fixed effects pre-treatment (1-MT, MYR), treatment (LPS, NaCl) replicate (4, 5, 6) and their interactions.
For the evaluation of activity in the 5 h observation period, the GLIMMIX procedure was applied
using a logistic model (model statement: distribution = binomial, link = logit) comprising the fixed
effects pre-treatment (1-MT, MYR), treatment (LPS, NaCl), replicate (4, 5, 6) and their interactions.
Repeated measurements on the same animal were taken into account by the “_RESIDUAL_” keyword
in the “random statement” of the GLIMMIX procedure using the autoregressive structure of the first
order (type = AR(1)) for the block diagonal residual covariance matrix.
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For the presentation of the results, the least square means (LS-means) and their standard errors (SE)
were calculated and tested for each fixed effect in the models described earlier using the Tukey–Kramer
procedure for all multiple pair-wise comparisons. Effects and differences were considered significant
at p < 0.05.
5. Conclusions
The results from the present study in pigs indicate that repeated administration of 1-MT does not
inhibit the LPS-induced increase of KYN/TRP ratio, which is used as a marker for IDO1 activation
in vivo. Therefore, no evidence is provided that the 1-MT-induced effects in this study are related
to a reduced IDO activity. Indeed, 1-MT increased the levels of KYNA prior to the LPS challenge,
indicating a pre-treatment effect of 1-MT facilitating the degradation to one branch of the KYN pathway.
The 1-MT-associated modulation of the LPS-induced haematopoiesis indicates an interference of 1-MT
with inflammatory signalling pathways. This might be due to the activation of AhR by 1-MT and
KYNA resulting in the transcriptional activation of several inflammation-associated target genes.
Furthermore, the general increase in TRP by 1-MT may cause an impaired antimicrobial defence
if applied in sepsis patients. These adverse effects of 1-MT should be considered in therapeutic
applications of 1-MT, which is used in clinical studies in tumour patients with the goal of preventing
IDO1-induced immune escape of cancer cells.
Author Contributions: E.W., W.O., E.K., M.T., A.T., and W.W. designed the study; E.W., E.K., M.T., W.O. and A.S.
performed the experiments; E.W., W.O., E.K., M.T. A.T., G.D., E.S., J.B., J.G. and D.O. analysed the data; E.W., W.O.,
E.K. and M.T. wrote the main manuscript. All authors reviewed the manuscript.
Funding: This work was funded by the Deutsche Forschungsgemeinschaft (www.dfg.de; grant numbers:
KA 1266/5-1, SCHU 853/7-1). The publication of this article was funded by the Open Access Fund of the
Leibniz Association and the Open Access Fund of the Leibniz Institute for Farm Animal Biology (FBN).
Acknowledgments: The authors are grateful for the excellent technical assistance of Silvia Langhoff, Dagmar
Mähling, Petra Müntzel, Martina Pohlmann, Birgit Sobczak and Regina Wal from the Institute of Behavioural
Physiology, Leibniz Institute for Farm Animal Biology (FBN), and Thomas Brand and Sabine Ristow from the
Institute of Pharmacy, University of Greifswald. The authors are also grateful to Cornelia Müller from the Institute
of Clinical Chemistry and Laboratory Medicine, University of Greifswald, for assisting with the quantification of
1-MT and TRP metabolites. In addition, the authors thank Evelin Normann, Heidi Sievert and colleagues from the
experimental pig unit for excellent animal care, Eduard Murani for providing porcine primers and Ulrike Gimsa
for critically reviewing the manuscript.










N/L ratio Neutrophil to lymphocyte count ratio
TDO2 Tryptophan 2,3-dioxygenase
AhR Aryl hydrocarbon receptor
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1
GM-CSF Granulocyte-macrophage colony-stimulating factor
iNOS Inducible nitric oxide synthase
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Appendix A
Figure A1. Effect of LPS on the 1-MT-dependent increase of KYNA concentrations in plasma.
Treatment with NaCl and pre-treatment with MYR were used as controls. KYNA was measured
using MS/MS, and differences in comparison to basal levels (0 h) were calculated to evaluate the
LPS effect. The i.p. applications of LPS or NaCl were injected directly after blood sampling at 0
h, respectively. The animals received the fifth s.c. 1-MT or MYR injection at 12 h after LPS/NaCl
treatment. The results are presented as LS-means ± SE. Significant differences were calculated using
the Tukey–Kramer test and are indicated between LPS and NaCl groups for each time point by asterisks.
For time points 0, 1, 3, 6 h: n = 11-12/group (total n = 47); for time point 24 h: n = 5-6/group (total n =
23); *** p < 0.001.
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Figure A2. Effect of 1-MT on TRP (A), KYN (B), KYN/TRP ratio (C), KYNA (D) and QUIN (E) in plasma
after i.p. NaCl administration. As a control for 1-MT-induced effects the excipient MYR was used.
TRP and its metabolites were measured using MS/MS and the KYN/TRP ratio was used as a marker
for IDO1 activity. NaCl was injected i.p. directly after blood sampling at 0 h. The animals received
the fifth s.c. 1-MT or MYR injection at 12 h after NaCl. The results are presented as LS-means ± SE.
Tukey–Kramer procedure was used for all pairwise comparisons. Significant differences are indicated
between 1-MT and MYR groups for each time point by asterisks, and between the sampling times
by hashes. For the sampling times 0, 1, 3, 6 h: n = 11-12/group (total n = 47); for time point 24 h:
n = 5-6/group (total n = 23); *** p < 0.001, # p < 0.01.
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Figure A3. Effects of 1-MT and TRP contained in 1-MT on the mRNA expression of CYP1-A1, IL-8,
GM-CSF and iNOS. Porcine lung fibroblasts were incubated with medium (unstimulated) or stimulated
with TRP (5 μM) or L-1-MT (100 μM) for 3 h. Data are presented as means ± SE. n = 6, ** p < 0.01.
Appendix B
Appendix B.1. Supplementary Experiment
The potential interactions of 1-methyltryptophan (1-MT) and the amount of tryptophan (TRP) contained
in 1-MT with aryl hydrocarbon receptor (AhR) and inflammatory pathways were evaluated in a primary
cell culture of porcine lung fibroblasts. As a sensitive marker for AhR activation, the mRNA expression of
cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) was evaluated [40]. To examine the potential
activation of inflammatory pathways by 1-MT, the mRNA expression of TNF-α, IL-8, granulocyte-macrophage
colony-stimulating factor (GM-CSF) and inducible nitric oxide synthase (iNOS) was analysed.
Appendix B.2. Methods
Lung fibroblasts were isolated from nine-week-old German Landrace pigs (n = 6) directly after
slaughter according to the isolation method of human colonic lamina propria fibroblasts as described
earlier [49]. Briefly, lung tissue was cut into 1-mm pieces and incubated for 30 min in Hank’s Balanced
Salt Solution without Ca2+ and Mg2+ (Lonza, Basel, Switzerland) with 2 mmol/L EDTA (Sigma-Aldrich,
Deisenhofen, Germany). The remaining tissue was rinsed and then digested for 1 hour at 37 ◦C with 1 mg/mL
collagenase 1 (Merck, Darmstadt, Germany), 0.3 mg/mL DNase I (Roche, Heidelberg, Germany) and 2 mg/mL
hyaluronidase (Sigma-Aldrich, Deisenhofen, Germany) in PBS. The isolated cells were cultured in DMEM
(Lonza, Basel, Switzerland) containing penicillin (100 IE/mL), streptomycin (100 μg/mL), and amphotericin B
(1 μg/mL) (Lonza, Basel, Switzerland) and 10% FCS (Biochrom, Berlin, Germany). Porcine lung fibroblasts
were used between passages 3 and 4. 1-MT (L-isomer, purity 95%; Sigma-Aldrich, Deisenhofen, Germany)
was dissolved in 1 N NaOH to a stock concentration of 1M. Since it is known that 1-MT contain 5% L-TRP,
a TRP control was prepared by dissolving 50 mM L-TRP (Sigma Aldrich, Deisenhofen, Germany) in 1 N NaOH.
For porcine lung fibroblast challenge, 1-MT was diluted in fibroblast cell culture medium to a concentration
of 100 μM. For TRP, 50 mM L-TRP stock was diluted to a concentration of 5 μM. A NaOH solvent control
was prepared by adding 1 N NaOH to cell culture medium to the same volume as actually used for 1-MT and
L-TRP challenge. After a cultivation time of 3 h, fibroblasts were dissolved in 900 μL Trizol (Thermo Fisher
Scientific, Waltham, MA, USA) per well and RNA was isolated using Direct-zol™ RNA MiniPrep (Zymo Research,
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Irvine, CA, USA) with subsequent quantification on NanoDrop ND-1000 spectrophotometer (NanoDrop, Peqlab,
Erlangen, Germany). The amounts of mRNA transcripts in cultured fibroblasts were determined by real-time PCR
using LightCycler® 480 instrumentation (Roche Diagnostics, Mannheim, Germany). Reverse transcription was
performed with 500 ng of total RNA using SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific)
with random hexamers and oligo (dT) primers. For gene-specific polymerase chain reaction (PCR), 12.5 ng cDNA
were used in reaction mixtures containing 20 μM each forward and reverse primers (Table A1) and GoTaq®
qPCR Master Mix (Promega, Madison, WI, USA), according to the manufacturer’s instructions. Templates were
amplified in duplicate after 2 min at 95 ◦C by 45 cycles of the following program: 15 s at 95 ◦C for denaturation
and 1 min at 60 ◦C for annealing and extension. B2M was not affected by the applied treatments (variance 1.9%)
between the analysed groups and therefore used as a housekeeping gene. The crossing points were analysed
using LightCycler® 480 software (Roche Diagnostics) and the 2−ΔΔCt method [50] was used to calculate transcript
levels of each target gene.
Table A1. Primer pairs for real-time PCR.
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Abstract: Aspirin down regulates transferrin receptor 1 (TfR1) and up regulates ferroportin 1 (Fpn1)
and ferritin expression in BV-2 microglial cells treated without lipopolysaccharides (LPS), as well as
down regulates hepcidin and interleukin 6 (IL-6) in cells treated with LPS. However, the relevant
mechanisms are unknown. Here, we investigate the effects of aspirin on expression of hepcidin and
iron regulatory protein 1 (IRP1), phosphorylation of Janus kinase 2 (JAK2), signal transducer and
activator of transcription 3 (STAT3) and P65 (nuclear factor-κB), and the production of nitric oxide
(NO) in BV-2 microglial cells treated with and without LPS. We demonstrated that aspirin inhibited
hepcidin mRNA as well as NO production in cells treated with LPS, but not in cells without LPS,
suppresses IL-6, JAK2, STAT3, and P65 (nuclear factor-κB) phosphorylation and has no effect on IRP1
in cells treated with or without LPS. These findings provide evidence that aspirin down regulates
hepcidin by inhibiting IL6/JAK2/STAT3 and P65 (nuclear factor-κB) pathways in the cells under
inflammatory conditions, and imply that an aspirin-induced reduction in TfR1 and an increase in
ferritin are not associated with IRP1 and NO.
Keywords: aspirin; hepcidin; P65 (nuclear factor-κB); IL-6/JAK2/STAT3 pathway;
lipopolysaccharide (LPS); nitric oxide (NO); iron regulatory protein 1 (IRP1)
1. Introduction
Aspirin is a non-steroidal anti-inflammatory drug (NSAID) and has been used for many years to
treat a wide range of maladies, including pain and inflammation [1]. Preclinical and clinical studies
have evidenced that aspirin has beneficial effects on mood disorders and schizophrenia and that
high-dose aspirin is associated with a reduced risk of Alzheimer’s disease (AD) [2]. This oldest agent
in medicine has also been considered to be a potential new therapy for a range of neuropsychiatric
disorders [2].
Studies have demonstrated that aspirin and sodium salicylate have a significant
neuro-protective role in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [3,4], rotenone [5],
1-methyl-4-phenylpyridiniumion (MPP+), and 6-hydroxydopamine (6-OHDA) [6] animal models
in vivo and in neurons exposed to 6-OHDA and MPP+ in vitro [7]. MPTP, rotenone, 6-OHDA,
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and MPP+ are all neurotoxins known to trigger oxidative stress [4,7]. The neuro-protective effects of
aspirin against oxidative stress induced by these neurotoxins have therefore been considered to be
related to its ability to scavenger free radicals [3,4,6].
Abnormally high levels of iron and oxidative stress have been observed in a number of
neurodegenerative disorders [8–11]. Iron is a major generator of reactive oxygen species (ROS),
and oxidative stress resulting from increased iron in the brain has been widely considered to be an
initial causes of neuronal death in some neurodegenerative diseases [12,13]. In addition, it has been
demonstrated that aspirin can affect iron metabolism by increasing ferritin synthesis in the cultured
bovine pulmonary artery endothelial cells [14] and reducing serum ferritin (SF) in humans [15].
The well-established association of inflammatory and expression of iron regulatory hormone
hepcidin [16,17], the anti-inflammatory character of aspirin [2], and the findings as discussed above
prompted us to speculate that aspirin might have the ability to affect iron metabolism. Recently,
we therefore investigated the effects of aspirin on the expression of three major iron metabolism
proteins, transferrin receptor 1 (TfR1), ferroportin 1 (Fpn1), and ferritin, as well as hepcidin and
interleukin 6 (IL-6) in BV-2 microglial cells. We found that aspirin significantly down regulates TfR1
and up regulates Fpn1 and ferritin expressions in cells treated without lipopolysaccharides (LPS)
in vitro, as well as down regulates hepcidin and IL-6 levels in cells treated with LPS [18]. However,
the relevant mechanisms are unknown. In the present study, we investigate the effects of aspirin
on expression of hepcidin mRNA and regulating molecules of hepcidin, including IL-6 mRNA, iron
regulatory protein 1 (IRP1) protein, phosphorylation of Janus kinase 2 (JAK2), signal transducer and
activator of transcription 3 (STAT3), P65 (nuclear factor-κB, NF-κB), and nitric oxide (NO) in BV-2
microglial cells treated with and without LPS.
2. Results
2.1. Aspirin Protects BV-2 Microglial Cells from Lipopolysaccharides (LPS)-Induced Damage
We first investigated the effects of aspirin (ASA) on the cell viability by treating BV-2 microglial
cells with a vehicle (0.1% ethanol) for 24 h (The Control), 0.1 mM aspirin for 24 h (ASA), 0.1%
ethanol for 18 h + 1 μg/mL of LPS for 6 h (LPS), or aspirin for 18 h + 1 μg/mL of LPS for 6 h
(LPS + 0.1 mM ASA). We used 0.1 mM aspirin because this concentration was found to have a
significant effect on hepcidin mRNA expression in LPS-treated BV-2 microglial cells in another recent
study [18]. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed
that there was no significant difference in cell viability between cells treated with the vehicle (control)
or with 0.1 mM aspirin (Figure 1). It was also found that the cell viability in cells treated with LPS
alone were significantly lower than those in the cells treated with the vehicle or the 0.1 mM aspirin,
implying that LPS could induce cell-damage under our in vitro experimental conditions. However,
the viability of the cells treated with 0.1 mM aspirin plus LPS was significantly higher than that of
the cells treated with LPS alone and almost the same as that of control cells (Figure 1). This result is
consistent with our recent findings [18] and re-confirmed that aspirin has a role in protecting BV-2
microglial cells from LPS-induced damage in vitro.
2.2. Aspirin Inhibits Hepcidin mRNA Expression But Has No Effect on IRP1 Protein Expression in BV-2
Microglial Cells Treated with LPS
We then investigated the effects of aspirin on hepcidin mRNA and IRP1 protein expression in
BV-2 microglial cells by treating with a vehicle (0.1% ethanol) for 24 h (The Control), 0.1 mM aspirin
for 24 h (ASA), 0.1% ethanol for 18 h + 1 μg/mL of LPS for 6 h (LPS), or aspirin for 18 h + 1 μg/mL
of LPS for 6 h (LPS + 0.1 mM ASA). Treatment with LPS induced a significant increase in hepcidin
mRNA expression, the levels of hepcidin mRNA in the cells treated with LPS being markedly higher
than those in the controls (Figure 2A). However, hepcidin mRNA expression in the cells treated with
aspirin plus LPS was significantly lower than that in the cells treated with LPS only, but there was
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no difference between the cells treated with aspirin or with the vehicle. These results demonstrated
that aspirin could inhibit hepcidin mRNA expression in BV-2 microglial cells treated with LPS but
not in the cells treated without LPS. Western blot analysis showed that there were no differences in
IRP1 protein content between cells treated with aspirin or the vehicle, or with LPS or aspirin plus LPS
(Figure 2B), evidencing that aspirin has no effect on IRP1 protein expression in BV-2 microglial cells
treated with or without LPS.
Figure 1. Aspirin protects BV-2 microglial cells from LPS-induced damage. BV-2 microglial cells
were treated with 0.1% ethanol (Control) or aspirin (ASA) for 24 h—0.1% ethanol for 18 h and then
1 μg/mL of LPS for another 6 h (LPS) or aspirin for 18 h and then 1 μg/mL of LPS for another 6 h
(LPS + 0.1 mM ASA). Cell viability was then conducted as described in Materials and Methods. Data
were represented as means ± SEM (n = 4). * p < 0.05 vs. the control; # p < 0.05 vs. the LPS-treated group.
Figure 2. Aspirin inhibits hepcidin mRNA expression but has no effect on IRP1 protein expression in
BV-2 microglial cells treated with LPS. BV-2 microglial cells were treated with 0.1% ethanol (Control) or
aspirin (ASA) for 24 h—0.1% ethanol for 18 h and then 1 μg/mL of LPS for another 6 h (LPS) or aspirin
for 18 h and then 1 μg/mL of LPS for another 6 h (LPS + 0.1 mM ASA). Expression of hepcidin mRNA
(A) and IRP1 protein (B) were measured by RT-PCR and Western blot analysis, respectively. Data were
presented as mean ± SEM (n = 5). * p < 0.05 vs. the control; # p < 0.05 vs. the LPS-treated group.
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2.3. Aspirin Inhibits Phosphorylation of JAK2, STAT3, and P65(NF-κB) and Expression of IL-6 mRNA in BV-2
Microglial Cells Treated with or without LPS
To understand why aspirin could inhibit hepcidin expression under inflammatory conditions,
we investigated the effects of aspirin on phosphorylation of JAK2, STAT3, and P65 by incubating BV-2
microglial cells with a vehicle (0.1% ethanol) for 24 h (The Control), 0.1 mM aspirin for 24 h (ASA),
0.1% ethanol for 18 h + 1 μg/mL of LPS for 6 h (LPS), or aspirin for 18 h + 1 μg/mL of LPS for 6 h
(LPS + 0.1 mM ASA). It was found that the contents of p-JAK2 (Figure 3A), p-STAT3 (Figure 3B), p-P65
(Figure 3C), and IL-6 mRNA (Figure 4A) in the cells treated with LPS were significantly higher than
those in the control cells as well as in the cells treated with aspirin plus LPS. This implied that LPS could
dramatically increase JAK2, STAT3, and P65(NF-κB) phosphorylation and IL-6 mRNA expression,
while aspirin was able to attenuate the LPS-induced increase in phosphorylation and expression.
In addition, our findings showed that the levels of IL-6, p-JAK2, p-STAT3, and p-P65(NF-κB) in the
cells treated with aspirin only were significantly lower than those in the control cells, suggesting that
aspirin was able to inhibit IL-6 mRNA expression, JAK2, STAT3, and P65(NF-κB) phosphorylation
under ‘normal’ conditions in vitro, not only under inflammatory conditions in vitro.
Figure 3. Aspirin inhibits phosphorylation of JAK2, STAT3, and P65(NF-κB) in BV-2 microglial cells
treated with or without LPS. BV-2 microglial cells were treated with 0.1% ethanol (Control) or aspirin
(ASA) for 24 h—0.1% ethanol for 18 h and then 1 μg/mL of LPS for another 6 h (LPS) or aspirin for
18 h and then 1 μg/mL of LPS for another 6 h (LPS + 0.1 mM ASA). Phosphorylation of JAK2 (A);
STAT3 (B); and P65(NF-κB) (C) was detected by Western blot analysis, as described in Materials and
Methods. Data were represented as mean ± SEM (n = 5). ** p < 0.01; *** p < 0.001 vs. the control;
# p < 0.05; ## p < 0.01 vs. the LPS-treated group.
Figure 4. Aspirin inhibits expression of IL-6 mRNA in BV-2 microglial cells treated with or without
LPS and NO production in BV-2 microglial cells treated with LPS but not in the cell treated without
LPS. BV-2 microglial cells were treated with 0.1% ethanol (Control) or aspirin (ASA) for 24 h—0.1%
ethanol for 18 h and then 1 μg/mL of LPS for another 6 h (LPS) or aspirin for 18 h and then 1 μg/mL
of LPS for another 6 h (LPS + 0.1 mM ASA). Expression of IL-6 mRNA (A) was measured by RT-PCR
and production of NO (B) was assayed by measuring the levels of nitrite (a metabolite of NO) in
culture medium as described in Materials and Methods. Data were represented as mean ± SEM (n = 5).
** p < 0.01; *** p < 0.001 vs. the control; # p < 0.05 vs. the LPS-treated group.
309
Int. J. Mol. Sci. 2016, 17, 1921
2.4. Aspirin Inhibits NO Production in BV-2 Microglial Cells Treated with LPS But Not in the Cell Treated
without LPS
In a previous study, we demonstrated that aspirin down regulates TfR1 and up regulates Fpn1 and
ferritin expression in BV-2 microglial cells in vitro; however, the mechanisms are unknown. It has been
documented that NO can regulate the expression of TfR1 and ferritin by interacting with IRP1 [19–21].
To find out whether NO is involved in the effects of ASA on TfR1 and ferritin expression, we also
investigated the effects of ASA on NO production in the cells treated with or without LPS. Treatment
with LPS was found to induce a significant increase in NO levels, while pre-treatment with ASA
displayed a marked inhibition on the LPS-induced increase in NO production, the levels of NO being
significantly lower in ASA + LPS-treated cells than in LPS-treated cells (Figure 4B). There were no
differences in NO content between the ASA-treated and the control cells.
3. Discussion
It has been well-demonstrated that LPS is able to up regulate hepcidin expression [22] via the
IL-6/STAT3 signaling pathway and then down regulate expression of TfR1 and Fpn1 in the brain [23].
In our recent study, we [18] demonstrated that aspirin significantly inhibits the LPS-induced increase
in IL-6 and hepcidin mRNA expression and revises the LPS-evoked reduction in TfR1 and Fpn1
expression in BV-2 microglial cells. The inhibition of aspirin on IL-6 and hepcidin mRNA expression
suggests that aspirin might have play a role in suppressing the activated IL-6/ JAK2/STAT3 signaling
pathway in LPS-treated BV-2 microglial cells. To test this hypothesis, we investigated the effects of
aspirin on the contents of IL-6 mRNA, p-JAK2, and p-STAT3 in LPS-treated BV-2 microglial cells.
We demonstrated that the significant increase in expression of IL-6 mRNA as well as phosphorylation
of JAK2 and STAT3 induced by LPS could be largely suppressed by pre-incubation of the cells with
aspirin. These findings provide evidence that aspirin down regulates hepcidin at least partly by
inhibiting the IL6/JAK2/STAT3 pathway and then alleviates the LPS-induced reduction in TfR1 and
Fpn1 expression in LPS-treated BV-2 microglial cells.
The transcription factor NF-κB is critical for the inducible expression of multiple cellular and
viral genes involved in inflammation and infection including IL-6 [24,25]. Studies have demonstrated
that aspirin and its metabolite sodium salicylate (another anti-inflammatory drug) are both able to
inhibit the activation of NF-κB by inhibiting the activity of IκB kinase-beta (IκB-β) to preventing the
translocation of NF-κB to the nucleus [24,26,27]. Evidence also shows that the toll-like receptor 4 (TLR4)
recognition of LPS (TLR4 ligand), a pathogen-associated molecular pattern, results in the triggering of
downstream signaling cascades leading to the activation of NF-κB [25]. These led us to speculate that
the activation of NF-κB might play a role in the LPS-induced increase in hepcidin mRNA expression,
while the inhibition of aspirin on hepcidin mRNA expression might be partly associated with its role
in inhibiting the activation of NF-κB, as has been found in human peripheral blood leukocytes [28].
We therefore investigated the effects of aspirin on P65(NF-κB) phosphorylation in BV-2 microglial cells
treated with LPS. P65(NF-κB) was examined here because the RelA(p65)–p50 heterodimer is the most
frequently activated form of NF-κB in TLR signaling [29]. Our findings show that LPS can induce
a marked increase in phosphorylation of P65(NF-κB), which can be significantly suppressed by the
pre-incubation of cells with aspirin. This implies that the down regulation of hepcidin might also be
partly associated with the inhibiting role of aspirin on NF-κB phosphorylation in LPS-treated BV-2
microglial cells.
It was noticed that aspirin was able to inhibit levels of phosphorylation of JAK2, STAT3,
and P65(NF-κB) not only under in vitro inflammatory conditions but also in vitro ‘normal’ conditions.
The levels of p-JAK2, p-STAT3, and p-P65 were found to be significantly lower in cells treated with
ASA than those in the control cells. In theory, this could lead to a reduction in hepcidin mRNA in
cells treated with ASA only. However, no difference was found in the contents of hepcidin mRNA
between the cells treated with ASA and control cells. Under in vitro ‘normal’ conditions, the base-line
level of JAK2, STAT3, and P65 is relatively lower, as compared with in vitro inflammatory conditions.
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Although aspirin can induce a reduction in the content of these mediators, the reduction might not be
enough to result in significant changes in hepcidin mRNA expression. This is probably one of causes
for the inconformity in the response of mediators and hepcidin to aspirin. Further studies on this
possibility and other relevant causes are needed.
In a previous study, we demonstrated that aspirin down regulates TfR1 and up regulates Fpn1
and ferritin expression in BV-2 microglial cells treated without LPS [16]; however, the mechanisms are
unknown. The responses of TfR1, Fpn1, and ferritin to aspirin are absolutely unrelated to hepcidin
because the peptide has no response to aspirin under in vitro “normal” conditions. Like hepcidin, IRP1
is a key protein involved in the regulation of iron homeostasis. In most types of cells, the coordinated
control of TfR1 and ferritin by cellular iron is mediated by IRP1 [30,31]. In addition, it has been
documented that NO regulates expression of TfR1 and ferritin by interacting with IRP1 [19–21].
To find out why aspirin is able to down regulate TfR1 and up regulate Fpn1 and ferritin expression
in BV-2 microglial cells under in vitro “normal” conditions, we examined the effects of aspirin on
IRP1 expression and NO production in BV-2 microglial cells. We found that the levels of IRP1 as
well as the NO in the cells treated with aspirin are no significantly different from those in the control
cells. This finding implies that an aspirin-induced reduction in TfR1 and an increase in ferritin are not
associated with IRP1 and NO and suggest that there might be some unknown mechanism by which
aspirin regulates TfR1 and ferritin expression under in vitro “normal” conditions.
Aspirin inhibits inflammation mainly through its ability to suppress cyclooxygenase (COX)
activity [32]. There are two isoforms of this enzyme—COX1 and COX2 [33]. COX-1 is constitutively
expressed in most tissues and produces prostanoids responsible for normal physiological functions.
COX-2 is sparsely present in most healthy tissues [33] and functions as a key enzyme for prostaglandin
biosynthesis. In addition, COX-2 has been shown to contribute to the LPS-induced inflammatory
process [34,35]. Cellular responses to inflammatory stimuli, including LPS, mainly involve the
activation of mitogen-activated protein kinase (MAPK) signaling cascades [36–38]. The p38MAPK and
JNK subfamilies play critical roles in regulating expression of pro-inflammatory mediators such as
COX-2 and interleukins such as IL-6 [39–42]. These data imply that aspirin should be able to inhibit a
LPS-induced increase in COX2 expression in BV-2 microglial cells, probably via inhibiting MAPK/JNK
pathway, although the content of COX2 was not measured in this study. In addition, we found that
the tendency in the effect of aspirin, LPS, or both on IL-6, JAK2, and P65 is very similar to that on
COX2 reported by others [34]. This might suggest that COX2 may play a role in the down regulation
of hepcidin induced by aspirin in LPS-treated BV-2 microglial cells. Further studies on this possibility
are needed.
4. Materials and Methods
4.1. Chemicals
Unless otherwise stated, all chemicals, including aspirin (ASA), LPS (Escherichia coli 055:B5), MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), and mouse monoclonal anti-β-actin,
were obtained from Sigma Chemical Co., St. Louis, MO, USA. A BCA protein assay kit and a Revert
Aid First Strand cDNA Synthesis Kit were purchased from Thermo Scientific, Waltham, MA, USA, and
TRIZOL Reagent from Life technologies, Carlsbad, CA, USA. Rabbit monoclonal anti-phospho-JAK2,
rabbit monoclonal anti-JAK2, rabbit polyclonal anti-phospho-STAT3, mouse monoclonal anti-STAT3,
rabbit monoclonal anti-phospho-P65, and rabbit monoclonal anti-P65 antibodies were supplied by
Cell Signaling Technology, Inc., Danvers, MA, USA, and mouse monoclonal anti-IRP1 was from
Abcam, San Francisco, CA, USA. Goat anti-rabbit and anti-mouse IRDye 800CW secondary antibodies
were bought from LI-COR bio sciences, Lincoln, NE, USA. The Health Department of Hong Kong
and Shanghai Government and the Animal Research Ethics Committee of The Chinese University
of Hong Kong (the project identification code: GRF14106914, 1 January 2015) and Fudan University
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(the project identification code: NSFC31271132, 1 January 2013; NSFC31330035, 1 January 2014)
approved the experimental procedures of this study.
4.2. BV-2 Microglia Cells
BV-2 microglia cells (a murine microglia cell line) were grown in a 5% CO2 incubator at
37 ◦C in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS (PAN Biotech,
Aidenbach Bavaria, Germany) and antibiotics (penicillin 100 U/mL, streptomycin 100 mg/mL),
and culture medium was changed every 2 days [24]. Then, BV-2 cells were seeded in 96-well
plates (6 × 103 cells/well) for cell viability assay, and 6-well plates (4 × 105 cells/well) for RT-PCR
and (8 × 105 cells/well) for Western blotting analysis [18]. The cells were treated with different
concentrations of 0.1 mM aspirin (in 0.1% ethanol) and/or LPS (1 mg/mL in PBS), which were
dissolved in fresh DMEM without serum.
4.3. Assessment of Cell Viability
The cell viability were measured using an MTT assay as described previously [43]. Briefly, a total
of 25 μL of MTT (1 g/L in PBS) was added to each well before the conduction of incubation at
37 ◦C for 4 h. The assay was stopped by the addition of a 100 μL of lysis buffer (20% SDS in 50%
N′N-dimethylformamide, pH 4.7). Optical density (OD) was measured at the 570 nm wavelength
by the use of an ELX-800 microplate assay reader (Bio-tek, Winooski, VT, USA), and the results were
expressed as a percentage of absorbance measured in the control cells.
4.4. NO Production Assay
Production of NO was assayed by measuring the levels of nitrite (a metabolite of NO) in the
culture medium using a colorimetric assay with Griess reagent according to Kim et al. [44], After 24 h
of treatment with LPS with or without ASA, the culture media were collected and reacted with an
equal volume of Griess reagent in 96-well culture plates and were incubated at room temperature for
10 min in the dark. The absorbance was measured at 540 nm using a microplate reader, and nitrite
concentrations were calculated by reference to a standard curve generated by known concentrations of
sodium nitrite.
4.5. Quantitative Real-Time PCR
Extraction of total RNA and preparation of cDNA were performed using a TRIZOL
reagent andreverse transcription kit (Thermo Scientific) in accordance with the instruction of the
manufacturers, respectively. The specific primers used for PCR are as follows: hepcidin forward,
5′-GAAGGCAAGATGGCACTAAGCA-3′; hepcidin reverse, 5′-TCTCGTCTGTTGCCGGAGATAG-3′;
IL-6 forward, 5′-GAGGATACCACTCCCAACAGACC-3′; IL-6 reverse, 5′-AAGTGCATCATCGT
TGTTCATACA-3′; β-actin forward, 5′-AAATCGTGCGTGACATCAAAGA-3′; β-actin reverse,
5′-GCCATCTCCTGCTCGAAGTC-3′ [19,45]. Quantitative real-time PCR was conducted with CFX96
PCR instrument (Bio-Rad, Hercules, CA, USA) using specific primers and SYBR Premix II kit
(Takara, Dalian, China). The Ct values of each target gene were normalized to that of the β-actin
mRNA. Relative gene expression was calculated by the 2−ΔΔCt method [46].
4.6. Western Blot Analysis
The cells were washed and lysed as described previously [47,48]. After centrifugation at 13,200× g
for 15 min at 4 ◦C, the supernatant was collected, and protein content was determined using the BCA
protein assay kit. Aliquots of the extract containing about 20 μg of protein were loaded and run on
a single track of 10% SDS-PAGE under reducing conditions and subsequently transferred to a pure
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). The blots were blocked and then incubated
with primary antibodies—rabbit monoclonal anti-phospho-JAK2 (1:1000), rabbit monoclonal anti-JAK2
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(1:1000), rabbit polyclonal anti-phospho-STAT3 (1:1000), mouse monoclonal anti-STAT3 (1:1000), rabbit
monoclonal anti-phospho-P65 (1:1000), rabbit monoclonal anti-P65 (1:1000), and mouse monoclonal
anti-IRP1 (1:1000) antibodies—overnight at 4 ◦C. After the incubation, the blots were washed three
times and then incubated with goat anti-rabbit (1:1000) or anti-mouse IRDye 800 CW secondary
antibodies (1:5000) for 2 h at room temperature. The intensity of the specific bands was detected and
analyzed by the Odyssey infrared image system (Li-Cor, Lincoln, NE, USA). To ensure even loading
of the samples, the same membrane was probed with a mouse monoclonal anti-β-actin antibody at a
1:5000 dilution.
4.7. Statistical Analysis
Statistical analyses were performed using Graphpad Prism. Data were presented as mean ± SEM.
The differences between the means were all determined by a two-way analysis of variance (ANOVA).
A probability value of p < 0.05 was considered statistically significant.
5. Conclusions
We demonstrated that aspirin inhibits hepcidin mRNA as well as NO production in cells treated
with LPS, but not in cells without LPS, suppresses IL-6, JAK2, STAT3, and P65(NF-κB) phosphorylation,
and has no effect on IRP1 protein in cells treated with or without LPS. The findings provided evidence
that aspirin down regulates hepcidin by inhibiting IL6/JAK2/STAT3 as well as P65(NF-κB) pathways
in cells under inflammatory conditions and implies that an aspirin-induced reduction in TfR1 and an
increase in ferritin were not associated with IRP1 and NO.
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Abstract: This study was conducted to envaluate whether glycine could alleviate Escherichia coli
lipopolysaccharide (LPS)-induced intestinal injury by regulating intestinal epithelial energy status,
protein synthesis, and inflammatory response via AMPK, mTOR, TLR4, and NOD signaling pathways.
A total of 24 weanling piglets were randomly allotted to 1 of 4 treatments: (1) non-challenged control;
(2) LPS-challenged control; (3) LPS + 1% glycine; (4) LPS + 2% glycine. After 28 days feeding,
piglets were injected intraperitoneally with saline or LPS. The pigs were slaughtered and intestinal
samples were collected at 4 h postinjection. The mRNA expression of key genes in these signaling
pathways was measured by real-time PCR. The protein abundance was measured by Western blot
analysis. Supplementation with glycine increased jejunal villus height/crypt depth ratio. Glycine
also increased the jejunal and ileal protein content, RNA/DNA ratio, and jejunal protein/DNA ratio.
The activities of citroyl synthetase in ileum, and α-ketoglutarate dehydrogenase complex in jejunum,
were increased in the piglets fed diets supplemented with glycine. In addition, glycine decreased
the jejunal and ileal phosphorylation of AMPKα, and increased ileal phosphorylation of mTOR.
Furthermore, glycine downregulated the mRNA expression of key genes in inflammatory signaling.
Meanwhile, glycine increased the mRNA expression of negative regulators of inflammatory signaling.
These results indicate that glycine supplementation could improve energy status and protein synthesis
by regulating AMPK and mTOR signaling pathways, and relieve inflammation by inhibiting of TLR4
and NOD signaling pathways to alleviate intestinal injury in LPS-challenged piglets.
Keywords: glycine; inflammatory response; intestine; LPS; weanling piglets
1. Introduction
The intestinal epithelium not only plays a key role in digestion and absorption of nutrients, but also
has an important function in preventing pathogen invasion and dissemination of commensals [1].
However, the intestinal epithelial health status, especially in young animals, could be easily injured by
many factors, such as inflammation and infection [2]. Inflammation often results in intestinal mucosal
damage and dysfunction, which negatively affects animal performance and health [3]. In order to
alleviate the inflammation and maintain health and function, the intestine needs a high level of energy
and amino acids (AAs) [4,5].
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Glycine, whose structure is the simplest of all AAs, is regarded as a conditionally essential AA
for young mammals, and a nutritionally essential amino acid for fetal and neonatal development of
poultry [6,7]. In addition, glycine is the most abundant AA in the body [8], and it is highly required for
neonatal growth and development [7,9]. Recently, some reports showed that glycine could alleviate
colitis induced by chemicals, small intestine injury induced by endotoxins, and inhibit overproduction
of pro-inflammatory cytokines in rats [10–12].
Activation of inflammatory signaling pathways can lead to intestinal damage [13]. Toll-like
receptors (TLRs) and nucleotide-binding oligomerization domain proteins (NODs) are important
protein families of inflammatory signaling pathways [14,15]. These proteins are expressed in many
tissues, including the intestine [16–18], and play key roles in induction of inflammatory responses
by recognition of pathogen-associated molecular patterns (PAMPs) [16,19]. Interactions of TLRs or
NODs with their specific PAMPs trigger downstream signaling events that lead to activation of nuclear
factor-κB (NF-κB), which could further induce the expression of genes related to pro-inflammatory
cytokines, such as interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) [20]. As a
consequence, these pro-inflammatory cytokines adjust the host’s defense against invading pathogens.
However, the intestine can be easily injured by overproduction of these cytokines, especially TNF-α.
Adenosine monophosphate-activated protein kinase (AMPK) is a serine/threonine protein kinase,
which widely exists in eukaryotic cells [21]. AMPK can directly mediate metabolic adaptations to a
change of energy status [22]. The overproduction of cytokines, such as TNF-α, increases energy
consumption which could activate AMPK [23]. The activated AMPK could further inhibit the
mammalian target of rapamycin (mTOR) signaling pathway to reduce the synthesis of protein in
tissues, including the intestine [24].
The aim of this study was to investigate whether glycine could mitigate lipopolysaccharide
(LPS)-induced intestinal injury, and to explore its molecular mechanism(s). We hypothesized that
dietary glycine addition could enhance energy status and protein synthesis by suppressing AMPK
activation and activating the mTOR signaling pathway, and reduce the production of pro-inflammatory
cytokines in the intestine through regulating inflammatory signaling pathways to maintain intestinal
integrity. LPS, a component of Gram-negative bacteria, is responsible for neonatal mortality and sepsis,
but low concentrations of LPS resulted in tissue protection in some studies [25]. In the present study,
Escherichia coli (E. coli) lipopolysaccharide (LPS; E. coli serotype 055:B5; potency ≥ 5,000,000 EU/mg)
was intraperitoneally injected at 100 μg/kg BW (body weight), aimed to establish the model of
endotoxemia [26]. Furthermore, we used the weanling piglet model, which is a suitable animal model
for human nutrition research [27,28].
2. Results
2.1. Growth Performance
During the 28 days feeding period (before LPS or saline injection), there was no difference in
average daily gain (510 ± 38 g), average feed intake (785 ± 76 g), and feed/gain ratio (1.54 ± 0.08)
among the four groups.
2.2. Intestinal Morphology
The intestinal mucosa in control group was in good condition (Figures 1 and 2). However, piglets
challenged with LPS exhibited intestinal mucosal damage. Supplementation with Gly alleviated
intestinal mucosal injury, to some extent. Compared to the CONTR (control group) piglets,
the intestinal morphology in LPS-challenged piglets had no significant difference (p > 0.05). Among the
LPS-challenged piglets, glycine supplementation decreased jejunal crypt depth (linear, p < 0.05; Table 1),
and increased jejunal villus height/crypt depth ratio (VCR; linear, p < 0.05; quadratic, p < 0.05).
However, there was no significant effect on intestinal morphology among the LPS-challenged piglets
fed diets supplemented with glycine (p > 0.05).
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Figure 1. Jejunal mucosal histological appearance (hematoxylin and eosin). (a) Pigs fed a control diet
and injected with sterile saline. No obvious damage was observed. (b) Pigs fed a control diet and
injected with LPS. Intestinal mucosa was seriously damaged by LPS. Arrow represents the damaged
intestinal mucosa in the piglets. (c) Pigs fed a 1.0% Gly diet and injected with LPS. Intestinal damage
was alleviated. (d) Pigs fed a 2.0% Gly diet and injected with LPS. Intestinal damage was alleviated.
Original magnification 100×. Scale bars = 82.3 μm.
Figure 2. Ileal mucosal histological appearance (hematoxylin and eosin). (a) Pigs fed a control
diet and injected with sterile saline. No obvious damage was observed. (b) Pigs fed a control
diet and injected with LPS. Intestinal mucosa was seriously damaged by LPS. Arrow represents the
damaged intestinal mucosa in the piglets. (c) Pigs fed a 1.0% Gly diet and injected with LPS. Intestinal
damage was still existed. (d) Pigs fed a 2.0% Gly diet and injected with LPS. Intestinal damage was
alleviated. Arrow represents the damaged intestinal mucosa in the piglets. Original magnification 100×.
Scale bars = 82.3 μm.
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Villus height (μm) 286 286 268 265 9.7 0.973 0.111 0.201
Crypt depth (μm) 106 103 88.6 88.1 5.0 0.688 0.037 0.058
VCR 2.76 2.82 2.91 2.94 0.03 0.356 0.012 0.038
Ileum
Villus height (μm) 244 241 255 254 10.0 0.902 0.368 0.560
Crypt depth (μm) 83.0 81.0 85.9 86.2 3.5 0.758 0.230 0.412
VCR 2.95 2.93 2.97 2.94 0.03 0.740 0.739 0.467
1 CONTR (non-challenged control), piglets fed a basal diet as well as injected with 0.9% NaCl solution;
LPS (LPS-challenged control), piglets fed the same basal diet as well as injected with E. coli LPS; LPS +
1.0% Gly, piglets fed a 1.0% glycine-supplemented diet and injected with LPS; LPS + 2.0% Gly, piglets fed a
2.0% glycine-supplemented diet and injected with LPS. VCR, villus height/crypt depth ratio. SEM, standard error
of mean. 2 CONTR vs. LPS was used to obtain the response of LPS challenge. Linear and quadratic polynomial
contrasts were used to obtain the response of glycine supplementation in LPS-challenged piglets.
2.3. Mucosal Protein, DNA, and RNA Content
Among the LPS-challenged piglets, supplementation with glycine increased mucosal protein
content (linear, p < 0.05; Table 2), RNA/DNA ratio (linear, p < 0.05), and protein/DNA ratio (linear,
p < 0.05) in jejunum. Compared with piglets in the CONTR group, the piglets in LPS group had a
reduced RNA/DNA ratio in the ileum (p < 0.05). Furthermore, the piglets challenged with LPS had
increased mucosal protein content (linear, p < 0.05; quadratic, p < 0.05), and RNA/DNA ratio (linear,
p < 0.05) in the ileum, when they were fed diets supplemented with glycine.















Protein (mg/g tissue) 84.4 81.3 89.7 90.8 3.7 0.614 0.049 0.099
RNA/DNA 3.30 3.35 3.77 3.82 0.20 0.888 0.049 0.097
Protein/DNA (mg/μg) 0.20 0.18 0.21 0.21 0.01 0.365 0.021 0.055
Ileum
Protein (mg/g tissue) 56.3 61.7 68.8 72.3 2.3 0.231 <0.001 0.001
RNA/DNA 11.4 8.29 9.64 9.65 0.59 0.011 0.048 0.125
Protein/DNA (mg/μg) 0.31 0.27 0.32 0.34 0.03 0.395 0.069 0.180
1 CONTR (non-challenged control), piglets fed a basal diet as well as injected with 0.9% NaCl solution;
LPS (LPS-challenged control), piglets fed the same basal diet as well as injected with E. coli LPS; LPS +
1.0% Gly, piglets fed a 1.0% glycine-supplemented diet and injected with LPS; LPS + 2.0% Gly, piglets fed a
2.0% glycine-supplemented diet and injected with LPS. SEM, standard error of mean. 2 CONTR vs. LPS was used to
obtain the response of LPS challenge. Linear and quadratic polynomial contrasts were used to obtain the response
of glycine supplementation in LPS-challenged piglets.
2.4. Intestinal Claudin-1 Protein Expression
As shown in Table 3 and Figure 3, the piglets challenged with LPS had decreased claudin-1 protein
abundance in the ileum, compared with the piglets in CONTR group (p < 0.05). However, there was no
significant difference in claudin-1 protein abundance in the jejunum between CONTR and LPS group
(p > 0.05). In addition, there was no significant effect on the intestinal claudin-1 protein abundance in
the piglets fed diets supplemented with glycine (p > 0.05).
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claudin-1/β-actin 0.43 0.50 0.52 0.47 0.07 0.282 0.772 0.902
Ileum
claudin-1/β-actin 1.03 0.60 0.80 0.64 0.13 0.032 0.814 0.482
1 CONTR (non-challenged control), piglets fed a basal diet as well as injected with 0.9% NaCl solution;
LPS (LPS-challenged control), piglets fed the same basal diet as well as injected with E. coli LPS; LPS +
1.0% Gly, piglets fed a 1.0% glycine-supplemented diet and injected with LPS; LPS + 2.0% Gly, piglets fed a
2.0% glycine-supplemented diet and injected with LPS. SEM, standard error of mean. 2 CONTR vs. LPS was used to
obtain the response of LPS challenge. Linear and quadratic polynomial contrasts were used to obtain the response
of glycine supplementation in LPS-challenged piglets.
Figure 3. Effects of glycine supplementation on intestinal protein abundance of claudin-1 after 4 h LPS
challenge in piglets.
2.5. Intestinal Key Enzyme Activities of the Tricarboxylic Acid (TCA) Cycle
Compared with the piglets in CONTR group, the piglets in LPS group had decreased ileal citrate
synthase (CS) and α-ketoglutarate dehydrogenase complex (α-KGDHC) activities (p < 0.05; Table 4).
Among the piglets challenged with LPS, supplementation with glycine in the diets increased the
activities of α-KGDHC (quadratic, p < 0.05) in jejunum, and the activity of CS (quadratic, p < 0.05)
in ileum.
Table 4. Effects of glycine supplementation on intestinal tricarboxylic acid cycle key enzyme activities














CS (U·g protein−1) 1.88 1.66 1.68 1.57 0.10 0.255 0.388 0.560
ICD (mIU·g protein−1) 187 168 173 190 7.82 0.088 0.064 0.708
α-KGDHC (μg·g protein−1) 3146 2706 2171 2844 169 0.140 0.615 0.015
Ileum
CS (U·g protein−1) 1.37 1.07 0.93 1.21 0.05 0.002 0.192 0.015
ICD (mIU·g protein−1) 127 109 110 108 7.62 0.160 0.941 0.979
α-KGDHC (μg·g protein−1) 2566 1638 1783 1966 182 0.019 0.196 0.443
CS: citrate synthase, ICD: isocitrate dehydrogenase, α-KGDHC: α-ketoglutarate dehydrogenase complex.
SEM, standard error of mean. 1 CONTR (non-challenged control), piglets fed a basal diet as well as injected
with 0.9% NaCl solution; LPS (LPS-challenged control), piglets fed the same basal diet as well as injected with E. coli
LPS; LPS + 1.0% Gly, piglets fed a 1.0% glycine-supplemented diet and injected with LPS; LPS + 2.0% Gly, piglets fed
a 2.0% glycine-supplemented diet and injected with LPS. 2 CONTR vs. LPS was used to obtain the response of LPS
challenge. Linear and quadratic polynomial contrasts were used to obtain the response of glycine supplementation
in LPS-challenged piglets.
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2.6. Intestinal Protein Expression of the Key Protein in AMPKα and mTOR Pathways
Among the LPS-challenged piglets, supplementation with glycine decreased the ratio of
p-AMPKα/t-AMPKα both in jejunum and ileum (linear, p < 0.05; quadratic, p < 0.05; Figure 4).
Relative to CONTR piglets, LPS challenge decreased the ratio of p-mTOR/t-mTOR in ileum (p < 0.05;
Figure 5), while there was no difference in the ratio of p-mTOR/t-mTOR in jejunum between CONTR
and LPS group (p > 0.05). As supplementation with glycine in the diets, the piglets challenged with
LPS increased ratio of p-mTOR/t-mTOR in ileum (linear, p < 0.05). However, there was no effect of
glycine or LPS on the ratio of t-AMPKα, t-mTOR, p-4EBP1, and t-4EBP1 in jejunum and ileum (p > 0.05;
Figures 4–6).
Figure 4. Effects of glycine supplementation on intestinal protein abundance of t-AMPKα and
p-AMPKα after 4 h LPS challenge in weanling piglets. Note: L (linear), Q (quadratic).
2.7. Intestinal mRNA Expression of the Key Genes in TLR4 and NOD Pathways
Relative to CONTR piglets, the LPS pigs had higher mRNA expression of TLR4, MyD88, NOD2,
RIPK2, and NF-κB (p < 0.05; Table 5) in jejunum. Among LPS challenged piglets, supplementation
with glycine decreased mRNA expression of TLR4, LBP, MyD88, TRAF6, NOD2, and NF-κB (linear,
p < 0.05; quadratic, p < 0.05) in jejunum. Compared to the piglets in CONTR group, the piglets in LPS
group had increased mRNA expression of NOD2, and RIPK2 (p < 0.05) in ileum. However, the mRNA
expression of IRAK1 in piglets challenged with LPS was reduced compared with the piglets in CONTR
group (p < 0.05). Glycine supplementation reduced mRNA expression of NOD2 and RIPK2 (quadratic,
p < 0.05) in ileum among the LPS-challenged pigs.
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Figure 5. Effects of glycine supplementation on intestinal protein abundance of t-mTOR and p-mTOR
after 4 h LPS challenge in weanling piglets. Note: L (linear), Q (quadratic).
Figure 6. Cont.
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Figure 6. Effects of glycine supplementation on intestinal protein abundance of t-4EBP1 and p-4EBP1
after 4 h LPS challenge in weanling piglets. Note: L (linear), Q (quadratic).
Table 5. Effect of glycine supplementation on intestinal mRNA expression of TLR4 and NOD and their














TLR4 1.00 1.67 1.17 1.22 0.09 <0.001 0.005 0.001
LBP 1.00 0.82 0.67 0.44 0.11 0.439 0.005 0.022
MyD88 1.00 1.17 0.92 0.93 0.04 0.017 0.007 0.003
IRAK1 1.00 1.00 0.89 0.95 0.06 0.943 0.579 0.509
TRAF6 1.00 1.22 0.84 0.93 0.07 0.079 0.034 0.007
NOD1 1.00 0.66 0.59 0.53 0.11 0.103 0.249 0.524
NOD2 1.00 2.45 1.42 1.53 0.20 0.006 0.019 0.011
RIPK2 1.00 1.84 1.39 1.68 0.09 <0.001 0.331 0.010
NF-κB 1.00 1.29 1.02 1.10 0.05 0.001 0.039 0.006
Ileum
TLR4 1.00 1.13 1.22 1.20 0.08 0.215 0.557 0.713
LBP 1.00 0.44 0.27 0.33 0.21 0.198 0.418 0.474
MyD88 1.00 1.04 0.95 0.98 0.06 0.646 0.403 0.431
IRAK1 1.00 0.83 0.69 0.92 0.08 0.021 0.490 0.199
TRAF6 1.00 1.15 1.07 1.16 0.06 0.125 0.972 0.583
NOD1 1.00 0.86 0.81 0.85 0.10 0.415 0.926 0.890
NOD2 1.00 1.97 1.07 1.54 0.20 0.006 0.255 0.039
RIPK2 1.00 1.85 1.37 1.82 0.11 <0.001 0.900 0.019
NF-κB 1.00 1.08 1.02 1.09 0.06 0.381 0.886 0.729
IRAK1: IL-1 receptor-associated kinase, LBP: lipopolysaccharide-binding protein, MyD88: myeloid differentiation
factor 88, NF-κB: nuclear factor-κB, NOD1: nucleotide-binding oligomerization domain protein 1, NOD2:
nucleotide-binding oligomerization domain protein 2, RIPK2: receptor-interacting protein kinase 2, TLR4: toll-like
receptor 4, TRAF6: TNF receptor-associated factor 6, SEM: standard error of mean. 1 CONTR (non-challenged
control), piglets fed a basal diet as well as injected with 0.9% NaCl solution; LPS (LPS-challenged control), piglets
fed the same basal diet as well as injected with E. coli LPS; LPS + 1.0% Gly, piglets fed a 1.0% glycine-supplemented
diet and injected with LPS; LPS + 2.0% Gly, piglets fed a 2.0% glycine-supplemented diet and injected with LPS.
2 CONTR vs. LPS was used to obtain the response of LPS challenge. Linear and quadratic polynomial contrasts
were used to obtain the response of glycine supplementation in LPS-challenged piglets.
2.8. Intestinal mRNA Expression of Negative Regulators of TLR4 and NOD Pathways
Compared with the pigs in CONTR group, LPS challenge decreased jejunal mRNA expression of
Tollip (p < 0.05; Table 6), and ileal mRNA expression of Tollip, ERBB2IP, and centaurin β1 (p < 0.05)
in the piglets. However, LPS challenge increased mRNA expression of SOCS1 in jejunum (p < 0.05)
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and SIGIRR in ileum (p < 0.05). Among the LPS challenged piglets, supplementation with glycine
increased mRNA expression of Tollip (quadratic, p < 0.05) and ERBB2IP (linear, p < 0.05) in ileum.
Table 6. Effects of glycine supplementation on intestinal mRNA expression of negative regulators of














RP105 1.00 1.94 0.95 1.59 0.34 0.190 0.558 0.216
SOCS1 1.00 2.74 1.69 1.94 0.30 0.019 0.128 0.103
Tollip 1.00 0.52 0.93 0.59 0.12 0.016 0.702 0.062
SIGIRR 1.00 0.96 1.01 1.00 0.05 0.524 0.525 0.736
ERBB2IP 1.00 0.88 0.76 0.79 0.04 0.074 0.136 0.125
centaurin β1 1.00 0.82 0.56 0.58 0.08 0.202 0.029 0.027
Ileum
RP105 1.00 0.73 0.79 0.84 0.10 0.116 0.355 0.661
SOCS1 1.00 0.87 1.03 1.10 0.08 0.242 0.063 0.170
Tollip 1.00 0.62 1.16 0.64 0.12 0.007 0.942 0.008
SIGIRR 1.00 1.23 1.13 1.26 0.06 0.001 0.797 0.328
ERBB2IP 1.00 0.77 0.82 0.97 0.06 0.028 0.029 0.082
centaurin β1 1.00 0.74 0.75 0.80 0.07 0.041 0.431 0.696
ERBB2IP: Erbb2 interacting protein, RP105: radioprotective 105, SIGIRR: single immunoglobulin IL-1 related
receptor, SOCS1: suppressor of cytokine signaling 1, Tollip: toll-interacting protein, SEM: standard error
of mean. 1 CONTR (non-challenged control), piglets fed a basal diet, as well as injected with 0.9% NaCl
solution; LPS (LPS-challenged control), piglets fed the same basal diet as well as injected with E. coli LPS; LPS +
1.0% Gly, piglets fed a 1.0% glycine-supplemented diet and injected with LPS; LPS + 2.0% Gly, piglets fed a 2.0%
glycine-supplemented diet and injected with LPS. 2 CONTR vs. LPS was used to obtain the response of LPS
challenge. Linear and quadratic polynomial contrasts were used to obtain the response of glycine supplementation
in LPS-challenged piglets.
3. Discussion
In the present study, the effect of glycine on intestinal integrity after a 4 h E. coli LPS challenge
was evaluated in a weaned piglet model. Dietary glycine supplementation improved the intestinal
energy status and protein synthesis associated with inhibiting AMPK signaling and activating
mTOR signaling, and simultaneously reduced the intestinal inflammatory response associated with
inhibiting inflammatory signaling pathways (TLR4 and NOD), and as a consequence, improved
intestinal integrity.
The intestinal mucosal integrity of weanling piglets is closely related to physical health and
nutrient digestion and absorption capability [24,29]. Villus height, crypt depth, and VCR were
determined to indicate gross intestinal morphology [3]. In this study, the decreased jejunal crypt
depth and increased jejunal VCR of the piglets fed glycine indicated that the digestive juice can be
secreted easily into intestinal lumen, which showed glycine played a role in maintaining the integrity
in mucosal structure in weanling piglets. Wang et al. reported supplementation with glycine increased
intestinal villus height in nursery piglets [7]. Effenberger-Neidnicht et al. found that supplementation
with glycine improved intestinal architecture and reduced the LPS-induced intestinal accumulation
of blood in rats [11]. The above studies indicated that glycine had a positive effect on the intestinal
mucosal integrity.
Protein and DNA are the basis for repair and proliferation of epithelial cells. The ratio of
RNA/DNA is an indicator reflecting the cell capacity for protein synthesis [30]. The ratio of
protein/DNA is a sensitive indicator of protein mass and cell size [24]. The decreased ileal RNA/DNA
ratio in LPS-challenged piglets indicated that the mucosal cell capacity for repair was decreased,
affected by LPS. The piglets fed diets containing glycine had increased jejunal and ileal protein
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mass, protein/DNA ratio, and RNA/DNA ratio in the present study. These results illustrated
that glycine is beneficial to intestine mucosal repair after LPS-induced injury. Similar to our data,
Lee et al. [31] reported that glycine supplementation increased intestinal protein mass in the rats under
ischemia–reperfusion injury. In addition, Stoll et al. [32] demonstrated that glycine could be utilized
directly to synthesize protein in the intestinal tract. Furthermore, Wang et al. [7] demonstrated that
glycine was the precursor of purines, which were involved in protein synthesis and cell proliferation.
The intestinal epithelial barrier can reduce the ability of luminal pathogens and their toxins to
invade the mucosa, preventing the penetration of luminal bacteria into the mucosa, to maintain
gut homeostasis [33]. The disordered function of the intestinal epithelial barrier often leads to
inflammatory disease in the intestine [34]. The integrity of the intestinal epithelial barrier is maintained
by cohesive interactions between epithelial cells to form tight junctions [34]. Claudin-1, which is an
important protein in formation of tight junctions, determines permeability characteristics in many
tissues, especially the intestine [35]. Therefore, the greater abundance of claudin-1 often reflects
improved function of the epithelial barrier [36]. In the present study, LPS injection decreased the ileal
protein abundance of claudin-1, which showed that LPS impaired the function of intestinal epithelial
barrier. Similarly, some previous reports demonstrated that LPS challenge decreased the abundance of
claudin-1 [37]. However, supplementation with glycine in the diets did not affect the abundance of
claudin-1 in the piglets in our study. Few reports studied the effect of glycine on the intestinal tight
junctions, so the pathway to repair injured tight junction in the intestine should be further studied in
the future.
Citrate synthase, ICD, and α-KGDHC are key enzymes involved in the TCA cycle, which is a
central route for energy production [38]. CS catalyzes the first step of the TCA cycle by attaching
molecules of acetate and attaching them to oxaloacetate [39]. ICD, which exists in mitochondria and
cytoplasm, is responsible for catalyzing the oxidative decarboxylation of isocitrate into α-ketoglutarate
and CO2 [40]. α-KGDHC is a multi-enzymatic complex which converts α-ketoglutarate into
succinyl-CoA [41]. In our experiment, LPS challenge reduced the activities of ICD in jejunum and
CS, and α-KGDHC in ileum, which indicated that the energy production efficiency decreased. This is
consistent with a previous report which showed that LPS challenge decreased the activities of jejunal
CS, ICD, and α-KGDHC, and ileal ICD in weanling piglets [4]. After supplementation with glycine
in the diets, the activities of α-KGDHC in jejunum and CS in ileum were increased. Therefore, it is
possible that glycine could improve the energy production efficiency in intestinal mucosa by enhancing
the key enzyme activities of the TCA cycle.
We hypothesized that glycine had a beneficial effect on intestinal integrity through enhancing
energy production and protein synthesis in epithelial cells. AMPK, as an energy regulator, maintains
the intracellular energy balance in eukaryons [42]. When the intracellular AMP/ATP ratio increases,
AMPK is activated by phosphorylation [43]. The activated AMPK can switch on ATP-producing
processes while synchronously switching off ATP-consuming processes to restore the cellular energy
status [44]. Supplementation with glycine decreased jejunal and ileal p-AMPK/t-AMPK ratio,
which illustrated dietary glycine could potentially enhance ATP-consumption to synthesize protein.
mTOR is a serine–threonine kinase which controls many important aspects in mammalian cell functions,
such as protein synthesis [45]. Its activity is modulated by various intracellular and extracellular factors
(especially AAs and energy), meanwhile, mTOR adjusts rates of translation, transcription, protein
degradation, cell signaling, and metabolism [44]. Specially, mTOR signaling plays a critical role in
maintaining intestinal health [45,46]. Similar to our results, a previous report showed that LPS injection
decreased jejunal mRNA expression of mTOR [47]. It is known that LPS could inhibit intestinal
protein synthesis through suppressing activation of mTOR. The piglets fed diets supplemented with
glycine had increased ileal p-mTOR/t-mTOR ratio, which demonstrated glycine could relieve the
reduction of mucosal protein synthesis caused by LPS injury in the ileum. These results are in
agreement with the decreased p-AMPK/t-AMPK ratio in piglets fed the diets supplemented with
glycine. Therefore, we propose that the mechanism may be that glycine improves the intestinal
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mucosal energy status, and further activates mTOR signaling pathway to enhance protein synthesis
and mucosal repair.
We hypothesized that supplementation with glycine improved intestinal integrity by inhibiting
intestinal TLR4 and NODs, and their respective downstream signals, further reducing the inflammatory
response. In the current study, LPS injection increased the mRNA abundance of TLR4 (TLR4, MyD88,
and NF-κB in jejunum) and NOD signaling-related genes (NOD2 and RIPK2 in jejunum and ileum)
which reflected LPS-induced intestinal inflammation by activation of TLR4 and NOD pathways.
Supplementation with glycine reduced mRNA expressions of TLR4 (TLR4, LBP, MyD88, TRAF6,
and NF-κB in jejunum) and NOD signaling-related genes (NOD2 and RIPK2 in jejunum and ileum)
in the LPS-challenged piglets, which illustrated that glycine could relieve intestinal inflammation by
inhibiting activation of inflammatory signaling pathways. In general, the inflammatory cytokines,
such as TNF-α, IL-1β, and IL-6 can be overproduced when the inflammatory signaling pathways
(TLR4 and NODs) are activated. Similar to our study, Tsune et al. [10] reported that glycine relieved
colitis in rats by reducing mRNA expression of TNF-α and IL-1β. Furthermore, Stoffels et al. [48]
demonstrated that injection of glycine before intestinal surgery could alleviate inflammation by
decreasing mRNA expression of IL-6 and TNF-α.
Activation of TLR4 and NOD signaling could prevent against pathogens invading by triggering
the production of pro-inflammatory cytokines and inflammatory response. However, over activation
of inflammatory signaling pathways also lead to collateral host tissue injury [49]. To prevent excessive
and harmful inflammatory responses, these inflammatory signaling pathways are negatively controlled
by multiple mechanisms. So far, many negative regulators of TLR4 signaling (Tollip and SOCS1) and
NOD signaling (ERBB2IP and centaurin β1) have been identified and characterized [50,51]. The current
results showed that the piglets challenged with LPS had decreased mRNA expression of Tollip both in
jejunum and ileum, as well as ERBB2IP and centaurin β1 in ileum, which is in agreement with the
report of Wang et al. [52]. These results reflect that LPS challenge reduced the mRNA expression of
TLR4 and NOD negative regulators, which is in agreement with increased mRNA expression of TLR4
and NOD signaling-related genes. Fujimoto et al. reported that excessive inflammatory cytokines
enforced the expression of SOCS1, which resulted in decreased response of cells to TLR ligands [53].
In accordance with this, our present study showed that LPS challenge increased mRNA expressions
of jejunal SOCS1, which indicates that SOCS1 might play a key role in intestinal self-protection.
Supplementation with glycine increased mRNA expression of ileal ERBB2IP. Previous studies showed
that Tollip bound to IL-1 receptor-associated kinase (IRAK) and inhibited IRAK phosphorylation to
downregulate TLR4 signaling [54]. This indicates that supplementation with glycine could suppress
the activity of IRAK by increasing the mRNA expression of Tollip, resulting in impairing the signaling
from TLR4 to downstream pathways, and reducing the synthesis of pro-inflammatory cytokines.
In the present study, the effects of LPS challenge or glycine supplementation on some parameters
were inconsistent in different sites of the intestine. This may be due to the difference in the anatomy
and physiology among the different sites of the intestine [37]. In addition, LPS caused dynamic
changes in the physiological variables, and gene and protein expression of inflammatory signaling
pathways [55,56]. After 28 days feeding of Gly, the efficacy of Gly has risen. However, having only
one time point (4 h) selected, to measure the effect of LPS on various physiological variables and
gene and protein expression, was not perfect. Therefore, in future studies, sample collections at
more time points are needed to better understand the dynamic effect of LPS on intestinal injury.
Furthermore, the maintenance of normal blood flow through microcirculation plays a fundamental
role in the protection and healing of intestinal mucosa [57]. Many previous studies reported that
the intestinal injury induced by various factors can be alleviated through improving blood flow
in microcirculation of duodenum and colon [58–61]. In the future, the blood flow of jejunal and
ileal mucosa needs to be measured to better explore the mechanism of effects of LPS or glycine on
the intestine.
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4. Materials and Methods
4.1. Animal Care and Diets
The experiments and animal care were approved by Animal Care and Use Committee of Wuhan
Polytechnic University, Hubei Province, China (EM628, 18 June 2016). Twenty-four weanling crossbred
barrows (Duroc × (Landrace × Large White), 28 ± 1 days of age), with an average body weight
(BW) of 7.17 ± 0.41 kg were used in this study. Piglets were housed individually in stainless steel
metabolic cages (1.80 × 1.10 m2). All piglets had free access to feed and water in an environmentally
controlled house, with ambient temperature maintained at 22–25 ◦C. The piglets were getting routine
immunization, and in good health condition without fever or diarrhea. The living environment was in
accordance with animal welfare guidelines in the whole experimental period. The basal diet (Table 7)
met or exceeded the National Research Council requirements for all nutrients [62].
Table 7. Ingredient composition of experimental diets (%, as-fed basis).
Ingredients Nutrient Level 4
Corn 57.02 Digestible energy (MJ/Kg) 13.5
Soybean meal (44% CP) 21.40 Crude protein 18.7
Wheat middling 5.00 Crude fat 4.75
Fish meal 3.60 Ca 0.88
Soy protein concentrate 1.40 Total P 0.67
Fat powder 2.00 Lysine 1.02
Defatted milk-replacer powder 3.00 Methionine + Cystine 0.72
Limestone 0.94 Threonine 0.74
Dicalcium phosphate 1.22 Glycine 0.70
Salt 0.34
Alanine 1 2.38





Vitamin and mineral premix 3 1.00
1 In the 1.0% glycine diet, we used 1.0% glycine, 1.19% alanine and 0.19% cornstarch to replace 2.38% alanine.
In the 2.0% glycine diet, we used 2.0% glycine and 0.38% cornstarch to replace 2.38% alanine. We made all diets
isonitrogenous. 2 A compound acidifier (lactic acid and phosphoric acid), was purchased from Wuhan Fanhua
Biotechnology Company, Wuhan, China. 3 Premix (defatted rice bran as carrier) supplied per kg diet: retinol acetate,
2700 μg; cholecalciferol, 62.5 μg; DL-α-tocopheryl acetate, 20 mg; menadione sodium bisulfite complex, 3 mg;
riboflavin, 4 mg; D-calcium-pantothenate, 15 mg; niacin, 40 mg; choline chloride, 400 mg; folic acid, 700 μg; thiamin,
1.5 mg; pyridoxine, 3 mg; biotin, 100 μg; Mn (MnSO4·5H2O), 20 mg; Fe (FeSO4·H2O), 83 mg; Zn (ZnSO4·7H2O),
80 mg; Cu (CuSO4·5H2O), 25 mg; I (KI), 0.48 mg; Se (Na2SeO3·5H2O), 0.36 mg. 4 The nutrients level was analyzed
value except digestible energy which is calculated value.
4.2. Experimental Design
All piglets were randomly divided into 4 treatments: (1) non-challenged control (CONTR;
piglets fed a basal diet and injected with 0.9% NaCl solution); (2) LPS-challenged control
(LPS; piglets fed the same basal diet and injected with E. coli LPS (E. coli serotype 055:B5;
potency ≥ 5,000,000 EU/mg; Sigma Chemical, St. Louis, MO, USA)); (3) LPS + 1.0% glycine group
(piglets fed a 1.0% glycine-supplemented diet and injected with LPS); and (4) LPS + 2.0% glycine group
(piglets fed a 2.0% glycine-supplemented diet and injected with LPS). We selected a supplementary
dose of glycine in accordance with a previous study by Wang et al. [7]. In order to get isonitrogenous
diets, 2.38%, 1.19%, and 0% alanine (purity > 99%; Amino Acid Bio-Chemical Co., Wuhan, China) were
supplemented to the control, 1.0% glycine, and 2.0% glycine diets, respectively. After a 28 days feeding
period, the piglets in the control, 1.0% glycine, and 2.0% glycine groups were given an intraperitoneal
injection of LPS at 100 μg/kg BW or the same volume of 0.9% NaCl solution. After administration
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with LPS or NaCl solution, all piglets were deprived of feed for 4 h until slaughter, so as to avoid the
potential influence on the intestinal mucosa caused by feed intake change [63].
4.3. Intestinal Sample Collections
Four hours after injection with saline or LPS, all piglets were euthanized via injection of sodium
pentobarbital. A 3 cm and 10 cm segments were collected from each mid-jejunum and mid-ileum,
referred to in our previous study [64]. Many previous studies demonstrated that LPS resulted in
intestinal morphologic impairment and dysfunction within 3–6 h postinjection, and it is caused by
increased production of pro-inflammatory cytokines [3,64,65]. Therefore, we choose the time point of
4 h following saline or LPS administration for sample collection. The 3 cm intestinal segments were
gently flushed and stored in 4% paraformaldehyde/PBS until histological analysis [3,64]. The 10 cm
intestinal samples were opened longitudinally, and gently flushed to remove digesta. The mucosa
samples were collected by scraping using sterile glass slides, then rapidly frozen in liquid nitrogen
and stored at −80 ◦C until measuring of DNA, RNA, protein content, tricarboxylic acid (TCA) cycle
key enzyme activities, mRNA, and protein expression levels. The intestinal samples were collected
within 15 min after slaughter.
4.4. Intestinal Morphology Analysis
The 3 cm intestinal segment samples were cut into small pieces, not exceeding 2 mm,
and enclosed into plastic tissue cassettes then processed over a 19 h period in an automatic tissue
processor. Fixed intestinal samples were prepared according to the conventional paraffin-embedding
techniques [66]. Samples were cut to 5 μm thickness and then stained with hematoxylin and
eosin. Villus height and crypt depth were determined at 40× magnification using a microscope
(Olympus CX31, Tokyo, Japan). Ten well-oriented and intact villi were selected at least. Villus height
was defined from the tip of the villus to the villus–crypt junction, and crypt depth was obtained as the
depth of the invagination between adjacent villi [3].
4.5. Intestinal Mucosal Protein, DNA, and RNA Contents
Frozen mucosal samples were firstly ground using a pestle with supplementation of liquid nitrogen,
and then homogenized in ice-cold saline water at a 1:10 (w/v) ratio, then centrifuged at 2500 rpm
for 10 min (4 ◦C) to collect the supernatant. The supernatant was used to measure protein, RNA,
and DNA contents. The content of intestinal mucosal protein was measured referred to the method of
Zhu et al. [67]. The content of DNA was measured through a fluorometric assay [68]. The content of
RNA was determined through spectrophotometry described by Schmidt-Tannhauser [69].
4.6. Intestinal Mucosal TCA Cycle Key Enzyme Activities
The key enzymes involved in TCA cycle include citrate synthase (CS), isocitrate dehydrogenase
(ICD), and α-ketoglutarate dehydrogenase complex (α-KGDHC). The activities of these enzymes in the
intestinal mucosal supernatant were determined according to the previous report by Wang et al. [4],
and assayed via commercial enzyme assay kits (#45126 for CS, #45234 for ICD and #45157 for
α-KGDHC; Shanghai Yuanye Biotechnology Company, Shanghai, China).
4.7. mRNA Abundance Analysis
All the procedures, such as RNA extraction, quantification, reverse transcription, as well as
real-time PCR, were carried out according to a previous report [65]. Primer pairs used in the present
study are shown in Table 8. The relative expression of target genes to housekeeping gene (GAPDH)
was analyzed via the 2−ΔΔCt method [70]. The results showed that the gene expression of GAPDH
was similar among 4 treatments. Relative mRNA expression of the target gene was normalized to the
control group (piglets fed a control diet and injected with 0.9% NaCl solution). In detail, the 2−ΔΔCt
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method is also named the comparative cycle threshold (Ct) method, where CT is the number of cycles
required to reach an arbitrary threshold. The Ct for target gene of each sample was corrected by
subtracting the Ct for GAPDH (ΔCt). The jejunal and ileal segments of the CONTR group were chosen
as reference samples, and the ΔCt for all experimental samples was subtracted by the average ΔCT
for the reference samples (ΔΔCt). Finally, experimental mRNA abundance relative to control mRNA
abundance was calculated with use of the formula 2−ΔΔCt. We tested several housekeeping genes by
analyzing gene stability as described by Vandesompele et al. [71]. We found the expression of GAPDH
to be more stable than that of other housekeeping genes, and there was no variation in the expression
of GAPDH among intestinal segments and treatments.
Table 8. Primer sequences used for real-time PCR.




TLR4 TCAGTTCTCACCTTCCTCCTG GTTCATTCCTCACCCAGTCTTC 166 GQ503242.1
LBP GAACACAGCCGAATGGTCTAC GGAAGGAGTTGGTGGTCAGT 151 NM 001128435.1
MyD88 GATGGTAGCGGTTGTCTCTGAT GATGCTGGGGAACTCTTTCTTC 148 AB292176.1
IRAK1 CAAGGCAGGTCAGGTTTCGT TTCGTGGGGCGTGTAGTGT 115 XM_003135490.1
TRAF6 CAAGAGAATACCCAGTCGCACA ATCCGAGACAAAGGGGAAGAA 122 NM_001105286.1
RP105 CGAGGCTTCTGACTGTTGTG GGTGCTGATTGCTGGTGTC 245 AB190767.1
SOCS1 GCGTGTAGGATGGTAGCA GAGGAGGAGGAGGAGGAAT 101 NM_001204768.1
Tollip GCAGCAGCAACAGCAGAT GGTCACGCCGTAGTTCTTC 133 AB490123.1
SIGIRR ACCTTCACCTGCTCCATCCA TTCCGTCATTCATCTCCACCTC 205 AB490122.1
NOD1 CTGTCGTCAACACCGATCCA CCAGTTGGTGACGCAGCTT 57 AB187219.1
NOD2 GAGCGCATCCTCTTAACTTTCG ACGCTCGTGATCCGTGAAC 66 AB195466.1
RIPK2 CAGTGTCCAGTAAATCGCAGTTG CAGGCTTCCGTCATCTGGTT 206 XM_003355027.1
NF-κB AGTACCCTGAGGCTATAACTCGC TCCGCAATGGAGGAGAAGTC 133 EU399817.1
ERBB2IP ACAATTCAGCGACAGAGTAGTG TGACATCATTGGAGGAGTTCTTC 147 GU990777.1
centaurin β1 GAAGCCGAAGTGTCCGAATT AGGTCACAGATGCCAAGAATG 125 XM_003358258.2
GAPDH CGTCCCTGAGACACGATGGT GCCTTGACTGTGCCGTGGAAT 194 AF017079.1
ERBB2IP: Erbb2 interacting protein, GAPDH: glyceraldehyde-3-phosphate dehydrogenase, IRAK1: IL-1
receptor-associated kinase, LBP: lipopolysaccharide-binding protein, MD2: myeloid differentiation protein 2,
MyD88: myeloid differentiation factor 88, NF-κB: nuclear factor-κB, NOD1: nucleotide-binding oligomerization
domain protein 1, NOD2: nucleotide-binding oligomerization domain protein 2, RIPK2: receptor-interacting protein
kinase 2, RP105: radioprotective 105, SIGIRR: single immunoglobulin IL-1 related receptor, SOCS1: suppressor of
cytokine signaling 1, TLR4: toll-like receptor 4, Tollip: toll-interacting protein, TRAF6: TNF receptor-associated
factor 6.
4.8. Protein Abundance Analysis
Protein abundance of claudin-1, AMPK, mTOR, and 4EBP1 in intestinal mucosa was measured
in accordance with a previous study [66]. In brief, the intestinal mucosa samples (150–200 mg)
were homogenized in 600 μL lysis buffer containing phenylmethanesulfonylfluoride, protease,
and phosphatase inhibitors, and centrifuged at 12,000× g for 15 min at 4 ◦C to collect supernatants.
Equal amounts of intestinal mucosa protein (65 μg) were transferred onto 10–15% polyacrylamide
gel and separated via SDS-PAGE, and then transferred to polyvinylidene difluoride membranes for
immunoblotting. Immunoblots were blocked with 5% nonfat milk in Tris-buffered saline/Tween-20
for 3 h at room temperature (21–25 ◦C). The membranes were incubated overnight at 4◦C with
primary antibodies, and then with the secondary antibodies for 2 h at room temperature. Specific
primary antibodies were used, including rabbit anti-claudin-1 (1:1000) (No. 519000, Invitrogen
Technology Inc., Danvers, MA, USA), rabbit anti-total AMPKα (t-AMPKα, 1:1000) (No. 2532,
Cell Signalling Technology Inc., Danvers, MA, USA), rabbit anti-phosphorylated AMPKα (p-AMPKα,
1:1000) (No. 2535, Cell Signalling Technology Inc.), rabbit anti-total mTOR (t-mTOR, 1:1000) (No. 2972,
Cell Signalling Technology Inc.), rabbit anti-phosphorylated mTOR (p-mTOR, 1:1000) (No. 2971, Cell
Signalling Technology Inc.), rabbit anti-total eukaryotic initiation factor 4E binding protein 1 (t-4EBP1,
1:1000) (No. 9452, Cell Signalling Technology Inc.), rabbit anti-phosphorylated 4EBP1 (p-4EBP1, 1:1000)
(No. 9455, Cell Signalling Technology Inc. and mouse anti-β-actin (1:10,000) (No. A2228, Sigma
Aldrich Inc., St. Louis, MO, USA). The secondary antibodies included goat anti-rabbit IgG-HRP
(1:5000) (No. ANT019, Antgene Biotech Inc., Wuhan, China), and rabbit anti-goat IgG-HRP (1:5000)
330
Int. J. Mol. Sci. 2018, 19, 1980
(No. ANT020, Antgene Biotech Inc.). Blots were developed using an Enhanced Chemiluminescence
Western blotting kit (Amersham Biosciences, Solna, Sweden), and visualized using a Gene Genome
bioimaging system. Bands were analyzed by densitometry using Gene Tool software (Syngene,
Frederick, MD, USA). β-Actin was used as a loading control in Western blotting analysis. The relative
protein abundance of claudin-1 was expressed as claudin-1/β-actin. Phosphorylated form of AMPKα,
mTOR and 4EBP1 were normalized with the total protein content.
4.9. Statistical Analysis
All data were analyzed as a randomized complete block design using the mixed procedure
(SAS Inst. Inc., Cary, NC, USA). Individual piglets were used as the experimental unit for all
statistic procedures. The data were firstly adjusted by homogeneity of variance. The model included
treatment as main effect, and replicates as random effects. The treatment effects were tested using the
following contrasts: (1) CONTR vs. LPS was used to test the effect of LPS challenge; (2) The different
dose–response effects of glycine were tested using linear and quadratic trends for the three glycine
levels (0, 1.0, and 2.0% glycine) among piglets challenged with LPS. Results were shown as mean and
pooled SEM. Significant differences were declared at p < 0.05.
5. Conclusions
In summary, supplementation with glycine improves intestinal integrity in piglets after LPS
challenge. The beneficial effects of glycine on the intestine may be related to (1) enhancing
mucosal energy status and protein synthesis via maintaining mTOR and inhibiting AMPK signaling;
(2) decreasing intestinal inflammation through inhibiting TLR4 and NOD signaling pathways.
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Abstract: A large body of experimental evidence suggests that neuroinflammation is a key
pathological event triggering and perpetuating the neurodegenerative process associated with
many neurological diseases. Therefore, different stimuli, such as lipopolysaccharide (LPS), are used
to model neuroinflammation associated with neurodegeneration. By acting at its receptors, LPS
activates various intracellular molecules, which alter the expression of a plethora of inflammatory
mediators. These factors, in turn, initiate or contribute to the development of neurodegenerative
processes. Therefore, LPS is an important tool for the study of neuroinflammation associated with
neurodegenerative diseases. However, the serotype, route of administration, and number of injections
of this toxin induce varied pathological responses. Thus, here, we review the use of LPS in various
models of neurodegeneration as well as discuss the neuroinflammatory mechanisms induced by this
toxin that could underpin the pathological events linked to the neurodegenerative process.
Keywords: lipopolysaccharide; inflammation; neurodegeneration; Alzheimer’s disease; Parkinson’s
disease; amyotrophic lateral sclerosis; Huntington’s disease
1. Introduction
Neurodegenerative diseases are devastating conditions for which there is no cure so far. In general,
the mechanisms involved in disease onset and development are still poorly understood. Therefore,
increasing efforts are being made to better comprehend their pathogenesis. Among the different
factors involved in these conditions, inflammation is considered a key contributor. Several lines of
experimental evidence have demonstrated that neuronal cell death may induce an inflammatory
process, and inflammation by itself may lead to cell death [1]. Thus, it is necessary to induce
inflammation in models of neurodegeneration in order to evaluate its intricate consequences.
Induction of inflammation may be achieved in different manners, and lipopolysaccharide (LPS) is
an important tool for this purpose. LPS is a molecule present in the outer membrane of Gram-negative
bacteria. Its main target is the toll-like receptor (TLR) 4, although it is known to act on other
receptors [2–4]. The activation of TLR4 by LPS recruits a series of downstream adaptors, such as
myeloid differentiation primary response protein 88 (MyD88), TIR-domain-containing adaptor-inducing
interferon-β (TRIF) and TRIF-related adaptor molecule (TRAM), which are crucial for the signaling of
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the receptor [5,6]. The recruitment of these adaptors can further activate downstream pathways which
culminate in the activation of transcription factors, which, in turn, induce a plethora of pro-inflammatory
genes [6–8]. The TLR4 signaling pathway has been fully reviewed elsewhere [9].
Although most of the work in this field uses LPS in order to stimulate glial cells, mainly microglia,
it is known that neurons also express TLR4. Indeed, activation of this receptor leads to the neuronal
production of different inflammatory mediators [10–13].
LPS is used in a variety of in vivo and in vitro protocols. This compound not only is used to
stimulate cell cultures, but also is injected either in the central nervous system (CNS) or in the periphery
by single or multiple injections. Thus, its effects may vary according to the experimental protocol.
Therefore, here, we review the various protocols that use LPS in order to provide an overview of
the current state of the art. We also discuss the advantages and limitations of the LPS models used
to understand the complex molecular and cellular mechanisms underlying the neuroinflammatory
process associated with neurodegeneration.
2. LPS-Induced Inflammation in Models of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder worldwide, and its
main clinical manifestation is progressive dementia [14]. It is characterized by the inability to form new
memories, reflecting the dysfunction of the episodic memory system [15,16]. AD is associated with
neuropathological changes such as the formation of tau aggregates seen as intraneuronal neurofibrillary
tangles and the presence of extracellular amyloid-beta (Aβ) plaques [17,18]. It was demonstrated that
activated microglia are present in regions of the brain where there are Aβ deposition and neuronal loss,
which culminates in memory impairment. Published data showed that chronic LPS administration
produced impaired spatial memory in Sprague Dawley [19] and Fisher rats [20].
Neuroinflammation frequently precedes the development of neurodegenerative pathologies such
as AD [21] and is one of the pathogenic factors for neurodegeneration [22]. Significant studies from
basic cellular neuroscience and human genetics support the important role of inflammation in the
pathogenesis of AD [23–25]. The myeloid cells of the CNS, microglia, can be beneficial and detrimental
to AD pathogenesis, since they can degrade amyloid plaques and promote neurotoxicity due to
excessive inflammatory cytokine release [23,26]. LPS-induced inflammation is used in experimental
in vitro and in vivo models of neuroinflammation and has been shown to also promote amyloid
deposition in vivo [27,28].
Some studies have associated AD neuropathology with LPS levels in the brain. The presence of LPS
and Aβ1–40/42 in amyloid plaques in gray and white matter of AD brains has been demonstrated [29].
Another study showed that LPS is abundant in the neocortex and hippocampus of AD-affected brains
and that there is a strong adherence of LPS to the nuclear periphery in AD brain cell nuclei [30]. Finally,
LPS was also found in lysates from the hippocampus and superior temporal lobe neocortex of AD
brains [31]. The role of LPS in the development of AD is reviewed by [32,33].
In this context, experimental models using LPS could serve as a link between neuroinflammation
and AD and are useful to understand the disease process and some events that occur in human AD.
2.1. Contribution of Central LPS Injection Models to Our Understanding AD Pathology
Animals can respond to LPS stimuli differently depending on age and species. In addition, the
source of the stimulus, the dose, the route, and the duration of the administration used in each study
may also influence the outcome [34]. LPS injection in different regions of the CNS leads to a variety of
responses in animals. In this section, we will discuss the data obtained from LPS-induced inflammation
in the CNS associated with AD.
Single intracerebroventricular (i.c.v.) injections of LPS resulted in increased levels of interleukin-1β
(IL-1β) in the brainstem and diencephalon of rats 2 h after injection, and in all the brain regions, except
cerebellum, 6 h after injection [35]. Besides, the induction of IL-1β mRNA in the nucleus basalis
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magno-cellularis and hippocampus was observed, as well as the presence of mRNA for tumor necrosis
factor-α (TNF-α) in the nucleus basalis magno-cellularis [19].
Microglia play an important role in immune defense and inflammatory responses in the CNS [36].
When microglia are exposed to stimulatory molecules such as LPS, their receptors such as TLRs
recognize LPS, inducing a series of intracellular signaling pathways [37,38]. Activation of microglia
and astrocytes was observed after both single i.c.v. LPS injection and chronic LPS injection in the 4th
ventricle with osmotic pumps [19,39]. In addition, single intrahippocampal LPS injections produced
elevations of glial fibrillary acidic protein (GFAP) after 24 h [40]. On the other hand, 28 days after a
single intrahippocampal LPS injection, chronic microglial activation was observed, marked by the
increase of CR3 and CD45 in the mouse hippocampus [40]. These are important findings, since glial
activation after intrahippocampal LPS injection has been related to AD-like amyloidogenic axonal
pathology and dendritic degeneration [41]. Chronic i.c.v. administration of LPS induced β-amyloid
precursor protein (β-APP) mRNA in the nucleus basalis magno-cellularis of rats [19]. In a marmoset
monkey model, LPS co-injected with Aβ fibrils in frontal, sensorimotor, and parietal cortices accelerated
the amyloidosis process, with all monkeys showing an early AD immune blood cell expression profile
of the apoptosis receptor CD95 [42], suggesting a potential synergic action.
In many neuroinflammatory conditions, including in mouse models of AD, microglia activation
and infiltration of peripheral immune cells are found in the brain parenchyma [43]. Microglia activation
is also associated with hyperphosphorylation and aggregation of the protein tau, another important
AD marker. Single intrahippocampal injection of LPS enhanced tau phosphorylation by about 2.5-fold
via microglial activation in rTg4510 mice, which carry a mutant tau [44].
Microglia response after stimulation with LPS may differ between transgenic and non-transgenic
mice. Although microglia in 12-month-old non-transgenic mice showed a stronger response to
LPS than in 2-month-old mice of the same strain, microglia in transgenic APP/PS1 mice exhibited
diminished immune response to LPS during aging. Microglial TLR4 signaling was altered in transgenic
mice, suggesting that changes in TLR4 signaling may have impaired the Aβ clearance capacity of
microglia [45]. In Tg2576 mice, which express a mutant form of APP, a single LPS intrahippocampal
injection reduced hippocampal Aβ levels in a time- and glial activation-dependent manner [46,47].
Another study showed that intrahippocampal LPS injection increased by about sixfold the bone marrow
cells recruitment from the periphery and reduced Aβ clearance in bone marrow-transplanted AD
transgenic mice [48].
2.2. Systemic LPS Challenge Models Utilized to Understand AD Pathology
Systemic inflammation may affect the brain. Cytokines, such as IL-1β, IL-6, and TNF-α,
produced by a systemic inflammatory response, can reach the CNS through the blood circulation [49].
The intraperitoneal (i.p.) injection of LPS, for example, leads to the detection of IL-1 in the plasma
and brain regions [35]. The levels of TNF-α, IL-1α, IL-1β, and IL-6 mRNAs were increased in the
hippocampus and cerebral cortex of mutated presenilin (PS) 1 transgenic mice compared to wild-type
mice after i.p. injection of LPS [50]. The increase in mRNAs levels of IL-1β and IL-6 due to a single LPS
i.p. injection was associated with changes in APP expression in the cerebellum of Staggerer mutant
mice, which show a severe Purkinje cell deficiency in the cerebellum, whereas the cerebral cortex
is not affected [51]. Similarly, a single LPS injection increased IL-1β and TNF-α by about twofold
in cortices and hippocampi of aged Tg2576 mice 1, 2, 4, and 6 h after stimulus [52] and increased
the blood and brain levels of IL-1β, IL-6, and TNF-α in Sprague Dawley rats [53]. In addition, in a
model of LPS-induced cognitive impairment in rats, TNF-α levels were increased by about 1.6-fold in
the hippocampus and frontal cortex after 7 days of a single LPS injection. Interestingly, TNF-α and
IL-18 were increased in the same areas after 10 months of a single LPS injection [54]. TNF-α plays an
important role in the induction of inflammatory processes, being recruited after the LPS stimulus and
inducing the production of pro-inflammatory cytokines, which are involved in the pathophysiology of
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neurodegeneration. IL-18 might act later, when the disease is already established, participating in the
progression of neurodegeneration and cognitive dysfunction.
Systemic administration of LPS also induces microglial activation. A single LPS injection increased
microglial density in Sprague Dawley rats [53]. The brain metabolic response to LPS-inducing
microglial activation was studied using magnetic resonance spectroscopy. Intraperitoneal injection
of LPS also increased the number of Iba-1(+) microglia and induced Aβ(1–16)(+) neurons in the
hippocampus in C57/CJ mice [55].
LPS has been used in different studies to stimulate the production of β-APP. Peripheral stimulation
with LPS induced an increase in IL-1β and IL-6 mRNAs, followed by changes in the expression of APP
isoforms in the cerebellum [51]. LPS administration for 7 days increased Aβ 1–42 cerebral expression
and triggered AD-like neuronal degeneration [56]. On the other hand, chronic LPS administration
increased by about twofold the number of Aβ and APP immunoreactive neurons in the neocortex
of APPswe mice [28]. A similar increase in Aβ was seen in the hippocampus of EFAD mice (a
model that expresses human APOE3 or APOE4 and overproduces human Aβ42) [57] and in the
hippocampus, cortex, and amygdala of APPswe mice receiving chronic LPS administration [28]. In all
these transgenic models, increased Aβ neuronal immunoreactivity was associated with an elevated
number of F4/80-immunoreactive microglia [28] and an increase in the 6E10-immunoreactive protein,
which contains Aβ fragments [58]. Repeated LPS systemic injections (three or seven times) promoted
Aβ 1–42 accumulation in the hippocampus and cerebral cortex of ICR albino mice, as a result of an
increase in beta- and gamma-secretase activities as well as in the activation of astrocytes in parallel to
cognitive impairment [59]. A reduction of Aβ accumulation in hippocampus, cortex, and amygdala
was demonstrated by chronic LPS injection in 3xTgAD mice, which exhibit both Aβ and tau pathologies,
in combination with an inhibitor of soluble TNF-α signaling [58]. In addition, young and old transgenic
mice showed an increase in Aβ 1–40 in the cortices between 4 and 6 h after LPS administration,
which returned to baseline 18 h after a single injection [52]. However, LPS once a week for 13 weeks
ameliorated amyloid pathology in the neocortex of APPSWE/PS11ΔE9 mice [60], which was associated
with increased aggregation of activated microglia around the Aβ deposits and by CNS myeloid cells
inducing Aβ clearance pathways and elevated levels of the lysosomal protease cathepsin Z as well as
clusterin [60]. Contradictory data suggest that there are differences in the amyloid production and that
the accumulation depends on the degree of severity of inflammatory stimuli and the animal model
used to evaluate the consequences of LPS injection. Indeed, it has been demonstrated that LPS-induced
inflammation can contribute to the progression of a series of neurodegenerative processes [61,62].
On the other hand, immune system stimulation with low doses of LPS can induce the activation of
cells that act on the resolution of the pathology in neurodegeneration [63–65].
A deficiency in Aβ clearance due to an impairment of the blood–brain barrier (BBB) has been
associated with AD development [66]. In this way, the integrity of the BBB is important, since Aβ
clearance ameliorates AD neuropathology [67]. Besides, an association between AD and lipoprotein
receptor-related protein-1 (LRP-1)—a member of the low-density lipoprotein receptor family—has been
demonstrated to participate in Aβ metabolism [68]. In this sense, some studies demonstrated that LPS
induced an Aβ transport dysfunction at the BBB dependent on LRP-1 [67,69]. Repeated i.p. injection
of LPS altered the BBB transport of Aβ by increasing the brain influx and decreasing the efflux of the
peptide. In addition, LPS also increased the expression of neuronal LRP-1, which can be responsible for
the increased production and accumulation of Aβ in the brain [69]. Similarly, another study showed a
decrease in Aβ efflux by LPS-induced dysfunction of LRP-1 at the BBB [70]. A disruption of the BBB by
LPS was observed in aging 5XFAD mice, which overexpress both mutant human APP and presenilin 1.
On the other hand, inflammation induced by LPS may also be an interesting tool for the crossing of
drugs through the BBB. Indeed, Barton et al. (2018) demonstrated that LPS may disrupt the BBB in
5XFAD mice, which improved the delivery of small molecules, such as thioflavin S, to the brain [71].
Therefore, the neuroinflammatory process could also play an important role in the pathophysiology of
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AD by disrupting the BBB and impairing the removal of Aβ from the brain, as well as in facilitating a
pharmacological treatment.
Increased levels of Aβ induced by LPS can promote tangle formation [53]. In fact, single
LPS injection increased the levels of soluble Aβ and phosphorylated tau in the brain of rats [53]
and mice [72]. Acute systemic LPS administration enhanced tau phosphorylation in wild-type and
corticotropin-releasing-factor-receptors (CRFR)-deficient mice, which was associated with the activation
of glycogen synthase kinase-3 (GSK-3) and cyclin-dependent kinase-5 (CDK5) [73]. Similarly, tau
hyperphosphorylation in 3xTgAD mice was also mediated by the activation of CDK5 after chronic LPS
administration [74].
Cognitive deficits were shown by studies using single LPS i.p. administration in rats [56] and by
repeated LPS injection in EFAD mice [57]. Besides the cognitive impairment and the increase by more
than tenfold in the levels of Aβ with a single i.p. administration of LPS, the elevation of nitric oxide
(NO) concentrations and the overexpression of N-methyl-d-aspartate receptor subunit 2B (NMDAR2B)
in the brain were described [75].
Finally, neuroinflammation is regulated through the cholinergic anti-inflammatory pathway by
the α7 nicotinic acetylcholine receptor (α7 nAChR), involved in regulating cognitive functions and
inflammatory reactions. It was demonstrated that systemic LPS injection in mice decreased α7 nAChR
in the brain [76,77]. Thus, this may be another mechanism by which LPS induces neuroinflammation
and cognitive impairment in models of AD.
The data presented in Section 2 demonstrate the large number of studies using LPS to induce
neuroinflammation in models associated with AD. There is enough evidence to support the singular
role of neuroinflammation in neurodegeneration in addition to the importance of animal models to
study Aβ accumulation and tau hyperphosphorylation. In summary, it can be assumed that LPS
injection models mimic memory loss and the neuropathology observed in AD. All these studies help
understand the role of neuroinflammation in the progression of AD.
3. LPS-Induced Models of Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder [78], and
its neuropathology is characterized by the degeneration of dopaminergic neurons in the substantia
nigra (SN), followed by the loss of axonal projections to the striatum, resulting in malfunction
of the dopaminergic system [79,80]. Dopaminergic dysfunction manifests in the characteristic
motor disabilities found in the disease, such as tremor, rigidity, bradykinesia, postural, and gait
abnormalities [81,82]. Cytoplasmic inclusions, known as Lewy bodies, which are essentially constituted
by protein deposits of α-synuclein [83], are the main hallmark feature of PD. Although the etiology of
PD is not well known, it has been described that inflammation contributes to PD progression and is an
important factor related to neuronal loss [84–86].
To focus on the potential role of inflammation in PD, several LPS-induced Parkinson models have
been validated and used. Different routes of injection, doses, species models, and sources of endotoxin
are described. In the following two sections, we will present the main contributions of LPS-induced
models to providing more insights into the pathophysiology of PD.
3.1. Contribution of Central LPS Injection Models to the Elucidation of PD Pathology
Part of the knowledge about the involvement of neuroinflammation in PD was obtained from
models of central injection of LPS into the SN or striatum (ST). Both models of injection can induce
the dopaminergic neurodegeneration and motor symptoms characteristic of the disease. A first
intranigral LPS injection was established in 1998, inducing microglial activation after 2 days, followed
by a reduction in dopamine levels in the SN and ST and a decrease in tyrosine hydroxylase (TH)
activity up to at least 21 days [87]. Later studies tested the impact of LPS injection on dopaminergic
neurodegeneration and microglial activation. A permanent dopaminergic neuron loss after a single
LPS injection into the SN was observed up to one year after the injection. Neuronal loss was associated
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with a strong macrophage/microglial reaction in the SN [88–91]. The inflammatory involvement was
supported by the use of drugs that reduce the effects mediated by microglia. Intranigral or systemic
administration of naloxone, an opioid receptor antagonist, prevented neuronal loss induced by local
LPS injection in the SN [92]. Eight or 15 days of systemic dexamethasone administration prevented the
reduction of TH activity and TH immunostaining induced by intranigral LPS injection, suggesting a
reduction of dopamine dysfunction in addition to the reduction of microglia activation [93]. This first
set of investigations supported the idea that microglia-mediated neuroinflammation plays an important
role in the neurodegenerative process of PD.
LPS injection into the CNS clearly increased the expression of inflammatory mediators in the brain.
Elevated levels of TNF-α and IL-6 in the SN and elevated IL-6 in the ST 90 minutes after intranigral LPS
injection were found in C57BL/6 mice. Interestingly, the authors observed a 29-fold and 36-fold increase
in peripheral circulating levels of TNF-α and IL-6, respectively. The peripheral levels of IL-2 and IFN-γ
were also increased at day 7 post-injection, whereas no changes in these inflammatory mediators were
detected in the SN. These effects were accompanied by increased CD11b immunostaining in the SN [94],
which suggests an ongoing microglial activation and neuroinflammation. A comparable cytokine
profile was observed after intranigral LPS injection [95,96]. In a chronic LPS injection approach that
mimics the early stages of many chronic neurodegenerative diseases, the injection of LPS into the
4th ventricle for 21 or 56 days induced different responses that depended on the animal’s age and
the stimulus duration [97]. Gene expression and protein levels of both pro- and anti-inflammatory
parameters were upregulated in the brainstem, with IL-1β, TNF-α, TGF-β, and CX3CR1 being the most
important ones. Importantly, these changes in cytokine expression and loss of TH-positive neurons
were more pronounced in middle-aged and aged rats compared to young rats.
A recent study evaluated the time-dependent expression of pro- and anti-inflammatory cytokines
after intranigral LPS injection in adult Wistar rats. The levels of TNF-α and IL-1β mRNA were
significantly increased at early time points, with a maximum after 5 h (~threefold and ~fourfold
increase, respectively), while IL-6 mRNA levels were maximal after 8 h (about fivefold increase).
Interestingly, IL-1β mRNA levels remained significantly increased up to 168 h after LPS injection [98].
On the other hand, anti-inflammatory mRNA expression was altered only at late time points (after
24 h and 168 h for IL-10 and IL-4, respectively). These effects were followed by microglial and
astrocytic activation and dopaminergic neurodegeneration in the SN [98]. Moreover, the changes in
the inflammatory mediator profile were in line with the increased expression of nuclear factor kappa B
(NF-κB) after intracerebral LPS injection, which can lead to a significant increase in the transcription of
pro-inflammatory cytokines (e.g., TNF-α and IL-1β) [99–102]. Furthermore, LPS intrastriatal injection
caused an oxidative stress response and apoptosis, which are strongly associated with the activation
of TLR/NF-κB signaling and the inhibition of the anti-oxidant Nrf/HO-1 pathway [103]. These data
suggest that the LPS injection models induce an acute initial pro-inflammatory profile and that the
neuronal degeneration process in the SN and ST are mediated by these inflammatory mediators, which
are therefore crucial for the progression of the pathology.
Mitochondrial dysfunction is also associated with neuronal cell death in the pathogenesis of
PD [104,105]. In this way, LPS injection models can contribute to evaluate possible impairments in
mitochondrial activity to elucidate their impact in the pathophysiology of PD. Intrastriatal LPS injection
induced changes in the mitochondrial respiratory chain, evidenced by increased levels of oxidative
stress markers including protein carbonyls, 4-hydroxynonenal (4-HNE), and 3-nitrotyrosine (3-NT),
and caused structural modifications in the mitochondrial cristae, leading to energy dysfunction and
neuronal loss in the striatum [106]. Mitochondrial dysfunction was also supported by increased PPAR-γ,
UCP2, and mitoNEET expression—three proteins involved in energy metabolism—in the SN [107].
Moreover, intrastriatal injection of LPS induced extensive S-nitrosylation/nitration of the mitochondrial
complex prior to dopaminergic neuronal loss [108]. Related to this previous finding, inhibition of
inducible nitric oxide synthase (iNOS) by l-N6-(l-iminoethyl)-lysine reduced mitochondrial injury and
dopaminergic degeneration induced by LPS injection into the SN, indicating that iNOS-derived NO is
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associated with mitochondrial dysfunction. iNOS activation is mediated by p38 MAP kinase, and cell
death was reduced by the inhibition of p38 [109].
Intranigral LPS injection upregulated iNOS expression (~twofold) and elevated total reactive
oxygen species (ROS) production (~twofold) and NADPH oxidase activity (~fivefold) [99]. Supranigral
administration of LPS induced an intense expression of NADPH-diaphorase and iNOS-immunoreactivity
in macrophage-like cells, followed by an important decrease of tyrosine hydroxylase-positive
neurons [110]. Pre-treatment of animals with the iNOS inhibitors S-methylisothiourea or L-NIL
prevented dopaminergic neuronal loss, suggesting that NO mediates the neurodegeneration observed
in the LPS-induced PD model [110,111]. Moreover, a single intrastriatal LPS injection was found
to be associated with increased striatal cyclooxygenase-2 (COX-2) and iNOS expression three days
post-injection and, in the SN, dopaminergic neuronal loss and an increase in microglia activation were
observed seven days post-injection [102,112]. Furthermore, a two-week intracerebral infusion of LPS
(5 ng/h, delivered using osmotic minipumps) induced a rapid activation of microglia that reached a
plateau at the end of the treatment, followed by a delayed and gradual loss of nigral dopaminergic
neurons starting between four and six weeks after treatment [90], suggesting that the initial activation
of the immune response preceded neuronal loss.
In line with the studies described above, LPS injection was shown to alter iron and ferritin levels in
glial cells of the SN of rats, which was associated with 1.5-fold and 2.5-fold decreases in TH expression
in the globus pallidus [113] and in the striatum [107], respectively. It was also demonstrated that iron
chelation with desferrioxamine attenuated behavior deficits, neuronal loss of dopaminergic neurons,
and striatal dopamine (DA) reduction induced by intrastriatal LPS injection in C57BL/6 mice [114].
The data from studies involving mitochondrial activity and the NO cascade suggest that oxidative
stress and mitochondrial dysfunction are important in PD progression, including dopaminergic
dysfunction and α-syn accumulation, which can promote neurodegeneration in SN and deficits in
locomotor activity.
Familial PD cases account for 10% of total cases of the disease [115,116], but the molecular
mechanisms involved in the onset of familial forms still need to be elucidated. Neuroinflammation
can also contribute to the progression of the genetic forms of PD. Mutations in the gene encoding for
leucine-rich repeat kinase 2 (LRRK2) are associated with familial PD [117], with an increased lifetime
risk for developing sporadic PD [118]. In an intranigral LPS-injection model of neuroinflammation, a
robust induction of LRRK2 in microglial cells was observed [119]. In addition, injection of LPS into the
SNpc of LRRK2 KO rats resulted in less pronounced TH-positive neuron loss, microglial activation,
and elevated level of iNOS compared to wild-type rats [120]. A morphological evaluation revealed
that the fractal dimension—a quantitative computer-based analysis for cell complexity evaluation—of
Lrrk2−/− microglia was significantly lower than that of Lrrk2+/+ cells in the striatum injected with
LPS [121]. The expression of the protein deglycase DJ-1 (PARK7)—whose gene is related to autosomal
recessive forms of PD [122,123]—can be also impacted by inflammatory challenges. It is known that
mutations in the PARK7 gene are associated with loss of dopaminergic neurons due to the upregulation
of inflammatory mediators within the SN, which was demonstrated by LPS intranigral injection in
PARK7 DJ-1−/− KO mice [124]. These data suggest that inflammatory events that occur throughout life
can contribute to the progression of diseases related to autosomal dominant or autosomal recessive
mutations, as shown by results from several experimental investigations.
Experimental data obtained from local injections of LPS into the CNS have contributed to the
elucidation of the pathophysiology of PD, including the familial form of the disease. In the next section,
data from models that used systemic LPS challenges will be presented. Inflammatory processes in
the periphery can induce both acute and adaptive responses and contribute to deleterious effects
on the CNS because of the action of inflammatory mediators from the periphery that are released
into the brain [35,125,126]. Thus, peripheral inflammatory challenges can contribute to a better
understanding of the crosstalk between inflammation, neuroinflammation, and basic aspects involved
in neurodegenerative conditions.
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3.2. Contribution of Systemic LPS Challenge Models to the Elucidation of PD Pathology
Systemic LPS challenge is another model to elucidate neuroinflammation in PD. Single or multiple
LPS injections were used to provide valuable insights into the potential pathogenesis of PD. Molecular
and cellular alterations were found after LPS i.p. injection in C57BL/6 mice. Brain TNF-α was elevated
for up to 10 months after LPS injection, suggesting a sustained brain TNF-α overproduction that was
parallel to microglial activation and delayed and progressive loss of nigral TH-positive neurons [127].
Extensive neuronal loss, decline in dopamine levels, glial activation, altered cytokine profile on SN,
and deficits in locomotor behavior were also observed after four consecutive days of peripheral LPS
injections [128]. Additionally, authors described a time-course shift of cytokine profiles from pro- to
anti-inflammatory. Five to 19 days after exposure, pro-inflammatory mediators were predominant, in
parallel with neuronal loss, while anti-inflammatory molecules were predominant between days 19
and 38 post-injection. Interestingly, a single dose of LPS failed to elicit neuroinflammatory responses
in female mice [129]. On the other hand, i.p. injections of LPS for five weeks (one injection per week)
or for five months (one injection per month) could cause loss of TH-positive neurons in the SN 9
and 20 months after injection, respectively. In addition, motor impairment as well as a more intense
immuno-staining for α-syn and inflammatory markers were observed [129]. The augmentation of
protein aggregation and nigral inflammatory process was also observed in a study that compared
the effect of LPS i.p. injections in wild-type mice and in transgenic mice that overexpressed α-syn.
It was demonstrated that transgenic mice, but not wild-type mice, developed a delayed chronic and
progressive degeneration of nigral TH-positive DA neurons, with a more prominent effect five months
after LPS injection. In addition, transgenic mice treated with LPS accumulated ~1.3-fold more α-syn
aggregation than non-treated or wild-type mice [61]. The synergic impact of α-syn and inflammation
on the BBB was also evaluated. Knockout mice for α-syn (Snca−/−) were subjected to LPS exposure, and
it was noticed that α-syn did not alter BBB permeability in the absence of an LPS challenge. However,
LPS injection induced significant augmentation in BBB permeability in normal wild-type, but not in
knockout, mice [130].
α-Syn overproduction and its accumulation appear to be associated with an impaired autophagy
process. Alterations in autophagic protein levels were noticed after LPS injection. Early-period
evaluations (starting at day 1) revealed increased levels of microtubule-associated protein 1 light chain
3-II (LC3-II) and histone deacetylase (HDAC) 6. On the other hand, p62 level remained increased until
late stages (from one day to seven months after LPS injection). A significant increase in α-syn protein
in the midbrain was also found in this study, suggesting that LPS might cause an impairment of α-syn
clearance [131]. Therefore, peripheral inflammatory stimuli may be an important synergic factor for
α-syn-induced pathology in PD, and autophagy activity failure might be involved in the increased
protein aggregation induced by the LPS challenge.
The participation of NO, oxidative stress, and mitochondrial impairment was also investigated
after peripheral LPS injection. Wide ultrastructural changes were observed in SN neuronal cells,
including axons alterations, the swelling of mitochondria and the Golgi complex, and the presence
of autophagolysosomes, lysosomes, and dense bodies in the cytoplasm. In addition, the presence
of apoptotic cells and glial activation was also observed [132]. iNOS induction was observed at the
initial phase of response to the peripheral LPS injection [128]. NOS activity in the midbrain and
in SN was increased 6 h after LPS treatment [132]. Furthermore, exposure of C57BL/6 mice to LPS
resulted in a large increase in NOX2 mRNA expression in the midbrain 24 h after exposure, associated
with a rapidly increased ROS production at 1 and 24 h [133]. Treatment of NOX2−/− mice with LPS
demonstrated the contribution of this mediator to the pathology-associated neuroinflammation, since
knockout mice presented less dopaminergic neuronal loss and reduction of microglial activation in the
midbrain after LPS i.p. injection [133]. It was also observed that, despite a lack of changes in caspase-3
activity, LPS injection induced apoptosis-inducing factor (AIF) translocation from the mitochondria to
the nucleus. Moreover, iNOS and nNOS (the neuronal constitutive form of NOS) inhibition prevented
LPS-evoked release of AIF from the mitochondria, indicating that the increased synthesis of NO
343
Int. J. Mol. Sci. 2019, 20, 2293
occurring in the brain during systemic inflammation might be responsible for the activation of apoptotic
pathways [132]. Lastly, iNOS and NADPH oxidase inhibition was also associated with the reduction
of chronic neuroinflammation and prevented α-syn pathology and dopaminergic neuronal loss in
transgenic mice that overexpressed human A53T mutant α-syn submitted to LPS i.p. injection [61].
The role of oxidative stress in PD seems to be age-dependent. The upregulation of pro-oxidant and
inflammatory factors was shown in the midbrain of aged C57BL/6 mice submitted to acute i.p. injection
of LPS, compared with young mice injected with LPS [134]. In addition, LPS induced a more severe
loss of DA neurons in aged female C57BL/6 mice. The upregulation of TLR2, p-NF-κB-p65, IL-1β,
TNF-α, iNOS, and gp91phox was also associated with aging [135]. These data indicate an important
aspect of aging in the neuroinflammatory process found in PD and evidence the overexpression and
overproduction of factors associated with oxidative stress in aged rodents injected with LPS.
In summary, SN and ST are highly sensitive and strongly affected by systemic LPS administration.
Findings from studies using peripheral LPS injection can contribute to the understanding of the
progression of PD, in particular, to the comprehension of its neuroinflammatory aspect.
4. LPS Models to Understanding Inflammatory and Neuroinflammatory Aspects in Amyotrophic
Lateral Sclerosis and Huntington’s Disease
4.1. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neuromuscular disorder associated with the voluntary
motor system, characterized by the progressive degeneration of anterior-lateral horn spinal cord motor
neurons leading to weakness and eventual death of the affected individuals by paralysis in a few
years [136,137]. The degenerating neurons present an abnormal accumulation of cytoplasmic inclusions
containing ubiquitinated proteins [138]. A role of inflammation in the pathogenesis of ALS has been
suggested [139,140]. In this sense, LPS-induced inflammation may contribute to the knowledge of the
involvement of neuroinflammation in the pathophysiology of ALS.
The overexpression of mutant copper, zinc superoxide dismutase (SOD) in mice is utilized as a
model of ALS, inducing severe hind limb motor deficits in animals [141]. These G93A-SOD1 mice
were challenged with LPS to evaluate the possible impact of systemic inflammation in this model. LPS
injection increased the nuclear expression of the transcription factor CCAAT/enhancer binding protein
δ (C/EBPδ), whose gene is associated with familial ALS, in the spinal cord of G93A-SOD1 mice [142].
Moreover, astroglial and microglial activation were also associated with LPS-induced inflammation in
an ALS experimental model [142,143].
About 5% of ALS cases are familial forms of the disease [144]. TAR DNA-binding protein (TDP-43),
a major component of cytoplasmic inclusions in sporadic and most familial ALS cases, appeared
accumulated and aggregated in the cytoplasm of spinal motor neurons of TDP-43A315T transgenic mice
after chronic LPS administration [145].
However, there are only a few studies using LPS to induce inflammation in animal models
of ALS, despite the knowledge about the role of immune and inflammatory components in this
neurodegenerative disease [146,147]. More studies are necessary to clarify the gaps associated with
this disorder.
4.2. Huntington’s Disease
Huntington’s disease (HD) is a neurodegenerative disease characterized by motor, cognitive, and
behavioral dysfunctions [148,149]. HD is originated by an autosomal mutation that is characterized by
an increase in the number of CAG repeats in the huntingtin (HTT) gene [150], resulting in the expansion
of a polyglutamine tract in the resulting mutated HTT (mHTT) protein that is neurotoxic. mHTT
aggregates are abundant in the nuclei and processes of neuronal cells and lead to several damages,
including protein malformation, transcriptional dysfunction, irregular protein and vesicle transport,
altered secretion of neurotrophic factors, and others [151–154]. The immune and inflammatory
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component has also been linked to the progression of HD. Changes in the cytokine profile were
reported in the post-mortem brain [155] and in the plasma and serum of patients [156], and several
lines of evidence of inflammation involvement have been provided by animal models [62,157–159].
Studies on the impact of inflammatory challenges in this neurodegenerative disease are rare.
Peripheral injection of LPS enhanced some aspects of HD, such as microglial alterations and vascular
dysfunction, as shown in 12-month-old YAC128 transgenic mice—a model that expresses human mutant
huntingtin protein—challenged chronically (four months) with LPS. Changes were characterized by
an increased number and morphological changes of microglia in the ST. Furthermore, an increased
vessel diameter and wall thickness in the same region and disruption of the BBB permeability were
observed [159]. These data indicate that LPS enhances the inflammatory response in this model of
HD. Levels of proinflammatory cytokines after a single LPS i.p. injection were higher in the cortex
and ST of brains obtained from Hdh150Q mice (which carry 150 CAG repeats in the first exon of the
endogenous gene) and R6/2 mice (which express exon 1 of the human HD gene with 150 CAG repeats)
compared with wild-type animals [62]. The authors observed that LPS exposure caused an increased
nuclear localization of p65—a NF-κB subunit—in both astrocytes and microglia in the cortex of R6/2
mice compared with wild-type mice, contributing to neuroinflammation. In addition, the levels of
TNF-α remained elevated in brain, serum, and liver of the two HD mouse models after systemic LPS
injection [62]. Thus, a peripheral inflammatory process contributed to the progression of HD and to a
more prolonged neuroinflammation mediated by glial cells.
Interestingly, a sex-dependent response of HD R6/1 mice to an LPS single injection was
demonstrated. Authors noticed that LPS-induced TNF-α expression was ~1.5-fold higher in the
hypothalamus of female HD mice as compared with female wild-type mice. In contrast, LPS treatment
induced an opposite effect in male HD subjects, with largely diminished TNF-α gene expression,
compared with wild-type mice [160]. More lines of evidence are necessary for a better exploration
of these sex-dependent aspects, but these observations might suggest differences in HD patients,
depending on their gender.
Nevertheless, chronically low-dose LPS injections activating the immune system showed a
significantly prolonged survival of HD R6/2 animals, less pronounced body weight loss, and an
attenuated clinical score of the clasping phenotype compared with wild-type animals treated with the
endotoxin [65]. Therefore, the role of inflammatory processes in HD needs to be further elucidated,
and the link between neuroinflammation and HD progression may be dependent on age, gender, and
severity of the inflammatory challenge.
As it can be observed by reading the reports mentioned above, different factors may be important
for the outcome of the studies, which include the source of LPS, dose, route and scheme of administration.
Therefore, we built tables (Tables 1–6) that further detail all these differences that must be considered
for the planning of an experimental protocol design. In the tables, only papers that provide full
information about the type of LPS used were included.
5. LPS in Cell Culture Models
The basic aspects of the neurodegenerative process were elucidated by numerous in vitro studies.
Inflammation triggered by microglia plays an important role in promoting neurodegeneration
by inducing the expression of pro-inflammatory factors [102,161–163]. In this way, LPS-induced
inflammatory neurotoxicity depends on the excessive production of pro-inflammatory factors by
microglia [164]. Activation of TLR4 on the cell membrane by LPS activates various signal cascades,
including NF-κB via the MyD88–IRAK–TRAF6–TAK1 signaling complex [38,165–167]. Upon LPS
stimulation, the transcription factor NF-κB plays an important role in the expression of pro-inflammatory
genes via its translocation to the nucleus [168] which can trigger a series of inflammatory pathways.
LPS stimulation of BV-2 microglial cells [169], co-cultures of neurons, astrocytes, and microglia [170],
or hippocampal neurons cultures [171] resulted in increased synthesis and release of IL-1β and
TNF-α. Besides its pro-inflammatory activity, LPS affected the viability of neurons, leading to
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highly condensed nuclei and the absence/retraction of neurites [170]. Treatment with LPS activated
microglia also in rat basal forebrain mixed neuron–glial cultures. Additionally, the number of choline
acetyltransferase-immunopositive neurons were decreased in these cultures treated with LPS [172].
Recently, a study also showed the activation of microglia by LPS, which induced corpus callosum
nerve fiber malfunction and fast axonal transport [173]. Microglial response induced by LPS was also
associated with the activation of COX-2 and the NOS pathway, resulting in a dramatic increase in
prostaglandin E2 (PGE2) and nitric oxide production [172,174–183], which contributed to neurotoxicity
and cellular dysfunction in neuron-glia cultures.
In mesencephalic mixed neuron–glia cultures, LPS exposure induced the reduction of TH-positive
neurons in the presence of glia. However, LPS treatment did not affect dopaminergic cells when neurons
were cultured in the absence of glia [89,184], suggesting that the glial-mediated neuronal damage was
induced by LPS. Moreover, the increased release of inflammatory mediators IL-1β and TNF-α induced
by LPS was associated with decreased TH-positive cells in primary mesencephalic cultures, which was
prevented by using neutralizing antibodies against IL-1β or TNF-α [185]. In contrast, pretreatment
with the anti-inflammatory cytokine IL-10 prevented dopaminergic neuron loss induced by LPS in
primary ventral mesencephalic cultures due to a reduced production of proinflammatory cytokines
and protection against a reduction of neurotrophic factors [186].
Finally, LPS treatment reduced the DA reuptake capacity of dopaminergic neurons in the
neuron–glia cultures [187], exposing other aspects that might contribute to PD pathology.
Many protein kinases, such as p38 mitogen-activated protein kinases (p38 MAPK) and protein kinase
C-δ (PKCδ) have been implicated in the release of inflammatory mediators from glia, resulting in neuronal
death [188–190]. p38 MAPK mediates LPS-induced neurodegeneration in mesencephalic neuron–glia
cultures through the induction of nitric oxide synthase resulting in increased NO production [179].
Another study using U373 cells showed an increased IL-6 production by stimulation with LPS, mediated
by the p38/Src kinase inhibitors-dependent pathway [77]. Treatment of primary and BV-2 microglial
cultures with LPS resulted in increased activation of phospho-p38 MAPK [178,181–183,191–193].
In addition, PKCδ was highly upregulated during chronic microglial activation, and a significant
increase in PKCδ kinase activity was observed [190], followed by ROS generation, NO production,
and proinflammatory cytokine and chemokine release. Proteolytic activation of PKCδ occurred during
dopaminergic degeneration and was mediated by caspase-3 [194–196]. Silencing of caspase-3 or AIF by
small interfering RNAs, exclusively in DA MN9D cells, protected DA cells from LPS-induced death,
demonstrating the key role of these molecules in LPS-induced neurotoxicity [96].
Finally, LPS increased the expression levels ofβ-site APP cleaving enzyme 1 (BACE-1), PS-1, β-APP,
and Aβ1-42 in neuron cultures treated with LPS [171]. LPS exposure also contributed synergistically
to the negative effects of α-synuclein on progressive dopaminergic degeneration, associated with
increased microglial superoxide production [197]. In addition, LPS could also induce conformational
changes in α-synuclein protein, which might accelerate the progression of PD [198].
It is noteworthy that in vitro investigations are widely used for the evaluation of mechanisms
associated with cell homeostasis or dysfunction. Data from cell cultures therefore also
contribute to the better understanding of gaps in intracellular signaling, molecular aspects, gene
transcription, mRNA translation, and protein synthesis involved in cell physiology. In this context,
LPS-induced in vitro models are very relevant to support the elucidation of the pathophysiology of
neurodegenerative diseases.
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6. Final Considerations and Conclusions
In the context of AD, models that use LPS contribute to the understanding of the intricate
relationship between neuroinflammation and the progression of the disease, mainly in regard to Aβ
processing and deposition. Besides, activation of TLR4 and of the inflammatory pathways leads to
glial reaction and neuronal loss, which contributes to memory impairment and behavioral changes.
Importantly, both acute and chronic inflammation seem to play a role in this neurodegenerative disease.
On the other hand, injection of LPS per se may be used as an animal model of PD, mainly because
of the high susceptibility of mesencephalic neurons to this toxin [89,131,199]. In this sense, injection
of LPS can contribute to the elucidation of the inflammatory pathways that induce glial activation
and the additional causes of neuronal death, dopamine signaling disbalance, α-syn aggregation, and
behavioral symptoms. Finally, in regard to ALS and HD, the role of inflammatory processes in these
two neurodegenerative diseases needs to be better studied and elucidated. The studies may consider
to include the use of the already established models to evaluate the impact of inflammatory challenges
in the development of these pathological conditions.
Importantly, the variety of protocols and serotypes of LPS used in the studies may induce a
plethora of results. This wide range of outcomes may contribute to the better understanding of the
intricate link between neurodegenerative diseases and peripheral and central inflammation.
In conclusion, LPS is an important tool for the evaluation of different parameters associated with
inflammatory processes and may be used in studies that aim to investigate the pathophysiological
mechanisms of neurodegenerative diseases. However, the serotype, route of administration, doses,
and other parameters should be considered when planning experimental protocols because of the
varied responses induced by the endotoxin.
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Abstract: Lipopolysaccharides (LPSs) are an integral part of the Gram-negative outer membrane,
playing important organizational and structural roles and taking part in the bacterial infection process.
In Aeromonas hydrophila, piscicola, and salmonicida, three different genomic regions taking part in the
LPS core oligosaccharide (Core-OS) assembly have been identified, although the characterization
of these clusters in most aeromonad species is still lacking. Here, we analyse the conservation of
these LPS biosynthesis gene clusters in the all the 170 currently public Aeromonas genomes, including
30 different species, and characterise the structure of a putative common inner Core-OS in the
Aeromonadaceae family. We describe three new genomic organizations for the inner Core-OS genomic
regions, which were more evolutionary conserved than the outer Core-OS regions, which presented
remarkable variability. We report how the degree of conservation of the genes from the inner and
outer Core-OS may be indicative of the taxonomic relationship between Aeromonas species.
Keywords: Aeromonas; genomics; inner core oligosaccharide; outer core oligosaccharide;
lipopolysaccharide
1. Introduction
Aeromonads are an heterogeneous group of Gram-negative bacteria emerging as important
pathogens of both gastrointestinal and extraintestinal diseases in a great evolutionary range of animals:
from fish to mammals, including humans [1]. In recent years, as our knowledge about Aeromonas
taxonomy, biology and pathogenicity has increased, and the number of reported infections caused by
these microorganisms in healthy and immunocompromised patients has also spiked [2]. Despite the
fact that, in humans, the most common complications derived from these pathogens are mild and easily
tractable, they can present a serious risk in immunocompromised patients, causing severe septicaemia
and even death [3]. Therefore, increasing our knowledge on the virulence factors governing aeromonad
pathogenicity is of crucial importance to prevent the increasing complications caused by these bacteria.
The virulence and pathogenicity of Aeromonas is multifactorial, varies between species and strains,
and has been linked to, among others, toxins, flagella, secretion systems, outer-membrane proteins
and capsules, and surface polysaccharides, such as lipopolysaccharides (LPSs) [4]. LPSs, also known
as endotoxins, are an integral part of the outer membrane for the great majority of Gram-negative
bacteria, covering approximately the 75% of its surface and playing a crucial role on its organization
and structure [5]. Although the exposed sections of LPSs are highly variable between species—and
sometimes even between strains—LPSs molecules follow the same structural architecture depicted
in Figure 1: a hydrophobic lipid component, the lipid A, bound to a hydrophilic polysaccharide [5].
The polysaccharide is composed by the core oligosaccharide (Core-OS), and the more variable
O-specific chain (O-antigen), which may be present (Smooth LPS) or not (Rough LPS). The Core-OS
can be further subdivided into the inner core and outer core. On the one side, the inner core, containing
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a high proportion of unusual sugars, predominantly one to three 3-deoxy-D-manno-oct-2-ulosonic acid
(Kdo) residues and two or three heptoses (Hep), tends to be evolutionarily conserved within and a
taxonomic family or genus, and is the part bound to the lipid A [6]. On the other side, the outer core is
usually formed by common sugars—as hexoses and hexosamines—present more variability, and this
is the region bound to the O-antigen, if present [6].
Figure 1. Structure and genomic organization of the Aeromonas piscicola AH-3 lipopolysaccharide (LPS).
(a) Chemical structure of the A. piscicola AH-3 LPS. From clearer to darker, the carbohydrates of the
inner core oligosaccharide, outer core oligosaccharide, and O-antigen (only the first two molecules) are
shown. The name of the proteins catalysing each reaction is shown in each link between components;
and (b) Genomic organization of the A. piscicola AH-3 genes coding for the proteins taking part in the
LPS biosynthesis.
While the Aeromonas LPS follows the same architectural pattern as the rest of Gram-negative
bacteria, this molecule displays remarkable diversity across species of this genus. We previously
reported the molecular structure of the LPS from wild-type A. hydrophila AH-1 [7], A. piscicola
AH-3 (formerly A. hydrophila AH-3) [8] and A. salmonicida subsp. salmonicida [9]. Furthermore,
we characterized the genes coding for the proteins taking part in the assembly of both the inner
and outer LPS core of these species, which are located in three different genomic regions: the wa
Regions 1 to 3 [8,9]. Roughly, wa Region 1 contains genes related to the outer core, whereas wa Regions
2 and 3 code for enzymes related to the inner core biosynthesis (Figure 1). To date, the conservation and
characterization of these LPS biosynthetic regions, which may be a key factor governing pathogenicity,
remains to be studied in the rest of Aeromonadaceae. In this article, we analyse the synteny of the
three Core-OS biosynthesis gene clusters across all the publicly available Aeromonas genomes and
predict, for the first time, a conserved inner LPS oligosaccharide core substructure in all the species of
Aeromonas genus.
2. Results
A total of 170 genomes comprising a variable number of strains and biovars from the Aeromonas
species A. allosaccharophila, A. aquatica, A. australiensis, A. bestiarum, A. bivalvium, A. caviae, A. dhakensis,
A. diversa, A. encheleia, A. enteropelogenes, A. eucreophila, A. finlandiensis, A. fluvialis, A. hydrophila,
A. jandaei, A. lacus, A. media, A. molluscorum, A. piscicola, A. popoffii, A. rivuli, A. salmonicida, A. sanarellii,
A. schubertii, A. simiae, A. sobria, A. taiwanensis, A. tecta, A. veronii, and other uncharacterized strains
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(Aeromonas sp.) were retrieved from the National Center for Biotechnology Information genome
database (Available online: https://www.ncbi.nlm.nih.gov/genome/). The complete list of genomes
and strains used in this study is available at the Table S1. Using the sequence of the A. hydrophila
ATCC7966 TetR, WaaA, and WaaC proteins, we located the wa Regions 1, 2, and 3, respectively, in each
of the genome assemblies, thus confirming the conservation of these LPS biosynthetic regions inside
Aeromonas.
2.1. Synteny of the wa Regions 2 and 3
The genomic wa Regions 2 and 3 were found in all the Aeromonadaceae genomes studied,
highlighting the importance of a conserved inner Core-OS structure in this family. While no differences
were found for wa Region 3—the genes waaC and kdkA were found highly conserved next to each other
across all Aeromonas genomes studied—we identified four different genomic organizations regarding
wa Region 2.
Overall, the synteny of the wa Region 2 gene cluster was predominantly conserved across most
of the Aeromonas species, with waaF, waaE, wahF, and waaA positioned sequentially, as we previously
described for A. piscicola AH-3 and A. salmonicida (Figure 2).
Figure 2. Comparison of the wa Region 2 in Aeromonas. (a) The most common genomic organization
for this region found in the majority of Aeromonas species, with waaF, waaE, wahF, and waaA positioned
sequentially in a gene cluster; (b) In the species A. diversa, A. schubertii, and A. simiae, this cluster is
divided in two different genomic regions. Moreover, A. simiae presents wahX instead of waaE, marked
with an asterisk; (c) A gene insertion of six genes containing wahX, a gene coding for an O-antigen
ligase domain-containing protein (OALDC, in orange), and two glycosyltransferases (in blue) between
waaF and wahF is found in the species A. bivalvium, A. molluscorum, and A. rivuli. Hypothetical proteins
with unknown function are shown in white; and (d) Similarly, in the A. fluvialis genome, there is a gene
insertion of seven genes containing wahX, a gene coding for an O-antigen ligase domain-containing
protein, and three glycosyltransferases between waaF and wahF.
In the sequenced genomes of A. schubertii, A. diversa, and A. simiae strains, these genes were found
split in two regions: waaF and waaE on one genomic site (wa Region 2.1); and wahF and waaA in another
(wa Region 2.2) (Figure 2). It is worth mentioning that a fully closed genome from a species with this
alternative genomic organization is not publicly available and, given the position of these regions in the
ending part of unassembled contigs, we cannot rule out that this genomic distribution may be caused
by an artefact in the genomic assembly. Although we did not detect major differences in the gene
sequences of A. schubertii and A. diversa, the highly-conserved glycosyltransferase waaE is substituted in
A. simiae by a gene which translated protein shows the same β-1-4-glucosyltransferase domain but less
than 30% aminoacidic homology with WaaE. We named this gene, found in Aeromonas for the first time,
wahX. The number of appearances and degree of conservation of wahX in Aeromonadaceae—together
with the rest of genes discussed in this article—can be found in the Table 1.
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Table 1. Common genes of the wa Regions 1, 2, and 3, and their conservation in the analysed genomes.




















The gene waaE codes for the L-glycero-D-manno-heptose β-1,4-D-glucosyltransferase, which
catalyses the union of a Glc residue to the highly conserved L-α-D-HepI of the inner Core-OS not
only in Aeromonas species (as A. piscicola [8] and A. salmonicida [9]), but also in other Enterobacteriaceae
as Klebsiella pneumoniae and Serratia marcescens [10]. Thus, the substitution of this gene inside the
Aeromonadaceae family is striking. Instead of with the rest of Aeromonas species, the protein sequence of
wahX displays high homology with glycosyltransferases of other Proteobacteria, as Methylomarinum
and Desulfovibrio. The chemical composition of the Desulfovibrio desulfuricans LPS polysaccharide
chain was recently revealed [11], containing residues of Kdo, rhamnose, methylopentose-fucose,
3 hexoses-mannoses, glucose, and galactose, but the structure of this bacterium Core-OS chain, and thus
the exact function of wahX, remains unknown for the time being.
We also detected major changes in the wa Region 2 of A. fluvialis, as well as in the
evolutionary-related group of A. bivalvium, A. molluscorum, and A. rivuli. As in A. simiae, these
species presented wahX instead of waaE. Furthermore, an insertion of six genes in A. fluvialis and
four genes in A. bivalvium, A. molluscorum, and A. rivuli, between wahX and wahF was found in these
genomes (Figure 2).
The four different subgroups of Aeromonas species as categorized by their wa Region 2 genomic
organization correlate well with the asumed evolution of this genus. Colston et al. recently
compared the genomes from 56 different strains to revise and improve the phylogenetic and taxonomic
relationships between Aeromonas species [12]. Despite that the evolutionary reconstruction of the genus
is still not completely resolved and varies depending on the gene set used for the phylogeny, their
results clearly defined of eight major monophyletic groups inside Aeromonas. Supporting our findings,
A. schubertii, A. diversa, and A. simiae on one side and A. bivalvium, A. molluscorum, and A. rivuli on the
other were precisely classified as two of these eight major Aeromonas monophyletic groups.
However, the resemblance between alternative wa Region 2 Types 3 and 4 despite their differential
evolutionary position is intriguing. While A. bivalvium, A. molluscorum, and A. rivuli are well-defined
evolutionary-related species [13], the A. fluvialis genomic sequence is more related to species of the
A. veronii monophyletic group (see [12]) both by DNA-DNA hybridization [14] and by in silico whole
genome analyses [12]. Therefore, an in-depth study of horizontal gene transfer between these species
may be warranted.
2.2. Synteny of the wa Region 1
Regarding wa Region 1, at least two glycosyltransferases were located next to tetR and hldD in all
genomes. The A. diversa 2478-85, A. lacus AE122, A. salmonicida subsp. achromogenes AS03, and A. veronii
VBF557 genomes were excluded from the analysis as the assembly of this region in these species was
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broken between different contigs. Thus, 166 genomes were analysed. Overall, we found considerable
variability in the outer core genes of the wa Region 1 cluster across the available Aeromonas genomes,
with at least 29 different genomic organizations containing different genes, based in their sequence
homology, in the 166 analysed genomes. The complete assignment of wa Region 1 types to each strain
can be found at the Table S1.
While the description and characterization of each of the outer LPS core biosynthetic clusters
expands far beyond the scope of this article, we can provide a rough set of patterns describing the
Aeromonadaceae wa Region 1 derived from our genome analysis, which are summarized in Figure 3. First,
the wa Region 1, containing hldD, at least two glycosyltransferases and one gene coding for a protein
with an O-antigen ligase domain (i.e., waaL in A. piscicola and A. salmonicida), was found upstream of
tetR. We found two exceptions to this pattern: the A. media strains CECT 4232 and WS, which showed
only one glycosyltransferase (wahY, characterized below) instead of more; and the species A. fluvialis,
A. bivalvium, A. molluscorum, and A. rivuli, in which this genomic region was composed only by hldD
and one glycosyltransferase (wahY), while the O-antigen ligase-domain containing gene was located in
the previously mentioned genomic insertion of the wa Region 2 (Figure 2).
 
Figure 3. Schematic description of the different Aeromonas wa Region 1 types reported. (a) The
gene hldD was found at the start of the wa Region 1 in all Aeromonas species. In A. salmonicida,
a glycosyltransferase-coding gene (in blue) is present between hldD and wahA. A gene coding for an
O-antigen ligase domain-containing was always found next to wahA, followed by a variable number of
hypothetical genes and glycosyltransferases, and, finally, wahE; (b) Most of the species of the A. veronii
monophyletic group present the same genomic architecture but with wahZ instead of wahE; and (c) In
the species in which genome wahA is not present, wahY is found next to hldD, followed by a gene
coding for an O-antigen ligase domain-containing protein (except in the species described above
where this gene is found in the wa Region 2, marked with an asterisk) and a variable number of
glycosyltransferases and hypothetical proteins. OALDC = O-antigen ligase domain containing gene.
Despite presenting high sequence variability between species, all the O-antigen ligases from the
different wa Region 1 genomic organizations shared 10 aminoacid positions that appear to be critical
for its function: four glycines, three arginines, one serine, one tryptophan and one histidine residues
(positions 123, 196, 245, 264, 268, 272, 286, 288, 318, and 329 for A. piscicola AH-3 WaaL) (Figure S1a).
Furthermore, all putative O-antigen ligases presented between 8 and 11 predicted transmembrane
domains, with 10 being the most common prediction (Figure S1b), as is characteristic for lipid-A-core,
O-antigen ligases [8,15].
The second pattern that we found is the high conservation of WahA, the protein that links
GlcNAc to the LPS outer Core-OS using UDP-GlcNAc as a substrate. A gene coding with a protein
with high homology to wahA was found in 153 of the 166 Aeromonas genomes. It was absent in the
genomes of A. bivalvium CECT 7113, A. caviae AE398, CECT 4221, and FDAARGOS_76, A. fluvialis
LMG 24681, A. media CECT 4232 and WS, A. molluscorum 848, A. rivuli DSM 22539, A. salmonicida Y47,
A. simiae CIP 107798, and A. veronii AVNIH1 and AVNIH2. Interestingly though, all these genomes
shared the presence of a common glycosyltransferase next to hldD with high homology to others from
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Vibrio coralliilyticus. We named this gene wahY, and it was not present in any of Aeromonas genomes
with wahA. Interestingly, wahY was presend in all the species with a wa Region 2 of the newly-described
Types 3 and 4.
The importance of WahA remains in its bifunctional nature: it has two domains, one
glycosyltransferase domain that catalyses the incorporation of GlcNAc to the LPS outer Core-OS;
and one carbohydrate esterase domain deacetylates the GlcNAc residue to GlcN [16]. The gene wahA,
is not only conserved in Aeromonas, but also in Vibrio cholerae and shilonii species. Thus, its substitution
for wahY, which is annotated as type I glycosyltransferase in the online databases but shows no protein
domains, technically negates the characteristic presence of GlcN in the outer Core-OS of these species.
Thirdly, the presence in the wa Region 1 of all genomes with wahA of a glycosyltransferase
belonging to the inner LPS Core-OS biosynthesis. More importantly, when present in the genome, this
gene was always found delimiting the end of the wa Region 1 cluster. We found two different
gene sequences based on their homology: those that displayed high homology with wahE and
were positioned contrary to the hldD direction; and those that displayed high homology to an
uncharacterized glycosyltransferase, which we named wahZ, and were positioned in the same direction
as hldD. Given the exclusivity of each of these genes in the genomes, we hypothesize that both genes
code for a protein that catalyse the union of a carbohydrate (HepIV in the case of wahE) in the same
position of the L-α-D-HepI.
An homolog of wahE was found on 101 of the 153 genomes with wahA, comprising the species
A. aquatica, A. bestiarum, A. caviae, A. dhakensis, A. encheleia, A. enteropelogenes, A. eucreophila, A. hydrophila,
A. jandaei, A. media, A. piscicola, A. popoffii, A. salmonicida, A. sanarellii, A. schubertii, A. taiwanensis, A. tecta,
and some undefined sp. strains; while wahZ was found in 52 of the 153 genomes, comprising the species
A. allosaccharophila, A. australiensis, A. diversa, A. enteropelogenes, A. finlandiensis, A. jandaei, A. sobria,
A. veronii, and a few undefined Aeromonas sp. strains. In consequence, the presence of wahZ seems to
be a defining characteristic of the A. veronii monophyletic group described by Colston et al. [12].
Most Common wa Region 1 Genomic Organizations and Notable Inconsistencies
A schematic representation of the six most common gene organizations for wa Region 1, depicting
122 of the 170 genomes, can be found at Figure 4. The most common wa Region 1 genomic structure, or
Type 1, was the one described for A. piscicola AH-3 [8]. We found this organization in the genomes
of the species A. bestiarum, A. dhakensis, A. hydrophila, A. piscicola, and A. schubertii. The second
type of wa Region 1 (Type 2) that we found was that of A. salmonicida, including the subspecies
masoucida, salmonicida, and smithia, but not pectinolytica or achromogenes. A group of A. caviae and
A. media species, together with A. aquatica and A. sanarelli also showed common genes for this genomic
region, which we assigned Type 3. The second most common genomic organization for this cluster,
Type 4, comprised 23 different A. veronii strains, A. australiensis, and A. jandaei. The Type 5 wa
Region 1—assigned to the genomic cluster found in A. enteropelogenes and A. finlandensis species—and
Type 6—in A. popoffi—highlight the high recombination capacity of this region in the genus: both types
present the same genomic architecture and high homology percentage between the genes, but wahZ is
found in the Type 5 while wahE is found in the Type 6 wa Region 1.
Our results at the genomic level largely agree with the presumed evolution of the Aeromonas
genus, and are corroborated by the published reports regarding LPS structure in the aforementioned
species. For example, A. bestiarum presents the same wa Region 1 Type 1 than A. hydrophila and
A. piscicola, and the mass spectrometry of the Core-OS from A. bestiarum Strain K296 (serotype O18)
shows the identical Hep6Hex1HexN1Kdo1P1 structure that we characterized for A. piscicola AH-3 and
A. hydrophila AH-1 [7,17]. Similarly, although the genome of the strain A. veronii strain Bs19 (serotype
O16), is not available, the LPS chemical structure of this strain is Hep5Hex3HexN1Kdo1P1, that is,
one more carbohydrate than the ones described for the Type 1 wa Region 1 [18]. Coinciding, the wa
Region 1 of the majority of A. veronii (Type 4) is composed by one more gene than the ones described
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for Type 1. Moreover, given the chemical structure, we hypothesize that wahZ catalyses the union of a
hexose to HepI.
Figure 4. Comparison of the six most common wa Region 1 genomic organization in Aeromonas.
Common genes (hldD and wahA) in these genomic organizations are shown in green, O-antigen ligase
domain containing proteins in orange, wahE in purple, wahZ in yellow, and both characterized and
uncharacterized glycosyltransferases are shown in blue. (a) Type 1 wa Region 1, found in A. bestiarum,
A. dhakensis, A. hydrophila, A. piscicola, and A. schubertii; (b) Type 2 wa Region 1, found in A. salmonicida
species; (c) Type 3 wa Region 1, as in A. aquatica, A. caviae, A. media and A. sanarelli; (d) Type 4 wa Region
1, found in A. australiensis, A. jandaei, and A. veronii; (e) Type 5 wa Region 1, in A. enteropelogenes and
A. finlandensis; and (f) Type 6 wa Region 1, as found in A. popoffi.
However, the previous description of these wa Region 1 organizations also arise notable
inconsistencies between taxonomic classifications in some species. Beyond the species mentioned
above, the wa Region 1 Type 1 was also found the strains A. enteropelogenes LK14 (that according to
the rest of A. enteropelogenes strains should be of Type 5), A. jandaei L14h (Type 4), and A. salmonicida
strains CBA100 and subsp. pectonolytica 34meI (both Type 2). Of note, we previously pointed out that
A. salmonicida subsp. pectinolytica presented a different outer LPS Core-OS than the rest of A. salmonicida
species and similar to A. hydrophila, supporting this exception [19].
Similarly, A. hydrophila 4AK4 and A. hydrophila BWH65 present a Type 3 wa Region 1 instead
of the Type 1 common for the rest of A. hydrophila species. A. hydrophila 4AK4 shows extreme
resemblance to A. caviae (also Type 3 for some strains) in many areas, such as the—almost exclusive
in aeromonads—production of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) [20] and the higher
sequence homology of virulence factors to A. caviae than A. hydrophila [21]. In fact, A. hydrophila 4AK4
shows low average nucleotide identity (ANI) values with A. hydrophila and has been proposed to
be a novel species relative to A. media [22], also represented in the Type 3 wa Region 1 organization.
Likewise, A. hydrophila BWH65 shows high genome homology with A. hydrophila 4AK4, and both
are found in the same branch as Aeromonas SSU (recently reclassified as A. dhakensis SSU) in the
genomic blast-based dendogram of the A. hydrophila webpage in the NCBI genomes (Available online:
https://www.ncbi.nlm.nih.gov/genome/1422).
Of note, notable variability between these regions was found in the species A. veronii, A. caviae,
and A. media, which may indicate a higher recombination capacity or taxonomic nomenclature
inconsistencies in this species.
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2.3. Reconstruction of the Common Aeromonas Inner LPS Core-OS
Using the above information, we could reconstruct a common LPS inner core in the entire
Aeromonas genus composed by three L-α-D-Heptoses and one α-Kdo-P, based on the conserved genes
kdkA, waaA, waaC, waaF, and wahF (Figure 5). Moreover, with the exception of the species A. bivalvium,
A. molluscorum, A. rivuli, A. fluvialis, and A. simiae, waaE was also found in all genomes. Similarly, only
in eight strains (A. caviae strains AE398, CECT4221, and FDAARGOS76; A. media strains CECT 4232 and
WS; A. salmonicida Y47; and A. veronii strains AVNIH1 and AVNIH2) more than in the aforementioned
five species wahA was not found in the genome—all of them presented wahY. Thus, we consider waaE
and wahA as highly conserved genes in aeromonads, and in consequence a high conservation of the
hexose β-1,4-Glc linked to HepI, and of the α-1,7-GlcN linked to HepIII in the aeromonad LPS core
(Figure 5). Furthermore, we found wahE to be well conserved across most of Aeromonas species except
in the A. veronii monophyletic group, which presented the gene wahZ instead, suggesting that they
may act in the carbohydrate same position.
Figure 5. Reconstruction of the Aeromonadaceae common Core-OS. The enzymes found in all genomes
are shown in black. WaaE and WahA (in blue), were also present in more than the 90% genomes
analysed. Finally, WahE (in orange) is substituted by WahZ (although the carbohydrate linked is still
unknown) in the species of the A. veronii monophyletic group.
Finally, it is worth mentioning that the absence of typical outer core homologs (as wahB/wasB,
wahD/wasD) and waaE in A. bivalvium, A. fluvialis, A. molluscorum, A. rivuli, and A. simiae, suggests that
either these species do not present O-antigen or their whole outer Core-OS may be entirely different
than in the rest of Aeromonas. The presence O-antigen ligase domain-containing protein with similar
homology in the wa Region 1 on A. simiae and wa Region 2 gene insertions of A. bivalvium, A. fluvialis,
A. molluscorum, and A. rivuli supports the latter. To prove the presence of O-antigen in these species,
we analysed the LPS profile gel of the species A. hydrophila AH-1, A. piscicola AH-3, and A. bivalvium
868ET by SDS-PAGE (Figure 6). The LPS profile gel confirmed the presence of O-antigen in A. bivalvium
(and therefore, probably in the other species questioned) as well as a considerable difference in the
LPS Core-OS size.
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Figure 6. LPS profiles of (a) A. hydrophila AH-1; (b) A. piscicola AH-3; and (c) A. bivalvium 868ET
by SDS-PAGE.
3. Discussion
Aeromonas are a ubiquitous, rod-shaped and flagellated genus of Gram-negative bacteria emerging
as important animal pathogens, especially in mammals and fish. Despite once being subdivided into
solely two subgroups, mesophilic (A. hydrophila) and psychrophilic (A. salmonicida) aeromonads [1],
there are currently dozens of characterized Aeromonas species in the literature, not including subspecies
or biovars (Available online: http://www.bacterio.net/aeromonas.html for a complete list).
However, the taxonomic and phylogenetic relationships of many of these species are still today
a matter of debate: practical evidence for some of these species is still lacking [1]; different names
have been found to be synonyms for the same species (e.g., A. enteropelogenes and A. trota [23,24]; and
A. culicicola, A. ichthiosmia and A. veronii [23]); characterized species have been reclassified outside the
Aeromonas genus (as A. sharmana [25]); and, historically, misclassifications in this family have been
usual (e.g., A. hydrophila AH-3 was recently reclassified into A. piscicola AH-3 [26]). This taxonomic
classification problem is further exacerbated by a considerably high genetic homologous recombination
rate and horizontal gene transfer capacity, which in fact has been demonstrated to be an important
driving force in the evolution of aeromonads [27]. When taking all of this together, it is not difficult to
understand why the evolutionary reconstruction of this family is still not resolved. The importance
of a correct classification of Aeromonas species resides not only in correctly knowledge of taxonomic
evolution, but also in studying the pathogenic source and potential of Aeromonas species and strains.
As the virulence of Aeromonas species is multifactorial and depends on the specific virulence
factors present on each strain as well as on environmental conditions [4], the description of common
processes governing aeromonad pathogenicity is of crucial importance. The LPS, an important
component of the Gram-negative membrane present in all aeromonads, also plays a key role in the
adhesion and infectivity process, thus directly affecting their pathogenicity. Therefore, the study of the
specific LPS biosynthesis routes and structure may be further exploited in, for example, the search for
common treatments against Aeromonas species or specific inhibitors for characteristic strains. To this
end, in this study, we compared the genomic structure of the three described locus for the LPS Core-OS
biosynthesis—wa Regions 1, 2, and 3—in all publicly available Aeromonas genomes, covering 170
strains spawning 30 different Aeromonas species to study their degree of conservation.
As expected, the genes and genomic organizations of the inner core regions were more
evolutionary conserved than the outer core region, but adding to our previously characterized wa
Region 2 in A. piscicola and A. salmonicida, we describe three new genomic organizations for these
regions affecting the species A. bivalvium, A. diversa, A. fluvialis, A. molluscorum, A. rivuli, A. schubertii,
and A. simiae.
In contrast, the outer Core-OS biosynthetic region presented remarkable variability within
Aeromonas. In fact, hldD (formerly rfaB, coding for ADP-L-glycero-D-manno-heptose 6-epimerase) was
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the only common gene of the wa Region 1 that we could locate in all analysed genomes. Therefore,
we consider hldD as a good marker for wa Region 1 position. Despite the differences between species,
we also found a gene coding for a O-antigen ligase domain-containing protein and at least two
glycosyltransferases in the wa Region 1 of all Aeromonas species except A. bivalvium, A. fluvialis,
A. molluscorum, and A. rivuli. We also detected high degree of conservation of wahA (in 154 of the 166
genomes analysed for wa Region 1), and the common presence of wahY in the 12 species lacking this
gene (Table 1). Similar exclusivity patterns were found between wahE and wahZ, which appears to be
an exclusive marker of the A. veronii monophyletic group. Furthermore, our results are supported by
both genome-wide phylogenetic and chemical mass spectrometry studies in the literature.
We report that, while horizontal gene transfer—not involving only Aeromonas species but also
other proteobacteria—seems to be a potential key process for the evolution of this regions, the genes of
the LPS Core-OS are considerably well conserved throughout Aeromonas evolution. Therefore, these
genomic regions can be useful when studying the taxonomic relationships between Aeromonas species.
Our study found notable inconsistencies between the conservation of the genomic organization
and the taxonomy of specific strains, such as A. enteropelogenes LK14, A. hydrophila strains 4AK4 and
BWH65, A. jandaei L14h, and A. salmonicida strains CBA100 and subsp. pectonolytica 34meI. Given that
extensive scrutiny of at least two of these strains arise important criticism and suspicion about their
taxonomic classification, an in-depth study of this species taxonomic classification may be necessary.
Finally, the recent reclassifications of several Aeromonas hydrophila species, as A. hydrophila AH-3
(now A. piscicola AH-3), led recently to a serious questioning if previous research involving pathogenic
factors on strains of now different Aeromonas species was still applicable to A. hydrophila [28]. The results
from this study support that the LPS Core-OS from A. hydrophila is identical to that of A. piscicola, and
thus previous research regarding this virulence factor should be applicable to A. hydrophila.
4. Materials and Methods
We retrieved the 170 different genomes for the Aeromonas genus available on NCBI Genome
website as of September 2016 (Table S1), regardless of their assembly completeness. To roughly locate
the position of the LPS core biosynthetic regions in the genomes, we performed a local tblastn of
A. hydrophila ATCC7966 tetR (wa Region 1), waaA (wa Region 2), and waaC (wa Region 3) in each
genome assembly. Due to the incomplete annotation of some of the analysed genomes, the 16,000 bp
region upstream of tetR, 10,000 bp region upstream of waaA, and 5,000 bp region downstream of
waaC were reannotated in each genome. Gene prediction was performed with Glimmer v.3.0.2 [29]
and hand-curated. Comparison of the genetic regions was performed using the CloVR Comparative
Pipeline [30] and explored using Sybil [31].
The predicted protein sequence of one arbitrarily selected O-antigen ligase from each wa Region 1
genomic organization was retrieved and aligned with MUSCLE [32]. Prediction of the transmembrane
domains was performed with TMHMM Server v2.0 [33].
Cultures of A. hydrophila AH-1, A. piscicola AH-3 and A. bivalvium 868ET where grown overnight
in Tryptic Soy Agar at 30 ◦C, except for A. piscicola AH-3 which was grown at 25◦C. LPS was obtained
after proteinase K digestion of whole cells, separated by SDS-PAGE and visualized by silver staining
as previously published [16].
5. Conclusions
We compared the LPS biosynthetic regions from 170 Aeromonas genomes and analysed the
conservation of the genes taking part in the assembly of this cell-wall component. We describe high
conservation of the genes related to the inner Core-OS biosynthesis, with only one organization for wa
Region 3 and 4 different genomic organizations regarding the wa Region 2; and remarkable variability
in the wa Region 1, composed roughly by genes affecting the outer Core-OS. Besides describing a
common LPS Core-OS structure of all the Aeromonas sequenced to date, we also report how these
regions can be useful for establishing evolutionary relationships between species.
376
Int. J. Mol. Sci. 2017, 18, 519
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/519/s1.
Acknowledgments: This work was partially funded by BIO2016-80329-P from the Spanish Ministerio de Economía
y Competitividad, and from the Generalitat de Catalunya (Centre de Referència en Biotecnologia). We thank
Maite Polo for her technical assistance and the Servicios Científico-Técnicos from the University of Barcelona.
Author Contributions: Gabriel Forn-Cuní, Susana Merino, and Juan M. Tomas conceived, designed,
and performed the experiments; analysed the data; and wrote the paper.





OALDC O-antigen Ligase Domain Containing gene
ANI Average Nucleotide Identity
1. Janda, J.M.; Abbott, S.L. The genus Aeromonas: Taxonomy, pathogenicity, and infection. Clin. Microbiol. Rev.
2010, 23, 35–73. [CrossRef] [PubMed]
2. Igbinosa, I.H.; Igumbor, E.U.; Aghdasi, F.; Tom, M.; Okoh, A.I. Emerging Aeromonas species infections and
their significance in public health. Sci. World J. 2012. [CrossRef] [PubMed]
3. Parker, J.L.; Shaw, J.G. Aeromonas spp. clinical microbiology and disease. J. Infect. 2011, 62, 109–118.
[CrossRef] [PubMed]
4. Tomás, J.M. The main Aeromonas pathogenic factors. ISRN Microbiol. 2012, 2012, 256261. [CrossRef] [PubMed]
5. Aquilini, E.; Tomás, J.M. Lipopolysaccharides (Endotoxins). In Reference Module in Biomedical Sciences;
Caplan, M.J., Ed.; Elsevier: Amsterdam, The Netherlands, 2015.
6. Holst, O. The structures of core regions from enterobacterial lipopolysaccharides—An update. FEMS
Microbiol. Lett. 2007, 271, 3–11. [CrossRef] [PubMed]
7. Merino, S.; Canals, R.; Knirel, Y.A.; Tomás, J.M. Molecular and chemical analysis of the lipopolysaccharide
from Aeromonas hydrophila strain AH-1 (Serotype O11). Mar. Drugs 2015, 13, 2233–2249. [CrossRef] [PubMed]
8. Jimenez, N.; Canals, R.; Lacasta, A.; Kondakova, A.N.; Lindner, B.; Knirel, Y.A.; Merino, S.; Regué, M.;
Tomás, J.M. Molecular analysis of three Aeromonas hydrophila AH-3 (serotype O34) lipopolysaccharide core
biosynthesis gene clusters. J. Bacteriol. 2008, 190, 3176–3184. [CrossRef] [PubMed]
9. Jimenez, N.; Lacasta, A.; Vilches, S.; Reyes, M.; Vazquez, J.; Aquillini, E.; Merino, S.; Regué, M.; Tomás, J.M.
Genetics and proteomics of Aeromonas salmonicida lipopolysaccharide core biosynthesis. J. Bacteriol. 2009,
191, 2228–2236. [CrossRef] [PubMed]
10. Izquierdo, L.; Abitiu, N.; Coderch, N.; Hita, B.; Merino, S.; Gavin, R.; Tomás, J.M.; Regué, M. The inner-core
lipopolysaccharide biosynthetic waaE gene: Function and genetic distribution among some Enterobacteriaceae.
Microbiology 2002, 148, 3485–3496. [CrossRef] [PubMed]
11. Lodowska, J.; Wolny, D.; Jaworska-Kik, M.; Kurkiewicz, S.; Dzierżewicz, Z.; Węglarz, L. The chemical
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